{"idx_source": 1, "tag": "div", "text_raw": "0000200406 12/31 2023 Q3 FALSE http://fasb.org/us-gaap/2023#AccountingStandardsUpdate202204Member 456 0000200406 2023-01-02 2023-10-01 0000200406 us-gaap:CommonStockMember 2023-01-02 2023-10-01 0000200406 jnj:A0.650NotesDue2024Member 2023-01-02 2023-10-01 0000200406 jnj:A5.50NotesDue2024Member 2023-01-02 2023-10-01 0000200406 jnj:A1.150NotesDue2028Member 2023-01-02 2023-10-01 0000200406 jnj:A1.650NotesDue2035Member 2023-01-02 2023-10-01 0000200406 2023-10-23 xbrli:shares 0000200406 2023-10-01 iso4217:USD 0000200406 2023-01-01 iso4217:USD xbrli:shares 0000200406 2023-07-03 2023-10-01 xbrli:pure 0000200406 2022-07-04 2022-10-02 0000200406 2022-01-03 2022-10-02 0000200406 2023-07-02 0000200406 us-gaap:RetainedEarningsMember 2023-07-02 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-02 0000200406 us-gaap:CommonStockMember 2023-07-02 0000200406 us-gaap:TreasuryStockCommonMember 2023-07-02 0000200406 us-gaap:NoncontrollingInterestMember 2023-07-02 0000200406 us-gaap:RetainedEarningsMember 2023-07-03 2023-10-01 0000200406 us-gaap:TreasuryStockCommonMember 2023-07-03 2023-10-01 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-03 2023-10-01 0000200406 us-gaap:NoncontrollingInterestMember 2023-07-03 2023-10-01 0000200406 us-gaap:RetainedEarningsMember 2023-10-01 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-10-01 0000200406 us-gaap:CommonStockMember 2023-10-01 0000200406 us-gaap:TreasuryStockCommonMember 2023-10-01 0000200406 us-gaap:NoncontrollingInterestMember 2023-10-01 0000200406 us-gaap:RetainedEarningsMember 2023-01-01 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 0000200406 us-gaap:CommonStockMember 2023-01-01 0000200406 us-gaap:TreasuryStockCommonMember 2023-01-01 0000200406 us-gaap:NoncontrollingInterestMember 2023-01-01 0000200406 us-gaap:RetainedEarningsMember 2023-01-02 2023-10-01 0000200406 us-gaap:TreasuryStockCommonMember 2023-01-02 2023-10-01 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-02 2023-10-01 0000200406 2022-07-03 0000200406 us-gaap:RetainedEarningsMember 2022-07-03 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-03 0000200406 us-gaap:CommonStockMember 2022-07-03 0000200406 us-gaap:TreasuryStockCommonMember 2022-07-03 0000200406 us-gaap:RetainedEarningsMember 2022-07-04 2022-10-02 0000200406 us-gaap:TreasuryStockCommonMember 2022-07-04 2022-10-02 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-04 2022-10-02 0000200406 2022-10-02 0000200406 us-gaap:RetainedEarningsMember 2022-10-02 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-10-02 0000200406 us-gaap:CommonStockMember 2022-10-02 0000200406 us-gaap:TreasuryStockCommonMember 2022-10-02 0000200406 2022-01-02 0000200406 us-gaap:RetainedEarningsMember 2022-01-02 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-02 0000200406 us-gaap:CommonStockMember 2022-01-02 0000200406 us-gaap:TreasuryStockCommonMember 2022-01-02 0000200406 us-gaap:RetainedEarningsMember 2022-01-03 2022-10-02 0000200406 us-gaap:TreasuryStockCommonMember 2022-01-03 2022-10-02 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-03 2022-10-02 0000200406 jnj:KenvueIncMember us-gaap:IPOMember 2023-05-08 2023-05-08 0000200406 jnj:KenvueIncMember 2023-05-08 0000200406 2023-05-08 2023-05-08 0000200406 jnj:KenvueIncMember jnj:JohnsonJohnsonMember 2023-05-08 2023-05-08 0000200406 jnj:KenvueIncMember jnj:JohnsonJohnsonMember 2023-07-02 0000200406 jnj:KenvueIncMember 2023-08-23 2023-08-23 0000200406 jnj:KenvueIncMember jnj:JohnsonJohnsonMember 2023-08-23 2023-08-23 jnj:segment 0000200406 jnj:PatentsAndTrademarksMember 2023-10-01 0000200406 jnj:PatentsAndTrademarksMember 2023-01-01 0000200406 us-gaap:OtherIntangibleAssetsMember 2023-10-01 0000200406 us-gaap:OtherIntangibleAssetsMember 2023-01-01 0000200406 us-gaap:TrademarksMember 2023-10-01 0000200406 us-gaap:TrademarksMember 2023-01-01 0000200406 jnj:PurchasedInProcessResearchAndDevelopmentMember 2023-10-01 0000200406 jnj:PurchasedInProcessResearchAndDevelopmentMember 2023-01-01 0000200406 jnj:PharmaceuticalMember 2023-01-01 0000200406 jnj:MedTechMember 2023-01-01 0000200406 jnj:PharmaceuticalMember 2023-01-02 2023-10-01 0000200406 jnj:MedTechMember 2023-01-02 2023-10-01 0000200406 jnj:PharmaceuticalMember 2023-10-01 0000200406 jnj:MedTechMember 2023-10-01 0000200406 us-gaap:ForeignExchangeContractMember 2023-10-01 0000200406 us-gaap:CrossCurrencyInterestRateContractMember 2023-10-01 0000200406 us-gaap:InterestRateSwapMember 2023-10-01 0000200406 us-gaap:ForeignExchangeContractMember 2023-01-01 0000200406 us-gaap:CrossCurrencyInterestRateContractMember 2023-01-01 0000200406 us-gaap:InterestRateSwapMember 2023-01-01 0000200406 us-gaap:SalesMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember 2023-07-03 2023-10-01 0000200406 us-gaap:CostOfSalesMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember 2023-07-03 2023-10-01 0000200406 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-03 2023-10-01 0000200406 jnj:InterestIncomeExpenseNetMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember 2023-07-03 2023-10-01 0000200406 jnj:OtherIncomeExpenseNetMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember 2023-07-03 2023-10-01 0000200406 us-gaap:SalesMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember 2022-07-04 2022-10-02 0000200406 us-gaap:CostOfSalesMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember 2022-07-04 2022-10-02 0000200406 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-04 2022-10-02 0000200406 jnj:InterestIncomeExpenseNetMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember 2022-07-04 2022-10-02 0000200406 jnj:OtherIncomeExpenseNetMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember 2022-07-04 2022-10-02 0000200406 us-gaap:NetInvestmentHedgingMember us-gaap:SalesMember us-gaap:NetInvestmentHedgingMember 2023-07-03 2023-10-01 0000200406 us-gaap:NetInvestmentHedgingMember us-gaap:CostOfSalesMember us-gaap:NetInvestmentHedgingMember 2023-07-03 2023-10-01 0000200406 us-gaap:NetInvestmentHedgingMember us-gaap:NetInvestmentHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-03 2023-10-01 0000200406 us-gaap:NetInvestmentHedgingMember jnj:InterestIncomeExpenseNetMember us-gaap:NetInvestmentHedgingMember 2023-07-03 2023-10-01 0000200406 us-gaap:NetInvestmentHedgingMember jnj:OtherIncomeExpenseNetMember us-gaap:NetInvestmentHedgingMember 2023-07-03 2023-10-01 0000200406 us-gaap:NetInvestmentHedgingMember us-gaap:SalesMember us-gaap:NetInvestmentHedgingMember 2022-07-04 2022-10-02 0000200406 us-gaap:NetInvestmentHedgingMember us-gaap:CostOfSalesMember us-gaap:NetInvestmentHedgingMember 2022-07-04 2022-10-02 0000200406 us-gaap:NetInvestmentHedgingMember us-gaap:NetInvestmentHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-04 2022-10-02 0000200406 us-gaap:NetInvestmentHedgingMember jnj:InterestIncomeExpenseNetMember us-gaap:NetInvestmentHedgingMember 2022-07-04 2022-10-02 0000200406 us-gaap:NetInvestmentHedgingMember jnj:OtherIncomeExpenseNetMember us-gaap:NetInvestmentHedgingMember 2022-07-04 2022-10-02 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:SalesMember us-gaap:CashFlowHedgingMember 2023-07-03 2023-10-01 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CostOfSalesMember us-gaap:CashFlowHedgingMember 2023-07-03 2023-10-01 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-03 2023-10-01 0000200406 us-gaap:ForeignExchangeContractMember jnj:InterestIncomeExpenseNetMember us-gaap:CashFlowHedgingMember 2023-07-03 2023-10-01 0000200406 us-gaap:ForeignExchangeContractMember jnj:OtherIncomeExpenseNetMember us-gaap:CashFlowHedgingMember 2023-07-03 2023-10-01 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:SalesMember us-gaap:CashFlowHedgingMember 2022-07-04 2022-10-02 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CostOfSalesMember us-gaap:CashFlowHedgingMember 2022-07-04 2022-10-02 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-04 2022-10-02 0000200406 us-gaap:ForeignExchangeContractMember jnj:InterestIncomeExpenseNetMember us-gaap:CashFlowHedgingMember 2022-07-04 2022-10-02 0000200406 us-gaap:ForeignExchangeContractMember jnj:OtherIncomeExpenseNetMember us-gaap:CashFlowHedgingMember 2022-07-04 2022-10-02 0000200406 us-gaap:SalesMember us-gaap:CashFlowHedgingMember us-gaap:CrossCurrencyInterestRateContractMember 2023-07-03 2023-10-01 0000200406 us-gaap:CostOfSalesMember us-gaap:CashFlowHedgingMember us-gaap:CrossCurrencyInterestRateContractMember 2023-07-03 2023-10-01 0000200406 us-gaap:CashFlowHedgingMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-03 2023-10-01 0000200406 jnj:InterestIncomeExpenseNetMember us-gaap:CashFlowHedgingMember us-gaap:CrossCurrencyInterestRateContractMember 2023-07-03 2023-10-01 0000200406 jnj:OtherIncomeExpenseNetMember us-gaap:CashFlowHedgingMember us-gaap:CrossCurrencyInterestRateContractMember 2023-07-03 2023-10-01 0000200406 us-gaap:SalesMember us-gaap:CashFlowHedgingMember us-gaap:CrossCurrencyInterestRateContractMember 2022-07-04 2022-10-02 0000200406 us-gaap:CostOfSalesMember us-gaap:CashFlowHedgingMember us-gaap:CrossCurrencyInterestRateContractMember 2022-07-04 2022-10-02 0000200406 us-gaap:CashFlowHedgingMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-04 2022-10-02 0000200406 jnj:InterestIncomeExpenseNetMember us-gaap:CashFlowHedgingMember us-gaap:CrossCurrencyInterestRateContractMember 2022-07-04 2022-10-02 0000200406 jnj:OtherIncomeExpenseNetMember us-gaap:CashFlowHedgingMember us-gaap:CrossCurrencyInterestRateContractMember 2022-07-04 2022-10-02 0000200406 us-gaap:SalesMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember 2023-01-02 2023-10-01 0000200406 us-gaap:CostOfSalesMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember 2023-01-02 2023-10-01 0000200406 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-02 2023-10-01 0000200406 jnj:InterestIncomeExpenseNetMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember 2023-01-02 2023-10-01 0000200406 jnj:OtherIncomeExpenseNetMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember 2023-01-02 2023-10-01 0000200406 us-gaap:SalesMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember 2022-01-03 2022-10-02 0000200406 us-gaap:CostOfSalesMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember 2022-01-03 2022-10-02 0000200406 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-03 2022-10-02 0000200406 jnj:InterestIncomeExpenseNetMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember 2022-01-03 2022-10-02 0000200406 jnj:OtherIncomeExpenseNetMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember 2022-01-03 2022-10-02 0000200406 us-gaap:SalesMember us-gaap:FairValueHedgingMember us-gaap:CrossCurrencyInterestRateContractMember 2023-01-02 2023-10-01 0000200406 us-gaap:CostOfSalesMember us-gaap:FairValueHedgingMember us-gaap:CrossCurrencyInterestRateContractMember 2023-01-02 2023-10-01 0000200406 us-gaap:FairValueHedgingMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-02 2023-10-01 0000200406 jnj:InterestIncomeExpenseNetMember us-gaap:FairValueHedgingMember us-gaap:CrossCurrencyInterestRateContractMember 2023-01-02 2023-10-01 0000200406 jnj:OtherIncomeExpenseNetMember us-gaap:FairValueHedgingMember us-gaap:CrossCurrencyInterestRateContractMember 2023-01-02 2023-10-01 0000200406 us-gaap:SalesMember us-gaap:FairValueHedgingMember us-gaap:CrossCurrencyInterestRateContractMember 2022-01-03 2022-10-02 0000200406 us-gaap:CostOfSalesMember us-gaap:FairValueHedgingMember us-gaap:CrossCurrencyInterestRateContractMember 2022-01-03 2022-10-02 0000200406 us-gaap:FairValueHedgingMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-03 2022-10-02 0000200406 jnj:InterestIncomeExpenseNetMember us-gaap:FairValueHedgingMember us-gaap:CrossCurrencyInterestRateContractMember 2022-01-03 2022-10-02 0000200406 jnj:OtherIncomeExpenseNetMember us-gaap:FairValueHedgingMember us-gaap:CrossCurrencyInterestRateContractMember 2022-01-03 2022-10-02 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:SalesMember us-gaap:CashFlowHedgingMember 2023-01-02 2023-10-01 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CostOfSalesMember us-gaap:CashFlowHedgingMember 2023-01-02 2023-10-01 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-02 2023-10-01 0000200406 us-gaap:ForeignExchangeContractMember jnj:InterestIncomeExpenseNetMember us-gaap:CashFlowHedgingMember 2023-01-02 2023-10-01 0000200406 us-gaap:ForeignExchangeContractMember jnj:OtherIncomeExpenseNetMember us-gaap:CashFlowHedgingMember 2023-01-02 2023-10-01 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:SalesMember us-gaap:CashFlowHedgingMember 2022-01-03 2022-10-02 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CostOfSalesMember us-gaap:CashFlowHedgingMember 2022-01-03 2022-10-02 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-03 2022-10-02 0000200406 us-gaap:ForeignExchangeContractMember jnj:InterestIncomeExpenseNetMember us-gaap:CashFlowHedgingMember 2022-01-03 2022-10-02 0000200406 us-gaap:ForeignExchangeContractMember jnj:OtherIncomeExpenseNetMember us-gaap:CashFlowHedgingMember 2022-01-03 2022-10-02 0000200406 us-gaap:SalesMember us-gaap:CashFlowHedgingMember us-gaap:CrossCurrencyInterestRateContractMember 2023-01-02 2023-10-01 0000200406 us-gaap:CostOfSalesMember us-gaap:CashFlowHedgingMember us-gaap:CrossCurrencyInterestRateContractMember 2023-01-02 2023-10-01 0000200406 us-gaap:CashFlowHedgingMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-02 2023-10-01 0000200406 jnj:InterestIncomeExpenseNetMember us-gaap:CashFlowHedgingMember us-gaap:CrossCurrencyInterestRateContractMember 2023-01-02 2023-10-01 0000200406 jnj:OtherIncomeExpenseNetMember us-gaap:CashFlowHedgingMember us-gaap:CrossCurrencyInterestRateContractMember 2023-01-02 2023-10-01 0000200406 us-gaap:SalesMember us-gaap:CashFlowHedgingMember us-gaap:CrossCurrencyInterestRateContractMember 2022-01-03 2022-10-02 0000200406 us-gaap:CostOfSalesMember us-gaap:CashFlowHedgingMember us-gaap:CrossCurrencyInterestRateContractMember 2022-01-03 2022-10-02 0000200406 us-gaap:CashFlowHedgingMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-03 2022-10-02 0000200406 jnj:InterestIncomeExpenseNetMember us-gaap:CashFlowHedgingMember us-gaap:CrossCurrencyInterestRateContractMember 2022-01-03 2022-10-02 0000200406 jnj:OtherIncomeExpenseNetMember us-gaap:CashFlowHedgingMember us-gaap:CrossCurrencyInterestRateContractMember 2022-01-03 2022-10-02 0000200406 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongTermDebtMember 2023-10-01 0000200406 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongTermDebtMember 2023-01-01 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2023-07-03 2023-10-01 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2022-07-04 2022-10-02 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2023-01-02 2023-10-01 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2022-01-03 2022-10-02 0000200406 jnj:OtherIncomeExpenseNetMember 2023-07-03 2023-10-01 0000200406 jnj:OtherIncomeExpenseNetMember 2022-07-04 2022-10-02 0000200406 us-gaap:CrossCurrencyInterestRateContractMember 2023-07-03 2023-10-01 0000200406 us-gaap:CrossCurrencyInterestRateContractMember 2022-07-04 2022-10-02 0000200406 jnj:OtherIncomeExpenseNetMember us-gaap:CrossCurrencyInterestRateContractMember 2023-07-03 2023-10-01 0000200406 jnj:OtherIncomeExpenseNetMember us-gaap:CrossCurrencyInterestRateContractMember 2022-07-04 2022-10-02 0000200406 jnj:OtherIncomeExpenseNetMember 2023-01-02 2023-10-01 0000200406 jnj:OtherIncomeExpenseNetMember 2022-01-03 2022-10-02 0000200406 us-gaap:CrossCurrencyInterestRateContractMember 2023-01-02 2023-10-01 0000200406 us-gaap:CrossCurrencyInterestRateContractMember 2022-01-03 2022-10-02 0000200406 jnj:OtherIncomeExpenseNetMember us-gaap:CrossCurrencyInterestRateContractMember 2023-01-02 2023-10-01 0000200406 jnj:OtherIncomeExpenseNetMember us-gaap:CrossCurrencyInterestRateContractMember 2022-01-03 2022-10-02 0000200406 jnj:EquityInvestmentswithReadilyDeterminableValueMember us-gaap:EquitySecuritiesMember 2023-01-01 0000200406 jnj:EquityInvestmentswithReadilyDeterminableValueMember us-gaap:EquitySecuritiesMember 2023-01-02 2023-10-01 0000200406 jnj:EquityInvestmentswithReadilyDeterminableValueMember us-gaap:EquitySecuritiesMember 2023-10-01 0000200406 jnj:EquityInvestmentswithoutReadilyDeterminableValueMember us-gaap:EquitySecuritiesMember 2023-01-01 0000200406 jnj:EquityInvestmentswithoutReadilyDeterminableValueMember us-gaap:EquitySecuritiesMember 2023-01-02 2023-10-01 0000200406 jnj:EquityInvestmentswithoutReadilyDeterminableValueMember us-gaap:EquitySecuritiesMember 2023-10-01 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member 2023-10-01 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member 2023-10-01 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member 2023-10-01 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member 2023-01-01 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel1Member 2023-10-01 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member 2023-10-01 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel3Member 2023-10-01 0000200406 us-gaap:InterestRateContractMember 2023-10-01 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member 2023-01-01 0000200406 us-gaap:FairValueInputsLevel1Member 2023-10-01 0000200406 us-gaap:FairValueInputsLevel2Member 2023-10-01 0000200406 us-gaap:FairValueInputsLevel3Member 2023-10-01 0000200406 us-gaap:FairValueInputsLevel2Member 2023-01-01 0000200406 us-gaap:FairValueInputsLevel1Member 2023-01-01 0000200406 us-gaap:FairValueInputsLevel3Member 2023-01-01 0000200406 jnj:AurisHealthMember us-gaap:OtherNoncurrentLiabilitiesMember 2023-10-01 0000200406 jnj:AurisHealthMember us-gaap:OtherNoncurrentLiabilitiesMember 2023-01-01 0000200406 us-gaap:HeldtomaturitySecuritiesMember us-gaap:CashMember 2023-10-01 0000200406 us-gaap:SovereignDebtSecuritiesMember us-gaap:HeldtomaturitySecuritiesMember 2023-10-01 0000200406 us-gaap:SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember us-gaap:HeldtomaturitySecuritiesMember 2023-10-01 0000200406 us-gaap:CorporateDebtSecuritiesMember us-gaap:HeldtomaturitySecuritiesMember 2023-10-01 0000200406 us-gaap:HeldtomaturitySecuritiesMember us-gaap:MoneyMarketFundsMember 2023-10-01 0000200406 us-gaap:HeldtomaturitySecuritiesMember us-gaap:BankTimeDepositsMember 2023-10-01 0000200406 us-gaap:HeldtomaturitySecuritiesMember 2023-10-01 0000200406 us-gaap:AvailableforsaleSecuritiesMember us-gaap:USTreasuryAndGovernmentMember 2023-10-01 0000200406 us-gaap:AvailableforsaleSecuritiesMember us-gaap:USTreasuryAndGovernmentMember 2023-10-01 0000200406 us-gaap:AvailableforsaleSecuritiesMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-10-01 0000200406 us-gaap:AvailableforsaleSecuritiesMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-10-01 0000200406 us-gaap:SovereignDebtSecuritiesMember us-gaap:AvailableforsaleSecuritiesMember 2023-10-01 0000200406 us-gaap:SovereignDebtSecuritiesMember us-gaap:AvailableforsaleSecuritiesMember 2023-10-01 0000200406 us-gaap:CorporateDebtSecuritiesMember us-gaap:AvailableforsaleSecuritiesMember 2023-10-01 0000200406 us-gaap:CorporateDebtSecuritiesMember us-gaap:AvailableforsaleSecuritiesMember 2023-10-01 0000200406 us-gaap:AvailableforsaleSecuritiesMember 2023-10-01 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-10-01 0000200406 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-10-01 0000200406 jnj:A5.50NotesDue2024Member 2023-10-01 iso4217:GBP 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:A5.50NotesDue2024Member 2023-10-01 0000200406 jnj:A5.50NotesDue2024Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-10-01 0000200406 jnj:A2.625Notesdue2025Member 2023-10-01 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:A2.625Notesdue2025Member 2023-10-01 0000200406 us-gaap:EstimateOfFairValueFairValueDisclosureMember jnj:A2.625Notesdue2025Member 2023-10-01 0000200406 jnj:A0550NotesDue2025Member 2023-10-01 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:A0550NotesDue2025Member 2023-10-01 0000200406 jnj:A0550NotesDue2025Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-10-01 0000200406 jnj:A2.45Notesdue2026Member 2023-10-01 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:A2.45Notesdue2026Member 2023-10-01 0000200406 jnj:A2.45Notesdue2026Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-10-01 0000200406 jnj:A2.95Notesdue2027Member 2023-10-01 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:A2.95Notesdue2027Member 2023-10-01 0000200406 jnj:A2.95Notesdue2027Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-10-01 0000200406 jnj:A095NotesDue2027Member 2023-10-01 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:A095NotesDue2027Member 2023-10-01 0000200406 us-gaap:EstimateOfFairValueFairValueDisclosureMember jnj:A095NotesDue2027Member 2023-10-01 0000200406 jnj:A2.900Notesdue2028Member 2023-10-01 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:A2.900Notesdue2028Member 2023-10-01 0000200406 us-gaap:EstimateOfFairValueFairValueDisclosureMember jnj:A2.900Notesdue2028Member 2023-10-01 0000200406 jnj:A1.150NotesDue2028Member 2023-10-01 iso4217:EUR 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:A1.150NotesDue2028Member 2023-10-01 0000200406 us-gaap:EstimateOfFairValueFairValueDisclosureMember jnj:A1.150NotesDue2028Member 2023-10-01 0000200406 jnj:A6.95Notesdue2029Member 2023-10-01 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:A6.95Notesdue2029Member 2023-10-01 0000200406 us-gaap:EstimateOfFairValueFairValueDisclosureMember jnj:A6.95Notesdue2029Member 2023-10-01 0000200406 jnj:A1300NotesDue2030Member 2023-10-01 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:A1300NotesDue2030Member 2023-10-01 0000200406 us-gaap:EstimateOfFairValueFairValueDisclosureMember jnj:A1300NotesDue2030Member 2023-10-01 0000200406 jnj:A4.95Debenturesdue2033Member 2023-10-01 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:A4.95Debenturesdue2033Member 2023-10-01 0000200406 us-gaap:EstimateOfFairValueFairValueDisclosureMember jnj:A4.95Debenturesdue2033Member 2023-10-01 0000200406 jnj:A4.375Notesdue2033Member 2023-10-01 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:A4.375Notesdue2033Member 2023-10-01 0000200406 jnj:A4.375Notesdue2033Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-10-01 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:A1.650NotesDue2035Member 2023-10-01 0000200406 jnj:A1.650NotesDue2035Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-10-01 0000200406 jnj:A3.55Notesdue2036Member 2023-10-01 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:A3.55Notesdue2036Member 2023-10-01 0000200406 us-gaap:EstimateOfFairValueFairValueDisclosureMember jnj:A3.55Notesdue2036Member 2023-10-01 0000200406 jnj:A5.95Notesdue2037Member 2023-10-01 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:A5.95Notesdue2037Member 2023-10-01 0000200406 us-gaap:EstimateOfFairValueFairValueDisclosureMember jnj:A5.95Notesdue2037Member 2023-10-01 0000200406 jnj:A3.625Notesdue2037Member 2023-10-01 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:A3.625Notesdue2037Member 2023-10-01 0000200406 us-gaap:EstimateOfFairValueFairValueDisclosureMember jnj:A3.625Notesdue2037Member 2023-10-01 0000200406 jnj:A3.400Notesdue2038Member 2023-10-01 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:A3.400Notesdue2038Member 2023-10-01 0000200406 jnj:A3.400Notesdue2038Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-10-01 0000200406 jnj:A5.85Debenturesdue2038Member 2023-10-01 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:A5.85Debenturesdue2038Member 2023-10-01 0000200406 us-gaap:EstimateOfFairValueFairValueDisclosureMember jnj:A5.85Debenturesdue2038Member 2023-10-01 0000200406 jnj:A4.50Debenturesdue2040Member 2023-10-01 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:A4.50Debenturesdue2040Member 2023-10-01 0000200406 us-gaap:EstimateOfFairValueFairValueDisclosureMember jnj:A4.50Debenturesdue2040Member 2023-10-01 0000200406 jnj:A210NotesDue2040Member 2023-10-01 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:A210NotesDue2040Member 2023-10-01 0000200406 us-gaap:EstimateOfFairValueFairValueDisclosureMember jnj:A210NotesDue2040Member 2023-10-01 0000200406 jnj:A4.85Notesdue2041Member 2023-10-01 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:A4.85Notesdue2041Member 2023-10-01 0000200406 us-gaap:EstimateOfFairValueFairValueDisclosureMember jnj:A4.85Notesdue2041Member 2023-10-01 0000200406 jnj:A4.50Notesdue2043Member 2023-10-01 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:A4.50Notesdue2043Member 2023-10-01 0000200406 us-gaap:EstimateOfFairValueFairValueDisclosureMember jnj:A4.50Notesdue2043Member 2023-10-01 0000200406 jnj:A3.70Notesdue2046Member 2023-10-01 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:A3.70Notesdue2046Member 2023-10-01 0000200406 us-gaap:EstimateOfFairValueFairValueDisclosureMember jnj:A3.70Notesdue2046Member 2023-10-01 0000200406 jnj:A3.75Notesdue2047Member 2023-10-01 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:A3.75Notesdue2047Member 2023-10-01 0000200406 us-gaap:EstimateOfFairValueFairValueDisclosureMember jnj:A3.75Notesdue2047Member 2023-10-01 0000200406 jnj:A3.500Notesdue2048Member 2023-10-01 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:A3.500Notesdue2048Member 2023-10-01 0000200406 us-gaap:EstimateOfFairValueFairValueDisclosureMember jnj:A3.500Notesdue2048Member 2023-10-01 0000200406 jnj:A2250NotesDue2050Member 2023-10-01 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:A2250NotesDue2050Member 2023-10-01 0000200406 us-gaap:EstimateOfFairValueFairValueDisclosureMember jnj:A2250NotesDue2050Member 2023-10-01 0000200406 jnj:A2450NotesDue2060Member 2023-10-01 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:A2450NotesDue2060Member 2023-10-01 0000200406 us-gaap:EstimateOfFairValueFairValueDisclosureMember jnj:A2450NotesDue2060Member 2023-10-01 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:NotesDuePeriodFifteenMember 2023-10-01 0000200406 us-gaap:EstimateOfFairValueFairValueDisclosureMember jnj:NotesDuePeriodFifteenMember 2023-10-01 0000200406 2023-01-02 2023-04-02 0000200406 us-gaap:CommercialPaperMember 2023-10-01 0000200406 us-gaap:CommercialPaperMember 2023-01-02 2023-10-01 0000200406 jnj:ConsumerMember jnj:TalcMember 2023-01-02 2023-10-01 0000200406 jnj:AccruedTaxesOnIncomeMember 2023-10-01 0000200406 us-gaap:InternalRevenueServiceIRSMember 2023-04-03 2023-07-02 0000200406 us-gaap:PensionPlansDefinedBenefitMember 2023-07-03 2023-10-01 0000200406 us-gaap:PensionPlansDefinedBenefitMember 2022-07-04 2022-10-02 0000200406 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-07-03 2023-10-01 0000200406 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-07-04 2022-10-02 0000200406 us-gaap:PensionPlansDefinedBenefitMember 2023-01-02 2023-10-01 0000200406 us-gaap:PensionPlansDefinedBenefitMember 2022-01-03 2022-10-02 0000200406 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-01-02 2023-10-01 0000200406 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-01-03 2022-10-02 0000200406 jnj:ConsumerHealthMember 2023-10-01 0000200406 country:US 2023-01-02 2023-10-01 0000200406 us-gaap:ForeignPlanMember 2023-01-02 2023-10-01 0000200406 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-01 0000200406 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-01-01 0000200406 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-01-01 0000200406 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-01-01 0000200406 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-02 2023-10-01 0000200406 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-01-02 2023-10-01 0000200406 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-01-02 2023-10-01 0000200406 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-01-02 2023-10-01 0000200406 us-gaap:AccumulatedTranslationAdjustmentMember 2023-10-01 0000200406 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-10-01 0000200406 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-10-01 0000200406 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-10-01 0000200406 us-gaap:AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember 2023-01-02 2023-10-01 0000200406 jnj:ImmunologyMember country:US jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:ImmunologyMember country:US jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:ImmunologyMember country:US jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:ImmunologyMember country:US jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:ImmunologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:ImmunologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:ImmunologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:ImmunologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:ImmunologyMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:ImmunologyMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:ImmunologyMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:ImmunologyMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:RemicadeMember jnj:ImmunologyMember country:US jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:RemicadeMember jnj:ImmunologyMember country:US jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:RemicadeMember jnj:ImmunologyMember country:US jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:RemicadeMember jnj:ImmunologyMember country:US jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:RemicadeMember jnj:ImmunologyMember jnj:UNITEDSTATESExportsMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:RemicadeMember jnj:ImmunologyMember jnj:UNITEDSTATESExportsMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:RemicadeMember jnj:ImmunologyMember jnj:UNITEDSTATESExportsMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:RemicadeMember jnj:ImmunologyMember jnj:UNITEDSTATESExportsMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:RemicadeMember jnj:ImmunologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:RemicadeMember jnj:ImmunologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:RemicadeMember jnj:ImmunologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:RemicadeMember jnj:ImmunologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:RemicadeMember jnj:ImmunologyMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:RemicadeMember jnj:ImmunologyMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:RemicadeMember jnj:ImmunologyMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:RemicadeMember jnj:ImmunologyMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:ImmunologyMember jnj:SimponiSimponiAriaMember country:US jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:ImmunologyMember jnj:SimponiSimponiAriaMember country:US jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:ImmunologyMember jnj:SimponiSimponiAriaMember country:US jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:ImmunologyMember jnj:SimponiSimponiAriaMember country:US jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:ImmunologyMember jnj:SimponiSimponiAriaMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:ImmunologyMember jnj:SimponiSimponiAriaMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:ImmunologyMember jnj:SimponiSimponiAriaMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:ImmunologyMember jnj:SimponiSimponiAriaMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:ImmunologyMember jnj:SimponiSimponiAriaMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:ImmunologyMember jnj:SimponiSimponiAriaMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:ImmunologyMember jnj:SimponiSimponiAriaMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:ImmunologyMember jnj:SimponiSimponiAriaMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:ImmunologyMember jnj:StelaraMember country:US jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:ImmunologyMember jnj:StelaraMember country:US jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:ImmunologyMember jnj:StelaraMember country:US jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:ImmunologyMember jnj:StelaraMember country:US jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:ImmunologyMember jnj:StelaraMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:ImmunologyMember jnj:StelaraMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:ImmunologyMember jnj:StelaraMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:ImmunologyMember jnj:StelaraMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:ImmunologyMember jnj:StelaraMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:ImmunologyMember jnj:StelaraMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:ImmunologyMember jnj:StelaraMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:ImmunologyMember jnj:StelaraMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:ImmunologyMember jnj:TremfyaMember country:US jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:ImmunologyMember jnj:TremfyaMember country:US jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:ImmunologyMember jnj:TremfyaMember country:US jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:ImmunologyMember jnj:TremfyaMember country:US jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:ImmunologyMember jnj:TremfyaMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:ImmunologyMember jnj:TremfyaMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:ImmunologyMember jnj:TremfyaMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:ImmunologyMember jnj:TremfyaMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:ImmunologyMember jnj:TremfyaMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:ImmunologyMember jnj:TremfyaMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:ImmunologyMember jnj:TremfyaMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:ImmunologyMember jnj:TremfyaMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:OtherImmunologyMember jnj:ImmunologyMember country:US jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:OtherImmunologyMember jnj:ImmunologyMember country:US jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:OtherImmunologyMember jnj:ImmunologyMember country:US jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:OtherImmunologyMember jnj:ImmunologyMember country:US jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:OtherImmunologyMember jnj:ImmunologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:OtherImmunologyMember jnj:ImmunologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:OtherImmunologyMember jnj:ImmunologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:OtherImmunologyMember jnj:ImmunologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:OtherImmunologyMember jnj:ImmunologyMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:OtherImmunologyMember jnj:ImmunologyMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:OtherImmunologyMember jnj:ImmunologyMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:OtherImmunologyMember jnj:ImmunologyMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:InfectiousDiseasesMember country:US jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:InfectiousDiseasesMember country:US jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:InfectiousDiseasesMember country:US jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:InfectiousDiseasesMember country:US jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:InfectiousDiseasesMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:InfectiousDiseasesMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:InfectiousDiseasesMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:InfectiousDiseasesMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:InfectiousDiseasesMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:InfectiousDiseasesMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:InfectiousDiseasesMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:InfectiousDiseasesMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:InfectiousDiseasesMember jnj:COVID19Member country:US jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:InfectiousDiseasesMember jnj:COVID19Member country:US jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:InfectiousDiseasesMember jnj:COVID19Member country:US jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:InfectiousDiseasesMember jnj:COVID19Member country:US jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:InfectiousDiseasesMember jnj:COVID19Member us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:InfectiousDiseasesMember jnj:COVID19Member us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:InfectiousDiseasesMember jnj:COVID19Member us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:InfectiousDiseasesMember jnj:COVID19Member us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:InfectiousDiseasesMember jnj:COVID19Member jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:InfectiousDiseasesMember jnj:COVID19Member jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:InfectiousDiseasesMember jnj:COVID19Member jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:InfectiousDiseasesMember jnj:COVID19Member jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:EDURANTrilpivirineMember jnj:InfectiousDiseasesMember country:US jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:EDURANTrilpivirineMember jnj:InfectiousDiseasesMember country:US jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:EDURANTrilpivirineMember jnj:InfectiousDiseasesMember country:US jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:EDURANTrilpivirineMember jnj:InfectiousDiseasesMember country:US jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:EDURANTrilpivirineMember jnj:InfectiousDiseasesMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:EDURANTrilpivirineMember jnj:InfectiousDiseasesMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:EDURANTrilpivirineMember jnj:InfectiousDiseasesMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:EDURANTrilpivirineMember jnj:InfectiousDiseasesMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:EDURANTrilpivirineMember jnj:InfectiousDiseasesMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:EDURANTrilpivirineMember jnj:InfectiousDiseasesMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:EDURANTrilpivirineMember jnj:InfectiousDiseasesMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:EDURANTrilpivirineMember jnj:InfectiousDiseasesMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:InfectiousDiseasesMember jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember country:US jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:InfectiousDiseasesMember jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember country:US jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:InfectiousDiseasesMember jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember country:US jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:InfectiousDiseasesMember jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember country:US jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:InfectiousDiseasesMember jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:InfectiousDiseasesMember jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:InfectiousDiseasesMember jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:InfectiousDiseasesMember jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:InfectiousDiseasesMember jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:InfectiousDiseasesMember jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:InfectiousDiseasesMember jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:InfectiousDiseasesMember jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:InfectiousDiseasesMember country:US jnj:InnovativeMedicineMember jnj:OtherInfectiousDiseasesMember 2023-07-03 2023-10-01 0000200406 jnj:InfectiousDiseasesMember country:US jnj:InnovativeMedicineMember jnj:OtherInfectiousDiseasesMember 2022-07-04 2022-10-02 0000200406 jnj:InfectiousDiseasesMember country:US jnj:InnovativeMedicineMember jnj:OtherInfectiousDiseasesMember 2023-01-02 2023-10-01 0000200406 jnj:InfectiousDiseasesMember country:US jnj:InnovativeMedicineMember jnj:OtherInfectiousDiseasesMember 2022-01-03 2022-10-02 0000200406 jnj:InfectiousDiseasesMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:OtherInfectiousDiseasesMember 2023-07-03 2023-10-01 0000200406 jnj:InfectiousDiseasesMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:OtherInfectiousDiseasesMember 2022-07-04 2022-10-02 0000200406 jnj:InfectiousDiseasesMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:OtherInfectiousDiseasesMember 2023-01-02 2023-10-01 0000200406 jnj:InfectiousDiseasesMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:OtherInfectiousDiseasesMember 2022-01-03 2022-10-02 0000200406 jnj:InfectiousDiseasesMember jnj:InnovativeMedicineMember jnj:OtherInfectiousDiseasesMember 2023-07-03 2023-10-01 0000200406 jnj:InfectiousDiseasesMember jnj:InnovativeMedicineMember jnj:OtherInfectiousDiseasesMember 2022-07-04 2022-10-02 0000200406 jnj:InfectiousDiseasesMember jnj:InnovativeMedicineMember jnj:OtherInfectiousDiseasesMember 2023-01-02 2023-10-01 0000200406 jnj:InfectiousDiseasesMember jnj:InnovativeMedicineMember jnj:OtherInfectiousDiseasesMember 2022-01-03 2022-10-02 0000200406 jnj:NeuroscienceMember country:US jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:NeuroscienceMember country:US jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:NeuroscienceMember country:US jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:NeuroscienceMember country:US jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:NeuroscienceMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:NeuroscienceMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:NeuroscienceMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:NeuroscienceMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:NeuroscienceMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:NeuroscienceMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:NeuroscienceMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:NeuroscienceMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:NeuroscienceMember jnj:CONCERTAMethylphenidateMember country:US jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:NeuroscienceMember jnj:CONCERTAMethylphenidateMember country:US jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:NeuroscienceMember jnj:CONCERTAMethylphenidateMember country:US jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:NeuroscienceMember jnj:CONCERTAMethylphenidateMember country:US jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:NeuroscienceMember jnj:CONCERTAMethylphenidateMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:NeuroscienceMember jnj:CONCERTAMethylphenidateMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:NeuroscienceMember jnj:CONCERTAMethylphenidateMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:NeuroscienceMember jnj:CONCERTAMethylphenidateMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:NeuroscienceMember jnj:CONCERTAMethylphenidateMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:NeuroscienceMember jnj:CONCERTAMethylphenidateMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:NeuroscienceMember jnj:CONCERTAMethylphenidateMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:NeuroscienceMember jnj:CONCERTAMethylphenidateMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:NeuroscienceMember jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember country:US jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:NeuroscienceMember jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember country:US jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:NeuroscienceMember jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember country:US jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:NeuroscienceMember jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember country:US jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:NeuroscienceMember jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:NeuroscienceMember jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:NeuroscienceMember jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:NeuroscienceMember jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:NeuroscienceMember jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:NeuroscienceMember jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:NeuroscienceMember jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:NeuroscienceMember jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:NeuroscienceMember jnj:SPRAVATOMember country:US jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:NeuroscienceMember jnj:SPRAVATOMember country:US jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:NeuroscienceMember jnj:SPRAVATOMember country:US jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:NeuroscienceMember jnj:SPRAVATOMember country:US jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:NeuroscienceMember jnj:SPRAVATOMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:NeuroscienceMember jnj:SPRAVATOMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:NeuroscienceMember jnj:SPRAVATOMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:NeuroscienceMember jnj:SPRAVATOMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:NeuroscienceMember jnj:SPRAVATOMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:NeuroscienceMember jnj:SPRAVATOMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:NeuroscienceMember jnj:SPRAVATOMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:NeuroscienceMember jnj:SPRAVATOMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:NeuroscienceMember country:US jnj:InnovativeMedicineMember jnj:OTHERNEUROSCIENCEMember 2023-07-03 2023-10-01 0000200406 jnj:NeuroscienceMember country:US jnj:InnovativeMedicineMember jnj:OTHERNEUROSCIENCEMember 2022-07-04 2022-10-02 0000200406 jnj:NeuroscienceMember country:US jnj:InnovativeMedicineMember jnj:OTHERNEUROSCIENCEMember 2023-01-02 2023-10-01 0000200406 jnj:NeuroscienceMember country:US jnj:InnovativeMedicineMember jnj:OTHERNEUROSCIENCEMember 2022-01-03 2022-10-02 0000200406 jnj:NeuroscienceMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:OTHERNEUROSCIENCEMember 2023-07-03 2023-10-01 0000200406 jnj:NeuroscienceMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:OTHERNEUROSCIENCEMember 2022-07-04 2022-10-02 0000200406 jnj:NeuroscienceMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:OTHERNEUROSCIENCEMember 2023-01-02 2023-10-01 0000200406 jnj:NeuroscienceMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:OTHERNEUROSCIENCEMember 2022-01-03 2022-10-02 0000200406 jnj:NeuroscienceMember jnj:InnovativeMedicineMember jnj:OTHERNEUROSCIENCEMember 2023-07-03 2023-10-01 0000200406 jnj:NeuroscienceMember jnj:InnovativeMedicineMember jnj:OTHERNEUROSCIENCEMember 2022-07-04 2022-10-02 0000200406 jnj:NeuroscienceMember jnj:InnovativeMedicineMember jnj:OTHERNEUROSCIENCEMember 2023-01-02 2023-10-01 0000200406 jnj:NeuroscienceMember jnj:InnovativeMedicineMember jnj:OTHERNEUROSCIENCEMember 2022-01-03 2022-10-02 0000200406 jnj:OncologyMember country:US jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:OncologyMember country:US jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:OncologyMember country:US jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:OncologyMember country:US jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:OncologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:OncologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:OncologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:OncologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:OncologyMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:OncologyMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:OncologyMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:OncologyMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:OncologyMember country:US jnj:InnovativeMedicineMember jnj:CARVYKTIMember 2023-07-03 2023-10-01 0000200406 jnj:OncologyMember country:US jnj:InnovativeMedicineMember jnj:CARVYKTIMember 2022-07-04 2022-10-02 0000200406 jnj:OncologyMember country:US jnj:InnovativeMedicineMember jnj:CARVYKTIMember 2023-01-02 2023-10-01 0000200406 jnj:OncologyMember country:US jnj:InnovativeMedicineMember jnj:CARVYKTIMember 2022-01-03 2022-10-02 0000200406 jnj:OncologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:CARVYKTIMember 2023-07-03 2023-10-01 0000200406 jnj:OncologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:CARVYKTIMember 2022-07-04 2022-10-02 0000200406 jnj:OncologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:CARVYKTIMember 2023-01-02 2023-10-01 0000200406 jnj:OncologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:CARVYKTIMember 2022-01-03 2022-10-02 0000200406 jnj:OncologyMember jnj:InnovativeMedicineMember jnj:CARVYKTIMember 2023-07-03 2023-10-01 0000200406 jnj:OncologyMember jnj:InnovativeMedicineMember jnj:CARVYKTIMember 2022-07-04 2022-10-02 0000200406 jnj:OncologyMember jnj:InnovativeMedicineMember jnj:CARVYKTIMember 2023-01-02 2023-10-01 0000200406 jnj:OncologyMember jnj:InnovativeMedicineMember jnj:CARVYKTIMember 2022-01-03 2022-10-02 0000200406 jnj:OncologyMember country:US jnj:DARZALEXMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:OncologyMember country:US jnj:DARZALEXMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:OncologyMember country:US jnj:DARZALEXMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:OncologyMember country:US jnj:DARZALEXMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:OncologyMember us-gaap:NonUsMember jnj:DARZALEXMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:OncologyMember us-gaap:NonUsMember jnj:DARZALEXMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:OncologyMember us-gaap:NonUsMember jnj:DARZALEXMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:OncologyMember us-gaap:NonUsMember jnj:DARZALEXMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:OncologyMember jnj:DARZALEXMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:OncologyMember jnj:DARZALEXMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:OncologyMember jnj:DARZALEXMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:OncologyMember jnj:DARZALEXMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:OncologyMember jnj:ERLEADAMember country:US jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:OncologyMember jnj:ERLEADAMember country:US jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:OncologyMember jnj:ERLEADAMember country:US jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:OncologyMember jnj:ERLEADAMember country:US jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:OncologyMember jnj:ERLEADAMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:OncologyMember jnj:ERLEADAMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:OncologyMember jnj:ERLEADAMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:OncologyMember jnj:ERLEADAMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:OncologyMember jnj:ERLEADAMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:OncologyMember jnj:ERLEADAMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:OncologyMember jnj:ERLEADAMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:OncologyMember jnj:ERLEADAMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:OncologyMember jnj:IMBRUVICAMember country:US jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:OncologyMember jnj:IMBRUVICAMember country:US jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:OncologyMember jnj:IMBRUVICAMember country:US jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:OncologyMember jnj:IMBRUVICAMember country:US jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:OncologyMember jnj:IMBRUVICAMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:OncologyMember jnj:IMBRUVICAMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:OncologyMember jnj:IMBRUVICAMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:OncologyMember jnj:IMBRUVICAMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:OncologyMember jnj:IMBRUVICAMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:OncologyMember jnj:IMBRUVICAMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:OncologyMember jnj:IMBRUVICAMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:OncologyMember jnj:IMBRUVICAMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:ZYTIGAMember jnj:OncologyMember country:US jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:ZYTIGAMember jnj:OncologyMember country:US jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:ZYTIGAMember jnj:OncologyMember country:US jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:ZYTIGAMember jnj:OncologyMember country:US jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:ZYTIGAMember jnj:OncologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:ZYTIGAMember jnj:OncologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:ZYTIGAMember jnj:OncologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:ZYTIGAMember jnj:OncologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:ZYTIGAMember jnj:OncologyMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:ZYTIGAMember jnj:OncologyMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:ZYTIGAMember jnj:OncologyMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:ZYTIGAMember jnj:OncologyMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:OncologyMember jnj:OtherOncologyMember country:US jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:OncologyMember jnj:OtherOncologyMember country:US jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:OncologyMember jnj:OtherOncologyMember country:US jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:OncologyMember jnj:OtherOncologyMember country:US jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:OncologyMember jnj:OtherOncologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:OncologyMember jnj:OtherOncologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:OncologyMember jnj:OtherOncologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:OncologyMember jnj:OtherOncologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:OncologyMember jnj:OtherOncologyMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:OncologyMember jnj:OtherOncologyMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:OncologyMember jnj:OtherOncologyMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:OncologyMember jnj:OtherOncologyMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:PulmonaryHypertensionMember country:US jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:PulmonaryHypertensionMember country:US jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:PulmonaryHypertensionMember country:US jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:PulmonaryHypertensionMember country:US jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:PulmonaryHypertensionMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:PulmonaryHypertensionMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:PulmonaryHypertensionMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:PulmonaryHypertensionMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:PulmonaryHypertensionMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:PulmonaryHypertensionMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:PulmonaryHypertensionMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:PulmonaryHypertensionMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:OPSUMITMember jnj:PulmonaryHypertensionMember country:US jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:OPSUMITMember jnj:PulmonaryHypertensionMember country:US jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:OPSUMITMember jnj:PulmonaryHypertensionMember country:US jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:OPSUMITMember jnj:PulmonaryHypertensionMember country:US jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:OPSUMITMember jnj:PulmonaryHypertensionMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:OPSUMITMember jnj:PulmonaryHypertensionMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:OPSUMITMember jnj:PulmonaryHypertensionMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:OPSUMITMember jnj:PulmonaryHypertensionMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:OPSUMITMember jnj:PulmonaryHypertensionMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:OPSUMITMember jnj:PulmonaryHypertensionMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:OPSUMITMember jnj:PulmonaryHypertensionMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:OPSUMITMember jnj:PulmonaryHypertensionMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:UPTRAVIMember jnj:PulmonaryHypertensionMember country:US jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:UPTRAVIMember jnj:PulmonaryHypertensionMember country:US jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:UPTRAVIMember jnj:PulmonaryHypertensionMember country:US jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:UPTRAVIMember jnj:PulmonaryHypertensionMember country:US jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:UPTRAVIMember jnj:PulmonaryHypertensionMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:UPTRAVIMember jnj:PulmonaryHypertensionMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:UPTRAVIMember jnj:PulmonaryHypertensionMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:UPTRAVIMember jnj:PulmonaryHypertensionMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:UPTRAVIMember jnj:PulmonaryHypertensionMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:UPTRAVIMember jnj:PulmonaryHypertensionMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:UPTRAVIMember jnj:PulmonaryHypertensionMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:UPTRAVIMember jnj:PulmonaryHypertensionMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:PulmonaryHypertensionMember country:US jnj:OtherMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:PulmonaryHypertensionMember country:US jnj:OtherMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:PulmonaryHypertensionMember country:US jnj:OtherMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:PulmonaryHypertensionMember country:US jnj:OtherMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:PulmonaryHypertensionMember us-gaap:NonUsMember jnj:OtherMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:PulmonaryHypertensionMember us-gaap:NonUsMember jnj:OtherMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:PulmonaryHypertensionMember us-gaap:NonUsMember jnj:OtherMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:PulmonaryHypertensionMember us-gaap:NonUsMember jnj:OtherMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:PulmonaryHypertensionMember jnj:OtherMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:PulmonaryHypertensionMember jnj:OtherMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:PulmonaryHypertensionMember jnj:OtherMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:PulmonaryHypertensionMember jnj:OtherMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:CardiovascularMetabolismOtherMember country:US jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:CardiovascularMetabolismOtherMember country:US jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:CardiovascularMetabolismOtherMember country:US jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:CardiovascularMetabolismOtherMember country:US jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:CardiovascularMetabolismOtherMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:CardiovascularMetabolismOtherMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:CardiovascularMetabolismOtherMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:CardiovascularMetabolismOtherMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:CardiovascularMetabolismOtherMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:CardiovascularMetabolismOtherMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:CardiovascularMetabolismOtherMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:CardiovascularMetabolismOtherMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:CardiovascularMetabolismOtherMember jnj:XareltoMember country:US jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:CardiovascularMetabolismOtherMember jnj:XareltoMember country:US jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:CardiovascularMetabolismOtherMember jnj:XareltoMember country:US jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:CardiovascularMetabolismOtherMember jnj:XareltoMember country:US jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:CardiovascularMetabolismOtherMember jnj:XareltoMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:CardiovascularMetabolismOtherMember jnj:XareltoMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:CardiovascularMetabolismOtherMember jnj:XareltoMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:CardiovascularMetabolismOtherMember jnj:XareltoMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:CardiovascularMetabolismOtherMember jnj:XareltoMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:CardiovascularMetabolismOtherMember jnj:XareltoMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:CardiovascularMetabolismOtherMember jnj:XareltoMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:CardiovascularMetabolismOtherMember jnj:XareltoMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:CardiovascularMetabolismOtherMember country:US jnj:OtherMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:CardiovascularMetabolismOtherMember country:US jnj:OtherMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:CardiovascularMetabolismOtherMember country:US jnj:OtherMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:CardiovascularMetabolismOtherMember country:US jnj:OtherMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:CardiovascularMetabolismOtherMember us-gaap:NonUsMember jnj:OtherMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:CardiovascularMetabolismOtherMember us-gaap:NonUsMember jnj:OtherMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:CardiovascularMetabolismOtherMember us-gaap:NonUsMember jnj:OtherMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:CardiovascularMetabolismOtherMember us-gaap:NonUsMember jnj:OtherMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:CardiovascularMetabolismOtherMember jnj:OtherMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:CardiovascularMetabolismOtherMember jnj:OtherMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:CardiovascularMetabolismOtherMember jnj:OtherMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:CardiovascularMetabolismOtherMember jnj:OtherMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 country:US jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 country:US jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 country:US jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 country:US jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:InterventionalSolutionsMember jnj:MedTechMember country:US 2023-07-03 2023-10-01 0000200406 jnj:InterventionalSolutionsMember jnj:MedTechMember country:US 2022-07-04 2022-10-02 0000200406 jnj:InterventionalSolutionsMember jnj:MedTechMember country:US 2023-01-02 2023-10-01 0000200406 jnj:InterventionalSolutionsMember jnj:MedTechMember country:US 2022-01-03 2022-10-02 0000200406 jnj:InterventionalSolutionsMember jnj:MedTechMember us-gaap:NonUsMember 2023-07-03 2023-10-01 0000200406 jnj:InterventionalSolutionsMember jnj:MedTechMember us-gaap:NonUsMember 2022-07-04 2022-10-02 0000200406 jnj:InterventionalSolutionsMember jnj:MedTechMember us-gaap:NonUsMember 2023-01-02 2023-10-01 0000200406 jnj:InterventionalSolutionsMember jnj:MedTechMember us-gaap:NonUsMember 2022-01-03 2022-10-02 0000200406 jnj:InterventionalSolutionsMember jnj:MedTechMember 2023-07-03 2023-10-01 0000200406 jnj:InterventionalSolutionsMember jnj:MedTechMember 2022-07-04 2022-10-02 0000200406 jnj:InterventionalSolutionsMember jnj:MedTechMember 2023-01-02 2023-10-01 0000200406 jnj:InterventionalSolutionsMember jnj:MedTechMember 2022-01-03 2022-10-02 0000200406 jnj:MedTechMember jnj:ElectrophysiologyMember country:US 2023-07-03 2023-10-01 0000200406 jnj:MedTechMember jnj:ElectrophysiologyMember country:US 2022-07-04 2022-10-02 0000200406 jnj:MedTechMember jnj:ElectrophysiologyMember country:US 2023-01-02 2023-10-01 0000200406 jnj:MedTechMember jnj:ElectrophysiologyMember country:US 2022-01-03 2022-10-02 0000200406 jnj:MedTechMember jnj:ElectrophysiologyMember us-gaap:NonUsMember 2023-07-03 2023-10-01 0000200406 jnj:MedTechMember jnj:ElectrophysiologyMember us-gaap:NonUsMember 2022-07-04 2022-10-02 0000200406 jnj:MedTechMember jnj:ElectrophysiologyMember us-gaap:NonUsMember 2023-01-02 2023-10-01 0000200406 jnj:MedTechMember jnj:ElectrophysiologyMember us-gaap:NonUsMember 2022-01-03 2022-10-02 0000200406 jnj:MedTechMember jnj:ElectrophysiologyMember 2023-07-03 2023-10-01 0000200406 jnj:MedTechMember jnj:ElectrophysiologyMember 2022-07-04 2022-10-02 0000200406 jnj:MedTechMember jnj:ElectrophysiologyMember 2023-01-02 2023-10-01 0000200406 jnj:MedTechMember jnj:ElectrophysiologyMember 2022-01-03 2022-10-02 0000200406 jnj:AbiomedMember jnj:MedTechMember country:US 2023-07-03 2023-10-01 0000200406 jnj:AbiomedMember jnj:MedTechMember country:US 2022-07-04 2022-10-02 0000200406 jnj:AbiomedMember jnj:MedTechMember country:US 2023-01-02 2023-10-01 0000200406 jnj:AbiomedMember jnj:MedTechMember country:US 2022-01-03 2022-10-02 0000200406 jnj:AbiomedMember jnj:MedTechMember us-gaap:NonUsMember 2023-07-03 2023-10-01 0000200406 jnj:AbiomedMember jnj:MedTechMember us-gaap:NonUsMember 2022-07-04 2022-10-02 0000200406 jnj:AbiomedMember jnj:MedTechMember us-gaap:NonUsMember 2023-01-02 2023-10-01 0000200406 jnj:AbiomedMember jnj:MedTechMember us-gaap:NonUsMember 2022-01-03 2022-10-02 0000200406 jnj:AbiomedMember jnj:MedTechMember 2023-07-03 2023-10-01 0000200406 jnj:AbiomedMember jnj:MedTechMember 2022-07-04 2022-10-02 0000200406 jnj:AbiomedMember jnj:MedTechMember 2023-01-02 2023-10-01 0000200406 jnj:AbiomedMember jnj:MedTechMember 2022-01-03 2022-10-02 0000200406 jnj:OtherInterventionalSolutionsMember jnj:MedTechMember country:US 2023-07-03 2023-10-01 0000200406 jnj:OtherInterventionalSolutionsMember jnj:MedTechMember country:US 2022-07-04 2022-10-02 0000200406 jnj:OtherInterventionalSolutionsMember jnj:MedTechMember country:US 2023-01-02 2023-10-01 0000200406 jnj:OtherInterventionalSolutionsMember jnj:MedTechMember country:US 2022-01-03 2022-10-02 0000200406 jnj:OtherInterventionalSolutionsMember jnj:MedTechMember us-gaap:NonUsMember 2023-07-03 2023-10-01 0000200406 jnj:OtherInterventionalSolutionsMember jnj:MedTechMember us-gaap:NonUsMember 2022-07-04 2022-10-02 0000200406 jnj:OtherInterventionalSolutionsMember jnj:MedTechMember us-gaap:NonUsMember 2023-01-02 2023-10-01 0000200406 jnj:OtherInterventionalSolutionsMember jnj:MedTechMember us-gaap:NonUsMember 2022-01-03 2022-10-02 0000200406 jnj:OtherInterventionalSolutionsMember jnj:MedTechMember 2023-07-03 2023-10-01 0000200406 jnj:OtherInterventionalSolutionsMember jnj:MedTechMember 2022-07-04 2022-10-02 0000200406 jnj:OtherInterventionalSolutionsMember jnj:MedTechMember 2023-01-02 2023-10-01 0000200406 jnj:OtherInterventionalSolutionsMember jnj:MedTechMember 2022-01-03 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:MedTechMember country:US 2023-07-03 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:MedTechMember country:US 2022-07-04 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:MedTechMember country:US 2023-01-02 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:MedTechMember country:US 2022-01-03 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:MedTechMember us-gaap:NonUsMember 2023-07-03 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:MedTechMember us-gaap:NonUsMember 2022-07-04 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:MedTechMember us-gaap:NonUsMember 2023-01-02 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:MedTechMember us-gaap:NonUsMember 2022-01-03 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:MedTechMember 2023-07-03 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:MedTechMember 2022-07-04 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:MedTechMember 2023-01-02 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:MedTechMember 2022-01-03 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:HIPSMember jnj:MedTechMember country:US 2023-07-03 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:HIPSMember jnj:MedTechMember country:US 2022-07-04 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:HIPSMember jnj:MedTechMember country:US 2023-01-02 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:HIPSMember jnj:MedTechMember country:US 2022-01-03 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:HIPSMember jnj:MedTechMember us-gaap:NonUsMember 2023-07-03 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:HIPSMember jnj:MedTechMember us-gaap:NonUsMember 2022-07-04 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:HIPSMember jnj:MedTechMember us-gaap:NonUsMember 2023-01-02 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:HIPSMember jnj:MedTechMember us-gaap:NonUsMember 2022-01-03 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:HIPSMember jnj:MedTechMember 2023-07-03 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:HIPSMember jnj:MedTechMember 2022-07-04 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:HIPSMember jnj:MedTechMember 2023-01-02 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:HIPSMember jnj:MedTechMember 2022-01-03 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:MedTechMember country:US jnj:KNEESMember 2023-07-03 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:MedTechMember country:US jnj:KNEESMember 2022-07-04 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:MedTechMember country:US jnj:KNEESMember 2023-01-02 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:MedTechMember country:US jnj:KNEESMember 2022-01-03 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:MedTechMember us-gaap:NonUsMember jnj:KNEESMember 2023-07-03 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:MedTechMember us-gaap:NonUsMember jnj:KNEESMember 2022-07-04 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:MedTechMember us-gaap:NonUsMember jnj:KNEESMember 2023-01-02 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:MedTechMember us-gaap:NonUsMember jnj:KNEESMember 2022-01-03 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:MedTechMember jnj:KNEESMember 2023-07-03 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:MedTechMember jnj:KNEESMember 2022-07-04 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:MedTechMember jnj:KNEESMember 2023-01-02 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:MedTechMember jnj:KNEESMember 2022-01-03 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:TRAUMAMember jnj:MedTechMember country:US 2023-07-03 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:TRAUMAMember jnj:MedTechMember country:US 2022-07-04 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:TRAUMAMember jnj:MedTechMember country:US 2023-01-02 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:TRAUMAMember jnj:MedTechMember country:US 2022-01-03 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:TRAUMAMember jnj:MedTechMember us-gaap:NonUsMember 2023-07-03 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:TRAUMAMember jnj:MedTechMember us-gaap:NonUsMember 2022-07-04 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:TRAUMAMember jnj:MedTechMember us-gaap:NonUsMember 2023-01-02 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:TRAUMAMember jnj:MedTechMember us-gaap:NonUsMember 2022-01-03 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:TRAUMAMember jnj:MedTechMember 2023-07-03 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:TRAUMAMember jnj:MedTechMember 2022-07-04 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:TRAUMAMember jnj:MedTechMember 2023-01-02 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:TRAUMAMember jnj:MedTechMember 2022-01-03 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:SPINEOTHERMember jnj:MedTechMember country:US 2023-07-03 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:SPINEOTHERMember jnj:MedTechMember country:US 2022-07-04 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:SPINEOTHERMember jnj:MedTechMember country:US 2023-01-02 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:SPINEOTHERMember jnj:MedTechMember country:US 2022-01-03 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:SPINEOTHERMember jnj:MedTechMember us-gaap:NonUsMember 2023-07-03 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:SPINEOTHERMember jnj:MedTechMember us-gaap:NonUsMember 2022-07-04 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:SPINEOTHERMember jnj:MedTechMember us-gaap:NonUsMember 2023-01-02 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:SPINEOTHERMember jnj:MedTechMember us-gaap:NonUsMember 2022-01-03 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:SPINEOTHERMember jnj:MedTechMember 2023-07-03 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:SPINEOTHERMember jnj:MedTechMember 2022-07-04 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:SPINEOTHERMember jnj:MedTechMember 2023-01-02 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:SPINEOTHERMember jnj:MedTechMember 2022-01-03 2022-10-02 0000200406 jnj:SurgeryMember jnj:MedTechMember country:US 2023-07-03 2023-10-01 0000200406 jnj:SurgeryMember jnj:MedTechMember country:US 2022-07-04 2022-10-02 0000200406 jnj:SurgeryMember jnj:MedTechMember country:US 2023-01-02 2023-10-01 0000200406 jnj:SurgeryMember jnj:MedTechMember country:US 2022-01-03 2022-10-02 0000200406 jnj:SurgeryMember jnj:MedTechMember us-gaap:NonUsMember 2023-07-03 2023-10-01 0000200406 jnj:SurgeryMember jnj:MedTechMember us-gaap:NonUsMember 2022-07-04 2022-10-02 0000200406 jnj:SurgeryMember jnj:MedTechMember us-gaap:NonUsMember 2023-01-02 2023-10-01 0000200406 jnj:SurgeryMember jnj:MedTechMember us-gaap:NonUsMember 2022-01-03 2022-10-02 0000200406 jnj:SurgeryMember jnj:MedTechMember 2023-07-03 2023-10-01 0000200406 jnj:SurgeryMember jnj:MedTechMember 2022-07-04 2022-10-02 0000200406 jnj:SurgeryMember jnj:MedTechMember 2023-01-02 2023-10-01 0000200406 jnj:SurgeryMember jnj:MedTechMember 2022-01-03 2022-10-02 0000200406 jnj:ADVANCEDMember jnj:SurgeryMember jnj:MedTechMember country:US 2023-07-03 2023-10-01 0000200406 jnj:ADVANCEDMember jnj:SurgeryMember jnj:MedTechMember country:US 2022-07-04 2022-10-02 0000200406 jnj:ADVANCEDMember jnj:SurgeryMember jnj:MedTechMember country:US 2023-01-02 2023-10-01 0000200406 jnj:ADVANCEDMember jnj:SurgeryMember jnj:MedTechMember country:US 2022-01-03 2022-10-02 0000200406 jnj:ADVANCEDMember jnj:SurgeryMember jnj:MedTechMember us-gaap:NonUsMember 2023-07-03 2023-10-01 0000200406 jnj:ADVANCEDMember jnj:SurgeryMember jnj:MedTechMember us-gaap:NonUsMember 2022-07-04 2022-10-02 0000200406 jnj:ADVANCEDMember jnj:SurgeryMember jnj:MedTechMember us-gaap:NonUsMember 2023-01-02 2023-10-01 0000200406 jnj:ADVANCEDMember jnj:SurgeryMember jnj:MedTechMember us-gaap:NonUsMember 2022-01-03 2022-10-02 0000200406 jnj:ADVANCEDMember jnj:SurgeryMember jnj:MedTechMember 2023-07-03 2023-10-01 0000200406 jnj:ADVANCEDMember jnj:SurgeryMember jnj:MedTechMember 2022-07-04 2022-10-02 0000200406 jnj:ADVANCEDMember jnj:SurgeryMember jnj:MedTechMember 2023-01-02 2023-10-01 0000200406 jnj:ADVANCEDMember jnj:SurgeryMember jnj:MedTechMember 2022-01-03 2022-10-02 0000200406 jnj:SurgeryMember jnj:MedTechMember jnj:GENERALMember country:US 2023-07-03 2023-10-01 0000200406 jnj:SurgeryMember jnj:MedTechMember jnj:GENERALMember country:US 2022-07-04 2022-10-02 0000200406 jnj:SurgeryMember jnj:MedTechMember jnj:GENERALMember country:US 2023-01-02 2023-10-01 0000200406 jnj:SurgeryMember jnj:MedTechMember jnj:GENERALMember country:US 2022-01-03 2022-10-02 0000200406 jnj:SurgeryMember jnj:MedTechMember jnj:GENERALMember us-gaap:NonUsMember 2023-07-03 2023-10-01 0000200406 jnj:SurgeryMember jnj:MedTechMember jnj:GENERALMember us-gaap:NonUsMember 2022-07-04 2022-10-02 0000200406 jnj:SurgeryMember jnj:MedTechMember jnj:GENERALMember us-gaap:NonUsMember 2023-01-02 2023-10-01 0000200406 jnj:SurgeryMember jnj:MedTechMember jnj:GENERALMember us-gaap:NonUsMember 2022-01-03 2022-10-02 0000200406 jnj:SurgeryMember jnj:MedTechMember jnj:GENERALMember 2023-07-03 2023-10-01 0000200406 jnj:SurgeryMember jnj:MedTechMember jnj:GENERALMember 2022-07-04 2022-10-02 0000200406 jnj:SurgeryMember jnj:MedTechMember jnj:GENERALMember 2023-01-02 2023-10-01 0000200406 jnj:SurgeryMember jnj:MedTechMember jnj:GENERALMember 2022-01-03 2022-10-02 0000200406 jnj:MedTechMember country:US jnj:VisionMember 2023-07-03 2023-10-01 0000200406 jnj:MedTechMember country:US jnj:VisionMember 2022-07-04 2022-10-02 0000200406 jnj:MedTechMember country:US jnj:VisionMember 2023-01-02 2023-10-01 0000200406 jnj:MedTechMember country:US jnj:VisionMember 2022-01-03 2022-10-02 0000200406 jnj:MedTechMember us-gaap:NonUsMember jnj:VisionMember 2023-07-03 2023-10-01 0000200406 jnj:MedTechMember us-gaap:NonUsMember jnj:VisionMember 2022-07-04 2022-10-02 0000200406 jnj:MedTechMember us-gaap:NonUsMember jnj:VisionMember 2023-01-02 2023-10-01 0000200406 jnj:MedTechMember us-gaap:NonUsMember jnj:VisionMember 2022-01-03 2022-10-02 0000200406 jnj:MedTechMember jnj:VisionMember 2023-07-03 2023-10-01 0000200406 jnj:MedTechMember jnj:VisionMember 2022-07-04 2022-10-02 0000200406 jnj:MedTechMember jnj:VisionMember 2023-01-02 2023-10-01 0000200406 jnj:MedTechMember jnj:VisionMember 2022-01-03 2022-10-02 0000200406 jnj:CONTACTLENSESOTHERMember jnj:MedTechMember country:US jnj:VisionMember 2023-07-03 2023-10-01 0000200406 jnj:CONTACTLENSESOTHERMember jnj:MedTechMember country:US jnj:VisionMember 2022-07-04 2022-10-02 0000200406 jnj:CONTACTLENSESOTHERMember jnj:MedTechMember country:US jnj:VisionMember 2023-01-02 2023-10-01 0000200406 jnj:CONTACTLENSESOTHERMember jnj:MedTechMember country:US jnj:VisionMember 2022-01-03 2022-10-02 0000200406 jnj:CONTACTLENSESOTHERMember jnj:MedTechMember us-gaap:NonUsMember jnj:VisionMember 2023-07-03 2023-10-01 0000200406 jnj:CONTACTLENSESOTHERMember jnj:MedTechMember us-gaap:NonUsMember jnj:VisionMember 2022-07-04 2022-10-02 0000200406 jnj:CONTACTLENSESOTHERMember jnj:MedTechMember us-gaap:NonUsMember jnj:VisionMember 2023-01-02 2023-10-01 0000200406 jnj:CONTACTLENSESOTHERMember jnj:MedTechMember us-gaap:NonUsMember jnj:VisionMember 2022-01-03 2022-10-02 0000200406 jnj:CONTACTLENSESOTHERMember jnj:MedTechMember jnj:VisionMember 2023-07-03 2023-10-01 0000200406 jnj:CONTACTLENSESOTHERMember jnj:MedTechMember jnj:VisionMember 2022-07-04 2022-10-02 0000200406 jnj:CONTACTLENSESOTHERMember jnj:MedTechMember jnj:VisionMember 2023-01-02 2023-10-01 0000200406 jnj:CONTACTLENSESOTHERMember jnj:MedTechMember jnj:VisionMember 2022-01-03 2022-10-02 0000200406 jnj:SURGICALMember jnj:MedTechMember country:US jnj:VisionMember 2023-07-03 2023-10-01 0000200406 jnj:SURGICALMember jnj:MedTechMember country:US jnj:VisionMember 2022-07-04 2022-10-02 0000200406 jnj:SURGICALMember jnj:MedTechMember country:US jnj:VisionMember 2023-01-02 2023-10-01 0000200406 jnj:SURGICALMember jnj:MedTechMember country:US jnj:VisionMember 2022-01-03 2022-10-02 0000200406 jnj:SURGICALMember jnj:MedTechMember us-gaap:NonUsMember jnj:VisionMember 2023-07-03 2023-10-01 0000200406 jnj:SURGICALMember jnj:MedTechMember us-gaap:NonUsMember jnj:VisionMember 2022-07-04 2022-10-02 0000200406 jnj:SURGICALMember jnj:MedTechMember us-gaap:NonUsMember jnj:VisionMember 2023-01-02 2023-10-01 0000200406 jnj:SURGICALMember jnj:MedTechMember us-gaap:NonUsMember jnj:VisionMember 2022-01-03 2022-10-02 0000200406 jnj:SURGICALMember jnj:MedTechMember jnj:VisionMember 2023-07-03 2023-10-01 0000200406 jnj:SURGICALMember jnj:MedTechMember jnj:VisionMember 2022-07-04 2022-10-02 0000200406 jnj:SURGICALMember jnj:MedTechMember jnj:VisionMember 2023-01-02 2023-10-01 0000200406 jnj:SURGICALMember jnj:MedTechMember jnj:VisionMember 2022-01-03 2022-10-02 0000200406 jnj:MedTechMember country:US 2023-07-03 2023-10-01 0000200406 jnj:MedTechMember country:US 2022-07-04 2022-10-02 0000200406 jnj:MedTechMember country:US 2023-01-02 2023-10-01 0000200406 jnj:MedTechMember country:US 2022-01-03 2022-10-02 0000200406 jnj:MedTechMember us-gaap:NonUsMember 2023-07-03 2023-10-01 0000200406 jnj:MedTechMember us-gaap:NonUsMember 2022-07-04 2022-10-02 0000200406 jnj:MedTechMember us-gaap:NonUsMember 2023-01-02 2023-10-01 0000200406 jnj:MedTechMember us-gaap:NonUsMember 2022-01-03 2022-10-02 0000200406 jnj:MedTechMember 2023-07-03 2023-10-01 0000200406 jnj:MedTechMember 2022-07-04 2022-10-02 0000200406 jnj:MedTechMember 2022-01-03 2022-10-02 0000200406 country:US 2023-07-03 2023-10-01 0000200406 country:US 2022-07-04 2022-10-02 0000200406 country:US 2023-01-02 2023-10-01 0000200406 country:US 2022-01-03 2022-10-02 0000200406 us-gaap:NonUsMember 2023-07-03 2023-10-01 0000200406 us-gaap:NonUsMember 2022-07-04 2022-10-02 0000200406 us-gaap:NonUsMember 2023-01-02 2023-10-01 0000200406 us-gaap:NonUsMember 2022-01-03 2022-10-02 0000200406 us-gaap:OperatingSegmentsMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 us-gaap:OperatingSegmentsMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 us-gaap:OperatingSegmentsMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 us-gaap:OperatingSegmentsMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 us-gaap:OperatingSegmentsMember jnj:MedTechMember 2023-07-03 2023-10-01 0000200406 us-gaap:OperatingSegmentsMember jnj:MedTechMember 2022-07-04 2022-10-02 0000200406 us-gaap:OperatingSegmentsMember jnj:MedTechMember 2023-01-02 2023-10-01 0000200406 us-gaap:OperatingSegmentsMember jnj:MedTechMember 2022-01-03 2022-10-02 0000200406 us-gaap:OperatingSegmentsMember 2023-07-03 2023-10-01 0000200406 us-gaap:OperatingSegmentsMember 2022-07-04 2022-10-02 0000200406 us-gaap:OperatingSegmentsMember 2023-01-02 2023-10-01 0000200406 us-gaap:OperatingSegmentsMember 2022-01-03 2022-10-02 0000200406 us-gaap:CorporateNonSegmentMember 2023-07-03 2023-10-01 0000200406 us-gaap:CorporateNonSegmentMember 2022-07-04 2022-10-02 0000200406 us-gaap:CorporateNonSegmentMember 2023-01-02 2023-10-01 0000200406 us-gaap:CorporateNonSegmentMember 2022-01-03 2022-10-02 0000200406 jnj:BermekimabMember 2023-01-02 2023-10-01 0000200406 jnj:BermekimabMember 2022-01-03 2022-10-02 0000200406 jnj:TalcMember jnj:ConsumerMember jnj:BabyPowderMember 2023-01-02 2023-10-01 0000200406 srt:EuropeMember 2023-07-03 2023-10-01 0000200406 srt:EuropeMember 2022-07-04 2022-10-02 0000200406 srt:EuropeMember 2023-01-02 2023-10-01 0000200406 srt:EuropeMember 2022-01-03 2022-10-02 0000200406 jnj:WesternHemisphereExcludingUSMember 2023-07-03 2023-10-01 0000200406 jnj:WesternHemisphereExcludingUSMember 2022-07-04 2022-10-02 0000200406 jnj:WesternHemisphereExcludingUSMember 2023-01-02 2023-10-01 0000200406 jnj:WesternHemisphereExcludingUSMember 2022-01-03 2022-10-02 0000200406 jnj:AsiaPacificAfricaMember 2023-07-03 2023-10-01 0000200406 jnj:AsiaPacificAfricaMember 2022-07-04 2022-10-02 0000200406 jnj:AsiaPacificAfricaMember 2023-01-02 2023-10-01 0000200406 jnj:AsiaPacificAfricaMember 2022-01-03 2022-10-02 0000200406 jnj:AbiomedMember 2022-12-22 0000200406 jnj:AbiomedMember 2022-12-22 2022-12-22 0000200406 jnj:AbiomedMember jnj:NonTradeableContingentValueRightMember 2022-12-22 2022-12-22 0000200406 jnj:AbiomedMember jnj:NonTradeableContingentValueRightMember 2022-12-22 0000200406 jnj:NonTradeableContingentValueRightMember 2022-12-22 0000200406 jnj:AbiomedMember jnj:ImpellaMember jnj:NonTradeableContingentValueRightMember 2022-12-22 0000200406 jnj:NonTradeableContingentValueRightMember jnj:ClassIRecommendationForImpellaMember 2022-12-22 0000200406 2023-04-03 2023-07-02 0000200406 2022-12-22 0000200406 jnj:AbiomedMember srt:MinimumMember 2022-12-22 0000200406 srt:MaximumMember jnj:AbiomedMember 2022-12-22 0000200406 jnj:InghamVsJohnsonJohnsonMember 2018-07-01 2018-07-31 0000200406 jnj:InghamVsJohnsonJohnsonMember 2020-06-01 2020-06-30 0000200406 jnj:InghamVsJohnsonJohnsonMember 2021-06-01 2021-06-30 0000200406 jnj:TalcMember jnj:BabyPowderMember 2021-10-01 2021-10-31 0000200406 jnj:TalcMember jnj:BabyPowderMember 2023-04-24 0000200406 jnj:TalcMember jnj:BabyPowderMember 2021-10-31 0000200406 2023-04-24 0000200406 jnj:OpioidMember 2023-10-01 jnj:claimant 0000200406 jnj:OpioidMember 2021-07-04 0000200406 jnj:OpioidMember 2023-01-02 2023-10-01 jnj:claim 0000200406 jnj:TalcMember 2023-10-01 0000200406 jnj:AsrMember 2023-10-01 0000200406 jnj:PinnacleAcetabularCupSystemMember 2023-10-01 0000200406 jnj:PelvicMeshesMember 2023-10-01 0000200406 jnj:PhysiomeshMember 2023-10-01 0000200406 jnj:RisperdalMember 2023-10-01 0000200406 jnj:ElmironMember 2023-10-01 0000200406 us-gaap:SettledLitigationMember jnj:DePuyASRU.S.Member 2023-01-02 2023-10-01 0000200406 jnj:PhysiomeshMember us-gaap:PendingLitigationMember 2021-05-31 jnj:cases 0000200406 jnj:PhysiomeshMember us-gaap:PendingLitigationMember 2021-09-30 0000200406 jnj:PhysiomeshMember us-gaap:PendingLitigationMember 2021-09-01 2021-09-30 0000200406 jnj:EthiconMember us-gaap:PendingLitigationMember 2021-09-30 0000200406 jnj:PhysiomeshMember us-gaap:PendingLitigationMember 2023-05-31 0000200406 us-gaap:JudicialRulingMember 2019-10-01 2019-10-31 0000200406 us-gaap:JudicialRulingMember 2020-01-01 2020-01-31 0000200406 jnj:KenvueIncMember 2023-08-23 2023-08-23 0000200406 jnj:KenvueIncMember 2023-08-23 2023-08-23 0000200406 2023-08-23 0000200406 jnj:KenvueIncMember jnj:JohnsonJohnsonMember 2023-08-23 0000200406 jnj:ConsumerHealthMember 2023-08-23 0000200406 jnj:ConsumerHealthMember 2023-08-23 2023-08-23 0000200406 jnj:KenvueIncMember jnj:ConsumerHealthMember jnj:JohnsonJohnsonMember 2023-08-23 0000200406 2023-08-23 2023-08-23 0000200406 srt:MinimumMember 2023-08-23 2023-08-23 0000200406 srt:MaximumMember 2023-08-23 2023-08-23 0000200406 jnj:RDRestructuringPlanMember 2023-07-03 2023-10-01 0000200406 jnj:RDRestructuringPlanMember 2023-01-02 2023-10-01 0000200406 jnj:RDRestructuringPlanMember srt:MinimumMember 2023-10-01 0000200406 srt:MaximumMember jnj:RDRestructuringPlanMember 2023-10-01 0000200406 jnj:OrthopaedicsRestructuringPlanMember 2023-07-03 2023-10-01 0000200406 jnj:OrthopaedicsRestructuringPlanMember srt:MinimumMember 2023-10-01 0000200406 srt:MaximumMember jnj:OrthopaedicsRestructuringPlanMember 2023-10-01 0000200406 jnj:MedTechMember us-gaap:RestructuringChargesMember 2023-01-02 2023-10-01 0000200406 jnj:MedTechMember us-gaap:RestructuringChargesMember 2023-07-03 2023-10-01 0000200406 jnj:CostsOfGoodsAndServicesSoldMember jnj:MedTechMember 2023-07-03 2023-10-01 0000200406 jnj:CostsOfGoodsAndServicesSoldMember jnj:MedTechMember 2023-01-02 2023-10-01 0000200406 jnj:PeterFasoloMember 2023-01-02 2023-10-01 0000200406 jnj:PeterFasoloMember 2023-07-03 2023-10-01 0000200406 jnj:PeterFasoloMember 2023-10-01", "text": "0000200406 12/31 2023 Q3 FALSE http://fasb.org/us-gaap/2023#AccountingStandardsUpdate202204Member 456 0000200406 2023-01-02 2023-10-01 0000200406 us-gaap:CommonStockMember 2023-01-02 2023-10-01 0000200406 jnj:A0.650NotesDue2024Member 2023-01-02 2023-10-01 0000200406 jnj:A5.50NotesDue2024Member 2023-01-02 2023-10-01 0000200406 jnj:A1.150NotesDue2028Member 2023-01-02 2023-10-01 0000200406 jnj:A1.650NotesDue2035Member 2023-01-02 2023-10-01 0000200406 2023-10-23 xbrli:shares 0000200406 2023-10-01 iso4217:USD 0000200406 2023-01-01 iso4217:USD xbrli:shares 0000200406 2023-07-03 2023-10-01 xbrli:pure 0000200406 2022-07-04 2022-10-02 0000200406 2022-01-03 2022-10-02 0000200406 2023-07-02 0000200406 us-gaap:RetainedEarningsMember 2023-07-02 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-02 0000200406 us-gaap:CommonStockMember 2023-07-02 0000200406 us-gaap:TreasuryStockCommonMember 2023-07-02 0000200406 us-gaap:NoncontrollingInterestMember 2023-07-02 0000200406 us-gaap:RetainedEarningsMember 2023-07-03 2023-10-01 0000200406 us-gaap:TreasuryStockCommonMember 2023-07-03 2023-10-01 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-03 2023-10-01 0000200406 us-gaap:NoncontrollingInterestMember 2023-07-03 2023-10-01 0000200406 us-gaap:RetainedEarningsMember 2023-10-01 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-10-01 0000200406 us-gaap:CommonStockMember 2023-10-01 0000200406 us-gaap:TreasuryStockCommonMember 2023-10-01 0000200406 us-gaap:NoncontrollingInterestMember 2023-10-01 0000200406 us-gaap:RetainedEarningsMember 2023-01-01 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 0000200406 us-gaap:CommonStockMember 2023-01-01 0000200406 us-gaap:TreasuryStockCommonMember 2023-01-01 0000200406 us-gaap:NoncontrollingInterestMember 2023-01-01 0000200406 us-gaap:RetainedEarningsMember 2023-01-02 2023-10-01 0000200406 us-gaap:TreasuryStockCommonMember 2023-01-02 2023-10-01 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-02 2023-10-01 0000200406 2022-07-03 0000200406 us-gaap:RetainedEarningsMember 2022-07-03 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-03 0000200406 us-gaap:CommonStockMember 2022-07-03 0000200406 us-gaap:TreasuryStockCommonMember 2022-07-03 0000200406 us-gaap:RetainedEarningsMember 2022-07-04 2022-10-02 0000200406 us-gaap:TreasuryStockCommonMember 2022-07-04 2022-10-02 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-04 2022-10-02 0000200406 2022-10-02 0000200406 us-gaap:RetainedEarningsMember 2022-10-02 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-10-02 0000200406 us-gaap:CommonStockMember 2022-10-02 0000200406 us-gaap:TreasuryStockCommonMember 2022-10-02 0000200406 2022-01-02 0000200406 us-gaap:RetainedEarningsMember 2022-01-02 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-02 0000200406 us-gaap:CommonStockMember 2022-01-02 0000200406 us-gaap:TreasuryStockCommonMember 2022-01-02 0000200406 us-gaap:RetainedEarningsMember 2022-01-03 2022-10-02 0000200406 us-gaap:TreasuryStockCommonMember 2022-01-03 2022-10-02 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-03 2022-10-02 0000200406 jnj:KenvueIncMember us-gaap:IPOMember 2023-05-08 2023-05-08 0000200406 jnj:KenvueIncMember 2023-05-08 0000200406 2023-05-08 2023-05-08 0000200406 jnj:KenvueIncMember jnj:JohnsonJohnsonMember 2023-05-08 2023-05-08 0000200406 jnj:KenvueIncMember jnj:JohnsonJohnsonMember 2023-07-02 0000200406 jnj:KenvueIncMember 2023-08-23 2023-08-23 0000200406 jnj:KenvueIncMember jnj:JohnsonJohnsonMember 2023-08-23 2023-08-23 jnj:segment 0000200406 jnj:PatentsAndTrademarksMember 2023-10-01 0000200406 jnj:PatentsAndTrademarksMember 2023-01-01 0000200406 us-gaap:OtherIntangibleAssetsMember 2023-10-01 0000200406 us-gaap:OtherIntangibleAssetsMember 2023-01-01 0000200406 us-gaap:TrademarksMember 2023-10-01 0000200406 us-gaap:TrademarksMember 2023-01-01 0000200406 jnj:PurchasedInProcessResearchAndDevelopmentMember 2023-10-01 0000200406 jnj:PurchasedInProcessResearchAndDevelopmentMember 2023-01-01 0000200406 jnj:PharmaceuticalMember 2023-01-01 0000200406 jnj:MedTechMember 2023-01-01 0000200406 jnj:PharmaceuticalMember 2023-01-02 2023-10-01 0000200406 jnj:MedTechMember 2023-01-02 2023-10-01 0000200406 jnj:PharmaceuticalMember 2023-10-01 0000200406 jnj:MedTechMember 2023-10-01 0000200406 us-gaap:ForeignExchangeContractMember 2023-10-01 0000200406 us-gaap:CrossCurrencyInterestRateContractMember 2023-10-01 0000200406 us-gaap:InterestRateSwapMember 2023-10-01 0000200406 us-gaap:ForeignExchangeContractMember 2023-01-01 0000200406 us-gaap:CrossCurrencyInterestRateContractMember 2023-01-01 0000200406 us-gaap:InterestRateSwapMember 2023-01-01 0000200406 us-gaap:SalesMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember 2023-07-03 2023-10-01 0000200406 us-gaap:CostOfSalesMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember 2023-07-03 2023-10-01 0000200406 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-03 2023-10-01 0000200406 jnj:InterestIncomeExpenseNetMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember 2023-07-03 2023-10-01 0000200406 jnj:OtherIncomeExpenseNetMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember 2023-07-03 2023-10-01 0000200406 us-gaap:SalesMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember 2022-07-04 2022-10-02 0000200406 us-gaap:CostOfSalesMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember 2022-07-04 2022-10-02 0000200406 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-04 2022-10-02 0000200406 jnj:InterestIncomeExpenseNetMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember 2022-07-04 2022-10-02 0000200406 jnj:OtherIncomeExpenseNetMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember 2022-07-04 2022-10-02 0000200406 us-gaap:NetInvestmentHedgingMember us-gaap:SalesMember us-gaap:NetInvestmentHedgingMember 2023-07-03 2023-10-01 0000200406 us-gaap:NetInvestmentHedgingMember us-gaap:CostOfSalesMember us-gaap:NetInvestmentHedgingMember 2023-07-03 2023-10-01 0000200406 us-gaap:NetInvestmentHedgingMember us-gaap:NetInvestmentHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-03 2023-10-01 0000200406 us-gaap:NetInvestmentHedgingMember jnj:InterestIncomeExpenseNetMember us-gaap:NetInvestmentHedgingMember 2023-07-03 2023-10-01 0000200406 us-gaap:NetInvestmentHedgingMember jnj:OtherIncomeExpenseNetMember us-gaap:NetInvestmentHedgingMember 2023-07-03 2023-10-01 0000200406 us-gaap:NetInvestmentHedgingMember us-gaap:SalesMember us-gaap:NetInvestmentHedgingMember 2022-07-04 2022-10-02 0000200406 us-gaap:NetInvestmentHedgingMember us-gaap:CostOfSalesMember us-gaap:NetInvestmentHedgingMember 2022-07-04 2022-10-02 0000200406 us-gaap:NetInvestmentHedgingMember us-gaap:NetInvestmentHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-04 2022-10-02 0000200406 us-gaap:NetInvestmentHedgingMember jnj:InterestIncomeExpenseNetMember us-gaap:NetInvestmentHedgingMember 2022-07-04 2022-10-02 0000200406 us-gaap:NetInvestmentHedgingMember jnj:OtherIncomeExpenseNetMember us-gaap:NetInvestmentHedgingMember 2022-07-04 2022-10-02 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:SalesMember us-gaap:CashFlowHedgingMember 2023-07-03 2023-10-01 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CostOfSalesMember us-gaap:CashFlowHedgingMember 2023-07-03 2023-10-01 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-03 2023-10-01 0000200406 us-gaap:ForeignExchangeContractMember jnj:InterestIncomeExpenseNetMember us-gaap:CashFlowHedgingMember 2023-07-03 2023-10-01 0000200406 us-gaap:ForeignExchangeContractMember jnj:OtherIncomeExpenseNetMember us-gaap:CashFlowHedgingMember 2023-07-03 2023-10-01 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:SalesMember us-gaap:CashFlowHedgingMember 2022-07-04 2022-10-02 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CostOfSalesMember us-gaap:CashFlowHedgingMember 2022-07-04 2022-10-02 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-04 2022-10-02 0000200406 us-gaap:ForeignExchangeContractMember jnj:InterestIncomeExpenseNetMember us-gaap:CashFlowHedgingMember 2022-07-04 2022-10-02 0000200406 us-gaap:ForeignExchangeContractMember jnj:OtherIncomeExpenseNetMember us-gaap:CashFlowHedgingMember 2022-07-04 2022-10-02 0000200406 us-gaap:SalesMember us-gaap:CashFlowHedgingMember us-gaap:CrossCurrencyInterestRateContractMember 2023-07-03 2023-10-01 0000200406 us-gaap:CostOfSalesMember us-gaap:CashFlowHedgingMember us-gaap:CrossCurrencyInterestRateContractMember 2023-07-03 2023-10-01 0000200406 us-gaap:CashFlowHedgingMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-03 2023-10-01 0000200406 jnj:InterestIncomeExpenseNetMember us-gaap:CashFlowHedgingMember us-gaap:CrossCurrencyInterestRateContractMember 2023-07-03 2023-10-01 0000200406 jnj:OtherIncomeExpenseNetMember us-gaap:CashFlowHedgingMember us-gaap:CrossCurrencyInterestRateContractMember 2023-07-03 2023-10-01 0000200406 us-gaap:SalesMember us-gaap:CashFlowHedgingMember us-gaap:CrossCurrencyInterestRateContractMember 2022-07-04 2022-10-02 0000200406 us-gaap:CostOfSalesMember us-gaap:CashFlowHedgingMember us-gaap:CrossCurrencyInterestRateContractMember 2022-07-04 2022-10-02 0000200406 us-gaap:CashFlowHedgingMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-04 2022-10-02 0000200406 jnj:InterestIncomeExpenseNetMember us-gaap:CashFlowHedgingMember us-gaap:CrossCurrencyInterestRateContractMember 2022-07-04 2022-10-02 0000200406 jnj:OtherIncomeExpenseNetMember us-gaap:CashFlowHedgingMember us-gaap:CrossCurrencyInterestRateContractMember 2022-07-04 2022-10-02 0000200406 us-gaap:SalesMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember 2023-01-02 2023-10-01 0000200406 us-gaap:CostOfSalesMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember 2023-01-02 2023-10-01 0000200406 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-02 2023-10-01 0000200406 jnj:InterestIncomeExpenseNetMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember 2023-01-02 2023-10-01 0000200406 jnj:OtherIncomeExpenseNetMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember 2023-01-02 2023-10-01 0000200406 us-gaap:SalesMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember 2022-01-03 2022-10-02 0000200406 us-gaap:CostOfSalesMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember 2022-01-03 2022-10-02 0000200406 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-03 2022-10-02 0000200406 jnj:InterestIncomeExpenseNetMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember 2022-01-03 2022-10-02 0000200406 jnj:OtherIncomeExpenseNetMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember 2022-01-03 2022-10-02 0000200406 us-gaap:SalesMember us-gaap:FairValueHedgingMember us-gaap:CrossCurrencyInterestRateContractMember 2023-01-02 2023-10-01 0000200406 us-gaap:CostOfSalesMember us-gaap:FairValueHedgingMember us-gaap:CrossCurrencyInterestRateContractMember 2023-01-02 2023-10-01 0000200406 us-gaap:FairValueHedgingMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-02 2023-10-01 0000200406 jnj:InterestIncomeExpenseNetMember us-gaap:FairValueHedgingMember us-gaap:CrossCurrencyInterestRateContractMember 2023-01-02 2023-10-01 0000200406 jnj:OtherIncomeExpenseNetMember us-gaap:FairValueHedgingMember us-gaap:CrossCurrencyInterestRateContractMember 2023-01-02 2023-10-01 0000200406 us-gaap:SalesMember us-gaap:FairValueHedgingMember us-gaap:CrossCurrencyInterestRateContractMember 2022-01-03 2022-10-02 0000200406 us-gaap:CostOfSalesMember us-gaap:FairValueHedgingMember us-gaap:CrossCurrencyInterestRateContractMember 2022-01-03 2022-10-02 0000200406 us-gaap:FairValueHedgingMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-03 2022-10-02 0000200406 jnj:InterestIncomeExpenseNetMember us-gaap:FairValueHedgingMember us-gaap:CrossCurrencyInterestRateContractMember 2022-01-03 2022-10-02 0000200406 jnj:OtherIncomeExpenseNetMember us-gaap:FairValueHedgingMember us-gaap:CrossCurrencyInterestRateContractMember 2022-01-03 2022-10-02 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:SalesMember us-gaap:CashFlowHedgingMember 2023-01-02 2023-10-01 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CostOfSalesMember us-gaap:CashFlowHedgingMember 2023-01-02 2023-10-01 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-02 2023-10-01 0000200406 us-gaap:ForeignExchangeContractMember jnj:InterestIncomeExpenseNetMember us-gaap:CashFlowHedgingMember 2023-01-02 2023-10-01 0000200406 us-gaap:ForeignExchangeContractMember jnj:OtherIncomeExpenseNetMember us-gaap:CashFlowHedgingMember 2023-01-02 2023-10-01 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:SalesMember us-gaap:CashFlowHedgingMember 2022-01-03 2022-10-02 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CostOfSalesMember us-gaap:CashFlowHedgingMember 2022-01-03 2022-10-02 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-03 2022-10-02 0000200406 us-gaap:ForeignExchangeContractMember jnj:InterestIncomeExpenseNetMember us-gaap:CashFlowHedgingMember 2022-01-03 2022-10-02 0000200406 us-gaap:ForeignExchangeContractMember jnj:OtherIncomeExpenseNetMember us-gaap:CashFlowHedgingMember 2022-01-03 2022-10-02 0000200406 us-gaap:SalesMember us-gaap:CashFlowHedgingMember us-gaap:CrossCurrencyInterestRateContractMember 2023-01-02 2023-10-01 0000200406 us-gaap:CostOfSalesMember us-gaap:CashFlowHedgingMember us-gaap:CrossCurrencyInterestRateContractMember 2023-01-02 2023-10-01 0000200406 us-gaap:CashFlowHedgingMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-02 2023-10-01 0000200406 jnj:InterestIncomeExpenseNetMember us-gaap:CashFlowHedgingMember us-gaap:CrossCurrencyInterestRateContractMember 2023-01-02 2023-10-01 0000200406 jnj:OtherIncomeExpenseNetMember us-gaap:CashFlowHedgingMember us-gaap:CrossCurrencyInterestRateContractMember 2023-01-02 2023-10-01 0000200406 us-gaap:SalesMember us-gaap:CashFlowHedgingMember us-gaap:CrossCurrencyInterestRateContractMember 2022-01-03 2022-10-02 0000200406 us-gaap:CostOfSalesMember us-gaap:CashFlowHedgingMember us-gaap:CrossCurrencyInterestRateContractMember 2022-01-03 2022-10-02 0000200406 us-gaap:CashFlowHedgingMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-03 2022-10-02 0000200406 jnj:InterestIncomeExpenseNetMember us-gaap:CashFlowHedgingMember us-gaap:CrossCurrencyInterestRateContractMember 2022-01-03 2022-10-02 0000200406 jnj:OtherIncomeExpenseNetMember us-gaap:CashFlowHedgingMember us-gaap:CrossCurrencyInterestRateContractMember 2022-01-03 2022-10-02 0000200406 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongTermDebtMember 2023-10-01 0000200406 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongTermDebtMember 2023-01-01 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2023-07-03 2023-10-01 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2022-07-04 2022-10-02 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2023-01-02 2023-10-01 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2022-01-03 2022-10-02 0000200406 jnj:OtherIncomeExpenseNetMember 2023-07-03 2023-10-01 0000200406 jnj:OtherIncomeExpenseNetMember 2022-07-04 2022-10-02 0000200406 us-gaap:CrossCurrencyInterestRateContractMember 2023-07-03 2023-10-01 0000200406 us-gaap:CrossCurrencyInterestRateContractMember 2022-07-04 2022-10-02 0000200406 jnj:OtherIncomeExpenseNetMember us-gaap:CrossCurrencyInterestRateContractMember 2023-07-03 2023-10-01 0000200406 jnj:OtherIncomeExpenseNetMember us-gaap:CrossCurrencyInterestRateContractMember 2022-07-04 2022-10-02 0000200406 jnj:OtherIncomeExpenseNetMember 2023-01-02 2023-10-01 0000200406 jnj:OtherIncomeExpenseNetMember 2022-01-03 2022-10-02 0000200406 us-gaap:CrossCurrencyInterestRateContractMember 2023-01-02 2023-10-01 0000200406 us-gaap:CrossCurrencyInterestRateContractMember 2022-01-03 2022-10-02 0000200406 jnj:OtherIncomeExpenseNetMember us-gaap:CrossCurrencyInterestRateContractMember 2023-01-02 2023-10-01 0000200406 jnj:OtherIncomeExpenseNetMember us-gaap:CrossCurrencyInterestRateContractMember 2022-01-03 2022-10-02 0000200406 jnj:EquityInvestmentswithReadilyDeterminableValueMember us-gaap:EquitySecuritiesMember 2023-01-01 0000200406 jnj:EquityInvestmentswithReadilyDeterminableValueMember us-gaap:EquitySecuritiesMember 2023-01-02 2023-10-01 0000200406 jnj:EquityInvestmentswithReadilyDeterminableValueMember us-gaap:EquitySecuritiesMember 2023-10-01 0000200406 jnj:EquityInvestmentswithoutReadilyDeterminableValueMember us-gaap:EquitySecuritiesMember 2023-01-01 0000200406 jnj:EquityInvestmentswithoutReadilyDeterminableValueMember us-gaap:EquitySecuritiesMember 2023-01-02 2023-10-01 0000200406 jnj:EquityInvestmentswithoutReadilyDeterminableValueMember us-gaap:EquitySecuritiesMember 2023-10-01 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member 2023-10-01 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member 2023-10-01 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member 2023-10-01 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member 2023-01-01 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel1Member 2023-10-01 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member 2023-10-01 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel3Member 2023-10-01 0000200406 us-gaap:InterestRateContractMember 2023-10-01 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member 2023-01-01 0000200406 us-gaap:FairValueInputsLevel1Member 2023-10-01 0000200406 us-gaap:FairValueInputsLevel2Member 2023-10-01 0000200406 us-gaap:FairValueInputsLevel3Member 2023-10-01 0000200406 us-gaap:FairValueInputsLevel2Member 2023-01-01 0000200406 us-gaap:FairValueInputsLevel1Member 2023-01-01 0000200406 us-gaap:FairValueInputsLevel3Member 2023-01-01 0000200406 jnj:AurisHealthMember us-gaap:OtherNoncurrentLiabilitiesMember 2023-10-01 0000200406 jnj:AurisHealthMember us-gaap:OtherNoncurrentLiabilitiesMember 2023-01-01 0000200406 us-gaap:HeldtomaturitySecuritiesMember us-gaap:CashMember 2023-10-01 0000200406 us-gaap:SovereignDebtSecuritiesMember us-gaap:HeldtomaturitySecuritiesMember 2023-10-01 0000200406 us-gaap:SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember us-gaap:HeldtomaturitySecuritiesMember 2023-10-01 0000200406 us-gaap:CorporateDebtSecuritiesMember us-gaap:HeldtomaturitySecuritiesMember 2023-10-01 0000200406 us-gaap:HeldtomaturitySecuritiesMember us-gaap:MoneyMarketFundsMember 2023-10-01 0000200406 us-gaap:HeldtomaturitySecuritiesMember us-gaap:BankTimeDepositsMember 2023-10-01 0000200406 us-gaap:HeldtomaturitySecuritiesMember 2023-10-01 0000200406 us-gaap:AvailableforsaleSecuritiesMember us-gaap:USTreasuryAndGovernmentMember 2023-10-01 0000200406 us-gaap:AvailableforsaleSecuritiesMember us-gaap:USTreasuryAndGovernmentMember 2023-10-01 0000200406 us-gaap:AvailableforsaleSecuritiesMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-10-01 0000200406 us-gaap:AvailableforsaleSecuritiesMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-10-01 0000200406 us-gaap:SovereignDebtSecuritiesMember us-gaap:AvailableforsaleSecuritiesMember 2023-10-01 0000200406 us-gaap:SovereignDebtSecuritiesMember us-gaap:AvailableforsaleSecuritiesMember 2023-10-01 0000200406 us-gaap:CorporateDebtSecuritiesMember us-gaap:AvailableforsaleSecuritiesMember 2023-10-01 0000200406 us-gaap:CorporateDebtSecuritiesMember us-gaap:AvailableforsaleSecuritiesMember 2023-10-01 0000200406 us-gaap:AvailableforsaleSecuritiesMember 2023-10-01 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-10-01 0000200406 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-10-01 0000200406 jnj:A5.50NotesDue2024Member 2023-10-01 iso4217:GBP 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:A5.50NotesDue2024Member 2023-10-01 0000200406 jnj:A5.50NotesDue2024Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-10-01 0000200406 jnj:A2.625Notesdue2025Member 2023-10-01 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:A2.625Notesdue2025Member 2023-10-01 0000200406 us-gaap:EstimateOfFairValueFairValueDisclosureMember jnj:A2.625Notesdue2025Member 2023-10-01 0000200406 jnj:A0550NotesDue2025Member 2023-10-01 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:A0550NotesDue2025Member 2023-10-01 0000200406 jnj:A0550NotesDue2025Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-10-01 0000200406 jnj:A2.45Notesdue2026Member 2023-10-01 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:A2.45Notesdue2026Member 2023-10-01 0000200406 jnj:A2.45Notesdue2026Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-10-01 0000200406 jnj:A2.95Notesdue2027Member 2023-10-01 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:A2.95Notesdue2027Member 2023-10-01 0000200406 jnj:A2.95Notesdue2027Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-10-01 0000200406 jnj:A095NotesDue2027Member 2023-10-01 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:A095NotesDue2027Member 2023-10-01 0000200406 us-gaap:EstimateOfFairValueFairValueDisclosureMember jnj:A095NotesDue2027Member 2023-10-01 0000200406 jnj:A2.900Notesdue2028Member 2023-10-01 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:A2.900Notesdue2028Member 2023-10-01 0000200406 us-gaap:EstimateOfFairValueFairValueDisclosureMember jnj:A2.900Notesdue2028Member 2023-10-01 0000200406 jnj:A1.150NotesDue2028Member 2023-10-01 iso4217:EUR 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:A1.150NotesDue2028Member 2023-10-01 0000200406 us-gaap:EstimateOfFairValueFairValueDisclosureMember jnj:A1.150NotesDue2028Member 2023-10-01 0000200406 jnj:A6.95Notesdue2029Member 2023-10-01 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:A6.95Notesdue2029Member 2023-10-01 0000200406 us-gaap:EstimateOfFairValueFairValueDisclosureMember jnj:A6.95Notesdue2029Member 2023-10-01 0000200406 jnj:A1300NotesDue2030Member 2023-10-01 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:A1300NotesDue2030Member 2023-10-01 0000200406 us-gaap:EstimateOfFairValueFairValueDisclosureMember jnj:A1300NotesDue2030Member 2023-10-01 0000200406 jnj:A4.95Debenturesdue2033Member 2023-10-01 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:A4.95Debenturesdue2033Member 2023-10-01 0000200406 us-gaap:EstimateOfFairValueFairValueDisclosureMember jnj:A4.95Debenturesdue2033Member 2023-10-01 0000200406 jnj:A4.375Notesdue2033Member 2023-10-01 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:A4.375Notesdue2033Member 2023-10-01 0000200406 jnj:A4.375Notesdue2033Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-10-01 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:A1.650NotesDue2035Member 2023-10-01 0000200406 jnj:A1.650NotesDue2035Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-10-01 0000200406 jnj:A3.55Notesdue2036Member 2023-10-01 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:A3.55Notesdue2036Member 2023-10-01 0000200406 us-gaap:EstimateOfFairValueFairValueDisclosureMember jnj:A3.55Notesdue2036Member 2023-10-01 0000200406 jnj:A5.95Notesdue2037Member 2023-10-01 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:A5.95Notesdue2037Member 2023-10-01 0000200406 us-gaap:EstimateOfFairValueFairValueDisclosureMember jnj:A5.95Notesdue2037Member 2023-10-01 0000200406 jnj:A3.625Notesdue2037Member 2023-10-01 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:A3.625Notesdue2037Member 2023-10-01 0000200406 us-gaap:EstimateOfFairValueFairValueDisclosureMember jnj:A3.625Notesdue2037Member 2023-10-01 0000200406 jnj:A3.400Notesdue2038Member 2023-10-01 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:A3.400Notesdue2038Member 2023-10-01 0000200406 jnj:A3.400Notesdue2038Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-10-01 0000200406 jnj:A5.85Debenturesdue2038Member 2023-10-01 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:A5.85Debenturesdue2038Member 2023-10-01 0000200406 us-gaap:EstimateOfFairValueFairValueDisclosureMember jnj:A5.85Debenturesdue2038Member 2023-10-01 0000200406 jnj:A4.50Debenturesdue2040Member 2023-10-01 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:A4.50Debenturesdue2040Member 2023-10-01 0000200406 us-gaap:EstimateOfFairValueFairValueDisclosureMember jnj:A4.50Debenturesdue2040Member 2023-10-01 0000200406 jnj:A210NotesDue2040Member 2023-10-01 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:A210NotesDue2040Member 2023-10-01 0000200406 us-gaap:EstimateOfFairValueFairValueDisclosureMember jnj:A210NotesDue2040Member 2023-10-01 0000200406 jnj:A4.85Notesdue2041Member 2023-10-01 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:A4.85Notesdue2041Member 2023-10-01 0000200406 us-gaap:EstimateOfFairValueFairValueDisclosureMember jnj:A4.85Notesdue2041Member 2023-10-01 0000200406 jnj:A4.50Notesdue2043Member 2023-10-01 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:A4.50Notesdue2043Member 2023-10-01 0000200406 us-gaap:EstimateOfFairValueFairValueDisclosureMember jnj:A4.50Notesdue2043Member 2023-10-01 0000200406 jnj:A3.70Notesdue2046Member 2023-10-01 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:A3.70Notesdue2046Member 2023-10-01 0000200406 us-gaap:EstimateOfFairValueFairValueDisclosureMember jnj:A3.70Notesdue2046Member 2023-10-01 0000200406 jnj:A3.75Notesdue2047Member 2023-10-01 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:A3.75Notesdue2047Member 2023-10-01 0000200406 us-gaap:EstimateOfFairValueFairValueDisclosureMember jnj:A3.75Notesdue2047Member 2023-10-01 0000200406 jnj:A3.500Notesdue2048Member 2023-10-01 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:A3.500Notesdue2048Member 2023-10-01 0000200406 us-gaap:EstimateOfFairValueFairValueDisclosureMember jnj:A3.500Notesdue2048Member 2023-10-01 0000200406 jnj:A2250NotesDue2050Member 2023-10-01 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:A2250NotesDue2050Member 2023-10-01 0000200406 us-gaap:EstimateOfFairValueFairValueDisclosureMember jnj:A2250NotesDue2050Member 2023-10-01 0000200406 jnj:A2450NotesDue2060Member 2023-10-01 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:A2450NotesDue2060Member 2023-10-01 0000200406 us-gaap:EstimateOfFairValueFairValueDisclosureMember jnj:A2450NotesDue2060Member 2023-10-01 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember jnj:NotesDuePeriodFifteenMember 2023-10-01 0000200406 us-gaap:EstimateOfFairValueFairValueDisclosureMember jnj:NotesDuePeriodFifteenMember 2023-10-01 0000200406 2023-01-02 2023-04-02 0000200406 us-gaap:CommercialPaperMember 2023-10-01 0000200406 us-gaap:CommercialPaperMember 2023-01-02 2023-10-01 0000200406 jnj:ConsumerMember jnj:TalcMember 2023-01-02 2023-10-01 0000200406 jnj:AccruedTaxesOnIncomeMember 2023-10-01 0000200406 us-gaap:InternalRevenueServiceIRSMember 2023-04-03 2023-07-02 0000200406 us-gaap:PensionPlansDefinedBenefitMember 2023-07-03 2023-10-01 0000200406 us-gaap:PensionPlansDefinedBenefitMember 2022-07-04 2022-10-02 0000200406 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-07-03 2023-10-01 0000200406 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-07-04 2022-10-02 0000200406 us-gaap:PensionPlansDefinedBenefitMember 2023-01-02 2023-10-01 0000200406 us-gaap:PensionPlansDefinedBenefitMember 2022-01-03 2022-10-02 0000200406 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-01-02 2023-10-01 0000200406 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-01-03 2022-10-02 0000200406 jnj:ConsumerHealthMember 2023-10-01 0000200406 country:US 2023-01-02 2023-10-01 0000200406 us-gaap:ForeignPlanMember 2023-01-02 2023-10-01 0000200406 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-01 0000200406 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-01-01 0000200406 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-01-01 0000200406 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-01-01 0000200406 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-02 2023-10-01 0000200406 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-01-02 2023-10-01 0000200406 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-01-02 2023-10-01 0000200406 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-01-02 2023-10-01 0000200406 us-gaap:AccumulatedTranslationAdjustmentMember 2023-10-01 0000200406 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-10-01 0000200406 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-10-01 0000200406 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-10-01 0000200406 us-gaap:AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember 2023-01-02 2023-10-01 0000200406 jnj:ImmunologyMember country:US jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:ImmunologyMember country:US jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:ImmunologyMember country:US jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:ImmunologyMember country:US jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:ImmunologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:ImmunologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:ImmunologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:ImmunologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:ImmunologyMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:ImmunologyMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:ImmunologyMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:ImmunologyMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:RemicadeMember jnj:ImmunologyMember country:US jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:RemicadeMember jnj:ImmunologyMember country:US jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:RemicadeMember jnj:ImmunologyMember country:US jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:RemicadeMember jnj:ImmunologyMember country:US jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:RemicadeMember jnj:ImmunologyMember jnj:UNITEDSTATESExportsMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:RemicadeMember jnj:ImmunologyMember jnj:UNITEDSTATESExportsMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:RemicadeMember jnj:ImmunologyMember jnj:UNITEDSTATESExportsMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:RemicadeMember jnj:ImmunologyMember jnj:UNITEDSTATESExportsMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:RemicadeMember jnj:ImmunologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:RemicadeMember jnj:ImmunologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:RemicadeMember jnj:ImmunologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:RemicadeMember jnj:ImmunologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:RemicadeMember jnj:ImmunologyMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:RemicadeMember jnj:ImmunologyMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:RemicadeMember jnj:ImmunologyMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:RemicadeMember jnj:ImmunologyMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:ImmunologyMember jnj:SimponiSimponiAriaMember country:US jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:ImmunologyMember jnj:SimponiSimponiAriaMember country:US jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:ImmunologyMember jnj:SimponiSimponiAriaMember country:US jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:ImmunologyMember jnj:SimponiSimponiAriaMember country:US jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:ImmunologyMember jnj:SimponiSimponiAriaMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:ImmunologyMember jnj:SimponiSimponiAriaMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:ImmunologyMember jnj:SimponiSimponiAriaMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:ImmunologyMember jnj:SimponiSimponiAriaMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:ImmunologyMember jnj:SimponiSimponiAriaMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:ImmunologyMember jnj:SimponiSimponiAriaMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:ImmunologyMember jnj:SimponiSimponiAriaMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:ImmunologyMember jnj:SimponiSimponiAriaMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:ImmunologyMember jnj:StelaraMember country:US jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:ImmunologyMember jnj:StelaraMember country:US jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:ImmunologyMember jnj:StelaraMember country:US jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:ImmunologyMember jnj:StelaraMember country:US jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:ImmunologyMember jnj:StelaraMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:ImmunologyMember jnj:StelaraMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:ImmunologyMember jnj:StelaraMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:ImmunologyMember jnj:StelaraMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:ImmunologyMember jnj:StelaraMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:ImmunologyMember jnj:StelaraMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:ImmunologyMember jnj:StelaraMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:ImmunologyMember jnj:StelaraMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:ImmunologyMember jnj:TremfyaMember country:US jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:ImmunologyMember jnj:TremfyaMember country:US jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:ImmunologyMember jnj:TremfyaMember country:US jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:ImmunologyMember jnj:TremfyaMember country:US jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:ImmunologyMember jnj:TremfyaMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:ImmunologyMember jnj:TremfyaMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:ImmunologyMember jnj:TremfyaMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:ImmunologyMember jnj:TremfyaMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:ImmunologyMember jnj:TremfyaMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:ImmunologyMember jnj:TremfyaMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:ImmunologyMember jnj:TremfyaMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:ImmunologyMember jnj:TremfyaMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:OtherImmunologyMember jnj:ImmunologyMember country:US jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:OtherImmunologyMember jnj:ImmunologyMember country:US jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:OtherImmunologyMember jnj:ImmunologyMember country:US jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:OtherImmunologyMember jnj:ImmunologyMember country:US jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:OtherImmunologyMember jnj:ImmunologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:OtherImmunologyMember jnj:ImmunologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:OtherImmunologyMember jnj:ImmunologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:OtherImmunologyMember jnj:ImmunologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:OtherImmunologyMember jnj:ImmunologyMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:OtherImmunologyMember jnj:ImmunologyMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:OtherImmunologyMember jnj:ImmunologyMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:OtherImmunologyMember jnj:ImmunologyMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:InfectiousDiseasesMember country:US jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:InfectiousDiseasesMember country:US jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:InfectiousDiseasesMember country:US jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:InfectiousDiseasesMember country:US jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:InfectiousDiseasesMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:InfectiousDiseasesMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:InfectiousDiseasesMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:InfectiousDiseasesMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:InfectiousDiseasesMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:InfectiousDiseasesMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:InfectiousDiseasesMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:InfectiousDiseasesMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:InfectiousDiseasesMember jnj:COVID19Member country:US jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:InfectiousDiseasesMember jnj:COVID19Member country:US jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:InfectiousDiseasesMember jnj:COVID19Member country:US jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:InfectiousDiseasesMember jnj:COVID19Member country:US jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:InfectiousDiseasesMember jnj:COVID19Member us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:InfectiousDiseasesMember jnj:COVID19Member us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:InfectiousDiseasesMember jnj:COVID19Member us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:InfectiousDiseasesMember jnj:COVID19Member us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:InfectiousDiseasesMember jnj:COVID19Member jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:InfectiousDiseasesMember jnj:COVID19Member jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:InfectiousDiseasesMember jnj:COVID19Member jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:InfectiousDiseasesMember jnj:COVID19Member jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:EDURANTrilpivirineMember jnj:InfectiousDiseasesMember country:US jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:EDURANTrilpivirineMember jnj:InfectiousDiseasesMember country:US jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:EDURANTrilpivirineMember jnj:InfectiousDiseasesMember country:US jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:EDURANTrilpivirineMember jnj:InfectiousDiseasesMember country:US jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:EDURANTrilpivirineMember jnj:InfectiousDiseasesMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:EDURANTrilpivirineMember jnj:InfectiousDiseasesMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:EDURANTrilpivirineMember jnj:InfectiousDiseasesMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:EDURANTrilpivirineMember jnj:InfectiousDiseasesMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:EDURANTrilpivirineMember jnj:InfectiousDiseasesMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:EDURANTrilpivirineMember jnj:InfectiousDiseasesMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:EDURANTrilpivirineMember jnj:InfectiousDiseasesMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:EDURANTrilpivirineMember jnj:InfectiousDiseasesMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:InfectiousDiseasesMember jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember country:US jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:InfectiousDiseasesMember jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember country:US jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:InfectiousDiseasesMember jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember country:US jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:InfectiousDiseasesMember jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember country:US jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:InfectiousDiseasesMember jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:InfectiousDiseasesMember jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:InfectiousDiseasesMember jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:InfectiousDiseasesMember jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:InfectiousDiseasesMember jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:InfectiousDiseasesMember jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:InfectiousDiseasesMember jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:InfectiousDiseasesMember jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:InfectiousDiseasesMember country:US jnj:InnovativeMedicineMember jnj:OtherInfectiousDiseasesMember 2023-07-03 2023-10-01 0000200406 jnj:InfectiousDiseasesMember country:US jnj:InnovativeMedicineMember jnj:OtherInfectiousDiseasesMember 2022-07-04 2022-10-02 0000200406 jnj:InfectiousDiseasesMember country:US jnj:InnovativeMedicineMember jnj:OtherInfectiousDiseasesMember 2023-01-02 2023-10-01 0000200406 jnj:InfectiousDiseasesMember country:US jnj:InnovativeMedicineMember jnj:OtherInfectiousDiseasesMember 2022-01-03 2022-10-02 0000200406 jnj:InfectiousDiseasesMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:OtherInfectiousDiseasesMember 2023-07-03 2023-10-01 0000200406 jnj:InfectiousDiseasesMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:OtherInfectiousDiseasesMember 2022-07-04 2022-10-02 0000200406 jnj:InfectiousDiseasesMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:OtherInfectiousDiseasesMember 2023-01-02 2023-10-01 0000200406 jnj:InfectiousDiseasesMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:OtherInfectiousDiseasesMember 2022-01-03 2022-10-02 0000200406 jnj:InfectiousDiseasesMember jnj:InnovativeMedicineMember jnj:OtherInfectiousDiseasesMember 2023-07-03 2023-10-01 0000200406 jnj:InfectiousDiseasesMember jnj:InnovativeMedicineMember jnj:OtherInfectiousDiseasesMember 2022-07-04 2022-10-02 0000200406 jnj:InfectiousDiseasesMember jnj:InnovativeMedicineMember jnj:OtherInfectiousDiseasesMember 2023-01-02 2023-10-01 0000200406 jnj:InfectiousDiseasesMember jnj:InnovativeMedicineMember jnj:OtherInfectiousDiseasesMember 2022-01-03 2022-10-02 0000200406 jnj:NeuroscienceMember country:US jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:NeuroscienceMember country:US jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:NeuroscienceMember country:US jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:NeuroscienceMember country:US jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:NeuroscienceMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:NeuroscienceMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:NeuroscienceMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:NeuroscienceMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:NeuroscienceMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:NeuroscienceMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:NeuroscienceMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:NeuroscienceMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:NeuroscienceMember jnj:CONCERTAMethylphenidateMember country:US jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:NeuroscienceMember jnj:CONCERTAMethylphenidateMember country:US jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:NeuroscienceMember jnj:CONCERTAMethylphenidateMember country:US jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:NeuroscienceMember jnj:CONCERTAMethylphenidateMember country:US jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:NeuroscienceMember jnj:CONCERTAMethylphenidateMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:NeuroscienceMember jnj:CONCERTAMethylphenidateMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:NeuroscienceMember jnj:CONCERTAMethylphenidateMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:NeuroscienceMember jnj:CONCERTAMethylphenidateMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:NeuroscienceMember jnj:CONCERTAMethylphenidateMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:NeuroscienceMember jnj:CONCERTAMethylphenidateMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:NeuroscienceMember jnj:CONCERTAMethylphenidateMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:NeuroscienceMember jnj:CONCERTAMethylphenidateMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:NeuroscienceMember jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember country:US jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:NeuroscienceMember jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember country:US jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:NeuroscienceMember jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember country:US jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:NeuroscienceMember jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember country:US jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:NeuroscienceMember jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:NeuroscienceMember jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:NeuroscienceMember jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:NeuroscienceMember jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:NeuroscienceMember jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:NeuroscienceMember jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:NeuroscienceMember jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:NeuroscienceMember jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:NeuroscienceMember jnj:SPRAVATOMember country:US jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:NeuroscienceMember jnj:SPRAVATOMember country:US jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:NeuroscienceMember jnj:SPRAVATOMember country:US jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:NeuroscienceMember jnj:SPRAVATOMember country:US jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:NeuroscienceMember jnj:SPRAVATOMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:NeuroscienceMember jnj:SPRAVATOMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:NeuroscienceMember jnj:SPRAVATOMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:NeuroscienceMember jnj:SPRAVATOMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:NeuroscienceMember jnj:SPRAVATOMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:NeuroscienceMember jnj:SPRAVATOMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:NeuroscienceMember jnj:SPRAVATOMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:NeuroscienceMember jnj:SPRAVATOMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:NeuroscienceMember country:US jnj:InnovativeMedicineMember jnj:OTHERNEUROSCIENCEMember 2023-07-03 2023-10-01 0000200406 jnj:NeuroscienceMember country:US jnj:InnovativeMedicineMember jnj:OTHERNEUROSCIENCEMember 2022-07-04 2022-10-02 0000200406 jnj:NeuroscienceMember country:US jnj:InnovativeMedicineMember jnj:OTHERNEUROSCIENCEMember 2023-01-02 2023-10-01 0000200406 jnj:NeuroscienceMember country:US jnj:InnovativeMedicineMember jnj:OTHERNEUROSCIENCEMember 2022-01-03 2022-10-02 0000200406 jnj:NeuroscienceMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:OTHERNEUROSCIENCEMember 2023-07-03 2023-10-01 0000200406 jnj:NeuroscienceMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:OTHERNEUROSCIENCEMember 2022-07-04 2022-10-02 0000200406 jnj:NeuroscienceMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:OTHERNEUROSCIENCEMember 2023-01-02 2023-10-01 0000200406 jnj:NeuroscienceMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:OTHERNEUROSCIENCEMember 2022-01-03 2022-10-02 0000200406 jnj:NeuroscienceMember jnj:InnovativeMedicineMember jnj:OTHERNEUROSCIENCEMember 2023-07-03 2023-10-01 0000200406 jnj:NeuroscienceMember jnj:InnovativeMedicineMember jnj:OTHERNEUROSCIENCEMember 2022-07-04 2022-10-02 0000200406 jnj:NeuroscienceMember jnj:InnovativeMedicineMember jnj:OTHERNEUROSCIENCEMember 2023-01-02 2023-10-01 0000200406 jnj:NeuroscienceMember jnj:InnovativeMedicineMember jnj:OTHERNEUROSCIENCEMember 2022-01-03 2022-10-02 0000200406 jnj:OncologyMember country:US jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:OncologyMember country:US jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:OncologyMember country:US jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:OncologyMember country:US jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:OncologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:OncologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:OncologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:OncologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:OncologyMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:OncologyMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:OncologyMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:OncologyMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:OncologyMember country:US jnj:InnovativeMedicineMember jnj:CARVYKTIMember 2023-07-03 2023-10-01 0000200406 jnj:OncologyMember country:US jnj:InnovativeMedicineMember jnj:CARVYKTIMember 2022-07-04 2022-10-02 0000200406 jnj:OncologyMember country:US jnj:InnovativeMedicineMember jnj:CARVYKTIMember 2023-01-02 2023-10-01 0000200406 jnj:OncologyMember country:US jnj:InnovativeMedicineMember jnj:CARVYKTIMember 2022-01-03 2022-10-02 0000200406 jnj:OncologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:CARVYKTIMember 2023-07-03 2023-10-01 0000200406 jnj:OncologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:CARVYKTIMember 2022-07-04 2022-10-02 0000200406 jnj:OncologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:CARVYKTIMember 2023-01-02 2023-10-01 0000200406 jnj:OncologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:CARVYKTIMember 2022-01-03 2022-10-02 0000200406 jnj:OncologyMember jnj:InnovativeMedicineMember jnj:CARVYKTIMember 2023-07-03 2023-10-01 0000200406 jnj:OncologyMember jnj:InnovativeMedicineMember jnj:CARVYKTIMember 2022-07-04 2022-10-02 0000200406 jnj:OncologyMember jnj:InnovativeMedicineMember jnj:CARVYKTIMember 2023-01-02 2023-10-01 0000200406 jnj:OncologyMember jnj:InnovativeMedicineMember jnj:CARVYKTIMember 2022-01-03 2022-10-02 0000200406 jnj:OncologyMember country:US jnj:DARZALEXMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:OncologyMember country:US jnj:DARZALEXMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:OncologyMember country:US jnj:DARZALEXMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:OncologyMember country:US jnj:DARZALEXMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:OncologyMember us-gaap:NonUsMember jnj:DARZALEXMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:OncologyMember us-gaap:NonUsMember jnj:DARZALEXMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:OncologyMember us-gaap:NonUsMember jnj:DARZALEXMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:OncologyMember us-gaap:NonUsMember jnj:DARZALEXMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:OncologyMember jnj:DARZALEXMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:OncologyMember jnj:DARZALEXMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:OncologyMember jnj:DARZALEXMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:OncologyMember jnj:DARZALEXMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:OncologyMember jnj:ERLEADAMember country:US jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:OncologyMember jnj:ERLEADAMember country:US jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:OncologyMember jnj:ERLEADAMember country:US jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:OncologyMember jnj:ERLEADAMember country:US jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:OncologyMember jnj:ERLEADAMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:OncologyMember jnj:ERLEADAMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:OncologyMember jnj:ERLEADAMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:OncologyMember jnj:ERLEADAMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:OncologyMember jnj:ERLEADAMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:OncologyMember jnj:ERLEADAMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:OncologyMember jnj:ERLEADAMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:OncologyMember jnj:ERLEADAMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:OncologyMember jnj:IMBRUVICAMember country:US jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:OncologyMember jnj:IMBRUVICAMember country:US jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:OncologyMember jnj:IMBRUVICAMember country:US jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:OncologyMember jnj:IMBRUVICAMember country:US jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:OncologyMember jnj:IMBRUVICAMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:OncologyMember jnj:IMBRUVICAMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:OncologyMember jnj:IMBRUVICAMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:OncologyMember jnj:IMBRUVICAMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:OncologyMember jnj:IMBRUVICAMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:OncologyMember jnj:IMBRUVICAMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:OncologyMember jnj:IMBRUVICAMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:OncologyMember jnj:IMBRUVICAMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:ZYTIGAMember jnj:OncologyMember country:US jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:ZYTIGAMember jnj:OncologyMember country:US jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:ZYTIGAMember jnj:OncologyMember country:US jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:ZYTIGAMember jnj:OncologyMember country:US jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:ZYTIGAMember jnj:OncologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:ZYTIGAMember jnj:OncologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:ZYTIGAMember jnj:OncologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:ZYTIGAMember jnj:OncologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:ZYTIGAMember jnj:OncologyMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:ZYTIGAMember jnj:OncologyMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:ZYTIGAMember jnj:OncologyMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:ZYTIGAMember jnj:OncologyMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:OncologyMember jnj:OtherOncologyMember country:US jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:OncologyMember jnj:OtherOncologyMember country:US jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:OncologyMember jnj:OtherOncologyMember country:US jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:OncologyMember jnj:OtherOncologyMember country:US jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:OncologyMember jnj:OtherOncologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:OncologyMember jnj:OtherOncologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:OncologyMember jnj:OtherOncologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:OncologyMember jnj:OtherOncologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:OncologyMember jnj:OtherOncologyMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:OncologyMember jnj:OtherOncologyMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:OncologyMember jnj:OtherOncologyMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:OncologyMember jnj:OtherOncologyMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:PulmonaryHypertensionMember country:US jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:PulmonaryHypertensionMember country:US jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:PulmonaryHypertensionMember country:US jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:PulmonaryHypertensionMember country:US jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:PulmonaryHypertensionMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:PulmonaryHypertensionMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:PulmonaryHypertensionMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:PulmonaryHypertensionMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:PulmonaryHypertensionMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:PulmonaryHypertensionMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:PulmonaryHypertensionMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:PulmonaryHypertensionMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:OPSUMITMember jnj:PulmonaryHypertensionMember country:US jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:OPSUMITMember jnj:PulmonaryHypertensionMember country:US jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:OPSUMITMember jnj:PulmonaryHypertensionMember country:US jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:OPSUMITMember jnj:PulmonaryHypertensionMember country:US jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:OPSUMITMember jnj:PulmonaryHypertensionMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:OPSUMITMember jnj:PulmonaryHypertensionMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:OPSUMITMember jnj:PulmonaryHypertensionMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:OPSUMITMember jnj:PulmonaryHypertensionMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:OPSUMITMember jnj:PulmonaryHypertensionMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:OPSUMITMember jnj:PulmonaryHypertensionMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:OPSUMITMember jnj:PulmonaryHypertensionMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:OPSUMITMember jnj:PulmonaryHypertensionMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:UPTRAVIMember jnj:PulmonaryHypertensionMember country:US jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:UPTRAVIMember jnj:PulmonaryHypertensionMember country:US jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:UPTRAVIMember jnj:PulmonaryHypertensionMember country:US jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:UPTRAVIMember jnj:PulmonaryHypertensionMember country:US jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:UPTRAVIMember jnj:PulmonaryHypertensionMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:UPTRAVIMember jnj:PulmonaryHypertensionMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:UPTRAVIMember jnj:PulmonaryHypertensionMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:UPTRAVIMember jnj:PulmonaryHypertensionMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:UPTRAVIMember jnj:PulmonaryHypertensionMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:UPTRAVIMember jnj:PulmonaryHypertensionMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:UPTRAVIMember jnj:PulmonaryHypertensionMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:UPTRAVIMember jnj:PulmonaryHypertensionMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:PulmonaryHypertensionMember country:US jnj:OtherMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:PulmonaryHypertensionMember country:US jnj:OtherMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:PulmonaryHypertensionMember country:US jnj:OtherMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:PulmonaryHypertensionMember country:US jnj:OtherMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:PulmonaryHypertensionMember us-gaap:NonUsMember jnj:OtherMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:PulmonaryHypertensionMember us-gaap:NonUsMember jnj:OtherMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:PulmonaryHypertensionMember us-gaap:NonUsMember jnj:OtherMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:PulmonaryHypertensionMember us-gaap:NonUsMember jnj:OtherMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:PulmonaryHypertensionMember jnj:OtherMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:PulmonaryHypertensionMember jnj:OtherMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:PulmonaryHypertensionMember jnj:OtherMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:PulmonaryHypertensionMember jnj:OtherMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:CardiovascularMetabolismOtherMember country:US jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:CardiovascularMetabolismOtherMember country:US jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:CardiovascularMetabolismOtherMember country:US jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:CardiovascularMetabolismOtherMember country:US jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:CardiovascularMetabolismOtherMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:CardiovascularMetabolismOtherMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:CardiovascularMetabolismOtherMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:CardiovascularMetabolismOtherMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:CardiovascularMetabolismOtherMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:CardiovascularMetabolismOtherMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:CardiovascularMetabolismOtherMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:CardiovascularMetabolismOtherMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:CardiovascularMetabolismOtherMember jnj:XareltoMember country:US jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:CardiovascularMetabolismOtherMember jnj:XareltoMember country:US jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:CardiovascularMetabolismOtherMember jnj:XareltoMember country:US jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:CardiovascularMetabolismOtherMember jnj:XareltoMember country:US jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:CardiovascularMetabolismOtherMember jnj:XareltoMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:CardiovascularMetabolismOtherMember jnj:XareltoMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:CardiovascularMetabolismOtherMember jnj:XareltoMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:CardiovascularMetabolismOtherMember jnj:XareltoMember us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:CardiovascularMetabolismOtherMember jnj:XareltoMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:CardiovascularMetabolismOtherMember jnj:XareltoMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:CardiovascularMetabolismOtherMember jnj:XareltoMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:CardiovascularMetabolismOtherMember jnj:XareltoMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:CardiovascularMetabolismOtherMember country:US jnj:OtherMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:CardiovascularMetabolismOtherMember country:US jnj:OtherMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:CardiovascularMetabolismOtherMember country:US jnj:OtherMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:CardiovascularMetabolismOtherMember country:US jnj:OtherMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:CardiovascularMetabolismOtherMember us-gaap:NonUsMember jnj:OtherMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:CardiovascularMetabolismOtherMember us-gaap:NonUsMember jnj:OtherMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:CardiovascularMetabolismOtherMember us-gaap:NonUsMember jnj:OtherMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:CardiovascularMetabolismOtherMember us-gaap:NonUsMember jnj:OtherMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:CardiovascularMetabolismOtherMember jnj:OtherMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:CardiovascularMetabolismOtherMember jnj:OtherMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:CardiovascularMetabolismOtherMember jnj:OtherMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:CardiovascularMetabolismOtherMember jnj:OtherMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 country:US jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 country:US jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 country:US jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 country:US jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 jnj:InterventionalSolutionsMember jnj:MedTechMember country:US 2023-07-03 2023-10-01 0000200406 jnj:InterventionalSolutionsMember jnj:MedTechMember country:US 2022-07-04 2022-10-02 0000200406 jnj:InterventionalSolutionsMember jnj:MedTechMember country:US 2023-01-02 2023-10-01 0000200406 jnj:InterventionalSolutionsMember jnj:MedTechMember country:US 2022-01-03 2022-10-02 0000200406 jnj:InterventionalSolutionsMember jnj:MedTechMember us-gaap:NonUsMember 2023-07-03 2023-10-01 0000200406 jnj:InterventionalSolutionsMember jnj:MedTechMember us-gaap:NonUsMember 2022-07-04 2022-10-02 0000200406 jnj:InterventionalSolutionsMember jnj:MedTechMember us-gaap:NonUsMember 2023-01-02 2023-10-01 0000200406 jnj:InterventionalSolutionsMember jnj:MedTechMember us-gaap:NonUsMember 2022-01-03 2022-10-02 0000200406 jnj:InterventionalSolutionsMember jnj:MedTechMember 2023-07-03 2023-10-01 0000200406 jnj:InterventionalSolutionsMember jnj:MedTechMember 2022-07-04 2022-10-02 0000200406 jnj:InterventionalSolutionsMember jnj:MedTechMember 2023-01-02 2023-10-01 0000200406 jnj:InterventionalSolutionsMember jnj:MedTechMember 2022-01-03 2022-10-02 0000200406 jnj:MedTechMember jnj:ElectrophysiologyMember country:US 2023-07-03 2023-10-01 0000200406 jnj:MedTechMember jnj:ElectrophysiologyMember country:US 2022-07-04 2022-10-02 0000200406 jnj:MedTechMember jnj:ElectrophysiologyMember country:US 2023-01-02 2023-10-01 0000200406 jnj:MedTechMember jnj:ElectrophysiologyMember country:US 2022-01-03 2022-10-02 0000200406 jnj:MedTechMember jnj:ElectrophysiologyMember us-gaap:NonUsMember 2023-07-03 2023-10-01 0000200406 jnj:MedTechMember jnj:ElectrophysiologyMember us-gaap:NonUsMember 2022-07-04 2022-10-02 0000200406 jnj:MedTechMember jnj:ElectrophysiologyMember us-gaap:NonUsMember 2023-01-02 2023-10-01 0000200406 jnj:MedTechMember jnj:ElectrophysiologyMember us-gaap:NonUsMember 2022-01-03 2022-10-02 0000200406 jnj:MedTechMember jnj:ElectrophysiologyMember 2023-07-03 2023-10-01 0000200406 jnj:MedTechMember jnj:ElectrophysiologyMember 2022-07-04 2022-10-02 0000200406 jnj:MedTechMember jnj:ElectrophysiologyMember 2023-01-02 2023-10-01 0000200406 jnj:MedTechMember jnj:ElectrophysiologyMember 2022-01-03 2022-10-02 0000200406 jnj:AbiomedMember jnj:MedTechMember country:US 2023-07-03 2023-10-01 0000200406 jnj:AbiomedMember jnj:MedTechMember country:US 2022-07-04 2022-10-02 0000200406 jnj:AbiomedMember jnj:MedTechMember country:US 2023-01-02 2023-10-01 0000200406 jnj:AbiomedMember jnj:MedTechMember country:US 2022-01-03 2022-10-02 0000200406 jnj:AbiomedMember jnj:MedTechMember us-gaap:NonUsMember 2023-07-03 2023-10-01 0000200406 jnj:AbiomedMember jnj:MedTechMember us-gaap:NonUsMember 2022-07-04 2022-10-02 0000200406 jnj:AbiomedMember jnj:MedTechMember us-gaap:NonUsMember 2023-01-02 2023-10-01 0000200406 jnj:AbiomedMember jnj:MedTechMember us-gaap:NonUsMember 2022-01-03 2022-10-02 0000200406 jnj:AbiomedMember jnj:MedTechMember 2023-07-03 2023-10-01 0000200406 jnj:AbiomedMember jnj:MedTechMember 2022-07-04 2022-10-02 0000200406 jnj:AbiomedMember jnj:MedTechMember 2023-01-02 2023-10-01 0000200406 jnj:AbiomedMember jnj:MedTechMember 2022-01-03 2022-10-02 0000200406 jnj:OtherInterventionalSolutionsMember jnj:MedTechMember country:US 2023-07-03 2023-10-01 0000200406 jnj:OtherInterventionalSolutionsMember jnj:MedTechMember country:US 2022-07-04 2022-10-02 0000200406 jnj:OtherInterventionalSolutionsMember jnj:MedTechMember country:US 2023-01-02 2023-10-01 0000200406 jnj:OtherInterventionalSolutionsMember jnj:MedTechMember country:US 2022-01-03 2022-10-02 0000200406 jnj:OtherInterventionalSolutionsMember jnj:MedTechMember us-gaap:NonUsMember 2023-07-03 2023-10-01 0000200406 jnj:OtherInterventionalSolutionsMember jnj:MedTechMember us-gaap:NonUsMember 2022-07-04 2022-10-02 0000200406 jnj:OtherInterventionalSolutionsMember jnj:MedTechMember us-gaap:NonUsMember 2023-01-02 2023-10-01 0000200406 jnj:OtherInterventionalSolutionsMember jnj:MedTechMember us-gaap:NonUsMember 2022-01-03 2022-10-02 0000200406 jnj:OtherInterventionalSolutionsMember jnj:MedTechMember 2023-07-03 2023-10-01 0000200406 jnj:OtherInterventionalSolutionsMember jnj:MedTechMember 2022-07-04 2022-10-02 0000200406 jnj:OtherInterventionalSolutionsMember jnj:MedTechMember 2023-01-02 2023-10-01 0000200406 jnj:OtherInterventionalSolutionsMember jnj:MedTechMember 2022-01-03 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:MedTechMember country:US 2023-07-03 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:MedTechMember country:US 2022-07-04 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:MedTechMember country:US 2023-01-02 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:MedTechMember country:US 2022-01-03 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:MedTechMember us-gaap:NonUsMember 2023-07-03 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:MedTechMember us-gaap:NonUsMember 2022-07-04 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:MedTechMember us-gaap:NonUsMember 2023-01-02 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:MedTechMember us-gaap:NonUsMember 2022-01-03 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:MedTechMember 2023-07-03 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:MedTechMember 2022-07-04 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:MedTechMember 2023-01-02 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:MedTechMember 2022-01-03 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:HIPSMember jnj:MedTechMember country:US 2023-07-03 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:HIPSMember jnj:MedTechMember country:US 2022-07-04 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:HIPSMember jnj:MedTechMember country:US 2023-01-02 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:HIPSMember jnj:MedTechMember country:US 2022-01-03 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:HIPSMember jnj:MedTechMember us-gaap:NonUsMember 2023-07-03 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:HIPSMember jnj:MedTechMember us-gaap:NonUsMember 2022-07-04 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:HIPSMember jnj:MedTechMember us-gaap:NonUsMember 2023-01-02 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:HIPSMember jnj:MedTechMember us-gaap:NonUsMember 2022-01-03 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:HIPSMember jnj:MedTechMember 2023-07-03 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:HIPSMember jnj:MedTechMember 2022-07-04 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:HIPSMember jnj:MedTechMember 2023-01-02 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:HIPSMember jnj:MedTechMember 2022-01-03 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:MedTechMember country:US jnj:KNEESMember 2023-07-03 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:MedTechMember country:US jnj:KNEESMember 2022-07-04 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:MedTechMember country:US jnj:KNEESMember 2023-01-02 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:MedTechMember country:US jnj:KNEESMember 2022-01-03 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:MedTechMember us-gaap:NonUsMember jnj:KNEESMember 2023-07-03 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:MedTechMember us-gaap:NonUsMember jnj:KNEESMember 2022-07-04 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:MedTechMember us-gaap:NonUsMember jnj:KNEESMember 2023-01-02 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:MedTechMember us-gaap:NonUsMember jnj:KNEESMember 2022-01-03 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:MedTechMember jnj:KNEESMember 2023-07-03 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:MedTechMember jnj:KNEESMember 2022-07-04 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:MedTechMember jnj:KNEESMember 2023-01-02 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:MedTechMember jnj:KNEESMember 2022-01-03 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:TRAUMAMember jnj:MedTechMember country:US 2023-07-03 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:TRAUMAMember jnj:MedTechMember country:US 2022-07-04 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:TRAUMAMember jnj:MedTechMember country:US 2023-01-02 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:TRAUMAMember jnj:MedTechMember country:US 2022-01-03 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:TRAUMAMember jnj:MedTechMember us-gaap:NonUsMember 2023-07-03 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:TRAUMAMember jnj:MedTechMember us-gaap:NonUsMember 2022-07-04 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:TRAUMAMember jnj:MedTechMember us-gaap:NonUsMember 2023-01-02 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:TRAUMAMember jnj:MedTechMember us-gaap:NonUsMember 2022-01-03 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:TRAUMAMember jnj:MedTechMember 2023-07-03 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:TRAUMAMember jnj:MedTechMember 2022-07-04 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:TRAUMAMember jnj:MedTechMember 2023-01-02 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:TRAUMAMember jnj:MedTechMember 2022-01-03 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:SPINEOTHERMember jnj:MedTechMember country:US 2023-07-03 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:SPINEOTHERMember jnj:MedTechMember country:US 2022-07-04 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:SPINEOTHERMember jnj:MedTechMember country:US 2023-01-02 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:SPINEOTHERMember jnj:MedTechMember country:US 2022-01-03 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:SPINEOTHERMember jnj:MedTechMember us-gaap:NonUsMember 2023-07-03 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:SPINEOTHERMember jnj:MedTechMember us-gaap:NonUsMember 2022-07-04 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:SPINEOTHERMember jnj:MedTechMember us-gaap:NonUsMember 2023-01-02 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:SPINEOTHERMember jnj:MedTechMember us-gaap:NonUsMember 2022-01-03 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:SPINEOTHERMember jnj:MedTechMember 2023-07-03 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:SPINEOTHERMember jnj:MedTechMember 2022-07-04 2022-10-02 0000200406 jnj:OrthopaedicsMember jnj:SPINEOTHERMember jnj:MedTechMember 2023-01-02 2023-10-01 0000200406 jnj:OrthopaedicsMember jnj:SPINEOTHERMember jnj:MedTechMember 2022-01-03 2022-10-02 0000200406 jnj:SurgeryMember jnj:MedTechMember country:US 2023-07-03 2023-10-01 0000200406 jnj:SurgeryMember jnj:MedTechMember country:US 2022-07-04 2022-10-02 0000200406 jnj:SurgeryMember jnj:MedTechMember country:US 2023-01-02 2023-10-01 0000200406 jnj:SurgeryMember jnj:MedTechMember country:US 2022-01-03 2022-10-02 0000200406 jnj:SurgeryMember jnj:MedTechMember us-gaap:NonUsMember 2023-07-03 2023-10-01 0000200406 jnj:SurgeryMember jnj:MedTechMember us-gaap:NonUsMember 2022-07-04 2022-10-02 0000200406 jnj:SurgeryMember jnj:MedTechMember us-gaap:NonUsMember 2023-01-02 2023-10-01 0000200406 jnj:SurgeryMember jnj:MedTechMember us-gaap:NonUsMember 2022-01-03 2022-10-02 0000200406 jnj:SurgeryMember jnj:MedTechMember 2023-07-03 2023-10-01 0000200406 jnj:SurgeryMember jnj:MedTechMember 2022-07-04 2022-10-02 0000200406 jnj:SurgeryMember jnj:MedTechMember 2023-01-02 2023-10-01 0000200406 jnj:SurgeryMember jnj:MedTechMember 2022-01-03 2022-10-02 0000200406 jnj:ADVANCEDMember jnj:SurgeryMember jnj:MedTechMember country:US 2023-07-03 2023-10-01 0000200406 jnj:ADVANCEDMember jnj:SurgeryMember jnj:MedTechMember country:US 2022-07-04 2022-10-02 0000200406 jnj:ADVANCEDMember jnj:SurgeryMember jnj:MedTechMember country:US 2023-01-02 2023-10-01 0000200406 jnj:ADVANCEDMember jnj:SurgeryMember jnj:MedTechMember country:US 2022-01-03 2022-10-02 0000200406 jnj:ADVANCEDMember jnj:SurgeryMember jnj:MedTechMember us-gaap:NonUsMember 2023-07-03 2023-10-01 0000200406 jnj:ADVANCEDMember jnj:SurgeryMember jnj:MedTechMember us-gaap:NonUsMember 2022-07-04 2022-10-02 0000200406 jnj:ADVANCEDMember jnj:SurgeryMember jnj:MedTechMember us-gaap:NonUsMember 2023-01-02 2023-10-01 0000200406 jnj:ADVANCEDMember jnj:SurgeryMember jnj:MedTechMember us-gaap:NonUsMember 2022-01-03 2022-10-02 0000200406 jnj:ADVANCEDMember jnj:SurgeryMember jnj:MedTechMember 2023-07-03 2023-10-01 0000200406 jnj:ADVANCEDMember jnj:SurgeryMember jnj:MedTechMember 2022-07-04 2022-10-02 0000200406 jnj:ADVANCEDMember jnj:SurgeryMember jnj:MedTechMember 2023-01-02 2023-10-01 0000200406 jnj:ADVANCEDMember jnj:SurgeryMember jnj:MedTechMember 2022-01-03 2022-10-02 0000200406 jnj:SurgeryMember jnj:MedTechMember jnj:GENERALMember country:US 2023-07-03 2023-10-01 0000200406 jnj:SurgeryMember jnj:MedTechMember jnj:GENERALMember country:US 2022-07-04 2022-10-02 0000200406 jnj:SurgeryMember jnj:MedTechMember jnj:GENERALMember country:US 2023-01-02 2023-10-01 0000200406 jnj:SurgeryMember jnj:MedTechMember jnj:GENERALMember country:US 2022-01-03 2022-10-02 0000200406 jnj:SurgeryMember jnj:MedTechMember jnj:GENERALMember us-gaap:NonUsMember 2023-07-03 2023-10-01 0000200406 jnj:SurgeryMember jnj:MedTechMember jnj:GENERALMember us-gaap:NonUsMember 2022-07-04 2022-10-02 0000200406 jnj:SurgeryMember jnj:MedTechMember jnj:GENERALMember us-gaap:NonUsMember 2023-01-02 2023-10-01 0000200406 jnj:SurgeryMember jnj:MedTechMember jnj:GENERALMember us-gaap:NonUsMember 2022-01-03 2022-10-02 0000200406 jnj:SurgeryMember jnj:MedTechMember jnj:GENERALMember 2023-07-03 2023-10-01 0000200406 jnj:SurgeryMember jnj:MedTechMember jnj:GENERALMember 2022-07-04 2022-10-02 0000200406 jnj:SurgeryMember jnj:MedTechMember jnj:GENERALMember 2023-01-02 2023-10-01 0000200406 jnj:SurgeryMember jnj:MedTechMember jnj:GENERALMember 2022-01-03 2022-10-02 0000200406 jnj:MedTechMember country:US jnj:VisionMember 2023-07-03 2023-10-01 0000200406 jnj:MedTechMember country:US jnj:VisionMember 2022-07-04 2022-10-02 0000200406 jnj:MedTechMember country:US jnj:VisionMember 2023-01-02 2023-10-01 0000200406 jnj:MedTechMember country:US jnj:VisionMember 2022-01-03 2022-10-02 0000200406 jnj:MedTechMember us-gaap:NonUsMember jnj:VisionMember 2023-07-03 2023-10-01 0000200406 jnj:MedTechMember us-gaap:NonUsMember jnj:VisionMember 2022-07-04 2022-10-02 0000200406 jnj:MedTechMember us-gaap:NonUsMember jnj:VisionMember 2023-01-02 2023-10-01 0000200406 jnj:MedTechMember us-gaap:NonUsMember jnj:VisionMember 2022-01-03 2022-10-02 0000200406 jnj:MedTechMember jnj:VisionMember 2023-07-03 2023-10-01 0000200406 jnj:MedTechMember jnj:VisionMember 2022-07-04 2022-10-02 0000200406 jnj:MedTechMember jnj:VisionMember 2023-01-02 2023-10-01 0000200406 jnj:MedTechMember jnj:VisionMember 2022-01-03 2022-10-02 0000200406 jnj:CONTACTLENSESOTHERMember jnj:MedTechMember country:US jnj:VisionMember 2023-07-03 2023-10-01 0000200406 jnj:CONTACTLENSESOTHERMember jnj:MedTechMember country:US jnj:VisionMember 2022-07-04 2022-10-02 0000200406 jnj:CONTACTLENSESOTHERMember jnj:MedTechMember country:US jnj:VisionMember 2023-01-02 2023-10-01 0000200406 jnj:CONTACTLENSESOTHERMember jnj:MedTechMember country:US jnj:VisionMember 2022-01-03 2022-10-02 0000200406 jnj:CONTACTLENSESOTHERMember jnj:MedTechMember us-gaap:NonUsMember jnj:VisionMember 2023-07-03 2023-10-01 0000200406 jnj:CONTACTLENSESOTHERMember jnj:MedTechMember us-gaap:NonUsMember jnj:VisionMember 2022-07-04 2022-10-02 0000200406 jnj:CONTACTLENSESOTHERMember jnj:MedTechMember us-gaap:NonUsMember jnj:VisionMember 2023-01-02 2023-10-01 0000200406 jnj:CONTACTLENSESOTHERMember jnj:MedTechMember us-gaap:NonUsMember jnj:VisionMember 2022-01-03 2022-10-02 0000200406 jnj:CONTACTLENSESOTHERMember jnj:MedTechMember jnj:VisionMember 2023-07-03 2023-10-01 0000200406 jnj:CONTACTLENSESOTHERMember jnj:MedTechMember jnj:VisionMember 2022-07-04 2022-10-02 0000200406 jnj:CONTACTLENSESOTHERMember jnj:MedTechMember jnj:VisionMember 2023-01-02 2023-10-01 0000200406 jnj:CONTACTLENSESOTHERMember jnj:MedTechMember jnj:VisionMember 2022-01-03 2022-10-02 0000200406 jnj:SURGICALMember jnj:MedTechMember country:US jnj:VisionMember 2023-07-03 2023-10-01 0000200406 jnj:SURGICALMember jnj:MedTechMember country:US jnj:VisionMember 2022-07-04 2022-10-02 0000200406 jnj:SURGICALMember jnj:MedTechMember country:US jnj:VisionMember 2023-01-02 2023-10-01 0000200406 jnj:SURGICALMember jnj:MedTechMember country:US jnj:VisionMember 2022-01-03 2022-10-02 0000200406 jnj:SURGICALMember jnj:MedTechMember us-gaap:NonUsMember jnj:VisionMember 2023-07-03 2023-10-01 0000200406 jnj:SURGICALMember jnj:MedTechMember us-gaap:NonUsMember jnj:VisionMember 2022-07-04 2022-10-02 0000200406 jnj:SURGICALMember jnj:MedTechMember us-gaap:NonUsMember jnj:VisionMember 2023-01-02 2023-10-01 0000200406 jnj:SURGICALMember jnj:MedTechMember us-gaap:NonUsMember jnj:VisionMember 2022-01-03 2022-10-02 0000200406 jnj:SURGICALMember jnj:MedTechMember jnj:VisionMember 2023-07-03 2023-10-01 0000200406 jnj:SURGICALMember jnj:MedTechMember jnj:VisionMember 2022-07-04 2022-10-02 0000200406 jnj:SURGICALMember jnj:MedTechMember jnj:VisionMember 2023-01-02 2023-10-01 0000200406 jnj:SURGICALMember jnj:MedTechMember jnj:VisionMember 2022-01-03 2022-10-02 0000200406 jnj:MedTechMember country:US 2023-07-03 2023-10-01 0000200406 jnj:MedTechMember country:US 2022-07-04 2022-10-02 0000200406 jnj:MedTechMember country:US 2023-01-02 2023-10-01 0000200406 jnj:MedTechMember country:US 2022-01-03 2022-10-02 0000200406 jnj:MedTechMember us-gaap:NonUsMember 2023-07-03 2023-10-01 0000200406 jnj:MedTechMember us-gaap:NonUsMember 2022-07-04 2022-10-02 0000200406 jnj:MedTechMember us-gaap:NonUsMember 2023-01-02 2023-10-01 0000200406 jnj:MedTechMember us-gaap:NonUsMember 2022-01-03 2022-10-02 0000200406 jnj:MedTechMember 2023-07-03 2023-10-01 0000200406 jnj:MedTechMember 2022-07-04 2022-10-02 0000200406 jnj:MedTechMember 2022-01-03 2022-10-02 0000200406 country:US 2023-07-03 2023-10-01 0000200406 country:US 2022-07-04 2022-10-02 0000200406 country:US 2023-01-02 2023-10-01 0000200406 country:US 2022-01-03 2022-10-02 0000200406 us-gaap:NonUsMember 2023-07-03 2023-10-01 0000200406 us-gaap:NonUsMember 2022-07-04 2022-10-02 0000200406 us-gaap:NonUsMember 2023-01-02 2023-10-01 0000200406 us-gaap:NonUsMember 2022-01-03 2022-10-02 0000200406 us-gaap:OperatingSegmentsMember jnj:InnovativeMedicineMember 2023-07-03 2023-10-01 0000200406 us-gaap:OperatingSegmentsMember jnj:InnovativeMedicineMember 2022-07-04 2022-10-02 0000200406 us-gaap:OperatingSegmentsMember jnj:InnovativeMedicineMember 2023-01-02 2023-10-01 0000200406 us-gaap:OperatingSegmentsMember jnj:InnovativeMedicineMember 2022-01-03 2022-10-02 0000200406 us-gaap:OperatingSegmentsMember jnj:MedTechMember 2023-07-03 2023-10-01 0000200406 us-gaap:OperatingSegmentsMember jnj:MedTechMember 2022-07-04 2022-10-02 0000200406 us-gaap:OperatingSegmentsMember jnj:MedTechMember 2023-01-02 2023-10-01 0000200406 us-gaap:OperatingSegmentsMember jnj:MedTechMember 2022-01-03 2022-10-02 0000200406 us-gaap:OperatingSegmentsMember 2023-07-03 2023-10-01 0000200406 us-gaap:OperatingSegmentsMember 2022-07-04 2022-10-02 0000200406 us-gaap:OperatingSegmentsMember 2023-01-02 2023-10-01 0000200406 us-gaap:OperatingSegmentsMember 2022-01-03 2022-10-02 0000200406 us-gaap:CorporateNonSegmentMember 2023-07-03 2023-10-01 0000200406 us-gaap:CorporateNonSegmentMember 2022-07-04 2022-10-02 0000200406 us-gaap:CorporateNonSegmentMember 2023-01-02 2023-10-01 0000200406 us-gaap:CorporateNonSegmentMember 2022-01-03 2022-10-02 0000200406 jnj:BermekimabMember 2023-01-02 2023-10-01 0000200406 jnj:BermekimabMember 2022-01-03 2022-10-02 0000200406 jnj:TalcMember jnj:ConsumerMember jnj:BabyPowderMember 2023-01-02 2023-10-01 0000200406 srt:EuropeMember 2023-07-03 2023-10-01 0000200406 srt:EuropeMember 2022-07-04 2022-10-02 0000200406 srt:EuropeMember 2023-01-02 2023-10-01 0000200406 srt:EuropeMember 2022-01-03 2022-10-02 0000200406 jnj:WesternHemisphereExcludingUSMember 2023-07-03 2023-10-01 0000200406 jnj:WesternHemisphereExcludingUSMember 2022-07-04 2022-10-02 0000200406 jnj:WesternHemisphereExcludingUSMember 2023-01-02 2023-10-01 0000200406 jnj:WesternHemisphereExcludingUSMember 2022-01-03 2022-10-02 0000200406 jnj:AsiaPacificAfricaMember 2023-07-03 2023-10-01 0000200406 jnj:AsiaPacificAfricaMember 2022-07-04 2022-10-02 0000200406 jnj:AsiaPacificAfricaMember 2023-01-02 2023-10-01 0000200406 jnj:AsiaPacificAfricaMember 2022-01-03 2022-10-02 0000200406 jnj:AbiomedMember 2022-12-22 0000200406 jnj:AbiomedMember 2022-12-22 2022-12-22 0000200406 jnj:AbiomedMember jnj:NonTradeableContingentValueRightMember 2022-12-22 2022-12-22 0000200406 jnj:AbiomedMember jnj:NonTradeableContingentValueRightMember 2022-12-22 0000200406 jnj:NonTradeableContingentValueRightMember 2022-12-22 0000200406 jnj:AbiomedMember jnj:ImpellaMember jnj:NonTradeableContingentValueRightMember 2022-12-22 0000200406 jnj:NonTradeableContingentValueRightMember jnj:ClassIRecommendationForImpellaMember 2022-12-22 0000200406 2023-04-03 2023-07-02 0000200406 2022-12-22 0000200406 jnj:AbiomedMember srt:MinimumMember 2022-12-22 0000200406 srt:MaximumMember jnj:AbiomedMember 2022-12-22 0000200406 jnj:InghamVsJohnsonJohnsonMember 2018-07-01 2018-07-31 0000200406 jnj:InghamVsJohnsonJohnsonMember 2020-06-01 2020-06-30 0000200406 jnj:InghamVsJohnsonJohnsonMember 2021-06-01 2021-06-30 0000200406 jnj:TalcMember jnj:BabyPowderMember 2021-10-01 2021-10-31 0000200406 jnj:TalcMember jnj:BabyPowderMember 2023-04-24 0000200406 jnj:TalcMember jnj:BabyPowderMember 2021-10-31 0000200406 2023-04-24 0000200406 jnj:OpioidMember 2023-10-01 jnj:claimant 0000200406 jnj:OpioidMember 2021-07-04 0000200406 jnj:OpioidMember 2023-01-02 2023-10-01 jnj:claim 0000200406 jnj:TalcMember 2023-10-01 0000200406 jnj:AsrMember 2023-10-01 0000200406 jnj:PinnacleAcetabularCupSystemMember 2023-10-01 0000200406 jnj:PelvicMeshesMember 2023-10-01 0000200406 jnj:PhysiomeshMember 2023-10-01 0000200406 jnj:RisperdalMember 2023-10-01 0000200406 jnj:ElmironMember 2023-10-01 0000200406 us-gaap:SettledLitigationMember jnj:DePuyASRU.S.Member 2023-01-02 2023-10-01 0000200406 jnj:PhysiomeshMember us-gaap:PendingLitigationMember 2021-05-31 jnj:cases 0000200406 jnj:PhysiomeshMember us-gaap:PendingLitigationMember 2021-09-30 0000200406 jnj:PhysiomeshMember us-gaap:PendingLitigationMember 2021-09-01 2021-09-30 0000200406 jnj:EthiconMember us-gaap:PendingLitigationMember 2021-09-30 0000200406 jnj:PhysiomeshMember us-gaap:PendingLitigationMember 2023-05-31 0000200406 us-gaap:JudicialRulingMember 2019-10-01 2019-10-31 0000200406 us-gaap:JudicialRulingMember 2020-01-01 2020-01-31 0000200406 jnj:KenvueIncMember 2023-08-23 2023-08-23 0000200406 jnj:KenvueIncMember 2023-08-23 2023-08-23 0000200406 2023-08-23 0000200406 jnj:KenvueIncMember jnj:JohnsonJohnsonMember 2023-08-23 0000200406 jnj:ConsumerHealthMember 2023-08-23 0000200406 jnj:ConsumerHealthMember 2023-08-23 2023-08-23 0000200406 jnj:KenvueIncMember jnj:ConsumerHealthMember jnj:JohnsonJohnsonMember 2023-08-23 0000200406 2023-08-23 2023-08-23 0000200406 srt:MinimumMember 2023-08-23 2023-08-23 0000200406 srt:MaximumMember 2023-08-23 2023-08-23 0000200406 jnj:RDRestructuringPlanMember 2023-07-03 2023-10-01 0000200406 jnj:RDRestructuringPlanMember 2023-01-02 2023-10-01 0000200406 jnj:RDRestructuringPlanMember srt:MinimumMember 2023-10-01 0000200406 srt:MaximumMember jnj:RDRestructuringPlanMember 2023-10-01 0000200406 jnj:OrthopaedicsRestructuringPlanMember 2023-07-03 2023-10-01 0000200406 jnj:OrthopaedicsRestructuringPlanMember srt:MinimumMember 2023-10-01 0000200406 srt:MaximumMember jnj:OrthopaedicsRestructuringPlanMember 2023-10-01 0000200406 jnj:MedTechMember us-gaap:RestructuringChargesMember 2023-01-02 2023-10-01 0000200406 jnj:MedTechMember us-gaap:RestructuringChargesMember 2023-07-03 2023-10-01 0000200406 jnj:CostsOfGoodsAndServicesSoldMember jnj:MedTechMember 2023-07-03 2023-10-01 0000200406 jnj:CostsOfGoodsAndServicesSoldMember jnj:MedTechMember 2023-01-02 2023-10-01 0000200406 jnj:PeterFasoloMember 2023-01-02 2023-10-01 0000200406 jnj:PeterFasoloMember 2023-07-03 2023-10-01 0000200406 jnj:PeterFasoloMember 2023-10-01", "length": 97690, "numbers_raw": ["000", "020", "040", "6", "12", "31", "202", "3", "3", "202", "3", "202", "204M", "456", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "0.650", "202", "4M", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "5.50", "202", "4M", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "1.150", "202", "8M", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "1.650", "203", "5M", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "10", "23", "000", "020", "040", "6", "202", "3", "10", "01", "421", "7", "000", "020", "040", "6", "202", "3", "01", "01", "421", "7", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "02", "000", "020", "040", "6", "202", "3", "07", "02", "000", "020", "040", "6", "202", "3", "07", "02", "000", "020", "040", "6", "202", "3", "07", "02", "000", "020", "040", "6", "202", "3", "07", "02", "000", "020", "040", "6", "202", "3", "07", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "01", "01", "000", "020", "040", "6", "202", "3", "01", "01", "000", "020", "040", "6", "202", "3", "01", "01", "000", "020", "040", "6", "202", "3", "01", "01", "000", "020", "040", "6", "202", "3", "01", "01", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "03", "000", "020", "040", "6", "202", "2", "07", "03", "000", "020", "040", "6", "202", "2", "07", "03", "000", "020", "040", "6", "202", "2", "07", "03", "000", "020", "040", "6", "202", "2", "07", "03", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "2", "10", "02", "000", "020", "040", "6", "202", "2", "10", "02", "000", "020", "040", "6", "202", "2", "10", "02", "000", "020", "040", "6", "202", "2", "10", "02", "000", "020", "040", "6", "202", "2", "10", "02", "000", "020", "040", "6", "202", "2", "01", "02", "000", "020", "040", "6", "202", "2", "01", "02", "000", "020", "040", "6", "202", "2", "01", "02", "000", "020", "040", "6", "202", "2", "01", "02", "000", "020", "040", "6", "202", "2", "01", "02", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "05", "08", "202", "3", "05", "08", "000", "020", "040", "6", "202", "3", "05", "08", "000", "020", "040", "6", "202", "3", "05", "08", "202", "3", "05", "08", "000", "020", "040", "6", "202", "3", "05", "08", "202", "3", "05", "08", "000", "020", "040", "6", "202", "3", "07", "02", "000", "020", "040", "6", "202", "3", "08", "23", "202", "3", "08", "23", "000", "020", "040", "6", "202", "3", "08", "23", "202", "3", "08", "23", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "01", "01", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "01", "01", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "01", "01", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "01", "01", "000", "020", "040", "6", "202", "3", "01", "01", "000", "020", "040", "6", "202", "3", "01", "01", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "01", "01", "000", "020", "040", "6", "202", "3", "01", "01", "000", "020", "040", "6", "202", "3", "01", "01", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "01", "01", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "01", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "01", "01", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "1M", "202", "3", "10", "01", "000", "020", "040", "6", "2M", "202", "3", "10", "01", "000", "020", "040", "6", "3M", "202", "3", "10", "01", "000", "020", "040", "6", "2M", "202", "3", "01", "01", "000", "020", "040", "6", "1M", "202", "3", "10", "01", "000", "020", "040", "6", "2M", "202", "3", "10", "01", "000", "020", "040", "6", "3M", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "2M", "202", "3", "01", "01", "000", "020", "040", "6", "1M", "202", "3", "10", "01", "000", "020", "040", "6", "2M", "202", "3", "10", "01", "000", "020", "040", "6", "3M", "202", "3", "10", "01", "000", "020", "040", "6", "2M", "202", "3", "01", "01", "000", "020", "040", "6", "1M", "202", "3", "01", "01", "000", "020", "040", "6", "3M", "202", "3", "01", "01", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "01", "01", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "5.50", "202", "4M", "202", "3", "10", "01", "421", "7", "000", "020", "040", "6", "5.50", "202", "4M", "202", "3", "10", "01", "000", "020", "040", "6", "5.50", "202", "4M", "202", "3", "10", "01", "000", "020", "040", "6", "2.625", "202", "5M", "202", "3", "10", "01", "000", "020", "040", "6", "2.625", "202", "5M", "202", "3", "10", "01", "000", "020", "040", "6", "2.625", "202", "5M", "202", "3", "10", "01", "000", "020", "040", "6", "055", "0", "202", "5M", "202", "3", "10", "01", "000", "020", "040", "6", "055", "0", "202", "5M", "202", "3", "10", "01", "000", "020", "040", "6", "055", "0", "202", "5M", "202", "3", "10", "01", "000", "020", "040", "6", "2.45", "202", "6M", "202", "3", "10", "01", "000", "020", "040", "6", "2.45", "202", "6M", "202", "3", "10", "01", "000", "020", "040", "6", "2.45", "202", "6M", "202", "3", "10", "01", "000", "020", "040", "6", "2.95", "202", "7M", "202", "3", "10", "01", "000", "020", "040", "6", "2.95", "202", "7M", "202", "3", "10", "01", "000", "020", "040", "6", "2.95", "202", "7M", "202", "3", "10", "01", "000", "020", "040", "6", "095", "202", "7M", "202", "3", "10", "01", "000", "020", "040", "6", "095", "202", "7M", "202", "3", "10", "01", "000", "020", "040", "6", "095", "202", "7M", "202", "3", "10", "01", "000", "020", "040", "6", "2.900", "202", "8M", "202", "3", "10", "01", "000", "020", "040", "6", "2.900", "202", "8M", "202", "3", "10", "01", "000", "020", "040", "6", "2.900", "202", "8M", "202", "3", "10", "01", "000", "020", "040", "6", "1.150", "202", "8M", "202", "3", "10", "01", "421", "7", "000", "020", "040", "6", "1.150", "202", "8M", "202", "3", "10", "01", "000", "020", "040", "6", "1.150", "202", "8M", "202", "3", "10", "01", "000", "020", "040", "6", "6.95", "202", "9M", "202", "3", "10", "01", "000", "020", "040", "6", "6.95", "202", "9M", "202", "3", "10", "01", "000", "020", "040", "6", "6.95", "202", "9M", "202", "3", "10", "01", "000", "020", "040", "6", "130", "0", "203", "0M", "202", "3", "10", "01", "000", "020", "040", "6", "130", "0", "203", "0M", "202", "3", "10", "01", "000", "020", "040", "6", "130", "0", "203", "0M", "202", "3", "10", "01", "000", "020", "040", "6", "4.95", "203", "3M", "202", "3", "10", "01", "000", "020", "040", "6", "4.95", "203", "3M", "202", "3", "10", "01", "000", "020", "040", "6", "4.95", "203", "3M", "202", "3", "10", "01", "000", "020", "040", "6", "4.375", "203", "3M", "202", "3", "10", "01", "000", "020", "040", "6", "4.375", "203", "3M", "202", "3", "10", "01", "000", "020", "040", "6", "4.375", "203", "3M", "202", "3", "10", "01", "000", "020", "040", "6", "1.650", "203", "5M", "202", "3", "10", "01", "000", "020", "040", "6", "1.650", "203", "5M", "202", "3", "10", "01", "000", "020", "040", "6", "3.55", "203", "6M", "202", "3", "10", "01", "000", "020", "040", "6", "3.55", "203", "6M", "202", "3", "10", "01", "000", "020", "040", "6", "3.55", "203", "6M", "202", "3", "10", "01", "000", "020", "040", "6", "5.95", "203", "7M", "202", "3", "10", "01", "000", "020", "040", "6", "5.95", "203", "7M", "202", "3", "10", "01", "000", "020", "040", "6", "5.95", "203", "7M", "202", "3", "10", "01", "000", "020", "040", "6", "3.625", "203", "7M", "202", "3", "10", "01", "000", "020", "040", "6", "3.625", "203", "7M", "202", "3", "10", "01", "000", "020", "040", "6", "3.625", "203", "7M", "202", "3", "10", "01", "000", "020", "040", "6", "3.400", "203", "8M", "202", "3", "10", "01", "000", "020", "040", "6", "3.400", "203", "8M", "202", "3", "10", "01", "000", "020", "040", "6", "3.400", "203", "8M", "202", "3", "10", "01", "000", "020", "040", "6", "5.85", "203", "8M", "202", "3", "10", "01", "000", "020", "040", "6", "5.85", "203", "8M", "202", "3", "10", "01", "000", "020", "040", "6", "5.85", "203", "8M", "202", "3", "10", "01", "000", "020", "040", "6", "4.50", "204", "0M", "202", "3", "10", "01", "000", "020", "040", "6", "4.50", "204", "0M", "202", "3", "10", "01", "000", "020", "040", "6", "4.50", "204", "0M", "202", "3", "10", "01", "000", "020", "040", "6", "210", "204", "0M", "202", "3", "10", "01", "000", "020", "040", "6", "210", "204", "0M", "202", "3", "10", "01", "000", "020", "040", "6", "210", "204", "0M", "202", "3", "10", "01", "000", "020", "040", "6", "4.85", "204", "1M", "202", "3", "10", "01", "000", "020", "040", "6", "4.85", "204", "1M", "202", "3", "10", "01", "000", "020", "040", "6", "4.85", "204", "1M", "202", "3", "10", "01", "000", "020", "040", "6", "4.50", "204", "3M", "202", "3", "10", "01", "000", "020", "040", "6", "4.50", "204", "3M", "202", "3", "10", "01", "000", "020", "040", "6", "4.50", "204", "3M", "202", "3", "10", "01", "000", "020", "040", "6", "3.70", "204", "6M", "202", "3", "10", "01", "000", "020", "040", "6", "3.70", "204", "6M", "202", "3", "10", "01", "000", "020", "040", "6", "3.70", "204", "6M", "202", "3", "10", "01", "000", "020", "040", "6", "3.75", "204", "7M", "202", "3", "10", "01", "000", "020", "040", "6", "3.75", "204", "7M", "202", "3", "10", "01", "000", "020", "040", "6", "3.75", "204", "7M", "202", "3", "10", "01", "000", "020", "040", "6", "3.500", "204", "8M", "202", "3", "10", "01", "000", "020", "040", "6", "3.500", "204", "8M", "202", "3", "10", "01", "000", "020", "040", "6", "3.500", "204", "8M", "202", "3", "10", "01", "000", "020", "040", "6", "225", "0", "205", "0M", "202", "3", "10", "01", "000", "020", "040", "6", "225", "0", "205", "0M", "202", "3", "10", "01", "000", "020", "040", "6", "225", "0", "205", "0M", "202", "3", "10", "01", "000", "020", "040", "6", "245", "0", "206", "0M", "202", "3", "10", "01", "000", "020", "040", "6", "245", "0", "206", "0M", "202", "3", "10", "01", "000", "020", "040", "6", "245", "0", "206", "0M", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "04", "02", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "04", "03", "202", "3", "07", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "01", "01", "000", "020", "040", "6", "202", "3", "01", "01", "000", "020", "040", "6", "202", "3", "01", "01", "000", "020", "040", "6", "202", "3", "01", "01", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "19M", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "19M", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "19M", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "19M", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "19M", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "19M", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "19M", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "19M", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "19M", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "19M", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "19M", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "19M", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "07", "04", "202", "2", "10", "02", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "2", "01", "03", "202", "2", "10", "02", "000", "020", "040", "6", "202", "2", "12", "22", "000", "020", "040", "6", "202", "2", "12", "22", "202", "2", "12", "22", "000", "020", "040", "6", "202", "2", "12", "22", "202", "2", "12", "22", "000", "020", "040", "6", "202", "2", "12", "22", "000", "020", "040", "6", "202", "2", "12", "22", "000", "020", "040", "6", "202", "2", "12", "22", "000", "020", "040", "6", "202", "2", "12", "22", "000", "020", "040", "6", "202", "3", "04", "03", "202", "3", "07", "02", "000", "020", "040", "6", "202", "2", "12", "22", "000", "020", "040", "6", "202", "2", "12", "22", "000", "020", "040", "6", "202", "2", "12", "22", "000", "020", "040", "6", "201", "8", "07", "01", "201", "8", "07", "31", "000", "020", "040", "6", "202", "0", "06", "01", "202", "0", "06", "30", "000", "020", "040", "6", "202", "1", "06", "01", "202", "1", "06", "30", "000", "020", "040", "6", "202", "1", "10", "01", "202", "1", "10", "31", "000", "020", "040", "6", "202", "3", "04", "24", "000", "020", "040", "6", "202", "1", "10", "31", "000", "020", "040", "6", "202", "3", "04", "24", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "1", "07", "04", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "1", "05", "31", "000", "020", "040", "6", "202", "1", "09", "30", "000", "020", "040", "6", "202", "1", "09", "01", "202", "1", "09", "30", "000", "020", "040", "6", "202", "1", "09", "30", "000", "020", "040", "6", "202", "3", "05", "31", "000", "020", "040", "6", "201", "9", "10", "01", "201", "9", "10", "31", "000", "020", "040", "6", "202", "0", "01", "01", "202", "0", "01", "31", "000", "020", "040", "6", "202", "3", "08", "23", "202", "3", "08", "23", "000", "020", "040", "6", "202", "3", "08", "23", "202", "3", "08", "23", "000", "020", "040", "6", "202", "3", "08", "23", "000", "020", "040", "6", "202", "3", "08", "23", "000", "020", "040", "6", "202", "3", "08", "23", "000", "020", "040", "6", "202", "3", "08", "23", "202", "3", "08", "23", "000", "020", "040", "6", "202", "3", "08", "23", "000", "020", "040", "6", "202", "3", "08", "23", "202", "3", "08", "23", "000", "020", "040", "6", "202", "3", "08", "23", "202", "3", "08", "23", "000", "020", "040", "6", "202", "3", "08", "23", "202", "3", "08", "23", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "01", "02", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "07", "03", "202", "3", "10", "01", "000", "020", "040", "6", "202", "3", "10", "01"], "numbers": [0.0, 20.0, 40.0, 6.0, 12.0, 31.0, 202.0, 3.0, 3.0, 202.0, 3.0, 202.0, 204000000.0, 456.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 0.65, 202.0, 4000000.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 5.5, 202.0, 4000000.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 1.15, 202.0, 8000000.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 1.65, 203.0, 5000000.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 23.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 421.0, 7.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 1.0, 421.0, 7.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 3.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 3.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 3.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 3.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 3.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 5.0, 8.0, 202.0, 3.0, 5.0, 8.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 5.0, 8.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 5.0, 8.0, 202.0, 3.0, 5.0, 8.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 5.0, 8.0, 202.0, 3.0, 5.0, 8.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 8.0, 23.0, 202.0, 3.0, 8.0, 23.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 8.0, 23.0, 202.0, 3.0, 8.0, 23.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 1000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 2000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 3000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 2000000.0, 202.0, 3.0, 1.0, 1.0, 0.0, 20.0, 40.0, 6.0, 1000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 2000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 3000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 2000000.0, 202.0, 3.0, 1.0, 1.0, 0.0, 20.0, 40.0, 6.0, 1000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 2000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 3000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 2000000.0, 202.0, 3.0, 1.0, 1.0, 0.0, 20.0, 40.0, 6.0, 1000000.0, 202.0, 3.0, 1.0, 1.0, 0.0, 20.0, 40.0, 6.0, 3000000.0, 202.0, 3.0, 1.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 5.5, 202.0, 4000000.0, 202.0, 3.0, 10.0, 1.0, 421.0, 7.0, 0.0, 20.0, 40.0, 6.0, 5.5, 202.0, 4000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 5.5, 202.0, 4000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 2.625, 202.0, 5000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 2.625, 202.0, 5000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 2.625, 202.0, 5000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 55.0, 0.0, 202.0, 5000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 55.0, 0.0, 202.0, 5000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 55.0, 0.0, 202.0, 5000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 2.45, 202.0, 6000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 2.45, 202.0, 6000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 2.45, 202.0, 6000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 2.95, 202.0, 7000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 2.95, 202.0, 7000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 2.95, 202.0, 7000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 95.0, 202.0, 7000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 95.0, 202.0, 7000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 95.0, 202.0, 7000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 2.9, 202.0, 8000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 2.9, 202.0, 8000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 2.9, 202.0, 8000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 1.15, 202.0, 8000000.0, 202.0, 3.0, 10.0, 1.0, 421.0, 7.0, 0.0, 20.0, 40.0, 6.0, 1.15, 202.0, 8000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 1.15, 202.0, 8000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 6.95, 202.0, 9000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 6.95, 202.0, 9000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 6.95, 202.0, 9000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 130.0, 0.0, 203.0, 0.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 130.0, 0.0, 203.0, 0.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 130.0, 0.0, 203.0, 0.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 4.95, 203.0, 3000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 4.95, 203.0, 3000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 4.95, 203.0, 3000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 4.375, 203.0, 3000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 4.375, 203.0, 3000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 4.375, 203.0, 3000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 1.65, 203.0, 5000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 1.65, 203.0, 5000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 3.55, 203.0, 6000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 3.55, 203.0, 6000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 3.55, 203.0, 6000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 5.95, 203.0, 7000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 5.95, 203.0, 7000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 5.95, 203.0, 7000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 3.625, 203.0, 7000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 3.625, 203.0, 7000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 3.625, 203.0, 7000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 3.4, 203.0, 8000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 3.4, 203.0, 8000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 3.4, 203.0, 8000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 5.85, 203.0, 8000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 5.85, 203.0, 8000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 5.85, 203.0, 8000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 4.5, 204.0, 0.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 4.5, 204.0, 0.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 4.5, 204.0, 0.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 210.0, 204.0, 0.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 210.0, 204.0, 0.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 210.0, 204.0, 0.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 4.85, 204.0, 1000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 4.85, 204.0, 1000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 4.85, 204.0, 1000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 4.5, 204.0, 3000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 4.5, 204.0, 3000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 4.5, 204.0, 3000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 3.7, 204.0, 6000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 3.7, 204.0, 6000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 3.7, 204.0, 6000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 3.75, 204.0, 7000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 3.75, 204.0, 7000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 3.75, 204.0, 7000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 3.5, 204.0, 8000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 3.5, 204.0, 8000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 3.5, 204.0, 8000000.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 225.0, 0.0, 205.0, 0.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 225.0, 0.0, 205.0, 0.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 225.0, 0.0, 205.0, 0.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 245.0, 0.0, 206.0, 0.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 245.0, 0.0, 206.0, 0.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 245.0, 0.0, 206.0, 0.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 4.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 4.0, 3.0, 202.0, 3.0, 7.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 19000000.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 19000000.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 19000000.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 19000000.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 19000000.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 19000000.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 19000000.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 19000000.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 19000000.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 19000000.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 19000000.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 19000000.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 7.0, 4.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 1.0, 3.0, 202.0, 2.0, 10.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 12.0, 22.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 12.0, 22.0, 202.0, 2.0, 12.0, 22.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 12.0, 22.0, 202.0, 2.0, 12.0, 22.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 12.0, 22.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 12.0, 22.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 12.0, 22.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 12.0, 22.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 4.0, 3.0, 202.0, 3.0, 7.0, 2.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 12.0, 22.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 12.0, 22.0, 0.0, 20.0, 40.0, 6.0, 202.0, 2.0, 12.0, 22.0, 0.0, 20.0, 40.0, 6.0, 201.0, 8.0, 7.0, 1.0, 201.0, 8.0, 7.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 0.0, 6.0, 1.0, 202.0, 0.0, 6.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 1.0, 6.0, 1.0, 202.0, 1.0, 6.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 1.0, 10.0, 1.0, 202.0, 1.0, 10.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 4.0, 24.0, 0.0, 20.0, 40.0, 6.0, 202.0, 1.0, 10.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 4.0, 24.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 1.0, 7.0, 4.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 1.0, 5.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 1.0, 9.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 1.0, 9.0, 1.0, 202.0, 1.0, 9.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 1.0, 9.0, 30.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 5.0, 31.0, 0.0, 20.0, 40.0, 6.0, 201.0, 9.0, 10.0, 1.0, 201.0, 9.0, 10.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 0.0, 1.0, 1.0, 202.0, 0.0, 1.0, 31.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 8.0, 23.0, 202.0, 3.0, 8.0, 23.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 8.0, 23.0, 202.0, 3.0, 8.0, 23.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 8.0, 23.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 8.0, 23.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 8.0, 23.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 8.0, 23.0, 202.0, 3.0, 8.0, 23.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 8.0, 23.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 8.0, 23.0, 202.0, 3.0, 8.0, 23.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 8.0, 23.0, 202.0, 3.0, 8.0, 23.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 8.0, 23.0, 202.0, 3.0, 8.0, 23.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 1.0, 2.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 7.0, 3.0, 202.0, 3.0, 10.0, 1.0, 0.0, 20.0, 40.0, 6.0, 202.0, 3.0, 10.0, 1.0], "percents_raw": [], "percents": [], "currencies": ["EUR", "GBP", "USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 9, "tag": "div", "text_raw": "Washington, D.C. 20549", "text": "20549", "length": 5, "numbers_raw": ["205", "49"], "numbers": [205.0, 49.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 10, "tag": "div", "text_raw": "FORM 10-Q", "text": "FORM 10-Q", "length": 9, "numbers_raw": ["10"], "numbers": [10.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 11, "tag": "div", "text_raw": " Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934", "text": " Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934", "length": 89, "numbers_raw": ["13", "15", "193", "4"], "numbers": [13.0, 15.0, 193.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 12, "tag": "div", "text_raw": "for the quarterly period ended October 1, 2023", "text": "for the quarterly period ended October 1, 2023", "length": 46, "numbers_raw": ["1", "202", "3"], "numbers": [1.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 15, "tag": "div", "text_raw": " Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to", "text": " Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to", "length": 124, "numbers_raw": ["13", "15", "193", "4"], "numbers": [13.0, 15.0, 193.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 16, "tag": "div", "text_raw": "Commission file number 1-3215", "text": "Commission file number 1-3215", "length": 29, "numbers_raw": ["1", "321", "5"], "numbers": [1.0, 321.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 18, "tag": "div", "text_raw": "(Exact name of registrant as specified in its charter)", "text": "(Exact name of registrant as specified in its charter)", "length": 54, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 19, "tag": "div", "text_raw": "New Jersey 22-1024240 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)", "text": "New Jersey 22-1024240 (State or other jurisdiction of incorporation or organization) (I.R.S.", "length": 92, "numbers_raw": ["22", "102", "424", "0"], "numbers": [22.0, 102.0, 424.0, 0.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 23, "tag": "div", "text_raw": "New Brunswick , New Jersey 08933", "text": "New Brunswick , New Jersey 08933", "length": 32, "numbers_raw": ["089", "33"], "numbers": [89.0, 33.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 24, "tag": "div", "text_raw": "(Address of principal executive offices)", "text": "(Address of principal executive offices)", "length": 40, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 25, "tag": "div", "text_raw": "Registrants telephone number, including area code ( 732 ) 524-0400", "text": "Registrants telephone number, including area code ( 732 ) 524-0400", "length": 67, "numbers_raw": ["732", "524", "040", "0"], "numbers": [732.0, 524.0, 40.0, 0.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 26, "tag": "div", "text_raw": "Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes  No", "text": "Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.", "length": 344, "numbers_raw": ["1", "13", "15", "193", "4", "12 m", "2", "90"], "numbers": [1.0, 13.0, 15.0, 193.0, 4.0, 12000000.0, 2.0, 90.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 27, "tag": "div", "text_raw": "Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes  No", "text": "Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "length": 281, "numbers_raw": ["405", "12 m"], "numbers": [405.0, 12000000.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 28, "tag": "div", "text_raw": "Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.", "text": "Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.", "length": 182, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 28, "tag": "div", "text_raw": "Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.", "text": "See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.", "length": 164, "numbers_raw": ["12", "2"], "numbers": [12.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 29, "tag": "div", "text_raw": "Large accelerated filer  Accelerated filer  Non-accelerated filer  Smaller reporting company  Emerging growth company ", "text": "Large accelerated filer  Accelerated filer  Non-accelerated filer  Smaller reporting company  Emerging growth company ", "length": 123, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 31, "tag": "div", "text_raw": "If an emerging growth company, indicated by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ", "text": "If an emerging growth company, indicated by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.", "length": 251, "numbers_raw": ["13"], "numbers": [13.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 32, "tag": "div", "text_raw": "Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes  No", "text": "Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).", "length": 112, "numbers_raw": ["12", "2"], "numbers": [12.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 36, "tag": "div", "text_raw": "SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT", "text": "SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT", "length": 58, "numbers_raw": ["12"], "numbers": [12.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 37, "tag": "div", "text_raw": "Title of each class Trading Symbol Name of each exchange on which registered Common Stock, Par Value $1.00 JNJ New York Stock Exchange 0.650% Notes Due May 2024 JNJ24C New York Stock Exchange 5.50% Notes Due November 2024 JNJ24BP New York Stock Exchange 1.150% Notes Due November 2028 JNJ28 New York Stock Exchange 1.650% Notes Due May 2035 JNJ35 New York Stock Exchange", "text": "Title of each class Trading Symbol Name of each exchange on which registered Common Stock, Par Value $1.00 JNJ New York Stock Exchange 0.650% Notes Due May 2024 JNJ24C New York Stock Exchange 5.50% Notes Due November 2024 JNJ24BP New York Stock Exchange 1.150% Notes Due November 2028 JNJ28 New York Stock Exchange 1.650% Notes Due May 2035 JNJ35 New York Stock Exchange", "length": 370, "numbers_raw": ["$1.00", "0.650", "202", "4", "24", "5.50", "202", "4", "24", "1.150", "202", "8", "28", "1.650", "203", "5", "35"], "numbers": [1.0, 0.65, 202.0, 4.0, 24.0, 5.5, 202.0, 4.0, 24.0, 1.15, 202.0, 8.0, 28.0, 1.65, 203.0, 5.0, 35.0], "percents_raw": ["0.650%", "5.50%", "1.150%", "1.650%"], "percents": [0.006500000000000001, 0.055, 0.0115, 0.0165], "currencies": ["USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 38, "tag": "div", "text_raw": "Indicate the number of shares outstanding of each of the issuers classes of common stock, as of the latest practicable date.", "text": "Indicate the number of shares outstanding of each of the issuers classes of common stock, as of the latest practicable date.", "length": 125, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 39, "tag": "div", "text_raw": "On October 23, 2023, 2,407,278,620 shares of Common Stock, $1.00 par value, were outstanding.", "text": "On October 23, 2023, 2,407,278,620 shares of Common Stock, $1.00 par value, were outstanding.", "length": 93, "numbers_raw": ["23", "202", "3", "2,407,278,620", "$1.00"], "numbers": [23.0, 202.0, 3.0, 2407278620.0, 1.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 47, "tag": "div", "text_raw": "JOHNSON & JOHNSON AND SUBSIDIARIES", "text": "JOHNSON & JOHNSON AND SUBSIDIARIES", "length": 34, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 49, "tag": "div", "text_raw": "Page No. Part I  Financial Information 1 Item 1. Financial Statements (unaudited) 1 Consolidated Balance Sheets  October 1 , 2023 and January 1, 2023 1 Consolidated Statements of Earnings for the Fiscal Third Quarters Ended October 1 , 2023 and October 2 , 2022 2 Consolidated Statements of Earnings for the Fiscal Nine Months Ended October 1 , 2023 and October 2 , 2022 3 Consolidated Statements of Comprehensive Income for the Fiscal Third Quarters and Fiscal Nine Months Ended October 1 , 2023 and October 2 , 2022 4 Consolidated Statements of Equity for the Fiscal Third Quarters and Fiscal Nine Months Ended October 1 , 2023 and October 2 , 2022 5 Consolidated Statements of Cash Flows for the Fiscal Nine Months Ended October 1 , 2023 and October 2 , 2022 7 Notes to Consolidated Financial Statements 9 Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations 43 Item 3. Quantitative and Qualitative Disclosures About Market Risk 58 Item 4. Controls and Procedures 58 Part II  Other Information 59 Item 1 - Legal Proceedings 59 Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds 59 Item 5 - Other Information 59 Item 6 - Exhibits 60 Signatures 61", "text": "Part I  Financial Information 1 Item 1.", "length": 40, "numbers_raw": ["1", "1"], "numbers": [1.0, 1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 49, "tag": "div", "text_raw": "Page No. Part I  Financial Information 1 Item 1. Financial Statements (unaudited) 1 Consolidated Balance Sheets  October 1 , 2023 and January 1, 2023 1 Consolidated Statements of Earnings for the Fiscal Third Quarters Ended October 1 , 2023 and October 2 , 2022 2 Consolidated Statements of Earnings for the Fiscal Nine Months Ended October 1 , 2023 and October 2 , 2022 3 Consolidated Statements of Comprehensive Income for the Fiscal Third Quarters and Fiscal Nine Months Ended October 1 , 2023 and October 2 , 2022 4 Consolidated Statements of Equity for the Fiscal Third Quarters and Fiscal Nine Months Ended October 1 , 2023 and October 2 , 2022 5 Consolidated Statements of Cash Flows for the Fiscal Nine Months Ended October 1 , 2023 and October 2 , 2022 7 Notes to Consolidated Financial Statements 9 Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations 43 Item 3. Quantitative and Qualitative Disclosures About Market Risk 58 Item 4. Controls and Procedures 58 Part II  Other Information 59 Item 1 - Legal Proceedings 59 Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds 59 Item 5 - Other Information 59 Item 6 - Exhibits 60 Signatures 61", "text": "Financial Statements (unaudited) 1 Consolidated Balance Sheets  October 1 , 2023 and January 1, 2023 1 Consolidated Statements of Earnings for the Fiscal Third Quarters Ended October 1 , 2023 and October 2 , 2022 2 Consolidated Statements of Earnings for the Fiscal Nine Months Ended October 1 , 2023 and October 2 , 2022 3 Consolidated Statements of Comprehensive Income for the Fiscal Third Quarters and Fiscal Nine Months Ended October 1 , 2023 and October 2 , 2022 4 Consolidated Statements of Equity for the Fiscal Third Quarters and Fiscal Nine Months Ended October 1 , 2023 and October 2 , 2022 5 Consolidated Statements of Cash Flows for the Fiscal Nine Months Ended October 1 , 2023 and October 2 , 2022 7 Notes to Consolidated Financial Statements 9 Item 2.", "length": 768, "numbers_raw": ["1", "1", "202", "3", "1", "202", "3", "1", "1", "202", "3", "2", "202", "2", "2", "1", "202", "3", "2", "202", "2", "3", "1", "202", "3", "2", "202", "2", "4", "1", "202", "3", "2", "202", "2", "5", "1", "202", "3", "2", "202", "2", "7", "9", "2"], "numbers": [1.0, 1.0, 202.0, 3.0, 1.0, 202.0, 3.0, 1.0, 1.0, 202.0, 3.0, 2.0, 202.0, 2.0, 2.0, 1.0, 202.0, 3.0, 2.0, 202.0, 2.0, 3.0, 1.0, 202.0, 3.0, 2.0, 202.0, 2.0, 4.0, 1.0, 202.0, 3.0, 2.0, 202.0, 2.0, 5.0, 1.0, 202.0, 3.0, 2.0, 202.0, 2.0, 7.0, 9.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 49, "tag": "div", "text_raw": "Page No. Part I  Financial Information 1 Item 1. Financial Statements (unaudited) 1 Consolidated Balance Sheets  October 1 , 2023 and January 1, 2023 1 Consolidated Statements of Earnings for the Fiscal Third Quarters Ended October 1 , 2023 and October 2 , 2022 2 Consolidated Statements of Earnings for the Fiscal Nine Months Ended October 1 , 2023 and October 2 , 2022 3 Consolidated Statements of Comprehensive Income for the Fiscal Third Quarters and Fiscal Nine Months Ended October 1 , 2023 and October 2 , 2022 4 Consolidated Statements of Equity for the Fiscal Third Quarters and Fiscal Nine Months Ended October 1 , 2023 and October 2 , 2022 5 Consolidated Statements of Cash Flows for the Fiscal Nine Months Ended October 1 , 2023 and October 2 , 2022 7 Notes to Consolidated Financial Statements 9 Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations 43 Item 3. Quantitative and Qualitative Disclosures About Market Risk 58 Item 4. Controls and Procedures 58 Part II  Other Information 59 Item 1 - Legal Proceedings 59 Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds 59 Item 5 - Other Information 59 Item 6 - Exhibits 60 Signatures 61", "text": "Managements Discussion and Analysis of Financial Condition and Results of Operations 43 Item 3.", "length": 96, "numbers_raw": ["43", "3"], "numbers": [43.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 49, "tag": "div", "text_raw": "Page No. Part I  Financial Information 1 Item 1. Financial Statements (unaudited) 1 Consolidated Balance Sheets  October 1 , 2023 and January 1, 2023 1 Consolidated Statements of Earnings for the Fiscal Third Quarters Ended October 1 , 2023 and October 2 , 2022 2 Consolidated Statements of Earnings for the Fiscal Nine Months Ended October 1 , 2023 and October 2 , 2022 3 Consolidated Statements of Comprehensive Income for the Fiscal Third Quarters and Fiscal Nine Months Ended October 1 , 2023 and October 2 , 2022 4 Consolidated Statements of Equity for the Fiscal Third Quarters and Fiscal Nine Months Ended October 1 , 2023 and October 2 , 2022 5 Consolidated Statements of Cash Flows for the Fiscal Nine Months Ended October 1 , 2023 and October 2 , 2022 7 Notes to Consolidated Financial Statements 9 Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations 43 Item 3. Quantitative and Qualitative Disclosures About Market Risk 58 Item 4. Controls and Procedures 58 Part II  Other Information 59 Item 1 - Legal Proceedings 59 Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds 59 Item 5 - Other Information 59 Item 6 - Exhibits 60 Signatures 61", "text": "Quantitative and Qualitative Disclosures About Market Risk 58 Item 4.", "length": 69, "numbers_raw": ["58", "4"], "numbers": [58.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 49, "tag": "div", "text_raw": "Page No. Part I  Financial Information 1 Item 1. Financial Statements (unaudited) 1 Consolidated Balance Sheets  October 1 , 2023 and January 1, 2023 1 Consolidated Statements of Earnings for the Fiscal Third Quarters Ended October 1 , 2023 and October 2 , 2022 2 Consolidated Statements of Earnings for the Fiscal Nine Months Ended October 1 , 2023 and October 2 , 2022 3 Consolidated Statements of Comprehensive Income for the Fiscal Third Quarters and Fiscal Nine Months Ended October 1 , 2023 and October 2 , 2022 4 Consolidated Statements of Equity for the Fiscal Third Quarters and Fiscal Nine Months Ended October 1 , 2023 and October 2 , 2022 5 Consolidated Statements of Cash Flows for the Fiscal Nine Months Ended October 1 , 2023 and October 2 , 2022 7 Notes to Consolidated Financial Statements 9 Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations 43 Item 3. Quantitative and Qualitative Disclosures About Market Risk 58 Item 4. Controls and Procedures 58 Part II  Other Information 59 Item 1 - Legal Proceedings 59 Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds 59 Item 5 - Other Information 59 Item 6 - Exhibits 60 Signatures 61", "text": "Controls and Procedures 58 Part II  Other Information 59 Item 1 - Legal Proceedings 59 Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds 59 Item 5 - Other Information 59 Item 6 - Exhibits 60 Signatures 61", "length": 224, "numbers_raw": ["58", "59", "1", "59", "2", "59", "5", "59", "6", "60", "61"], "numbers": [58.0, 59.0, 1.0, 59.0, 2.0, 59.0, 5.0, 59.0, 6.0, 60.0, 61.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 50, "tag": "div", "text_raw": "Part I  Financial Information", "text": "Part I  Financial Information", "length": 30, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 51, "tag": "div", "text_raw": "1", "text": "1", "length": 1, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 52, "tag": "div", "text_raw": "Item 1. Financial Statements (unaudited)", "text": "Item 1.", "length": 7, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 52, "tag": "div", "text_raw": "Item 1. Financial Statements (unaudited)", "text": "Financial Statements (unaudited)", "length": 32, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 53, "tag": "div", "text_raw": "1", "text": "1", "length": 1, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 54, "tag": "div", "text_raw": "Consolidated Balance Sheets  October 1 , 2023 and January 1, 2023", "text": "Consolidated Balance Sheets  October 1 , 2023 and January 1, 2023", "length": 66, "numbers_raw": ["1", "202", "3", "1", "202", "3"], "numbers": [1.0, 202.0, 3.0, 1.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 55, "tag": "div", "text_raw": "1", "text": "1", "length": 1, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 56, "tag": "div", "text_raw": "Consolidated Statements of Earnings for the Fiscal Third Quarters Ended October 1 , 2023 and October 2 , 2022", "text": "Consolidated Statements of Earnings for the Fiscal Third Quarters Ended October 1 , 2023 and October 2 , 2022", "length": 109, "numbers_raw": ["1", "202", "3", "2", "202", "2"], "numbers": [1.0, 202.0, 3.0, 2.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 57, "tag": "div", "text_raw": "2", "text": "2", "length": 1, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 58, "tag": "div", "text_raw": "Consolidated Statements of Earnings for the Fiscal Nine Months Ended October 1 , 2023 and October 2 , 2022", "text": "Consolidated Statements of Earnings for the Fiscal Nine Months Ended October 1 , 2023 and October 2 , 2022", "length": 106, "numbers_raw": ["1", "202", "3", "2", "202", "2"], "numbers": [1.0, 202.0, 3.0, 2.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 59, "tag": "div", "text_raw": "3", "text": "3", "length": 1, "numbers_raw": ["3"], "numbers": [3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 60, "tag": "div", "text_raw": "Consolidated Statements of Comprehensive Income for the Fiscal Third Quarters and Fiscal Nine Months Ended October 1 , 2023 and October 2 , 2022", "text": "Consolidated Statements of Comprehensive Income for the Fiscal Third Quarters and Fiscal Nine Months Ended October 1 , 2023 and October 2 , 2022", "length": 144, "numbers_raw": ["1", "202", "3", "2", "202", "2"], "numbers": [1.0, 202.0, 3.0, 2.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 61, "tag": "div", "text_raw": "4", "text": "4", "length": 1, "numbers_raw": ["4"], "numbers": [4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 62, "tag": "div", "text_raw": "Consolidated Statements of Equity for the Fiscal Third Quarters and Fiscal Nine Months Ended October 1 , 2023 and October 2 , 2022", "text": "Consolidated Statements of Equity for the Fiscal Third Quarters and Fiscal Nine Months Ended October 1 , 2023 and October 2 , 2022", "length": 130, "numbers_raw": ["1", "202", "3", "2", "202", "2"], "numbers": [1.0, 202.0, 3.0, 2.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 63, "tag": "div", "text_raw": "5", "text": "5", "length": 1, "numbers_raw": ["5"], "numbers": [5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 64, "tag": "div", "text_raw": "Consolidated Statements of Cash Flows for the Fiscal Nine Months Ended October 1 , 2023 and October 2 , 2022", "text": "Consolidated Statements of Cash Flows for the Fiscal Nine Months Ended October 1 , 2023 and October 2 , 2022", "length": 108, "numbers_raw": ["1", "202", "3", "2", "202", "2"], "numbers": [1.0, 202.0, 3.0, 2.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 65, "tag": "div", "text_raw": "7", "text": "7", "length": 1, "numbers_raw": ["7"], "numbers": [7.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 66, "tag": "div", "text_raw": "Notes to Consolidated Financial Statements", "text": "Notes to Consolidated Financial Statements", "length": 42, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 67, "tag": "div", "text_raw": "9", "text": "9", "length": 1, "numbers_raw": ["9"], "numbers": [9.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 68, "tag": "div", "text_raw": "Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations", "text": "Item 2.", "length": 7, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 68, "tag": "div", "text_raw": "Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations", "text": "Managements Discussion and Analysis of Financial Condition and Results of Operations", "length": 85, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 69, "tag": "div", "text_raw": "43", "text": "43", "length": 2, "numbers_raw": ["43"], "numbers": [43.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 70, "tag": "div", "text_raw": "Item 3. Quantitative and Qualitative Disclosures About Market Risk", "text": "Item 3.", "length": 7, "numbers_raw": ["3"], "numbers": [3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 70, "tag": "div", "text_raw": "Item 3. Quantitative and Qualitative Disclosures About Market Risk", "text": "Quantitative and Qualitative Disclosures About Market Risk", "length": 58, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 71, "tag": "div", "text_raw": "58", "text": "58", "length": 2, "numbers_raw": ["58"], "numbers": [58.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 72, "tag": "div", "text_raw": "Item 4. Controls and Procedures", "text": "Item 4.", "length": 7, "numbers_raw": ["4"], "numbers": [4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 73, "tag": "div", "text_raw": "58", "text": "58", "length": 2, "numbers_raw": ["58"], "numbers": [58.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 75, "tag": "div", "text_raw": "59", "text": "59", "length": 2, "numbers_raw": ["59"], "numbers": [59.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 76, "tag": "div", "text_raw": "Item 1 - Legal Proceedings", "text": "Item 1 - Legal Proceedings", "length": 26, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 77, "tag": "div", "text_raw": "59", "text": "59", "length": 2, "numbers_raw": ["59"], "numbers": [59.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 78, "tag": "div", "text_raw": "Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds", "text": "Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds", "length": 68, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 79, "tag": "div", "text_raw": "59", "text": "59", "length": 2, "numbers_raw": ["59"], "numbers": [59.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 80, "tag": "div", "text_raw": "Item 5 - Other Information", "text": "Item 5 - Other Information", "length": 26, "numbers_raw": ["5"], "numbers": [5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 81, "tag": "div", "text_raw": "59", "text": "59", "length": 2, "numbers_raw": ["59"], "numbers": [59.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 82, "tag": "div", "text_raw": "Item 6 - Exhibits", "text": "Item 6 - Exhibits", "length": 17, "numbers_raw": ["6"], "numbers": [6.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 83, "tag": "div", "text_raw": "60", "text": "60", "length": 2, "numbers_raw": ["60"], "numbers": [60.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 85, "tag": "div", "text_raw": "61", "text": "61", "length": 2, "numbers_raw": ["61"], "numbers": [61.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 92, "tag": "div", "text_raw": "CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS", "text": "CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS", "length": 52, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 94, "tag": "div", "text_raw": "This Quarterly Report on Form 10-Q and Johnson & Johnson  s other publicly available documents contain  forward-looking statements  within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Management and representatives of Johnson & Johnson and its subsidiaries (the Company) also may from time to time make forward-looking statements. Forward-looking statements do not relate strictly to historical or current facts and reflect managements assumptions, views, plans, objectives and projections about the future. Forward-looking statements may be identified by the use of words such as plans, expects, will, anticipates, estimates, and other words of similar meaning in conjunction with, among other things: discussions of future operations, expected operating results, financial performance; impact of planned acquisitions and dispositions; impact and timing of restructuring initiatives including associated cost savings and other benefits; the Companys strategy for growth; product development activities; regulatory approvals; market position and expenditures.", "text": "This Quarterly Report on Form 10-Q and Johnson & Johnson  s other publicly available documents contain  forward-looking statements  within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995.", "length": 254, "numbers_raw": ["10", "199", "5"], "numbers": [10.0, 199.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 94, "tag": "div", "text_raw": "This Quarterly Report on Form 10-Q and Johnson & Johnson  s other publicly available documents contain  forward-looking statements  within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Management and representatives of Johnson & Johnson and its subsidiaries (the Company) also may from time to time make forward-looking statements. Forward-looking statements do not relate strictly to historical or current facts and reflect managements assumptions, views, plans, objectives and projections about the future. Forward-looking statements may be identified by the use of words such as plans, expects, will, anticipates, estimates, and other words of similar meaning in conjunction with, among other things: discussions of future operations, expected operating results, financial performance; impact of planned acquisitions and dispositions; impact and timing of restructuring initiatives including associated cost savings and other benefits; the Companys strategy for growth; product development activities; regulatory approvals; market position and expenditures.", "text": "Management and representatives of Johnson & Johnson and its subsidiaries (the Company) also may from time to time make forward-looking statements.", "length": 146, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 94, "tag": "div", "text_raw": "This Quarterly Report on Form 10-Q and Johnson & Johnson  s other publicly available documents contain  forward-looking statements  within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Management and representatives of Johnson & Johnson and its subsidiaries (the Company) also may from time to time make forward-looking statements. Forward-looking statements do not relate strictly to historical or current facts and reflect managements assumptions, views, plans, objectives and projections about the future. Forward-looking statements may be identified by the use of words such as plans, expects, will, anticipates, estimates, and other words of similar meaning in conjunction with, among other things: discussions of future operations, expected operating results, financial performance; impact of planned acquisitions and dispositions; impact and timing of restructuring initiatives including associated cost savings and other benefits; the Companys strategy for growth; product development activities; regulatory approvals; market position and expenditures.", "text": "Forward-looking statements do not relate strictly to historical or current facts and reflect managements assumptions, views, plans, objectives and projections about the future.", "length": 177, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 94, "tag": "div", "text_raw": "This Quarterly Report on Form 10-Q and Johnson & Johnson  s other publicly available documents contain  forward-looking statements  within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Management and representatives of Johnson & Johnson and its subsidiaries (the Company) also may from time to time make forward-looking statements. Forward-looking statements do not relate strictly to historical or current facts and reflect managements assumptions, views, plans, objectives and projections about the future. Forward-looking statements may be identified by the use of words such as plans, expects, will, anticipates, estimates, and other words of similar meaning in conjunction with, among other things: discussions of future operations, expected operating results, financial performance; impact of planned acquisitions and dispositions; impact and timing of restructuring initiatives including associated cost savings and other benefits; the Companys strategy for growth; product development activities; regulatory approvals; market position and expenditures.", "text": "Forward-looking statements may be identified by the use of words such as plans, expects, will, anticipates, estimates, and other words of similar meaning in conjunction with, among other things:", "length": 204, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 94, "tag": "div", "text_raw": "This Quarterly Report on Form 10-Q and Johnson & Johnson  s other publicly available documents contain  forward-looking statements  within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Management and representatives of Johnson & Johnson and its subsidiaries (the Company) also may from time to time make forward-looking statements. Forward-looking statements do not relate strictly to historical or current facts and reflect managements assumptions, views, plans, objectives and projections about the future. Forward-looking statements may be identified by the use of words such as plans, expects, will, anticipates, estimates, and other words of similar meaning in conjunction with, among other things: discussions of future operations, expected operating results, financial performance; impact of planned acquisitions and dispositions; impact and timing of restructuring initiatives including associated cost savings and other benefits; the Companys strategy for growth; product development activities; regulatory approvals; market position and expenditures.", "text": "discussions of future operations, expected operating results, financial performance;", "length": 84, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 94, "tag": "div", "text_raw": "This Quarterly Report on Form 10-Q and Johnson & Johnson  s other publicly available documents contain  forward-looking statements  within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Management and representatives of Johnson & Johnson and its subsidiaries (the Company) also may from time to time make forward-looking statements. Forward-looking statements do not relate strictly to historical or current facts and reflect managements assumptions, views, plans, objectives and projections about the future. Forward-looking statements may be identified by the use of words such as plans, expects, will, anticipates, estimates, and other words of similar meaning in conjunction with, among other things: discussions of future operations, expected operating results, financial performance; impact of planned acquisitions and dispositions; impact and timing of restructuring initiatives including associated cost savings and other benefits; the Companys strategy for growth; product development activities; regulatory approvals; market position and expenditures.", "text": "impact of planned acquisitions and dispositions;", "length": 48, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 94, "tag": "div", "text_raw": "This Quarterly Report on Form 10-Q and Johnson & Johnson  s other publicly available documents contain  forward-looking statements  within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Management and representatives of Johnson & Johnson and its subsidiaries (the Company) also may from time to time make forward-looking statements. Forward-looking statements do not relate strictly to historical or current facts and reflect managements assumptions, views, plans, objectives and projections about the future. Forward-looking statements may be identified by the use of words such as plans, expects, will, anticipates, estimates, and other words of similar meaning in conjunction with, among other things: discussions of future operations, expected operating results, financial performance; impact of planned acquisitions and dispositions; impact and timing of restructuring initiatives including associated cost savings and other benefits; the Companys strategy for growth; product development activities; regulatory approvals; market position and expenditures.", "text": "impact and timing of restructuring initiatives including associated cost savings and other benefits;", "length": 100, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 94, "tag": "div", "text_raw": "This Quarterly Report on Form 10-Q and Johnson & Johnson  s other publicly available documents contain  forward-looking statements  within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Management and representatives of Johnson & Johnson and its subsidiaries (the Company) also may from time to time make forward-looking statements. Forward-looking statements do not relate strictly to historical or current facts and reflect managements assumptions, views, plans, objectives and projections about the future. Forward-looking statements may be identified by the use of words such as plans, expects, will, anticipates, estimates, and other words of similar meaning in conjunction with, among other things: discussions of future operations, expected operating results, financial performance; impact of planned acquisitions and dispositions; impact and timing of restructuring initiatives including associated cost savings and other benefits; the Companys strategy for growth; product development activities; regulatory approvals; market position and expenditures.", "text": "the Companys strategy for growth;", "length": 34, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 94, "tag": "div", "text_raw": "This Quarterly Report on Form 10-Q and Johnson & Johnson  s other publicly available documents contain  forward-looking statements  within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Management and representatives of Johnson & Johnson and its subsidiaries (the Company) also may from time to time make forward-looking statements. Forward-looking statements do not relate strictly to historical or current facts and reflect managements assumptions, views, plans, objectives and projections about the future. Forward-looking statements may be identified by the use of words such as plans, expects, will, anticipates, estimates, and other words of similar meaning in conjunction with, among other things: discussions of future operations, expected operating results, financial performance; impact of planned acquisitions and dispositions; impact and timing of restructuring initiatives including associated cost savings and other benefits; the Companys strategy for growth; product development activities; regulatory approvals; market position and expenditures.", "text": "product development activities;", "length": 31, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 94, "tag": "div", "text_raw": "This Quarterly Report on Form 10-Q and Johnson & Johnson  s other publicly available documents contain  forward-looking statements  within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Management and representatives of Johnson & Johnson and its subsidiaries (the Company) also may from time to time make forward-looking statements. Forward-looking statements do not relate strictly to historical or current facts and reflect managements assumptions, views, plans, objectives and projections about the future. Forward-looking statements may be identified by the use of words such as plans, expects, will, anticipates, estimates, and other words of similar meaning in conjunction with, among other things: discussions of future operations, expected operating results, financial performance; impact of planned acquisitions and dispositions; impact and timing of restructuring initiatives including associated cost savings and other benefits; the Companys strategy for growth; product development activities; regulatory approvals; market position and expenditures.", "text": "market position and expenditures.", "length": 33, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 95, "tag": "div", "text_raw": "Because forward-looking statements are based on current beliefs, expectations and assumptions regarding future events, they are subject to uncertainties, risks and changes that are difficult to predict and many of which are outside of the Companys control. Investors should realize that if underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, the Companys actual results and financial condition could vary materially from expectations and projections expressed or implied in its forward-looking statements. Investors are therefore cautioned not to rely on these forward-looking statements. Risks and uncertainties include, but are not limited to:", "text": "Because forward-looking statements are based on current beliefs, expectations and assumptions regarding future events, they are subject to uncertainties, risks and changes that are difficult to predict and many of which are outside of the Companys control.", "length": 257, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 95, "tag": "div", "text_raw": "Because forward-looking statements are based on current beliefs, expectations and assumptions regarding future events, they are subject to uncertainties, risks and changes that are difficult to predict and many of which are outside of the Companys control. Investors should realize that if underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, the Companys actual results and financial condition could vary materially from expectations and projections expressed or implied in its forward-looking statements. Investors are therefore cautioned not to rely on these forward-looking statements. Risks and uncertainties include, but are not limited to:", "text": "Investors should realize that if underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, the Companys actual results and financial condition could vary materially from expectations and projections expressed or implied in its forward-looking statements.", "length": 294, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 95, "tag": "div", "text_raw": "Because forward-looking statements are based on current beliefs, expectations and assumptions regarding future events, they are subject to uncertainties, risks and changes that are difficult to predict and many of which are outside of the Companys control. Investors should realize that if underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, the Companys actual results and financial condition could vary materially from expectations and projections expressed or implied in its forward-looking statements. Investors are therefore cautioned not to rely on these forward-looking statements. Risks and uncertainties include, but are not limited to:", "text": "Investors are therefore cautioned not to rely on these forward-looking statements.", "length": 82, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 95, "tag": "div", "text_raw": "Because forward-looking statements are based on current beliefs, expectations and assumptions regarding future events, they are subject to uncertainties, risks and changes that are difficult to predict and many of which are outside of the Companys control. Investors should realize that if underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, the Companys actual results and financial condition could vary materially from expectations and projections expressed or implied in its forward-looking statements. Investors are therefore cautioned not to rely on these forward-looking statements. Risks and uncertainties include, but are not limited to:", "text": "Risks and uncertainties include, but are not limited to:", "length": 56, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 96, "tag": "div", "text_raw": "Risks Related to Product Development, Market Success and Competition", "text": "Risks Related to Product Development, Market Success and Competition", "length": 68, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 97, "tag": "div", "text_raw": " Challenges and uncertainties inherent in innovation and development of new and improved products and technologies on which the Companys continued growth and success depend, including uncertainty of clinical outcomes, additional analysis of existing clinical data, obtaining regulatory approvals, health plan coverage and customer access, and initial and continued commercial success;", "text": " Challenges and uncertainties inherent in innovation and development of new and improved products and technologies on which the Companys continued growth and success depend, including uncertainty of clinical outcomes, additional analysis of existing clinical data, obtaining regulatory approvals, health plan coverage and customer access, and initial and continued commercial success;", "length": 386, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 98, "tag": "div", "text_raw": " Challenges to the Companys ability to obtain and protect adequate patent and other intellectual property rights for new and existing products and technologies in the United States and other important markets;", "text": " Challenges to the Companys ability to obtain and protect adequate patent and other intellectual property rights for new and existing products and technologies in the United States and other important markets;", "length": 211, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 99, "tag": "div", "text_raw": " The impact of patent expirations, typically followed by the introduction of competing generic, biosimilar or other products and resulting revenue and market share losses;", "text": " The impact of patent expirations, typically followed by the introduction of competing generic, biosimilar or other products and resulting revenue and market share losses;", "length": 172, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 100, "tag": "div", "text_raw": " Increasingly aggressive and frequent challenges to the Companys patents by competitors and others seeking to launch competing generic, biosimilar or other products and increased receptivity of courts, the United States Patent and Trademark Office and other decision makers to such challenges, potentially resulting in loss of market exclusivity and rapid decline in sales for the relevant product sooner than expected;", "text": " Increasingly aggressive and frequent challenges to the Companys patents by competitors and others seeking to launch competing generic, biosimilar or other products and increased receptivity of courts, the United States Patent and Trademark Office and other decision makers to such challenges, potentially resulting in loss of market exclusivity and rapid decline in sales for the relevant product sooner than expected;", "length": 421, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 101, "tag": "div", "text_raw": " Competition in research and development of new and improved products, processes and technologies, which can result in product and process obsolescence;", "text": " Competition in research and development of new and improved products, processes and technologies, which can result in product and process obsolescence;", "length": 153, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 102, "tag": "div", "text_raw": " Competition to reach agreement with third parties for collaboration, licensing, development and marketing agreements for products and technologies;", "text": " Competition to reach agreement with third parties for collaboration, licensing, development and marketing agreements for products and technologies;", "length": 149, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 103, "tag": "div", "text_raw": " Competition based on cost-effectiveness, product performance, technological advances and patents attained by competitors; and", "text": " Competition based on cost-effectiveness, product performance, technological advances and patents attained by competitors;", "length": 123, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 104, "tag": "div", "text_raw": " Allegations that the Companys products infringe the patents and other intellectual property rights of third parties, which could adversely affect the Companys ability to sell the products in question and require the payment of money damages and future royalties.", "text": " Allegations that the Companys products infringe the patents and other intellectual property rights of third parties, which could adversely affect the Companys ability to sell the products in question and require the payment of money damages and future royalties.", "length": 266, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 105, "tag": "div", "text_raw": "Risks Related to Product Liability, Litigation and Regulatory Activity", "text": "Risks Related to Product Liability, Litigation and Regulatory Activity", "length": 70, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 106, "tag": "div", "text_raw": " Product efficacy or safety concerns, whether or not based on scientific evidence, potentially resulting in product withdrawals, recalls, regulatory action on the part of the United States Food and Drug Administration (or international counterparts), declining sales, reputational damage, increased litigation expense and share price impact;", "text": " Product efficacy or safety concerns, whether or not based on scientific evidence, potentially resulting in product withdrawals, recalls, regulatory action on the part of the United States Food and Drug Administration (or international counterparts), declining sales, reputational damage, increased litigation expense and share price impact;", "length": 342, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 107, "tag": "div", "text_raw": " The impact, including declining sales and reputational damage, of significant litigation or government action adverse to the Company, including product liability claims and allegations related to pharmaceutical marketing practices and contracting strategies;", "text": " The impact, including declining sales and reputational damage, of significant litigation or government action adverse to the Company, including product liability claims and allegations related to pharmaceutical marketing practices and contracting strategies;", "length": 260, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 108, "tag": "div", "text_raw": " The impact of an adverse judgment or settlement and the adequacy of reserves related to legal proceedings, including patent litigation, product liability, personal injury claims, securities class actions, government investigations, employment and other legal proceedings;", "text": " The impact of an adverse judgment or settlement and the adequacy of reserves related to legal proceedings, including patent litigation, product liability, personal injury claims, securities class actions, government investigations, employment and other legal proceedings;", "length": 273, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 114, "tag": "div", "text_raw": " Increased scrutiny of the healthcare industry by government agencies and state attorneys general resulting in investigations and prosecutions, which carry the risk of significant civil and criminal penalties, including, but not limited to, debarment from government business;", "text": " Increased scrutiny of the healthcare industry by government agencies and state attorneys general resulting in investigations and prosecutions, which carry the risk of significant civil and criminal penalties, including, but not limited to, debarment from government business;", "length": 277, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 115, "tag": "div", "text_raw": " Failure to meet compliance obligations in compliance agreements with governments or government agencies, which could result in significant sanctions;", "text": " Failure to meet compliance obligations in compliance agreements with governments or government agencies, which could result in significant sanctions;", "length": 151, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 116, "tag": "div", "text_raw": " Potential changes to applicable laws and regulations affecting United States and international operations, including relating to: approval of new products; licensing and patent rights; sales and promotion of healthcare products; access to, and reimbursement and pricing for, healthcare products and services; environmental protection; and sourcing of raw materials;", "text": " Potential changes to applicable laws and regulations affecting United States and international operations, including relating to:", "length": 131, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 116, "tag": "div", "text_raw": " Potential changes to applicable laws and regulations affecting United States and international operations, including relating to: approval of new products; licensing and patent rights; sales and promotion of healthcare products; access to, and reimbursement and pricing for, healthcare products and services; environmental protection; and sourcing of raw materials;", "text": "sales and promotion of healthcare products;", "length": 43, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 116, "tag": "div", "text_raw": " Potential changes to applicable laws and regulations affecting United States and international operations, including relating to: approval of new products; licensing and patent rights; sales and promotion of healthcare products; access to, and reimbursement and pricing for, healthcare products and services; environmental protection; and sourcing of raw materials;", "text": "access to, and reimbursement and pricing for, healthcare products and services;", "length": 79, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 116, "tag": "div", "text_raw": " Potential changes to applicable laws and regulations affecting United States and international operations, including relating to: approval of new products; licensing and patent rights; sales and promotion of healthcare products; access to, and reimbursement and pricing for, healthcare products and services; environmental protection; and sourcing of raw materials;", "text": "and sourcing of raw materials;", "length": 30, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 117, "tag": "div", "text_raw": " Compliance with local regulations and laws that may restrict the Companys ability to manufacture or sell its products in relevant markets, including requirements to comply with medical device reporting regulations and other requirements such as the European Unions Medical Devices Regulation;", "text": " Compliance with local regulations and laws that may restrict the Companys ability to manufacture or sell its products in relevant markets, including requirements to comply with medical device reporting regulations and other requirements such as the European Unions Medical Devices Regulation;", "length": 296, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": ["EUR"], "has_numbers": false, "has_percents": false}
{"idx_source": 118, "tag": "div", "text_raw": " Changes in domestic and international tax laws and regulations, increasing audit scrutiny by tax authorities around the world and exposures to additional tax liabilities potentially in excess of existing reserves; and", "text": " Changes in domestic and international tax laws and regulations, increasing audit scrutiny by tax authorities around the world and exposures to additional tax liabilities potentially in excess of existing reserves;", "length": 215, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 119, "tag": "div", "text_raw": " The issuance of new or revised accounting standards by the Financial Accounting Standards Board and regulations by the Securities and Exchange Commission.", "text": " The issuance of new or revised accounting standards by the Financial Accounting Standards Board and regulations by the Securities and Exchange Commission.", "length": 156, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 120, "tag": "div", "text_raw": "Risks Related to the Companys Strategic Initiatives, Healthcare Market Trends and the Separation of the Companys Consumer Health Business", "text": "Risks Related to the Companys Strategic Initiatives, Healthcare Market Trends and the Separation of the Companys Consumer Health Business", "length": 139, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 121, "tag": "div", "text_raw": " Pricing pressures resulting from trends toward healthcare cost containment, including the continued consolidation among healthcare providers and other market participants, trends toward managed care, the shift toward governments increasingly becoming the primary payers of healthcare expenses, significant new entrants to the healthcare markets seeking to reduce costs and government pressure on companies to voluntarily reduce costs and price increases;", "text": " Pricing pressures resulting from trends toward healthcare cost containment, including the continued consolidation among healthcare providers and other market participants, trends toward managed care, the shift toward governments increasingly becoming the primary payers of healthcare expenses, significant new entrants to the healthcare markets seeking to reduce costs and government pressure on companies to voluntarily reduce costs and price increases;", "length": 456, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 122, "tag": "div", "text_raw": " Restricted spending patterns of individual, institutional and governmental purchasers of healthcare products and services due to economic hardship and budgetary constraints;", "text": " Restricted spending patterns of individual, institutional and governmental purchasers of healthcare products and services due to economic hardship and budgetary constraints;", "length": 175, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 123, "tag": "div", "text_raw": " Challenges to the Companys ability to realize its strategy for growth including through externally sourced innovations, such as development collaborations, strategic acquisitions, licensing and marketing agreements, and the potential heightened costs of any such external arrangements due to competitive pressures;", "text": " Challenges to the Companys ability to realize its strategy for growth including through externally sourced innovations, such as development collaborations, strategic acquisitions, licensing and marketing agreements, and the potential heightened costs of any such external arrangements due to competitive pressures;", "length": 317, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 124, "tag": "div", "text_raw": " The potential that the expected strategic benefits and opportunities from any planned or completed acquisition or divestiture by the Company may not be realized or may take longer to realize than expected;", "text": " The potential that the expected strategic benefits and opportunities from any planned or completed acquisition or divestiture by the Company may not be realized or may take longer to realize than expected;", "length": 207, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 125, "tag": "div", "text_raw": " The potential that the expected benefits and opportunities related to past and ongoing restructuring actions may not be realized or may take longer to realize than expected;", "text": " The potential that the expected benefits and opportunities related to past and ongoing restructuring actions may not be realized or may take longer to realize than expected;", "length": 175, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 126, "tag": "div", "text_raw": " The Companys ability to divest the Companys remaining ownership interest in Kenvue Inc. (Kenvue) and realize the anticipated benefits from the separation; and", "text": " The Companys ability to divest the Companys remaining ownership interest in Kenvue Inc.", "length": 91, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 126, "tag": "div", "text_raw": " The Companys ability to divest the Companys remaining ownership interest in Kenvue Inc. (Kenvue) and realize the anticipated benefits from the separation; and", "text": "(Kenvue) and realize the anticipated benefits from the separation;", "length": 66, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 127, "tag": "div", "text_raw": " Kenvue's ability to succeed as a standalone publicly traded company.", "text": " Kenvue's ability to succeed as a standalone publicly traded company.", "length": 70, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 128, "tag": "div", "text_raw": "Risks Related to Economic Conditions, Financial Markets and Operating Internationally", "text": "Risks Related to Economic Conditions, Financial Markets and Operating Internationally", "length": 85, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 129, "tag": "div", "text_raw": " The risks associated with global operations on the Company and its customers and suppliers, including foreign governments in countries in which the Company operates;", "text": " The risks associated with global operations on the Company and its customers and suppliers, including foreign governments in countries in which the Company operates;", "length": 167, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 130, "tag": "div", "text_raw": " The impact of inflation and fluctuations in interest rates and currency exchange rates and the potential effect of such fluctuations on revenues, expenses and resulting margins;", "text": " The impact of inflation and fluctuations in interest rates and currency exchange rates and the potential effect of such fluctuations on revenues, expenses and resulting margins;", "length": 179, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 131, "tag": "div", "text_raw": " Potential changes in export/import and trade laws, regulations and policies of the United States and other countries, including any increased trade restrictions or tariffs and potential drug reimportation legislation;", "text": " Potential changes in export/import and trade laws, regulations and policies of the United States and other countries, including any increased trade restrictions or tariffs and potential drug reimportation legislation;", "length": 219, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 132, "tag": "div", "text_raw": " The impact on international operations from financial instability in international economies, sovereign risk, possible imposition of governmental controls and restrictive economic policies, and unstable international governments and legal systems;", "text": " The impact on international operations from financial instability in international economies, sovereign risk, possible imposition of governmental controls and restrictive economic policies, and unstable international governments and legal systems;", "length": 249, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 133, "tag": "div", "text_raw": " The impact of global public health crises and pandemics;", "text": " The impact of global public health crises and pandemics;", "length": 58, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 134, "tag": "div", "text_raw": " Changes to global climate, extreme weather and natural disasters that could affect demand for the Companys products and services, cause disruptions in manufacturing and distribution networks, alter the availability of goods and services within the supply chain, and affect the overall design and integrity of the Companys products and operations; and", "text": " Changes to global climate, extreme weather and natural disasters that could affect demand for the Companys products and services, cause disruptions in manufacturing and distribution networks, alter the availability of goods and services within the supply chain, and affect the overall design and integrity of the Companys products and operations;", "length": 350, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 135, "tag": "div", "text_raw": " The impact of armed conflicts and terrorist attacks in the United States and other parts of the world, including social and economic disruptions and instability of financial and other markets.", "text": " The impact of armed conflicts and terrorist attacks in the United States and other parts of the world, including social and economic disruptions and instability of financial and other markets.", "length": 194, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 141, "tag": "div", "text_raw": "Risks Related to Supply Chain and Operations", "text": "Risks Related to Supply Chain and Operations", "length": 44, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 142, "tag": "div", "text_raw": " Difficulties and delays in manufacturing, internally, through third-party providers or otherwise within the supply chain, that may lead to voluntary or involuntary business interruptions or shutdowns, product shortages, withdrawals or suspensions of products from the market, and potential regulatory action;", "text": " Difficulties and delays in manufacturing, internally, through third-party providers or otherwise within the supply chain, that may lead to voluntary or involuntary business interruptions or shutdowns, product shortages, withdrawals or suspensions of products from the market, and potential regulatory action;", "length": 310, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 143, "tag": "div", "text_raw": " Interruptions and breaches of the Companys information technology systems or those of the Companys vendors, which could result in reputational, competitive, operational or other business harm as well as financial costs and regulatory action;", "text": " Interruptions and breaches of the Companys information technology systems or those of the Companys vendors, which could result in reputational, competitive, operational or other business harm as well as financial costs and regulatory action;", "length": 245, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 144, "tag": "div", "text_raw": " Reliance on global supply chains and production and distribution processes that are complex and subject to increasing regulatory requirements that may adversely affect supply, sourcing and pricing of materials used in the Companys products; and", "text": " Reliance on global supply chains and production and distribution processes that are complex and subject to increasing regulatory requirements that may adversely affect supply, sourcing and pricing of materials used in the Companys products;", "length": 243, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 145, "tag": "div", "text_raw": " The potential that the expected benefits and opportunities related to restructuring actions may not be realized or may take longer to realize than expected, including due to any required approvals from applicable regulatory authorities.", "text": " The potential that the expected benefits and opportunities related to restructuring actions may not be realized or may take longer to realize than expected, including due to any required approvals from applicable regulatory authorities.", "length": 238, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 147, "tag": "div", "text_raw": "Investors also should carefully read the Risk Factors described in Item 1A of the Company's Annual Report on Form 10-K for the fiscal year ended January 1, 2023, for a description of certain risks that could, among other things, cause the Companys actual results to differ materially from those expressed in its forward-looking statements. Investors should understand that it is not possible to predict or identify all such factors and should not consider the risks described above to be a complete statement of all potential risks and uncertainties. The Company does not undertake to publicly update any forward-looking statement that may be made from time to time, whether as a result of new information or future events or developments.", "text": "Investors also should carefully read the Risk Factors described in Item 1A of the Company's Annual Report on Form 10-K for the fiscal year ended January 1, 2023, for a description of certain risks that could, among other things, cause the Companys actual results to differ materially from those expressed in its forward-looking statements.", "length": 340, "numbers_raw": ["1", "10", "1", "202", "3"], "numbers": [1.0, 10.0, 1.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 147, "tag": "div", "text_raw": "Investors also should carefully read the Risk Factors described in Item 1A of the Company's Annual Report on Form 10-K for the fiscal year ended January 1, 2023, for a description of certain risks that could, among other things, cause the Companys actual results to differ materially from those expressed in its forward-looking statements. Investors should understand that it is not possible to predict or identify all such factors and should not consider the risks described above to be a complete statement of all potential risks and uncertainties. The Company does not undertake to publicly update any forward-looking statement that may be made from time to time, whether as a result of new information or future events or developments.", "text": "Investors should understand that it is not possible to predict or identify all such factors and should not consider the risks described above to be a complete statement of all potential risks and uncertainties.", "length": 210, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 147, "tag": "div", "text_raw": "Investors also should carefully read the Risk Factors described in Item 1A of the Company's Annual Report on Form 10-K for the fiscal year ended January 1, 2023, for a description of certain risks that could, among other things, cause the Companys actual results to differ materially from those expressed in its forward-looking statements. Investors should understand that it is not possible to predict or identify all such factors and should not consider the risks described above to be a complete statement of all potential risks and uncertainties. The Company does not undertake to publicly update any forward-looking statement that may be made from time to time, whether as a result of new information or future events or developments.", "text": "The Company does not undertake to publicly update any forward-looking statement that may be made from time to time, whether as a result of new information or future events or developments.", "length": 188, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 154, "tag": "div", "text_raw": "Part I  FINANCIAL INFORMATION", "text": "Part I  FINANCIAL INFORMATION", "length": 30, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 156, "tag": "div", "text_raw": "Item 1  FINANCIAL STATEMENTS", "text": "Item 1  FINANCIAL STATEMENTS", "length": 29, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 158, "tag": "div", "text_raw": "JOHNSON & JOHNSON AND SUBSIDIARIES", "text": "JOHNSON & JOHNSON AND SUBSIDIARIES", "length": 34, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 160, "tag": "div", "text_raw": "(Unaudited; Dollars in Millions Except Share and Per Share Data)", "text": "Dollars in Millions Except Share and Per Share Data)", "length": 52, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 161, "tag": "div", "text_raw": "October 1, 2023 January 1, 2023 ASSETS Current assets: Cash and cash equivalents (Note 4) $ 19,728 12,889 Marketable securities 3,783 9,392 Accounts receivable, trade, less allowances $ 160 (2022, $ 169 ) 14,798 14,039 Inventories (Note 2) 11,198 10,268 Prepaid expenses and other 4,196 2,876 Current assets of discontinued operations (Note 12)  5,830 Total current assets 53,703 55,294 Property, plant and equipment at cost 45,626 43,534 Less: accumulated depreciation ( 26,805 ) ( 25,552 ) Property, plant and equipment, net 18,821 17,982 Intangible assets, net (Note 3) 35,021 38,489 Goodwill (Note 3) 36,124 36,047 Deferred taxes on income (Note 5) 9,259 8,947 Other assets 13,133 9,212 Noncurrent assets of discontinued operations (Note 12)  21,407 Total assets $ 166,061 187,378 LIABILITIES AND SHAREHOLDERS EQUITY Current liabilities: Loans and notes payable $ 3,870 12,756 Accounts payable 8,355 9,889 Accrued liabilities 10,101 10,719 Accrued rebates, returns and promotions 15,808 13,579 Accrued compensation and employee related obligations 3,337 3,049 Accrued taxes on income (Note 5) 2,899 2,220 Current liabilities of discontinued operations (Note 12)  3,590 Total current liabilities 44,370 55,802 Long-term debt (Note 4) 26,051 26,886 Deferred taxes on income (Note 5) 2,623 3,991 Employee related obligations (Note 6) 5,687 6,542 Long-term taxes payable (Note 5) 2,540 4,306 Other liabilities 13,562 10,146 Noncurrent liabilities of discontinued operations (Note 12)  2,901 Total liabilities $ 94,833 110,574 Commitments and Contingencies (Note 11) Shareholders equity: Common stock  par value $ 1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares) $ 3,120 3,120 Accumulated other comprehensive income (loss) (Note 7) ( 8,780 ) ( 12,967 ) Retained earnings and Additional paid-in capital 152,536 128,345 Less: common stock held in treasury, at cost ( 712,665,000 and 506,246,000 shares) 75,648 41,694 Total shareholders equity $ 71,228 76,804 Total liabilities and shareholders equity $ 166,061 187,378", "text": "October 1, 2023 January 1, 2023 ASSETS Current assets:", "length": 54, "numbers_raw": ["1", "202", "3", "1", "202", "3"], "numbers": [1.0, 202.0, 3.0, 1.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 161, "tag": "div", "text_raw": "October 1, 2023 January 1, 2023 ASSETS Current assets: Cash and cash equivalents (Note 4) $ 19,728 12,889 Marketable securities 3,783 9,392 Accounts receivable, trade, less allowances $ 160 (2022, $ 169 ) 14,798 14,039 Inventories (Note 2) 11,198 10,268 Prepaid expenses and other 4,196 2,876 Current assets of discontinued operations (Note 12)  5,830 Total current assets 53,703 55,294 Property, plant and equipment at cost 45,626 43,534 Less: accumulated depreciation ( 26,805 ) ( 25,552 ) Property, plant and equipment, net 18,821 17,982 Intangible assets, net (Note 3) 35,021 38,489 Goodwill (Note 3) 36,124 36,047 Deferred taxes on income (Note 5) 9,259 8,947 Other assets 13,133 9,212 Noncurrent assets of discontinued operations (Note 12)  21,407 Total assets $ 166,061 187,378 LIABILITIES AND SHAREHOLDERS EQUITY Current liabilities: Loans and notes payable $ 3,870 12,756 Accounts payable 8,355 9,889 Accrued liabilities 10,101 10,719 Accrued rebates, returns and promotions 15,808 13,579 Accrued compensation and employee related obligations 3,337 3,049 Accrued taxes on income (Note 5) 2,899 2,220 Current liabilities of discontinued operations (Note 12)  3,590 Total current liabilities 44,370 55,802 Long-term debt (Note 4) 26,051 26,886 Deferred taxes on income (Note 5) 2,623 3,991 Employee related obligations (Note 6) 5,687 6,542 Long-term taxes payable (Note 5) 2,540 4,306 Other liabilities 13,562 10,146 Noncurrent liabilities of discontinued operations (Note 12)  2,901 Total liabilities $ 94,833 110,574 Commitments and Contingencies (Note 11) Shareholders equity: Common stock  par value $ 1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares) $ 3,120 3,120 Accumulated other comprehensive income (loss) (Note 7) ( 8,780 ) ( 12,967 ) Retained earnings and Additional paid-in capital 152,536 128,345 Less: common stock held in treasury, at cost ( 712,665,000 and 506,246,000 shares) 75,648 41,694 Total shareholders equity $ 71,228 76,804 Total liabilities and shareholders equity $ 166,061 187,378", "text": "Cash and cash equivalents (Note 4) $ 19,728 12,889 Marketable securities 3,783 9,392 Accounts receivable, trade, less allowances $ 160 (2022, $ 169 ) 14,798 14,039 Inventories (Note 2) 11,198 10,268 Prepaid expenses and other 4,196 2,876 Current assets of discontinued operations (Note 12)  5,830 Total current assets 53,703 55,294 Property, plant and equipment at cost 45,626 43,534 Less:", "length": 390, "numbers_raw": ["4", "19,728", "12,889 M", "3,783", "9,392", "160", "202", "2", "169", "14,798", "14,039", "2", "11,198", "10,268", "4,196", "2,876", "12", "5,830", "53,703", "55,294", "45,626", "43,534"], "numbers": [4.0, 19728.0, 12889000000.0, 3783.0, 9392.0, 160.0, 202.0, 2.0, 169.0, 14798.0, 14039.0, 2.0, 11198.0, 10268.0, 4196.0, 2876.0, 12.0, 5830.0, 53703.0, 55294.0, 45626.0, 43534.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 161, "tag": "div", "text_raw": "October 1, 2023 January 1, 2023 ASSETS Current assets: Cash and cash equivalents (Note 4) $ 19,728 12,889 Marketable securities 3,783 9,392 Accounts receivable, trade, less allowances $ 160 (2022, $ 169 ) 14,798 14,039 Inventories (Note 2) 11,198 10,268 Prepaid expenses and other 4,196 2,876 Current assets of discontinued operations (Note 12)  5,830 Total current assets 53,703 55,294 Property, plant and equipment at cost 45,626 43,534 Less: accumulated depreciation ( 26,805 ) ( 25,552 ) Property, plant and equipment, net 18,821 17,982 Intangible assets, net (Note 3) 35,021 38,489 Goodwill (Note 3) 36,124 36,047 Deferred taxes on income (Note 5) 9,259 8,947 Other assets 13,133 9,212 Noncurrent assets of discontinued operations (Note 12)  21,407 Total assets $ 166,061 187,378 LIABILITIES AND SHAREHOLDERS EQUITY Current liabilities: Loans and notes payable $ 3,870 12,756 Accounts payable 8,355 9,889 Accrued liabilities 10,101 10,719 Accrued rebates, returns and promotions 15,808 13,579 Accrued compensation and employee related obligations 3,337 3,049 Accrued taxes on income (Note 5) 2,899 2,220 Current liabilities of discontinued operations (Note 12)  3,590 Total current liabilities 44,370 55,802 Long-term debt (Note 4) 26,051 26,886 Deferred taxes on income (Note 5) 2,623 3,991 Employee related obligations (Note 6) 5,687 6,542 Long-term taxes payable (Note 5) 2,540 4,306 Other liabilities 13,562 10,146 Noncurrent liabilities of discontinued operations (Note 12)  2,901 Total liabilities $ 94,833 110,574 Commitments and Contingencies (Note 11) Shareholders equity: Common stock  par value $ 1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares) $ 3,120 3,120 Accumulated other comprehensive income (loss) (Note 7) ( 8,780 ) ( 12,967 ) Retained earnings and Additional paid-in capital 152,536 128,345 Less: common stock held in treasury, at cost ( 712,665,000 and 506,246,000 shares) 75,648 41,694 Total shareholders equity $ 71,228 76,804 Total liabilities and shareholders equity $ 166,061 187,378", "text": "accumulated depreciation ( 26,805 ) ( 25,552 ) Property, plant and equipment, net 18,821 17,982 Intangible assets, net (Note 3) 35,021 38,489 Goodwill (Note 3) 36,124 36,047 Deferred taxes on income (Note 5) 9,259 8,947 Other assets 13,133 9,212 Noncurrent assets of discontinued operations (Note 12)  21,407 Total assets $ 166,061 187,378 LIABILITIES AND SHAREHOLDERS EQUITY Current liabilities:", "length": 398, "numbers_raw": ["26,805", "25,552", "18,821", "17,982", "3", "35,021", "38,489", "3", "36,124", "36,047", "5", "9,259", "8,947", "13,133", "9,212", "12", "21,407", "166,061", "187,378"], "numbers": [26805.0, 25552.0, 18821.0, 17982.0, 3.0, 35021.0, 38489.0, 3.0, 36124.0, 36047.0, 5.0, 9259.0, 8947.0, 13133.0, 9212.0, 12.0, 21407.0, 166061.0, 187378.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 161, "tag": "div", "text_raw": "October 1, 2023 January 1, 2023 ASSETS Current assets: Cash and cash equivalents (Note 4) $ 19,728 12,889 Marketable securities 3,783 9,392 Accounts receivable, trade, less allowances $ 160 (2022, $ 169 ) 14,798 14,039 Inventories (Note 2) 11,198 10,268 Prepaid expenses and other 4,196 2,876 Current assets of discontinued operations (Note 12)  5,830 Total current assets 53,703 55,294 Property, plant and equipment at cost 45,626 43,534 Less: accumulated depreciation ( 26,805 ) ( 25,552 ) Property, plant and equipment, net 18,821 17,982 Intangible assets, net (Note 3) 35,021 38,489 Goodwill (Note 3) 36,124 36,047 Deferred taxes on income (Note 5) 9,259 8,947 Other assets 13,133 9,212 Noncurrent assets of discontinued operations (Note 12)  21,407 Total assets $ 166,061 187,378 LIABILITIES AND SHAREHOLDERS EQUITY Current liabilities: Loans and notes payable $ 3,870 12,756 Accounts payable 8,355 9,889 Accrued liabilities 10,101 10,719 Accrued rebates, returns and promotions 15,808 13,579 Accrued compensation and employee related obligations 3,337 3,049 Accrued taxes on income (Note 5) 2,899 2,220 Current liabilities of discontinued operations (Note 12)  3,590 Total current liabilities 44,370 55,802 Long-term debt (Note 4) 26,051 26,886 Deferred taxes on income (Note 5) 2,623 3,991 Employee related obligations (Note 6) 5,687 6,542 Long-term taxes payable (Note 5) 2,540 4,306 Other liabilities 13,562 10,146 Noncurrent liabilities of discontinued operations (Note 12)  2,901 Total liabilities $ 94,833 110,574 Commitments and Contingencies (Note 11) Shareholders equity: Common stock  par value $ 1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares) $ 3,120 3,120 Accumulated other comprehensive income (loss) (Note 7) ( 8,780 ) ( 12,967 ) Retained earnings and Additional paid-in capital 152,536 128,345 Less: common stock held in treasury, at cost ( 712,665,000 and 506,246,000 shares) 75,648 41,694 Total shareholders equity $ 71,228 76,804 Total liabilities and shareholders equity $ 166,061 187,378", "text": "Loans and notes payable $ 3,870 12,756 Accounts payable 8,355 9,889 Accrued liabilities 10,101 10,719 Accrued rebates, returns and promotions 15,808 13,579 Accrued compensation and employee related obligations 3,337 3,049 Accrued taxes on income (Note 5) 2,899 2,220 Current liabilities of discontinued operations (Note 12)  3,590 Total current liabilities 44,370 55,802 Long-term debt (Note 4) 26,051 26,886 Deferred taxes on income (Note 5) 2,623 3,991 Employee related obligations (Note 6) 5,687 6,542 Long-term taxes payable (Note 5) 2,540 4,306 Other liabilities 13,562 10,146 Noncurrent liabilities of discontinued operations (Note 12)  2,901 Total liabilities $ 94,833 110,574 Commitments and Contingencies (Note 11) Shareholders equity:", "length": 747, "numbers_raw": ["3,870", "12,756", "8,355", "9,889", "10,101", "10,719", "15,808", "13,579", "3,337", "3,049", "5", "2,899", "2,220", "12", "3,590", "44,370", "55,802", "4", "26,051", "26,886", "5", "2,623", "3,991", "6", "5,687", "6,542", "5", "2,540", "4,306", "13,562", "10,146", "12", "2,901", "94,833", "110,574", "11"], "numbers": [3870.0, 12756.0, 8355.0, 9889.0, 10101.0, 10719.0, 15808.0, 13579.0, 3337.0, 3049.0, 5.0, 2899.0, 2220.0, 12.0, 3590.0, 44370.0, 55802.0, 4.0, 26051.0, 26886.0, 5.0, 2623.0, 3991.0, 6.0, 5687.0, 6542.0, 5.0, 2540.0, 4306.0, 13562.0, 10146.0, 12.0, 2901.0, 94833.0, 110574.0, 11.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 161, "tag": "div", "text_raw": "October 1, 2023 January 1, 2023 ASSETS Current assets: Cash and cash equivalents (Note 4) $ 19,728 12,889 Marketable securities 3,783 9,392 Accounts receivable, trade, less allowances $ 160 (2022, $ 169 ) 14,798 14,039 Inventories (Note 2) 11,198 10,268 Prepaid expenses and other 4,196 2,876 Current assets of discontinued operations (Note 12)  5,830 Total current assets 53,703 55,294 Property, plant and equipment at cost 45,626 43,534 Less: accumulated depreciation ( 26,805 ) ( 25,552 ) Property, plant and equipment, net 18,821 17,982 Intangible assets, net (Note 3) 35,021 38,489 Goodwill (Note 3) 36,124 36,047 Deferred taxes on income (Note 5) 9,259 8,947 Other assets 13,133 9,212 Noncurrent assets of discontinued operations (Note 12)  21,407 Total assets $ 166,061 187,378 LIABILITIES AND SHAREHOLDERS EQUITY Current liabilities: Loans and notes payable $ 3,870 12,756 Accounts payable 8,355 9,889 Accrued liabilities 10,101 10,719 Accrued rebates, returns and promotions 15,808 13,579 Accrued compensation and employee related obligations 3,337 3,049 Accrued taxes on income (Note 5) 2,899 2,220 Current liabilities of discontinued operations (Note 12)  3,590 Total current liabilities 44,370 55,802 Long-term debt (Note 4) 26,051 26,886 Deferred taxes on income (Note 5) 2,623 3,991 Employee related obligations (Note 6) 5,687 6,542 Long-term taxes payable (Note 5) 2,540 4,306 Other liabilities 13,562 10,146 Noncurrent liabilities of discontinued operations (Note 12)  2,901 Total liabilities $ 94,833 110,574 Commitments and Contingencies (Note 11) Shareholders equity: Common stock  par value $ 1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares) $ 3,120 3,120 Accumulated other comprehensive income (loss) (Note 7) ( 8,780 ) ( 12,967 ) Retained earnings and Additional paid-in capital 152,536 128,345 Less: common stock held in treasury, at cost ( 712,665,000 and 506,246,000 shares) 75,648 41,694 Total shareholders equity $ 71,228 76,804 Total liabilities and shareholders equity $ 166,061 187,378", "text": "Common stock  par value $ 1.00 per share (authorized 4,320,000,000 shares;", "length": 75, "numbers_raw": ["1.00", "4,320,000,000"], "numbers": [1.0, 4320000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 161, "tag": "div", "text_raw": "October 1, 2023 January 1, 2023 ASSETS Current assets: Cash and cash equivalents (Note 4) $ 19,728 12,889 Marketable securities 3,783 9,392 Accounts receivable, trade, less allowances $ 160 (2022, $ 169 ) 14,798 14,039 Inventories (Note 2) 11,198 10,268 Prepaid expenses and other 4,196 2,876 Current assets of discontinued operations (Note 12)  5,830 Total current assets 53,703 55,294 Property, plant and equipment at cost 45,626 43,534 Less: accumulated depreciation ( 26,805 ) ( 25,552 ) Property, plant and equipment, net 18,821 17,982 Intangible assets, net (Note 3) 35,021 38,489 Goodwill (Note 3) 36,124 36,047 Deferred taxes on income (Note 5) 9,259 8,947 Other assets 13,133 9,212 Noncurrent assets of discontinued operations (Note 12)  21,407 Total assets $ 166,061 187,378 LIABILITIES AND SHAREHOLDERS EQUITY Current liabilities: Loans and notes payable $ 3,870 12,756 Accounts payable 8,355 9,889 Accrued liabilities 10,101 10,719 Accrued rebates, returns and promotions 15,808 13,579 Accrued compensation and employee related obligations 3,337 3,049 Accrued taxes on income (Note 5) 2,899 2,220 Current liabilities of discontinued operations (Note 12)  3,590 Total current liabilities 44,370 55,802 Long-term debt (Note 4) 26,051 26,886 Deferred taxes on income (Note 5) 2,623 3,991 Employee related obligations (Note 6) 5,687 6,542 Long-term taxes payable (Note 5) 2,540 4,306 Other liabilities 13,562 10,146 Noncurrent liabilities of discontinued operations (Note 12)  2,901 Total liabilities $ 94,833 110,574 Commitments and Contingencies (Note 11) Shareholders equity: Common stock  par value $ 1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares) $ 3,120 3,120 Accumulated other comprehensive income (loss) (Note 7) ( 8,780 ) ( 12,967 ) Retained earnings and Additional paid-in capital 152,536 128,345 Less: common stock held in treasury, at cost ( 712,665,000 and 506,246,000 shares) 75,648 41,694 Total shareholders equity $ 71,228 76,804 Total liabilities and shareholders equity $ 166,061 187,378", "text": "issued 3,119,843,000 shares) $ 3,120 3,120 Accumulated other comprehensive income (loss) (Note 7) ( 8,780 ) ( 12,967 ) Retained earnings and Additional paid-in capital 152,536 128,345 Less:", "length": 189, "numbers_raw": ["3,119,843,000", "3,120", "3,120", "7", "8,780", "12,967", "152,536", "128,345"], "numbers": [3119843000.0, 3120.0, 3120.0, 7.0, 8780.0, 12967.0, 152536.0, 128345.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 161, "tag": "div", "text_raw": "October 1, 2023 January 1, 2023 ASSETS Current assets: Cash and cash equivalents (Note 4) $ 19,728 12,889 Marketable securities 3,783 9,392 Accounts receivable, trade, less allowances $ 160 (2022, $ 169 ) 14,798 14,039 Inventories (Note 2) 11,198 10,268 Prepaid expenses and other 4,196 2,876 Current assets of discontinued operations (Note 12)  5,830 Total current assets 53,703 55,294 Property, plant and equipment at cost 45,626 43,534 Less: accumulated depreciation ( 26,805 ) ( 25,552 ) Property, plant and equipment, net 18,821 17,982 Intangible assets, net (Note 3) 35,021 38,489 Goodwill (Note 3) 36,124 36,047 Deferred taxes on income (Note 5) 9,259 8,947 Other assets 13,133 9,212 Noncurrent assets of discontinued operations (Note 12)  21,407 Total assets $ 166,061 187,378 LIABILITIES AND SHAREHOLDERS EQUITY Current liabilities: Loans and notes payable $ 3,870 12,756 Accounts payable 8,355 9,889 Accrued liabilities 10,101 10,719 Accrued rebates, returns and promotions 15,808 13,579 Accrued compensation and employee related obligations 3,337 3,049 Accrued taxes on income (Note 5) 2,899 2,220 Current liabilities of discontinued operations (Note 12)  3,590 Total current liabilities 44,370 55,802 Long-term debt (Note 4) 26,051 26,886 Deferred taxes on income (Note 5) 2,623 3,991 Employee related obligations (Note 6) 5,687 6,542 Long-term taxes payable (Note 5) 2,540 4,306 Other liabilities 13,562 10,146 Noncurrent liabilities of discontinued operations (Note 12)  2,901 Total liabilities $ 94,833 110,574 Commitments and Contingencies (Note 11) Shareholders equity: Common stock  par value $ 1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares) $ 3,120 3,120 Accumulated other comprehensive income (loss) (Note 7) ( 8,780 ) ( 12,967 ) Retained earnings and Additional paid-in capital 152,536 128,345 Less: common stock held in treasury, at cost ( 712,665,000 and 506,246,000 shares) 75,648 41,694 Total shareholders equity $ 71,228 76,804 Total liabilities and shareholders equity $ 166,061 187,378", "text": "common stock held in treasury, at cost ( 712,665,000 and 506,246,000 shares) 75,648 41,694 Total shareholders equity $ 71,228 76,804 Total liabilities and shareholders equity $ 166,061 187,378", "length": 194, "numbers_raw": ["712,665,000", "506,246,000", "75,648", "41,694", "71,228", "76,804", "166,061", "187,378"], "numbers": [712665000.0, 506246000.0, 75648.0, 41694.0, 71228.0, 76804.0, 166061.0, 187378.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 162, "tag": "div", "text_raw": "Accounts receivable, trade, less allowances $ 160 (2022, $ 169 )", "text": "Accounts receivable, trade, less allowances $ 160 (2022, $ 169 )", "length": 64, "numbers_raw": ["160", "202", "2", "169"], "numbers": [160.0, 202.0, 2.0, 169.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 163, "tag": "div", "text_raw": "LIABILITIES AND SHAREHOLDERS EQUITY", "text": "LIABILITIES AND SHAREHOLDERS EQUITY", "length": 36, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 164, "tag": "div", "text_raw": "Common stock  par value $ 1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)", "text": "Common stock  par value $ 1.00 per share (authorized 4,320,000,000 shares;", "length": 75, "numbers_raw": ["1.00", "4,320,000,000"], "numbers": [1.0, 4320000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 164, "tag": "div", "text_raw": "Common stock  par value $ 1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)", "text": "issued 3,119,843,000 shares)", "length": 28, "numbers_raw": ["3,119,843,000"], "numbers": [3119843000.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 165, "tag": "div", "text_raw": "Less: common stock held in treasury, at cost ( 712,665,000 and 506,246,000 shares)", "text": "common stock held in treasury, at cost ( 712,665,000 and 506,246,000 shares)", "length": 76, "numbers_raw": ["712,665,000", "506,246,000"], "numbers": [712665000.0, 506246000.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 166, "tag": "div", "text_raw": "See Notes to Consolidated Financial Statements", "text": "See Notes to Consolidated Financial Statements", "length": 46, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 167, "tag": "div", "text_raw": "1", "text": "1", "length": 1, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 168, "tag": "div", "text_raw": "1", "text": "1", "length": 1, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 169, "tag": "div", "text_raw": "1", "text": "1", "length": 1, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 175, "tag": "div", "text_raw": "JOHNSON & JOHNSON AND SUBSIDIARIES", "text": "JOHNSON & JOHNSON AND SUBSIDIARIES", "length": 34, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 176, "tag": "div", "text_raw": "CONSOLIDATED STATEMENTS OF EARNINGS", "text": "CONSOLIDATED STATEMENTS OF EARNINGS", "length": 35, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 177, "tag": "div", "text_raw": "(Unaudited; Dollars & Shares in Millions Except Per Share Amounts)", "text": "Dollars & Shares in Millions Except Per Share Amounts)", "length": 54, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 178, "tag": "div", "text_raw": "Fiscal Third Quarter Ended October 1, 2023 Percent to Sales October 2, 2022 Percent to Sales Sales to customers (Note 9) $ 21,351 100.0 % $ 19,996 100.0 % Cost of products sold 6,606 30.9 6,172 30.9 Gross profit 14,745 69.1 13,824 69.1 Selling, marketing and administrative expenses 5,400 25.3 4,975 24.9 Research and development expense 3,447 16.2 3,485 17.4 In-process research and development impairments 206 1.0   Interest income ( 374 ) ( 1.7 ) ( 150 ) ( 0.8 ) Interest expense, net of portion capitalized 192 0.9 51 0.3 Other (income) expense, net 499 2.3 226 1.1 Restructuring 158 0.7 65 0.3 Earnings before provision for taxes on income 5,217 24.4 5,172 25.9 Provision for taxes on income (Note 5) 908 4.2 862 4.3 Net earnings from continuing operations 4,309 20.2 % 4,310 21.6 % Net earnings from discontinued operations, net of tax (Note 12) 21,719 148 NET EARNINGS $ 26,028 $ 4,458 NET EARNINGS PER SHARE (Note 8) Continuing operations - basic $ 1.71 $ 1.64 Discontinued operations - basic $ 8.61 $ 0.06 Total net earnings per share - basic $ 10.32 $ 1.70 Continuing operations - diluted $ 1.69 $ 1.62 Discontinued operations - diluted $ 8.52 $ 0.06 Total net earnings per share - diluted $ 10.21 $ 1.68 AVG. SHARES OUTSTANDING Basic 2,522.9 2,627.9 Diluted 2,549.7 2,661.3", "text": "Fiscal Third Quarter Ended October 1, 2023 Percent to Sales October 2, 2022 Percent to Sales Sales to customers (Note 9) $ 21,351 100.0 % $ 19,996 100.0 % Cost of products sold 6,606 30.9 6,172 30.9 Gross profit 14,745 69.1 13,824 69.1 Selling, marketing and administrative expenses 5,400 25.3 4,975 24.9 Research and development expense 3,447 16.2 3,485 17.4 In-process research and development impairments 206 1.0   Interest income ( 374 ) ( 1.7 ) ( 150 ) ( 0.8 ) Interest expense, net of portion capitalized 192 0.9 51 0.3 Other (income) expense, net 499 2.3 226 1.1 Restructuring 158 0.7 65 0.3 Earnings before provision for taxes on income 5,217 24.4 5,172 25.9 Provision for taxes on income (Note 5) 908 4.2 862 4.3 Net earnings from continuing operations 4,309 20.2 % 4,310 21.6 % Net earnings from discontinued operations, net of tax (Note 12) 21,719 148 NET EARNINGS $ 26,028 $ 4,458 NET EARNINGS PER SHARE (Note 8) Continuing operations - basic $ 1.71 $ 1.64 Discontinued operations - basic $ 8.61 $ 0.06 Total net earnings per share - basic $ 10.32 $ 1.70 Continuing operations - diluted $ 1.69 $ 1.62 Discontinued operations - diluted $ 8.52 $ 0.06 Total net earnings per share - diluted $ 10.21 $ 1.68 AVG.", "length": 1221, "numbers_raw": ["1", "202", "3", "2", "202", "2", "9", "21,351", "100.0", "19,996", "100.0", "6,606", "30.9", "6,172", "30.9", "14,745", "69.1", "13,824", "69.1", "5,400", "25.3", "4,975", "24.9", "3,447", "16.2", "3,485", "17.4", "206", "1.0", "374", "1.7", "150", "0.8", "192", "0.9", "51", "0.3", "499", "2.3", "226", "1.1", "158", "0.7", "65", "0.3", "5,217", "24.4", "5,172", "25.9", "5", "908", "4.2", "862", "4.3", "4,309", "20.2", "4,310", "21.6", "12", "21,719", "148", "26,028", "4,458", "8", "1.71", "1.64", "8.61", "0.06", "10.32", "1.70", "1.69", "1.62", "8.52", "0.06", "10.21", "1.68"], "numbers": [1.0, 202.0, 3.0, 2.0, 202.0, 2.0, 9.0, 21351.0, 100.0, 19996.0, 100.0, 6606.0, 30.9, 6172.0, 30.9, 14745.0, 69.1, 13824.0, 69.1, 5400.0, 25.3, 4975.0, 24.9, 3447.0, 16.2, 3485.0, 17.4, 206.0, 1.0, 374.0, 1.7, 150.0, 0.8, 192.0, 0.9, 51.0, 0.3, 499.0, 2.3, 226.0, 1.1, 158.0, 0.7, 65.0, 0.3, 5217.0, 24.4, 5172.0, 25.9, 5.0, 908.0, 4.2, 862.0, 4.3, 4309.0, 20.2, 4310.0, 21.6, 12.0, 21719.0, 148.0, 26028.0, 4458.0, 8.0, 1.71, 1.64, 8.61, 0.06, 10.32, 1.7, 1.69, 1.62, 8.52, 0.06, 10.21, 1.68], "percents_raw": ["100.0 %", "100.0 %", "20.2 %", "21.6 %"], "percents": [1.0, 1.0, 0.20199999999999999, 0.21600000000000003], "currencies": ["USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 178, "tag": "div", "text_raw": "Fiscal Third Quarter Ended October 1, 2023 Percent to Sales October 2, 2022 Percent to Sales Sales to customers (Note 9) $ 21,351 100.0 % $ 19,996 100.0 % Cost of products sold 6,606 30.9 6,172 30.9 Gross profit 14,745 69.1 13,824 69.1 Selling, marketing and administrative expenses 5,400 25.3 4,975 24.9 Research and development expense 3,447 16.2 3,485 17.4 In-process research and development impairments 206 1.0   Interest income ( 374 ) ( 1.7 ) ( 150 ) ( 0.8 ) Interest expense, net of portion capitalized 192 0.9 51 0.3 Other (income) expense, net 499 2.3 226 1.1 Restructuring 158 0.7 65 0.3 Earnings before provision for taxes on income 5,217 24.4 5,172 25.9 Provision for taxes on income (Note 5) 908 4.2 862 4.3 Net earnings from continuing operations 4,309 20.2 % 4,310 21.6 % Net earnings from discontinued operations, net of tax (Note 12) 21,719 148 NET EARNINGS $ 26,028 $ 4,458 NET EARNINGS PER SHARE (Note 8) Continuing operations - basic $ 1.71 $ 1.64 Discontinued operations - basic $ 8.61 $ 0.06 Total net earnings per share - basic $ 10.32 $ 1.70 Continuing operations - diluted $ 1.69 $ 1.62 Discontinued operations - diluted $ 8.52 $ 0.06 Total net earnings per share - diluted $ 10.21 $ 1.68 AVG. SHARES OUTSTANDING Basic 2,522.9 2,627.9 Diluted 2,549.7 2,661.3", "text": "SHARES OUTSTANDING Basic 2,522.9 2,627.9 Diluted 2,549.7 2,661.3", "length": 64, "numbers_raw": ["2,522.9", "2,627.9", "2,549.7", "2,661.3"], "numbers": [2522.9, 2627.9, 2549.7, 2661.3], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 183, "tag": "div", "text_raw": "See Notes to Consolidated Financial Statements", "text": "See Notes to Consolidated Financial Statements", "length": 46, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 187, "tag": "div", "text_raw": "2", "text": "2", "length": 1, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 188, "tag": "div", "text_raw": "2", "text": "2", "length": 1, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 189, "tag": "div", "text_raw": "2", "text": "2", "length": 1, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 193, "tag": "div", "text_raw": "JOHNSON & JOHNSON AND SUBSIDIARIES", "text": "JOHNSON & JOHNSON AND SUBSIDIARIES", "length": 34, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 194, "tag": "div", "text_raw": "CONSOLIDATED STATEMENTS OF EARNINGS", "text": "CONSOLIDATED STATEMENTS OF EARNINGS", "length": 35, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 195, "tag": "div", "text_raw": "(Unaudited; Dollars & Shares in Millions Except Per Share Amounts)", "text": "Dollars & Shares in Millions Except Per Share Amounts)", "length": 54, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 196, "tag": "div", "text_raw": "Fiscal Nine Months Ended October 1, 2023 Percent to Sales October 2, 2022 Percent to Sales Sales to customers (Note 9) $ 63,764 100.0 % $ 60,051 100.0 % Cost of products sold 19,755 31.0 18,512 30.8 Gross profit 44,009 69.0 41,539 69.2 Selling, marketing and administrative expenses 15,702 24.6 14,907 24.8 Research and development expense 10,605 16.6 10,425 17.4 In-process research and development impairments 255 0.4 610 1.0 Interest income ( 898 ) ( 1.4 ) ( 236 ) ( 0.4 ) Interest expense, net of portion capitalized 621 1.0 99 0.2 Other (income) expense, net 7,055 11.1 15 0.0 Restructuring 433 0.6 200 0.4 Earnings before provision for taxes on income 10,236 16.1 15,519 25.8 Provision for taxes on income (Note 5) 1,042 1.7 2,376 3.9 Net earnings from continuing operations 9,194 14.4 % 13,143 21.9 % Net earnings from discontinued operations, net of tax (Note 12) 21,910 1,278 NET EARNINGS $ 31,104 $ 14,421 NET EARNINGS PER SHARE (Note 8) Continuing operations - basic $ 3.57 $ 5.00 Discontinued operations - basic $ 8.51 $ 0.49 Total net earnings per share - basic $ 12.08 $ 5.49 Continuing operations - diluted $ 3.53 $ 4.93 Discontinued operations - diluted $ 8.42 $ 0.48 Total net earnings per share - diluted $ 11.95 $ 5.41 AVG. SHARES OUTSTANDING Basic 2,575.6 2,628.9 Diluted 2,603.4 2,667.5", "text": "Fiscal Nine Months Ended October 1, 2023 Percent to Sales October 2, 2022 Percent to Sales Sales to customers (Note 9) $ 63,764 100.0 % $ 60,051 100.0 % Cost of products sold 19,755 31.0 18,512 30.8 Gross profit 44,009 69.0 41,539 69.2 Selling, marketing and administrative expenses 15,702 24.6 14,907 24.8 Research and development expense 10,605 16.6 10,425 17.4 In-process research and development impairments 255 0.4 610 1.0 Interest income ( 898 ) ( 1.4 ) ( 236 ) ( 0.4 ) Interest expense, net of portion capitalized 621 1.0 99 0.2 Other (income) expense, net 7,055 11.1 15 0.0 Restructuring 433 0.6 200 0.4 Earnings before provision for taxes on income 10,236 16.1 15,519 25.8 Provision for taxes on income (Note 5) 1,042 1.7 2,376 3.9 Net earnings from continuing operations 9,194 14.4 % 13,143 21.9 % Net earnings from discontinued operations, net of tax (Note 12) 21,910 1,278 NET EARNINGS $ 31,104 $ 14,421 NET EARNINGS PER SHARE (Note 8) Continuing operations - basic $ 3.57 $ 5.00 Discontinued operations - basic $ 8.51 $ 0.49 Total net earnings per share - basic $ 12.08 $ 5.49 Continuing operations - diluted $ 3.53 $ 4.93 Discontinued operations - diluted $ 8.42 $ 0.48 Total net earnings per share - diluted $ 11.95 $ 5.41 AVG.", "length": 1242, "numbers_raw": ["1", "202", "3", "2", "202", "2", "9", "63,764", "100.0", "60,051", "100.0", "19,755", "31.0", "18,512", "30.8", "44,009", "69.0", "41,539", "69.2", "15,702", "24.6", "14,907", "24.8", "10,605", "16.6", "10,425", "17.4", "255", "0.4", "610", "1.0", "898", "1.4", "236", "0.4", "621", "1.0", "99", "0.2", "7,055", "11.1", "15", "0.0", "433", "0.6", "200", "0.4", "10,236", "16.1", "15,519", "25.8", "5", "1,042", "1.7", "2,376", "3.9", "9,194", "14.4", "13,143", "21.9", "12", "21,910", "1,278", "31,104", "14,421", "8", "3.57", "5.00", "8.51", "0.49", "12.08", "5.49", "3.53", "4.93", "8.42", "0.48", "11.95", "5.41"], "numbers": [1.0, 202.0, 3.0, 2.0, 202.0, 2.0, 9.0, 63764.0, 100.0, 60051.0, 100.0, 19755.0, 31.0, 18512.0, 30.8, 44009.0, 69.0, 41539.0, 69.2, 15702.0, 24.6, 14907.0, 24.8, 10605.0, 16.6, 10425.0, 17.4, 255.0, 0.4, 610.0, 1.0, 898.0, 1.4, 236.0, 0.4, 621.0, 1.0, 99.0, 0.2, 7055.0, 11.1, 15.0, 0.0, 433.0, 0.6, 200.0, 0.4, 10236.0, 16.1, 15519.0, 25.8, 5.0, 1042.0, 1.7, 2376.0, 3.9, 9194.0, 14.4, 13143.0, 21.9, 12.0, 21910.0, 1278.0, 31104.0, 14421.0, 8.0, 3.57, 5.0, 8.51, 0.49, 12.08, 5.49, 3.53, 4.93, 8.42, 0.48, 11.95, 5.41], "percents_raw": ["100.0 %", "100.0 %", "14.4 %", "21.9 %"], "percents": [1.0, 1.0, 0.14400000000000002, 0.21899999999999997], "currencies": ["USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 196, "tag": "div", "text_raw": "Fiscal Nine Months Ended October 1, 2023 Percent to Sales October 2, 2022 Percent to Sales Sales to customers (Note 9) $ 63,764 100.0 % $ 60,051 100.0 % Cost of products sold 19,755 31.0 18,512 30.8 Gross profit 44,009 69.0 41,539 69.2 Selling, marketing and administrative expenses 15,702 24.6 14,907 24.8 Research and development expense 10,605 16.6 10,425 17.4 In-process research and development impairments 255 0.4 610 1.0 Interest income ( 898 ) ( 1.4 ) ( 236 ) ( 0.4 ) Interest expense, net of portion capitalized 621 1.0 99 0.2 Other (income) expense, net 7,055 11.1 15 0.0 Restructuring 433 0.6 200 0.4 Earnings before provision for taxes on income 10,236 16.1 15,519 25.8 Provision for taxes on income (Note 5) 1,042 1.7 2,376 3.9 Net earnings from continuing operations 9,194 14.4 % 13,143 21.9 % Net earnings from discontinued operations, net of tax (Note 12) 21,910 1,278 NET EARNINGS $ 31,104 $ 14,421 NET EARNINGS PER SHARE (Note 8) Continuing operations - basic $ 3.57 $ 5.00 Discontinued operations - basic $ 8.51 $ 0.49 Total net earnings per share - basic $ 12.08 $ 5.49 Continuing operations - diluted $ 3.53 $ 4.93 Discontinued operations - diluted $ 8.42 $ 0.48 Total net earnings per share - diluted $ 11.95 $ 5.41 AVG. SHARES OUTSTANDING Basic 2,575.6 2,628.9 Diluted 2,603.4 2,667.5", "text": "SHARES OUTSTANDING Basic 2,575.6 2,628.9 Diluted 2,603.4 2,667.5", "length": 64, "numbers_raw": ["2,575.6", "2,628.9", "2,603.4", "2,667.5"], "numbers": [2575.6, 2628.9, 2603.4, 2667.5], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 200, "tag": "div", "text_raw": "See Notes to Consolidated Financial Statements", "text": "See Notes to Consolidated Financial Statements", "length": 46, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 201, "tag": "div", "text_raw": "3", "text": "3", "length": 1, "numbers_raw": ["3"], "numbers": [3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 202, "tag": "div", "text_raw": "3", "text": "3", "length": 1, "numbers_raw": ["3"], "numbers": [3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 203, "tag": "div", "text_raw": "3", "text": "3", "length": 1, "numbers_raw": ["3"], "numbers": [3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 207, "tag": "div", "text_raw": "JOHNSON & JOHNSON AND SUBSIDIARIES", "text": "JOHNSON & JOHNSON AND SUBSIDIARIES", "length": 34, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 208, "tag": "div", "text_raw": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "text": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "length": 47, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 210, "tag": "div", "text_raw": "Fiscal Third Quarter Ended Fiscal Nine Months Ended October 1, 2023 October 2, 2022 October 1, 2023 October 2, 2022 Net earnings $ 26,028 4,458 $ 31,104 14,421 Other comprehensive income (loss), net of tax Foreign currency translation 448 ( 1,252 ) ( 448 ) ( 1,957 ) Securities: Unrealized holding gain (loss) arising during period 4 ( 2 ) 25 ( 35 ) Net change 4 ( 2 ) 25 ( 35 ) Employee benefit plans: Prior service cost amortization during period ( 36 ) ( 37 ) ( 107 ) ( 110 ) Gain (loss) amortization during period ( 34 ) 151 ( 101 ) 454 Consumer settlement/curtailment 33  33  Net change ( 37 ) 114 ( 175 ) 344 Derivatives & hedges: Unrealized gain (loss) arising during period ( 513 ) ( 204 ) ( 80 ) ( 254 ) Reclassifications to earnings ( 180 ) ( 105 ) ( 316 ) ( 332 ) Net change ( 693 ) ( 309 ) ( 396 ) ( 586 ) Other comprehensive income (loss) ( 278 ) ( 1,449 ) ( 994 ) ( 2,234 ) Comprehensive income $ 25,750 3,009 $ 30,110 12,187", "text": "Fiscal Third Quarter Ended Fiscal Nine Months Ended October 1, 2023 October 2, 2022 October 1, 2023 October 2, 2022 Net earnings $ 26,028 4,458 $ 31,104 14,421 Other comprehensive income (loss), net of tax Foreign currency translation 448 ( 1,252 ) ( 448 ) ( 1,957 ) Securities:", "length": 278, "numbers_raw": ["1", "202", "3", "2", "202", "2", "1", "202", "3", "2", "202", "2", "26,028", "4,458", "31,104", "14,421", "448", "1,252", "448", "1,957"], "numbers": [1.0, 202.0, 3.0, 2.0, 202.0, 2.0, 1.0, 202.0, 3.0, 2.0, 202.0, 2.0, 26028.0, 4458.0, 31104.0, 14421.0, 448.0, 1252.0, 448.0, 1957.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 210, "tag": "div", "text_raw": "Fiscal Third Quarter Ended Fiscal Nine Months Ended October 1, 2023 October 2, 2022 October 1, 2023 October 2, 2022 Net earnings $ 26,028 4,458 $ 31,104 14,421 Other comprehensive income (loss), net of tax Foreign currency translation 448 ( 1,252 ) ( 448 ) ( 1,957 ) Securities: Unrealized holding gain (loss) arising during period 4 ( 2 ) 25 ( 35 ) Net change 4 ( 2 ) 25 ( 35 ) Employee benefit plans: Prior service cost amortization during period ( 36 ) ( 37 ) ( 107 ) ( 110 ) Gain (loss) amortization during period ( 34 ) 151 ( 101 ) 454 Consumer settlement/curtailment 33  33  Net change ( 37 ) 114 ( 175 ) 344 Derivatives & hedges: Unrealized gain (loss) arising during period ( 513 ) ( 204 ) ( 80 ) ( 254 ) Reclassifications to earnings ( 180 ) ( 105 ) ( 316 ) ( 332 ) Net change ( 693 ) ( 309 ) ( 396 ) ( 586 ) Other comprehensive income (loss) ( 278 ) ( 1,449 ) ( 994 ) ( 2,234 ) Comprehensive income $ 25,750 3,009 $ 30,110 12,187", "text": "Unrealized holding gain (loss) arising during period 4 ( 2 ) 25 ( 35 ) Net change 4 ( 2 ) 25 ( 35 ) Employee benefit plans:", "length": 123, "numbers_raw": ["4", "2", "25", "35", "4", "2", "25", "35"], "numbers": [4.0, 2.0, 25.0, 35.0, 4.0, 2.0, 25.0, 35.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 210, "tag": "div", "text_raw": "Fiscal Third Quarter Ended Fiscal Nine Months Ended October 1, 2023 October 2, 2022 October 1, 2023 October 2, 2022 Net earnings $ 26,028 4,458 $ 31,104 14,421 Other comprehensive income (loss), net of tax Foreign currency translation 448 ( 1,252 ) ( 448 ) ( 1,957 ) Securities: Unrealized holding gain (loss) arising during period 4 ( 2 ) 25 ( 35 ) Net change 4 ( 2 ) 25 ( 35 ) Employee benefit plans: Prior service cost amortization during period ( 36 ) ( 37 ) ( 107 ) ( 110 ) Gain (loss) amortization during period ( 34 ) 151 ( 101 ) 454 Consumer settlement/curtailment 33  33  Net change ( 37 ) 114 ( 175 ) 344 Derivatives & hedges: Unrealized gain (loss) arising during period ( 513 ) ( 204 ) ( 80 ) ( 254 ) Reclassifications to earnings ( 180 ) ( 105 ) ( 316 ) ( 332 ) Net change ( 693 ) ( 309 ) ( 396 ) ( 586 ) Other comprehensive income (loss) ( 278 ) ( 1,449 ) ( 994 ) ( 2,234 ) Comprehensive income $ 25,750 3,009 $ 30,110 12,187", "text": "Prior service cost amortization during period ( 36 ) ( 37 ) ( 107 ) ( 110 ) Gain (loss) amortization during period ( 34 ) 151 ( 101 ) 454 Consumer settlement/curtailment 33  33  Net change ( 37 ) 114 ( 175 ) 344 Derivatives & hedges:", "length": 235, "numbers_raw": ["36", "37", "107", "110", "34", "151", "101", "454", "33", "33", "37", "114", "175", "344"], "numbers": [36.0, 37.0, 107.0, 110.0, 34.0, 151.0, 101.0, 454.0, 33.0, 33.0, 37.0, 114.0, 175.0, 344.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 210, "tag": "div", "text_raw": "Fiscal Third Quarter Ended Fiscal Nine Months Ended October 1, 2023 October 2, 2022 October 1, 2023 October 2, 2022 Net earnings $ 26,028 4,458 $ 31,104 14,421 Other comprehensive income (loss), net of tax Foreign currency translation 448 ( 1,252 ) ( 448 ) ( 1,957 ) Securities: Unrealized holding gain (loss) arising during period 4 ( 2 ) 25 ( 35 ) Net change 4 ( 2 ) 25 ( 35 ) Employee benefit plans: Prior service cost amortization during period ( 36 ) ( 37 ) ( 107 ) ( 110 ) Gain (loss) amortization during period ( 34 ) 151 ( 101 ) 454 Consumer settlement/curtailment 33  33  Net change ( 37 ) 114 ( 175 ) 344 Derivatives & hedges: Unrealized gain (loss) arising during period ( 513 ) ( 204 ) ( 80 ) ( 254 ) Reclassifications to earnings ( 180 ) ( 105 ) ( 316 ) ( 332 ) Net change ( 693 ) ( 309 ) ( 396 ) ( 586 ) Other comprehensive income (loss) ( 278 ) ( 1,449 ) ( 994 ) ( 2,234 ) Comprehensive income $ 25,750 3,009 $ 30,110 12,187", "text": "Unrealized gain (loss) arising during period ( 513 ) ( 204 ) ( 80 ) ( 254 ) Reclassifications to earnings ( 180 ) ( 105 ) ( 316 ) ( 332 ) Net change ( 693 ) ( 309 ) ( 396 ) ( 586 ) Other comprehensive income (loss) ( 278 ) ( 1,449 ) ( 994 ) ( 2,234 ) Comprehensive income $ 25,750 3,009 $ 30,110 12,187", "length": 302, "numbers_raw": ["513", "204", "80", "254", "180", "105", "316", "332", "693", "309", "396", "586", "278", "1,449", "994", "2,234", "25,750", "3,009", "30,110", "12,187"], "numbers": [513.0, 204.0, 80.0, 254.0, 180.0, 105.0, 316.0, 332.0, 693.0, 309.0, 396.0, 586.0, 278.0, 1449.0, 994.0, 2234.0, 25750.0, 3009.0, 30110.0, 12187.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 211, "tag": "div", "text_raw": "See Notes to Consolidated Financial Statements", "text": "See Notes to Consolidated Financial Statements", "length": 46, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 212, "tag": "div", "text_raw": "Amounts presented have not been recast to exclude discontinued operations", "text": "Amounts presented have not been recast to exclude discontinued operations", "length": 73, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 213, "tag": "div", "text_raw": "The tax effects in other comprehensive income/(loss) for the fiscal third quarter were as follows for 2023 and 2022, respectively: Foreign Currency Translation: $ 335 million and $ 181 million; Securities: $ 1 million and $ 0 million; Employee Benefit Plans: $ 8 million and $ 33 million; Derivatives & Hedges: $ 185 million and $ 82 million. The tax effects in other comprehensive income/(loss) for the fiscal nine months were as follows for 2023 and 2022, respectively: Foreign Currency Translation: $ 69 million and $ 859 million; Securities: $ 7 million and $ 9 million; Employee Benefit Plans: $ 51 million and $ 98 million; Derivatives & Hedges: $ 105 million and $ 155 million.", "text": "The tax effects in other comprehensive income/(loss) for the fiscal third quarter were as follows for 2023 and 2022, respectively:", "length": 130, "numbers_raw": ["202", "3", "202", "2"], "numbers": [202.0, 3.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 213, "tag": "div", "text_raw": "The tax effects in other comprehensive income/(loss) for the fiscal third quarter were as follows for 2023 and 2022, respectively: Foreign Currency Translation: $ 335 million and $ 181 million; Securities: $ 1 million and $ 0 million; Employee Benefit Plans: $ 8 million and $ 33 million; Derivatives & Hedges: $ 185 million and $ 82 million. The tax effects in other comprehensive income/(loss) for the fiscal nine months were as follows for 2023 and 2022, respectively: Foreign Currency Translation: $ 69 million and $ 859 million; Securities: $ 7 million and $ 9 million; Employee Benefit Plans: $ 51 million and $ 98 million; Derivatives & Hedges: $ 105 million and $ 155 million.", "text": "$ 335 million and $ 181 million;", "length": 32, "numbers_raw": ["335 million", "181 million"], "numbers": [335000000.0, 181000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 213, "tag": "div", "text_raw": "The tax effects in other comprehensive income/(loss) for the fiscal third quarter were as follows for 2023 and 2022, respectively: Foreign Currency Translation: $ 335 million and $ 181 million; Securities: $ 1 million and $ 0 million; Employee Benefit Plans: $ 8 million and $ 33 million; Derivatives & Hedges: $ 185 million and $ 82 million. The tax effects in other comprehensive income/(loss) for the fiscal nine months were as follows for 2023 and 2022, respectively: Foreign Currency Translation: $ 69 million and $ 859 million; Securities: $ 7 million and $ 9 million; Employee Benefit Plans: $ 51 million and $ 98 million; Derivatives & Hedges: $ 105 million and $ 155 million.", "text": "$ 1 million and $ 0 million;", "length": 28, "numbers_raw": ["1 million", "0 million"], "numbers": [1000000.0, 0.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 213, "tag": "div", "text_raw": "The tax effects in other comprehensive income/(loss) for the fiscal third quarter were as follows for 2023 and 2022, respectively: Foreign Currency Translation: $ 335 million and $ 181 million; Securities: $ 1 million and $ 0 million; Employee Benefit Plans: $ 8 million and $ 33 million; Derivatives & Hedges: $ 185 million and $ 82 million. The tax effects in other comprehensive income/(loss) for the fiscal nine months were as follows for 2023 and 2022, respectively: Foreign Currency Translation: $ 69 million and $ 859 million; Securities: $ 7 million and $ 9 million; Employee Benefit Plans: $ 51 million and $ 98 million; Derivatives & Hedges: $ 105 million and $ 155 million.", "text": "$ 8 million and $ 33 million;", "length": 29, "numbers_raw": ["8 million", "33 million"], "numbers": [8000000.0, 33000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 213, "tag": "div", "text_raw": "The tax effects in other comprehensive income/(loss) for the fiscal third quarter were as follows for 2023 and 2022, respectively: Foreign Currency Translation: $ 335 million and $ 181 million; Securities: $ 1 million and $ 0 million; Employee Benefit Plans: $ 8 million and $ 33 million; Derivatives & Hedges: $ 185 million and $ 82 million. The tax effects in other comprehensive income/(loss) for the fiscal nine months were as follows for 2023 and 2022, respectively: Foreign Currency Translation: $ 69 million and $ 859 million; Securities: $ 7 million and $ 9 million; Employee Benefit Plans: $ 51 million and $ 98 million; Derivatives & Hedges: $ 105 million and $ 155 million.", "text": "$ 185 million and $ 82 million.", "length": 31, "numbers_raw": ["185 million", "82 million"], "numbers": [185000000.0, 82000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 213, "tag": "div", "text_raw": "The tax effects in other comprehensive income/(loss) for the fiscal third quarter were as follows for 2023 and 2022, respectively: Foreign Currency Translation: $ 335 million and $ 181 million; Securities: $ 1 million and $ 0 million; Employee Benefit Plans: $ 8 million and $ 33 million; Derivatives & Hedges: $ 185 million and $ 82 million. The tax effects in other comprehensive income/(loss) for the fiscal nine months were as follows for 2023 and 2022, respectively: Foreign Currency Translation: $ 69 million and $ 859 million; Securities: $ 7 million and $ 9 million; Employee Benefit Plans: $ 51 million and $ 98 million; Derivatives & Hedges: $ 105 million and $ 155 million.", "text": "The tax effects in other comprehensive income/(loss) for the fiscal nine months were as follows for 2023 and 2022, respectively:", "length": 128, "numbers_raw": ["202", "3", "202", "2"], "numbers": [202.0, 3.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 213, "tag": "div", "text_raw": "The tax effects in other comprehensive income/(loss) for the fiscal third quarter were as follows for 2023 and 2022, respectively: Foreign Currency Translation: $ 335 million and $ 181 million; Securities: $ 1 million and $ 0 million; Employee Benefit Plans: $ 8 million and $ 33 million; Derivatives & Hedges: $ 185 million and $ 82 million. The tax effects in other comprehensive income/(loss) for the fiscal nine months were as follows for 2023 and 2022, respectively: Foreign Currency Translation: $ 69 million and $ 859 million; Securities: $ 7 million and $ 9 million; Employee Benefit Plans: $ 51 million and $ 98 million; Derivatives & Hedges: $ 105 million and $ 155 million.", "text": "$ 69 million and $ 859 million;", "length": 31, "numbers_raw": ["69 million", "859 million"], "numbers": [69000000.0, 859000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 213, "tag": "div", "text_raw": "The tax effects in other comprehensive income/(loss) for the fiscal third quarter were as follows for 2023 and 2022, respectively: Foreign Currency Translation: $ 335 million and $ 181 million; Securities: $ 1 million and $ 0 million; Employee Benefit Plans: $ 8 million and $ 33 million; Derivatives & Hedges: $ 185 million and $ 82 million. The tax effects in other comprehensive income/(loss) for the fiscal nine months were as follows for 2023 and 2022, respectively: Foreign Currency Translation: $ 69 million and $ 859 million; Securities: $ 7 million and $ 9 million; Employee Benefit Plans: $ 51 million and $ 98 million; Derivatives & Hedges: $ 105 million and $ 155 million.", "text": "$ 7 million and $ 9 million;", "length": 28, "numbers_raw": ["7 million", "9 million"], "numbers": [7000000.0, 9000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 213, "tag": "div", "text_raw": "The tax effects in other comprehensive income/(loss) for the fiscal third quarter were as follows for 2023 and 2022, respectively: Foreign Currency Translation: $ 335 million and $ 181 million; Securities: $ 1 million and $ 0 million; Employee Benefit Plans: $ 8 million and $ 33 million; Derivatives & Hedges: $ 185 million and $ 82 million. The tax effects in other comprehensive income/(loss) for the fiscal nine months were as follows for 2023 and 2022, respectively: Foreign Currency Translation: $ 69 million and $ 859 million; Securities: $ 7 million and $ 9 million; Employee Benefit Plans: $ 51 million and $ 98 million; Derivatives & Hedges: $ 105 million and $ 155 million.", "text": "$ 51 million and $ 98 million;", "length": 30, "numbers_raw": ["51 million", "98 million"], "numbers": [51000000.0, 98000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 213, "tag": "div", "text_raw": "The tax effects in other comprehensive income/(loss) for the fiscal third quarter were as follows for 2023 and 2022, respectively: Foreign Currency Translation: $ 335 million and $ 181 million; Securities: $ 1 million and $ 0 million; Employee Benefit Plans: $ 8 million and $ 33 million; Derivatives & Hedges: $ 185 million and $ 82 million. The tax effects in other comprehensive income/(loss) for the fiscal nine months were as follows for 2023 and 2022, respectively: Foreign Currency Translation: $ 69 million and $ 859 million; Securities: $ 7 million and $ 9 million; Employee Benefit Plans: $ 51 million and $ 98 million; Derivatives & Hedges: $ 105 million and $ 155 million.", "text": "$ 105 million and $ 155 million.", "length": 32, "numbers_raw": ["105 million", "155 million"], "numbers": [105000000.0, 155000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 214, "tag": "div", "text_raw": "The tax effects in other comprehensive income/(loss) for the fiscal third quarter were as follows for 2023 and 2022, respectively: Foreign Currency Translation: $ 335 million and $ 181 million; Securities: $ 1 million and $ 0 million; Employee Benefit Plans: $ 8 million and $ 33 million; Derivatives & Hedges: $ 185 million and $ 82 million.", "text": "The tax effects in other comprehensive income/(loss) for the fiscal third quarter were as follows for 2023 and 2022, respectively:", "length": 130, "numbers_raw": ["202", "3", "202", "2"], "numbers": [202.0, 3.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 214, "tag": "div", "text_raw": "The tax effects in other comprehensive income/(loss) for the fiscal third quarter were as follows for 2023 and 2022, respectively: Foreign Currency Translation: $ 335 million and $ 181 million; Securities: $ 1 million and $ 0 million; Employee Benefit Plans: $ 8 million and $ 33 million; Derivatives & Hedges: $ 185 million and $ 82 million.", "text": "$ 335 million and $ 181 million;", "length": 32, "numbers_raw": ["335 million", "181 million"], "numbers": [335000000.0, 181000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 214, "tag": "div", "text_raw": "The tax effects in other comprehensive income/(loss) for the fiscal third quarter were as follows for 2023 and 2022, respectively: Foreign Currency Translation: $ 335 million and $ 181 million; Securities: $ 1 million and $ 0 million; Employee Benefit Plans: $ 8 million and $ 33 million; Derivatives & Hedges: $ 185 million and $ 82 million.", "text": "$ 1 million and $ 0 million;", "length": 28, "numbers_raw": ["1 million", "0 million"], "numbers": [1000000.0, 0.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 214, "tag": "div", "text_raw": "The tax effects in other comprehensive income/(loss) for the fiscal third quarter were as follows for 2023 and 2022, respectively: Foreign Currency Translation: $ 335 million and $ 181 million; Securities: $ 1 million and $ 0 million; Employee Benefit Plans: $ 8 million and $ 33 million; Derivatives & Hedges: $ 185 million and $ 82 million.", "text": "$ 8 million and $ 33 million;", "length": 29, "numbers_raw": ["8 million", "33 million"], "numbers": [8000000.0, 33000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 214, "tag": "div", "text_raw": "The tax effects in other comprehensive income/(loss) for the fiscal third quarter were as follows for 2023 and 2022, respectively: Foreign Currency Translation: $ 335 million and $ 181 million; Securities: $ 1 million and $ 0 million; Employee Benefit Plans: $ 8 million and $ 33 million; Derivatives & Hedges: $ 185 million and $ 82 million.", "text": "$ 185 million and $ 82 million.", "length": 31, "numbers_raw": ["185 million", "82 million"], "numbers": [185000000.0, 82000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 215, "tag": "div", "text_raw": "The tax effects in other comprehensive income/(loss) for the fiscal nine months were as follows for 2023 and 2022, respectively: Foreign Currency Translation: $ 69 million and $ 859 million; Securities: $ 7 million and $ 9 million; Employee Benefit Plans: $ 51 million and $ 98 million; Derivatives & Hedges: $ 105 million and $ 155 million.", "text": "The tax effects in other comprehensive income/(loss) for the fiscal nine months were as follows for 2023 and 2022, respectively:", "length": 128, "numbers_raw": ["202", "3", "202", "2"], "numbers": [202.0, 3.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 215, "tag": "div", "text_raw": "The tax effects in other comprehensive income/(loss) for the fiscal nine months were as follows for 2023 and 2022, respectively: Foreign Currency Translation: $ 69 million and $ 859 million; Securities: $ 7 million and $ 9 million; Employee Benefit Plans: $ 51 million and $ 98 million; Derivatives & Hedges: $ 105 million and $ 155 million.", "text": "$ 69 million and $ 859 million;", "length": 31, "numbers_raw": ["69 million", "859 million"], "numbers": [69000000.0, 859000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 215, "tag": "div", "text_raw": "The tax effects in other comprehensive income/(loss) for the fiscal nine months were as follows for 2023 and 2022, respectively: Foreign Currency Translation: $ 69 million and $ 859 million; Securities: $ 7 million and $ 9 million; Employee Benefit Plans: $ 51 million and $ 98 million; Derivatives & Hedges: $ 105 million and $ 155 million.", "text": "$ 7 million and $ 9 million;", "length": 28, "numbers_raw": ["7 million", "9 million"], "numbers": [7000000.0, 9000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 215, "tag": "div", "text_raw": "The tax effects in other comprehensive income/(loss) for the fiscal nine months were as follows for 2023 and 2022, respectively: Foreign Currency Translation: $ 69 million and $ 859 million; Securities: $ 7 million and $ 9 million; Employee Benefit Plans: $ 51 million and $ 98 million; Derivatives & Hedges: $ 105 million and $ 155 million.", "text": "$ 51 million and $ 98 million;", "length": 30, "numbers_raw": ["51 million", "98 million"], "numbers": [51000000.0, 98000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 215, "tag": "div", "text_raw": "The tax effects in other comprehensive income/(loss) for the fiscal nine months were as follows for 2023 and 2022, respectively: Foreign Currency Translation: $ 69 million and $ 859 million; Securities: $ 7 million and $ 9 million; Employee Benefit Plans: $ 51 million and $ 98 million; Derivatives & Hedges: $ 105 million and $ 155 million.", "text": "$ 105 million and $ 155 million.", "length": 32, "numbers_raw": ["105 million", "155 million"], "numbers": [105000000.0, 155000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 217, "tag": "div", "text_raw": "4", "text": "4", "length": 1, "numbers_raw": ["4"], "numbers": [4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 218, "tag": "div", "text_raw": "4", "text": "4", "length": 1, "numbers_raw": ["4"], "numbers": [4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 219, "tag": "div", "text_raw": "4", "text": "4", "length": 1, "numbers_raw": ["4"], "numbers": [4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 223, "tag": "div", "text_raw": "JOHNSON & JOHNSON AND SUBSIDIARIES", "text": "JOHNSON & JOHNSON AND SUBSIDIARIES", "length": 34, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 224, "tag": "div", "text_raw": "CONSOLIDATED STATEMENTS OF EQUITY", "text": "CONSOLIDATED STATEMENTS OF EQUITY", "length": 33, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 228, "tag": "div", "text_raw": "Fiscal Third Quarter Ended October 1, 2023", "text": "Fiscal Third Quarter Ended October 1, 2023", "length": 42, "numbers_raw": ["1", "202", "3"], "numbers": [1.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 230, "tag": "div", "text_raw": "Total Retained Earnings and Additional paid-in capital Accumulated Other Comprehensive Income Common Stock Issued Amount Treasury Stock Amount Non-controlling interest (NCI) Balance, July 2, 2023 $ 76,409 129,381 ( 13,135 ) 3,120 ( 44,217 ) 1,260 Net earnings 26,028 26,028     Cash dividends paid ($ 1.19 per share) ( 2,871 ) ( 2,871 )     Employee compensation and stock option plans 948 41   907 Repurchase of common stock ( 920 )   ( 920 ) Kenvue Separation (Note 12) ( 28,088 ) ( 43 ) 4,633  ( 31,418 ) ( 1,260 ) Other comprehensive income (loss), net of tax ( 278 )  ( 278 )    Balance, October 1, 2023 $ 71,228 152,536 ( 8,780 ) 3,120 ( 75,648 ) ", "text": "Total Retained Earnings and Additional paid-in capital Accumulated Other Comprehensive Income Common Stock Issued Amount Treasury Stock Amount Non-controlling interest (NCI) Balance, July 2, 2023 $ 76,409 129,381 ( 13,135 ) 3,120 ( 44,217 ) 1,260 Net earnings 26,028 26,028     Cash dividends paid ($ 1.19 per share) ( 2,871 ) ( 2,871 )     Employee compensation and stock option plans 948 41   907 Repurchase of common stock ( 920 )   ( 920 ) Kenvue Separation (Note 12) ( 28,088 ) ( 43 ) 4,633  ( 31,418 ) ( 1,260 ) Other comprehensive income (loss), net of tax ( 278 )  ( 278 )    Balance, October 1, 2023 $ 71,228 152,536 ( 8,780 ) 3,120 ( 75,648 ) ", "length": 671, "numbers_raw": ["2", "202", "3", "76,409", "129,381", "13,135", "3,120", "44,217", "1,260", "26,028", "26,028", "1.19", "2,871", "2,871", "948", "41", "907", "920", "920", "12", "28,088", "43", "4,633", "31,418", "1,260", "278", "278", "1", "202", "3", "71,228", "152,536", "8,780", "3,120", "75,648"], "numbers": [2.0, 202.0, 3.0, 76409.0, 129381.0, 13135.0, 3120.0, 44217.0, 1260.0, 26028.0, 26028.0, 1.19, 2871.0, 2871.0, 948.0, 41.0, 907.0, 920.0, 920.0, 12.0, 28088.0, 43.0, 4633.0, 31418.0, 1260.0, 278.0, 278.0, 1.0, 202.0, 3.0, 71228.0, 152536.0, 8780.0, 3120.0, 75648.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 231, "tag": "div", "text_raw": "Cash dividends paid ($ 1.19 per share)", "text": "Cash dividends paid ($ 1.19 per share)", "length": 38, "numbers_raw": ["1.19"], "numbers": [1.19], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 235, "tag": "div", "text_raw": "Fiscal Nine Months Ended October 1, 2023", "text": "Fiscal Nine Months Ended October 1, 2023", "length": 40, "numbers_raw": ["1", "202", "3"], "numbers": [1.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 236, "tag": "div", "text_raw": "Total Retained Earnings and Additional paid-in capital Accumulated Other Comprehensive Income Common Stock Issued Amount Treasury Stock Amount Non-controlling interest (NCI) Balance, January 1, 2023 $ 76,804 128,345 ( 12,967 ) 3,120 ( 41,694 )  Net earnings 31,104 31,104     Cash dividends paid ($ 3.51 per share) ( 8,905 ) ( 8,905 )     Employee compensation and stock option plans 1,892 ( 435 )   2,327  Repurchase of common stock ( 4,838 )    ( 4,838 )  Other ( 25 )    ( 25 )  Kenvue Separation/IPO (Note 12) ( 23,810 ) 2,427 5,181  ( 31,418 )  Other comprehensive income (loss), net of tax ( 994 )  ( 994 )    Balance, October 1, 2023 $ 71,228 152,536 ( 8,780 ) 3,120 ( 75,648 ) ", "text": "Total Retained Earnings and Additional paid-in capital Accumulated Other Comprehensive Income Common Stock Issued Amount Treasury Stock Amount Non-controlling interest (NCI) Balance, January 1, 2023 $ 76,804 128,345 ( 12,967 ) 3,120 ( 41,694 )  Net earnings 31,104 31,104     Cash dividends paid ($ 3.51 per share) ( 8,905 ) ( 8,905 )     Employee compensation and stock option plans 1,892 ( 435 )   2,327  Repurchase of common stock ( 4,838 )    ( 4,838 )  Other ( 25 )    ( 25 )  Kenvue Separation/IPO (Note 12) ( 23,810 ) 2,427 5,181  ( 31,418 )  Other comprehensive income (loss), net of tax ( 994 )  ( 994 )    Balance, October 1, 2023 $ 71,228 152,536 ( 8,780 ) 3,120 ( 75,648 ) ", "length": 712, "numbers_raw": ["1", "202", "3", "76,804", "128,345", "12,967", "3,120", "41,694", "31,104", "31,104", "3.51", "8,905", "8,905", "1,892", "435", "2,327", "4,838", "4,838", "25", "25", "12", "23,810", "2,427", "5,181", "31,418", "994", "994", "1", "202", "3", "71,228", "152,536", "8,780", "3,120", "75,648"], "numbers": [1.0, 202.0, 3.0, 76804.0, 128345.0, 12967.0, 3120.0, 41694.0, 31104.0, 31104.0, 3.51, 8905.0, 8905.0, 1892.0, 435.0, 2327.0, 4838.0, 4838.0, 25.0, 25.0, 12.0, 23810.0, 2427.0, 5181.0, 31418.0, 994.0, 994.0, 1.0, 202.0, 3.0, 71228.0, 152536.0, 8780.0, 3120.0, 75648.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 237, "tag": "div", "text_raw": "Cash dividends paid ($ 3.51 per share)", "text": "Cash dividends paid ($ 3.51 per share)", "length": 38, "numbers_raw": ["3.51"], "numbers": [3.51], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 240, "tag": "div", "text_raw": "5", "text": "5", "length": 1, "numbers_raw": ["5"], "numbers": [5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 241, "tag": "div", "text_raw": "5", "text": "5", "length": 1, "numbers_raw": ["5"], "numbers": [5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 242, "tag": "div", "text_raw": "5", "text": "5", "length": 1, "numbers_raw": ["5"], "numbers": [5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 248, "tag": "div", "text_raw": "Fiscal Third Quarter Ended October 2, 2022", "text": "Fiscal Third Quarter Ended October 2, 2022", "length": 42, "numbers_raw": ["2", "202", "2"], "numbers": [2.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 250, "tag": "div", "text_raw": "Total Retained Earnings and Additional paid-in capital Accumulated Other Comprehensive Income Common Stock Issued Amount Treasury Stock Amount Balance, July 3, 2022 $ 76,357 126,216 ( 13,843 ) 3,120 ( 39,136 ) Net earnings 4,458 4,458    Cash dividends paid ($ 1.13 per share) ( 2,970 ) ( 2,970 )    Employee compensation and stock option plans 368 213   155 Repurchase of common stock ( 2,165 )    ( 2,165 ) Other comprehensive income (loss), net of tax ( 1,449 )  ( 1,449 )   Balance, October 2, 2022 $ 74,599 127,917 ( 15,292 ) 3,120 ( 41,146 )", "text": "Total Retained Earnings and Additional paid-in capital Accumulated Other Comprehensive Income Common Stock Issued Amount Treasury Stock Amount Balance, July 3, 2022 $ 76,357 126,216 ( 13,843 ) 3,120 ( 39,136 ) Net earnings 4,458 4,458    Cash dividends paid ($ 1.13 per share) ( 2,970 ) ( 2,970 )    Employee compensation and stock option plans 368 213   155 Repurchase of common stock ( 2,165 )    ( 2,165 ) Other comprehensive income (loss), net of tax ( 1,449 )  ( 1,449 )   Balance, October 2, 2022 $ 74,599 127,917 ( 15,292 ) 3,120 ( 41,146 )", "length": 561, "numbers_raw": ["3", "202", "2", "76,357", "126,216", "13,843", "3,120", "39,136", "4,458", "4,458", "1.13", "2,970", "2,970", "368", "213", "155", "2,165", "2,165", "1,449", "1,449", "2", "202", "2", "74,599", "127,917", "15,292", "3,120", "41,146"], "numbers": [3.0, 202.0, 2.0, 76357.0, 126216.0, 13843.0, 3120.0, 39136.0, 4458.0, 4458.0, 1.13, 2970.0, 2970.0, 368.0, 213.0, 155.0, 2165.0, 2165.0, 1449.0, 1449.0, 2.0, 202.0, 2.0, 74599.0, 127917.0, 15292.0, 3120.0, 41146.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 251, "tag": "div", "text_raw": "Cash dividends paid ($ 1.13 per share)", "text": "Cash dividends paid ($ 1.13 per share)", "length": 38, "numbers_raw": ["1.13"], "numbers": [1.13], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 254, "tag": "div", "text_raw": "Fiscal nine Months Ended October 2, 2022 Total Retained Earnings and Additional paid-in capital Accumulated Other Comprehensive Income Common Stock Issued Amount Treasury Stock Amount Balance, January 2, 2022 $ 74,023 123,060 ( 13,058 ) 3,120 ( 39,099 ) Net earnings 14,421 14,421    Cash dividends paid ($ 3.32 per share) ( 8,728 ) ( 8,728 )    Employee compensation and stock option plans 1,832 ( 836 )   2,668 Repurchase of common stock ( 4,715 )    ( 4,715 ) Other comprehensive income (loss), net of tax ( 2,234 )  ( 2,234 )   Balance, October 2, 2022 $ 74,599 127,917 ( 15,292 ) 3,120 ( 41,146 )", "text": "Fiscal nine Months Ended October 2, 2022 Total Retained Earnings and Additional paid-in capital Accumulated Other Comprehensive Income Common Stock Issued Amount Treasury Stock Amount Balance, January 2, 2022 $ 74,023 123,060 ( 13,058 ) 3,120 ( 39,099 ) Net earnings 14,421 14,421    Cash dividends paid ($ 3.32 per share) ( 8,728 ) ( 8,728 )    Employee compensation and stock option plans 1,832 ( 836 )   2,668 Repurchase of common stock ( 4,715 )    ( 4,715 ) Other comprehensive income (loss), net of tax ( 2,234 )  ( 2,234 )   Balance, October 2, 2022 $ 74,599 127,917 ( 15,292 ) 3,120 ( 41,146 )", "length": 615, "numbers_raw": ["2", "202", "2", "2", "202", "2", "74,023", "123,060", "13,058", "3,120", "39,099", "14,421", "14,421", "3.32", "8,728", "8,728", "1,832", "836", "2,668", "4,715", "4,715", "2,234", "2,234", "2", "202", "2", "74,599", "127,917", "15,292", "3,120", "41,146"], "numbers": [2.0, 202.0, 2.0, 2.0, 202.0, 2.0, 74023.0, 123060.0, 13058.0, 3120.0, 39099.0, 14421.0, 14421.0, 3.32, 8728.0, 8728.0, 1832.0, 836.0, 2668.0, 4715.0, 4715.0, 2234.0, 2234.0, 2.0, 202.0, 2.0, 74599.0, 127917.0, 15292.0, 3120.0, 41146.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 255, "tag": "div", "text_raw": "Cash dividends paid ($ 3.32 per share)", "text": "Cash dividends paid ($ 3.32 per share)", "length": 38, "numbers_raw": ["3.32"], "numbers": [3.32], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 257, "tag": "div", "text_raw": "See Notes to Consolidated Financial Statements", "text": "See Notes to Consolidated Financial Statements", "length": 46, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 258, "tag": "div", "text_raw": "6", "text": "6", "length": 1, "numbers_raw": ["6"], "numbers": [6.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 259, "tag": "div", "text_raw": "6", "text": "6", "length": 1, "numbers_raw": ["6"], "numbers": [6.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 260, "tag": "div", "text_raw": "6", "text": "6", "length": 1, "numbers_raw": ["6"], "numbers": [6.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 264, "tag": "div", "text_raw": "JOHNSON & JOHNSON AND SUBSIDIARIES", "text": "JOHNSON & JOHNSON AND SUBSIDIARIES", "length": 34, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 265, "tag": "div", "text_raw": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "text": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "length": 37, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 267, "tag": "div", "text_raw": "Fiscal Nine Months Ended October 1, 2023 October 2, 2022 CASH FLOWS FROM OPERATING ACTIVITIES Net earnings $ 31,104 14,421 Adjustments to reconcile net earnings to cash flows from operating activities: Depreciation and amortization of property and intangibles 5,643 5,198 Stock based compensation 984 925 Asset write-downs 820 787 Gain on Kenvue separation ( 20,984 )  Net gain on sale of assets/businesses ( 117 ) ( 213 ) Deferred tax provision ( 1,782 ) ( 2,488 ) Credit losses and accounts receivable allowances  ( 14 ) Changes in assets and liabilities, net of effects from acquisitions and divestitures: Increase in accounts receivable ( 851 ) ( 1,591 ) Increase in inventories ( 1,447 ) ( 1,877 ) Increase in accounts payable and accrued liabilities 664 141 (Increase)/Decrease in other current and non-current assets ( 1,366 ) 4,563 Increase/(Decrease) in other current and non-current liabilities 2,260 ( 4,008 ) NET CASH FLOWS FROM OPERATING ACTIVITIES 14,928 15,844 CASH FLOWS FROM INVESTING ACTIVITIES Additions to property, plant and equipment ( 2,954 ) ( 2,422 ) Proceeds from the disposal of assets/businesses, net (Note 10) 237 322 Acquisitions, net of cash acquired (Note 10)  ( 522 ) Purchases of investments ( 9,981 ) ( 31,163 ) Sales of investments 15,787 26,324 Credit support agreements activity, net ( 917 ) ( 305 ) Other (primarily licenses and milestones) ( 92 ) ( 208 ) NET CASH FROM (USED BY) INVESTING ACTIVITIES 2,080 ( 7,974 ) CASH FLOWS FROM FINANCING ACTIVITIES Dividends to shareholders ( 8,905 ) ( 8,728 ) Repurchase of common stock ( 4,838 ) ( 4,715 ) Proceeds from short-term debt (Note 4) 12,462 7,099 Repayment of short-term debt ( 21,645 ) ( 4,808 ) Proceeds from long-term debt, net of issuance costs (Note 4)  1 Repayment of long-term debt ( 502 ) ( 2,133 ) Proceeds from the exercise of stock options/employee withholding tax on stock awards, net 907 907 Credit support agreements activity, net 62 1,678 Proceeds of short and long-term debt, net of issuance cost, related to the debt that transferred to Kenvue at separation 8,047  Proceeds from Kenvue initial public offering (Note 12) 4,241  Cash transferred to Kenvue at separation ( 1,114 )  Other 115 128 NET CASH USED BY FINANCING ACTIVITIES ( 11,170 ) ( 10,571 )", "text": "Fiscal Nine Months Ended October 1, 2023 October 2, 2022 CASH FLOWS FROM OPERATING ACTIVITIES Net earnings $ 31,104 14,421 Adjustments to reconcile net earnings to cash flows from operating activities:", "length": 201, "numbers_raw": ["1", "202", "3", "2", "202", "2", "31,104", "14,421"], "numbers": [1.0, 202.0, 3.0, 2.0, 202.0, 2.0, 31104.0, 14421.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 267, "tag": "div", "text_raw": "Fiscal Nine Months Ended October 1, 2023 October 2, 2022 CASH FLOWS FROM OPERATING ACTIVITIES Net earnings $ 31,104 14,421 Adjustments to reconcile net earnings to cash flows from operating activities: Depreciation and amortization of property and intangibles 5,643 5,198 Stock based compensation 984 925 Asset write-downs 820 787 Gain on Kenvue separation ( 20,984 )  Net gain on sale of assets/businesses ( 117 ) ( 213 ) Deferred tax provision ( 1,782 ) ( 2,488 ) Credit losses and accounts receivable allowances  ( 14 ) Changes in assets and liabilities, net of effects from acquisitions and divestitures: Increase in accounts receivable ( 851 ) ( 1,591 ) Increase in inventories ( 1,447 ) ( 1,877 ) Increase in accounts payable and accrued liabilities 664 141 (Increase)/Decrease in other current and non-current assets ( 1,366 ) 4,563 Increase/(Decrease) in other current and non-current liabilities 2,260 ( 4,008 ) NET CASH FLOWS FROM OPERATING ACTIVITIES 14,928 15,844 CASH FLOWS FROM INVESTING ACTIVITIES Additions to property, plant and equipment ( 2,954 ) ( 2,422 ) Proceeds from the disposal of assets/businesses, net (Note 10) 237 322 Acquisitions, net of cash acquired (Note 10)  ( 522 ) Purchases of investments ( 9,981 ) ( 31,163 ) Sales of investments 15,787 26,324 Credit support agreements activity, net ( 917 ) ( 305 ) Other (primarily licenses and milestones) ( 92 ) ( 208 ) NET CASH FROM (USED BY) INVESTING ACTIVITIES 2,080 ( 7,974 ) CASH FLOWS FROM FINANCING ACTIVITIES Dividends to shareholders ( 8,905 ) ( 8,728 ) Repurchase of common stock ( 4,838 ) ( 4,715 ) Proceeds from short-term debt (Note 4) 12,462 7,099 Repayment of short-term debt ( 21,645 ) ( 4,808 ) Proceeds from long-term debt, net of issuance costs (Note 4)  1 Repayment of long-term debt ( 502 ) ( 2,133 ) Proceeds from the exercise of stock options/employee withholding tax on stock awards, net 907 907 Credit support agreements activity, net 62 1,678 Proceeds of short and long-term debt, net of issuance cost, related to the debt that transferred to Kenvue at separation 8,047  Proceeds from Kenvue initial public offering (Note 12) 4,241  Cash transferred to Kenvue at separation ( 1,114 )  Other 115 128 NET CASH USED BY FINANCING ACTIVITIES ( 11,170 ) ( 10,571 )", "text": "Depreciation and amortization of property and intangibles 5,643 5,198 Stock based compensation 984 925 Asset write-downs 820 787 Gain on Kenvue separation ( 20,984 )  Net gain on sale of assets/businesses ( 117 ) ( 213 ) Deferred tax provision ( 1,782 ) ( 2,488 ) Credit losses and accounts receivable allowances  ( 14 ) Changes in assets and liabilities, net of effects from acquisitions and divestitures:", "length": 408, "numbers_raw": ["5,643", "5,198", "984", "925", "820", "787", "20,984", "117", "213", "1,782", "2,488", "14"], "numbers": [5643.0, 5198.0, 984.0, 925.0, 820.0, 787.0, 20984.0, 117.0, 213.0, 1782.0, 2488.0, 14.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 267, "tag": "div", "text_raw": "Fiscal Nine Months Ended October 1, 2023 October 2, 2022 CASH FLOWS FROM OPERATING ACTIVITIES Net earnings $ 31,104 14,421 Adjustments to reconcile net earnings to cash flows from operating activities: Depreciation and amortization of property and intangibles 5,643 5,198 Stock based compensation 984 925 Asset write-downs 820 787 Gain on Kenvue separation ( 20,984 )  Net gain on sale of assets/businesses ( 117 ) ( 213 ) Deferred tax provision ( 1,782 ) ( 2,488 ) Credit losses and accounts receivable allowances  ( 14 ) Changes in assets and liabilities, net of effects from acquisitions and divestitures: Increase in accounts receivable ( 851 ) ( 1,591 ) Increase in inventories ( 1,447 ) ( 1,877 ) Increase in accounts payable and accrued liabilities 664 141 (Increase)/Decrease in other current and non-current assets ( 1,366 ) 4,563 Increase/(Decrease) in other current and non-current liabilities 2,260 ( 4,008 ) NET CASH FLOWS FROM OPERATING ACTIVITIES 14,928 15,844 CASH FLOWS FROM INVESTING ACTIVITIES Additions to property, plant and equipment ( 2,954 ) ( 2,422 ) Proceeds from the disposal of assets/businesses, net (Note 10) 237 322 Acquisitions, net of cash acquired (Note 10)  ( 522 ) Purchases of investments ( 9,981 ) ( 31,163 ) Sales of investments 15,787 26,324 Credit support agreements activity, net ( 917 ) ( 305 ) Other (primarily licenses and milestones) ( 92 ) ( 208 ) NET CASH FROM (USED BY) INVESTING ACTIVITIES 2,080 ( 7,974 ) CASH FLOWS FROM FINANCING ACTIVITIES Dividends to shareholders ( 8,905 ) ( 8,728 ) Repurchase of common stock ( 4,838 ) ( 4,715 ) Proceeds from short-term debt (Note 4) 12,462 7,099 Repayment of short-term debt ( 21,645 ) ( 4,808 ) Proceeds from long-term debt, net of issuance costs (Note 4)  1 Repayment of long-term debt ( 502 ) ( 2,133 ) Proceeds from the exercise of stock options/employee withholding tax on stock awards, net 907 907 Credit support agreements activity, net 62 1,678 Proceeds of short and long-term debt, net of issuance cost, related to the debt that transferred to Kenvue at separation 8,047  Proceeds from Kenvue initial public offering (Note 12) 4,241  Cash transferred to Kenvue at separation ( 1,114 )  Other 115 128 NET CASH USED BY FINANCING ACTIVITIES ( 11,170 ) ( 10,571 )", "text": "Increase in accounts receivable ( 851 ) ( 1,591 ) Increase in inventories ( 1,447 ) ( 1,877 ) Increase in accounts payable and accrued liabilities 664 141 (Increase)/Decrease in other current and non-current assets ( 1,366 ) 4,563 Increase/(Decrease) in other current and non-current liabilities 2,260 ( 4,008 ) NET CASH FLOWS FROM OPERATING ACTIVITIES 14,928 15,844 CASH FLOWS FROM INVESTING ACTIVITIES Additions to property, plant and equipment ( 2,954 ) ( 2,422 ) Proceeds from the disposal of assets/businesses, net (Note 10) 237 322 Acquisitions, net of cash acquired (Note 10)  ( 522 ) Purchases of investments ( 9,981 ) ( 31,163 ) Sales of investments 15,787 26,324 Credit support agreements activity, net ( 917 ) ( 305 ) Other (primarily licenses and milestones) ( 92 ) ( 208 ) NET CASH FROM (USED BY) INVESTING ACTIVITIES 2,080 ( 7,974 ) CASH FLOWS FROM FINANCING ACTIVITIES Dividends to shareholders ( 8,905 ) ( 8,728 ) Repurchase of common stock ( 4,838 ) ( 4,715 ) Proceeds from short-term debt (Note 4) 12,462 7,099 Repayment of short-term debt ( 21,645 ) ( 4,808 ) Proceeds from long-term debt, net of issuance costs (Note 4)  1 Repayment of long-term debt ( 502 ) ( 2,133 ) Proceeds from the exercise of stock options/employee withholding tax on stock awards, net 907 907 Credit support agreements activity, net 62 1,678 Proceeds of short and long-term debt, net of issuance cost, related to the debt that transferred to Kenvue at separation 8,047  Proceeds from Kenvue initial public offering (Note 12) 4,241  Cash transferred to Kenvue at separation ( 1,114 )  Other 115 128 NET CASH USED BY FINANCING ACTIVITIES ( 11,170 ) ( 10,571 )", "length": 1656, "numbers_raw": ["851", "1,591", "1,447", "1,877", "664", "141", "1,366", "4,563", "2,260", "4,008", "14,928", "15,844", "2,954", "2,422", "10", "237", "322", "10", "522", "9,981", "31,163", "15,787", "26,324", "917", "305", "92", "208", "2,080", "7,974", "8,905", "8,728", "4,838", "4,715", "4", "12,462", "7,099", "21,645", "4,808", "4", "1", "502", "2,133", "907", "907", "62", "1,678", "8,047", "12", "4,241", "1,114", "115", "128", "11,170", "10,571"], "numbers": [851.0, 1591.0, 1447.0, 1877.0, 664.0, 141.0, 1366.0, 4563.0, 2260.0, 4008.0, 14928.0, 15844.0, 2954.0, 2422.0, 10.0, 237.0, 322.0, 10.0, 522.0, 9981.0, 31163.0, 15787.0, 26324.0, 917.0, 305.0, 92.0, 208.0, 2080.0, 7974.0, 8905.0, 8728.0, 4838.0, 4715.0, 4.0, 12462.0, 7099.0, 21645.0, 4808.0, 4.0, 1.0, 502.0, 2133.0, 907.0, 907.0, 62.0, 1678.0, 8047.0, 12.0, 4241.0, 1114.0, 115.0, 128.0, 11170.0, 10571.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 268, "tag": "div", "text_raw": "7", "text": "7", "length": 1, "numbers_raw": ["7"], "numbers": [7.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 269, "tag": "div", "text_raw": "7", "text": "7", "length": 1, "numbers_raw": ["7"], "numbers": [7.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 270, "tag": "div", "text_raw": "7", "text": "7", "length": 1, "numbers_raw": ["7"], "numbers": [7.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 273, "tag": "div", "text_raw": "Fiscal Nine Months Ended October 1, 2023 October 2, 2022 Effect of exchange rate changes on cash and cash equivalents ( 237 ) ( 431 ) Increase/(Decrease) in cash and cash equivalents 5,601 ( 3,132 ) Cash and cash equivalents from continuing operations, beginning of period 12,889 13,309 Cash and cash equivalents from discontinued operations, beginning of period 1,238 1,178 Cash and Cash equivalents beginning of period 14,127 14,487 Cash and cash equivalents from continuing operations, end of period 19,728 10,347 Cash and cash equivalents from discontinued operations, end of period  1,008 CASH AND CASH EQUIVALENTS, END OF PERIOD $ 19,728 11,355 Acquisitions Fair value of assets acquired $  620 Fair value of liabilities assumed  ( 98 ) Net cash paid for acquisitions $  522", "text": "Fiscal Nine Months Ended October 1, 2023 October 2, 2022 Effect of exchange rate changes on cash and cash equivalents ( 237 ) ( 431 ) Increase/(Decrease) in cash and cash equivalents 5,601 ( 3,132 ) Cash and cash equivalents from continuing operations, beginning of period 12,889 13,309 Cash and cash equivalents from discontinued operations, beginning of period 1,238 1,178 Cash and Cash equivalents beginning of period 14,127 14,487 Cash and cash equivalents from continuing operations, end of period 19,728 10,347 Cash and cash equivalents from discontinued operations, end of period  1,008 CASH AND CASH EQUIVALENTS, END OF PERIOD $ 19,728 11,355 Acquisitions Fair value of assets acquired $  620 Fair value of liabilities assumed  ( 98 ) Net cash paid for acquisitions $  522", "length": 784, "numbers_raw": ["1", "202", "3", "2", "202", "2", "237", "431", "5,601", "3,132", "12,889", "13,309", "1,238", "1,178", "14,127", "14,487", "19,728", "10,347", "1,008", "19,728", "11,355", "620", "98", "522"], "numbers": [1.0, 202.0, 3.0, 2.0, 202.0, 2.0, 237.0, 431.0, 5601.0, 3132.0, 12889.0, 13309.0, 1238.0, 1178.0, 14127.0, 14487.0, 19728.0, 10347.0, 1008.0, 19728.0, 11355.0, 620.0, 98.0, 522.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 274, "tag": "div", "text_raw": "See Notes to Consolidated Financial Statements", "text": "See Notes to Consolidated Financial Statements", "length": 46, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 275, "tag": "div", "text_raw": "Amounts presented have not been recast to exclude discontinued operations.", "text": "Amounts presented have not been recast to exclude discontinued operations.", "length": 74, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 276, "tag": "div", "text_raw": "8", "text": "8", "length": 1, "numbers_raw": ["8"], "numbers": [8.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 277, "tag": "div", "text_raw": "8", "text": "8", "length": 1, "numbers_raw": ["8"], "numbers": [8.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 278, "tag": "div", "text_raw": "8", "text": "8", "length": 1, "numbers_raw": ["8"], "numbers": [8.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 282, "tag": "div", "text_raw": "NOTES TO CONSOLIDATED FINANCIAL STATEMENTS", "text": "NOTES TO CONSOLIDATED FINANCIAL STATEMENTS", "length": 42, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 285, "tag": "div", "text_raw": "NOTE 1  The accompanying unaudited interim consolidated financial statements and related notes should be read in conjunction with the audited Consolidated Financial Statements of Johnson & Johnson and its subsidiaries (the Company) and related notes as contained in the Companys Annual Report on Form 10-K for the fiscal year ended January 1, 2023. The unaudited interim financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair statement of the results for the periods presented.", "text": "NOTE 1  The accompanying unaudited interim consolidated financial statements and related notes should be read in conjunction with the audited Consolidated Financial Statements of Johnson & Johnson and its subsidiaries (the Company) and related notes as contained in the Companys Annual Report on Form 10-K for the fiscal year ended January 1, 2023.", "length": 350, "numbers_raw": ["1", "10", "1", "202", "3"], "numbers": [1.0, 10.0, 1.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 285, "tag": "div", "text_raw": "NOTE 1  The accompanying unaudited interim consolidated financial statements and related notes should be read in conjunction with the audited Consolidated Financial Statements of Johnson & Johnson and its subsidiaries (the Company) and related notes as contained in the Companys Annual Report on Form 10-K for the fiscal year ended January 1, 2023. The unaudited interim financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair statement of the results for the periods presented.", "text": "The unaudited interim financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair statement of the results for the periods presented.", "length": 232, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 287, "tag": "div", "text_raw": "Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.", "text": "Columns and rows within tables may not add due to rounding.", "length": 59, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 287, "tag": "div", "text_raw": "Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.", "text": "Percentages have been calculated using actual, non-rounded figures.", "length": 67, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 291, "tag": "div", "text_raw": "On May 8, 2023, Kenvue, completed an initial public offering (the IPO) resulting in the issuance of 198,734,444 shares of its common stock, par value $ 0.01 per share (the Kenvue Common Stock), at an initial public offering of $ 22.00 per share for net proceeds of $ 4.2 billion. The excess of the net proceeds from the IPO over the net book value of the Johnson & Johnson divested interest was $ 2.5 billion and was recorded to additional paid-in capital. As of the closing of the IPO, Johnson & Johnson owned approximately 89.6 % of the total outstanding shares of Kenvue Common Stock and at July 2, 2023, the non-controlling interest of $ 1.3 billion associated with Kenvue was reflected in equity attributable to non-controlling interests in the consolidated balance sheet in the fiscal second quarter.", "text": "On May 8, 2023, Kenvue, completed an initial public offering (the IPO) resulting in the issuance of 198,734,444 shares of its common stock, par value $ 0.01 per share (the Kenvue Common Stock), at an initial public offering of $ 22.00 per share for net proceeds of $ 4.2 billion.", "length": 281, "numbers_raw": ["8", "202", "3", "198,734,444", "0.01", "22.00", "4.2 billion"], "numbers": [8.0, 202.0, 3.0, 198734444.0, 0.01, 22.0, 4200000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 291, "tag": "div", "text_raw": "On May 8, 2023, Kenvue, completed an initial public offering (the IPO) resulting in the issuance of 198,734,444 shares of its common stock, par value $ 0.01 per share (the Kenvue Common Stock), at an initial public offering of $ 22.00 per share for net proceeds of $ 4.2 billion. The excess of the net proceeds from the IPO over the net book value of the Johnson & Johnson divested interest was $ 2.5 billion and was recorded to additional paid-in capital. As of the closing of the IPO, Johnson & Johnson owned approximately 89.6 % of the total outstanding shares of Kenvue Common Stock and at July 2, 2023, the non-controlling interest of $ 1.3 billion associated with Kenvue was reflected in equity attributable to non-controlling interests in the consolidated balance sheet in the fiscal second quarter.", "text": "The excess of the net proceeds from the IPO over the net book value of the Johnson & Johnson divested interest was $ 2.5 billion and was recorded to additional paid-in capital.", "length": 176, "numbers_raw": ["2.5 billion"], "numbers": [2500000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 291, "tag": "div", "text_raw": "On May 8, 2023, Kenvue, completed an initial public offering (the IPO) resulting in the issuance of 198,734,444 shares of its common stock, par value $ 0.01 per share (the Kenvue Common Stock), at an initial public offering of $ 22.00 per share for net proceeds of $ 4.2 billion. The excess of the net proceeds from the IPO over the net book value of the Johnson & Johnson divested interest was $ 2.5 billion and was recorded to additional paid-in capital. As of the closing of the IPO, Johnson & Johnson owned approximately 89.6 % of the total outstanding shares of Kenvue Common Stock and at July 2, 2023, the non-controlling interest of $ 1.3 billion associated with Kenvue was reflected in equity attributable to non-controlling interests in the consolidated balance sheet in the fiscal second quarter.", "text": "As of the closing of the IPO, Johnson & Johnson owned approximately 89.6 % of the total outstanding shares of Kenvue Common Stock and at July 2, 2023, the non-controlling interest of $ 1.3 billion associated with Kenvue was reflected in equity attributable to non-controlling interests in the consolidated balance sheet in the fiscal second quarter.", "length": 349, "numbers_raw": ["89.6", "2", "202", "3", "1.3 billion"], "numbers": [89.6, 2.0, 202.0, 3.0, 1300000000.0], "percents_raw": ["89.6 %"], "percents": [0.8959999999999999], "currencies": ["USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 293, "tag": "div", "text_raw": "On August 23, 2023, Johnson & Johnson completed the disposition of an additional 80.1 % ownership of the shares of Kenvue through an exchange offer. Following the exchange offer, the Company owns 9.5 % of the shares of Kenvue which are accounted for as an equity investment carried at fair value within continuing operations. The historical results of the Consumer Health business (which previously represented the Consumer Health business segment) are reflected as discontinued operations in the Companys consolidated financial statements through the date of the exchange offer (see Note 12 for additional details). Unless otherwise indicated, the information in the notes to the Consolidated Financial Statements refer only to Johnson & Johnsons continuing operations.", "text": "On August 23, 2023, Johnson & Johnson completed the disposition of an additional 80.1 % ownership of the shares of Kenvue through an exchange offer.", "length": 148, "numbers_raw": ["23", "202", "3", "80.1"], "numbers": [23.0, 202.0, 3.0, 80.1], "percents_raw": ["80.1 %"], "percents": [0.8009999999999999], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 293, "tag": "div", "text_raw": "On August 23, 2023, Johnson & Johnson completed the disposition of an additional 80.1 % ownership of the shares of Kenvue through an exchange offer. Following the exchange offer, the Company owns 9.5 % of the shares of Kenvue which are accounted for as an equity investment carried at fair value within continuing operations. The historical results of the Consumer Health business (which previously represented the Consumer Health business segment) are reflected as discontinued operations in the Companys consolidated financial statements through the date of the exchange offer (see Note 12 for additional details). Unless otherwise indicated, the information in the notes to the Consolidated Financial Statements refer only to Johnson & Johnsons continuing operations.", "text": "Following the exchange offer, the Company owns 9.5 % of the shares of Kenvue which are accounted for as an equity investment carried at fair value within continuing operations.", "length": 176, "numbers_raw": ["9.5"], "numbers": [9.5], "percents_raw": ["9.5 %"], "percents": [0.095], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 293, "tag": "div", "text_raw": "On August 23, 2023, Johnson & Johnson completed the disposition of an additional 80.1 % ownership of the shares of Kenvue through an exchange offer. Following the exchange offer, the Company owns 9.5 % of the shares of Kenvue which are accounted for as an equity investment carried at fair value within continuing operations. The historical results of the Consumer Health business (which previously represented the Consumer Health business segment) are reflected as discontinued operations in the Companys consolidated financial statements through the date of the exchange offer (see Note 12 for additional details). Unless otherwise indicated, the information in the notes to the Consolidated Financial Statements refer only to Johnson & Johnsons continuing operations.", "text": "The historical results of the Consumer Health business (which previously represented the Consumer Health business segment) are reflected as discontinued operations in the Companys consolidated financial statements through the date of the exchange offer (see Note 12 for additional details).", "length": 291, "numbers_raw": ["12"], "numbers": [12.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 293, "tag": "div", "text_raw": "On August 23, 2023, Johnson & Johnson completed the disposition of an additional 80.1 % ownership of the shares of Kenvue through an exchange offer. Following the exchange offer, the Company owns 9.5 % of the shares of Kenvue which are accounted for as an equity investment carried at fair value within continuing operations. The historical results of the Consumer Health business (which previously represented the Consumer Health business segment) are reflected as discontinued operations in the Companys consolidated financial statements through the date of the exchange offer (see Note 12 for additional details). Unless otherwise indicated, the information in the notes to the Consolidated Financial Statements refer only to Johnson & Johnsons continuing operations.", "text": "Unless otherwise indicated, the information in the notes to the Consolidated Financial Statements refer only to Johnson & Johnsons continuing operations.", "length": 154, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 295, "tag": "div", "text_raw": "Following the completion of the exchange offer, Johnson & Johnson is now organized into two business segments: Innovative Medicine (formerly referred to as Pharmaceutical) and MedTech (see Note 9 for additional details).", "text": "Following the completion of the exchange offer, Johnson & Johnson is now organized into two business segments:", "length": 110, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 295, "tag": "div", "text_raw": "Following the completion of the exchange offer, Johnson & Johnson is now organized into two business segments: Innovative Medicine (formerly referred to as Pharmaceutical) and MedTech (see Note 9 for additional details).", "text": "Innovative Medicine (formerly referred to as Pharmaceutical) and MedTech (see Note 9 for additional details).", "length": 109, "numbers_raw": ["9"], "numbers": [9.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 298, "tag": "div", "text_raw": "The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Companys Annual Report on Form 10-K for the fiscal year ended January 1, 2023.", "text": "The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Companys Annual Report on Form 10-K for the fiscal year ended January 1, 2023.", "length": 313, "numbers_raw": ["10", "1", "202", "3"], "numbers": [10.0, 1.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 300, "tag": "div", "text_raw": "Recently Adopted Accounting Standards", "text": "Recently Adopted Accounting Standards", "length": 37, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 301, "tag": "div", "text_raw": "ASU 2022-04: Liabilities-Supplier Finance Programs (Topic 405-50)  Disclosure of Supplier Finance Program Obligations", "text": "ASU 2022-04:", "length": 12, "numbers_raw": ["202", "2", "04"], "numbers": [202.0, 2.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 301, "tag": "div", "text_raw": "ASU 2022-04: Liabilities-Supplier Finance Programs (Topic 405-50)  Disclosure of Supplier Finance Program Obligations", "text": "Liabilities-Supplier Finance Programs (Topic 405-50)  Disclosure of Supplier Finance Program Obligations", "length": 105, "numbers_raw": ["405", "50"], "numbers": [405.0, 50.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 302, "tag": "div", "text_raw": "The Company adopted the standard as of the beginning of fiscal year 2023, which requires that a buyer in a supplier finance program disclose additional information about the program for financial statement users.", "text": "The Company adopted the standard as of the beginning of fiscal year 2023, which requires that a buyer in a supplier finance program disclose additional information about the program for financial statement users.", "length": 212, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 304, "tag": "div", "text_raw": "The Company has agreements for supplier finance programs with third-party financial institutions. These programs provide participating suppliers the ability to finance payment obligations from the Company with the third-party financial institutions. The Company is not a party to the arrangements between the suppliers and the third-party financial institutions. The Companys obligations to its suppliers, including amounts due, and scheduled payment dates (which have general payment terms of 90 days), are not affected by a participating suppliers decision to participate in the program.", "text": "The Company has agreements for supplier finance programs with third-party financial institutions.", "length": 97, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 304, "tag": "div", "text_raw": "The Company has agreements for supplier finance programs with third-party financial institutions. These programs provide participating suppliers the ability to finance payment obligations from the Company with the third-party financial institutions. The Company is not a party to the arrangements between the suppliers and the third-party financial institutions. The Companys obligations to its suppliers, including amounts due, and scheduled payment dates (which have general payment terms of 90 days), are not affected by a participating suppliers decision to participate in the program.", "text": "These programs provide participating suppliers the ability to finance payment obligations from the Company with the third-party financial institutions.", "length": 151, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 304, "tag": "div", "text_raw": "The Company has agreements for supplier finance programs with third-party financial institutions. These programs provide participating suppliers the ability to finance payment obligations from the Company with the third-party financial institutions. The Company is not a party to the arrangements between the suppliers and the third-party financial institutions. The Companys obligations to its suppliers, including amounts due, and scheduled payment dates (which have general payment terms of 90 days), are not affected by a participating suppliers decision to participate in the program.", "text": "The Company is not a party to the arrangements between the suppliers and the third-party financial institutions.", "length": 112, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 304, "tag": "div", "text_raw": "The Company has agreements for supplier finance programs with third-party financial institutions. These programs provide participating suppliers the ability to finance payment obligations from the Company with the third-party financial institutions. The Company is not a party to the arrangements between the suppliers and the third-party financial institutions. The Companys obligations to its suppliers, including amounts due, and scheduled payment dates (which have general payment terms of 90 days), are not affected by a participating suppliers decision to participate in the program.", "text": "The Companys obligations to its suppliers, including amounts due, and scheduled payment dates (which have general payment terms of 90 days), are not affected by a participating suppliers decision to participate in the program.", "length": 228, "numbers_raw": ["90"], "numbers": [90.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 306, "tag": "div", "text_raw": "As of October 1, 2023, and January 1, 2023, $ 0.5 billion and $ 0.7 billion, respectively, were valid obligations under the program. The obligations are presented as Accounts payable on the Consolidated Balance Sheets.", "text": "As of October 1, 2023, and January 1, 2023, $ 0.5 billion and $ 0.7 billion, respectively, were valid obligations under the program.", "length": 132, "numbers_raw": ["1", "202", "3", "1", "202", "3", "0.5 billion", "0.7 billion"], "numbers": [1.0, 202.0, 3.0, 1.0, 202.0, 3.0, 500000000.0, 700000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 306, "tag": "div", "text_raw": "As of October 1, 2023, and January 1, 2023, $ 0.5 billion and $ 0.7 billion, respectively, were valid obligations under the program. The obligations are presented as Accounts payable on the Consolidated Balance Sheets.", "text": "The obligations are presented as Accounts payable on the Consolidated Balance Sheets.", "length": 85, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 308, "tag": "div", "text_raw": "Recently Issued Accounting Standards", "text": "Recently Issued Accounting Standards", "length": 36, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 309, "tag": "div", "text_raw": "Not Adopted as of October 1, 2023", "text": "Not Adopted as of October 1, 2023", "length": 33, "numbers_raw": ["1", "202", "3"], "numbers": [1.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 310, "tag": "div", "text_raw": "There were no new material accounting standards issued in the fiscal nine months of 2023.", "text": "There were no new material accounting standards issued in the fiscal nine months of 2023.", "length": 89, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 313, "tag": "div", "text_raw": "Certain prior period amounts have been reclassified to conform to current year presentation.", "text": "Certain prior period amounts have been reclassified to conform to current year presentation.", "length": 92, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 318, "tag": "div", "text_raw": "9", "text": "9", "length": 1, "numbers_raw": ["9"], "numbers": [9.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 319, "tag": "div", "text_raw": "9", "text": "9", "length": 1, "numbers_raw": ["9"], "numbers": [9.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 320, "tag": "div", "text_raw": "9", "text": "9", "length": 1, "numbers_raw": ["9"], "numbers": [9.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 325, "tag": "div", "text_raw": "NOTE 2  INVENTORIES", "text": "NOTE 2  INVENTORIES", "length": 20, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 326, "tag": "div", "text_raw": "(Dollars in Millions) October 1, 2023 January 1, 2023 Raw materials and supplies $ 2,233 1,719 Goods in process 1,961 1,577 Finished goods 7,004 6,972 Total inventories $ 11,198 10,268", "text": "(Dollars in Millions) October 1, 2023 January 1, 2023 Raw materials and supplies $ 2,233 1,719 Goods in process 1,961 1,577 Finished goods 7,004 6,972 Total inventories $ 11,198 10,268", "length": 184, "numbers_raw": ["1", "202", "3", "1", "202", "3", "2,233", "1,719", "1,961", "1,577", "7,004", "6,972", "11,198", "10,268"], "numbers": [1.0, 202.0, 3.0, 1.0, 202.0, 3.0, 2233.0, 1719.0, 1961.0, 1577.0, 7004.0, 6972.0, 11198.0, 10268.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 330, "tag": "div", "text_raw": "NOTE 3  INTANGIBLE ASSETS AND GOODWILL", "text": "NOTE 3  INTANGIBLE ASSETS AND GOODWILL", "length": 39, "numbers_raw": ["3"], "numbers": [3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 332, "tag": "div", "text_raw": "Intangible assets that have finite useful lives are amortized over their estimated useful lives. The latest annual impairment assessment of goodwill and indefinite lived intangible assets was completed in the fiscal fourth quarter of 2022. Future impairment tests for goodwill and indefinite lived intangible assets will be performed annually in the fiscal fourth quarter, or sooner, if warranted.", "text": "Intangible assets that have finite useful lives are amortized over their estimated useful lives.", "length": 96, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 332, "tag": "div", "text_raw": "Intangible assets that have finite useful lives are amortized over their estimated useful lives. The latest annual impairment assessment of goodwill and indefinite lived intangible assets was completed in the fiscal fourth quarter of 2022. Future impairment tests for goodwill and indefinite lived intangible assets will be performed annually in the fiscal fourth quarter, or sooner, if warranted.", "text": "The latest annual impairment assessment of goodwill and indefinite lived intangible assets was completed in the fiscal fourth quarter of 2022.", "length": 142, "numbers_raw": ["202", "2"], "numbers": [202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 332, "tag": "div", "text_raw": "Intangible assets that have finite useful lives are amortized over their estimated useful lives. The latest annual impairment assessment of goodwill and indefinite lived intangible assets was completed in the fiscal fourth quarter of 2022. Future impairment tests for goodwill and indefinite lived intangible assets will be performed annually in the fiscal fourth quarter, or sooner, if warranted.", "text": "Future impairment tests for goodwill and indefinite lived intangible assets will be performed annually in the fiscal fourth quarter, or sooner, if warranted.", "length": 157, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 333, "tag": "div", "text_raw": "(Dollars in Millions) October 1, 2023 January 1, 2023 Intangible assets with definite lives: Patents and trademarks  gross $ 39,284 39,388 Less accumulated amortization ( 23,052 ) ( 20,616 ) Patents and trademarks  net 16,232 18,772 Customer relationships and other intangibles  gross 19,844 19,764 Less accumulated amortization ( 12,159 ) ( 11,363 ) Customer relationships and other intangibles  net (1) 7,685 8,401 Intangible assets with indefinite lives: Trademarks 1,640 1,630 Purchased in-process research and development 9,464 9,686 Total intangible assets with indefinite lives 11,104 11,316 Total intangible assets  net $ 35,021 38,489", "text": "(Dollars in Millions) October 1, 2023 January 1, 2023 Intangible assets with definite lives:", "length": 92, "numbers_raw": ["1", "202", "3", "1", "202", "3"], "numbers": [1.0, 202.0, 3.0, 1.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 333, "tag": "div", "text_raw": "(Dollars in Millions) October 1, 2023 January 1, 2023 Intangible assets with definite lives: Patents and trademarks  gross $ 39,284 39,388 Less accumulated amortization ( 23,052 ) ( 20,616 ) Patents and trademarks  net 16,232 18,772 Customer relationships and other intangibles  gross 19,844 19,764 Less accumulated amortization ( 12,159 ) ( 11,363 ) Customer relationships and other intangibles  net (1) 7,685 8,401 Intangible assets with indefinite lives: Trademarks 1,640 1,630 Purchased in-process research and development 9,464 9,686 Total intangible assets with indefinite lives 11,104 11,316 Total intangible assets  net $ 35,021 38,489", "text": "Patents and trademarks  gross $ 39,284 39,388 Less accumulated amortization ( 23,052 ) ( 20,616 ) Patents and trademarks  net 16,232 18,772 Customer relationships and other intangibles  gross 19,844 19,764 Less accumulated amortization ( 12,159 ) ( 11,363 ) Customer relationships and other intangibles  net (1) 7,685 8,401 Intangible assets with indefinite lives:", "length": 368, "numbers_raw": ["39,284", "39,388", "23,052", "20,616", "16,232", "18,772", "19,844", "19,764", "12,159", "11,363", "1", "7,685", "8,401"], "numbers": [39284.0, 39388.0, 23052.0, 20616.0, 16232.0, 18772.0, 19844.0, 19764.0, 12159.0, 11363.0, 1.0, 7685.0, 8401.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 333, "tag": "div", "text_raw": "(Dollars in Millions) October 1, 2023 January 1, 2023 Intangible assets with definite lives: Patents and trademarks  gross $ 39,284 39,388 Less accumulated amortization ( 23,052 ) ( 20,616 ) Patents and trademarks  net 16,232 18,772 Customer relationships and other intangibles  gross 19,844 19,764 Less accumulated amortization ( 12,159 ) ( 11,363 ) Customer relationships and other intangibles  net (1) 7,685 8,401 Intangible assets with indefinite lives: Trademarks 1,640 1,630 Purchased in-process research and development 9,464 9,686 Total intangible assets with indefinite lives 11,104 11,316 Total intangible assets  net $ 35,021 38,489", "text": "Trademarks 1,640 1,630 Purchased in-process research and development 9,464 9,686 Total intangible assets with indefinite lives 11,104 11,316 Total intangible assets  net $ 35,021 38,489", "length": 186, "numbers_raw": ["1,640", "1,630", "9,464", "9,686", "11,104", "11,316", "35,021", "38,489"], "numbers": [1640.0, 1630.0, 9464.0, 9686.0, 11104.0, 11316.0, 35021.0, 38489.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 334, "tag": "div", "text_raw": "Customer relationships and other intangibles  net (1)", "text": "Customer relationships and other intangibles  net (1)", "length": 54, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 335, "tag": "div", "text_raw": "(1) The majority is comprised of customer relationships", "text": "(1) The majority is comprised of customer relationships", "length": 55, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 338, "tag": "div", "text_raw": "Goodwill as of October 1, 2023 was allocated by segment of business as follows:", "text": "Goodwill as of October 1, 2023 was allocated by segment of business as follows:", "length": 79, "numbers_raw": ["1", "202", "3"], "numbers": [1.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 339, "tag": "div", "text_raw": "(Dollars in Millions) Innovative Medicine MedTech Total Goodwill at January 1, 2023 $ 10,184 25,863 36,047 Goodwill, related to acquisitions    Goodwill, related to divestitures    Currency translation/Other ( 35 ) 112 * 77 Goodwill at October 1, 2023 $ 10,149 25,975 36,124", "text": "(Dollars in Millions) Innovative Medicine MedTech Total Goodwill at January 1, 2023 $ 10,184 25,863 36,047 Goodwill, related to acquisitions    Goodwill, related to divestitures    Currency translation/Other ( 35 ) 112 * 77 Goodwill at October 1, 2023 $ 10,149 25,975 36,124", "length": 280, "numbers_raw": ["1", "202", "3", "10,184", "25,863", "36,047", "35", "112", "77", "1", "202", "3", "10,149", "25,975", "36,124"], "numbers": [1.0, 202.0, 3.0, 10184.0, 25863.0, 36047.0, 35.0, 112.0, 77.0, 1.0, 202.0, 3.0, 10149.0, 25975.0, 36124.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 340, "tag": "div", "text_raw": "Goodwill at January 1, 2023", "text": "Goodwill at January 1, 2023", "length": 27, "numbers_raw": ["1", "202", "3"], "numbers": [1.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 341, "tag": "div", "text_raw": "Goodwill at October 1, 2023", "text": "Goodwill at October 1, 2023", "length": 27, "numbers_raw": ["1", "202", "3"], "numbers": [1.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 342, "tag": "div", "text_raw": "*Includes purchase price allocation adjustment for Abiomed", "text": "*Includes purchase price allocation adjustment for Abiomed", "length": 58, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 344, "tag": "div", "text_raw": "The weighted average amortization period for patents and trademarks is 11 years. The weighted average amortization period for customer relationships and other intangible assets is 18 years. The amortization expense of amortizable intangible assets for continuing operations included in cost of products sold was $ 1.1 billion and $ 1.0 billion for the fiscal third quarters ended October 1, 2023 and October 2, 2022, respectively. The amortization expense of amortizable intangible assets for continuing operations included in cost of products sold was $ 3.4 billion and $ 3.0 billion for the fiscal nine months ended October 1, 2023 and October 2, 2022, respectively. Intangible asset write-downs are included in Other (income) expense, net, with the exception of In-Process research and development which are included in the In-Process research and development impairments line.", "text": "The weighted average amortization period for patents and trademarks is 11 years.", "length": 80, "numbers_raw": ["11"], "numbers": [11.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 344, "tag": "div", "text_raw": "The weighted average amortization period for patents and trademarks is 11 years. The weighted average amortization period for customer relationships and other intangible assets is 18 years. The amortization expense of amortizable intangible assets for continuing operations included in cost of products sold was $ 1.1 billion and $ 1.0 billion for the fiscal third quarters ended October 1, 2023 and October 2, 2022, respectively. The amortization expense of amortizable intangible assets for continuing operations included in cost of products sold was $ 3.4 billion and $ 3.0 billion for the fiscal nine months ended October 1, 2023 and October 2, 2022, respectively. Intangible asset write-downs are included in Other (income) expense, net, with the exception of In-Process research and development which are included in the In-Process research and development impairments line.", "text": "The weighted average amortization period for customer relationships and other intangible assets is 18 years.", "length": 108, "numbers_raw": ["18"], "numbers": [18.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 344, "tag": "div", "text_raw": "The weighted average amortization period for patents and trademarks is 11 years. The weighted average amortization period for customer relationships and other intangible assets is 18 years. The amortization expense of amortizable intangible assets for continuing operations included in cost of products sold was $ 1.1 billion and $ 1.0 billion for the fiscal third quarters ended October 1, 2023 and October 2, 2022, respectively. The amortization expense of amortizable intangible assets for continuing operations included in cost of products sold was $ 3.4 billion and $ 3.0 billion for the fiscal nine months ended October 1, 2023 and October 2, 2022, respectively. Intangible asset write-downs are included in Other (income) expense, net, with the exception of In-Process research and development which are included in the In-Process research and development impairments line.", "text": "The amortization expense of amortizable intangible assets for continuing operations included in cost of products sold was $ 1.1 billion and $ 1.0 billion for the fiscal third quarters ended October 1, 2023 and October 2, 2022, respectively.", "length": 240, "numbers_raw": ["1.1 billion", "1.0 billion", "1", "202", "3", "2", "202", "2"], "numbers": [1100000000.0, 1000000000.0, 1.0, 202.0, 3.0, 2.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 344, "tag": "div", "text_raw": "The weighted average amortization period for patents and trademarks is 11 years. The weighted average amortization period for customer relationships and other intangible assets is 18 years. The amortization expense of amortizable intangible assets for continuing operations included in cost of products sold was $ 1.1 billion and $ 1.0 billion for the fiscal third quarters ended October 1, 2023 and October 2, 2022, respectively. The amortization expense of amortizable intangible assets for continuing operations included in cost of products sold was $ 3.4 billion and $ 3.0 billion for the fiscal nine months ended October 1, 2023 and October 2, 2022, respectively. Intangible asset write-downs are included in Other (income) expense, net, with the exception of In-Process research and development which are included in the In-Process research and development impairments line.", "text": "The amortization expense of amortizable intangible assets for continuing operations included in cost of products sold was $ 3.4 billion and $ 3.0 billion for the fiscal nine months ended October 1, 2023 and October 2, 2022, respectively.", "length": 237, "numbers_raw": ["3.4 billion", "3.0 billion", "1", "202", "3", "2", "202", "2"], "numbers": [3400000000.0, 3000000000.0, 1.0, 202.0, 3.0, 2.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 344, "tag": "div", "text_raw": "The weighted average amortization period for patents and trademarks is 11 years. The weighted average amortization period for customer relationships and other intangible assets is 18 years. The amortization expense of amortizable intangible assets for continuing operations included in cost of products sold was $ 1.1 billion and $ 1.0 billion for the fiscal third quarters ended October 1, 2023 and October 2, 2022, respectively. The amortization expense of amortizable intangible assets for continuing operations included in cost of products sold was $ 3.4 billion and $ 3.0 billion for the fiscal nine months ended October 1, 2023 and October 2, 2022, respectively. Intangible asset write-downs are included in Other (income) expense, net, with the exception of In-Process research and development which are included in the In-Process research and development impairments line.", "text": "Intangible asset write-downs are included in Other (income) expense, net, with the exception of In-Process research and development which are included in the In-Process research and development impairments line.", "length": 211, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 346, "tag": "div", "text_raw": "10", "text": "10", "length": 2, "numbers_raw": ["10"], "numbers": [10.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 347, "tag": "div", "text_raw": "10", "text": "10", "length": 2, "numbers_raw": ["10"], "numbers": [10.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 348, "tag": "div", "text_raw": "10", "text": "10", "length": 2, "numbers_raw": ["10"], "numbers": [10.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 351, "tag": "div", "text_raw": "The estimated amortization expense for approved products from continuing operations, before tax, for the five succeeding years is approximately:", "text": "The estimated amortization expense for approved products from continuing operations, before tax, for the five succeeding years is approximately:", "length": 144, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 352, "tag": "div", "text_raw": "(Dollars in Millions) 2023 2024 2025 2026 2027 $ 4,500 4,300 3,500 2,900 2,300", "text": "(Dollars in Millions) 2023 2024 2025 2026 2027 $ 4,500 4,300 3,500 2,900 2,300", "length": 78, "numbers_raw": ["202", "3", "202", "4", "202", "5", "202", "6", "202", "7", "4,500", "4,300", "3,500", "2,900", "2,300"], "numbers": [202.0, 3.0, 202.0, 4.0, 202.0, 5.0, 202.0, 6.0, 202.0, 7.0, 4500.0, 4300.0, 3500.0, 2900.0, 2300.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 355, "tag": "div", "text_raw": "See Note 10 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.", "text": "See Note 10 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.", "length": 117, "numbers_raw": ["10"], "numbers": [10.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 356, "tag": "div", "text_raw": "See Note 12 to the Consolidated Financial Statements for additional details related to discontinued operations.", "text": "See Note 12 to the Consolidated Financial Statements for additional details related to discontinued operations.", "length": 111, "numbers_raw": ["12"], "numbers": [12.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 359, "tag": "div", "text_raw": "NOTE 4  FAIR VALUE MEASUREMENTS", "text": "NOTE 4  FAIR VALUE MEASUREMENTS", "length": 32, "numbers_raw": ["4"], "numbers": [4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 361, "tag": "div", "text_raw": "The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany product and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges.", "text": "The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany product and third-party purchases of materials denominated in a foreign currency.", "length": 268, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 361, "tag": "div", "text_raw": "The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany product and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges.", "text": "The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings.", "length": 108, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 361, "tag": "div", "text_raw": "The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany product and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges.", "text": "Both types of derivatives are designated as cash flow hedges.", "length": 61, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 363, "tag": "div", "text_raw": "Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings. These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges, and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities.", "text": "Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings.", "length": 130, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 363, "tag": "div", "text_raw": "Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings. These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges, and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities.", "text": "These derivatives are designated as fair value hedges.", "length": 54, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 363, "tag": "div", "text_raw": "Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings. These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges, and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities.", "text": "The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges.", "length": 127, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 363, "tag": "div", "text_raw": "Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings. These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges, and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities.", "text": "Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities.", "length": 140, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 363, "tag": "div", "text_raw": "Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings. These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges, and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities.", "text": "These forward foreign exchange contracts are not designated as hedges, and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities.", "length": 264, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 365, "tag": "div", "text_raw": "The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of October 1, 2023, the cumulative amount of cash collateral paid by the Company under the CSA amounted to $ 1.7 billion net, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of October 1, 2023, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $ 42.9 billion, $ 39.5 billion and $ 10.0 billion, respectively. As of January 1, 2023, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $ 41.5 billion, $ 36.2 billion and $ 10.0 billion, respectively.", "text": "The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features.", "length": 158, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 365, "tag": "div", "text_raw": "The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of October 1, 2023, the cumulative amount of cash collateral paid by the Company under the CSA amounted to $ 1.7 billion net, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of October 1, 2023, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $ 42.9 billion, $ 39.5 billion and $ 10.0 billion, respectively. As of January 1, 2023, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $ 41.5 billion, $ 36.2 billion and $ 10.0 billion, respectively.", "text": "The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements.", "length": 186, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 365, "tag": "div", "text_raw": "The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of October 1, 2023, the cumulative amount of cash collateral paid by the Company under the CSA amounted to $ 1.7 billion net, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of October 1, 2023, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $ 42.9 billion, $ 39.5 billion and $ 10.0 billion, respectively. As of January 1, 2023, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $ 41.5 billion, $ 36.2 billion and $ 10.0 billion, respectively.", "text": "As of October 1, 2023, the cumulative amount of cash collateral paid by the Company under the CSA amounted to $ 1.7 billion net, related to net investment and cash flow hedges.", "length": 176, "numbers_raw": ["1", "202", "3", "1.7 billion"], "numbers": [1.0, 202.0, 3.0, 1700000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 365, "tag": "div", "text_raw": "The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of October 1, 2023, the cumulative amount of cash collateral paid by the Company under the CSA amounted to $ 1.7 billion net, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of October 1, 2023, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $ 42.9 billion, $ 39.5 billion and $ 10.0 billion, respectively. As of January 1, 2023, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $ 41.5 billion, $ 36.2 billion and $ 10.0 billion, respectively.", "text": "On an ongoing basis, the Company monitors counter-party credit ratings.", "length": 71, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 365, "tag": "div", "text_raw": "The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of October 1, 2023, the cumulative amount of cash collateral paid by the Company under the CSA amounted to $ 1.7 billion net, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of October 1, 2023, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $ 42.9 billion, $ 39.5 billion and $ 10.0 billion, respectively. As of January 1, 2023, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $ 41.5 billion, $ 36.2 billion and $ 10.0 billion, respectively.", "text": "The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating.", "length": 196, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 365, "tag": "div", "text_raw": "The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of October 1, 2023, the cumulative amount of cash collateral paid by the Company under the CSA amounted to $ 1.7 billion net, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of October 1, 2023, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $ 42.9 billion, $ 39.5 billion and $ 10.0 billion, respectively. As of January 1, 2023, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $ 41.5 billion, $ 36.2 billion and $ 10.0 billion, respectively.", "text": "Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions.", "length": 181, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 365, "tag": "div", "text_raw": "The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of October 1, 2023, the cumulative amount of cash collateral paid by the Company under the CSA amounted to $ 1.7 billion net, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of October 1, 2023, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $ 42.9 billion, $ 39.5 billion and $ 10.0 billion, respectively. As of January 1, 2023, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $ 41.5 billion, $ 36.2 billion and $ 10.0 billion, respectively.", "text": "As of October 1, 2023, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $ 42.9 billion, $ 39.5 billion and $ 10.0 billion, respectively.", "length": 234, "numbers_raw": ["1", "202", "3", "42.9 billion", "39.5 billion", "10.0 billion"], "numbers": [1.0, 202.0, 3.0, 42900000000.0, 39500000000.0, 10000000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 365, "tag": "div", "text_raw": "The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of October 1, 2023, the cumulative amount of cash collateral paid by the Company under the CSA amounted to $ 1.7 billion net, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of October 1, 2023, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $ 42.9 billion, $ 39.5 billion and $ 10.0 billion, respectively. As of January 1, 2023, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $ 41.5 billion, $ 36.2 billion and $ 10.0 billion, respectively.", "text": "As of January 1, 2023, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $ 41.5 billion, $ 36.2 billion and $ 10.0 billion, respectively.", "length": 234, "numbers_raw": ["1", "202", "3", "41.5 billion", "36.2 billion", "10.0 billion"], "numbers": [1.0, 202.0, 3.0, 41500000000.0, 36200000000.0, 10000000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 367, "tag": "div", "text_raw": "All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.", "text": "All derivative instruments are recorded on the balance sheet at fair value.", "length": 75, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 367, "tag": "div", "text_raw": "All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.", "text": "Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.", "length": 240, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 369, "tag": "div", "text_raw": "The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings. Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings and are then reclassified to earnings in the same account as the hedged transaction.", "text": "The designation as a cash flow hedge is made at the entrance date of the derivative contract.", "length": 93, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 369, "tag": "div", "text_raw": "The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings. Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings and are then reclassified to earnings in the same account as the hedged transaction.", "text": "At inception, all derivatives are expected to be highly effective.", "length": 66, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 369, "tag": "div", "text_raw": "The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings. Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings and are then reclassified to earnings in the same account as the hedged transaction.", "text": "Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings.", "length": 235, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 369, "tag": "div", "text_raw": "The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings. Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings and are then reclassified to earnings in the same account as the hedged transaction.", "text": "Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings and are then reclassified to earnings in the same account as the hedged transaction.", "length": 236, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 371, "tag": "div", "text_raw": "Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur. Gains and losses on net investment hedges are accounted for through the currency translation account within accumulated other comprehensive income. The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued.", "text": "Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur.", "length": 203, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 371, "tag": "div", "text_raw": "Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur. Gains and losses on net investment hedges are accounted for through the currency translation account within accumulated other comprehensive income. The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued.", "text": "Gains and losses on net investment hedges are accounted for through the currency translation account within accumulated other comprehensive income.", "length": 147, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 371, "tag": "div", "text_raw": "Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur. Gains and losses on net investment hedges are accounted for through the currency translation account within accumulated other comprehensive income. The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued.", "text": "The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method.", "length": 116, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 371, "tag": "div", "text_raw": "Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur. Gains and losses on net investment hedges are accounted for through the currency translation account within accumulated other comprehensive income. The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued.", "text": "On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items.", "length": 137, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 371, "tag": "div", "text_raw": "Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur. Gains and losses on net investment hedges are accounted for through the currency translation account within accumulated other comprehensive income. The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued.", "text": "If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued.", "length": 104, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 373, "tag": "div", "text_raw": "The Company designated its Euro denominated notes issued in May 2016 with due dates ranging from 2022 to 2035 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates.", "text": "The Company designated its Euro denominated notes issued in May 2016 with due dates ranging from 2022 to 2035 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates.", "length": 327, "numbers_raw": ["201", "6", "202", "2", "203", "5"], "numbers": [201.0, 6.0, 202.0, 2.0, 203.0, 5.0], "percents_raw": [], "percents": [], "currencies": ["EUR"], "has_numbers": true, "has_percents": false}
{"idx_source": 375, "tag": "div", "text_raw": "11", "text": "11", "length": 2, "numbers_raw": ["11"], "numbers": [11.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 376, "tag": "div", "text_raw": "11", "text": "11", "length": 2, "numbers_raw": ["11"], "numbers": [11.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 377, "tag": "div", "text_raw": "11", "text": "11", "length": 2, "numbers_raw": ["11"], "numbers": [11.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 380, "tag": "div", "text_raw": "As of October 1, 2023, the balance of deferred net loss on derivatives included in accumulated other comprehensive income was $ 626 million after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 7. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months, excluding interest rate contracts and net investment hedge contracts. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.", "text": "As of October 1, 2023, the balance of deferred net loss on derivatives included in accumulated other comprehensive income was $ 626 million after-tax.", "length": 150, "numbers_raw": ["1", "202", "3", "626 million"], "numbers": [1.0, 202.0, 3.0, 626000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 380, "tag": "div", "text_raw": "As of October 1, 2023, the balance of deferred net loss on derivatives included in accumulated other comprehensive income was $ 626 million after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 7. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months, excluding interest rate contracts and net investment hedge contracts. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.", "text": "For additional information, see the Consolidated Statements of Comprehensive Income and Note 7.", "length": 95, "numbers_raw": ["7"], "numbers": [7.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 380, "tag": "div", "text_raw": "As of October 1, 2023, the balance of deferred net loss on derivatives included in accumulated other comprehensive income was $ 626 million after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 7. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months, excluding interest rate contracts and net investment hedge contracts. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.", "text": "The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period.", "length": 235, "numbers_raw": ["12 m"], "numbers": [12000000.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 380, "tag": "div", "text_raw": "As of October 1, 2023, the balance of deferred net loss on derivatives included in accumulated other comprehensive income was $ 626 million after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 7. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months, excluding interest rate contracts and net investment hedge contracts. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.", "text": "The maximum length of time over which the Company is hedging transaction exposure is 18 months, excluding interest rate contracts and net investment hedge contracts.", "length": 165, "numbers_raw": ["18 m"], "numbers": [18000000.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 380, "tag": "div", "text_raw": "As of October 1, 2023, the balance of deferred net loss on derivatives included in accumulated other comprehensive income was $ 626 million after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 7. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months, excluding interest rate contracts and net investment hedge contracts. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.", "text": "The amount ultimately realized in earnings may differ as foreign exchange rates change.", "length": 87, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 380, "tag": "div", "text_raw": "As of October 1, 2023, the balance of deferred net loss on derivatives included in accumulated other comprehensive income was $ 626 million after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 7. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months, excluding interest rate contracts and net investment hedge contracts. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.", "text": "Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.", "length": 107, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 383, "tag": "div", "text_raw": "The following table is a summary of the activity related to derivatives and hedges for the fiscal third quarters ended October 1, 2023 and October 2, 2022, net of tax:", "text": "The following table is a summary of the activity related to derivatives and hedges for the fiscal third quarters ended October 1, 2023 and October 2, 2022, net of tax:", "length": 167, "numbers_raw": ["1", "202", "3", "2", "202", "2"], "numbers": [1.0, 202.0, 3.0, 2.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 385, "tag": "div", "text_raw": "October 1, 2023 October 2, 2022 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on fair value hedging relationship: Interest rate swaps contracts: Hedged items $    ( 61 )     ( 322 )  Derivatives designated as hedging instruments    61     322  Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing    31     13  Amount of gain or (loss) recognized in AOCI    31     13  Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income 6 102 ( 5 )  4 ( 20 ) ( 83 ) 53  22 Amount of gain or (loss) recognized in AOCI ( 11 ) ( 166 ) 49  38 ( 45 ) ( 94 ) 91  36 Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income    41     120  Amount of gain or (loss) recognized in AOCI $    ( 454 )     ( 205 ) ", "text": "October 1, 2023 October 2, 2022 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging:", "length": 296, "numbers_raw": ["1", "202", "3", "2", "202", "2"], "numbers": [1.0, 202.0, 3.0, 2.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 385, "tag": "div", "text_raw": "October 1, 2023 October 2, 2022 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on fair value hedging relationship: Interest rate swaps contracts: Hedged items $    ( 61 )     ( 322 )  Derivatives designated as hedging instruments    61     322  Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing    31     13  Amount of gain or (loss) recognized in AOCI    31     13  Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income 6 102 ( 5 )  4 ( 20 ) ( 83 ) 53  22 Amount of gain or (loss) recognized in AOCI ( 11 ) ( 166 ) 49  38 ( 45 ) ( 94 ) 91  36 Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income    41     120  Amount of gain or (loss) recognized in AOCI $    ( 454 )     ( 205 ) ", "text": "Gain (Loss) on fair value hedging relationship:", "length": 47, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 385, "tag": "div", "text_raw": "October 1, 2023 October 2, 2022 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on fair value hedging relationship: Interest rate swaps contracts: Hedged items $    ( 61 )     ( 322 )  Derivatives designated as hedging instruments    61     322  Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing    31     13  Amount of gain or (loss) recognized in AOCI    31     13  Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income 6 102 ( 5 )  4 ( 20 ) ( 83 ) 53  22 Amount of gain or (loss) recognized in AOCI ( 11 ) ( 166 ) 49  38 ( 45 ) ( 94 ) 91  36 Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income    41     120  Amount of gain or (loss) recognized in AOCI $    ( 454 )     ( 205 ) ", "text": "Interest rate swaps contracts:", "length": 30, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 385, "tag": "div", "text_raw": "October 1, 2023 October 2, 2022 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on fair value hedging relationship: Interest rate swaps contracts: Hedged items $    ( 61 )     ( 322 )  Derivatives designated as hedging instruments    61     322  Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing    31     13  Amount of gain or (loss) recognized in AOCI    31     13  Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income 6 102 ( 5 )  4 ( 20 ) ( 83 ) 53  22 Amount of gain or (loss) recognized in AOCI ( 11 ) ( 166 ) 49  38 ( 45 ) ( 94 ) 91  36 Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income    41     120  Amount of gain or (loss) recognized in AOCI $    ( 454 )     ( 205 ) ", "text": "Hedged items $    ( 61 )     ( 322 )  Derivatives designated as hedging instruments    61     322  Gain (Loss) on net investment hedging relationship:", "length": 166, "numbers_raw": ["61", "322", "61", "322"], "numbers": [61.0, 322.0, 61.0, 322.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 385, "tag": "div", "text_raw": "October 1, 2023 October 2, 2022 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on fair value hedging relationship: Interest rate swaps contracts: Hedged items $    ( 61 )     ( 322 )  Derivatives designated as hedging instruments    61     322  Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing    31     13  Amount of gain or (loss) recognized in AOCI    31     13  Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income 6 102 ( 5 )  4 ( 20 ) ( 83 ) 53  22 Amount of gain or (loss) recognized in AOCI ( 11 ) ( 166 ) 49  38 ( 45 ) ( 94 ) 91  36 Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income    41     120  Amount of gain or (loss) recognized in AOCI $    ( 454 )     ( 205 ) ", "text": "Cross currency interest rate swaps contracts:", "length": 45, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 385, "tag": "div", "text_raw": "October 1, 2023 October 2, 2022 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on fair value hedging relationship: Interest rate swaps contracts: Hedged items $    ( 61 )     ( 322 )  Derivatives designated as hedging instruments    61     322  Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing    31     13  Amount of gain or (loss) recognized in AOCI    31     13  Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income 6 102 ( 5 )  4 ( 20 ) ( 83 ) 53  22 Amount of gain or (loss) recognized in AOCI ( 11 ) ( 166 ) 49  38 ( 45 ) ( 94 ) 91  36 Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income    41     120  Amount of gain or (loss) recognized in AOCI $    ( 454 )     ( 205 ) ", "text": "Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing    31     13  Amount of gain or (loss) recognized in AOCI    31     13  Gain (Loss) on cash flow hedging relationship:", "length": 237, "numbers_raw": ["31", "13", "31", "13"], "numbers": [31.0, 13.0, 31.0, 13.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 385, "tag": "div", "text_raw": "October 1, 2023 October 2, 2022 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on fair value hedging relationship: Interest rate swaps contracts: Hedged items $    ( 61 )     ( 322 )  Derivatives designated as hedging instruments    61     322  Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing    31     13  Amount of gain or (loss) recognized in AOCI    31     13  Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income 6 102 ( 5 )  4 ( 20 ) ( 83 ) 53  22 Amount of gain or (loss) recognized in AOCI ( 11 ) ( 166 ) 49  38 ( 45 ) ( 94 ) 91  36 Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income    41     120  Amount of gain or (loss) recognized in AOCI $    ( 454 )     ( 205 ) ", "text": "Forward foreign exchange contracts:", "length": 35, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 385, "tag": "div", "text_raw": "October 1, 2023 October 2, 2022 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on fair value hedging relationship: Interest rate swaps contracts: Hedged items $    ( 61 )     ( 322 )  Derivatives designated as hedging instruments    61     322  Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing    31     13  Amount of gain or (loss) recognized in AOCI    31     13  Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income 6 102 ( 5 )  4 ( 20 ) ( 83 ) 53  22 Amount of gain or (loss) recognized in AOCI ( 11 ) ( 166 ) 49  38 ( 45 ) ( 94 ) 91  36 Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income    41     120  Amount of gain or (loss) recognized in AOCI $    ( 454 )     ( 205 ) ", "text": "Amount of gain or (loss) reclassified from AOCI into income 6 102 ( 5 )  4 ( 20 ) ( 83 ) 53  22 Amount of gain or (loss) recognized in AOCI ( 11 ) ( 166 ) 49  38 ( 45 ) ( 94 ) 91  36 Cross currency interest rate swaps contracts:", "length": 232, "numbers_raw": ["6", "102", "5", "4", "20", "83", "53", "22", "11", "166", "49", "38", "45", "94", "91", "36"], "numbers": [6.0, 102.0, 5.0, 4.0, 20.0, 83.0, 53.0, 22.0, 11.0, 166.0, 49.0, 38.0, 45.0, 94.0, 91.0, 36.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 385, "tag": "div", "text_raw": "October 1, 2023 October 2, 2022 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on fair value hedging relationship: Interest rate swaps contracts: Hedged items $    ( 61 )     ( 322 )  Derivatives designated as hedging instruments    61     322  Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing    31     13  Amount of gain or (loss) recognized in AOCI    31     13  Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income 6 102 ( 5 )  4 ( 20 ) ( 83 ) 53  22 Amount of gain or (loss) recognized in AOCI ( 11 ) ( 166 ) 49  38 ( 45 ) ( 94 ) 91  36 Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income    41     120  Amount of gain or (loss) recognized in AOCI $    ( 454 )     ( 205 ) ", "text": "Amount of gain or (loss) reclassified from AOCI into income    41     120  Amount of gain or (loss) recognized in AOCI $    ( 454 )     ( 205 ) ", "length": 160, "numbers_raw": ["41", "120", "454", "205"], "numbers": [41.0, 120.0, 454.0, 205.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 394, "tag": "div", "text_raw": "12", "text": "12", "length": 2, "numbers_raw": ["12"], "numbers": [12.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 395, "tag": "div", "text_raw": "12", "text": "12", "length": 2, "numbers_raw": ["12"], "numbers": [12.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 396, "tag": "div", "text_raw": "12", "text": "12", "length": 2, "numbers_raw": ["12"], "numbers": [12.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 407, "tag": "div", "text_raw": "The following table is a summary of the activity related to derivatives and hedges for the fiscal nine months ended October 1, 2023 and October 2, 2022, net of tax:", "text": "The following table is a summary of the activity related to derivatives and hedges for the fiscal nine months ended October 1, 2023 and October 2, 2022, net of tax:", "length": 164, "numbers_raw": ["1", "202", "3", "2", "202", "2"], "numbers": [1.0, 202.0, 3.0, 2.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 409, "tag": "div", "text_raw": "October 1, 2023 October 2, 2022 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on fair value hedging relationship: Interest rate swaps contracts: Hedged items $    ( 1,165 )     ( 1,094 )  Derivatives designated as hedging instruments    1,165     1,094  Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing    98     102  Amount of gain or (loss) recognized in AOCI    98     102  Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income 3 12 ( 30 )  9 ( 54 ) ( 141 ) 118  ( 35 ) Amount of gain or (loss) recognized in AOCI ( 1 ) 230 20  42 ( 48 ) ( 153 ) 193  ( 75 ) Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income    223     342  Amount of gain or (loss) recognized in AOCI $    ( 469 )     ( 273 ) ", "text": "October 1, 2023 October 2, 2022 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging:", "length": 296, "numbers_raw": ["1", "202", "3", "2", "202", "2"], "numbers": [1.0, 202.0, 3.0, 2.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 409, "tag": "div", "text_raw": "October 1, 2023 October 2, 2022 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on fair value hedging relationship: Interest rate swaps contracts: Hedged items $    ( 1,165 )     ( 1,094 )  Derivatives designated as hedging instruments    1,165     1,094  Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing    98     102  Amount of gain or (loss) recognized in AOCI    98     102  Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income 3 12 ( 30 )  9 ( 54 ) ( 141 ) 118  ( 35 ) Amount of gain or (loss) recognized in AOCI ( 1 ) 230 20  42 ( 48 ) ( 153 ) 193  ( 75 ) Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income    223     342  Amount of gain or (loss) recognized in AOCI $    ( 469 )     ( 273 ) ", "text": "Gain (Loss) on fair value hedging relationship:", "length": 47, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 409, "tag": "div", "text_raw": "October 1, 2023 October 2, 2022 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on fair value hedging relationship: Interest rate swaps contracts: Hedged items $    ( 1,165 )     ( 1,094 )  Derivatives designated as hedging instruments    1,165     1,094  Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing    98     102  Amount of gain or (loss) recognized in AOCI    98     102  Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income 3 12 ( 30 )  9 ( 54 ) ( 141 ) 118  ( 35 ) Amount of gain or (loss) recognized in AOCI ( 1 ) 230 20  42 ( 48 ) ( 153 ) 193  ( 75 ) Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income    223     342  Amount of gain or (loss) recognized in AOCI $    ( 469 )     ( 273 ) ", "text": "Interest rate swaps contracts:", "length": 30, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 409, "tag": "div", "text_raw": "October 1, 2023 October 2, 2022 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on fair value hedging relationship: Interest rate swaps contracts: Hedged items $    ( 1,165 )     ( 1,094 )  Derivatives designated as hedging instruments    1,165     1,094  Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing    98     102  Amount of gain or (loss) recognized in AOCI    98     102  Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income 3 12 ( 30 )  9 ( 54 ) ( 141 ) 118  ( 35 ) Amount of gain or (loss) recognized in AOCI ( 1 ) 230 20  42 ( 48 ) ( 153 ) 193  ( 75 ) Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income    223     342  Amount of gain or (loss) recognized in AOCI $    ( 469 )     ( 273 ) ", "text": "Hedged items $    ( 1,165 )     ( 1,094 )  Derivatives designated as hedging instruments    1,165     1,094  Gain (Loss) on net investment hedging relationship:", "length": 176, "numbers_raw": ["1,165", "1,094", "1,165", "1,094"], "numbers": [1165.0, 1094.0, 1165.0, 1094.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 409, "tag": "div", "text_raw": "October 1, 2023 October 2, 2022 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on fair value hedging relationship: Interest rate swaps contracts: Hedged items $    ( 1,165 )     ( 1,094 )  Derivatives designated as hedging instruments    1,165     1,094  Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing    98     102  Amount of gain or (loss) recognized in AOCI    98     102  Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income 3 12 ( 30 )  9 ( 54 ) ( 141 ) 118  ( 35 ) Amount of gain or (loss) recognized in AOCI ( 1 ) 230 20  42 ( 48 ) ( 153 ) 193  ( 75 ) Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income    223     342  Amount of gain or (loss) recognized in AOCI $    ( 469 )     ( 273 ) ", "text": "Cross currency interest rate swaps contracts:", "length": 45, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 409, "tag": "div", "text_raw": "October 1, 2023 October 2, 2022 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on fair value hedging relationship: Interest rate swaps contracts: Hedged items $    ( 1,165 )     ( 1,094 )  Derivatives designated as hedging instruments    1,165     1,094  Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing    98     102  Amount of gain or (loss) recognized in AOCI    98     102  Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income 3 12 ( 30 )  9 ( 54 ) ( 141 ) 118  ( 35 ) Amount of gain or (loss) recognized in AOCI ( 1 ) 230 20  42 ( 48 ) ( 153 ) 193  ( 75 ) Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income    223     342  Amount of gain or (loss) recognized in AOCI $    ( 469 )     ( 273 ) ", "text": "Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing    98     102  Amount of gain or (loss) recognized in AOCI    98     102  Gain (Loss) on cash flow hedging relationship:", "length": 239, "numbers_raw": ["98", "102", "98", "102"], "numbers": [98.0, 102.0, 98.0, 102.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 409, "tag": "div", "text_raw": "October 1, 2023 October 2, 2022 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on fair value hedging relationship: Interest rate swaps contracts: Hedged items $    ( 1,165 )     ( 1,094 )  Derivatives designated as hedging instruments    1,165     1,094  Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing    98     102  Amount of gain or (loss) recognized in AOCI    98     102  Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income 3 12 ( 30 )  9 ( 54 ) ( 141 ) 118  ( 35 ) Amount of gain or (loss) recognized in AOCI ( 1 ) 230 20  42 ( 48 ) ( 153 ) 193  ( 75 ) Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income    223     342  Amount of gain or (loss) recognized in AOCI $    ( 469 )     ( 273 ) ", "text": "Forward foreign exchange contracts:", "length": 35, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 409, "tag": "div", "text_raw": "October 1, 2023 October 2, 2022 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on fair value hedging relationship: Interest rate swaps contracts: Hedged items $    ( 1,165 )     ( 1,094 )  Derivatives designated as hedging instruments    1,165     1,094  Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing    98     102  Amount of gain or (loss) recognized in AOCI    98     102  Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income 3 12 ( 30 )  9 ( 54 ) ( 141 ) 118  ( 35 ) Amount of gain or (loss) recognized in AOCI ( 1 ) 230 20  42 ( 48 ) ( 153 ) 193  ( 75 ) Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income    223     342  Amount of gain or (loss) recognized in AOCI $    ( 469 )     ( 273 ) ", "text": "Amount of gain or (loss) reclassified from AOCI into income 3 12 ( 30 )  9 ( 54 ) ( 141 ) 118  ( 35 ) Amount of gain or (loss) recognized in AOCI ( 1 ) 230 20  42 ( 48 ) ( 153 ) 193  ( 75 ) Cross currency interest rate swaps contracts:", "length": 239, "numbers_raw": ["3", "12", "30", "9", "54", "141", "118", "35", "1", "230", "20", "42", "48", "153", "193", "75"], "numbers": [3.0, 12.0, 30.0, 9.0, 54.0, 141.0, 118.0, 35.0, 1.0, 230.0, 20.0, 42.0, 48.0, 153.0, 193.0, 75.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 409, "tag": "div", "text_raw": "October 1, 2023 October 2, 2022 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on fair value hedging relationship: Interest rate swaps contracts: Hedged items $    ( 1,165 )     ( 1,094 )  Derivatives designated as hedging instruments    1,165     1,094  Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing    98     102  Amount of gain or (loss) recognized in AOCI    98     102  Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income 3 12 ( 30 )  9 ( 54 ) ( 141 ) 118  ( 35 ) Amount of gain or (loss) recognized in AOCI ( 1 ) 230 20  42 ( 48 ) ( 153 ) 193  ( 75 ) Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income    223     342  Amount of gain or (loss) recognized in AOCI $    ( 469 )     ( 273 ) ", "text": "Amount of gain or (loss) reclassified from AOCI into income    223     342  Amount of gain or (loss) recognized in AOCI $    ( 469 )     ( 273 ) ", "length": 161, "numbers_raw": ["223", "342", "469", "273"], "numbers": [223.0, 342.0, 469.0, 273.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 414, "tag": "div", "text_raw": "13", "text": "13", "length": 2, "numbers_raw": ["13"], "numbers": [13.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 415, "tag": "div", "text_raw": "13", "text": "13", "length": 2, "numbers_raw": ["13"], "numbers": [13.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 416, "tag": "div", "text_raw": "13", "text": "13", "length": 2, "numbers_raw": ["13"], "numbers": [13.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 423, "tag": "div", "text_raw": "As of October 1, 2023, and January 1, 2023, the following amounts were recorded on the Consolidated Balance Sheet related to cumulative basis adjustment for fair value hedges:", "text": "As of October 1, 2023, and January 1, 2023, the following amounts were recorded on the Consolidated Balance Sheet related to cumulative basis adjustment for fair value hedges:", "length": 175, "numbers_raw": ["1", "202", "3", "1", "202", "3"], "numbers": [1.0, 202.0, 3.0, 1.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 425, "tag": "div", "text_raw": "Line item in the Consolidated Balance Sheet in which the hedged item is included Carrying Amount of the Hedged Liability Cumulative Amount of Fair Value Hedging Gain/ (Loss) Included in the Carrying Amount of the Hedged Liability (Dollars in Millions) October 1, 2023 January 1, 2023 October 1, 2023 January 1, 2023 Long-term Debt $ 8,589 8,665 ( 1,523 ) ( 1,435 )", "text": "Line item in the Consolidated Balance Sheet in which the hedged item is included Carrying Amount of the Hedged Liability Cumulative Amount of Fair Value Hedging Gain/ (Loss) Included in the Carrying Amount of the Hedged Liability (Dollars in Millions) October 1, 2023 January 1, 2023 October 1, 2023 January 1, 2023 Long-term Debt $ 8,589 8,665 ( 1,523 ) ( 1,435 )", "length": 364, "numbers_raw": ["1", "202", "3", "1", "202", "3", "1", "202", "3", "1", "202", "3", "8,589", "8,665", "1,523", "1,435"], "numbers": [1.0, 202.0, 3.0, 1.0, 202.0, 3.0, 1.0, 202.0, 3.0, 1.0, 202.0, 3.0, 8589.0, 8665.0, 1523.0, 1435.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 427, "tag": "div", "text_raw": "The following table is the effect of derivatives not designated as hedging instruments for the fiscal third quarters ended 2023 and 2022:", "text": "The following table is the effect of derivatives not designated as hedging instruments for the fiscal third quarters ended 2023 and 2022:", "length": 137, "numbers_raw": ["202", "3", "202", "2"], "numbers": [202.0, 3.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 428, "tag": "div", "text_raw": "Gain/(Loss) Recognized In Income on Derivative Gain/(Loss) Recognized In Income on Derivative (Dollars in Millions) Location of Gain /(Loss) Recognized in Income on Derivative Fiscal Third Quarter Ended Fiscal Nine Months Ended Derivatives Not Designated as Hedging Instruments October 1, 2023 October 2, 2022 October 1, 2023 October 2, 2022 Foreign Exchange Contracts Other (income) expense $  109 2 211", "text": "Gain/(Loss) Recognized In Income on Derivative Gain/(Loss) Recognized In Income on Derivative (Dollars in Millions) Location of Gain /(Loss) Recognized in Income on Derivative Fiscal Third Quarter Ended Fiscal Nine Months Ended Derivatives Not Designated as Hedging Instruments October 1, 2023 October 2, 2022 October 1, 2023 October 2, 2022 Foreign Exchange Contracts Other (income) expense $  109 2 211", "length": 405, "numbers_raw": ["1", "202", "3", "2", "202", "2", "1", "202", "3", "2", "202", "2", "109", "2", "211"], "numbers": [1.0, 202.0, 3.0, 2.0, 202.0, 2.0, 1.0, 202.0, 3.0, 2.0, 202.0, 2.0, 109.0, 2.0, 211.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 431, "tag": "div", "text_raw": "The following table is the effect of net investment hedges for the fiscal third quarters ended in 2023 and 2022:", "text": "The following table is the effect of net investment hedges for the fiscal third quarters ended in 2023 and 2022:", "length": 112, "numbers_raw": ["202", "3", "202", "2"], "numbers": [202.0, 3.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 432, "tag": "div", "text_raw": "Gain/(Loss) Recognized In Accumulated OCI Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income Gain/(Loss) Reclassified From Accumulated OCI Into Income (Dollars in Millions) October 1, 2023 October 2, 2022 October 1, 2023 October 2, 2022 Debt $ 101 208 Interest (income) expense   Cross Currency interest rate swaps $ 214 261 Interest (income) expense  ", "text": "Gain/(Loss) Recognized In Accumulated OCI Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income Gain/(Loss) Reclassified From Accumulated OCI Into Income (Dollars in Millions) October 1, 2023 October 2, 2022 October 1, 2023 October 2, 2022 Debt $ 101 208 Interest (income) expense   Cross Currency interest rate swaps $ 214 261 Interest (income) expense  ", "length": 401, "numbers_raw": ["1", "202", "3", "2", "202", "2", "1", "202", "3", "2", "202", "2", "101", "208", "214", "261"], "numbers": [1.0, 202.0, 3.0, 2.0, 202.0, 2.0, 1.0, 202.0, 3.0, 2.0, 202.0, 2.0, 101.0, 208.0, 214.0, 261.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 434, "tag": "div", "text_raw": "The following table is the effect of net investment hedges for the fiscal nine months ended in 2023 and 2022:", "text": "The following table is the effect of net investment hedges for the fiscal nine months ended in 2023 and 2022:", "length": 109, "numbers_raw": ["202", "3", "202", "2"], "numbers": [202.0, 3.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 435, "tag": "div", "text_raw": "Gain/(Loss) Recognized In Accumulated OCI Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income Gain/(Loss) Reclassified From Accumulated OCI Into Income (Dollars in Millions) October 1, 2023 October 2, 2022 October 1, 2023 October 2, 2022 Debt $ 35 478 Interest (income) expense   Cross Currency interest rate swaps $ 880 1,134 Interest (income) expense  ", "text": "Gain/(Loss) Recognized In Accumulated OCI Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income Gain/(Loss) Reclassified From Accumulated OCI Into Income (Dollars in Millions) October 1, 2023 October 2, 2022 October 1, 2023 October 2, 2022 Debt $ 35 478 Interest (income) expense   Cross Currency interest rate swaps $ 880 1,134 Interest (income) expense  ", "length": 402, "numbers_raw": ["1", "202", "3", "2", "202", "2", "1", "202", "3", "2", "202", "2", "35", "478", "880", "1,134"], "numbers": [1.0, 202.0, 3.0, 2.0, 202.0, 2.0, 1.0, 202.0, 3.0, 2.0, 202.0, 2.0, 35.0, 478.0, 880.0, 1134.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 436, "tag": "div", "text_raw": "The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values. The Company has elected to measure equity investments that do not have readily determinable fair", "text": "The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values.", "length": 139, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 436, "tag": "div", "text_raw": "The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values. The Company has elected to measure equity investments that do not have readily determinable fair", "text": "The Company has elected to measure equity investments that do not have readily determinable fair", "length": 96, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 437, "tag": "div", "text_raw": "14", "text": "14", "length": 2, "numbers_raw": ["14"], "numbers": [14.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 438, "tag": "div", "text_raw": "14", "text": "14", "length": 2, "numbers_raw": ["14"], "numbers": [14.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 439, "tag": "div", "text_raw": "14", "text": "14", "length": 2, "numbers_raw": ["14"], "numbers": [14.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 442, "tag": "div", "text_raw": "values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.", "text": "values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.", "length": 188, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 443, "tag": "div", "text_raw": "The following table is a summary of the activity related to equity investments:", "text": "The following table is a summary of the activity related to equity investments:", "length": 79, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 444, "tag": "div", "text_raw": "(Dollars in Millions) January 1, 2023 October 1, 2023 Carrying Value Changes in Fair Value Reflected in Net Income (1) Sales/ Purchases/Other (2) Carrying Value Non Current Other Assets Equity Investments with readily determinable value* $ 576 ( 813 ) 4,260 4,023 4,023 Equity Investments without readily determinable value $ 613 ( 24 ) 96 685 685", "text": "(Dollars in Millions) January 1, 2023 October 1, 2023 Carrying Value Changes in Fair Value Reflected in Net Income (1) Sales/ Purchases/Other (2) Carrying Value Non Current Other Assets Equity Investments with readily determinable value* $ 576 ( 813 ) 4,260 4,023 4,023 Equity Investments without readily determinable value $ 613 ( 24 ) 96 685 685", "length": 347, "numbers_raw": ["1", "202", "3", "1", "202", "3", "1", "2", "576", "813", "4,260", "4,023", "4,023", "613", "24", "96", "685", "685"], "numbers": [1.0, 202.0, 3.0, 1.0, 202.0, 3.0, 1.0, 2.0, 576.0, 813.0, 4260.0, 4023.0, 4023.0, 613.0, 24.0, 96.0, 685.0, 685.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 445, "tag": "div", "text_raw": "Changes in Fair Value Reflected in Net Income (1)", "text": "Changes in Fair Value Reflected in Net Income (1)", "length": 49, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 446, "tag": "div", "text_raw": "Sales/ Purchases/Other (2)", "text": "Sales/ Purchases/Other (2)", "length": 26, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 447, "tag": "div", "text_raw": "(1) Recorded in Other Income/Expense", "text": "(1) Recorded in Other Income/Expense", "length": 36, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 448, "tag": "div", "text_raw": "(2) Other includes impact of currency", "text": "(2) Other includes impact of currency", "length": 37, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 449, "tag": "div", "text_raw": "* Includes the 9.5 % remaining stake in Kenvue and the $ 0.6 billion unfavorable change in the fair value of the investment between the separation date and the end of the fiscal quarter.", "text": "* Includes the 9.5 % remaining stake in Kenvue and the $ 0.6 billion unfavorable change in the fair value of the investment between the separation date and the end of the fiscal quarter.", "length": 186, "numbers_raw": ["9.5", "0.6 billion"], "numbers": [9.5, 600000000.0], "percents_raw": ["9.5 %"], "percents": [0.095], "currencies": ["USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 451, "tag": "div", "text_raw": "Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. In accordance with ASC 820, a three-level hierarchy was established to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level 1 inputs having the highest priority and Level 3 inputs having the lowest.", "text": "Fair value is the exit price that would be received to sell an asset or paid to transfer a liability.", "length": 101, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 451, "tag": "div", "text_raw": "Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. In accordance with ASC 820, a three-level hierarchy was established to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level 1 inputs having the highest priority and Level 3 inputs having the lowest.", "text": "Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability.", "length": 138, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 451, "tag": "div", "text_raw": "Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. In accordance with ASC 820, a three-level hierarchy was established to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level 1 inputs having the highest priority and Level 3 inputs having the lowest.", "text": "In accordance with ASC 820, a three-level hierarchy was established to prioritize the inputs used in measuring fair value.", "length": 122, "numbers_raw": ["820"], "numbers": [820.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 451, "tag": "div", "text_raw": "Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. In accordance with ASC 820, a three-level hierarchy was established to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level 1 inputs having the highest priority and Level 3 inputs having the lowest.", "text": "The levels within the hierarchy are described below with Level 1 inputs having the highest priority and Level 3 inputs having the lowest.", "length": 137, "numbers_raw": ["1", "3"], "numbers": [1.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 453, "tag": "div", "text_raw": "The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Companys results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations.", "text": "The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S.", "length": 286, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 453, "tag": "div", "text_raw": "The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Companys results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations.", "text": "Dollar at the current spot foreign exchange rate.", "length": 49, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 453, "tag": "div", "text_raw": "The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Companys results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations.", "text": "The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Companys results of operations, cash flows or financial position.", "length": 300, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 453, "tag": "div", "text_raw": "The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Companys results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations.", "text": "The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2.", "length": 126, "numbers_raw": ["1", "2"], "numbers": [1.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 453, "tag": "div", "text_raw": "The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Companys results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations.", "text": "The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations.", "length": 325, "numbers_raw": ["3"], "numbers": [3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 455, "tag": "div", "text_raw": "The following three levels of inputs are used to measure fair value:", "text": "The following three levels of inputs are used to measure fair value:", "length": 68, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 457, "tag": "div", "text_raw": "Level 1  Quoted prices in active markets for identical assets and liabilities.", "text": "Level 1  Quoted prices in active markets for identical assets and liabilities.", "length": 79, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 458, "tag": "div", "text_raw": "Level 2  Significant other observable inputs.", "text": "Level 2  Significant other observable inputs.", "length": 46, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 459, "tag": "div", "text_raw": "Level 3  Significant unobservable inputs.", "text": "Level 3  Significant unobservable inputs.", "length": 42, "numbers_raw": ["3"], "numbers": [3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 461, "tag": "div", "text_raw": "15", "text": "15", "length": 2, "numbers_raw": ["15"], "numbers": [15.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 462, "tag": "div", "text_raw": "15", "text": "15", "length": 2, "numbers_raw": ["15"], "numbers": [15.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 463, "tag": "div", "text_raw": "15", "text": "15", "length": 2, "numbers_raw": ["15"], "numbers": [15.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 466, "tag": "div", "text_raw": "The Companys significant financial assets and liabilities measured at fair value as of October 1, 2023 and January 1, 2023 were as follows:", "text": "The Companys significant financial assets and liabilities measured at fair value as of October 1, 2023 and January 1, 2023 were as follows:", "length": 140, "numbers_raw": ["1", "202", "3", "1", "202", "3"], "numbers": [1.0, 202.0, 3.0, 1.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 467, "tag": "div", "text_raw": "October 1, 2023 January 1, 2023 (Dollars in Millions) Level 1 Level 2 Level 3 Total Total (1) Derivatives designated as hedging instruments: Assets: Forward foreign exchange contracts $  901  901 629 Interest rate contracts (2)  1,534  1,534 1,534 Total  2,435  2,435 2,163 Liabilities: Forward foreign exchange contracts  577  577 511 Interest rate contracts (2)  3,669  3,669 2,778 Total  4,246  4,246 3,289 Derivatives not designated as hedging instruments: Assets: Forward foreign exchange contracts  58  58 38 Liabilities: Forward foreign exchange contracts  47  47 68 Other Investments: Equity investments (3) 4,023   4,023 576 Debt securities (4)  8,407  8,407 10,487 Other Liabilities Contingent consideration (5) $   1,178 1,178 1,120", "text": "October 1, 2023 January 1, 2023 (Dollars in Millions) Level 1 Level 2 Level 3 Total Total (1) Derivatives designated as hedging instruments:", "length": 140, "numbers_raw": ["1", "202", "3", "1", "202", "3", "1", "2", "3", "1"], "numbers": [1.0, 202.0, 3.0, 1.0, 202.0, 3.0, 1.0, 2.0, 3.0, 1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 467, "tag": "div", "text_raw": "October 1, 2023 January 1, 2023 (Dollars in Millions) Level 1 Level 2 Level 3 Total Total (1) Derivatives designated as hedging instruments: Assets: Forward foreign exchange contracts $  901  901 629 Interest rate contracts (2)  1,534  1,534 1,534 Total  2,435  2,435 2,163 Liabilities: Forward foreign exchange contracts  577  577 511 Interest rate contracts (2)  3,669  3,669 2,778 Total  4,246  4,246 3,289 Derivatives not designated as hedging instruments: Assets: Forward foreign exchange contracts  58  58 38 Liabilities: Forward foreign exchange contracts  47  47 68 Other Investments: Equity investments (3) 4,023   4,023 576 Debt securities (4)  8,407  8,407 10,487 Other Liabilities Contingent consideration (5) $   1,178 1,178 1,120", "text": "Forward foreign exchange contracts $  901  901 629 Interest rate contracts (2)  1,534  1,534 1,534 Total  2,435  2,435 2,163 Liabilities:", "length": 143, "numbers_raw": ["901", "901", "629", "2", "1,534", "1,534", "1,534", "2,435", "2,435", "2,163"], "numbers": [901.0, 901.0, 629.0, 2.0, 1534.0, 1534.0, 1534.0, 2435.0, 2435.0, 2163.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 467, "tag": "div", "text_raw": "October 1, 2023 January 1, 2023 (Dollars in Millions) Level 1 Level 2 Level 3 Total Total (1) Derivatives designated as hedging instruments: Assets: Forward foreign exchange contracts $  901  901 629 Interest rate contracts (2)  1,534  1,534 1,534 Total  2,435  2,435 2,163 Liabilities: Forward foreign exchange contracts  577  577 511 Interest rate contracts (2)  3,669  3,669 2,778 Total  4,246  4,246 3,289 Derivatives not designated as hedging instruments: Assets: Forward foreign exchange contracts  58  58 38 Liabilities: Forward foreign exchange contracts  47  47 68 Other Investments: Equity investments (3) 4,023   4,023 576 Debt securities (4)  8,407  8,407 10,487 Other Liabilities Contingent consideration (5) $   1,178 1,178 1,120", "text": "Forward foreign exchange contracts  577  577 511 Interest rate contracts (2)  3,669  3,669 2,778 Total  4,246  4,246 3,289 Derivatives not designated as hedging instruments:", "length": 179, "numbers_raw": ["577", "577", "511", "2", "3,669", "3,669", "2,778", "4,246", "4,246", "3,289"], "numbers": [577.0, 577.0, 511.0, 2.0, 3669.0, 3669.0, 2778.0, 4246.0, 4246.0, 3289.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 467, "tag": "div", "text_raw": "October 1, 2023 January 1, 2023 (Dollars in Millions) Level 1 Level 2 Level 3 Total Total (1) Derivatives designated as hedging instruments: Assets: Forward foreign exchange contracts $  901  901 629 Interest rate contracts (2)  1,534  1,534 1,534 Total  2,435  2,435 2,163 Liabilities: Forward foreign exchange contracts  577  577 511 Interest rate contracts (2)  3,669  3,669 2,778 Total  4,246  4,246 3,289 Derivatives not designated as hedging instruments: Assets: Forward foreign exchange contracts  58  58 38 Liabilities: Forward foreign exchange contracts  47  47 68 Other Investments: Equity investments (3) 4,023   4,023 576 Debt securities (4)  8,407  8,407 10,487 Other Liabilities Contingent consideration (5) $   1,178 1,178 1,120", "text": "Forward foreign exchange contracts  58  58 38 Liabilities:", "length": 60, "numbers_raw": ["58", "58", "38"], "numbers": [58.0, 58.0, 38.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 467, "tag": "div", "text_raw": "October 1, 2023 January 1, 2023 (Dollars in Millions) Level 1 Level 2 Level 3 Total Total (1) Derivatives designated as hedging instruments: Assets: Forward foreign exchange contracts $  901  901 629 Interest rate contracts (2)  1,534  1,534 1,534 Total  2,435  2,435 2,163 Liabilities: Forward foreign exchange contracts  577  577 511 Interest rate contracts (2)  3,669  3,669 2,778 Total  4,246  4,246 3,289 Derivatives not designated as hedging instruments: Assets: Forward foreign exchange contracts  58  58 38 Liabilities: Forward foreign exchange contracts  47  47 68 Other Investments: Equity investments (3) 4,023   4,023 576 Debt securities (4)  8,407  8,407 10,487 Other Liabilities Contingent consideration (5) $   1,178 1,178 1,120", "text": "Forward foreign exchange contracts  47  47 68 Other Investments:", "length": 66, "numbers_raw": ["47", "47", "68"], "numbers": [47.0, 47.0, 68.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 467, "tag": "div", "text_raw": "October 1, 2023 January 1, 2023 (Dollars in Millions) Level 1 Level 2 Level 3 Total Total (1) Derivatives designated as hedging instruments: Assets: Forward foreign exchange contracts $  901  901 629 Interest rate contracts (2)  1,534  1,534 1,534 Total  2,435  2,435 2,163 Liabilities: Forward foreign exchange contracts  577  577 511 Interest rate contracts (2)  3,669  3,669 2,778 Total  4,246  4,246 3,289 Derivatives not designated as hedging instruments: Assets: Forward foreign exchange contracts  58  58 38 Liabilities: Forward foreign exchange contracts  47  47 68 Other Investments: Equity investments (3) 4,023   4,023 576 Debt securities (4)  8,407  8,407 10,487 Other Liabilities Contingent consideration (5) $   1,178 1,178 1,120", "text": "Equity investments (3) 4,023   4,023 576 Debt securities (4)  8,407  8,407 10,487 Other Liabilities Contingent consideration (5) $   1,178 1,178 1,120", "length": 156, "numbers_raw": ["3", "4,023", "4,023", "576", "4", "8,407", "8,407", "10,487", "5", "1,178", "1,178", "1,120"], "numbers": [3.0, 4023.0, 4023.0, 576.0, 4.0, 8407.0, 8407.0, 10487.0, 5.0, 1178.0, 1178.0, 1120.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 468, "tag": "div", "text_raw": "Total (1)", "text": "Total (1)", "length": 9, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 469, "tag": "div", "text_raw": "Interest rate contracts (2)", "text": "Interest rate contracts (2)", "length": 27, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 470, "tag": "div", "text_raw": "Interest rate contracts (2)", "text": "Interest rate contracts (2)", "length": 27, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 471, "tag": "div", "text_raw": "Equity investments (3)", "text": "Equity investments (3)", "length": 22, "numbers_raw": ["3"], "numbers": [3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 472, "tag": "div", "text_raw": "Debt securities (4)", "text": "Debt securities (4)", "length": 19, "numbers_raw": ["4"], "numbers": [4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 473, "tag": "div", "text_raw": "Contingent consideration (5)", "text": "Contingent consideration (5)", "length": 28, "numbers_raw": ["5"], "numbers": [5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 475, "tag": "div", "text_raw": "Gross to Net Derivative Reconciliation October 1, 2023 January 1, 2023 (Dollars in Millions) Total Gross Assets $ 2,493 2,201 Credit Support Agreement (CSA) ( 2,472 ) ( 2,176 ) Total Net Asset 21 25 Total Gross Liabilities 4,293 3,357 Credit Support Agreement (CSA) ( 4,174 ) ( 3,023 ) Total Net Liabilities $ 119 334", "text": "Gross to Net Derivative Reconciliation October 1, 2023 January 1, 2023 (Dollars in Millions) Total Gross Assets $ 2,493 2,201 Credit Support Agreement (CSA) ( 2,472 ) ( 2,176 ) Total Net Asset 21 25 Total Gross Liabilities 4,293 3,357 Credit Support Agreement (CSA) ( 4,174 ) ( 3,023 ) Total Net Liabilities $ 119 334", "length": 317, "numbers_raw": ["1", "202", "3", "1", "202", "3", "2,493", "2,201", "2,472", "2,176", "21", "25", "4,293", "3,357", "4,174", "3,023", "119", "334"], "numbers": [1.0, 202.0, 3.0, 1.0, 202.0, 3.0, 2493.0, 2201.0, 2472.0, 2176.0, 21.0, 25.0, 4293.0, 3357.0, 4174.0, 3023.0, 119.0, 334.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 478, "tag": "div", "text_raw": "Summarized information about changes in liabilities for contingent consideration for the fiscal third quarters ended October 1, 2023 and October 2, 2022 is as follows:", "text": "Summarized information about changes in liabilities for contingent consideration for the fiscal third quarters ended October 1, 2023 and October 2, 2022 is as follows:", "length": 167, "numbers_raw": ["1", "202", "3", "2", "202", "2"], "numbers": [1.0, 202.0, 3.0, 2.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 479, "tag": "div", "text_raw": "October 1, 2023 October 2, 2022 (Dollars in Millions) Beginning Balance $ 1,120 533 Changes in estimated fair value (6) 62 ( 85 ) Additions  89 Payments ( 4 ) ( 12 ) Ending Balance $ 1,178 525", "text": "October 1, 2023 October 2, 2022 (Dollars in Millions) Beginning Balance $ 1,120 533 Changes in estimated fair value (6) 62 ( 85 ) Additions  89 Payments ( 4 ) ( 12 ) Ending Balance $ 1,178 525", "length": 193, "numbers_raw": ["1", "202", "3", "2", "202", "2", "1,120", "533", "6", "62", "85", "89", "4", "12", "1,178", "525"], "numbers": [1.0, 202.0, 3.0, 2.0, 202.0, 2.0, 1120.0, 533.0, 6.0, 62.0, 85.0, 89.0, 4.0, 12.0, 1178.0, 525.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 480, "tag": "div", "text_raw": "Changes in estimated fair value (6)", "text": "Changes in estimated fair value (6)", "length": 35, "numbers_raw": ["6"], "numbers": [6.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 484, "tag": "div", "text_raw": "16", "text": "16", "length": 2, "numbers_raw": ["16"], "numbers": [16.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 485, "tag": "div", "text_raw": "16", "text": "16", "length": 2, "numbers_raw": ["16"], "numbers": [16.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 486, "tag": "div", "text_raw": "16", "text": "16", "length": 2, "numbers_raw": ["16"], "numbers": [16.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 489, "tag": "div", "text_raw": "(1) 2022 assets and liabilities are all classified as Level 2 with the exception of equity investments of $ 576 million, which are classified as Level 1 and contingent consideration of $ 1,120 million, classified as Level 3.", "text": "(1) 2022 assets and liabilities are all classified as Level 2 with the exception of equity investments of $ 576 million, which are classified as Level 1 and contingent consideration of $ 1,120 million, classified as Level 3.", "length": 224, "numbers_raw": ["1", "202", "2", "2", "576 million", "1", "1,120 million", "3"], "numbers": [1.0, 202.0, 2.0, 2.0, 576000000.0, 1.0, 1120000000.0, 3.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 490, "tag": "div", "text_raw": "(2) Includes cross currency interest rate swaps and interest rate swaps.", "text": "(2) Includes cross currency interest rate swaps and interest rate swaps.", "length": 72, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 491, "tag": "div", "text_raw": "(3) Classified as non-current other assets.", "text": "(3) Classified as non-current other assets.", "length": 43, "numbers_raw": ["3"], "numbers": [3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 492, "tag": "div", "text_raw": "(4) Classified within cash equivalents and current marketable securities.", "text": "(4) Classified within cash equivalents and current marketable securities.", "length": 73, "numbers_raw": ["4"], "numbers": [4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 493, "tag": "div", "text_raw": "(5) Includes $ 1,172 million and $ 1,116 million, classified as non-current other liabilities as of October 1, 2023 and January 1, 2023, respectively.", "text": "(5) Includes $ 1,172 million and $ 1,116 million, classified as non-current other liabilities as of October 1, 2023 and January 1, 2023, respectively.", "length": 150, "numbers_raw": ["5", "1,172 million", "1,116 million", "1", "202", "3", "1", "202", "3"], "numbers": [5.0, 1172000000.0, 1116000000.0, 1.0, 202.0, 3.0, 1.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 494, "tag": "div", "text_raw": "(6) Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense.", "text": "(6) Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense.", "length": 101, "numbers_raw": ["6"], "numbers": [6.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 497, "tag": "div", "text_raw": "The Company's cash, cash equivalents and current marketable securities as of October 1, 2023 comprised:", "text": "The Company's cash, cash equivalents and current marketable securities as of October 1, 2023 comprised:", "length": 103, "numbers_raw": ["1", "202", "3"], "numbers": [1.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 498, "tag": "div", "text_raw": "(Dollars in Millions) Carrying Amount Gain/(Loss) Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities Cash $ 3,214  3,214 3,214  Non-U.S. sovereign securities 150  150 150  U.S. reverse repurchase agreements 7,261  7,261 7,261  Corporate debt securities (1) 228  228 78 150 Money market funds 3,503  3,503 3,503  Time deposits (1) 748  748 748  Subtotal 15,104  15,104 14,954 150 Unrealized Loss U.S. Govt securities 8,062 ( 1 ) 8,061 4,728 3,333 U.S. Govt Agencies 95 ( 2 ) 93  93 Other sovereign securities 6  6 2 4 Corporate debt securities 247  247 44 203 Subtotal available for sale debt (2) $ 8,410 ( 3 ) 8,407 4,774 3,633 Total cash, cash equivalents and current marketable securities $ 23,514 ( 3 ) 23,511 19,728 3,783", "text": "(Dollars in Millions) Carrying Amount Gain/(Loss) Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities Cash $ 3,214  3,214 3,214  Non-U.S.", "length": 162, "numbers_raw": ["3,214", "3,214", "3,214"], "numbers": [3214.0, 3214.0, 3214.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 498, "tag": "div", "text_raw": "(Dollars in Millions) Carrying Amount Gain/(Loss) Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities Cash $ 3,214  3,214 3,214  Non-U.S. sovereign securities 150  150 150  U.S. reverse repurchase agreements 7,261  7,261 7,261  Corporate debt securities (1) 228  228 78 150 Money market funds 3,503  3,503 3,503  Time deposits (1) 748  748 748  Subtotal 15,104  15,104 14,954 150 Unrealized Loss U.S. Govt securities 8,062 ( 1 ) 8,061 4,728 3,333 U.S. Govt Agencies 95 ( 2 ) 93  93 Other sovereign securities 6  6 2 4 Corporate debt securities 247  247 44 203 Subtotal available for sale debt (2) $ 8,410 ( 3 ) 8,407 4,774 3,633 Total cash, cash equivalents and current marketable securities $ 23,514 ( 3 ) 23,511 19,728 3,783", "text": "sovereign securities 150  150 150  U.S.", "length": 41, "numbers_raw": ["150", "150", "150"], "numbers": [150.0, 150.0, 150.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 498, "tag": "div", "text_raw": "(Dollars in Millions) Carrying Amount Gain/(Loss) Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities Cash $ 3,214  3,214 3,214  Non-U.S. sovereign securities 150  150 150  U.S. reverse repurchase agreements 7,261  7,261 7,261  Corporate debt securities (1) 228  228 78 150 Money market funds 3,503  3,503 3,503  Time deposits (1) 748  748 748  Subtotal 15,104  15,104 14,954 150 Unrealized Loss U.S. Govt securities 8,062 ( 1 ) 8,061 4,728 3,333 U.S. Govt Agencies 95 ( 2 ) 93  93 Other sovereign securities 6  6 2 4 Corporate debt securities 247  247 44 203 Subtotal available for sale debt (2) $ 8,410 ( 3 ) 8,407 4,774 3,633 Total cash, cash equivalents and current marketable securities $ 23,514 ( 3 ) 23,511 19,728 3,783", "text": "reverse repurchase agreements 7,261  7,261 7,261  Corporate debt securities (1) 228  228 78 150 Money market funds 3,503  3,503 3,503  Time deposits (1) 748  748 748  Subtotal 15,104  15,104 14,954 150 Unrealized Loss U.S.", "length": 230, "numbers_raw": ["7,261", "7,261", "7,261", "1", "228", "228", "78", "150 M", "3,503", "3,503", "3,503", "1", "748", "748", "748", "15,104", "15,104", "14,954", "150"], "numbers": [7261.0, 7261.0, 7261.0, 1.0, 228.0, 228.0, 78.0, 150000000.0, 3503.0, 3503.0, 3503.0, 1.0, 748.0, 748.0, 748.0, 15104.0, 15104.0, 14954.0, 150.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 498, "tag": "div", "text_raw": "(Dollars in Millions) Carrying Amount Gain/(Loss) Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities Cash $ 3,214  3,214 3,214  Non-U.S. sovereign securities 150  150 150  U.S. reverse repurchase agreements 7,261  7,261 7,261  Corporate debt securities (1) 228  228 78 150 Money market funds 3,503  3,503 3,503  Time deposits (1) 748  748 748  Subtotal 15,104  15,104 14,954 150 Unrealized Loss U.S. Govt securities 8,062 ( 1 ) 8,061 4,728 3,333 U.S. Govt Agencies 95 ( 2 ) 93  93 Other sovereign securities 6  6 2 4 Corporate debt securities 247  247 44 203 Subtotal available for sale debt (2) $ 8,410 ( 3 ) 8,407 4,774 3,633 Total cash, cash equivalents and current marketable securities $ 23,514 ( 3 ) 23,511 19,728 3,783", "text": "Govt securities 8,062 ( 1 ) 8,061 4,728 3,333 U.S.", "length": 51, "numbers_raw": ["8,062", "1", "8,061", "4,728", "3,333"], "numbers": [8062.0, 1.0, 8061.0, 4728.0, 3333.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 498, "tag": "div", "text_raw": "(Dollars in Millions) Carrying Amount Gain/(Loss) Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities Cash $ 3,214  3,214 3,214  Non-U.S. sovereign securities 150  150 150  U.S. reverse repurchase agreements 7,261  7,261 7,261  Corporate debt securities (1) 228  228 78 150 Money market funds 3,503  3,503 3,503  Time deposits (1) 748  748 748  Subtotal 15,104  15,104 14,954 150 Unrealized Loss U.S. Govt securities 8,062 ( 1 ) 8,061 4,728 3,333 U.S. Govt Agencies 95 ( 2 ) 93  93 Other sovereign securities 6  6 2 4 Corporate debt securities 247  247 44 203 Subtotal available for sale debt (2) $ 8,410 ( 3 ) 8,407 4,774 3,633 Total cash, cash equivalents and current marketable securities $ 23,514 ( 3 ) 23,511 19,728 3,783", "text": "Govt Agencies 95 ( 2 ) 93  93 Other sovereign securities 6  6 2 4 Corporate debt securities 247  247 44 203 Subtotal available for sale debt (2) $ 8,410 ( 3 ) 8,407 4,774 3,633 Total cash, cash equivalents and current marketable securities $ 23,514 ( 3 ) 23,511 19,728 3,783", "length": 278, "numbers_raw": ["95", "2", "93", "93", "6", "6", "2", "4", "247", "247", "44", "203", "2", "8,410", "3", "8,407", "4,774", "3,633", "23,514", "3", "23,511", "19,728", "3,783"], "numbers": [95.0, 2.0, 93.0, 93.0, 6.0, 6.0, 2.0, 4.0, 247.0, 247.0, 44.0, 203.0, 2.0, 8410.0, 3.0, 8407.0, 4774.0, 3633.0, 23514.0, 3.0, 23511.0, 19728.0, 3783.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 499, "tag": "div", "text_raw": "Corporate debt securities (1)", "text": "Corporate debt securities (1)", "length": 29, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 500, "tag": "div", "text_raw": "Time deposits (1)", "text": "Time deposits (1)", "length": 17, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 501, "tag": "div", "text_raw": "Subtotal available for sale debt (2)", "text": "Subtotal available for sale debt (2)", "length": 36, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 502, "tag": "div", "text_raw": "(1) Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings.", "text": "(1) Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings.", "length": 109, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 503, "tag": "div", "text_raw": "(2) Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.", "text": "(2) Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.", "length": 151, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 505, "tag": "div", "text_raw": "As of the fiscal year ended January 1, 2023, the carrying amount was approximately the same as the estimated fair value.", "text": "As of the fiscal year ended January 1, 2023, the carrying amount was approximately the same as the estimated fair value.", "length": 120, "numbers_raw": ["1", "202", "3"], "numbers": [1.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 507, "tag": "div", "text_raw": "Fair value of government securities and obligations and corporate debt securities was estimated using quoted broker prices and significant other observable inputs.", "text": "Fair value of government securities and obligations and corporate debt securities was estimated using quoted broker prices and significant other observable inputs.", "length": 163, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 509, "tag": "div", "text_raw": "The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as either cash equivalents or current marketable securities.", "text": "The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities.", "length": 287, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 509, "tag": "div", "text_raw": "The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as either cash equivalents or current marketable securities.", "text": "Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as either cash equivalents or current marketable securities.", "length": 224, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 511, "tag": "div", "text_raw": "The contractual maturities of the available for sale securities as of October 1, 2023 are as follows:", "text": "The contractual maturities of the available for sale securities as of October 1, 2023 are as follows:", "length": 101, "numbers_raw": ["1", "202", "3"], "numbers": [1.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 512, "tag": "div", "text_raw": "(Dollars in Millions) Cost Basis Fair Value Due within one year $ 8,400 8,397 Due after one year through five years 10 10 Due after five years through ten years   Total debt securities $ 8,410 8,407", "text": "(Dollars in Millions) Cost Basis Fair Value Due within one year $ 8,400 8,397 Due after one year through five years 10 10 Due after five years through ten years   Total debt securities $ 8,410 8,407", "length": 200, "numbers_raw": ["8,400", "8,397", "10", "10", "8,410", "8,407"], "numbers": [8400.0, 8397.0, 10.0, 10.0, 8410.0, 8407.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 513, "tag": "div", "text_raw": "17", "text": "17", "length": 2, "numbers_raw": ["17"], "numbers": [17.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 514, "tag": "div", "text_raw": "17", "text": "17", "length": 2, "numbers_raw": ["17"], "numbers": [17.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 515, "tag": "div", "text_raw": "17", "text": "17", "length": 2, "numbers_raw": ["17"], "numbers": [17.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 519, "tag": "div", "text_raw": "Financial Instruments not measured at Fair Value", "text": "Financial Instruments not measured at Fair Value", "length": 48, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 521, "tag": "div", "text_raw": "The following financial liabilities are held at carrying amount on the consolidated balance sheet as of October 1, 2023:", "text": "The following financial liabilities are held at carrying amount on the consolidated balance sheet as of October 1, 2023:", "length": 120, "numbers_raw": ["1", "202", "3"], "numbers": [1.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 522, "tag": "div", "text_raw": "(Dollars in Millions) Carrying Amount Estimated Fair Value Financial Liabilities Current Debt $ 3,870 3,852 Non-Current Debt 5.50 % Notes due 2024 ( 500 MM GBP 1.2190 ) 609 609 2.625 % Notes due 2025 750 726 0.55 % Notes due 2025 947 916 2.45 % Notes due 2026 1,997 1,879 2.95 % Notes due 2027 882 937 0.95 % Notes due 2027 1,409 1,290 2.90 % Notes due 2028 1,497 1,384 1.150 % Notes due 2028 ( 750 MM Euro 1.0534 ) 786 705 6.95 % Notes due 2029 298 337 1.30 % Notes due 2030 1,604 1,377 4.95 % Debentures due 2033 499 507 4.375 % Notes due 2033 854 809 1.650 % Notes due 2035 ( 1.5 B Euro 1.0534 ) 1,568 1,282 3.55 % Notes due 2036 831 852 5.95 % Notes due 2037 994 1,060 3.625 % Notes due 2037 1,321 1,261 3.40 % Notes due 2038 993 823 5.85 % Debentures due 2038 697 735 4.50 % Debentures due 2040 541 502 2.10 % Notes due 2040 809 639 4.85 % Notes due 2041 297 282 4.50 % Notes due 2043 496 450 3.70 % Notes due 2046 1,977 1,555 3.75 % Notes due 2047 787 788 3.50 % Notes due 2048 743 564 2.25 % Notes due 2050 776 573 2.45 % Notes due 2060 1,025 695 Other 64 62 Total Non-Current Debt $ 26,051 23,599", "text": "(Dollars in Millions) Carrying Amount Estimated Fair Value Financial Liabilities Current Debt $ 3,870 3,852 Non-Current Debt 5.50 % Notes due 2024 ( 500 MM GBP 1.2190 ) 609 609 2.625 % Notes due 2025 750 726 0.55 % Notes due 2025 947 916 2.45 % Notes due 2026 1,997 1,879 2.95 % Notes due 2027 882 937 0.95 % Notes due 2027 1,409 1,290 2.90 % Notes due 2028 1,497 1,384 1.150 % Notes due 2028 ( 750 MM Euro 1.0534 ) 786 705 6.95 % Notes due 2029 298 337 1.30 % Notes due 2030 1,604 1,377 4.95 % Debentures due 2033 499 507 4.375 % Notes due 2033 854 809 1.650 % Notes due 2035 ( 1.5 B Euro 1.0534 ) 1,568 1,282 3.55 % Notes due 2036 831 852 5.95 % Notes due 2037 994 1,060 3.625 % Notes due 2037 1,321 1,261 3.40 % Notes due 2038 993 823 5.85 % Debentures due 2038 697 735 4.50 % Debentures due 2040 541 502 2.10 % Notes due 2040 809 639 4.85 % Notes due 2041 297 282 4.50 % Notes due 2043 496 450 3.70 % Notes due 2046 1,977 1,555 3.75 % Notes due 2047 787 788 3.50 % Notes due 2048 743 564 2.25 % Notes due 2050 776 573 2.45 % Notes due 2060 1,025 695 Other 64 62 Total Non-Current Debt $ 26,051 23,599", "length": 1104, "numbers_raw": ["3,870", "3,852", "5.50", "202", "4", "500 M", "1.2190", "609", "609", "2.625", "202", "5", "750", "726", "0.55", "202", "5", "947", "916", "2.45", "202", "6", "1,997", "1,879", "2.95", "202", "7", "882", "937", "0.95", "202", "7", "1,409", "1,290", "2.90", "202", "8", "1,497", "1,384", "1.150", "202", "8", "750 M", "1.0534", "786", "705", "6.95", "202", "9", "298", "337", "1.30", "203", "0", "1,604", "1,377", "4.95", "203", "3", "499", "507", "4.375", "203", "3", "854", "809", "1.650", "203", "5", "1.5", "1.0534", "1,568", "1,282", "3.55", "203", "6", "831", "852", "5.95", "203", "7", "994", "1,060", "3.625", "203", "7", "1,321", "1,261", "3.40", "203", "8", "993", "823", "5.85", "203", "8", "697", "735", "4.50", "204", "0", "541", "502", "2.10", "204", "0", "809", "639", "4.85", "204", "1", "297", "282", "4.50", "204", "3", "496", "450", "3.70", "204", "6", "1,977", "1,555", "3.75", "204", "7", "787", "788", "3.50", "204", "8", "743", "564", "2.25", "205", "0", "776", "573", "2.45", "206", "0", "1,025", "695", "64", "62", "26,051", "23,599"], "numbers": [3870.0, 3852.0, 5.5, 202.0, 4.0, 500000000.0, 1.219, 609.0, 609.0, 2.625, 202.0, 5.0, 750.0, 726.0, 0.55, 202.0, 5.0, 947.0, 916.0, 2.45, 202.0, 6.0, 1997.0, 1879.0, 2.95, 202.0, 7.0, 882.0, 937.0, 0.95, 202.0, 7.0, 1409.0, 1290.0, 2.9, 202.0, 8.0, 1497.0, 1384.0, 1.15, 202.0, 8.0, 750000000.0, 1.0534, 786.0, 705.0, 6.95, 202.0, 9.0, 298.0, 337.0, 1.3, 203.0, 0.0, 1604.0, 1377.0, 4.95, 203.0, 3.0, 499.0, 507.0, 4.375, 203.0, 3.0, 854.0, 809.0, 1.65, 203.0, 5.0, 1.5, 1.0534, 1568.0, 1282.0, 3.55, 203.0, 6.0, 831.0, 852.0, 5.95, 203.0, 7.0, 994.0, 1060.0, 3.625, 203.0, 7.0, 1321.0, 1261.0, 3.4, 203.0, 8.0, 993.0, 823.0, 5.85, 203.0, 8.0, 697.0, 735.0, 4.5, 204.0, 0.0, 541.0, 502.0, 2.1, 204.0, 0.0, 809.0, 639.0, 4.85, 204.0, 1.0, 297.0, 282.0, 4.5, 204.0, 3.0, 496.0, 450.0, 3.7, 204.0, 6.0, 1977.0, 1555.0, 3.75, 204.0, 7.0, 787.0, 788.0, 3.5, 204.0, 8.0, 743.0, 564.0, 2.25, 205.0, 0.0, 776.0, 573.0, 2.45, 206.0, 0.0, 1025.0, 695.0, 64.0, 62.0, 26051.0, 23599.0], "percents_raw": ["5.50 %", "2.625 %", "0.55 %", "2.45 %", "2.95 %", "0.95 %", "2.90 %", "1.150 %", "6.95 %", "1.30 %", "4.95 %", "4.375 %", "1.650 %", "3.55 %", "5.95 %", "3.625 %", "3.40 %", "5.85 %", "4.50 %", "2.10 %", "4.85 %", "4.50 %", "3.70 %", "3.75 %", "3.50 %", "2.25 %", "2.45 %"], "percents": [0.055, 0.02625, 0.0055000000000000005, 0.0245, 0.029500000000000002, 0.0095, 0.028999999999999998, 0.0115, 0.0695, 0.013000000000000001, 0.0495, 0.04375, 0.0165, 0.0355, 0.059500000000000004, 0.03625, 0.034, 0.058499999999999996, 0.045, 0.021, 0.048499999999999995, 0.045, 0.037000000000000005, 0.0375, 0.035, 0.0225, 0.0245], "currencies": ["EUR", "GBP", "USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 523, "tag": "div", "text_raw": "5.50 % Notes due 2024 ( 500 MM GBP 1.2190 )", "text": "5.50 % Notes due 2024 ( 500 MM GBP 1.2190 )", "length": 43, "numbers_raw": ["5.50", "202", "4", "500 M", "1.2190"], "numbers": [5.5, 202.0, 4.0, 500000000.0, 1.219], "percents_raw": ["5.50 %"], "percents": [0.055], "currencies": ["GBP"], "has_numbers": true, "has_percents": true}
{"idx_source": 524, "tag": "div", "text_raw": "2.625 % Notes due 2025", "text": "2.625 % Notes due 2025", "length": 22, "numbers_raw": ["2.625", "202", "5"], "numbers": [2.625, 202.0, 5.0], "percents_raw": ["2.625 %"], "percents": [0.02625], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 525, "tag": "div", "text_raw": "0.55 % Notes due 2025", "text": "0.55 % Notes due 2025", "length": 21, "numbers_raw": ["0.55", "202", "5"], "numbers": [0.55, 202.0, 5.0], "percents_raw": ["0.55 %"], "percents": [0.0055000000000000005], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 526, "tag": "div", "text_raw": "2.45 % Notes due 2026", "text": "2.45 % Notes due 2026", "length": 21, "numbers_raw": ["2.45", "202", "6"], "numbers": [2.45, 202.0, 6.0], "percents_raw": ["2.45 %"], "percents": [0.0245], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 527, "tag": "div", "text_raw": "2.95 % Notes due 2027", "text": "2.95 % Notes due 2027", "length": 21, "numbers_raw": ["2.95", "202", "7"], "numbers": [2.95, 202.0, 7.0], "percents_raw": ["2.95 %"], "percents": [0.029500000000000002], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 528, "tag": "div", "text_raw": "0.95 % Notes due 2027", "text": "0.95 % Notes due 2027", "length": 21, "numbers_raw": ["0.95", "202", "7"], "numbers": [0.95, 202.0, 7.0], "percents_raw": ["0.95 %"], "percents": [0.0095], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 529, "tag": "div", "text_raw": "2.90 % Notes due 2028", "text": "2.90 % Notes due 2028", "length": 21, "numbers_raw": ["2.90", "202", "8"], "numbers": [2.9, 202.0, 8.0], "percents_raw": ["2.90 %"], "percents": [0.028999999999999998], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 530, "tag": "div", "text_raw": "1.150 % Notes due 2028 ( 750 MM Euro 1.0534 )", "text": "1.150 % Notes due 2028 ( 750 MM Euro 1.0534 )", "length": 45, "numbers_raw": ["1.150", "202", "8", "750 M", "1.0534"], "numbers": [1.15, 202.0, 8.0, 750000000.0, 1.0534], "percents_raw": ["1.150 %"], "percents": [0.0115], "currencies": ["EUR"], "has_numbers": true, "has_percents": true}
{"idx_source": 531, "tag": "div", "text_raw": "6.95 % Notes due 2029", "text": "6.95 % Notes due 2029", "length": 21, "numbers_raw": ["6.95", "202", "9"], "numbers": [6.95, 202.0, 9.0], "percents_raw": ["6.95 %"], "percents": [0.0695], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 532, "tag": "div", "text_raw": "1.30 % Notes due 2030", "text": "1.30 % Notes due 2030", "length": 21, "numbers_raw": ["1.30", "203", "0"], "numbers": [1.3, 203.0, 0.0], "percents_raw": ["1.30 %"], "percents": [0.013000000000000001], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 533, "tag": "div", "text_raw": "4.95 % Debentures due 2033", "text": "4.95 % Debentures due 2033", "length": 26, "numbers_raw": ["4.95", "203", "3"], "numbers": [4.95, 203.0, 3.0], "percents_raw": ["4.95 %"], "percents": [0.0495], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 534, "tag": "div", "text_raw": "4.375 % Notes due 2033", "text": "4.375 % Notes due 2033", "length": 22, "numbers_raw": ["4.375", "203", "3"], "numbers": [4.375, 203.0, 3.0], "percents_raw": ["4.375 %"], "percents": [0.04375], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 535, "tag": "div", "text_raw": "1.650 % Notes due 2035 ( 1.5 B Euro 1.0534 )", "text": "1.650 % Notes due 2035 ( 1.5 B Euro 1.0534 )", "length": 44, "numbers_raw": ["1.650", "203", "5", "1.5", "1.0534"], "numbers": [1.65, 203.0, 5.0, 1.5, 1.0534], "percents_raw": ["1.650 %"], "percents": [0.0165], "currencies": ["EUR"], "has_numbers": true, "has_percents": true}
{"idx_source": 536, "tag": "div", "text_raw": "3.55 % Notes due 2036", "text": "3.55 % Notes due 2036", "length": 21, "numbers_raw": ["3.55", "203", "6"], "numbers": [3.55, 203.0, 6.0], "percents_raw": ["3.55 %"], "percents": [0.0355], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 537, "tag": "div", "text_raw": "5.95 % Notes due 2037", "text": "5.95 % Notes due 2037", "length": 21, "numbers_raw": ["5.95", "203", "7"], "numbers": [5.95, 203.0, 7.0], "percents_raw": ["5.95 %"], "percents": [0.059500000000000004], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 538, "tag": "div", "text_raw": "3.625 % Notes due 2037", "text": "3.625 % Notes due 2037", "length": 22, "numbers_raw": ["3.625", "203", "7"], "numbers": [3.625, 203.0, 7.0], "percents_raw": ["3.625 %"], "percents": [0.03625], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 539, "tag": "div", "text_raw": "3.40 % Notes due 2038", "text": "3.40 % Notes due 2038", "length": 21, "numbers_raw": ["3.40", "203", "8"], "numbers": [3.4, 203.0, 8.0], "percents_raw": ["3.40 %"], "percents": [0.034], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 540, "tag": "div", "text_raw": "5.85 % Debentures due 2038", "text": "5.85 % Debentures due 2038", "length": 26, "numbers_raw": ["5.85", "203", "8"], "numbers": [5.85, 203.0, 8.0], "percents_raw": ["5.85 %"], "percents": [0.058499999999999996], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 541, "tag": "div", "text_raw": "4.50 % Debentures due 2040", "text": "4.50 % Debentures due 2040", "length": 26, "numbers_raw": ["4.50", "204", "0"], "numbers": [4.5, 204.0, 0.0], "percents_raw": ["4.50 %"], "percents": [0.045], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 542, "tag": "div", "text_raw": "2.10 % Notes due 2040", "text": "2.10 % Notes due 2040", "length": 21, "numbers_raw": ["2.10", "204", "0"], "numbers": [2.1, 204.0, 0.0], "percents_raw": ["2.10 %"], "percents": [0.021], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 543, "tag": "div", "text_raw": "4.85 % Notes due 2041", "text": "4.85 % Notes due 2041", "length": 21, "numbers_raw": ["4.85", "204", "1"], "numbers": [4.85, 204.0, 1.0], "percents_raw": ["4.85 %"], "percents": [0.048499999999999995], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 544, "tag": "div", "text_raw": "4.50 % Notes due 2043", "text": "4.50 % Notes due 2043", "length": 21, "numbers_raw": ["4.50", "204", "3"], "numbers": [4.5, 204.0, 3.0], "percents_raw": ["4.50 %"], "percents": [0.045], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 545, "tag": "div", "text_raw": "3.70 % Notes due 2046", "text": "3.70 % Notes due 2046", "length": 21, "numbers_raw": ["3.70", "204", "6"], "numbers": [3.7, 204.0, 6.0], "percents_raw": ["3.70 %"], "percents": [0.037000000000000005], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 546, "tag": "div", "text_raw": "3.75 % Notes due 2047", "text": "3.75 % Notes due 2047", "length": 21, "numbers_raw": ["3.75", "204", "7"], "numbers": [3.75, 204.0, 7.0], "percents_raw": ["3.75 %"], "percents": [0.0375], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 547, "tag": "div", "text_raw": "3.50 % Notes due 2048", "text": "3.50 % Notes due 2048", "length": 21, "numbers_raw": ["3.50", "204", "8"], "numbers": [3.5, 204.0, 8.0], "percents_raw": ["3.50 %"], "percents": [0.035], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 548, "tag": "div", "text_raw": "2.25 % Notes due 2050", "text": "2.25 % Notes due 2050", "length": 21, "numbers_raw": ["2.25", "205", "0"], "numbers": [2.25, 205.0, 0.0], "percents_raw": ["2.25 %"], "percents": [0.0225], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 549, "tag": "div", "text_raw": "2.45 % Notes due 2060", "text": "2.45 % Notes due 2060", "length": 21, "numbers_raw": ["2.45", "206", "0"], "numbers": [2.45, 206.0, 0.0], "percents_raw": ["2.45 %"], "percents": [0.0245], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 551, "tag": "div", "text_raw": "The weighted average effective interest rate on non-current debt is 3.08 %.", "text": "The weighted average effective interest rate on non-current debt is 3.08 %.", "length": 75, "numbers_raw": ["3.08"], "numbers": [3.08], "percents_raw": ["3.08 %"], "percents": [0.0308], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 553, "tag": "div", "text_raw": "The excess of the carrying value over the estimated fair value of debt was $ 1.6 billion at January 1, 2023.", "text": "The excess of the carrying value over the estimated fair value of debt was $ 1.6 billion at January 1, 2023.", "length": 108, "numbers_raw": ["1.6 billion", "1", "202", "3"], "numbers": [1600000000.0, 1.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 555, "tag": "div", "text_raw": "Fair value of the non-current debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.", "text": "Fair value of the non-current debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.", "length": 158, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 557, "tag": "div", "text_raw": "The current debt balance as of October 1, 2023 includes $ 2.0 billion of commercial paper which has a weighted average interest rate of 5.31 % and a weighted average maturity of approximately two months .", "text": "The current debt balance as of October 1, 2023 includes $ 2.0 billion of commercial paper which has a weighted average interest rate of 5.31 % and a weighted average maturity of approximately two months .", "length": 204, "numbers_raw": ["1", "202", "3", "2.0 billion", "5.31"], "numbers": [1.0, 202.0, 3.0, 2000000000.0, 5.31], "percents_raw": ["5.31 %"], "percents": [0.053099999999999994], "currencies": ["USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 558, "tag": "div", "text_raw": "18", "text": "18", "length": 2, "numbers_raw": ["18"], "numbers": [18.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 559, "tag": "div", "text_raw": "18", "text": "18", "length": 2, "numbers_raw": ["18"], "numbers": [18.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 560, "tag": "div", "text_raw": "18", "text": "18", "length": 2, "numbers_raw": ["18"], "numbers": [18.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 567, "tag": "div", "text_raw": "NOTE 5  INCOME TAXES", "text": "NOTE 5  INCOME TAXES", "length": 21, "numbers_raw": ["5"], "numbers": [5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 569, "tag": "div", "text_raw": "The worldwide effective income tax rates for the fiscal nine months of 2023 and 2022 were 10.2 % and 15.3 %, respectively. The decrease in the current year consolidated tax rate is primarily due to more income in lower tax jurisdictions relative to higher tax jurisdictions versus the prior year, due primarily to the approximately $ 7 billion charge related to the talc settlement proposal in the United States at an effective tax rate of 23.5 % in the fiscal nine months of 2023 (for further information see Note 11 to the Consolidated Financial Statements). The prior years effective tax rate benefited from the impact of certain provisions of the Tax Cuts and Jobs Act of 2017 that became effective in 2022, which are offset by one-time tax costs in the fiscal nine months of 2022.", "text": "The worldwide effective income tax rates for the fiscal nine months of 2023 and 2022 were 10.2 % and 15.3 %, respectively.", "length": 122, "numbers_raw": ["202", "3", "202", "2", "10.2", "15.3"], "numbers": [202.0, 3.0, 202.0, 2.0, 10.2, 15.3], "percents_raw": ["10.2 %", "15.3 %"], "percents": [0.102, 0.153], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 569, "tag": "div", "text_raw": "The worldwide effective income tax rates for the fiscal nine months of 2023 and 2022 were 10.2 % and 15.3 %, respectively. The decrease in the current year consolidated tax rate is primarily due to more income in lower tax jurisdictions relative to higher tax jurisdictions versus the prior year, due primarily to the approximately $ 7 billion charge related to the talc settlement proposal in the United States at an effective tax rate of 23.5 % in the fiscal nine months of 2023 (for further information see Note 11 to the Consolidated Financial Statements). The prior years effective tax rate benefited from the impact of certain provisions of the Tax Cuts and Jobs Act of 2017 that became effective in 2022, which are offset by one-time tax costs in the fiscal nine months of 2022.", "text": "The decrease in the current year consolidated tax rate is primarily due to more income in lower tax jurisdictions relative to higher tax jurisdictions versus the prior year, due primarily to the approximately $ 7 billion charge related to the talc settlement proposal in the United States at an effective tax rate of 23.5 % in the fiscal nine months of 2023 (for further information see Note 11 to the Consolidated Financial Statements).", "length": 437, "numbers_raw": ["7 billion", "23.5", "202", "3", "11"], "numbers": [7000000000.0, 23.5, 202.0, 3.0, 11.0], "percents_raw": ["23.5 %"], "percents": [0.235], "currencies": ["USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 569, "tag": "div", "text_raw": "The worldwide effective income tax rates for the fiscal nine months of 2023 and 2022 were 10.2 % and 15.3 %, respectively. The decrease in the current year consolidated tax rate is primarily due to more income in lower tax jurisdictions relative to higher tax jurisdictions versus the prior year, due primarily to the approximately $ 7 billion charge related to the talc settlement proposal in the United States at an effective tax rate of 23.5 % in the fiscal nine months of 2023 (for further information see Note 11 to the Consolidated Financial Statements). The prior years effective tax rate benefited from the impact of certain provisions of the Tax Cuts and Jobs Act of 2017 that became effective in 2022, which are offset by one-time tax costs in the fiscal nine months of 2022.", "text": "The prior years effective tax rate benefited from the impact of certain provisions of the Tax Cuts and Jobs Act of 2017 that became effective in 2022, which are offset by one-time tax costs in the fiscal nine months of 2022.", "length": 225, "numbers_raw": ["201", "7", "202", "2", "202", "2"], "numbers": [201.0, 7.0, 202.0, 2.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 571, "tag": "div", "text_raw": "The Company also received tax benefits from stock-based compensation that were either exercised or vested during each of the fiscal nine months ended.", "text": "The Company also received tax benefits from stock-based compensation that were either exercised or vested during each of the fiscal nine months ended.", "length": 150, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 573, "tag": "div", "text_raw": "As of October 1, 2023, the Company had approximately $ 2.3 billion of liabilities from unrecognized tax benefits. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of jurisdictions. With respect to the United States, the IRS has completed its audit for the tax years through 2012 and is currently auditing tax years 2013 through 2016. The Company currently expects completion of this audit and settlement of the related tax liabilities within the next 6 months. As a result, the Company has classified approximatel y $ 0.5 billion of unrecognized tax benefits and associated interest as a current liability on the Accrued taxes on Income line of the Consolidated Balance Sheet as of the end of the third fiscal quarter of 2023 in anticipation of final settlement. The Company made a payment in the fiscal second quarter for approximately $ 1.4 billion to the U.S. Treasury for the previously reserved estimated liability of the 2013-2016 IRS Audit. The completion of this tax audit may result in additional adjustments to the Companys unrecognized tax benefit liability. In other major jurisdictions where the Company conducts business, the years that remain open to tax audit go back to the year 2008. The Company believes it is possible that some tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions. However, the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments relating to uncertain tax positions.", "text": "As of October 1, 2023, the Company had approximately $ 2.3 billion of liabilities from unrecognized tax benefits.", "length": 113, "numbers_raw": ["1", "202", "3", "2.3 billion"], "numbers": [1.0, 202.0, 3.0, 2300000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 573, "tag": "div", "text_raw": "As of October 1, 2023, the Company had approximately $ 2.3 billion of liabilities from unrecognized tax benefits. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of jurisdictions. With respect to the United States, the IRS has completed its audit for the tax years through 2012 and is currently auditing tax years 2013 through 2016. The Company currently expects completion of this audit and settlement of the related tax liabilities within the next 6 months. As a result, the Company has classified approximatel y $ 0.5 billion of unrecognized tax benefits and associated interest as a current liability on the Accrued taxes on Income line of the Consolidated Balance Sheet as of the end of the third fiscal quarter of 2023 in anticipation of final settlement. The Company made a payment in the fiscal second quarter for approximately $ 1.4 billion to the U.S. Treasury for the previously reserved estimated liability of the 2013-2016 IRS Audit. The completion of this tax audit may result in additional adjustments to the Companys unrecognized tax benefit liability. In other major jurisdictions where the Company conducts business, the years that remain open to tax audit go back to the year 2008. The Company believes it is possible that some tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions. However, the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments relating to uncertain tax positions.", "text": "The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of jurisdictions.", "length": 144, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 573, "tag": "div", "text_raw": "As of October 1, 2023, the Company had approximately $ 2.3 billion of liabilities from unrecognized tax benefits. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of jurisdictions. With respect to the United States, the IRS has completed its audit for the tax years through 2012 and is currently auditing tax years 2013 through 2016. The Company currently expects completion of this audit and settlement of the related tax liabilities within the next 6 months. As a result, the Company has classified approximatel y $ 0.5 billion of unrecognized tax benefits and associated interest as a current liability on the Accrued taxes on Income line of the Consolidated Balance Sheet as of the end of the third fiscal quarter of 2023 in anticipation of final settlement. The Company made a payment in the fiscal second quarter for approximately $ 1.4 billion to the U.S. Treasury for the previously reserved estimated liability of the 2013-2016 IRS Audit. The completion of this tax audit may result in additional adjustments to the Companys unrecognized tax benefit liability. In other major jurisdictions where the Company conducts business, the years that remain open to tax audit go back to the year 2008. The Company believes it is possible that some tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions. However, the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments relating to uncertain tax positions.", "text": "With respect to the United States, the IRS has completed its audit for the tax years through 2012 and is currently auditing tax years 2013 through 2016.", "length": 152, "numbers_raw": ["201", "2", "201", "3", "201", "6"], "numbers": [201.0, 2.0, 201.0, 3.0, 201.0, 6.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 573, "tag": "div", "text_raw": "As of October 1, 2023, the Company had approximately $ 2.3 billion of liabilities from unrecognized tax benefits. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of jurisdictions. With respect to the United States, the IRS has completed its audit for the tax years through 2012 and is currently auditing tax years 2013 through 2016. The Company currently expects completion of this audit and settlement of the related tax liabilities within the next 6 months. As a result, the Company has classified approximatel y $ 0.5 billion of unrecognized tax benefits and associated interest as a current liability on the Accrued taxes on Income line of the Consolidated Balance Sheet as of the end of the third fiscal quarter of 2023 in anticipation of final settlement. The Company made a payment in the fiscal second quarter for approximately $ 1.4 billion to the U.S. Treasury for the previously reserved estimated liability of the 2013-2016 IRS Audit. The completion of this tax audit may result in additional adjustments to the Companys unrecognized tax benefit liability. In other major jurisdictions where the Company conducts business, the years that remain open to tax audit go back to the year 2008. The Company believes it is possible that some tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions. However, the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments relating to uncertain tax positions.", "text": "The Company currently expects completion of this audit and settlement of the related tax liabilities within the next 6 months.", "length": 126, "numbers_raw": ["6 m"], "numbers": [6000000.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 573, "tag": "div", "text_raw": "As of October 1, 2023, the Company had approximately $ 2.3 billion of liabilities from unrecognized tax benefits. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of jurisdictions. With respect to the United States, the IRS has completed its audit for the tax years through 2012 and is currently auditing tax years 2013 through 2016. The Company currently expects completion of this audit and settlement of the related tax liabilities within the next 6 months. As a result, the Company has classified approximatel y $ 0.5 billion of unrecognized tax benefits and associated interest as a current liability on the Accrued taxes on Income line of the Consolidated Balance Sheet as of the end of the third fiscal quarter of 2023 in anticipation of final settlement. The Company made a payment in the fiscal second quarter for approximately $ 1.4 billion to the U.S. Treasury for the previously reserved estimated liability of the 2013-2016 IRS Audit. The completion of this tax audit may result in additional adjustments to the Companys unrecognized tax benefit liability. In other major jurisdictions where the Company conducts business, the years that remain open to tax audit go back to the year 2008. The Company believes it is possible that some tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions. However, the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments relating to uncertain tax positions.", "text": "As a result, the Company has classified approximatel y $ 0.5 billion of unrecognized tax benefits and associated interest as a current liability on the Accrued taxes on Income line of the Consolidated Balance Sheet as of the end of the third fiscal quarter of 2023 in anticipation of final settlement.", "length": 303, "numbers_raw": ["0.5 billion", "202", "3"], "numbers": [500000000.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 573, "tag": "div", "text_raw": "As of October 1, 2023, the Company had approximately $ 2.3 billion of liabilities from unrecognized tax benefits. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of jurisdictions. With respect to the United States, the IRS has completed its audit for the tax years through 2012 and is currently auditing tax years 2013 through 2016. The Company currently expects completion of this audit and settlement of the related tax liabilities within the next 6 months. As a result, the Company has classified approximatel y $ 0.5 billion of unrecognized tax benefits and associated interest as a current liability on the Accrued taxes on Income line of the Consolidated Balance Sheet as of the end of the third fiscal quarter of 2023 in anticipation of final settlement. The Company made a payment in the fiscal second quarter for approximately $ 1.4 billion to the U.S. Treasury for the previously reserved estimated liability of the 2013-2016 IRS Audit. The completion of this tax audit may result in additional adjustments to the Companys unrecognized tax benefit liability. In other major jurisdictions where the Company conducts business, the years that remain open to tax audit go back to the year 2008. The Company believes it is possible that some tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions. However, the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments relating to uncertain tax positions.", "text": "The Company made a payment in the fiscal second quarter for approximately $ 1.4 billion to the U.S.", "length": 99, "numbers_raw": ["1.4 billion"], "numbers": [1400000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 573, "tag": "div", "text_raw": "As of October 1, 2023, the Company had approximately $ 2.3 billion of liabilities from unrecognized tax benefits. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of jurisdictions. With respect to the United States, the IRS has completed its audit for the tax years through 2012 and is currently auditing tax years 2013 through 2016. The Company currently expects completion of this audit and settlement of the related tax liabilities within the next 6 months. As a result, the Company has classified approximatel y $ 0.5 billion of unrecognized tax benefits and associated interest as a current liability on the Accrued taxes on Income line of the Consolidated Balance Sheet as of the end of the third fiscal quarter of 2023 in anticipation of final settlement. The Company made a payment in the fiscal second quarter for approximately $ 1.4 billion to the U.S. Treasury for the previously reserved estimated liability of the 2013-2016 IRS Audit. The completion of this tax audit may result in additional adjustments to the Companys unrecognized tax benefit liability. In other major jurisdictions where the Company conducts business, the years that remain open to tax audit go back to the year 2008. The Company believes it is possible that some tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions. However, the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments relating to uncertain tax positions.", "text": "Treasury for the previously reserved estimated liability of the 2013-2016 IRS Audit.", "length": 84, "numbers_raw": ["201", "3", "201", "6"], "numbers": [201.0, 3.0, 201.0, 6.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 573, "tag": "div", "text_raw": "As of October 1, 2023, the Company had approximately $ 2.3 billion of liabilities from unrecognized tax benefits. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of jurisdictions. With respect to the United States, the IRS has completed its audit for the tax years through 2012 and is currently auditing tax years 2013 through 2016. The Company currently expects completion of this audit and settlement of the related tax liabilities within the next 6 months. As a result, the Company has classified approximatel y $ 0.5 billion of unrecognized tax benefits and associated interest as a current liability on the Accrued taxes on Income line of the Consolidated Balance Sheet as of the end of the third fiscal quarter of 2023 in anticipation of final settlement. The Company made a payment in the fiscal second quarter for approximately $ 1.4 billion to the U.S. Treasury for the previously reserved estimated liability of the 2013-2016 IRS Audit. The completion of this tax audit may result in additional adjustments to the Companys unrecognized tax benefit liability. In other major jurisdictions where the Company conducts business, the years that remain open to tax audit go back to the year 2008. The Company believes it is possible that some tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions. However, the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments relating to uncertain tax positions.", "text": "The completion of this tax audit may result in additional adjustments to the Companys unrecognized tax benefit liability.", "length": 122, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 573, "tag": "div", "text_raw": "As of October 1, 2023, the Company had approximately $ 2.3 billion of liabilities from unrecognized tax benefits. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of jurisdictions. With respect to the United States, the IRS has completed its audit for the tax years through 2012 and is currently auditing tax years 2013 through 2016. The Company currently expects completion of this audit and settlement of the related tax liabilities within the next 6 months. As a result, the Company has classified approximatel y $ 0.5 billion of unrecognized tax benefits and associated interest as a current liability on the Accrued taxes on Income line of the Consolidated Balance Sheet as of the end of the third fiscal quarter of 2023 in anticipation of final settlement. The Company made a payment in the fiscal second quarter for approximately $ 1.4 billion to the U.S. Treasury for the previously reserved estimated liability of the 2013-2016 IRS Audit. The completion of this tax audit may result in additional adjustments to the Companys unrecognized tax benefit liability. In other major jurisdictions where the Company conducts business, the years that remain open to tax audit go back to the year 2008. The Company believes it is possible that some tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions. However, the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments relating to uncertain tax positions.", "text": "In other major jurisdictions where the Company conducts business, the years that remain open to tax audit go back to the year 2008.", "length": 131, "numbers_raw": ["200", "8"], "numbers": [200.0, 8.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 573, "tag": "div", "text_raw": "As of October 1, 2023, the Company had approximately $ 2.3 billion of liabilities from unrecognized tax benefits. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of jurisdictions. With respect to the United States, the IRS has completed its audit for the tax years through 2012 and is currently auditing tax years 2013 through 2016. The Company currently expects completion of this audit and settlement of the related tax liabilities within the next 6 months. As a result, the Company has classified approximatel y $ 0.5 billion of unrecognized tax benefits and associated interest as a current liability on the Accrued taxes on Income line of the Consolidated Balance Sheet as of the end of the third fiscal quarter of 2023 in anticipation of final settlement. The Company made a payment in the fiscal second quarter for approximately $ 1.4 billion to the U.S. Treasury for the previously reserved estimated liability of the 2013-2016 IRS Audit. The completion of this tax audit may result in additional adjustments to the Companys unrecognized tax benefit liability. In other major jurisdictions where the Company conducts business, the years that remain open to tax audit go back to the year 2008. The Company believes it is possible that some tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions. However, the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments relating to uncertain tax positions.", "text": "The Company believes it is possible that some tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions.", "length": 146, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 573, "tag": "div", "text_raw": "As of October 1, 2023, the Company had approximately $ 2.3 billion of liabilities from unrecognized tax benefits. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of jurisdictions. With respect to the United States, the IRS has completed its audit for the tax years through 2012 and is currently auditing tax years 2013 through 2016. The Company currently expects completion of this audit and settlement of the related tax liabilities within the next 6 months. As a result, the Company has classified approximatel y $ 0.5 billion of unrecognized tax benefits and associated interest as a current liability on the Accrued taxes on Income line of the Consolidated Balance Sheet as of the end of the third fiscal quarter of 2023 in anticipation of final settlement. The Company made a payment in the fiscal second quarter for approximately $ 1.4 billion to the U.S. Treasury for the previously reserved estimated liability of the 2013-2016 IRS Audit. The completion of this tax audit may result in additional adjustments to the Companys unrecognized tax benefit liability. In other major jurisdictions where the Company conducts business, the years that remain open to tax audit go back to the year 2008. The Company believes it is possible that some tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions. However, the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments relating to uncertain tax positions.", "text": "However, the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments relating to uncertain tax positions.", "length": 158, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 579, "tag": "div", "text_raw": "NOTE 6  PENSIONS AND OTHER BENEFIT PLANS", "text": "NOTE 6  PENSIONS AND OTHER BENEFIT PLANS", "length": 41, "numbers_raw": ["6"], "numbers": [6.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 581, "tag": "div", "text_raw": "Components of Net Periodic Benefit Cost", "text": "Components of Net Periodic Benefit Cost", "length": 39, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 582, "tag": "div", "text_raw": "Net periodic benefit costs for the Companys defined benefit retirement plans and other benefit plans include the following components:", "text": "Net periodic benefit costs for the Companys defined benefit retirement plans and other benefit plans include the following components:", "length": 135, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 583, "tag": "div", "text_raw": "Fiscal Third Quarter Ended Fiscal Nine Months Ended Retirement Plans Other Benefit Plans Retirement Plans Other Benefit Plans (Dollars in Millions) October 1, 2023 October 2, 2022 October 1, 2023 October 2, 2022 October 1, 2023 October 2, 2022 October 1, 2023 October 2, 2022 Service cost $ 210 313 61 80 638 953 198 240 Interest cost 363 226 51 26 1,090 685 160 79 Expected return on plan assets ( 680 ) ( 683 ) ( 1 ) ( 2 ) ( 2,042 ) ( 2,075 ) ( 4 ) ( 6 ) Amortization of prior service cost/(credit) ( 47 ) ( 46 )  ( 1 ) ( 139 ) ( 138 ) ( 1 ) ( 4 ) Recognized actuarial (gains) losses ( 50 ) 163 4 30 ( 150 ) 492 17 91 Curtailments and settlements 72  ( 9 )  72 1 ( 9 )  Net periodic benefit cost/(credit) $ ( 132 ) ( 27 ) 106 133 ( 531 ) ( 82 ) 361 400", "text": "Fiscal Third Quarter Ended Fiscal Nine Months Ended Retirement Plans Other Benefit Plans Retirement Plans Other Benefit Plans (Dollars in Millions) October 1, 2023 October 2, 2022 October 1, 2023 October 2, 2022 October 1, 2023 October 2, 2022 October 1, 2023 October 2, 2022 Service cost $ 210 313 61 80 638 953 198 240 Interest cost 363 226 51 26 1,090 685 160 79 Expected return on plan assets ( 680 ) ( 683 ) ( 1 ) ( 2 ) ( 2,042 ) ( 2,075 ) ( 4 ) ( 6 ) Amortization of prior service cost/(credit) ( 47 ) ( 46 )  ( 1 ) ( 139 ) ( 138 ) ( 1 ) ( 4 ) Recognized actuarial (gains) losses ( 50 ) 163 4 30 ( 150 ) 492 17 91 Curtailments and settlements 72  ( 9 )  72 1 ( 9 )  Net periodic benefit cost/(credit) $ ( 132 ) ( 27 ) 106 133 ( 531 ) ( 82 ) 361 400", "length": 758, "numbers_raw": ["1", "202", "3", "2", "202", "2", "1", "202", "3", "2", "202", "2", "1", "202", "3", "2", "202", "2", "1", "202", "3", "2", "202", "2", "210", "313", "61", "80", "638", "953", "198", "240", "363", "226", "51", "26", "1,090", "685", "160", "79", "680", "683", "1", "2", "2,042", "2,075", "4", "6", "47", "46", "1", "139", "138", "1", "4", "50", "163", "4", "30", "150", "492", "17", "91", "72", "9", "72", "1", "9", "132", "27", "106", "133", "531", "82", "361", "400"], "numbers": [1.0, 202.0, 3.0, 2.0, 202.0, 2.0, 1.0, 202.0, 3.0, 2.0, 202.0, 2.0, 1.0, 202.0, 3.0, 2.0, 202.0, 2.0, 1.0, 202.0, 3.0, 2.0, 202.0, 2.0, 210.0, 313.0, 61.0, 80.0, 638.0, 953.0, 198.0, 240.0, 363.0, 226.0, 51.0, 26.0, 1090.0, 685.0, 160.0, 79.0, 680.0, 683.0, 1.0, 2.0, 2042.0, 2075.0, 4.0, 6.0, 47.0, 46.0, 1.0, 139.0, 138.0, 1.0, 4.0, 50.0, 163.0, 4.0, 30.0, 150.0, 492.0, 17.0, 91.0, 72.0, 9.0, 72.0, 1.0, 9.0, 132.0, 27.0, 106.0, 133.0, 531.0, 82.0, 361.0, 400.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 584, "tag": "div", "text_raw": "19", "text": "19", "length": 2, "numbers_raw": ["19"], "numbers": [19.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 585, "tag": "div", "text_raw": "19", "text": "19", "length": 2, "numbers_raw": ["19"], "numbers": [19.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 586, "tag": "div", "text_raw": "19", "text": "19", "length": 2, "numbers_raw": ["19"], "numbers": [19.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 590, "tag": "div", "text_raw": "Net periodic benefit cost (credit) for pension and other benefit plans in the third quarter and first nine months of 2023 includes expenses for curtailments and settlements in connection with the separation of Kenvue. In addition, approximately $ 0.1 billion of net pension liabilities were transferred to Kenvue.", "text": "Net periodic benefit cost (credit) for pension and other benefit plans in the third quarter and first nine months of 2023 includes expenses for curtailments and settlements in connection with the separation of Kenvue.", "length": 217, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 590, "tag": "div", "text_raw": "Net periodic benefit cost (credit) for pension and other benefit plans in the third quarter and first nine months of 2023 includes expenses for curtailments and settlements in connection with the separation of Kenvue. In addition, approximately $ 0.1 billion of net pension liabilities were transferred to Kenvue.", "text": "In addition, approximately $ 0.1 billion of net pension liabilities were transferred to Kenvue.", "length": 95, "numbers_raw": ["0.1 billion"], "numbers": [100000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 592, "tag": "div", "text_raw": "The service cost component of net periodic benefit cost is presented in the same line items on the Consolidated Statement of Earnings where other employee compensation costs are reported, including Cost of products sold, Research and development expense, Selling, marketing and administrative expenses, and Net earnings from discontinued operations, net of taxes if related to the separation of Kenvue. All other components of net periodic benefit cost are presented as part of Other (income) expense, net on the Consolidated Statement of Earnings, with the exception of certain amounts for curtailments and settlements, which are reported in Net earnings from discontinued operations, net of taxes if related to the separation of Kenvue (as noted above).", "text": "The service cost component of net periodic benefit cost is presented in the same line items on the Consolidated Statement of Earnings where other employee compensation costs are reported, including Cost of products sold, Research and development expense, Selling, marketing and administrative expenses, and Net earnings from discontinued operations, net of taxes if related to the separation of Kenvue.", "length": 402, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 592, "tag": "div", "text_raw": "The service cost component of net periodic benefit cost is presented in the same line items on the Consolidated Statement of Earnings where other employee compensation costs are reported, including Cost of products sold, Research and development expense, Selling, marketing and administrative expenses, and Net earnings from discontinued operations, net of taxes if related to the separation of Kenvue. All other components of net periodic benefit cost are presented as part of Other (income) expense, net on the Consolidated Statement of Earnings, with the exception of certain amounts for curtailments and settlements, which are reported in Net earnings from discontinued operations, net of taxes if related to the separation of Kenvue (as noted above).", "text": "All other components of net periodic benefit cost are presented as part of Other (income) expense, net on the Consolidated Statement of Earnings, with the exception of certain amounts for curtailments and settlements, which are reported in Net earnings from discontinued operations, net of taxes if related to the separation of Kenvue (as noted above).", "length": 352, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 595, "tag": "div", "text_raw": "For the fiscal nine months ended October 1, 2023, the Company contributed $ 92 million and $ 18 million to its U.S. and international retirement plans, respectively. The Company plans to continue to fund its U.S. defined benefit plans to comply with the Pension Protection Act of 2006. International plans are funded in accordance with local regulations.", "text": "For the fiscal nine months ended October 1, 2023, the Company contributed $ 92 million and $ 18 million to its U.S.", "length": 115, "numbers_raw": ["1", "202", "3", "92 million", "18 million"], "numbers": [1.0, 202.0, 3.0, 92000000.0, 18000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 595, "tag": "div", "text_raw": "For the fiscal nine months ended October 1, 2023, the Company contributed $ 92 million and $ 18 million to its U.S. and international retirement plans, respectively. The Company plans to continue to fund its U.S. defined benefit plans to comply with the Pension Protection Act of 2006. International plans are funded in accordance with local regulations.", "text": "and international retirement plans, respectively.", "length": 49, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 595, "tag": "div", "text_raw": "For the fiscal nine months ended October 1, 2023, the Company contributed $ 92 million and $ 18 million to its U.S. and international retirement plans, respectively. The Company plans to continue to fund its U.S. defined benefit plans to comply with the Pension Protection Act of 2006. International plans are funded in accordance with local regulations.", "text": "The Company plans to continue to fund its U.S.", "length": 46, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 595, "tag": "div", "text_raw": "For the fiscal nine months ended October 1, 2023, the Company contributed $ 92 million and $ 18 million to its U.S. and international retirement plans, respectively. The Company plans to continue to fund its U.S. defined benefit plans to comply with the Pension Protection Act of 2006. International plans are funded in accordance with local regulations.", "text": "defined benefit plans to comply with the Pension Protection Act of 2006.", "length": 72, "numbers_raw": ["200", "6"], "numbers": [200.0, 6.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 595, "tag": "div", "text_raw": "For the fiscal nine months ended October 1, 2023, the Company contributed $ 92 million and $ 18 million to its U.S. and international retirement plans, respectively. The Company plans to continue to fund its U.S. defined benefit plans to comply with the Pension Protection Act of 2006. International plans are funded in accordance with local regulations.", "text": "International plans are funded in accordance with local regulations.", "length": 68, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 599, "tag": "div", "text_raw": "NOTE 7  ACCUMULATED OTHER COMPREHENSIVE INCOME", "text": "NOTE 7  ACCUMULATED OTHER COMPREHENSIVE INCOME", "length": 47, "numbers_raw": ["7"], "numbers": [7.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 601, "tag": "div", "text_raw": "Components of other comprehensive income (loss) consist of the following:", "text": "Components of other comprehensive income (loss) consist of the following:", "length": 73, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 602, "tag": "div", "text_raw": "Foreign Currency Gain/(Loss) On Employee Benefit Gain/(Loss) On Derivatives Total Accumulated Other Comprehensive (Dollars in Millions) Translation Securities Plans & Hedges Income (Loss) January 1, 2023 $ ( 11,813 ) ( 27 ) ( 897 ) ( 230 ) ( 12,967 ) Change from continuing operations ( 448 ) 25 ( 175 ) ( 396 ) ( 994 ) Kenvue Separation 4,885 ** 0 296 * 0 5,181 Net change 4,437 25 121 ( 396 ) 4,187 October 1, 2023 ( 7,376 ) ( 2 ) ( 776 ) ( 626 ) ( 8,780 )", "text": "Foreign Currency Gain/(Loss) On Employee Benefit Gain/(Loss) On Derivatives Total Accumulated Other Comprehensive (Dollars in Millions) Translation Securities Plans & Hedges Income (Loss) January 1, 2023 $ ( 11,813 ) ( 27 ) ( 897 ) ( 230 ) ( 12,967 ) Change from continuing operations ( 448 ) 25 ( 175 ) ( 396 ) ( 994 ) Kenvue Separation 4,885 ** 0 296 * 0 5,181 Net change 4,437 25 121 ( 396 ) 4,187 October 1, 2023 ( 7,376 ) ( 2 ) ( 776 ) ( 626 ) ( 8,780 )", "length": 458, "numbers_raw": ["1", "202", "3", "11,813", "27", "897", "230", "12,967", "448", "25", "175", "396", "994", "4,885", "0", "296", "0", "5,181", "4,437", "25", "121", "396", "4,187", "1", "202", "3", "7,376", "2", "776", "626", "8,780"], "numbers": [1.0, 202.0, 3.0, 11813.0, 27.0, 897.0, 230.0, 12967.0, 448.0, 25.0, 175.0, 396.0, 994.0, 4885.0, 0.0, 296.0, 0.0, 5181.0, 4437.0, 25.0, 121.0, 396.0, 4187.0, 1.0, 202.0, 3.0, 7376.0, 2.0, 776.0, 626.0, 8780.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 604, "tag": "div", "text_raw": "Amounts in accumulated other comprehensive income are presented net of the related tax impact. Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries. For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income.", "text": "Amounts in accumulated other comprehensive income are presented net of the related tax impact.", "length": 94, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 604, "tag": "div", "text_raw": "Amounts in accumulated other comprehensive income are presented net of the related tax impact. Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries. For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income.", "text": "Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries.", "length": 134, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 604, "tag": "div", "text_raw": "Amounts in accumulated other comprehensive income are presented net of the related tax impact. Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries. For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income.", "text": "For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income.", "length": 103, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 606, "tag": "div", "text_raw": "Details on reclassifications out of Accumulated Other Comprehensive Income:", "text": "Details on reclassifications out of Accumulated Other Comprehensive Income:", "length": 75, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 607, "tag": "div", "text_raw": "Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net.", "text": "Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net.", "length": 86, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 608, "tag": "div", "text_raw": "Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 6 for additional details.", "text": "Employee Benefit Plans - reclassifications are included in net periodic benefit cost.", "length": 85, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 608, "tag": "div", "text_raw": "Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 6 for additional details.", "text": "See Note 6 for additional details.", "length": 34, "numbers_raw": ["6"], "numbers": [6.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 609, "tag": "div", "text_raw": "Gain/(Loss) On Derivatives & Hedges - reclassifications to earnings are recorded in the same account as the underlying transaction. See Note 4 for additional details. *Includes impact of curtailments and settlements in connection with the separation from Kenvue. **Includes $ 548 million of foreign currency translation associated with the non controlling interest.", "text": "Gain/(Loss) On Derivatives & Hedges - reclassifications to earnings are recorded in the same account as the underlying transaction.", "length": 131, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 609, "tag": "div", "text_raw": "Gain/(Loss) On Derivatives & Hedges - reclassifications to earnings are recorded in the same account as the underlying transaction. See Note 4 for additional details. *Includes impact of curtailments and settlements in connection with the separation from Kenvue. **Includes $ 548 million of foreign currency translation associated with the non controlling interest.", "text": "See Note 4 for additional details.", "length": 34, "numbers_raw": ["4"], "numbers": [4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 609, "tag": "div", "text_raw": "Gain/(Loss) On Derivatives & Hedges - reclassifications to earnings are recorded in the same account as the underlying transaction. See Note 4 for additional details. *Includes impact of curtailments and settlements in connection with the separation from Kenvue. **Includes $ 548 million of foreign currency translation associated with the non controlling interest.", "text": "*Includes impact of curtailments and settlements in connection with the separation from Kenvue.", "length": 95, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 609, "tag": "div", "text_raw": "Gain/(Loss) On Derivatives & Hedges - reclassifications to earnings are recorded in the same account as the underlying transaction. See Note 4 for additional details. *Includes impact of curtailments and settlements in connection with the separation from Kenvue. **Includes $ 548 million of foreign currency translation associated with the non controlling interest.", "text": "**Includes $ 548 million of foreign currency translation associated with the non controlling interest.", "length": 102, "numbers_raw": ["548 million"], "numbers": [548000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 613, "tag": "div", "text_raw": "20", "text": "20", "length": 2, "numbers_raw": ["20"], "numbers": [20.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 614, "tag": "div", "text_raw": "20", "text": "20", "length": 2, "numbers_raw": ["20"], "numbers": [20.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 615, "tag": "div", "text_raw": "20", "text": "20", "length": 2, "numbers_raw": ["20"], "numbers": [20.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 620, "tag": "div", "text_raw": "NOTE 8  EARNINGS PER SHARE", "text": "NOTE 8  EARNINGS PER SHARE", "length": 27, "numbers_raw": ["8"], "numbers": [8.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 622, "tag": "div", "text_raw": "The following is a reconciliation of basic net earnings per share to diluted net earnings per share:", "text": "The following is a reconciliation of basic net earnings per share to diluted net earnings per share:", "length": 100, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 623, "tag": "div", "text_raw": "Fiscal Third Quarter Ended Fiscal Nine Months Ended (Shares in Millions) October 1, 2023 October 2, 2022 October 1, 2023 October 2, 2022 Basic net earnings per share from continuing operations $ 1.71 1.64 3.57 5.00 Basic net earnings per share from discontinued operations 8.61 0.06 8.51 0.49 Total net earnings per share - basic 10.32 1.70 12.08 5.49 Average shares outstanding  basic 2,522.9 2,627.9 2,575.6 2,628.9 Potential shares exercisable under stock option plans 119.2 140.1 96.9 141.1 Less: shares which could be repurchased under treasury stock method ( 92.4 ) ( 106.7 ) ( 69.1 ) ( 102.5 ) Average shares outstanding  diluted 2,549.7 2,661.3 2,603.4 2,667.5 Diluted net earnings per share from continuing operations 1.69 1.62 3.53 4.93 Diluted net earnings per share from discontinuing operations 8.52 0.06 8.42 0.48 Total net earnings per share - diluted $ 10.21 1.68 11.95 5.41", "text": "Fiscal Third Quarter Ended Fiscal Nine Months Ended (Shares in Millions) October 1, 2023 October 2, 2022 October 1, 2023 October 2, 2022 Basic net earnings per share from continuing operations $ 1.71 1.64 3.57 5.00 Basic net earnings per share from discontinued operations 8.61 0.06 8.51 0.49 Total net earnings per share - basic 10.32 1.70 12.08 5.49 Average shares outstanding  basic 2,522.9 2,627.9 2,575.6 2,628.9 Potential shares exercisable under stock option plans 119.2 140.1 96.9 141.1 Less:", "length": 501, "numbers_raw": ["1", "202", "3", "2", "202", "2", "1", "202", "3", "2", "202", "2", "1.71", "1.64", "3.57", "5.00", "8.61", "0.06", "8.51", "0.49", "10.32", "1.70", "12.08", "5.49", "2,522.9", "2,627.9", "2,575.6", "2,628.9", "119.2", "140.1", "96.9", "141.1"], "numbers": [1.0, 202.0, 3.0, 2.0, 202.0, 2.0, 1.0, 202.0, 3.0, 2.0, 202.0, 2.0, 1.71, 1.64, 3.57, 5.0, 8.61, 0.06, 8.51, 0.49, 10.32, 1.7, 12.08, 5.49, 2522.9, 2627.9, 2575.6, 2628.9, 119.2, 140.1, 96.9, 141.1], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 623, "tag": "div", "text_raw": "Fiscal Third Quarter Ended Fiscal Nine Months Ended (Shares in Millions) October 1, 2023 October 2, 2022 October 1, 2023 October 2, 2022 Basic net earnings per share from continuing operations $ 1.71 1.64 3.57 5.00 Basic net earnings per share from discontinued operations 8.61 0.06 8.51 0.49 Total net earnings per share - basic 10.32 1.70 12.08 5.49 Average shares outstanding  basic 2,522.9 2,627.9 2,575.6 2,628.9 Potential shares exercisable under stock option plans 119.2 140.1 96.9 141.1 Less: shares which could be repurchased under treasury stock method ( 92.4 ) ( 106.7 ) ( 69.1 ) ( 102.5 ) Average shares outstanding  diluted 2,549.7 2,661.3 2,603.4 2,667.5 Diluted net earnings per share from continuing operations 1.69 1.62 3.53 4.93 Diluted net earnings per share from discontinuing operations 8.52 0.06 8.42 0.48 Total net earnings per share - diluted $ 10.21 1.68 11.95 5.41", "text": "shares which could be repurchased under treasury stock method ( 92.4 ) ( 106.7 ) ( 69.1 ) ( 102.5 ) Average shares outstanding  diluted 2,549.7 2,661.3 2,603.4 2,667.5 Diluted net earnings per share from continuing operations 1.69 1.62 3.53 4.93 Diluted net earnings per share from discontinuing operations 8.52 0.06 8.42 0.48 Total net earnings per share - diluted $ 10.21 1.68 11.95 5.41", "length": 390, "numbers_raw": ["92.4", "106.7", "69.1", "102.5", "2,549.7", "2,661.3", "2,603.4", "2,667.5", "1.69", "1.62", "3.53", "4.93", "8.52", "0.06", "8.42", "0.48", "10.21", "1.68", "11.95", "5.41"], "numbers": [92.4, 106.7, 69.1, 102.5, 2549.7, 2661.3, 2603.4, 2667.5, 1.69, 1.62, 3.53, 4.93, 8.52, 0.06, 8.42, 0.48, 10.21, 1.68, 11.95, 5.41], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 625, "tag": "div", "text_raw": "The diluted net earnings per share calculation for the fiscal third quarter ended October 1, 2023 excluded 16.4 million shares related to stock options, as the exercise price of these options was greater than the average market value of the Companys stock. The diluted net earnings per share calculation for the fiscal third quarter ended October 2, 2022 included all shares related to stock options, as the exercise price of all options was less than the average market value of the Companys stock.", "text": "The diluted net earnings per share calculation for the fiscal third quarter ended October 1, 2023 excluded 16.4 million shares related to stock options, as the exercise price of these options was greater than the average market value of the Companys stock.", "length": 257, "numbers_raw": ["1", "202", "3", "16.4 million"], "numbers": [1.0, 202.0, 3.0, 16399999.999999998], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 625, "tag": "div", "text_raw": "The diluted net earnings per share calculation for the fiscal third quarter ended October 1, 2023 excluded 16.4 million shares related to stock options, as the exercise price of these options was greater than the average market value of the Companys stock. The diluted net earnings per share calculation for the fiscal third quarter ended October 2, 2022 included all shares related to stock options, as the exercise price of all options was less than the average market value of the Companys stock.", "text": "The diluted net earnings per share calculation for the fiscal third quarter ended October 2, 2022 included all shares related to stock options, as the exercise price of all options was less than the average market value of the Companys stock.", "length": 243, "numbers_raw": ["2", "202", "2"], "numbers": [2.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 627, "tag": "div", "text_raw": "The diluted net earnings per share calculation for the fiscal nine months ended October 1, 2023 excluded 42.9 million shares related to stock options, as the exercise price of these options was greater than the average market value of the Companys stock. The diluted net earnings per share calculation for the fiscal nine months ended October 2, 2022 included all shares related to stock options, as the exercise price of all options was less than the average market value of the Companys stock.", "text": "The diluted net earnings per share calculation for the fiscal nine months ended October 1, 2023 excluded 42.9 million shares related to stock options, as the exercise price of these options was greater than the average market value of the Companys stock.", "length": 255, "numbers_raw": ["1", "202", "3", "42.9 million"], "numbers": [1.0, 202.0, 3.0, 42900000.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 627, "tag": "div", "text_raw": "The diluted net earnings per share calculation for the fiscal nine months ended October 1, 2023 excluded 42.9 million shares related to stock options, as the exercise price of these options was greater than the average market value of the Companys stock. The diluted net earnings per share calculation for the fiscal nine months ended October 2, 2022 included all shares related to stock options, as the exercise price of all options was less than the average market value of the Companys stock.", "text": "The diluted net earnings per share calculation for the fiscal nine months ended October 2, 2022 included all shares related to stock options, as the exercise price of all options was less than the average market value of the Companys stock.", "length": 241, "numbers_raw": ["2", "202", "2"], "numbers": [2.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 630, "tag": "div", "text_raw": "21", "text": "21", "length": 2, "numbers_raw": ["21"], "numbers": [21.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 631, "tag": "div", "text_raw": "21", "text": "21", "length": 2, "numbers_raw": ["21"], "numbers": [21.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 632, "tag": "div", "text_raw": "21", "text": "21", "length": 2, "numbers_raw": ["21"], "numbers": [21.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 636, "tag": "div", "text_raw": "NOTE 9  SEGMENTS OF BUSINESS AND GEOGRAPHIC AREAS", "text": "NOTE 9  SEGMENTS OF BUSINESS AND GEOGRAPHIC AREAS", "length": 50, "numbers_raw": ["9"], "numbers": [9.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 638, "tag": "div", "text_raw": "Following the separation of the Consumer Health business in the fiscal third quarter of 2023, the Company is now organized into two business segments: Innovative Medicine (formerly referred to as Pharmaceutical) and MedTech. The segment results have been recast for all periods to reflect the continuing operations of the Company.", "text": "Following the separation of the Consumer Health business in the fiscal third quarter of 2023, the Company is now organized into two business segments:", "length": 150, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 638, "tag": "div", "text_raw": "Following the separation of the Consumer Health business in the fiscal third quarter of 2023, the Company is now organized into two business segments: Innovative Medicine (formerly referred to as Pharmaceutical) and MedTech. The segment results have been recast for all periods to reflect the continuing operations of the Company.", "text": "Innovative Medicine (formerly referred to as Pharmaceutical) and MedTech.", "length": 73, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 638, "tag": "div", "text_raw": "Following the separation of the Consumer Health business in the fiscal third quarter of 2023, the Company is now organized into two business segments: Innovative Medicine (formerly referred to as Pharmaceutical) and MedTech. The segment results have been recast for all periods to reflect the continuing operations of the Company.", "text": "The segment results have been recast for all periods to reflect the continuing operations of the Company.", "length": 105, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 641, "tag": "div", "text_raw": "Fiscal Third Quarter Ended Fiscal Nine Months Ended (Dollars in Millions) October 1, 2023 October 2, 2022 Percent Change October 1, 2023 October 2, 2022 Percent Change INNOVATIVE MEDICINE Immunology U.S. 3,193 2,876 11.0 8,506 8,230 3.3 International 1,656 1,411 17.4 4,951 4,587 7.9 Worldwide 4,849 4,287 13.1 13,457 12,817 5.0 REMICADE U.S. 296 350 ( 15.4 ) 849 1,099 ( 22.7 ) U.S. Exports 38 39 ( 2.5 ) 112 163 ( 31.3 ) International 127 169 ( 25.1 ) 449 606 ( 25.9 ) Worldwide 461 558 ( 17.4 ) 1,410 1,868 ( 24.5 ) SIMPONI / SIMPONI ARIA U.S. 310 298 3.9 866 886 ( 2.3 ) International 319 248 29.1 829 797 4.1 Worldwide 629 545 15.3 1,695 1,682 0.8 STELARA U.S. 1,912 1,655 15.5 5,180 4,766 8.7 International 951 794 19.9 2,925 2,571 13.8 Worldwide 2,864 2,449 16.9 8,105 7,336 10.5 TREMFYA U.S. 634 530 19.6 1,490 1,303 14.4 International 258 200 29.0 747 613 21.9 Worldwide 891 729 22.2 2,237 1,916 16.8 OTHER IMMUNOLOGY U.S. 2 5 ( 47.1 ) 9 14 ( 36.1 ) International 0 0  0 0  Worldwide 2 5 ( 47.1 ) 9 14 ( 36.1 ) Infectious Diseases U.S. 360 390 ( 7.8 ) 1,147 1,266 ( 9.4 ) International 500 905 ( 44.8 ) 2,420 2,642 ( 8.4 ) Worldwide 859 1,295 ( 33.6 ) 3,566 3,908 ( 8.7 ) COVID-19 VACCINE U.S.     120 * International 41 489 ( 91.5 ) 1,073 1,370 ( 21.6 ) Worldwide 41 489 ( 91.5 ) 1,073 1,490 ( 27.9 ) EDURANT / rilpivirine U.S. 9 9 10.2 26 27 ( 0.5 ) International 287 237 21.4 816 691 18.2", "text": "Fiscal Third Quarter Ended Fiscal Nine Months Ended (Dollars in Millions) October 1, 2023 October 2, 2022 Percent Change October 1, 2023 October 2, 2022 Percent Change INNOVATIVE MEDICINE Immunology U.S.", "length": 203, "numbers_raw": ["1", "202", "3", "2", "202", "2", "1", "202", "3", "2", "202", "2"], "numbers": [1.0, 202.0, 3.0, 2.0, 202.0, 2.0, 1.0, 202.0, 3.0, 2.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 641, "tag": "div", "text_raw": "Fiscal Third Quarter Ended Fiscal Nine Months Ended (Dollars in Millions) October 1, 2023 October 2, 2022 Percent Change October 1, 2023 October 2, 2022 Percent Change INNOVATIVE MEDICINE Immunology U.S. 3,193 2,876 11.0 8,506 8,230 3.3 International 1,656 1,411 17.4 4,951 4,587 7.9 Worldwide 4,849 4,287 13.1 13,457 12,817 5.0 REMICADE U.S. 296 350 ( 15.4 ) 849 1,099 ( 22.7 ) U.S. Exports 38 39 ( 2.5 ) 112 163 ( 31.3 ) International 127 169 ( 25.1 ) 449 606 ( 25.9 ) Worldwide 461 558 ( 17.4 ) 1,410 1,868 ( 24.5 ) SIMPONI / SIMPONI ARIA U.S. 310 298 3.9 866 886 ( 2.3 ) International 319 248 29.1 829 797 4.1 Worldwide 629 545 15.3 1,695 1,682 0.8 STELARA U.S. 1,912 1,655 15.5 5,180 4,766 8.7 International 951 794 19.9 2,925 2,571 13.8 Worldwide 2,864 2,449 16.9 8,105 7,336 10.5 TREMFYA U.S. 634 530 19.6 1,490 1,303 14.4 International 258 200 29.0 747 613 21.9 Worldwide 891 729 22.2 2,237 1,916 16.8 OTHER IMMUNOLOGY U.S. 2 5 ( 47.1 ) 9 14 ( 36.1 ) International 0 0  0 0  Worldwide 2 5 ( 47.1 ) 9 14 ( 36.1 ) Infectious Diseases U.S. 360 390 ( 7.8 ) 1,147 1,266 ( 9.4 ) International 500 905 ( 44.8 ) 2,420 2,642 ( 8.4 ) Worldwide 859 1,295 ( 33.6 ) 3,566 3,908 ( 8.7 ) COVID-19 VACCINE U.S.     120 * International 41 489 ( 91.5 ) 1,073 1,370 ( 21.6 ) Worldwide 41 489 ( 91.5 ) 1,073 1,490 ( 27.9 ) EDURANT / rilpivirine U.S. 9 9 10.2 26 27 ( 0.5 ) International 287 237 21.4 816 691 18.2", "text": "3,193 2,876 11.0 8,506 8,230 3.3 International 1,656 1,411 17.4 4,951 4,587 7.9 Worldwide 4,849 4,287 13.1 13,457 12,817 5.0 REMICADE U.S.", "length": 138, "numbers_raw": ["3,193", "2,876", "11.0", "8,506", "8,230", "3.3", "1,656", "1,411", "17.4", "4,951", "4,587", "7.9", "4,849", "4,287", "13.1", "13,457", "12,817", "5.0"], "numbers": [3193.0, 2876.0, 11.0, 8506.0, 8230.0, 3.3, 1656.0, 1411.0, 17.4, 4951.0, 4587.0, 7.9, 4849.0, 4287.0, 13.1, 13457.0, 12817.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 641, "tag": "div", "text_raw": "Fiscal Third Quarter Ended Fiscal Nine Months Ended (Dollars in Millions) October 1, 2023 October 2, 2022 Percent Change October 1, 2023 October 2, 2022 Percent Change INNOVATIVE MEDICINE Immunology U.S. 3,193 2,876 11.0 8,506 8,230 3.3 International 1,656 1,411 17.4 4,951 4,587 7.9 Worldwide 4,849 4,287 13.1 13,457 12,817 5.0 REMICADE U.S. 296 350 ( 15.4 ) 849 1,099 ( 22.7 ) U.S. Exports 38 39 ( 2.5 ) 112 163 ( 31.3 ) International 127 169 ( 25.1 ) 449 606 ( 25.9 ) Worldwide 461 558 ( 17.4 ) 1,410 1,868 ( 24.5 ) SIMPONI / SIMPONI ARIA U.S. 310 298 3.9 866 886 ( 2.3 ) International 319 248 29.1 829 797 4.1 Worldwide 629 545 15.3 1,695 1,682 0.8 STELARA U.S. 1,912 1,655 15.5 5,180 4,766 8.7 International 951 794 19.9 2,925 2,571 13.8 Worldwide 2,864 2,449 16.9 8,105 7,336 10.5 TREMFYA U.S. 634 530 19.6 1,490 1,303 14.4 International 258 200 29.0 747 613 21.9 Worldwide 891 729 22.2 2,237 1,916 16.8 OTHER IMMUNOLOGY U.S. 2 5 ( 47.1 ) 9 14 ( 36.1 ) International 0 0  0 0  Worldwide 2 5 ( 47.1 ) 9 14 ( 36.1 ) Infectious Diseases U.S. 360 390 ( 7.8 ) 1,147 1,266 ( 9.4 ) International 500 905 ( 44.8 ) 2,420 2,642 ( 8.4 ) Worldwide 859 1,295 ( 33.6 ) 3,566 3,908 ( 8.7 ) COVID-19 VACCINE U.S.     120 * International 41 489 ( 91.5 ) 1,073 1,370 ( 21.6 ) Worldwide 41 489 ( 91.5 ) 1,073 1,490 ( 27.9 ) EDURANT / rilpivirine U.S. 9 9 10.2 26 27 ( 0.5 ) International 287 237 21.4 816 691 18.2", "text": "296 350 ( 15.4 ) 849 1,099 ( 22.7 ) U.S.", "length": 40, "numbers_raw": ["296", "350", "15.4", "849", "1,099", "22.7"], "numbers": [296.0, 350.0, 15.4, 849.0, 1099.0, 22.7], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 641, "tag": "div", "text_raw": "Fiscal Third Quarter Ended Fiscal Nine Months Ended (Dollars in Millions) October 1, 2023 October 2, 2022 Percent Change October 1, 2023 October 2, 2022 Percent Change INNOVATIVE MEDICINE Immunology U.S. 3,193 2,876 11.0 8,506 8,230 3.3 International 1,656 1,411 17.4 4,951 4,587 7.9 Worldwide 4,849 4,287 13.1 13,457 12,817 5.0 REMICADE U.S. 296 350 ( 15.4 ) 849 1,099 ( 22.7 ) U.S. Exports 38 39 ( 2.5 ) 112 163 ( 31.3 ) International 127 169 ( 25.1 ) 449 606 ( 25.9 ) Worldwide 461 558 ( 17.4 ) 1,410 1,868 ( 24.5 ) SIMPONI / SIMPONI ARIA U.S. 310 298 3.9 866 886 ( 2.3 ) International 319 248 29.1 829 797 4.1 Worldwide 629 545 15.3 1,695 1,682 0.8 STELARA U.S. 1,912 1,655 15.5 5,180 4,766 8.7 International 951 794 19.9 2,925 2,571 13.8 Worldwide 2,864 2,449 16.9 8,105 7,336 10.5 TREMFYA U.S. 634 530 19.6 1,490 1,303 14.4 International 258 200 29.0 747 613 21.9 Worldwide 891 729 22.2 2,237 1,916 16.8 OTHER IMMUNOLOGY U.S. 2 5 ( 47.1 ) 9 14 ( 36.1 ) International 0 0  0 0  Worldwide 2 5 ( 47.1 ) 9 14 ( 36.1 ) Infectious Diseases U.S. 360 390 ( 7.8 ) 1,147 1,266 ( 9.4 ) International 500 905 ( 44.8 ) 2,420 2,642 ( 8.4 ) Worldwide 859 1,295 ( 33.6 ) 3,566 3,908 ( 8.7 ) COVID-19 VACCINE U.S.     120 * International 41 489 ( 91.5 ) 1,073 1,370 ( 21.6 ) Worldwide 41 489 ( 91.5 ) 1,073 1,490 ( 27.9 ) EDURANT / rilpivirine U.S. 9 9 10.2 26 27 ( 0.5 ) International 287 237 21.4 816 691 18.2", "text": "Exports 38 39 ( 2.5 ) 112 163 ( 31.3 ) International 127 169 ( 25.1 ) 449 606 ( 25.9 ) Worldwide 461 558 ( 17.4 ) 1,410 1,868 ( 24.5 ) SIMPONI / SIMPONI ARIA U.S.", "length": 162, "numbers_raw": ["38", "39", "2.5", "112", "163", "31.3", "127", "169", "25.1", "449", "606", "25.9", "461", "558", "17.4", "1,410", "1,868", "24.5"], "numbers": [38.0, 39.0, 2.5, 112.0, 163.0, 31.3, 127.0, 169.0, 25.1, 449.0, 606.0, 25.9, 461.0, 558.0, 17.4, 1410.0, 1868.0, 24.5], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 641, "tag": "div", "text_raw": "Fiscal Third Quarter Ended Fiscal Nine Months Ended (Dollars in Millions) October 1, 2023 October 2, 2022 Percent Change October 1, 2023 October 2, 2022 Percent Change INNOVATIVE MEDICINE Immunology U.S. 3,193 2,876 11.0 8,506 8,230 3.3 International 1,656 1,411 17.4 4,951 4,587 7.9 Worldwide 4,849 4,287 13.1 13,457 12,817 5.0 REMICADE U.S. 296 350 ( 15.4 ) 849 1,099 ( 22.7 ) U.S. Exports 38 39 ( 2.5 ) 112 163 ( 31.3 ) International 127 169 ( 25.1 ) 449 606 ( 25.9 ) Worldwide 461 558 ( 17.4 ) 1,410 1,868 ( 24.5 ) SIMPONI / SIMPONI ARIA U.S. 310 298 3.9 866 886 ( 2.3 ) International 319 248 29.1 829 797 4.1 Worldwide 629 545 15.3 1,695 1,682 0.8 STELARA U.S. 1,912 1,655 15.5 5,180 4,766 8.7 International 951 794 19.9 2,925 2,571 13.8 Worldwide 2,864 2,449 16.9 8,105 7,336 10.5 TREMFYA U.S. 634 530 19.6 1,490 1,303 14.4 International 258 200 29.0 747 613 21.9 Worldwide 891 729 22.2 2,237 1,916 16.8 OTHER IMMUNOLOGY U.S. 2 5 ( 47.1 ) 9 14 ( 36.1 ) International 0 0  0 0  Worldwide 2 5 ( 47.1 ) 9 14 ( 36.1 ) Infectious Diseases U.S. 360 390 ( 7.8 ) 1,147 1,266 ( 9.4 ) International 500 905 ( 44.8 ) 2,420 2,642 ( 8.4 ) Worldwide 859 1,295 ( 33.6 ) 3,566 3,908 ( 8.7 ) COVID-19 VACCINE U.S.     120 * International 41 489 ( 91.5 ) 1,073 1,370 ( 21.6 ) Worldwide 41 489 ( 91.5 ) 1,073 1,490 ( 27.9 ) EDURANT / rilpivirine U.S. 9 9 10.2 26 27 ( 0.5 ) International 287 237 21.4 816 691 18.2", "text": "310 298 3.9 866 886 ( 2.3 ) International 319 248 29.1 829 797 4.1 Worldwide 629 545 15.3 1,695 1,682 0.8 STELARA U.S.", "length": 118, "numbers_raw": ["310", "298", "3.9", "866", "886", "2.3", "319", "248", "29.1", "829", "797", "4.1", "629", "545", "15.3", "1,695", "1,682", "0.8"], "numbers": [310.0, 298.0, 3.9, 866.0, 886.0, 2.3, 319.0, 248.0, 29.1, 829.0, 797.0, 4.1, 629.0, 545.0, 15.3, 1695.0, 1682.0, 0.8], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 641, "tag": "div", "text_raw": "Fiscal Third Quarter Ended Fiscal Nine Months Ended (Dollars in Millions) October 1, 2023 October 2, 2022 Percent Change October 1, 2023 October 2, 2022 Percent Change INNOVATIVE MEDICINE Immunology U.S. 3,193 2,876 11.0 8,506 8,230 3.3 International 1,656 1,411 17.4 4,951 4,587 7.9 Worldwide 4,849 4,287 13.1 13,457 12,817 5.0 REMICADE U.S. 296 350 ( 15.4 ) 849 1,099 ( 22.7 ) U.S. Exports 38 39 ( 2.5 ) 112 163 ( 31.3 ) International 127 169 ( 25.1 ) 449 606 ( 25.9 ) Worldwide 461 558 ( 17.4 ) 1,410 1,868 ( 24.5 ) SIMPONI / SIMPONI ARIA U.S. 310 298 3.9 866 886 ( 2.3 ) International 319 248 29.1 829 797 4.1 Worldwide 629 545 15.3 1,695 1,682 0.8 STELARA U.S. 1,912 1,655 15.5 5,180 4,766 8.7 International 951 794 19.9 2,925 2,571 13.8 Worldwide 2,864 2,449 16.9 8,105 7,336 10.5 TREMFYA U.S. 634 530 19.6 1,490 1,303 14.4 International 258 200 29.0 747 613 21.9 Worldwide 891 729 22.2 2,237 1,916 16.8 OTHER IMMUNOLOGY U.S. 2 5 ( 47.1 ) 9 14 ( 36.1 ) International 0 0  0 0  Worldwide 2 5 ( 47.1 ) 9 14 ( 36.1 ) Infectious Diseases U.S. 360 390 ( 7.8 ) 1,147 1,266 ( 9.4 ) International 500 905 ( 44.8 ) 2,420 2,642 ( 8.4 ) Worldwide 859 1,295 ( 33.6 ) 3,566 3,908 ( 8.7 ) COVID-19 VACCINE U.S.     120 * International 41 489 ( 91.5 ) 1,073 1,370 ( 21.6 ) Worldwide 41 489 ( 91.5 ) 1,073 1,490 ( 27.9 ) EDURANT / rilpivirine U.S. 9 9 10.2 26 27 ( 0.5 ) International 287 237 21.4 816 691 18.2", "text": "1,912 1,655 15.5 5,180 4,766 8.7 International 951 794 19.9 2,925 2,571 13.8 Worldwide 2,864 2,449 16.9 8,105 7,336 10.5 TREMFYA U.S.", "length": 133, "numbers_raw": ["1,912", "1,655", "15.5", "5,180", "4,766", "8.7", "951", "794", "19.9", "2,925", "2,571", "13.8", "2,864", "2,449", "16.9", "8,105", "7,336", "10.5"], "numbers": [1912.0, 1655.0, 15.5, 5180.0, 4766.0, 8.7, 951.0, 794.0, 19.9, 2925.0, 2571.0, 13.8, 2864.0, 2449.0, 16.9, 8105.0, 7336.0, 10.5], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 641, "tag": "div", "text_raw": "Fiscal Third Quarter Ended Fiscal Nine Months Ended (Dollars in Millions) October 1, 2023 October 2, 2022 Percent Change October 1, 2023 October 2, 2022 Percent Change INNOVATIVE MEDICINE Immunology U.S. 3,193 2,876 11.0 8,506 8,230 3.3 International 1,656 1,411 17.4 4,951 4,587 7.9 Worldwide 4,849 4,287 13.1 13,457 12,817 5.0 REMICADE U.S. 296 350 ( 15.4 ) 849 1,099 ( 22.7 ) U.S. Exports 38 39 ( 2.5 ) 112 163 ( 31.3 ) International 127 169 ( 25.1 ) 449 606 ( 25.9 ) Worldwide 461 558 ( 17.4 ) 1,410 1,868 ( 24.5 ) SIMPONI / SIMPONI ARIA U.S. 310 298 3.9 866 886 ( 2.3 ) International 319 248 29.1 829 797 4.1 Worldwide 629 545 15.3 1,695 1,682 0.8 STELARA U.S. 1,912 1,655 15.5 5,180 4,766 8.7 International 951 794 19.9 2,925 2,571 13.8 Worldwide 2,864 2,449 16.9 8,105 7,336 10.5 TREMFYA U.S. 634 530 19.6 1,490 1,303 14.4 International 258 200 29.0 747 613 21.9 Worldwide 891 729 22.2 2,237 1,916 16.8 OTHER IMMUNOLOGY U.S. 2 5 ( 47.1 ) 9 14 ( 36.1 ) International 0 0  0 0  Worldwide 2 5 ( 47.1 ) 9 14 ( 36.1 ) Infectious Diseases U.S. 360 390 ( 7.8 ) 1,147 1,266 ( 9.4 ) International 500 905 ( 44.8 ) 2,420 2,642 ( 8.4 ) Worldwide 859 1,295 ( 33.6 ) 3,566 3,908 ( 8.7 ) COVID-19 VACCINE U.S.     120 * International 41 489 ( 91.5 ) 1,073 1,370 ( 21.6 ) Worldwide 41 489 ( 91.5 ) 1,073 1,490 ( 27.9 ) EDURANT / rilpivirine U.S. 9 9 10.2 26 27 ( 0.5 ) International 287 237 21.4 816 691 18.2", "text": "634 530 19.6 1,490 1,303 14.4 International 258 200 29.0 747 613 21.9 Worldwide 891 729 22.2 2,237 1,916 16.8 OTHER IMMUNOLOGY U.S.", "length": 131, "numbers_raw": ["634", "530", "19.6", "1,490", "1,303", "14.4", "258", "200", "29.0", "747", "613", "21.9", "891", "729", "22.2", "2,237", "1,916", "16.8"], "numbers": [634.0, 530.0, 19.6, 1490.0, 1303.0, 14.4, 258.0, 200.0, 29.0, 747.0, 613.0, 21.9, 891.0, 729.0, 22.2, 2237.0, 1916.0, 16.8], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 641, "tag": "div", "text_raw": "Fiscal Third Quarter Ended Fiscal Nine Months Ended (Dollars in Millions) October 1, 2023 October 2, 2022 Percent Change October 1, 2023 October 2, 2022 Percent Change INNOVATIVE MEDICINE Immunology U.S. 3,193 2,876 11.0 8,506 8,230 3.3 International 1,656 1,411 17.4 4,951 4,587 7.9 Worldwide 4,849 4,287 13.1 13,457 12,817 5.0 REMICADE U.S. 296 350 ( 15.4 ) 849 1,099 ( 22.7 ) U.S. Exports 38 39 ( 2.5 ) 112 163 ( 31.3 ) International 127 169 ( 25.1 ) 449 606 ( 25.9 ) Worldwide 461 558 ( 17.4 ) 1,410 1,868 ( 24.5 ) SIMPONI / SIMPONI ARIA U.S. 310 298 3.9 866 886 ( 2.3 ) International 319 248 29.1 829 797 4.1 Worldwide 629 545 15.3 1,695 1,682 0.8 STELARA U.S. 1,912 1,655 15.5 5,180 4,766 8.7 International 951 794 19.9 2,925 2,571 13.8 Worldwide 2,864 2,449 16.9 8,105 7,336 10.5 TREMFYA U.S. 634 530 19.6 1,490 1,303 14.4 International 258 200 29.0 747 613 21.9 Worldwide 891 729 22.2 2,237 1,916 16.8 OTHER IMMUNOLOGY U.S. 2 5 ( 47.1 ) 9 14 ( 36.1 ) International 0 0  0 0  Worldwide 2 5 ( 47.1 ) 9 14 ( 36.1 ) Infectious Diseases U.S. 360 390 ( 7.8 ) 1,147 1,266 ( 9.4 ) International 500 905 ( 44.8 ) 2,420 2,642 ( 8.4 ) Worldwide 859 1,295 ( 33.6 ) 3,566 3,908 ( 8.7 ) COVID-19 VACCINE U.S.     120 * International 41 489 ( 91.5 ) 1,073 1,370 ( 21.6 ) Worldwide 41 489 ( 91.5 ) 1,073 1,490 ( 27.9 ) EDURANT / rilpivirine U.S. 9 9 10.2 26 27 ( 0.5 ) International 287 237 21.4 816 691 18.2", "text": "2 5 ( 47.1 ) 9 14 ( 36.1 ) International 0 0  0 0  Worldwide 2 5 ( 47.1 ) 9 14 ( 36.1 ) Infectious Diseases U.S.", "length": 114, "numbers_raw": ["2", "5", "47.1", "9", "14", "36.1", "0", "0", "0", "0", "2", "5", "47.1", "9", "14", "36.1"], "numbers": [2.0, 5.0, 47.1, 9.0, 14.0, 36.1, 0.0, 0.0, 0.0, 0.0, 2.0, 5.0, 47.1, 9.0, 14.0, 36.1], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 641, "tag": "div", "text_raw": "Fiscal Third Quarter Ended Fiscal Nine Months Ended (Dollars in Millions) October 1, 2023 October 2, 2022 Percent Change October 1, 2023 October 2, 2022 Percent Change INNOVATIVE MEDICINE Immunology U.S. 3,193 2,876 11.0 8,506 8,230 3.3 International 1,656 1,411 17.4 4,951 4,587 7.9 Worldwide 4,849 4,287 13.1 13,457 12,817 5.0 REMICADE U.S. 296 350 ( 15.4 ) 849 1,099 ( 22.7 ) U.S. Exports 38 39 ( 2.5 ) 112 163 ( 31.3 ) International 127 169 ( 25.1 ) 449 606 ( 25.9 ) Worldwide 461 558 ( 17.4 ) 1,410 1,868 ( 24.5 ) SIMPONI / SIMPONI ARIA U.S. 310 298 3.9 866 886 ( 2.3 ) International 319 248 29.1 829 797 4.1 Worldwide 629 545 15.3 1,695 1,682 0.8 STELARA U.S. 1,912 1,655 15.5 5,180 4,766 8.7 International 951 794 19.9 2,925 2,571 13.8 Worldwide 2,864 2,449 16.9 8,105 7,336 10.5 TREMFYA U.S. 634 530 19.6 1,490 1,303 14.4 International 258 200 29.0 747 613 21.9 Worldwide 891 729 22.2 2,237 1,916 16.8 OTHER IMMUNOLOGY U.S. 2 5 ( 47.1 ) 9 14 ( 36.1 ) International 0 0  0 0  Worldwide 2 5 ( 47.1 ) 9 14 ( 36.1 ) Infectious Diseases U.S. 360 390 ( 7.8 ) 1,147 1,266 ( 9.4 ) International 500 905 ( 44.8 ) 2,420 2,642 ( 8.4 ) Worldwide 859 1,295 ( 33.6 ) 3,566 3,908 ( 8.7 ) COVID-19 VACCINE U.S.     120 * International 41 489 ( 91.5 ) 1,073 1,370 ( 21.6 ) Worldwide 41 489 ( 91.5 ) 1,073 1,490 ( 27.9 ) EDURANT / rilpivirine U.S. 9 9 10.2 26 27 ( 0.5 ) International 287 237 21.4 816 691 18.2", "text": "360 390 ( 7.8 ) 1,147 1,266 ( 9.4 ) International 500 905 ( 44.8 ) 2,420 2,642 ( 8.4 ) Worldwide 859 1,295 ( 33.6 ) 3,566 3,908 ( 8.7 ) COVID-19 VACCINE U.S.", "length": 157, "numbers_raw": ["360", "390", "7.8", "1,147", "1,266", "9.4", "500", "905", "44.8", "2,420", "2,642", "8.4", "859", "1,295", "33.6", "3,566", "3,908", "8.7", "19"], "numbers": [360.0, 390.0, 7.8, 1147.0, 1266.0, 9.4, 500.0, 905.0, 44.8, 2420.0, 2642.0, 8.4, 859.0, 1295.0, 33.6, 3566.0, 3908.0, 8.7, 19.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 641, "tag": "div", "text_raw": "Fiscal Third Quarter Ended Fiscal Nine Months Ended (Dollars in Millions) October 1, 2023 October 2, 2022 Percent Change October 1, 2023 October 2, 2022 Percent Change INNOVATIVE MEDICINE Immunology U.S. 3,193 2,876 11.0 8,506 8,230 3.3 International 1,656 1,411 17.4 4,951 4,587 7.9 Worldwide 4,849 4,287 13.1 13,457 12,817 5.0 REMICADE U.S. 296 350 ( 15.4 ) 849 1,099 ( 22.7 ) U.S. Exports 38 39 ( 2.5 ) 112 163 ( 31.3 ) International 127 169 ( 25.1 ) 449 606 ( 25.9 ) Worldwide 461 558 ( 17.4 ) 1,410 1,868 ( 24.5 ) SIMPONI / SIMPONI ARIA U.S. 310 298 3.9 866 886 ( 2.3 ) International 319 248 29.1 829 797 4.1 Worldwide 629 545 15.3 1,695 1,682 0.8 STELARA U.S. 1,912 1,655 15.5 5,180 4,766 8.7 International 951 794 19.9 2,925 2,571 13.8 Worldwide 2,864 2,449 16.9 8,105 7,336 10.5 TREMFYA U.S. 634 530 19.6 1,490 1,303 14.4 International 258 200 29.0 747 613 21.9 Worldwide 891 729 22.2 2,237 1,916 16.8 OTHER IMMUNOLOGY U.S. 2 5 ( 47.1 ) 9 14 ( 36.1 ) International 0 0  0 0  Worldwide 2 5 ( 47.1 ) 9 14 ( 36.1 ) Infectious Diseases U.S. 360 390 ( 7.8 ) 1,147 1,266 ( 9.4 ) International 500 905 ( 44.8 ) 2,420 2,642 ( 8.4 ) Worldwide 859 1,295 ( 33.6 ) 3,566 3,908 ( 8.7 ) COVID-19 VACCINE U.S.     120 * International 41 489 ( 91.5 ) 1,073 1,370 ( 21.6 ) Worldwide 41 489 ( 91.5 ) 1,073 1,490 ( 27.9 ) EDURANT / rilpivirine U.S. 9 9 10.2 26 27 ( 0.5 ) International 287 237 21.4 816 691 18.2", "text": "    120 * International 41 489 ( 91.5 ) 1,073 1,370 ( 21.6 ) Worldwide 41 489 ( 91.5 ) 1,073 1,490 ( 27.9 ) EDURANT / rilpivirine U.S.", "length": 138, "numbers_raw": ["120", "41", "489", "91.5", "1,073", "1,370", "21.6", "41", "489", "91.5", "1,073", "1,490", "27.9"], "numbers": [120.0, 41.0, 489.0, 91.5, 1073.0, 1370.0, 21.6, 41.0, 489.0, 91.5, 1073.0, 1490.0, 27.9], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 641, "tag": "div", "text_raw": "Fiscal Third Quarter Ended Fiscal Nine Months Ended (Dollars in Millions) October 1, 2023 October 2, 2022 Percent Change October 1, 2023 October 2, 2022 Percent Change INNOVATIVE MEDICINE Immunology U.S. 3,193 2,876 11.0 8,506 8,230 3.3 International 1,656 1,411 17.4 4,951 4,587 7.9 Worldwide 4,849 4,287 13.1 13,457 12,817 5.0 REMICADE U.S. 296 350 ( 15.4 ) 849 1,099 ( 22.7 ) U.S. Exports 38 39 ( 2.5 ) 112 163 ( 31.3 ) International 127 169 ( 25.1 ) 449 606 ( 25.9 ) Worldwide 461 558 ( 17.4 ) 1,410 1,868 ( 24.5 ) SIMPONI / SIMPONI ARIA U.S. 310 298 3.9 866 886 ( 2.3 ) International 319 248 29.1 829 797 4.1 Worldwide 629 545 15.3 1,695 1,682 0.8 STELARA U.S. 1,912 1,655 15.5 5,180 4,766 8.7 International 951 794 19.9 2,925 2,571 13.8 Worldwide 2,864 2,449 16.9 8,105 7,336 10.5 TREMFYA U.S. 634 530 19.6 1,490 1,303 14.4 International 258 200 29.0 747 613 21.9 Worldwide 891 729 22.2 2,237 1,916 16.8 OTHER IMMUNOLOGY U.S. 2 5 ( 47.1 ) 9 14 ( 36.1 ) International 0 0  0 0  Worldwide 2 5 ( 47.1 ) 9 14 ( 36.1 ) Infectious Diseases U.S. 360 390 ( 7.8 ) 1,147 1,266 ( 9.4 ) International 500 905 ( 44.8 ) 2,420 2,642 ( 8.4 ) Worldwide 859 1,295 ( 33.6 ) 3,566 3,908 ( 8.7 ) COVID-19 VACCINE U.S.     120 * International 41 489 ( 91.5 ) 1,073 1,370 ( 21.6 ) Worldwide 41 489 ( 91.5 ) 1,073 1,490 ( 27.9 ) EDURANT / rilpivirine U.S. 9 9 10.2 26 27 ( 0.5 ) International 287 237 21.4 816 691 18.2", "text": "9 9 10.2 26 27 ( 0.5 ) International 287 237 21.4 816 691 18.2", "length": 62, "numbers_raw": ["9", "9", "10.2", "26", "27", "0.5", "287", "237", "21.4", "816", "691", "18.2"], "numbers": [9.0, 9.0, 10.2, 26.0, 27.0, 0.5, 287.0, 237.0, 21.4, 816.0, 691.0, 18.2], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 647, "tag": "div", "text_raw": "COVID-19 VACCINE", "text": "COVID-19 VACCINE", "length": 16, "numbers_raw": ["19"], "numbers": [19.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 649, "tag": "div", "text_raw": "22", "text": "22", "length": 2, "numbers_raw": ["22"], "numbers": [22.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 650, "tag": "div", "text_raw": "22", "text": "22", "length": 2, "numbers_raw": ["22"], "numbers": [22.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 651, "tag": "div", "text_raw": "22", "text": "22", "length": 2, "numbers_raw": ["22"], "numbers": [22.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 654, "tag": "div", "text_raw": "Worldwide 297 245 21.0 843 718 17.5 PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA U.S. 345 372 ( 7.3 ) 1,105 1,096 0.9 International 102 112 ( 9.5 ) 310 354 ( 12.5 ) Worldwide 447 485 ( 7.8 ) 1,415 1,450 ( 2.4 ) OTHER INFECTIOUS DISEASES U.S. 5 10 ( 42.7 ) 15 24 ( 35.5 ) International 69 68 2.0 220 228 ( 3.4 ) Worldwide 74 77 ( 3.6 ) 235 251 ( 6.4 ) Neuroscience U.S. 1,036 919 12.7 3,043 2,658 14.5 International 706 763 ( 7.4 ) 2,296 2,498 ( 8.1 ) Worldwide 1,742 1,681 3.6 5,339 5,156 3.5 CONCERTA / methylphenidate U.S. 57 41 38.1 191 114 67.4 International 133 117 13.6 412 362 13.8 Worldwide 189 158 20.0 603 476 26.7 INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA U.S. 730 684 6.8 2,164 2,036 6.3 International 299 348 ( 14.0 ) 940 1,097 ( 14.3 ) Worldwide 1,029 1,031 ( 0.2 ) 3,104 3,132 ( 0.9 ) SPRAVATO U.S. 154 88 75.1 409 223 83.1 International 29 12 * 74 32 * Worldwide 183 100 82.1 483 255 88.8 OTHER NEUROSCIENCE (1) U.S. 94 106 ( 11.3 ) 278 285 ( 2.3 ) International 245 286 ( 13.9 ) 870 1,007 ( 13.5 ) Worldwide 340 393 ( 13.2 ) 1,149 1,293 ( 11.0 ) Oncology U.S. 2,219 1,812 22.5 6,177 5,073 21.8 International 2,313 2,252 2.7 6,865 6,983 ( 1.7 ) Worldwide 4,533 4,064 11.5 13,043 12,056 8.2 CARVYKTI U.S. 140 55 * 324 79 * International 12  * 17  * Worldwide 152 55 * 341 79 * DARZALEX U.S. 1,369 1,097 24.8 3,882 3,071 26.4 International 1,130 955 18.3 3,312 2,823 17.3 Worldwide 2,499 2,052 21.8 7,194 5,894 22.1 ERLEADA U.S. 288 254 12.9 778 693 12.2 International 342 235 45.8 961 647 48.7 Worldwide 631 490 28.7 1,740 1,340 29.8", "text": "Worldwide 297 245 21.0 843 718 17.5 PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA U.S.", "length": 82, "numbers_raw": ["297", "245", "21.0", "843", "718", "17.5"], "numbers": [297.0, 245.0, 21.0, 843.0, 718.0, 17.5], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 654, "tag": "div", "text_raw": "Worldwide 297 245 21.0 843 718 17.5 PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA U.S. 345 372 ( 7.3 ) 1,105 1,096 0.9 International 102 112 ( 9.5 ) 310 354 ( 12.5 ) Worldwide 447 485 ( 7.8 ) 1,415 1,450 ( 2.4 ) OTHER INFECTIOUS DISEASES U.S. 5 10 ( 42.7 ) 15 24 ( 35.5 ) International 69 68 2.0 220 228 ( 3.4 ) Worldwide 74 77 ( 3.6 ) 235 251 ( 6.4 ) Neuroscience U.S. 1,036 919 12.7 3,043 2,658 14.5 International 706 763 ( 7.4 ) 2,296 2,498 ( 8.1 ) Worldwide 1,742 1,681 3.6 5,339 5,156 3.5 CONCERTA / methylphenidate U.S. 57 41 38.1 191 114 67.4 International 133 117 13.6 412 362 13.8 Worldwide 189 158 20.0 603 476 26.7 INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA U.S. 730 684 6.8 2,164 2,036 6.3 International 299 348 ( 14.0 ) 940 1,097 ( 14.3 ) Worldwide 1,029 1,031 ( 0.2 ) 3,104 3,132 ( 0.9 ) SPRAVATO U.S. 154 88 75.1 409 223 83.1 International 29 12 * 74 32 * Worldwide 183 100 82.1 483 255 88.8 OTHER NEUROSCIENCE (1) U.S. 94 106 ( 11.3 ) 278 285 ( 2.3 ) International 245 286 ( 13.9 ) 870 1,007 ( 13.5 ) Worldwide 340 393 ( 13.2 ) 1,149 1,293 ( 11.0 ) Oncology U.S. 2,219 1,812 22.5 6,177 5,073 21.8 International 2,313 2,252 2.7 6,865 6,983 ( 1.7 ) Worldwide 4,533 4,064 11.5 13,043 12,056 8.2 CARVYKTI U.S. 140 55 * 324 79 * International 12  * 17  * Worldwide 152 55 * 341 79 * DARZALEX U.S. 1,369 1,097 24.8 3,882 3,071 26.4 International 1,130 955 18.3 3,312 2,823 17.3 Worldwide 2,499 2,052 21.8 7,194 5,894 22.1 ERLEADA U.S. 288 254 12.9 778 693 12.2 International 342 235 45.8 961 647 48.7 Worldwide 631 490 28.7 1,740 1,340 29.8", "text": "345 372 ( 7.3 ) 1,105 1,096 0.9 International 102 112 ( 9.5 ) 310 354 ( 12.5 ) Worldwide 447 485 ( 7.8 ) 1,415 1,450 ( 2.4 ) OTHER INFECTIOUS DISEASES U.S.", "length": 155, "numbers_raw": ["345", "372", "7.3", "1,105", "1,096", "0.9", "102", "112", "9.5", "310", "354", "12.5", "447", "485", "7.8", "1,415", "1,450", "2.4"], "numbers": [345.0, 372.0, 7.3, 1105.0, 1096.0, 0.9, 102.0, 112.0, 9.5, 310.0, 354.0, 12.5, 447.0, 485.0, 7.8, 1415.0, 1450.0, 2.4], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 654, "tag": "div", "text_raw": "Worldwide 297 245 21.0 843 718 17.5 PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA U.S. 345 372 ( 7.3 ) 1,105 1,096 0.9 International 102 112 ( 9.5 ) 310 354 ( 12.5 ) Worldwide 447 485 ( 7.8 ) 1,415 1,450 ( 2.4 ) OTHER INFECTIOUS DISEASES U.S. 5 10 ( 42.7 ) 15 24 ( 35.5 ) International 69 68 2.0 220 228 ( 3.4 ) Worldwide 74 77 ( 3.6 ) 235 251 ( 6.4 ) Neuroscience U.S. 1,036 919 12.7 3,043 2,658 14.5 International 706 763 ( 7.4 ) 2,296 2,498 ( 8.1 ) Worldwide 1,742 1,681 3.6 5,339 5,156 3.5 CONCERTA / methylphenidate U.S. 57 41 38.1 191 114 67.4 International 133 117 13.6 412 362 13.8 Worldwide 189 158 20.0 603 476 26.7 INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA U.S. 730 684 6.8 2,164 2,036 6.3 International 299 348 ( 14.0 ) 940 1,097 ( 14.3 ) Worldwide 1,029 1,031 ( 0.2 ) 3,104 3,132 ( 0.9 ) SPRAVATO U.S. 154 88 75.1 409 223 83.1 International 29 12 * 74 32 * Worldwide 183 100 82.1 483 255 88.8 OTHER NEUROSCIENCE (1) U.S. 94 106 ( 11.3 ) 278 285 ( 2.3 ) International 245 286 ( 13.9 ) 870 1,007 ( 13.5 ) Worldwide 340 393 ( 13.2 ) 1,149 1,293 ( 11.0 ) Oncology U.S. 2,219 1,812 22.5 6,177 5,073 21.8 International 2,313 2,252 2.7 6,865 6,983 ( 1.7 ) Worldwide 4,533 4,064 11.5 13,043 12,056 8.2 CARVYKTI U.S. 140 55 * 324 79 * International 12  * 17  * Worldwide 152 55 * 341 79 * DARZALEX U.S. 1,369 1,097 24.8 3,882 3,071 26.4 International 1,130 955 18.3 3,312 2,823 17.3 Worldwide 2,499 2,052 21.8 7,194 5,894 22.1 ERLEADA U.S. 288 254 12.9 778 693 12.2 International 342 235 45.8 961 647 48.7 Worldwide 631 490 28.7 1,740 1,340 29.8", "text": "5 10 ( 42.7 ) 15 24 ( 35.5 ) International 69 68 2.0 220 228 ( 3.4 ) Worldwide 74 77 ( 3.6 ) 235 251 ( 6.4 ) Neuroscience U.S.", "length": 126, "numbers_raw": ["5", "10", "42.7", "15", "24", "35.5", "69", "68", "2.0", "220", "228", "3.4", "74", "77", "3.6", "235", "251", "6.4"], "numbers": [5.0, 10.0, 42.7, 15.0, 24.0, 35.5, 69.0, 68.0, 2.0, 220.0, 228.0, 3.4, 74.0, 77.0, 3.6, 235.0, 251.0, 6.4], "percents_raw": [], "percents": [], "currencies": ["EUR"], "has_numbers": true, "has_percents": false}
{"idx_source": 654, "tag": "div", "text_raw": "Worldwide 297 245 21.0 843 718 17.5 PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA U.S. 345 372 ( 7.3 ) 1,105 1,096 0.9 International 102 112 ( 9.5 ) 310 354 ( 12.5 ) Worldwide 447 485 ( 7.8 ) 1,415 1,450 ( 2.4 ) OTHER INFECTIOUS DISEASES U.S. 5 10 ( 42.7 ) 15 24 ( 35.5 ) International 69 68 2.0 220 228 ( 3.4 ) Worldwide 74 77 ( 3.6 ) 235 251 ( 6.4 ) Neuroscience U.S. 1,036 919 12.7 3,043 2,658 14.5 International 706 763 ( 7.4 ) 2,296 2,498 ( 8.1 ) Worldwide 1,742 1,681 3.6 5,339 5,156 3.5 CONCERTA / methylphenidate U.S. 57 41 38.1 191 114 67.4 International 133 117 13.6 412 362 13.8 Worldwide 189 158 20.0 603 476 26.7 INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA U.S. 730 684 6.8 2,164 2,036 6.3 International 299 348 ( 14.0 ) 940 1,097 ( 14.3 ) Worldwide 1,029 1,031 ( 0.2 ) 3,104 3,132 ( 0.9 ) SPRAVATO U.S. 154 88 75.1 409 223 83.1 International 29 12 * 74 32 * Worldwide 183 100 82.1 483 255 88.8 OTHER NEUROSCIENCE (1) U.S. 94 106 ( 11.3 ) 278 285 ( 2.3 ) International 245 286 ( 13.9 ) 870 1,007 ( 13.5 ) Worldwide 340 393 ( 13.2 ) 1,149 1,293 ( 11.0 ) Oncology U.S. 2,219 1,812 22.5 6,177 5,073 21.8 International 2,313 2,252 2.7 6,865 6,983 ( 1.7 ) Worldwide 4,533 4,064 11.5 13,043 12,056 8.2 CARVYKTI U.S. 140 55 * 324 79 * International 12  * 17  * Worldwide 152 55 * 341 79 * DARZALEX U.S. 1,369 1,097 24.8 3,882 3,071 26.4 International 1,130 955 18.3 3,312 2,823 17.3 Worldwide 2,499 2,052 21.8 7,194 5,894 22.1 ERLEADA U.S. 288 254 12.9 778 693 12.2 International 342 235 45.8 961 647 48.7 Worldwide 631 490 28.7 1,740 1,340 29.8", "text": "1,036 919 12.7 3,043 2,658 14.5 International 706 763 ( 7.4 ) 2,296 2,498 ( 8.1 ) Worldwide 1,742 1,681 3.6 5,339 5,156 3.5 CONCERTA / methylphenidate U.S.", "length": 155, "numbers_raw": ["1,036", "919", "12.7", "3,043", "2,658", "14.5", "706", "763", "7.4", "2,296", "2,498", "8.1", "1,742", "1,681", "3.6", "5,339", "5,156", "3.5"], "numbers": [1036.0, 919.0, 12.7, 3043.0, 2658.0, 14.5, 706.0, 763.0, 7.4, 2296.0, 2498.0, 8.1, 1742.0, 1681.0, 3.6, 5339.0, 5156.0, 3.5], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 654, "tag": "div", "text_raw": "Worldwide 297 245 21.0 843 718 17.5 PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA U.S. 345 372 ( 7.3 ) 1,105 1,096 0.9 International 102 112 ( 9.5 ) 310 354 ( 12.5 ) Worldwide 447 485 ( 7.8 ) 1,415 1,450 ( 2.4 ) OTHER INFECTIOUS DISEASES U.S. 5 10 ( 42.7 ) 15 24 ( 35.5 ) International 69 68 2.0 220 228 ( 3.4 ) Worldwide 74 77 ( 3.6 ) 235 251 ( 6.4 ) Neuroscience U.S. 1,036 919 12.7 3,043 2,658 14.5 International 706 763 ( 7.4 ) 2,296 2,498 ( 8.1 ) Worldwide 1,742 1,681 3.6 5,339 5,156 3.5 CONCERTA / methylphenidate U.S. 57 41 38.1 191 114 67.4 International 133 117 13.6 412 362 13.8 Worldwide 189 158 20.0 603 476 26.7 INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA U.S. 730 684 6.8 2,164 2,036 6.3 International 299 348 ( 14.0 ) 940 1,097 ( 14.3 ) Worldwide 1,029 1,031 ( 0.2 ) 3,104 3,132 ( 0.9 ) SPRAVATO U.S. 154 88 75.1 409 223 83.1 International 29 12 * 74 32 * Worldwide 183 100 82.1 483 255 88.8 OTHER NEUROSCIENCE (1) U.S. 94 106 ( 11.3 ) 278 285 ( 2.3 ) International 245 286 ( 13.9 ) 870 1,007 ( 13.5 ) Worldwide 340 393 ( 13.2 ) 1,149 1,293 ( 11.0 ) Oncology U.S. 2,219 1,812 22.5 6,177 5,073 21.8 International 2,313 2,252 2.7 6,865 6,983 ( 1.7 ) Worldwide 4,533 4,064 11.5 13,043 12,056 8.2 CARVYKTI U.S. 140 55 * 324 79 * International 12  * 17  * Worldwide 152 55 * 341 79 * DARZALEX U.S. 1,369 1,097 24.8 3,882 3,071 26.4 International 1,130 955 18.3 3,312 2,823 17.3 Worldwide 2,499 2,052 21.8 7,194 5,894 22.1 ERLEADA U.S. 288 254 12.9 778 693 12.2 International 342 235 45.8 961 647 48.7 Worldwide 631 490 28.7 1,740 1,340 29.8", "text": "57 41 38.1 191 114 67.4 International 133 117 13.6 412 362 13.8 Worldwide 189 158 20.0 603 476 26.7 INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA U.S.", "length": 157, "numbers_raw": ["57", "41", "38.1", "191", "114", "67.4", "133", "117", "13.6", "412", "362", "13.8", "189", "158", "20.0", "603", "476", "26.7"], "numbers": [57.0, 41.0, 38.1, 191.0, 114.0, 67.4, 133.0, 117.0, 13.6, 412.0, 362.0, 13.8, 189.0, 158.0, 20.0, 603.0, 476.0, 26.7], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 654, "tag": "div", "text_raw": "Worldwide 297 245 21.0 843 718 17.5 PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA U.S. 345 372 ( 7.3 ) 1,105 1,096 0.9 International 102 112 ( 9.5 ) 310 354 ( 12.5 ) Worldwide 447 485 ( 7.8 ) 1,415 1,450 ( 2.4 ) OTHER INFECTIOUS DISEASES U.S. 5 10 ( 42.7 ) 15 24 ( 35.5 ) International 69 68 2.0 220 228 ( 3.4 ) Worldwide 74 77 ( 3.6 ) 235 251 ( 6.4 ) Neuroscience U.S. 1,036 919 12.7 3,043 2,658 14.5 International 706 763 ( 7.4 ) 2,296 2,498 ( 8.1 ) Worldwide 1,742 1,681 3.6 5,339 5,156 3.5 CONCERTA / methylphenidate U.S. 57 41 38.1 191 114 67.4 International 133 117 13.6 412 362 13.8 Worldwide 189 158 20.0 603 476 26.7 INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA U.S. 730 684 6.8 2,164 2,036 6.3 International 299 348 ( 14.0 ) 940 1,097 ( 14.3 ) Worldwide 1,029 1,031 ( 0.2 ) 3,104 3,132 ( 0.9 ) SPRAVATO U.S. 154 88 75.1 409 223 83.1 International 29 12 * 74 32 * Worldwide 183 100 82.1 483 255 88.8 OTHER NEUROSCIENCE (1) U.S. 94 106 ( 11.3 ) 278 285 ( 2.3 ) International 245 286 ( 13.9 ) 870 1,007 ( 13.5 ) Worldwide 340 393 ( 13.2 ) 1,149 1,293 ( 11.0 ) Oncology U.S. 2,219 1,812 22.5 6,177 5,073 21.8 International 2,313 2,252 2.7 6,865 6,983 ( 1.7 ) Worldwide 4,533 4,064 11.5 13,043 12,056 8.2 CARVYKTI U.S. 140 55 * 324 79 * International 12  * 17  * Worldwide 152 55 * 341 79 * DARZALEX U.S. 1,369 1,097 24.8 3,882 3,071 26.4 International 1,130 955 18.3 3,312 2,823 17.3 Worldwide 2,499 2,052 21.8 7,194 5,894 22.1 ERLEADA U.S. 288 254 12.9 778 693 12.2 International 342 235 45.8 961 647 48.7 Worldwide 631 490 28.7 1,740 1,340 29.8", "text": "730 684 6.8 2,164 2,036 6.3 International 299 348 ( 14.0 ) 940 1,097 ( 14.3 ) Worldwide 1,029 1,031 ( 0.2 ) 3,104 3,132 ( 0.9 ) SPRAVATO U.S.", "length": 141, "numbers_raw": ["730", "684", "6.8", "2,164", "2,036", "6.3", "299", "348", "14.0", "940", "1,097", "14.3", "1,029", "1,031", "0.2", "3,104", "3,132", "0.9"], "numbers": [730.0, 684.0, 6.8, 2164.0, 2036.0, 6.3, 299.0, 348.0, 14.0, 940.0, 1097.0, 14.3, 1029.0, 1031.0, 0.2, 3104.0, 3132.0, 0.9], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 654, "tag": "div", "text_raw": "Worldwide 297 245 21.0 843 718 17.5 PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA U.S. 345 372 ( 7.3 ) 1,105 1,096 0.9 International 102 112 ( 9.5 ) 310 354 ( 12.5 ) Worldwide 447 485 ( 7.8 ) 1,415 1,450 ( 2.4 ) OTHER INFECTIOUS DISEASES U.S. 5 10 ( 42.7 ) 15 24 ( 35.5 ) International 69 68 2.0 220 228 ( 3.4 ) Worldwide 74 77 ( 3.6 ) 235 251 ( 6.4 ) Neuroscience U.S. 1,036 919 12.7 3,043 2,658 14.5 International 706 763 ( 7.4 ) 2,296 2,498 ( 8.1 ) Worldwide 1,742 1,681 3.6 5,339 5,156 3.5 CONCERTA / methylphenidate U.S. 57 41 38.1 191 114 67.4 International 133 117 13.6 412 362 13.8 Worldwide 189 158 20.0 603 476 26.7 INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA U.S. 730 684 6.8 2,164 2,036 6.3 International 299 348 ( 14.0 ) 940 1,097 ( 14.3 ) Worldwide 1,029 1,031 ( 0.2 ) 3,104 3,132 ( 0.9 ) SPRAVATO U.S. 154 88 75.1 409 223 83.1 International 29 12 * 74 32 * Worldwide 183 100 82.1 483 255 88.8 OTHER NEUROSCIENCE (1) U.S. 94 106 ( 11.3 ) 278 285 ( 2.3 ) International 245 286 ( 13.9 ) 870 1,007 ( 13.5 ) Worldwide 340 393 ( 13.2 ) 1,149 1,293 ( 11.0 ) Oncology U.S. 2,219 1,812 22.5 6,177 5,073 21.8 International 2,313 2,252 2.7 6,865 6,983 ( 1.7 ) Worldwide 4,533 4,064 11.5 13,043 12,056 8.2 CARVYKTI U.S. 140 55 * 324 79 * International 12  * 17  * Worldwide 152 55 * 341 79 * DARZALEX U.S. 1,369 1,097 24.8 3,882 3,071 26.4 International 1,130 955 18.3 3,312 2,823 17.3 Worldwide 2,499 2,052 21.8 7,194 5,894 22.1 ERLEADA U.S. 288 254 12.9 778 693 12.2 International 342 235 45.8 961 647 48.7 Worldwide 631 490 28.7 1,740 1,340 29.8", "text": "154 88 75.1 409 223 83.1 International 29 12 * 74 32 * Worldwide 183 100 82.1 483 255 88.8 OTHER NEUROSCIENCE (1) U.S.", "length": 118, "numbers_raw": ["154", "88", "75.1", "409", "223", "83.1", "29", "12", "74", "32", "183", "100", "82.1", "483", "255", "88.8", "1"], "numbers": [154.0, 88.0, 75.1, 409.0, 223.0, 83.1, 29.0, 12.0, 74.0, 32.0, 183.0, 100.0, 82.1, 483.0, 255.0, 88.8, 1.0], "percents_raw": [], "percents": [], "currencies": ["EUR"], "has_numbers": true, "has_percents": false}
{"idx_source": 654, "tag": "div", "text_raw": "Worldwide 297 245 21.0 843 718 17.5 PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA U.S. 345 372 ( 7.3 ) 1,105 1,096 0.9 International 102 112 ( 9.5 ) 310 354 ( 12.5 ) Worldwide 447 485 ( 7.8 ) 1,415 1,450 ( 2.4 ) OTHER INFECTIOUS DISEASES U.S. 5 10 ( 42.7 ) 15 24 ( 35.5 ) International 69 68 2.0 220 228 ( 3.4 ) Worldwide 74 77 ( 3.6 ) 235 251 ( 6.4 ) Neuroscience U.S. 1,036 919 12.7 3,043 2,658 14.5 International 706 763 ( 7.4 ) 2,296 2,498 ( 8.1 ) Worldwide 1,742 1,681 3.6 5,339 5,156 3.5 CONCERTA / methylphenidate U.S. 57 41 38.1 191 114 67.4 International 133 117 13.6 412 362 13.8 Worldwide 189 158 20.0 603 476 26.7 INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA U.S. 730 684 6.8 2,164 2,036 6.3 International 299 348 ( 14.0 ) 940 1,097 ( 14.3 ) Worldwide 1,029 1,031 ( 0.2 ) 3,104 3,132 ( 0.9 ) SPRAVATO U.S. 154 88 75.1 409 223 83.1 International 29 12 * 74 32 * Worldwide 183 100 82.1 483 255 88.8 OTHER NEUROSCIENCE (1) U.S. 94 106 ( 11.3 ) 278 285 ( 2.3 ) International 245 286 ( 13.9 ) 870 1,007 ( 13.5 ) Worldwide 340 393 ( 13.2 ) 1,149 1,293 ( 11.0 ) Oncology U.S. 2,219 1,812 22.5 6,177 5,073 21.8 International 2,313 2,252 2.7 6,865 6,983 ( 1.7 ) Worldwide 4,533 4,064 11.5 13,043 12,056 8.2 CARVYKTI U.S. 140 55 * 324 79 * International 12  * 17  * Worldwide 152 55 * 341 79 * DARZALEX U.S. 1,369 1,097 24.8 3,882 3,071 26.4 International 1,130 955 18.3 3,312 2,823 17.3 Worldwide 2,499 2,052 21.8 7,194 5,894 22.1 ERLEADA U.S. 288 254 12.9 778 693 12.2 International 342 235 45.8 961 647 48.7 Worldwide 631 490 28.7 1,740 1,340 29.8", "text": "94 106 ( 11.3 ) 278 285 ( 2.3 ) International 245 286 ( 13.9 ) 870 1,007 ( 13.5 ) Worldwide 340 393 ( 13.2 ) 1,149 1,293 ( 11.0 ) Oncology U.S.", "length": 143, "numbers_raw": ["94", "106", "11.3", "278", "285", "2.3", "245", "286", "13.9", "870", "1,007", "13.5", "340", "393", "13.2", "1,149", "1,293", "11.0"], "numbers": [94.0, 106.0, 11.3, 278.0, 285.0, 2.3, 245.0, 286.0, 13.9, 870.0, 1007.0, 13.5, 340.0, 393.0, 13.2, 1149.0, 1293.0, 11.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 654, "tag": "div", "text_raw": "Worldwide 297 245 21.0 843 718 17.5 PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA U.S. 345 372 ( 7.3 ) 1,105 1,096 0.9 International 102 112 ( 9.5 ) 310 354 ( 12.5 ) Worldwide 447 485 ( 7.8 ) 1,415 1,450 ( 2.4 ) OTHER INFECTIOUS DISEASES U.S. 5 10 ( 42.7 ) 15 24 ( 35.5 ) International 69 68 2.0 220 228 ( 3.4 ) Worldwide 74 77 ( 3.6 ) 235 251 ( 6.4 ) Neuroscience U.S. 1,036 919 12.7 3,043 2,658 14.5 International 706 763 ( 7.4 ) 2,296 2,498 ( 8.1 ) Worldwide 1,742 1,681 3.6 5,339 5,156 3.5 CONCERTA / methylphenidate U.S. 57 41 38.1 191 114 67.4 International 133 117 13.6 412 362 13.8 Worldwide 189 158 20.0 603 476 26.7 INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA U.S. 730 684 6.8 2,164 2,036 6.3 International 299 348 ( 14.0 ) 940 1,097 ( 14.3 ) Worldwide 1,029 1,031 ( 0.2 ) 3,104 3,132 ( 0.9 ) SPRAVATO U.S. 154 88 75.1 409 223 83.1 International 29 12 * 74 32 * Worldwide 183 100 82.1 483 255 88.8 OTHER NEUROSCIENCE (1) U.S. 94 106 ( 11.3 ) 278 285 ( 2.3 ) International 245 286 ( 13.9 ) 870 1,007 ( 13.5 ) Worldwide 340 393 ( 13.2 ) 1,149 1,293 ( 11.0 ) Oncology U.S. 2,219 1,812 22.5 6,177 5,073 21.8 International 2,313 2,252 2.7 6,865 6,983 ( 1.7 ) Worldwide 4,533 4,064 11.5 13,043 12,056 8.2 CARVYKTI U.S. 140 55 * 324 79 * International 12  * 17  * Worldwide 152 55 * 341 79 * DARZALEX U.S. 1,369 1,097 24.8 3,882 3,071 26.4 International 1,130 955 18.3 3,312 2,823 17.3 Worldwide 2,499 2,052 21.8 7,194 5,894 22.1 ERLEADA U.S. 288 254 12.9 778 693 12.2 International 342 235 45.8 961 647 48.7 Worldwide 631 490 28.7 1,740 1,340 29.8", "text": "2,219 1,812 22.5 6,177 5,073 21.8 International 2,313 2,252 2.7 6,865 6,983 ( 1.7 ) Worldwide 4,533 4,064 11.5 13,043 12,056 8.2 CARVYKTI U.S.", "length": 142, "numbers_raw": ["2,219", "1,812", "22.5", "6,177", "5,073", "21.8", "2,313", "2,252", "2.7", "6,865", "6,983", "1.7", "4,533", "4,064", "11.5", "13,043", "12,056", "8.2"], "numbers": [2219.0, 1812.0, 22.5, 6177.0, 5073.0, 21.8, 2313.0, 2252.0, 2.7, 6865.0, 6983.0, 1.7, 4533.0, 4064.0, 11.5, 13043.0, 12056.0, 8.2], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 654, "tag": "div", "text_raw": "Worldwide 297 245 21.0 843 718 17.5 PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA U.S. 345 372 ( 7.3 ) 1,105 1,096 0.9 International 102 112 ( 9.5 ) 310 354 ( 12.5 ) Worldwide 447 485 ( 7.8 ) 1,415 1,450 ( 2.4 ) OTHER INFECTIOUS DISEASES U.S. 5 10 ( 42.7 ) 15 24 ( 35.5 ) International 69 68 2.0 220 228 ( 3.4 ) Worldwide 74 77 ( 3.6 ) 235 251 ( 6.4 ) Neuroscience U.S. 1,036 919 12.7 3,043 2,658 14.5 International 706 763 ( 7.4 ) 2,296 2,498 ( 8.1 ) Worldwide 1,742 1,681 3.6 5,339 5,156 3.5 CONCERTA / methylphenidate U.S. 57 41 38.1 191 114 67.4 International 133 117 13.6 412 362 13.8 Worldwide 189 158 20.0 603 476 26.7 INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA U.S. 730 684 6.8 2,164 2,036 6.3 International 299 348 ( 14.0 ) 940 1,097 ( 14.3 ) Worldwide 1,029 1,031 ( 0.2 ) 3,104 3,132 ( 0.9 ) SPRAVATO U.S. 154 88 75.1 409 223 83.1 International 29 12 * 74 32 * Worldwide 183 100 82.1 483 255 88.8 OTHER NEUROSCIENCE (1) U.S. 94 106 ( 11.3 ) 278 285 ( 2.3 ) International 245 286 ( 13.9 ) 870 1,007 ( 13.5 ) Worldwide 340 393 ( 13.2 ) 1,149 1,293 ( 11.0 ) Oncology U.S. 2,219 1,812 22.5 6,177 5,073 21.8 International 2,313 2,252 2.7 6,865 6,983 ( 1.7 ) Worldwide 4,533 4,064 11.5 13,043 12,056 8.2 CARVYKTI U.S. 140 55 * 324 79 * International 12  * 17  * Worldwide 152 55 * 341 79 * DARZALEX U.S. 1,369 1,097 24.8 3,882 3,071 26.4 International 1,130 955 18.3 3,312 2,823 17.3 Worldwide 2,499 2,052 21.8 7,194 5,894 22.1 ERLEADA U.S. 288 254 12.9 778 693 12.2 International 342 235 45.8 961 647 48.7 Worldwide 631 490 28.7 1,740 1,340 29.8", "text": "140 55 * 324 79 * International 12  * 17  * Worldwide 152 55 * 341 79 * DARZALEX U.S.", "length": 87, "numbers_raw": ["140", "55", "324", "79", "12", "17", "152", "55", "341", "79"], "numbers": [140.0, 55.0, 324.0, 79.0, 12.0, 17.0, 152.0, 55.0, 341.0, 79.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 654, "tag": "div", "text_raw": "Worldwide 297 245 21.0 843 718 17.5 PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA U.S. 345 372 ( 7.3 ) 1,105 1,096 0.9 International 102 112 ( 9.5 ) 310 354 ( 12.5 ) Worldwide 447 485 ( 7.8 ) 1,415 1,450 ( 2.4 ) OTHER INFECTIOUS DISEASES U.S. 5 10 ( 42.7 ) 15 24 ( 35.5 ) International 69 68 2.0 220 228 ( 3.4 ) Worldwide 74 77 ( 3.6 ) 235 251 ( 6.4 ) Neuroscience U.S. 1,036 919 12.7 3,043 2,658 14.5 International 706 763 ( 7.4 ) 2,296 2,498 ( 8.1 ) Worldwide 1,742 1,681 3.6 5,339 5,156 3.5 CONCERTA / methylphenidate U.S. 57 41 38.1 191 114 67.4 International 133 117 13.6 412 362 13.8 Worldwide 189 158 20.0 603 476 26.7 INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA U.S. 730 684 6.8 2,164 2,036 6.3 International 299 348 ( 14.0 ) 940 1,097 ( 14.3 ) Worldwide 1,029 1,031 ( 0.2 ) 3,104 3,132 ( 0.9 ) SPRAVATO U.S. 154 88 75.1 409 223 83.1 International 29 12 * 74 32 * Worldwide 183 100 82.1 483 255 88.8 OTHER NEUROSCIENCE (1) U.S. 94 106 ( 11.3 ) 278 285 ( 2.3 ) International 245 286 ( 13.9 ) 870 1,007 ( 13.5 ) Worldwide 340 393 ( 13.2 ) 1,149 1,293 ( 11.0 ) Oncology U.S. 2,219 1,812 22.5 6,177 5,073 21.8 International 2,313 2,252 2.7 6,865 6,983 ( 1.7 ) Worldwide 4,533 4,064 11.5 13,043 12,056 8.2 CARVYKTI U.S. 140 55 * 324 79 * International 12  * 17  * Worldwide 152 55 * 341 79 * DARZALEX U.S. 1,369 1,097 24.8 3,882 3,071 26.4 International 1,130 955 18.3 3,312 2,823 17.3 Worldwide 2,499 2,052 21.8 7,194 5,894 22.1 ERLEADA U.S. 288 254 12.9 778 693 12.2 International 342 235 45.8 961 647 48.7 Worldwide 631 490 28.7 1,740 1,340 29.8", "text": "1,369 1,097 24.8 3,882 3,071 26.4 International 1,130 955 18.3 3,312 2,823 17.3 Worldwide 2,499 2,052 21.8 7,194 5,894 22.1 ERLEADA U.S.", "length": 136, "numbers_raw": ["1,369", "1,097", "24.8", "3,882", "3,071", "26.4", "1,130", "955", "18.3", "3,312", "2,823", "17.3", "2,499", "2,052", "21.8", "7,194", "5,894", "22.1"], "numbers": [1369.0, 1097.0, 24.8, 3882.0, 3071.0, 26.4, 1130.0, 955.0, 18.3, 3312.0, 2823.0, 17.3, 2499.0, 2052.0, 21.8, 7194.0, 5894.0, 22.1], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 654, "tag": "div", "text_raw": "Worldwide 297 245 21.0 843 718 17.5 PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA U.S. 345 372 ( 7.3 ) 1,105 1,096 0.9 International 102 112 ( 9.5 ) 310 354 ( 12.5 ) Worldwide 447 485 ( 7.8 ) 1,415 1,450 ( 2.4 ) OTHER INFECTIOUS DISEASES U.S. 5 10 ( 42.7 ) 15 24 ( 35.5 ) International 69 68 2.0 220 228 ( 3.4 ) Worldwide 74 77 ( 3.6 ) 235 251 ( 6.4 ) Neuroscience U.S. 1,036 919 12.7 3,043 2,658 14.5 International 706 763 ( 7.4 ) 2,296 2,498 ( 8.1 ) Worldwide 1,742 1,681 3.6 5,339 5,156 3.5 CONCERTA / methylphenidate U.S. 57 41 38.1 191 114 67.4 International 133 117 13.6 412 362 13.8 Worldwide 189 158 20.0 603 476 26.7 INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA U.S. 730 684 6.8 2,164 2,036 6.3 International 299 348 ( 14.0 ) 940 1,097 ( 14.3 ) Worldwide 1,029 1,031 ( 0.2 ) 3,104 3,132 ( 0.9 ) SPRAVATO U.S. 154 88 75.1 409 223 83.1 International 29 12 * 74 32 * Worldwide 183 100 82.1 483 255 88.8 OTHER NEUROSCIENCE (1) U.S. 94 106 ( 11.3 ) 278 285 ( 2.3 ) International 245 286 ( 13.9 ) 870 1,007 ( 13.5 ) Worldwide 340 393 ( 13.2 ) 1,149 1,293 ( 11.0 ) Oncology U.S. 2,219 1,812 22.5 6,177 5,073 21.8 International 2,313 2,252 2.7 6,865 6,983 ( 1.7 ) Worldwide 4,533 4,064 11.5 13,043 12,056 8.2 CARVYKTI U.S. 140 55 * 324 79 * International 12  * 17  * Worldwide 152 55 * 341 79 * DARZALEX U.S. 1,369 1,097 24.8 3,882 3,071 26.4 International 1,130 955 18.3 3,312 2,823 17.3 Worldwide 2,499 2,052 21.8 7,194 5,894 22.1 ERLEADA U.S. 288 254 12.9 778 693 12.2 International 342 235 45.8 961 647 48.7 Worldwide 631 490 28.7 1,740 1,340 29.8", "text": "288 254 12.9 778 693 12.2 International 342 235 45.8 961 647 48.7 Worldwide 631 490 28.7 1,740 1,340 29.8", "length": 105, "numbers_raw": ["288", "254", "12.9", "778", "693", "12.2", "342", "235", "45.8", "961", "647", "48.7", "631", "490", "28.7", "1,740", "1,340", "29.8"], "numbers": [288.0, 254.0, 12.9, 778.0, 693.0, 12.2, 342.0, 235.0, 45.8, 961.0, 647.0, 48.7, 631.0, 490.0, 28.7, 1740.0, 1340.0, 29.8], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 655, "tag": "div", "text_raw": "PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA", "text": "PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA", "length": 41, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 658, "tag": "div", "text_raw": "INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA", "text": "INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA", "length": 52, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 660, "tag": "div", "text_raw": "OTHER NEUROSCIENCE (1)", "text": "OTHER NEUROSCIENCE (1)", "length": 22, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": ["EUR"], "has_numbers": true, "has_percents": false}
{"idx_source": 664, "tag": "div", "text_raw": "23", "text": "23", "length": 2, "numbers_raw": ["23"], "numbers": [23.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 665, "tag": "div", "text_raw": "23", "text": "23", "length": 2, "numbers_raw": ["23"], "numbers": [23.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 666, "tag": "div", "text_raw": "23", "text": "23", "length": 2, "numbers_raw": ["23"], "numbers": [23.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 669, "tag": "div", "text_raw": "IMBRUVICA U.S. 264 353 ( 25.2 ) 796 1,072 ( 25.8 ) International 545 559 ( 2.5 ) 1,681 1,847 ( 9.0 ) Worldwide 808 911 ( 11.3 ) 2,476 2,918 ( 15.2 ) ZYTIGA / abiraterone acetate U.S. 16 16 ( 2.8 ) 41 54 ( 24.9 ) International 199 440 ( 54.9 ) 646 1,446 ( 55.3 ) Worldwide 214 456 ( 53.0 ) 686 1,500 ( 54.2 ) OTHER ONCOLOGY U.S. 143 37 * 357 104 * International 86 64 34.5 248 220 12.5 Worldwide 229 100 * 605 324 86.5 Pulmonary Hypertension U.S. 680 604 12.6 1,964 1,736 13.1 International 274 247 10.5 835 810 3.0 Worldwide 954 852 12.0 2,798 2,547 9.9 OPSUMIT U.S. 323 289 12.2 924 827 11.8 International 166 152 9.3 512 495 3.5 Worldwide 490 441 11.2 1,437 1,322 8.7 UPTRAVI U.S. 336 283 18.9 978 824 18.7 International 66 50 30.9 185 162 14.1 Worldwide 402 333 20.7 1,163 986 18.0 OTHER PULMONARY HYPERTENSION U.S. 20 33 ( 37.1 ) 61 86 ( 28.4 ) International 42 46 ( 7.5 ) 137 154 ( 10.5 ) Worldwide 63 78 ( 19.8 ) 199 239 ( 16.9 ) Cardiovascular / Metabolism / Other U.S. 763 837 ( 8.8 ) 2,254 2,266 ( 0.5 ) International 194 198 ( 2.1 ) 580 651 ( 10.8 ) Worldwide 957 1,034 ( 7.5 ) 2,834 2,916 ( 2.8 ) XARELTO U.S. 625 689 ( 9.4 ) 1,840 1,806 1.9 International       Worldwide 625 689 ( 9.4 ) 1,840 1,806 1.9 OTHER (2) U.S. 139 147 ( 6.1 ) 414 459 ( 9.9 ) International 194 198 ( 2.1 ) 580 651 ( 10.8 ) Worldwide 332 345 ( 3.8 ) 994 1,110 ( 10.5 ) TOTAL INNOVATIVE MEDICINE U.S. 8,249 7,438 10.9 23,090 21,229 8.8 International 5,644 5,776 ( 2.3 ) 17,947 18,171 ( 1.2 ) Worldwide 13,893 13,214 5.1 41,037 39,400 4.2", "text": "264 353 ( 25.2 ) 796 1,072 ( 25.8 ) International 545 559 ( 2.5 ) 1,681 1,847 ( 9.0 ) Worldwide 808 911 ( 11.3 ) 2,476 2,918 ( 15.2 ) ZYTIGA / abiraterone acetate U.S.", "length": 167, "numbers_raw": ["264", "353", "25.2", "796", "1,072", "25.8", "545", "559", "2.5", "1,681", "1,847", "9.0", "808", "911", "11.3", "2,476", "2,918", "15.2"], "numbers": [264.0, 353.0, 25.2, 796.0, 1072.0, 25.8, 545.0, 559.0, 2.5, 1681.0, 1847.0, 9.0, 808.0, 911.0, 11.3, 2476.0, 2918.0, 15.2], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 669, "tag": "div", "text_raw": "IMBRUVICA U.S. 264 353 ( 25.2 ) 796 1,072 ( 25.8 ) International 545 559 ( 2.5 ) 1,681 1,847 ( 9.0 ) Worldwide 808 911 ( 11.3 ) 2,476 2,918 ( 15.2 ) ZYTIGA / abiraterone acetate U.S. 16 16 ( 2.8 ) 41 54 ( 24.9 ) International 199 440 ( 54.9 ) 646 1,446 ( 55.3 ) Worldwide 214 456 ( 53.0 ) 686 1,500 ( 54.2 ) OTHER ONCOLOGY U.S. 143 37 * 357 104 * International 86 64 34.5 248 220 12.5 Worldwide 229 100 * 605 324 86.5 Pulmonary Hypertension U.S. 680 604 12.6 1,964 1,736 13.1 International 274 247 10.5 835 810 3.0 Worldwide 954 852 12.0 2,798 2,547 9.9 OPSUMIT U.S. 323 289 12.2 924 827 11.8 International 166 152 9.3 512 495 3.5 Worldwide 490 441 11.2 1,437 1,322 8.7 UPTRAVI U.S. 336 283 18.9 978 824 18.7 International 66 50 30.9 185 162 14.1 Worldwide 402 333 20.7 1,163 986 18.0 OTHER PULMONARY HYPERTENSION U.S. 20 33 ( 37.1 ) 61 86 ( 28.4 ) International 42 46 ( 7.5 ) 137 154 ( 10.5 ) Worldwide 63 78 ( 19.8 ) 199 239 ( 16.9 ) Cardiovascular / Metabolism / Other U.S. 763 837 ( 8.8 ) 2,254 2,266 ( 0.5 ) International 194 198 ( 2.1 ) 580 651 ( 10.8 ) Worldwide 957 1,034 ( 7.5 ) 2,834 2,916 ( 2.8 ) XARELTO U.S. 625 689 ( 9.4 ) 1,840 1,806 1.9 International       Worldwide 625 689 ( 9.4 ) 1,840 1,806 1.9 OTHER (2) U.S. 139 147 ( 6.1 ) 414 459 ( 9.9 ) International 194 198 ( 2.1 ) 580 651 ( 10.8 ) Worldwide 332 345 ( 3.8 ) 994 1,110 ( 10.5 ) TOTAL INNOVATIVE MEDICINE U.S. 8,249 7,438 10.9 23,090 21,229 8.8 International 5,644 5,776 ( 2.3 ) 17,947 18,171 ( 1.2 ) Worldwide 13,893 13,214 5.1 41,037 39,400 4.2", "text": "16 16 ( 2.8 ) 41 54 ( 24.9 ) International 199 440 ( 54.9 ) 646 1,446 ( 55.3 ) Worldwide 214 456 ( 53.0 ) 686 1,500 ( 54.2 ) OTHER ONCOLOGY U.S.", "length": 144, "numbers_raw": ["16", "16", "2.8", "41", "54", "24.9", "199", "440", "54.9", "646", "1,446", "55.3", "214", "456", "53.0", "686", "1,500", "54.2"], "numbers": [16.0, 16.0, 2.8, 41.0, 54.0, 24.9, 199.0, 440.0, 54.9, 646.0, 1446.0, 55.3, 214.0, 456.0, 53.0, 686.0, 1500.0, 54.2], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 669, "tag": "div", "text_raw": "IMBRUVICA U.S. 264 353 ( 25.2 ) 796 1,072 ( 25.8 ) International 545 559 ( 2.5 ) 1,681 1,847 ( 9.0 ) Worldwide 808 911 ( 11.3 ) 2,476 2,918 ( 15.2 ) ZYTIGA / abiraterone acetate U.S. 16 16 ( 2.8 ) 41 54 ( 24.9 ) International 199 440 ( 54.9 ) 646 1,446 ( 55.3 ) Worldwide 214 456 ( 53.0 ) 686 1,500 ( 54.2 ) OTHER ONCOLOGY U.S. 143 37 * 357 104 * International 86 64 34.5 248 220 12.5 Worldwide 229 100 * 605 324 86.5 Pulmonary Hypertension U.S. 680 604 12.6 1,964 1,736 13.1 International 274 247 10.5 835 810 3.0 Worldwide 954 852 12.0 2,798 2,547 9.9 OPSUMIT U.S. 323 289 12.2 924 827 11.8 International 166 152 9.3 512 495 3.5 Worldwide 490 441 11.2 1,437 1,322 8.7 UPTRAVI U.S. 336 283 18.9 978 824 18.7 International 66 50 30.9 185 162 14.1 Worldwide 402 333 20.7 1,163 986 18.0 OTHER PULMONARY HYPERTENSION U.S. 20 33 ( 37.1 ) 61 86 ( 28.4 ) International 42 46 ( 7.5 ) 137 154 ( 10.5 ) Worldwide 63 78 ( 19.8 ) 199 239 ( 16.9 ) Cardiovascular / Metabolism / Other U.S. 763 837 ( 8.8 ) 2,254 2,266 ( 0.5 ) International 194 198 ( 2.1 ) 580 651 ( 10.8 ) Worldwide 957 1,034 ( 7.5 ) 2,834 2,916 ( 2.8 ) XARELTO U.S. 625 689 ( 9.4 ) 1,840 1,806 1.9 International       Worldwide 625 689 ( 9.4 ) 1,840 1,806 1.9 OTHER (2) U.S. 139 147 ( 6.1 ) 414 459 ( 9.9 ) International 194 198 ( 2.1 ) 580 651 ( 10.8 ) Worldwide 332 345 ( 3.8 ) 994 1,110 ( 10.5 ) TOTAL INNOVATIVE MEDICINE U.S. 8,249 7,438 10.9 23,090 21,229 8.8 International 5,644 5,776 ( 2.3 ) 17,947 18,171 ( 1.2 ) Worldwide 13,893 13,214 5.1 41,037 39,400 4.2", "text": "143 37 * 357 104 * International 86 64 34.5 248 220 12.5 Worldwide 229 100 * 605 324 86.5 Pulmonary Hypertension U.S.", "length": 117, "numbers_raw": ["143", "37", "357", "104", "86", "64", "34.5", "248", "220", "12.5", "229", "100", "605", "324", "86.5"], "numbers": [143.0, 37.0, 357.0, 104.0, 86.0, 64.0, 34.5, 248.0, 220.0, 12.5, 229.0, 100.0, 605.0, 324.0, 86.5], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 669, "tag": "div", "text_raw": "IMBRUVICA U.S. 264 353 ( 25.2 ) 796 1,072 ( 25.8 ) International 545 559 ( 2.5 ) 1,681 1,847 ( 9.0 ) Worldwide 808 911 ( 11.3 ) 2,476 2,918 ( 15.2 ) ZYTIGA / abiraterone acetate U.S. 16 16 ( 2.8 ) 41 54 ( 24.9 ) International 199 440 ( 54.9 ) 646 1,446 ( 55.3 ) Worldwide 214 456 ( 53.0 ) 686 1,500 ( 54.2 ) OTHER ONCOLOGY U.S. 143 37 * 357 104 * International 86 64 34.5 248 220 12.5 Worldwide 229 100 * 605 324 86.5 Pulmonary Hypertension U.S. 680 604 12.6 1,964 1,736 13.1 International 274 247 10.5 835 810 3.0 Worldwide 954 852 12.0 2,798 2,547 9.9 OPSUMIT U.S. 323 289 12.2 924 827 11.8 International 166 152 9.3 512 495 3.5 Worldwide 490 441 11.2 1,437 1,322 8.7 UPTRAVI U.S. 336 283 18.9 978 824 18.7 International 66 50 30.9 185 162 14.1 Worldwide 402 333 20.7 1,163 986 18.0 OTHER PULMONARY HYPERTENSION U.S. 20 33 ( 37.1 ) 61 86 ( 28.4 ) International 42 46 ( 7.5 ) 137 154 ( 10.5 ) Worldwide 63 78 ( 19.8 ) 199 239 ( 16.9 ) Cardiovascular / Metabolism / Other U.S. 763 837 ( 8.8 ) 2,254 2,266 ( 0.5 ) International 194 198 ( 2.1 ) 580 651 ( 10.8 ) Worldwide 957 1,034 ( 7.5 ) 2,834 2,916 ( 2.8 ) XARELTO U.S. 625 689 ( 9.4 ) 1,840 1,806 1.9 International       Worldwide 625 689 ( 9.4 ) 1,840 1,806 1.9 OTHER (2) U.S. 139 147 ( 6.1 ) 414 459 ( 9.9 ) International 194 198 ( 2.1 ) 580 651 ( 10.8 ) Worldwide 332 345 ( 3.8 ) 994 1,110 ( 10.5 ) TOTAL INNOVATIVE MEDICINE U.S. 8,249 7,438 10.9 23,090 21,229 8.8 International 5,644 5,776 ( 2.3 ) 17,947 18,171 ( 1.2 ) Worldwide 13,893 13,214 5.1 41,037 39,400 4.2", "text": "680 604 12.6 1,964 1,736 13.1 International 274 247 10.5 835 810 3.0 Worldwide 954 852 12.0 2,798 2,547 9.9 OPSUMIT U.S.", "length": 120, "numbers_raw": ["680", "604", "12.6", "1,964", "1,736", "13.1", "274", "247", "10.5", "835", "810", "3.0", "954", "852", "12.0", "2,798", "2,547", "9.9"], "numbers": [680.0, 604.0, 12.6, 1964.0, 1736.0, 13.1, 274.0, 247.0, 10.5, 835.0, 810.0, 3.0, 954.0, 852.0, 12.0, 2798.0, 2547.0, 9.9], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 669, "tag": "div", "text_raw": "IMBRUVICA U.S. 264 353 ( 25.2 ) 796 1,072 ( 25.8 ) International 545 559 ( 2.5 ) 1,681 1,847 ( 9.0 ) Worldwide 808 911 ( 11.3 ) 2,476 2,918 ( 15.2 ) ZYTIGA / abiraterone acetate U.S. 16 16 ( 2.8 ) 41 54 ( 24.9 ) International 199 440 ( 54.9 ) 646 1,446 ( 55.3 ) Worldwide 214 456 ( 53.0 ) 686 1,500 ( 54.2 ) OTHER ONCOLOGY U.S. 143 37 * 357 104 * International 86 64 34.5 248 220 12.5 Worldwide 229 100 * 605 324 86.5 Pulmonary Hypertension U.S. 680 604 12.6 1,964 1,736 13.1 International 274 247 10.5 835 810 3.0 Worldwide 954 852 12.0 2,798 2,547 9.9 OPSUMIT U.S. 323 289 12.2 924 827 11.8 International 166 152 9.3 512 495 3.5 Worldwide 490 441 11.2 1,437 1,322 8.7 UPTRAVI U.S. 336 283 18.9 978 824 18.7 International 66 50 30.9 185 162 14.1 Worldwide 402 333 20.7 1,163 986 18.0 OTHER PULMONARY HYPERTENSION U.S. 20 33 ( 37.1 ) 61 86 ( 28.4 ) International 42 46 ( 7.5 ) 137 154 ( 10.5 ) Worldwide 63 78 ( 19.8 ) 199 239 ( 16.9 ) Cardiovascular / Metabolism / Other U.S. 763 837 ( 8.8 ) 2,254 2,266 ( 0.5 ) International 194 198 ( 2.1 ) 580 651 ( 10.8 ) Worldwide 957 1,034 ( 7.5 ) 2,834 2,916 ( 2.8 ) XARELTO U.S. 625 689 ( 9.4 ) 1,840 1,806 1.9 International       Worldwide 625 689 ( 9.4 ) 1,840 1,806 1.9 OTHER (2) U.S. 139 147 ( 6.1 ) 414 459 ( 9.9 ) International 194 198 ( 2.1 ) 580 651 ( 10.8 ) Worldwide 332 345 ( 3.8 ) 994 1,110 ( 10.5 ) TOTAL INNOVATIVE MEDICINE U.S. 8,249 7,438 10.9 23,090 21,229 8.8 International 5,644 5,776 ( 2.3 ) 17,947 18,171 ( 1.2 ) Worldwide 13,893 13,214 5.1 41,037 39,400 4.2", "text": "323 289 12.2 924 827 11.8 International 166 152 9.3 512 495 3.5 Worldwide 490 441 11.2 1,437 1,322 8.7 UPTRAVI U.S.", "length": 115, "numbers_raw": ["323", "289", "12.2", "924", "827", "11.8", "166", "152", "9.3", "512", "495", "3.5", "490", "441", "11.2", "1,437", "1,322", "8.7"], "numbers": [323.0, 289.0, 12.2, 924.0, 827.0, 11.8, 166.0, 152.0, 9.3, 512.0, 495.0, 3.5, 490.0, 441.0, 11.2, 1437.0, 1322.0, 8.7], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 669, "tag": "div", "text_raw": "IMBRUVICA U.S. 264 353 ( 25.2 ) 796 1,072 ( 25.8 ) International 545 559 ( 2.5 ) 1,681 1,847 ( 9.0 ) Worldwide 808 911 ( 11.3 ) 2,476 2,918 ( 15.2 ) ZYTIGA / abiraterone acetate U.S. 16 16 ( 2.8 ) 41 54 ( 24.9 ) International 199 440 ( 54.9 ) 646 1,446 ( 55.3 ) Worldwide 214 456 ( 53.0 ) 686 1,500 ( 54.2 ) OTHER ONCOLOGY U.S. 143 37 * 357 104 * International 86 64 34.5 248 220 12.5 Worldwide 229 100 * 605 324 86.5 Pulmonary Hypertension U.S. 680 604 12.6 1,964 1,736 13.1 International 274 247 10.5 835 810 3.0 Worldwide 954 852 12.0 2,798 2,547 9.9 OPSUMIT U.S. 323 289 12.2 924 827 11.8 International 166 152 9.3 512 495 3.5 Worldwide 490 441 11.2 1,437 1,322 8.7 UPTRAVI U.S. 336 283 18.9 978 824 18.7 International 66 50 30.9 185 162 14.1 Worldwide 402 333 20.7 1,163 986 18.0 OTHER PULMONARY HYPERTENSION U.S. 20 33 ( 37.1 ) 61 86 ( 28.4 ) International 42 46 ( 7.5 ) 137 154 ( 10.5 ) Worldwide 63 78 ( 19.8 ) 199 239 ( 16.9 ) Cardiovascular / Metabolism / Other U.S. 763 837 ( 8.8 ) 2,254 2,266 ( 0.5 ) International 194 198 ( 2.1 ) 580 651 ( 10.8 ) Worldwide 957 1,034 ( 7.5 ) 2,834 2,916 ( 2.8 ) XARELTO U.S. 625 689 ( 9.4 ) 1,840 1,806 1.9 International       Worldwide 625 689 ( 9.4 ) 1,840 1,806 1.9 OTHER (2) U.S. 139 147 ( 6.1 ) 414 459 ( 9.9 ) International 194 198 ( 2.1 ) 580 651 ( 10.8 ) Worldwide 332 345 ( 3.8 ) 994 1,110 ( 10.5 ) TOTAL INNOVATIVE MEDICINE U.S. 8,249 7,438 10.9 23,090 21,229 8.8 International 5,644 5,776 ( 2.3 ) 17,947 18,171 ( 1.2 ) Worldwide 13,893 13,214 5.1 41,037 39,400 4.2", "text": "336 283 18.9 978 824 18.7 International 66 50 30.9 185 162 14.1 Worldwide 402 333 20.7 1,163 986 18.0 OTHER PULMONARY HYPERTENSION U.S.", "length": 135, "numbers_raw": ["336", "283", "18.9", "978", "824", "18.7", "66", "50", "30.9", "185", "162", "14.1", "402", "333", "20.7", "1,163", "986", "18.0"], "numbers": [336.0, 283.0, 18.9, 978.0, 824.0, 18.7, 66.0, 50.0, 30.9, 185.0, 162.0, 14.1, 402.0, 333.0, 20.7, 1163.0, 986.0, 18.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 669, "tag": "div", "text_raw": "IMBRUVICA U.S. 264 353 ( 25.2 ) 796 1,072 ( 25.8 ) International 545 559 ( 2.5 ) 1,681 1,847 ( 9.0 ) Worldwide 808 911 ( 11.3 ) 2,476 2,918 ( 15.2 ) ZYTIGA / abiraterone acetate U.S. 16 16 ( 2.8 ) 41 54 ( 24.9 ) International 199 440 ( 54.9 ) 646 1,446 ( 55.3 ) Worldwide 214 456 ( 53.0 ) 686 1,500 ( 54.2 ) OTHER ONCOLOGY U.S. 143 37 * 357 104 * International 86 64 34.5 248 220 12.5 Worldwide 229 100 * 605 324 86.5 Pulmonary Hypertension U.S. 680 604 12.6 1,964 1,736 13.1 International 274 247 10.5 835 810 3.0 Worldwide 954 852 12.0 2,798 2,547 9.9 OPSUMIT U.S. 323 289 12.2 924 827 11.8 International 166 152 9.3 512 495 3.5 Worldwide 490 441 11.2 1,437 1,322 8.7 UPTRAVI U.S. 336 283 18.9 978 824 18.7 International 66 50 30.9 185 162 14.1 Worldwide 402 333 20.7 1,163 986 18.0 OTHER PULMONARY HYPERTENSION U.S. 20 33 ( 37.1 ) 61 86 ( 28.4 ) International 42 46 ( 7.5 ) 137 154 ( 10.5 ) Worldwide 63 78 ( 19.8 ) 199 239 ( 16.9 ) Cardiovascular / Metabolism / Other U.S. 763 837 ( 8.8 ) 2,254 2,266 ( 0.5 ) International 194 198 ( 2.1 ) 580 651 ( 10.8 ) Worldwide 957 1,034 ( 7.5 ) 2,834 2,916 ( 2.8 ) XARELTO U.S. 625 689 ( 9.4 ) 1,840 1,806 1.9 International       Worldwide 625 689 ( 9.4 ) 1,840 1,806 1.9 OTHER (2) U.S. 139 147 ( 6.1 ) 414 459 ( 9.9 ) International 194 198 ( 2.1 ) 580 651 ( 10.8 ) Worldwide 332 345 ( 3.8 ) 994 1,110 ( 10.5 ) TOTAL INNOVATIVE MEDICINE U.S. 8,249 7,438 10.9 23,090 21,229 8.8 International 5,644 5,776 ( 2.3 ) 17,947 18,171 ( 1.2 ) Worldwide 13,893 13,214 5.1 41,037 39,400 4.2", "text": "20 33 ( 37.1 ) 61 86 ( 28.4 ) International 42 46 ( 7.5 ) 137 154 ( 10.5 ) Worldwide 63 78 ( 19.8 ) 199 239 ( 16.9 ) Cardiovascular / Metabolism / Other U.S.", "length": 157, "numbers_raw": ["20", "33", "37.1", "61", "86", "28.4", "42", "46", "7.5", "137", "154", "10.5", "63", "78", "19.8", "199", "239", "16.9"], "numbers": [20.0, 33.0, 37.1, 61.0, 86.0, 28.4, 42.0, 46.0, 7.5, 137.0, 154.0, 10.5, 63.0, 78.0, 19.8, 199.0, 239.0, 16.9], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 669, "tag": "div", "text_raw": "IMBRUVICA U.S. 264 353 ( 25.2 ) 796 1,072 ( 25.8 ) International 545 559 ( 2.5 ) 1,681 1,847 ( 9.0 ) Worldwide 808 911 ( 11.3 ) 2,476 2,918 ( 15.2 ) ZYTIGA / abiraterone acetate U.S. 16 16 ( 2.8 ) 41 54 ( 24.9 ) International 199 440 ( 54.9 ) 646 1,446 ( 55.3 ) Worldwide 214 456 ( 53.0 ) 686 1,500 ( 54.2 ) OTHER ONCOLOGY U.S. 143 37 * 357 104 * International 86 64 34.5 248 220 12.5 Worldwide 229 100 * 605 324 86.5 Pulmonary Hypertension U.S. 680 604 12.6 1,964 1,736 13.1 International 274 247 10.5 835 810 3.0 Worldwide 954 852 12.0 2,798 2,547 9.9 OPSUMIT U.S. 323 289 12.2 924 827 11.8 International 166 152 9.3 512 495 3.5 Worldwide 490 441 11.2 1,437 1,322 8.7 UPTRAVI U.S. 336 283 18.9 978 824 18.7 International 66 50 30.9 185 162 14.1 Worldwide 402 333 20.7 1,163 986 18.0 OTHER PULMONARY HYPERTENSION U.S. 20 33 ( 37.1 ) 61 86 ( 28.4 ) International 42 46 ( 7.5 ) 137 154 ( 10.5 ) Worldwide 63 78 ( 19.8 ) 199 239 ( 16.9 ) Cardiovascular / Metabolism / Other U.S. 763 837 ( 8.8 ) 2,254 2,266 ( 0.5 ) International 194 198 ( 2.1 ) 580 651 ( 10.8 ) Worldwide 957 1,034 ( 7.5 ) 2,834 2,916 ( 2.8 ) XARELTO U.S. 625 689 ( 9.4 ) 1,840 1,806 1.9 International       Worldwide 625 689 ( 9.4 ) 1,840 1,806 1.9 OTHER (2) U.S. 139 147 ( 6.1 ) 414 459 ( 9.9 ) International 194 198 ( 2.1 ) 580 651 ( 10.8 ) Worldwide 332 345 ( 3.8 ) 994 1,110 ( 10.5 ) TOTAL INNOVATIVE MEDICINE U.S. 8,249 7,438 10.9 23,090 21,229 8.8 International 5,644 5,776 ( 2.3 ) 17,947 18,171 ( 1.2 ) Worldwide 13,893 13,214 5.1 41,037 39,400 4.2", "text": "763 837 ( 8.8 ) 2,254 2,266 ( 0.5 ) International 194 198 ( 2.1 ) 580 651 ( 10.8 ) Worldwide 957 1,034 ( 7.5 ) 2,834 2,916 ( 2.8 ) XARELTO U.S.", "length": 143, "numbers_raw": ["763", "837", "8.8", "2,254", "2,266", "0.5", "194", "198", "2.1", "580", "651", "10.8", "957", "1,034", "7.5", "2,834", "2,916", "2.8"], "numbers": [763.0, 837.0, 8.8, 2254.0, 2266.0, 0.5, 194.0, 198.0, 2.1, 580.0, 651.0, 10.8, 957.0, 1034.0, 7.5, 2834.0, 2916.0, 2.8], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 669, "tag": "div", "text_raw": "IMBRUVICA U.S. 264 353 ( 25.2 ) 796 1,072 ( 25.8 ) International 545 559 ( 2.5 ) 1,681 1,847 ( 9.0 ) Worldwide 808 911 ( 11.3 ) 2,476 2,918 ( 15.2 ) ZYTIGA / abiraterone acetate U.S. 16 16 ( 2.8 ) 41 54 ( 24.9 ) International 199 440 ( 54.9 ) 646 1,446 ( 55.3 ) Worldwide 214 456 ( 53.0 ) 686 1,500 ( 54.2 ) OTHER ONCOLOGY U.S. 143 37 * 357 104 * International 86 64 34.5 248 220 12.5 Worldwide 229 100 * 605 324 86.5 Pulmonary Hypertension U.S. 680 604 12.6 1,964 1,736 13.1 International 274 247 10.5 835 810 3.0 Worldwide 954 852 12.0 2,798 2,547 9.9 OPSUMIT U.S. 323 289 12.2 924 827 11.8 International 166 152 9.3 512 495 3.5 Worldwide 490 441 11.2 1,437 1,322 8.7 UPTRAVI U.S. 336 283 18.9 978 824 18.7 International 66 50 30.9 185 162 14.1 Worldwide 402 333 20.7 1,163 986 18.0 OTHER PULMONARY HYPERTENSION U.S. 20 33 ( 37.1 ) 61 86 ( 28.4 ) International 42 46 ( 7.5 ) 137 154 ( 10.5 ) Worldwide 63 78 ( 19.8 ) 199 239 ( 16.9 ) Cardiovascular / Metabolism / Other U.S. 763 837 ( 8.8 ) 2,254 2,266 ( 0.5 ) International 194 198 ( 2.1 ) 580 651 ( 10.8 ) Worldwide 957 1,034 ( 7.5 ) 2,834 2,916 ( 2.8 ) XARELTO U.S. 625 689 ( 9.4 ) 1,840 1,806 1.9 International       Worldwide 625 689 ( 9.4 ) 1,840 1,806 1.9 OTHER (2) U.S. 139 147 ( 6.1 ) 414 459 ( 9.9 ) International 194 198 ( 2.1 ) 580 651 ( 10.8 ) Worldwide 332 345 ( 3.8 ) 994 1,110 ( 10.5 ) TOTAL INNOVATIVE MEDICINE U.S. 8,249 7,438 10.9 23,090 21,229 8.8 International 5,644 5,776 ( 2.3 ) 17,947 18,171 ( 1.2 ) Worldwide 13,893 13,214 5.1 41,037 39,400 4.2", "text": "625 689 ( 9.4 ) 1,840 1,806 1.9 International       Worldwide 625 689 ( 9.4 ) 1,840 1,806 1.9 OTHER (2) U.S.", "length": 114, "numbers_raw": ["625", "689", "9.4", "1,840", "1,806", "1.9", "625", "689", "9.4", "1,840", "1,806", "1.9", "2"], "numbers": [625.0, 689.0, 9.4, 1840.0, 1806.0, 1.9, 625.0, 689.0, 9.4, 1840.0, 1806.0, 1.9, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 669, "tag": "div", "text_raw": "IMBRUVICA U.S. 264 353 ( 25.2 ) 796 1,072 ( 25.8 ) International 545 559 ( 2.5 ) 1,681 1,847 ( 9.0 ) Worldwide 808 911 ( 11.3 ) 2,476 2,918 ( 15.2 ) ZYTIGA / abiraterone acetate U.S. 16 16 ( 2.8 ) 41 54 ( 24.9 ) International 199 440 ( 54.9 ) 646 1,446 ( 55.3 ) Worldwide 214 456 ( 53.0 ) 686 1,500 ( 54.2 ) OTHER ONCOLOGY U.S. 143 37 * 357 104 * International 86 64 34.5 248 220 12.5 Worldwide 229 100 * 605 324 86.5 Pulmonary Hypertension U.S. 680 604 12.6 1,964 1,736 13.1 International 274 247 10.5 835 810 3.0 Worldwide 954 852 12.0 2,798 2,547 9.9 OPSUMIT U.S. 323 289 12.2 924 827 11.8 International 166 152 9.3 512 495 3.5 Worldwide 490 441 11.2 1,437 1,322 8.7 UPTRAVI U.S. 336 283 18.9 978 824 18.7 International 66 50 30.9 185 162 14.1 Worldwide 402 333 20.7 1,163 986 18.0 OTHER PULMONARY HYPERTENSION U.S. 20 33 ( 37.1 ) 61 86 ( 28.4 ) International 42 46 ( 7.5 ) 137 154 ( 10.5 ) Worldwide 63 78 ( 19.8 ) 199 239 ( 16.9 ) Cardiovascular / Metabolism / Other U.S. 763 837 ( 8.8 ) 2,254 2,266 ( 0.5 ) International 194 198 ( 2.1 ) 580 651 ( 10.8 ) Worldwide 957 1,034 ( 7.5 ) 2,834 2,916 ( 2.8 ) XARELTO U.S. 625 689 ( 9.4 ) 1,840 1,806 1.9 International       Worldwide 625 689 ( 9.4 ) 1,840 1,806 1.9 OTHER (2) U.S. 139 147 ( 6.1 ) 414 459 ( 9.9 ) International 194 198 ( 2.1 ) 580 651 ( 10.8 ) Worldwide 332 345 ( 3.8 ) 994 1,110 ( 10.5 ) TOTAL INNOVATIVE MEDICINE U.S. 8,249 7,438 10.9 23,090 21,229 8.8 International 5,644 5,776 ( 2.3 ) 17,947 18,171 ( 1.2 ) Worldwide 13,893 13,214 5.1 41,037 39,400 4.2", "text": "139 147 ( 6.1 ) 414 459 ( 9.9 ) International 194 198 ( 2.1 ) 580 651 ( 10.8 ) Worldwide 332 345 ( 3.8 ) 994 1,110 ( 10.5 ) TOTAL INNOVATIVE MEDICINE U.S.", "length": 154, "numbers_raw": ["139", "147", "6.1", "414", "459", "9.9", "194", "198", "2.1", "580", "651", "10.8", "332", "345", "3.8", "994", "1,110", "10.5"], "numbers": [139.0, 147.0, 6.1, 414.0, 459.0, 9.9, 194.0, 198.0, 2.1, 580.0, 651.0, 10.8, 332.0, 345.0, 3.8, 994.0, 1110.0, 10.5], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 669, "tag": "div", "text_raw": "IMBRUVICA U.S. 264 353 ( 25.2 ) 796 1,072 ( 25.8 ) International 545 559 ( 2.5 ) 1,681 1,847 ( 9.0 ) Worldwide 808 911 ( 11.3 ) 2,476 2,918 ( 15.2 ) ZYTIGA / abiraterone acetate U.S. 16 16 ( 2.8 ) 41 54 ( 24.9 ) International 199 440 ( 54.9 ) 646 1,446 ( 55.3 ) Worldwide 214 456 ( 53.0 ) 686 1,500 ( 54.2 ) OTHER ONCOLOGY U.S. 143 37 * 357 104 * International 86 64 34.5 248 220 12.5 Worldwide 229 100 * 605 324 86.5 Pulmonary Hypertension U.S. 680 604 12.6 1,964 1,736 13.1 International 274 247 10.5 835 810 3.0 Worldwide 954 852 12.0 2,798 2,547 9.9 OPSUMIT U.S. 323 289 12.2 924 827 11.8 International 166 152 9.3 512 495 3.5 Worldwide 490 441 11.2 1,437 1,322 8.7 UPTRAVI U.S. 336 283 18.9 978 824 18.7 International 66 50 30.9 185 162 14.1 Worldwide 402 333 20.7 1,163 986 18.0 OTHER PULMONARY HYPERTENSION U.S. 20 33 ( 37.1 ) 61 86 ( 28.4 ) International 42 46 ( 7.5 ) 137 154 ( 10.5 ) Worldwide 63 78 ( 19.8 ) 199 239 ( 16.9 ) Cardiovascular / Metabolism / Other U.S. 763 837 ( 8.8 ) 2,254 2,266 ( 0.5 ) International 194 198 ( 2.1 ) 580 651 ( 10.8 ) Worldwide 957 1,034 ( 7.5 ) 2,834 2,916 ( 2.8 ) XARELTO U.S. 625 689 ( 9.4 ) 1,840 1,806 1.9 International       Worldwide 625 689 ( 9.4 ) 1,840 1,806 1.9 OTHER (2) U.S. 139 147 ( 6.1 ) 414 459 ( 9.9 ) International 194 198 ( 2.1 ) 580 651 ( 10.8 ) Worldwide 332 345 ( 3.8 ) 994 1,110 ( 10.5 ) TOTAL INNOVATIVE MEDICINE U.S. 8,249 7,438 10.9 23,090 21,229 8.8 International 5,644 5,776 ( 2.3 ) 17,947 18,171 ( 1.2 ) Worldwide 13,893 13,214 5.1 41,037 39,400 4.2", "text": "8,249 7,438 10.9 23,090 21,229 8.8 International 5,644 5,776 ( 2.3 ) 17,947 18,171 ( 1.2 ) Worldwide 13,893 13,214 5.1 41,037 39,400 4.2", "length": 136, "numbers_raw": ["8,249", "7,438", "10.9", "23,090", "21,229", "8.8", "5,644", "5,776", "2.3", "17,947", "18,171", "1.2", "13,893", "13,214", "5.1", "41,037", "39,400", "4.2"], "numbers": [8249.0, 7438.0, 10.9, 23090.0, 21229.0, 8.8, 5644.0, 5776.0, 2.3, 17947.0, 18171.0, 1.2, 13893.0, 13214.0, 5.1, 41037.0, 39400.0, 4.2], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 677, "tag": "div", "text_raw": "OTHER (2)", "text": "OTHER (2)", "length": 9, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 678, "tag": "div", "text_raw": "24", "text": "24", "length": 2, "numbers_raw": ["24"], "numbers": [24.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 679, "tag": "div", "text_raw": "24", "text": "24", "length": 2, "numbers_raw": ["24"], "numbers": [24.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 680, "tag": "div", "text_raw": "24", "text": "24", "length": 2, "numbers_raw": ["24"], "numbers": [24.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 683, "tag": "div", "text_raw": "MEDTECH Interventional Solutions U.S. 891 547 63.0 2,662 1,566 70.0 International 667 513 29.9 2,019 1,636 23.4 Worldwide 1,558 1,060 47.0 4,681 3,202 46.2 ELECTROPHYSIOLOGY U.S. 611 520 17.6 1,791 1,489 20.3 International 549 453 21.2 1,658 1,454 14.0 Worldwide 1,161 973 19.3 3,449 2,943 17.2 ABIOMED (3) U.S. 254  * 790  * International 57  * 176  * Worldwide 311  * 966  * OTHER INTERVENTIONAL SOLUTIONS U.S. 26 27 ( 3.2 ) 81 77 5.9 International 61 60 1.0 186 181 2.2 Worldwide 87 87 ( 0.3 ) 267 258 3.3 Orthopaedics U.S. 1,349 1,309 3.1 4,100 3,936 4.2 International 815 785 3.9 2,574 2,504 2.8 Worldwide 2,164 2,095 3.4 6,674 6,440 3.6 HIPS U.S. 239 228 4.9 730 693 5.4 International 136 124 9.3 432 437 ( 1.0 ) Worldwide 375 352 6.5 1,162 1,129 2.9 KNEES U.S. 207 203 2.3 654 620 5.6 International 131 115 14.6 415 386 7.7 Worldwide 338 317 6.7 1,069 1,005 6.4 TRAUMA U.S. 488 473 3.2 1,462 1,412 3.5 International 253 244 4.2 775 749 3.5 Worldwide 742 717 3.5 2,238 2,161 3.5 SPINE, SPORTS & OTHER U.S. 415 406 2.3 1,254 1,211 3.5 International 295 303 ( 2.6 ) 952 933 2.0 Worldwide 710 708 0.2 2,205 2,144 2.8 Surgery U.S. 994 984 1.1 2,984 2,897 3.0 International 1,483 1,439 3.1 4,522 4,410 2.6 Worldwide 2,479 2,422 2.3 7,507 7,306 2.7 ADVANCED U.S. 455 457 ( 0.4 ) 1,365 1,328 2.8 International 709 701 1.0 2,139 2,132 0.3 Worldwide 1,164 1,158 0.5 3,504 3,460 1.3 GENERAL U.S. 540 527 2.4 1,619 1,569 3.2", "text": "MEDTECH Interventional Solutions U.S.", "length": 37, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 683, "tag": "div", "text_raw": "MEDTECH Interventional Solutions U.S. 891 547 63.0 2,662 1,566 70.0 International 667 513 29.9 2,019 1,636 23.4 Worldwide 1,558 1,060 47.0 4,681 3,202 46.2 ELECTROPHYSIOLOGY U.S. 611 520 17.6 1,791 1,489 20.3 International 549 453 21.2 1,658 1,454 14.0 Worldwide 1,161 973 19.3 3,449 2,943 17.2 ABIOMED (3) U.S. 254  * 790  * International 57  * 176  * Worldwide 311  * 966  * OTHER INTERVENTIONAL SOLUTIONS U.S. 26 27 ( 3.2 ) 81 77 5.9 International 61 60 1.0 186 181 2.2 Worldwide 87 87 ( 0.3 ) 267 258 3.3 Orthopaedics U.S. 1,349 1,309 3.1 4,100 3,936 4.2 International 815 785 3.9 2,574 2,504 2.8 Worldwide 2,164 2,095 3.4 6,674 6,440 3.6 HIPS U.S. 239 228 4.9 730 693 5.4 International 136 124 9.3 432 437 ( 1.0 ) Worldwide 375 352 6.5 1,162 1,129 2.9 KNEES U.S. 207 203 2.3 654 620 5.6 International 131 115 14.6 415 386 7.7 Worldwide 338 317 6.7 1,069 1,005 6.4 TRAUMA U.S. 488 473 3.2 1,462 1,412 3.5 International 253 244 4.2 775 749 3.5 Worldwide 742 717 3.5 2,238 2,161 3.5 SPINE, SPORTS & OTHER U.S. 415 406 2.3 1,254 1,211 3.5 International 295 303 ( 2.6 ) 952 933 2.0 Worldwide 710 708 0.2 2,205 2,144 2.8 Surgery U.S. 994 984 1.1 2,984 2,897 3.0 International 1,483 1,439 3.1 4,522 4,410 2.6 Worldwide 2,479 2,422 2.3 7,507 7,306 2.7 ADVANCED U.S. 455 457 ( 0.4 ) 1,365 1,328 2.8 International 709 701 1.0 2,139 2,132 0.3 Worldwide 1,164 1,158 0.5 3,504 3,460 1.3 GENERAL U.S. 540 527 2.4 1,619 1,569 3.2", "text": "891 547 63.0 2,662 1,566 70.0 International 667 513 29.9 2,019 1,636 23.4 Worldwide 1,558 1,060 47.0 4,681 3,202 46.2 ELECTROPHYSIOLOGY U.S.", "length": 140, "numbers_raw": ["891", "547", "63.0", "2,662", "1,566", "70.0", "667", "513", "29.9", "2,019", "1,636", "23.4", "1,558", "1,060", "47.0", "4,681", "3,202", "46.2"], "numbers": [891.0, 547.0, 63.0, 2662.0, 1566.0, 70.0, 667.0, 513.0, 29.9, 2019.0, 1636.0, 23.4, 1558.0, 1060.0, 47.0, 4681.0, 3202.0, 46.2], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 683, "tag": "div", "text_raw": "MEDTECH Interventional Solutions U.S. 891 547 63.0 2,662 1,566 70.0 International 667 513 29.9 2,019 1,636 23.4 Worldwide 1,558 1,060 47.0 4,681 3,202 46.2 ELECTROPHYSIOLOGY U.S. 611 520 17.6 1,791 1,489 20.3 International 549 453 21.2 1,658 1,454 14.0 Worldwide 1,161 973 19.3 3,449 2,943 17.2 ABIOMED (3) U.S. 254  * 790  * International 57  * 176  * Worldwide 311  * 966  * OTHER INTERVENTIONAL SOLUTIONS U.S. 26 27 ( 3.2 ) 81 77 5.9 International 61 60 1.0 186 181 2.2 Worldwide 87 87 ( 0.3 ) 267 258 3.3 Orthopaedics U.S. 1,349 1,309 3.1 4,100 3,936 4.2 International 815 785 3.9 2,574 2,504 2.8 Worldwide 2,164 2,095 3.4 6,674 6,440 3.6 HIPS U.S. 239 228 4.9 730 693 5.4 International 136 124 9.3 432 437 ( 1.0 ) Worldwide 375 352 6.5 1,162 1,129 2.9 KNEES U.S. 207 203 2.3 654 620 5.6 International 131 115 14.6 415 386 7.7 Worldwide 338 317 6.7 1,069 1,005 6.4 TRAUMA U.S. 488 473 3.2 1,462 1,412 3.5 International 253 244 4.2 775 749 3.5 Worldwide 742 717 3.5 2,238 2,161 3.5 SPINE, SPORTS & OTHER U.S. 415 406 2.3 1,254 1,211 3.5 International 295 303 ( 2.6 ) 952 933 2.0 Worldwide 710 708 0.2 2,205 2,144 2.8 Surgery U.S. 994 984 1.1 2,984 2,897 3.0 International 1,483 1,439 3.1 4,522 4,410 2.6 Worldwide 2,479 2,422 2.3 7,507 7,306 2.7 ADVANCED U.S. 455 457 ( 0.4 ) 1,365 1,328 2.8 International 709 701 1.0 2,139 2,132 0.3 Worldwide 1,164 1,158 0.5 3,504 3,460 1.3 GENERAL U.S. 540 527 2.4 1,619 1,569 3.2", "text": "611 520 17.6 1,791 1,489 20.3 International 549 453 21.2 1,658 1,454 14.0 Worldwide 1,161 973 19.3 3,449 2,943 17.2 ABIOMED (3) U.S.", "length": 132, "numbers_raw": ["611", "520", "17.6", "1,791", "1,489", "20.3", "549", "453", "21.2", "1,658", "1,454", "14.0", "1,161", "973", "19.3", "3,449", "2,943", "17.2", "3"], "numbers": [611.0, 520.0, 17.6, 1791.0, 1489.0, 20.3, 549.0, 453.0, 21.2, 1658.0, 1454.0, 14.0, 1161.0, 973.0, 19.3, 3449.0, 2943.0, 17.2, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 683, "tag": "div", "text_raw": "MEDTECH Interventional Solutions U.S. 891 547 63.0 2,662 1,566 70.0 International 667 513 29.9 2,019 1,636 23.4 Worldwide 1,558 1,060 47.0 4,681 3,202 46.2 ELECTROPHYSIOLOGY U.S. 611 520 17.6 1,791 1,489 20.3 International 549 453 21.2 1,658 1,454 14.0 Worldwide 1,161 973 19.3 3,449 2,943 17.2 ABIOMED (3) U.S. 254  * 790  * International 57  * 176  * Worldwide 311  * 966  * OTHER INTERVENTIONAL SOLUTIONS U.S. 26 27 ( 3.2 ) 81 77 5.9 International 61 60 1.0 186 181 2.2 Worldwide 87 87 ( 0.3 ) 267 258 3.3 Orthopaedics U.S. 1,349 1,309 3.1 4,100 3,936 4.2 International 815 785 3.9 2,574 2,504 2.8 Worldwide 2,164 2,095 3.4 6,674 6,440 3.6 HIPS U.S. 239 228 4.9 730 693 5.4 International 136 124 9.3 432 437 ( 1.0 ) Worldwide 375 352 6.5 1,162 1,129 2.9 KNEES U.S. 207 203 2.3 654 620 5.6 International 131 115 14.6 415 386 7.7 Worldwide 338 317 6.7 1,069 1,005 6.4 TRAUMA U.S. 488 473 3.2 1,462 1,412 3.5 International 253 244 4.2 775 749 3.5 Worldwide 742 717 3.5 2,238 2,161 3.5 SPINE, SPORTS & OTHER U.S. 415 406 2.3 1,254 1,211 3.5 International 295 303 ( 2.6 ) 952 933 2.0 Worldwide 710 708 0.2 2,205 2,144 2.8 Surgery U.S. 994 984 1.1 2,984 2,897 3.0 International 1,483 1,439 3.1 4,522 4,410 2.6 Worldwide 2,479 2,422 2.3 7,507 7,306 2.7 ADVANCED U.S. 455 457 ( 0.4 ) 1,365 1,328 2.8 International 709 701 1.0 2,139 2,132 0.3 Worldwide 1,164 1,158 0.5 3,504 3,460 1.3 GENERAL U.S. 540 527 2.4 1,619 1,569 3.2", "text": "254  * 790  * International 57  * 176  * Worldwide 311  * 966  * OTHER INTERVENTIONAL SOLUTIONS U.S.", "length": 106, "numbers_raw": ["254", "790", "57", "176", "311", "966"], "numbers": [254.0, 790.0, 57.0, 176.0, 311.0, 966.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 683, "tag": "div", "text_raw": "MEDTECH Interventional Solutions U.S. 891 547 63.0 2,662 1,566 70.0 International 667 513 29.9 2,019 1,636 23.4 Worldwide 1,558 1,060 47.0 4,681 3,202 46.2 ELECTROPHYSIOLOGY U.S. 611 520 17.6 1,791 1,489 20.3 International 549 453 21.2 1,658 1,454 14.0 Worldwide 1,161 973 19.3 3,449 2,943 17.2 ABIOMED (3) U.S. 254  * 790  * International 57  * 176  * Worldwide 311  * 966  * OTHER INTERVENTIONAL SOLUTIONS U.S. 26 27 ( 3.2 ) 81 77 5.9 International 61 60 1.0 186 181 2.2 Worldwide 87 87 ( 0.3 ) 267 258 3.3 Orthopaedics U.S. 1,349 1,309 3.1 4,100 3,936 4.2 International 815 785 3.9 2,574 2,504 2.8 Worldwide 2,164 2,095 3.4 6,674 6,440 3.6 HIPS U.S. 239 228 4.9 730 693 5.4 International 136 124 9.3 432 437 ( 1.0 ) Worldwide 375 352 6.5 1,162 1,129 2.9 KNEES U.S. 207 203 2.3 654 620 5.6 International 131 115 14.6 415 386 7.7 Worldwide 338 317 6.7 1,069 1,005 6.4 TRAUMA U.S. 488 473 3.2 1,462 1,412 3.5 International 253 244 4.2 775 749 3.5 Worldwide 742 717 3.5 2,238 2,161 3.5 SPINE, SPORTS & OTHER U.S. 415 406 2.3 1,254 1,211 3.5 International 295 303 ( 2.6 ) 952 933 2.0 Worldwide 710 708 0.2 2,205 2,144 2.8 Surgery U.S. 994 984 1.1 2,984 2,897 3.0 International 1,483 1,439 3.1 4,522 4,410 2.6 Worldwide 2,479 2,422 2.3 7,507 7,306 2.7 ADVANCED U.S. 455 457 ( 0.4 ) 1,365 1,328 2.8 International 709 701 1.0 2,139 2,132 0.3 Worldwide 1,164 1,158 0.5 3,504 3,460 1.3 GENERAL U.S. 540 527 2.4 1,619 1,569 3.2", "text": "26 27 ( 3.2 ) 81 77 5.9 International 61 60 1.0 186 181 2.2 Worldwide 87 87 ( 0.3 ) 267 258 3.3 Orthopaedics U.S.", "length": 113, "numbers_raw": ["26", "27", "3.2", "81", "77", "5.9", "61", "60", "1.0", "186", "181", "2.2", "87", "87", "0.3", "267", "258", "3.3"], "numbers": [26.0, 27.0, 3.2, 81.0, 77.0, 5.9, 61.0, 60.0, 1.0, 186.0, 181.0, 2.2, 87.0, 87.0, 0.3, 267.0, 258.0, 3.3], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 683, "tag": "div", "text_raw": "MEDTECH Interventional Solutions U.S. 891 547 63.0 2,662 1,566 70.0 International 667 513 29.9 2,019 1,636 23.4 Worldwide 1,558 1,060 47.0 4,681 3,202 46.2 ELECTROPHYSIOLOGY U.S. 611 520 17.6 1,791 1,489 20.3 International 549 453 21.2 1,658 1,454 14.0 Worldwide 1,161 973 19.3 3,449 2,943 17.2 ABIOMED (3) U.S. 254  * 790  * International 57  * 176  * Worldwide 311  * 966  * OTHER INTERVENTIONAL SOLUTIONS U.S. 26 27 ( 3.2 ) 81 77 5.9 International 61 60 1.0 186 181 2.2 Worldwide 87 87 ( 0.3 ) 267 258 3.3 Orthopaedics U.S. 1,349 1,309 3.1 4,100 3,936 4.2 International 815 785 3.9 2,574 2,504 2.8 Worldwide 2,164 2,095 3.4 6,674 6,440 3.6 HIPS U.S. 239 228 4.9 730 693 5.4 International 136 124 9.3 432 437 ( 1.0 ) Worldwide 375 352 6.5 1,162 1,129 2.9 KNEES U.S. 207 203 2.3 654 620 5.6 International 131 115 14.6 415 386 7.7 Worldwide 338 317 6.7 1,069 1,005 6.4 TRAUMA U.S. 488 473 3.2 1,462 1,412 3.5 International 253 244 4.2 775 749 3.5 Worldwide 742 717 3.5 2,238 2,161 3.5 SPINE, SPORTS & OTHER U.S. 415 406 2.3 1,254 1,211 3.5 International 295 303 ( 2.6 ) 952 933 2.0 Worldwide 710 708 0.2 2,205 2,144 2.8 Surgery U.S. 994 984 1.1 2,984 2,897 3.0 International 1,483 1,439 3.1 4,522 4,410 2.6 Worldwide 2,479 2,422 2.3 7,507 7,306 2.7 ADVANCED U.S. 455 457 ( 0.4 ) 1,365 1,328 2.8 International 709 701 1.0 2,139 2,132 0.3 Worldwide 1,164 1,158 0.5 3,504 3,460 1.3 GENERAL U.S. 540 527 2.4 1,619 1,569 3.2", "text": "1,349 1,309 3.1 4,100 3,936 4.2 International 815 785 3.9 2,574 2,504 2.8 Worldwide 2,164 2,095 3.4 6,674 6,440 3.6 HIPS U.S.", "length": 125, "numbers_raw": ["1,349", "1,309", "3.1", "4,100", "3,936", "4.2", "815", "785", "3.9", "2,574", "2,504", "2.8", "2,164", "2,095", "3.4", "6,674", "6,440", "3.6"], "numbers": [1349.0, 1309.0, 3.1, 4100.0, 3936.0, 4.2, 815.0, 785.0, 3.9, 2574.0, 2504.0, 2.8, 2164.0, 2095.0, 3.4, 6674.0, 6440.0, 3.6], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 683, "tag": "div", "text_raw": "MEDTECH Interventional Solutions U.S. 891 547 63.0 2,662 1,566 70.0 International 667 513 29.9 2,019 1,636 23.4 Worldwide 1,558 1,060 47.0 4,681 3,202 46.2 ELECTROPHYSIOLOGY U.S. 611 520 17.6 1,791 1,489 20.3 International 549 453 21.2 1,658 1,454 14.0 Worldwide 1,161 973 19.3 3,449 2,943 17.2 ABIOMED (3) U.S. 254  * 790  * International 57  * 176  * Worldwide 311  * 966  * OTHER INTERVENTIONAL SOLUTIONS U.S. 26 27 ( 3.2 ) 81 77 5.9 International 61 60 1.0 186 181 2.2 Worldwide 87 87 ( 0.3 ) 267 258 3.3 Orthopaedics U.S. 1,349 1,309 3.1 4,100 3,936 4.2 International 815 785 3.9 2,574 2,504 2.8 Worldwide 2,164 2,095 3.4 6,674 6,440 3.6 HIPS U.S. 239 228 4.9 730 693 5.4 International 136 124 9.3 432 437 ( 1.0 ) Worldwide 375 352 6.5 1,162 1,129 2.9 KNEES U.S. 207 203 2.3 654 620 5.6 International 131 115 14.6 415 386 7.7 Worldwide 338 317 6.7 1,069 1,005 6.4 TRAUMA U.S. 488 473 3.2 1,462 1,412 3.5 International 253 244 4.2 775 749 3.5 Worldwide 742 717 3.5 2,238 2,161 3.5 SPINE, SPORTS & OTHER U.S. 415 406 2.3 1,254 1,211 3.5 International 295 303 ( 2.6 ) 952 933 2.0 Worldwide 710 708 0.2 2,205 2,144 2.8 Surgery U.S. 994 984 1.1 2,984 2,897 3.0 International 1,483 1,439 3.1 4,522 4,410 2.6 Worldwide 2,479 2,422 2.3 7,507 7,306 2.7 ADVANCED U.S. 455 457 ( 0.4 ) 1,365 1,328 2.8 International 709 701 1.0 2,139 2,132 0.3 Worldwide 1,164 1,158 0.5 3,504 3,460 1.3 GENERAL U.S. 540 527 2.4 1,619 1,569 3.2", "text": "239 228 4.9 730 693 5.4 International 136 124 9.3 432 437 ( 1.0 ) Worldwide 375 352 6.5 1,162 1,129 2.9 KNEES U.S.", "length": 114, "numbers_raw": ["239", "228", "4.9", "730", "693", "5.4", "136", "124", "9.3", "432", "437", "1.0", "375", "352", "6.5", "1,162", "1,129", "2.9 K"], "numbers": [239.0, 228.0, 4.9, 730.0, 693.0, 5.4, 136.0, 124.0, 9.3, 432.0, 437.0, 1.0, 375.0, 352.0, 6.5, 1162.0, 1129.0, 2900.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 683, "tag": "div", "text_raw": "MEDTECH Interventional Solutions U.S. 891 547 63.0 2,662 1,566 70.0 International 667 513 29.9 2,019 1,636 23.4 Worldwide 1,558 1,060 47.0 4,681 3,202 46.2 ELECTROPHYSIOLOGY U.S. 611 520 17.6 1,791 1,489 20.3 International 549 453 21.2 1,658 1,454 14.0 Worldwide 1,161 973 19.3 3,449 2,943 17.2 ABIOMED (3) U.S. 254  * 790  * International 57  * 176  * Worldwide 311  * 966  * OTHER INTERVENTIONAL SOLUTIONS U.S. 26 27 ( 3.2 ) 81 77 5.9 International 61 60 1.0 186 181 2.2 Worldwide 87 87 ( 0.3 ) 267 258 3.3 Orthopaedics U.S. 1,349 1,309 3.1 4,100 3,936 4.2 International 815 785 3.9 2,574 2,504 2.8 Worldwide 2,164 2,095 3.4 6,674 6,440 3.6 HIPS U.S. 239 228 4.9 730 693 5.4 International 136 124 9.3 432 437 ( 1.0 ) Worldwide 375 352 6.5 1,162 1,129 2.9 KNEES U.S. 207 203 2.3 654 620 5.6 International 131 115 14.6 415 386 7.7 Worldwide 338 317 6.7 1,069 1,005 6.4 TRAUMA U.S. 488 473 3.2 1,462 1,412 3.5 International 253 244 4.2 775 749 3.5 Worldwide 742 717 3.5 2,238 2,161 3.5 SPINE, SPORTS & OTHER U.S. 415 406 2.3 1,254 1,211 3.5 International 295 303 ( 2.6 ) 952 933 2.0 Worldwide 710 708 0.2 2,205 2,144 2.8 Surgery U.S. 994 984 1.1 2,984 2,897 3.0 International 1,483 1,439 3.1 4,522 4,410 2.6 Worldwide 2,479 2,422 2.3 7,507 7,306 2.7 ADVANCED U.S. 455 457 ( 0.4 ) 1,365 1,328 2.8 International 709 701 1.0 2,139 2,132 0.3 Worldwide 1,164 1,158 0.5 3,504 3,460 1.3 GENERAL U.S. 540 527 2.4 1,619 1,569 3.2", "text": "207 203 2.3 654 620 5.6 International 131 115 14.6 415 386 7.7 Worldwide 338 317 6.7 1,069 1,005 6.4 TRAUMA U.S.", "length": 112, "numbers_raw": ["207", "203", "2.3", "654", "620", "5.6", "131", "115", "14.6", "415", "386", "7.7", "338", "317", "6.7", "1,069", "1,005", "6.4"], "numbers": [207.0, 203.0, 2.3, 654.0, 620.0, 5.6, 131.0, 115.0, 14.6, 415.0, 386.0, 7.7, 338.0, 317.0, 6.7, 1069.0, 1005.0, 6.4], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 683, "tag": "div", "text_raw": "MEDTECH Interventional Solutions U.S. 891 547 63.0 2,662 1,566 70.0 International 667 513 29.9 2,019 1,636 23.4 Worldwide 1,558 1,060 47.0 4,681 3,202 46.2 ELECTROPHYSIOLOGY U.S. 611 520 17.6 1,791 1,489 20.3 International 549 453 21.2 1,658 1,454 14.0 Worldwide 1,161 973 19.3 3,449 2,943 17.2 ABIOMED (3) U.S. 254  * 790  * International 57  * 176  * Worldwide 311  * 966  * OTHER INTERVENTIONAL SOLUTIONS U.S. 26 27 ( 3.2 ) 81 77 5.9 International 61 60 1.0 186 181 2.2 Worldwide 87 87 ( 0.3 ) 267 258 3.3 Orthopaedics U.S. 1,349 1,309 3.1 4,100 3,936 4.2 International 815 785 3.9 2,574 2,504 2.8 Worldwide 2,164 2,095 3.4 6,674 6,440 3.6 HIPS U.S. 239 228 4.9 730 693 5.4 International 136 124 9.3 432 437 ( 1.0 ) Worldwide 375 352 6.5 1,162 1,129 2.9 KNEES U.S. 207 203 2.3 654 620 5.6 International 131 115 14.6 415 386 7.7 Worldwide 338 317 6.7 1,069 1,005 6.4 TRAUMA U.S. 488 473 3.2 1,462 1,412 3.5 International 253 244 4.2 775 749 3.5 Worldwide 742 717 3.5 2,238 2,161 3.5 SPINE, SPORTS & OTHER U.S. 415 406 2.3 1,254 1,211 3.5 International 295 303 ( 2.6 ) 952 933 2.0 Worldwide 710 708 0.2 2,205 2,144 2.8 Surgery U.S. 994 984 1.1 2,984 2,897 3.0 International 1,483 1,439 3.1 4,522 4,410 2.6 Worldwide 2,479 2,422 2.3 7,507 7,306 2.7 ADVANCED U.S. 455 457 ( 0.4 ) 1,365 1,328 2.8 International 709 701 1.0 2,139 2,132 0.3 Worldwide 1,164 1,158 0.5 3,504 3,460 1.3 GENERAL U.S. 540 527 2.4 1,619 1,569 3.2", "text": "488 473 3.2 1,462 1,412 3.5 International 253 244 4.2 775 749 3.5 Worldwide 742 717 3.5 2,238 2,161 3.5 SPINE, SPORTS & OTHER U.S.", "length": 130, "numbers_raw": ["488", "473", "3.2", "1,462", "1,412", "3.5", "253", "244", "4.2", "775", "749", "3.5", "742", "717", "3.5", "2,238", "2,161", "3.5"], "numbers": [488.0, 473.0, 3.2, 1462.0, 1412.0, 3.5, 253.0, 244.0, 4.2, 775.0, 749.0, 3.5, 742.0, 717.0, 3.5, 2238.0, 2161.0, 3.5], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 683, "tag": "div", "text_raw": "MEDTECH Interventional Solutions U.S. 891 547 63.0 2,662 1,566 70.0 International 667 513 29.9 2,019 1,636 23.4 Worldwide 1,558 1,060 47.0 4,681 3,202 46.2 ELECTROPHYSIOLOGY U.S. 611 520 17.6 1,791 1,489 20.3 International 549 453 21.2 1,658 1,454 14.0 Worldwide 1,161 973 19.3 3,449 2,943 17.2 ABIOMED (3) U.S. 254  * 790  * International 57  * 176  * Worldwide 311  * 966  * OTHER INTERVENTIONAL SOLUTIONS U.S. 26 27 ( 3.2 ) 81 77 5.9 International 61 60 1.0 186 181 2.2 Worldwide 87 87 ( 0.3 ) 267 258 3.3 Orthopaedics U.S. 1,349 1,309 3.1 4,100 3,936 4.2 International 815 785 3.9 2,574 2,504 2.8 Worldwide 2,164 2,095 3.4 6,674 6,440 3.6 HIPS U.S. 239 228 4.9 730 693 5.4 International 136 124 9.3 432 437 ( 1.0 ) Worldwide 375 352 6.5 1,162 1,129 2.9 KNEES U.S. 207 203 2.3 654 620 5.6 International 131 115 14.6 415 386 7.7 Worldwide 338 317 6.7 1,069 1,005 6.4 TRAUMA U.S. 488 473 3.2 1,462 1,412 3.5 International 253 244 4.2 775 749 3.5 Worldwide 742 717 3.5 2,238 2,161 3.5 SPINE, SPORTS & OTHER U.S. 415 406 2.3 1,254 1,211 3.5 International 295 303 ( 2.6 ) 952 933 2.0 Worldwide 710 708 0.2 2,205 2,144 2.8 Surgery U.S. 994 984 1.1 2,984 2,897 3.0 International 1,483 1,439 3.1 4,522 4,410 2.6 Worldwide 2,479 2,422 2.3 7,507 7,306 2.7 ADVANCED U.S. 455 457 ( 0.4 ) 1,365 1,328 2.8 International 709 701 1.0 2,139 2,132 0.3 Worldwide 1,164 1,158 0.5 3,504 3,460 1.3 GENERAL U.S. 540 527 2.4 1,619 1,569 3.2", "text": "415 406 2.3 1,254 1,211 3.5 International 295 303 ( 2.6 ) 952 933 2.0 Worldwide 710 708 0.2 2,205 2,144 2.8 Surgery U.S.", "length": 120, "numbers_raw": ["415", "406", "2.3", "1,254", "1,211", "3.5", "295", "303", "2.6", "952", "933", "2.0", "710", "708", "0.2", "2,205", "2,144", "2.8"], "numbers": [415.0, 406.0, 2.3, 1254.0, 1211.0, 3.5, 295.0, 303.0, 2.6, 952.0, 933.0, 2.0, 710.0, 708.0, 0.2, 2205.0, 2144.0, 2.8], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 683, "tag": "div", "text_raw": "MEDTECH Interventional Solutions U.S. 891 547 63.0 2,662 1,566 70.0 International 667 513 29.9 2,019 1,636 23.4 Worldwide 1,558 1,060 47.0 4,681 3,202 46.2 ELECTROPHYSIOLOGY U.S. 611 520 17.6 1,791 1,489 20.3 International 549 453 21.2 1,658 1,454 14.0 Worldwide 1,161 973 19.3 3,449 2,943 17.2 ABIOMED (3) U.S. 254  * 790  * International 57  * 176  * Worldwide 311  * 966  * OTHER INTERVENTIONAL SOLUTIONS U.S. 26 27 ( 3.2 ) 81 77 5.9 International 61 60 1.0 186 181 2.2 Worldwide 87 87 ( 0.3 ) 267 258 3.3 Orthopaedics U.S. 1,349 1,309 3.1 4,100 3,936 4.2 International 815 785 3.9 2,574 2,504 2.8 Worldwide 2,164 2,095 3.4 6,674 6,440 3.6 HIPS U.S. 239 228 4.9 730 693 5.4 International 136 124 9.3 432 437 ( 1.0 ) Worldwide 375 352 6.5 1,162 1,129 2.9 KNEES U.S. 207 203 2.3 654 620 5.6 International 131 115 14.6 415 386 7.7 Worldwide 338 317 6.7 1,069 1,005 6.4 TRAUMA U.S. 488 473 3.2 1,462 1,412 3.5 International 253 244 4.2 775 749 3.5 Worldwide 742 717 3.5 2,238 2,161 3.5 SPINE, SPORTS & OTHER U.S. 415 406 2.3 1,254 1,211 3.5 International 295 303 ( 2.6 ) 952 933 2.0 Worldwide 710 708 0.2 2,205 2,144 2.8 Surgery U.S. 994 984 1.1 2,984 2,897 3.0 International 1,483 1,439 3.1 4,522 4,410 2.6 Worldwide 2,479 2,422 2.3 7,507 7,306 2.7 ADVANCED U.S. 455 457 ( 0.4 ) 1,365 1,328 2.8 International 709 701 1.0 2,139 2,132 0.3 Worldwide 1,164 1,158 0.5 3,504 3,460 1.3 GENERAL U.S. 540 527 2.4 1,619 1,569 3.2", "text": "994 984 1.1 2,984 2,897 3.0 International 1,483 1,439 3.1 4,522 4,410 2.6 Worldwide 2,479 2,422 2.3 7,507 7,306 2.7 ADVANCED U.S.", "length": 129, "numbers_raw": ["994", "984", "1.1", "2,984", "2,897", "3.0", "1,483", "1,439", "3.1", "4,522", "4,410", "2.6", "2,479", "2,422", "2.3", "7,507", "7,306", "2.7"], "numbers": [994.0, 984.0, 1.1, 2984.0, 2897.0, 3.0, 1483.0, 1439.0, 3.1, 4522.0, 4410.0, 2.6, 2479.0, 2422.0, 2.3, 7507.0, 7306.0, 2.7], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 683, "tag": "div", "text_raw": "MEDTECH Interventional Solutions U.S. 891 547 63.0 2,662 1,566 70.0 International 667 513 29.9 2,019 1,636 23.4 Worldwide 1,558 1,060 47.0 4,681 3,202 46.2 ELECTROPHYSIOLOGY U.S. 611 520 17.6 1,791 1,489 20.3 International 549 453 21.2 1,658 1,454 14.0 Worldwide 1,161 973 19.3 3,449 2,943 17.2 ABIOMED (3) U.S. 254  * 790  * International 57  * 176  * Worldwide 311  * 966  * OTHER INTERVENTIONAL SOLUTIONS U.S. 26 27 ( 3.2 ) 81 77 5.9 International 61 60 1.0 186 181 2.2 Worldwide 87 87 ( 0.3 ) 267 258 3.3 Orthopaedics U.S. 1,349 1,309 3.1 4,100 3,936 4.2 International 815 785 3.9 2,574 2,504 2.8 Worldwide 2,164 2,095 3.4 6,674 6,440 3.6 HIPS U.S. 239 228 4.9 730 693 5.4 International 136 124 9.3 432 437 ( 1.0 ) Worldwide 375 352 6.5 1,162 1,129 2.9 KNEES U.S. 207 203 2.3 654 620 5.6 International 131 115 14.6 415 386 7.7 Worldwide 338 317 6.7 1,069 1,005 6.4 TRAUMA U.S. 488 473 3.2 1,462 1,412 3.5 International 253 244 4.2 775 749 3.5 Worldwide 742 717 3.5 2,238 2,161 3.5 SPINE, SPORTS & OTHER U.S. 415 406 2.3 1,254 1,211 3.5 International 295 303 ( 2.6 ) 952 933 2.0 Worldwide 710 708 0.2 2,205 2,144 2.8 Surgery U.S. 994 984 1.1 2,984 2,897 3.0 International 1,483 1,439 3.1 4,522 4,410 2.6 Worldwide 2,479 2,422 2.3 7,507 7,306 2.7 ADVANCED U.S. 455 457 ( 0.4 ) 1,365 1,328 2.8 International 709 701 1.0 2,139 2,132 0.3 Worldwide 1,164 1,158 0.5 3,504 3,460 1.3 GENERAL U.S. 540 527 2.4 1,619 1,569 3.2", "text": "455 457 ( 0.4 ) 1,365 1,328 2.8 International 709 701 1.0 2,139 2,132 0.3 Worldwide 1,164 1,158 0.5 3,504 3,460 1.3 GENERAL U.S.", "length": 128, "numbers_raw": ["455", "457", "0.4", "1,365", "1,328", "2.8", "709", "701", "1.0", "2,139", "2,132", "0.3", "1,164", "1,158", "0.5", "3,504", "3,460", "1.3"], "numbers": [455.0, 457.0, 0.4, 1365.0, 1328.0, 2.8, 709.0, 701.0, 1.0, 2139.0, 2132.0, 0.3, 1164.0, 1158.0, 0.5, 3504.0, 3460.0, 1.3], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 683, "tag": "div", "text_raw": "MEDTECH Interventional Solutions U.S. 891 547 63.0 2,662 1,566 70.0 International 667 513 29.9 2,019 1,636 23.4 Worldwide 1,558 1,060 47.0 4,681 3,202 46.2 ELECTROPHYSIOLOGY U.S. 611 520 17.6 1,791 1,489 20.3 International 549 453 21.2 1,658 1,454 14.0 Worldwide 1,161 973 19.3 3,449 2,943 17.2 ABIOMED (3) U.S. 254  * 790  * International 57  * 176  * Worldwide 311  * 966  * OTHER INTERVENTIONAL SOLUTIONS U.S. 26 27 ( 3.2 ) 81 77 5.9 International 61 60 1.0 186 181 2.2 Worldwide 87 87 ( 0.3 ) 267 258 3.3 Orthopaedics U.S. 1,349 1,309 3.1 4,100 3,936 4.2 International 815 785 3.9 2,574 2,504 2.8 Worldwide 2,164 2,095 3.4 6,674 6,440 3.6 HIPS U.S. 239 228 4.9 730 693 5.4 International 136 124 9.3 432 437 ( 1.0 ) Worldwide 375 352 6.5 1,162 1,129 2.9 KNEES U.S. 207 203 2.3 654 620 5.6 International 131 115 14.6 415 386 7.7 Worldwide 338 317 6.7 1,069 1,005 6.4 TRAUMA U.S. 488 473 3.2 1,462 1,412 3.5 International 253 244 4.2 775 749 3.5 Worldwide 742 717 3.5 2,238 2,161 3.5 SPINE, SPORTS & OTHER U.S. 415 406 2.3 1,254 1,211 3.5 International 295 303 ( 2.6 ) 952 933 2.0 Worldwide 710 708 0.2 2,205 2,144 2.8 Surgery U.S. 994 984 1.1 2,984 2,897 3.0 International 1,483 1,439 3.1 4,522 4,410 2.6 Worldwide 2,479 2,422 2.3 7,507 7,306 2.7 ADVANCED U.S. 455 457 ( 0.4 ) 1,365 1,328 2.8 International 709 701 1.0 2,139 2,132 0.3 Worldwide 1,164 1,158 0.5 3,504 3,460 1.3 GENERAL U.S. 540 527 2.4 1,619 1,569 3.2", "text": "540 527 2.4 1,619 1,569 3.2", "length": 27, "numbers_raw": ["540", "527", "2.4", "1,619", "1,569", "3.2"], "numbers": [540.0, 527.0, 2.4, 1619.0, 1569.0, 3.2], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 685, "tag": "div", "text_raw": "ABIOMED (3)", "text": "ABIOMED (3)", "length": 11, "numbers_raw": ["3"], "numbers": [3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 686, "tag": "div", "text_raw": "OTHER INTERVENTIONAL SOLUTIONS", "text": "OTHER INTERVENTIONAL SOLUTIONS", "length": 30, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 693, "tag": "div", "text_raw": "25", "text": "25", "length": 2, "numbers_raw": ["25"], "numbers": [25.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 694, "tag": "div", "text_raw": "25", "text": "25", "length": 2, "numbers_raw": ["25"], "numbers": [25.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 695, "tag": "div", "text_raw": "25", "text": "25", "length": 2, "numbers_raw": ["25"], "numbers": [25.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 698, "tag": "div", "text_raw": "International 775 737 5.1 2,383 2,277 4.7 Worldwide 1,314 1,264 4.0 4,002 3,846 4.1 Vision U.S. 512 517 ( 1.0 ) 1,599 1,534 4.2 International 744 689 8.1 2,265 2,170 4.4 Worldwide 1,256 1,206 4.2 3,864 3,704 4.3 CONTACT LENSES / OTHER U.S. 399 405 ( 1.2 ) 1,252 1,179 6.2 International 529 503 4.9 1,568 1,533 2.3 Worldwide 928 908 2.2 2,820 2,712 4.0 SURGICAL U.S. 112 112 ( 0.1 ) 346 355 ( 2.5 ) International 216 186 16.6 698 637 9.6 Worldwide 328 298 10.3 1,044 992 5.3 TOTAL MEDTECH U.S. 3,747 3,356 11.6 11,345 9,932 14.2 International 3,711 3,426 8.3 11,382 10,719 6.2 Worldwide 7,458 6,782 10.0 22,727 20,651 10.0 WORLDWIDE U.S. 11,996 10,794 11.1 34,435 31,161 10.5 International 9,355 9,202 1.6 29,329 28,890 1.5 Worldwide $ 21,351 19,996 6.8 % $ 63,764 60,051 6.2 %", "text": "International 775 737 5.1 2,383 2,277 4.7 Worldwide 1,314 1,264 4.0 4,002 3,846 4.1 Vision U.S.", "length": 95, "numbers_raw": ["775", "737", "5.1", "2,383", "2,277", "4.7", "1,314", "1,264", "4.0", "4,002", "3,846", "4.1"], "numbers": [775.0, 737.0, 5.1, 2383.0, 2277.0, 4.7, 1314.0, 1264.0, 4.0, 4002.0, 3846.0, 4.1], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 698, "tag": "div", "text_raw": "International 775 737 5.1 2,383 2,277 4.7 Worldwide 1,314 1,264 4.0 4,002 3,846 4.1 Vision U.S. 512 517 ( 1.0 ) 1,599 1,534 4.2 International 744 689 8.1 2,265 2,170 4.4 Worldwide 1,256 1,206 4.2 3,864 3,704 4.3 CONTACT LENSES / OTHER U.S. 399 405 ( 1.2 ) 1,252 1,179 6.2 International 529 503 4.9 1,568 1,533 2.3 Worldwide 928 908 2.2 2,820 2,712 4.0 SURGICAL U.S. 112 112 ( 0.1 ) 346 355 ( 2.5 ) International 216 186 16.6 698 637 9.6 Worldwide 328 298 10.3 1,044 992 5.3 TOTAL MEDTECH U.S. 3,747 3,356 11.6 11,345 9,932 14.2 International 3,711 3,426 8.3 11,382 10,719 6.2 Worldwide 7,458 6,782 10.0 22,727 20,651 10.0 WORLDWIDE U.S. 11,996 10,794 11.1 34,435 31,161 10.5 International 9,355 9,202 1.6 29,329 28,890 1.5 Worldwide $ 21,351 19,996 6.8 % $ 63,764 60,051 6.2 %", "text": "512 517 ( 1.0 ) 1,599 1,534 4.2 International 744 689 8.1 2,265 2,170 4.4 Worldwide 1,256 1,206 4.2 3,864 3,704 4.3 CONTACT LENSES / OTHER U.S.", "length": 143, "numbers_raw": ["512", "517", "1.0", "1,599", "1,534", "4.2", "744", "689", "8.1", "2,265", "2,170", "4.4", "1,256", "1,206", "4.2", "3,864", "3,704", "4.3"], "numbers": [512.0, 517.0, 1.0, 1599.0, 1534.0, 4.2, 744.0, 689.0, 8.1, 2265.0, 2170.0, 4.4, 1256.0, 1206.0, 4.2, 3864.0, 3704.0, 4.3], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 698, "tag": "div", "text_raw": "International 775 737 5.1 2,383 2,277 4.7 Worldwide 1,314 1,264 4.0 4,002 3,846 4.1 Vision U.S. 512 517 ( 1.0 ) 1,599 1,534 4.2 International 744 689 8.1 2,265 2,170 4.4 Worldwide 1,256 1,206 4.2 3,864 3,704 4.3 CONTACT LENSES / OTHER U.S. 399 405 ( 1.2 ) 1,252 1,179 6.2 International 529 503 4.9 1,568 1,533 2.3 Worldwide 928 908 2.2 2,820 2,712 4.0 SURGICAL U.S. 112 112 ( 0.1 ) 346 355 ( 2.5 ) International 216 186 16.6 698 637 9.6 Worldwide 328 298 10.3 1,044 992 5.3 TOTAL MEDTECH U.S. 3,747 3,356 11.6 11,345 9,932 14.2 International 3,711 3,426 8.3 11,382 10,719 6.2 Worldwide 7,458 6,782 10.0 22,727 20,651 10.0 WORLDWIDE U.S. 11,996 10,794 11.1 34,435 31,161 10.5 International 9,355 9,202 1.6 29,329 28,890 1.5 Worldwide $ 21,351 19,996 6.8 % $ 63,764 60,051 6.2 %", "text": "399 405 ( 1.2 ) 1,252 1,179 6.2 International 529 503 4.9 1,568 1,533 2.3 Worldwide 928 908 2.2 2,820 2,712 4.0 SURGICAL U.S.", "length": 125, "numbers_raw": ["399", "405", "1.2", "1,252", "1,179", "6.2", "529", "503", "4.9", "1,568", "1,533", "2.3", "928", "908", "2.2", "2,820", "2,712", "4.0"], "numbers": [399.0, 405.0, 1.2, 1252.0, 1179.0, 6.2, 529.0, 503.0, 4.9, 1568.0, 1533.0, 2.3, 928.0, 908.0, 2.2, 2820.0, 2712.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 698, "tag": "div", "text_raw": "International 775 737 5.1 2,383 2,277 4.7 Worldwide 1,314 1,264 4.0 4,002 3,846 4.1 Vision U.S. 512 517 ( 1.0 ) 1,599 1,534 4.2 International 744 689 8.1 2,265 2,170 4.4 Worldwide 1,256 1,206 4.2 3,864 3,704 4.3 CONTACT LENSES / OTHER U.S. 399 405 ( 1.2 ) 1,252 1,179 6.2 International 529 503 4.9 1,568 1,533 2.3 Worldwide 928 908 2.2 2,820 2,712 4.0 SURGICAL U.S. 112 112 ( 0.1 ) 346 355 ( 2.5 ) International 216 186 16.6 698 637 9.6 Worldwide 328 298 10.3 1,044 992 5.3 TOTAL MEDTECH U.S. 3,747 3,356 11.6 11,345 9,932 14.2 International 3,711 3,426 8.3 11,382 10,719 6.2 Worldwide 7,458 6,782 10.0 22,727 20,651 10.0 WORLDWIDE U.S. 11,996 10,794 11.1 34,435 31,161 10.5 International 9,355 9,202 1.6 29,329 28,890 1.5 Worldwide $ 21,351 19,996 6.8 % $ 63,764 60,051 6.2 %", "text": "112 112 ( 0.1 ) 346 355 ( 2.5 ) International 216 186 16.6 698 637 9.6 Worldwide 328 298 10.3 1,044 992 5.3 TOTAL MEDTECH U.S.", "length": 126, "numbers_raw": ["112", "112", "0.1", "346", "355", "2.5", "216", "186", "16.6", "698", "637", "9.6", "328", "298", "10.3", "1,044", "992", "5.3"], "numbers": [112.0, 112.0, 0.1, 346.0, 355.0, 2.5, 216.0, 186.0, 16.6, 698.0, 637.0, 9.6, 328.0, 298.0, 10.3, 1044.0, 992.0, 5.3], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 698, "tag": "div", "text_raw": "International 775 737 5.1 2,383 2,277 4.7 Worldwide 1,314 1,264 4.0 4,002 3,846 4.1 Vision U.S. 512 517 ( 1.0 ) 1,599 1,534 4.2 International 744 689 8.1 2,265 2,170 4.4 Worldwide 1,256 1,206 4.2 3,864 3,704 4.3 CONTACT LENSES / OTHER U.S. 399 405 ( 1.2 ) 1,252 1,179 6.2 International 529 503 4.9 1,568 1,533 2.3 Worldwide 928 908 2.2 2,820 2,712 4.0 SURGICAL U.S. 112 112 ( 0.1 ) 346 355 ( 2.5 ) International 216 186 16.6 698 637 9.6 Worldwide 328 298 10.3 1,044 992 5.3 TOTAL MEDTECH U.S. 3,747 3,356 11.6 11,345 9,932 14.2 International 3,711 3,426 8.3 11,382 10,719 6.2 Worldwide 7,458 6,782 10.0 22,727 20,651 10.0 WORLDWIDE U.S. 11,996 10,794 11.1 34,435 31,161 10.5 International 9,355 9,202 1.6 29,329 28,890 1.5 Worldwide $ 21,351 19,996 6.8 % $ 63,764 60,051 6.2 %", "text": "3,747 3,356 11.6 11,345 9,932 14.2 International 3,711 3,426 8.3 11,382 10,719 6.2 Worldwide 7,458 6,782 10.0 22,727 20,651 10.0 WORLDWIDE U.S.", "length": 143, "numbers_raw": ["3,747", "3,356", "11.6", "11,345", "9,932", "14.2", "3,711", "3,426", "8.3", "11,382", "10,719", "6.2", "7,458", "6,782", "10.0", "22,727", "20,651", "10.0"], "numbers": [3747.0, 3356.0, 11.6, 11345.0, 9932.0, 14.2, 3711.0, 3426.0, 8.3, 11382.0, 10719.0, 6.2, 7458.0, 6782.0, 10.0, 22727.0, 20651.0, 10.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 698, "tag": "div", "text_raw": "International 775 737 5.1 2,383 2,277 4.7 Worldwide 1,314 1,264 4.0 4,002 3,846 4.1 Vision U.S. 512 517 ( 1.0 ) 1,599 1,534 4.2 International 744 689 8.1 2,265 2,170 4.4 Worldwide 1,256 1,206 4.2 3,864 3,704 4.3 CONTACT LENSES / OTHER U.S. 399 405 ( 1.2 ) 1,252 1,179 6.2 International 529 503 4.9 1,568 1,533 2.3 Worldwide 928 908 2.2 2,820 2,712 4.0 SURGICAL U.S. 112 112 ( 0.1 ) 346 355 ( 2.5 ) International 216 186 16.6 698 637 9.6 Worldwide 328 298 10.3 1,044 992 5.3 TOTAL MEDTECH U.S. 3,747 3,356 11.6 11,345 9,932 14.2 International 3,711 3,426 8.3 11,382 10,719 6.2 Worldwide 7,458 6,782 10.0 22,727 20,651 10.0 WORLDWIDE U.S. 11,996 10,794 11.1 34,435 31,161 10.5 International 9,355 9,202 1.6 29,329 28,890 1.5 Worldwide $ 21,351 19,996 6.8 % $ 63,764 60,051 6.2 %", "text": "11,996 10,794 11.1 34,435 31,161 10.5 International 9,355 9,202 1.6 29,329 28,890 1.5 Worldwide $ 21,351 19,996 6.8 % $ 63,764 60,051 6.2 %", "length": 139, "numbers_raw": ["11,996", "10,794", "11.1", "34,435", "31,161", "10.5", "9,355", "9,202", "1.6", "29,329", "28,890", "1.5", "21,351", "19,996", "6.8", "63,764", "60,051", "6.2"], "numbers": [11996.0, 10794.0, 11.1, 34435.0, 31161.0, 10.5, 9355.0, 9202.0, 1.6, 29329.0, 28890.0, 1.5, 21351.0, 19996.0, 6.8, 63764.0, 60051.0, 6.2], "percents_raw": ["6.8 %", "6.2 %"], "percents": [0.068, 0.062], "currencies": ["USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 701, "tag": "div", "text_raw": "*Percentage greater than 100% or not meaningful", "text": "*Percentage greater than 100% or not meaningful", "length": 47, "numbers_raw": ["100"], "numbers": [100.0], "percents_raw": ["100%"], "percents": [1.0], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 702, "tag": "div", "text_raw": "(1) Inclusive of RISPERDAL CONSTA which was previously disclosed separately", "text": "(1) Inclusive of RISPERDAL CONSTA which was previously disclosed separately", "length": 75, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 703, "tag": "div", "text_raw": "(2) Inclusive of INVOKANA which was previously disclosed separately", "text": "(2) Inclusive of INVOKANA which was previously disclosed separately", "length": 67, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 704, "tag": "div", "text_raw": "(3) Acquired on December 22, 2022", "text": "(3) Acquired on December 22, 2022", "length": 33, "numbers_raw": ["3", "22", "202", "2"], "numbers": [3.0, 22.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 706, "tag": "div", "text_raw": "EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT", "text": "EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT", "length": 46, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 707, "tag": "div", "text_raw": "Fiscal Third Quarter Ended Fiscal Nine Months Ended (Dollars in Millions) October 1, 2023 October 2, 2022 Percent Change October 1, 2023 October 2, 2022 Percent Change Innovative Medicine (1) $ 4,794 4,186 14.5 % $ 14,008 12,424 12.7 % MedTech (2) 1,185 1,090 8.7 4,265 3,641 17.1 Segment earnings before provision for taxes 5,979 5,276 13.3 18,273 16,065 13.7 Less: Expense not allocated to segments (3) 762 104 8,037 546 Worldwide income before tax $ 5,217 5,172 0.9 % $ 10,236 15,519 ( 34.0 ) %", "text": "Fiscal Third Quarter Ended Fiscal Nine Months Ended (Dollars in Millions) October 1, 2023 October 2, 2022 Percent Change October 1, 2023 October 2, 2022 Percent Change Innovative Medicine (1) $ 4,794 4,186 14.5 % $ 14,008 12,424 12.7 % MedTech (2) 1,185 1,090 8.7 4,265 3,641 17.1 Segment earnings before provision for taxes 5,979 5,276 13.3 18,273 16,065 13.7 Less:", "length": 366, "numbers_raw": ["1", "202", "3", "2", "202", "2", "1", "202", "3", "2", "202", "2", "1", "4,794", "4,186", "14.5", "14,008", "12,424", "12.7", "2", "1,185", "1,090", "8.7", "4,265", "3,641", "17.1", "5,979", "5,276", "13.3", "18,273", "16,065", "13.7"], "numbers": [1.0, 202.0, 3.0, 2.0, 202.0, 2.0, 1.0, 202.0, 3.0, 2.0, 202.0, 2.0, 1.0, 4794.0, 4186.0, 14.5, 14008.0, 12424.0, 12.7, 2.0, 1185.0, 1090.0, 8.7, 4265.0, 3641.0, 17.1, 5979.0, 5276.0, 13.3, 18273.0, 16065.0, 13.7], "percents_raw": ["14.5 %", "12.7 %"], "percents": [0.145, 0.127], "currencies": ["USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 707, "tag": "div", "text_raw": "Fiscal Third Quarter Ended Fiscal Nine Months Ended (Dollars in Millions) October 1, 2023 October 2, 2022 Percent Change October 1, 2023 October 2, 2022 Percent Change Innovative Medicine (1) $ 4,794 4,186 14.5 % $ 14,008 12,424 12.7 % MedTech (2) 1,185 1,090 8.7 4,265 3,641 17.1 Segment earnings before provision for taxes 5,979 5,276 13.3 18,273 16,065 13.7 Less: Expense not allocated to segments (3) 762 104 8,037 546 Worldwide income before tax $ 5,217 5,172 0.9 % $ 10,236 15,519 ( 34.0 ) %", "text": "Expense not allocated to segments (3) 762 104 8,037 546 Worldwide income before tax $ 5,217 5,172 0.9 % $ 10,236 15,519 ( 34.0 ) %", "length": 130, "numbers_raw": ["3", "762", "104", "8,037", "546", "5,217", "5,172", "0.9", "10,236", "15,519", "34.0"], "numbers": [3.0, 762.0, 104.0, 8037.0, 546.0, 5217.0, 5172.0, 0.9, 10236.0, 15519.0, 34.0], "percents_raw": ["0.9 %"], "percents": [0.009000000000000001], "currencies": ["USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 708, "tag": "div", "text_raw": "Innovative Medicine (1)", "text": "Innovative Medicine (1)", "length": 23, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 709, "tag": "div", "text_raw": "MedTech (2)", "text": "MedTech (2)", "length": 11, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 710, "tag": "div", "text_raw": "Less: Expense not allocated to segments (3)", "text": "Expense not allocated to segments (3)", "length": 37, "numbers_raw": ["3"], "numbers": [3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 712, "tag": "div", "text_raw": "(1) Innovative Medicine includes:", "text": "(1) Innovative Medicine includes:", "length": 33, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 713, "tag": "div", "text_raw": " Intangible amortization expense of $ 0.7 billion in both the fiscal third quarter of 2023 and 2022.", "text": " Intangible amortization expense of $ 0.7 billion in both the fiscal third quarter of 2023 and 2022.", "length": 101, "numbers_raw": ["0.7 billion", "202", "3", "202", "2"], "numbers": [700000000.0, 202.0, 3.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 714, "tag": "div", "text_raw": "Intangible amortization expense of $ 2.2 billion in both the fiscal nine months of 2023 and 2022.", "text": "Intangible amortization expense of $ 2.2 billion in both the fiscal nine months of 2023 and 2022.", "length": 97, "numbers_raw": ["2.2 billion", "202", "3", "202", "2"], "numbers": [2200000000.0, 202.0, 3.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 715, "tag": "div", "text_raw": " One-time COVID-19 Vaccine related exit costs of $ 0.4 billion in the fiscal third quarter of 2022 and $ 0.7 billion in both the fiscal nine months of 2023 and 2022.", "text": " One-time COVID-19 Vaccine related exit costs of $ 0.4 billion in the fiscal third quarter of 2022 and $ 0.7 billion in both the fiscal nine months of 2023 and 2022.", "length": 166, "numbers_raw": ["19", "0.4 billion", "202", "2", "0.7 billion", "202", "3", "202", "2"], "numbers": [19.0, 400000000.0, 202.0, 2.0, 700000000.0, 202.0, 3.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 716, "tag": "div", "text_raw": " A restructuring related charge of $ 0.1 billion and $ 0.4 billion in the fiscal third quarter and fiscal nine months of 2023, respectively.", "text": " A restructuring related charge of $ 0.1 billion and $ 0.4 billion in the fiscal third quarter and fiscal nine months of 2023, respectively.", "length": 141, "numbers_raw": ["0.1 billion", "0.4 billion", "202", "3"], "numbers": [100000000.0, 400000000.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 717, "tag": "div", "text_raw": " In the fiscal third quarter and fiscal nine months of 2023, the Company recorded an intangible asset impairment charge of approximately $ 0.2 billion related to market dynamics associated with a non-strategic asset (M710) acquired as part of the acquisition of Momenta Pharmaceuticals in 2020. In the fiscal nine months of 2022, the Company recorded an intangible asset impairment charge of approximately $ 0.6 billion related to an in-process research and development", "text": " In the fiscal third quarter and fiscal nine months of 2023, the Company recorded an intangible asset impairment charge of approximately $ 0.2 billion related to market dynamics associated with a non-strategic asset (M710) acquired as part of the acquisition of Momenta Pharmaceuticals in 2020.", "length": 295, "numbers_raw": ["202", "3", "0.2 billion", "710", "202", "0"], "numbers": [202.0, 3.0, 200000000.0, 710.0, 202.0, 0.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 717, "tag": "div", "text_raw": " In the fiscal third quarter and fiscal nine months of 2023, the Company recorded an intangible asset impairment charge of approximately $ 0.2 billion related to market dynamics associated with a non-strategic asset (M710) acquired as part of the acquisition of Momenta Pharmaceuticals in 2020. In the fiscal nine months of 2022, the Company recorded an intangible asset impairment charge of approximately $ 0.6 billion related to an in-process research and development", "text": "In the fiscal nine months of 2022, the Company recorded an intangible asset impairment charge of approximately $ 0.6 billion related to an in-process research and development", "length": 174, "numbers_raw": ["202", "2", "0.6 billion"], "numbers": [202.0, 2.0, 600000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 718, "tag": "div", "text_raw": "26", "text": "26", "length": 2, "numbers_raw": ["26"], "numbers": [26.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 719, "tag": "div", "text_raw": "26", "text": "26", "length": 2, "numbers_raw": ["26"], "numbers": [26.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 720, "tag": "div", "text_raw": "26", "text": "26", "length": 2, "numbers_raw": ["26"], "numbers": [26.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 723, "tag": "div", "text_raw": "asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS).", "text": "asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS).", "length": 136, "numbers_raw": ["774", "744", "62"], "numbers": [774.0, 744.0, 62.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 724, "tag": "div", "text_raw": " Unfavorable changes in the fair value of securities of $ 0.4 billion and $ 0.2 billion in the fiscal third quarter of 2023 and 2022, respectively. Unfavorable changes in the fair value of securities of $ 0.5 billion and $ 0.7 billion in the fiscal nine months of 2023 and 2022, respectively.", "text": " Unfavorable changes in the fair value of securities of $ 0.4 billion and $ 0.2 billion in the fiscal third quarter of 2023 and 2022, respectively.", "length": 148, "numbers_raw": ["0.4 billion", "0.2 billion", "202", "3", "202", "2"], "numbers": [400000000.0, 200000000.0, 202.0, 3.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 724, "tag": "div", "text_raw": " Unfavorable changes in the fair value of securities of $ 0.4 billion and $ 0.2 billion in the fiscal third quarter of 2023 and 2022, respectively. Unfavorable changes in the fair value of securities of $ 0.5 billion and $ 0.7 billion in the fiscal nine months of 2023 and 2022, respectively.", "text": "Unfavorable changes in the fair value of securities of $ 0.5 billion and $ 0.7 billion in the fiscal nine months of 2023 and 2022, respectively.", "length": 144, "numbers_raw": ["0.5 billion", "0.7 billion", "202", "3", "202", "2"], "numbers": [500000000.0, 700000000.0, 202.0, 3.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 725, "tag": "div", "text_raw": " Favorable litigation related items of $ 0.1 billion in the fiscal nine months of 2023.", "text": " Favorable litigation related items of $ 0.1 billion in the fiscal nine months of 2023.", "length": 88, "numbers_raw": ["0.1 billion", "202", "3"], "numbers": [100000000.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 727, "tag": "div", "text_raw": "(2) MedTech includes:", "text": "(2) MedTech includes:", "length": 21, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 728, "tag": "div", "text_raw": " Intangible amortization expense of $ 0.4 billion and $ 0.3 billion in the fiscal third quarter of 2023 and 2022, respectively. Intangible amortization expense of $ 1.1 billion and $ 0.8 billion in the fiscal nine months of 2023 and 2022, respectively.", "text": " Intangible amortization expense of $ 0.4 billion and $ 0.3 billion in the fiscal third quarter of 2023 and 2022, respectively.", "length": 128, "numbers_raw": ["0.4 billion", "0.3 billion", "202", "3", "202", "2"], "numbers": [400000000.0, 300000000.0, 202.0, 3.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 728, "tag": "div", "text_raw": " Intangible amortization expense of $ 0.4 billion and $ 0.3 billion in the fiscal third quarter of 2023 and 2022, respectively. Intangible amortization expense of $ 1.1 billion and $ 0.8 billion in the fiscal nine months of 2023 and 2022, respectively.", "text": "Intangible amortization expense of $ 1.1 billion and $ 0.8 billion in the fiscal nine months of 2023 and 2022, respectively.", "length": 124, "numbers_raw": ["1.1 billion", "0.8 billion", "202", "3", "202", "2"], "numbers": [1100000000.0, 800000000.0, 202.0, 3.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 729, "tag": "div", "text_raw": " Litigation expense of $ 0.2 billion and $ 0.5 billion in the fiscal third quarter and fiscal nine months of 2022.", "text": " Litigation expense of $ 0.2 billion and $ 0.5 billion in the fiscal third quarter and fiscal nine months of 2022.", "length": 115, "numbers_raw": ["0.2 billion", "0.5 billion", "202", "2"], "numbers": [200000000.0, 500000000.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 730, "tag": "div", "text_raw": " Acquisition and integration related expense of $ 0.1 billion in the fiscal nine months of 2023.", "text": " Acquisition and integration related expense of $ 0.1 billion in the fiscal nine months of 2023.", "length": 97, "numbers_raw": ["0.1 billion", "202", "3"], "numbers": [100000000.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 731, "tag": "div", "text_raw": " A restructuring related charge of $ 0.2 billion in the fiscal third quarter and fiscal nine months of 2023. A restructuring related charge of $ 0.1 billion in the fiscal third quarter of 2022 and $ 0.2 billion in the fiscal nine months of 2022.", "text": " A restructuring related charge of $ 0.2 billion in the fiscal third quarter and fiscal nine months of 2023.", "length": 109, "numbers_raw": ["0.2 billion", "202", "3"], "numbers": [200000000.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 731, "tag": "div", "text_raw": " A restructuring related charge of $ 0.2 billion in the fiscal third quarter and fiscal nine months of 2023. A restructuring related charge of $ 0.1 billion in the fiscal third quarter of 2022 and $ 0.2 billion in the fiscal nine months of 2022.", "text": "A restructuring related charge of $ 0.1 billion in the fiscal third quarter of 2022 and $ 0.2 billion in the fiscal nine months of 2022.", "length": 136, "numbers_raw": ["0.1 billion", "202", "2", "0.2 billion", "202", "2"], "numbers": [100000000.0, 202.0, 2.0, 200000000.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 733, "tag": "div", "text_raw": "(3) Amounts not allocated to segments include interest income/expense and general corporate income/expense. The fiscal nine months of 2023 includes an approximately $ 7 billion incremental charge primarily related to the talc settlement proposal (See Note 11, Legal Proceedings, for additional details) and $ 0.6 billion related to the unfavorable change in the fair value of Kenvue shares.", "text": "(3) Amounts not allocated to segments include interest income/expense and general corporate income/expense.", "length": 107, "numbers_raw": ["3"], "numbers": [3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 733, "tag": "div", "text_raw": "(3) Amounts not allocated to segments include interest income/expense and general corporate income/expense. The fiscal nine months of 2023 includes an approximately $ 7 billion incremental charge primarily related to the talc settlement proposal (See Note 11, Legal Proceedings, for additional details) and $ 0.6 billion related to the unfavorable change in the fair value of Kenvue shares.", "text": "The fiscal nine months of 2023 includes an approximately $ 7 billion incremental charge primarily related to the talc settlement proposal (See Note 11, Legal Proceedings, for additional details) and $ 0.6 billion related to the unfavorable change in the fair value of Kenvue shares.", "length": 282, "numbers_raw": ["202", "3", "7 billion", "11", "0.6 billion"], "numbers": [202.0, 3.0, 7000000000.0, 11.0, 600000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 736, "tag": "div", "text_raw": "Fiscal Third Quarter Ended Fiscal Nine Months Ended (Dollars in Millions) October 1, 2023 October 2, 2022 Percent Change October 1, 2023 October 2, 2022 Percent Change United States $ 11,996 10,794 11.1 % $ 34,435 31,161 10.5 % Europe 4,727 4,844 ( 2.4 ) 15,448 15,540 ( 0.6 ) Western Hemisphere, excluding U.S. 1,171 1,059 10.5 3,383 3,084 9.7 Asia-Pacific, Africa 3,457 3,299 4.8 10,498 10,266 2.2 Total $ 21,351 19,996 6.8 % $ 63,764 60,051 6.2 %", "text": "Fiscal Third Quarter Ended Fiscal Nine Months Ended (Dollars in Millions) October 1, 2023 October 2, 2022 Percent Change October 1, 2023 October 2, 2022 Percent Change United States $ 11,996 10,794 11.1 % $ 34,435 31,161 10.5 % Europe 4,727 4,844 ( 2.4 ) 15,448 15,540 ( 0.6 ) Western Hemisphere, excluding U.S.", "length": 311, "numbers_raw": ["1", "202", "3", "2", "202", "2", "1", "202", "3", "2", "202", "2", "11,996", "10,794", "11.1", "34,435", "31,161", "10.5", "4,727", "4,844", "2.4", "15,448", "15,540", "0.6"], "numbers": [1.0, 202.0, 3.0, 2.0, 202.0, 2.0, 1.0, 202.0, 3.0, 2.0, 202.0, 2.0, 11996.0, 10794.0, 11.1, 34435.0, 31161.0, 10.5, 4727.0, 4844.0, 2.4, 15448.0, 15540.0, 0.6], "percents_raw": ["11.1 %", "10.5 %"], "percents": [0.111, 0.105], "currencies": ["EUR", "USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 736, "tag": "div", "text_raw": "Fiscal Third Quarter Ended Fiscal Nine Months Ended (Dollars in Millions) October 1, 2023 October 2, 2022 Percent Change October 1, 2023 October 2, 2022 Percent Change United States $ 11,996 10,794 11.1 % $ 34,435 31,161 10.5 % Europe 4,727 4,844 ( 2.4 ) 15,448 15,540 ( 0.6 ) Western Hemisphere, excluding U.S. 1,171 1,059 10.5 3,383 3,084 9.7 Asia-Pacific, Africa 3,457 3,299 4.8 10,498 10,266 2.2 Total $ 21,351 19,996 6.8 % $ 63,764 60,051 6.2 %", "text": "1,171 1,059 10.5 3,383 3,084 9.7 Asia-Pacific, Africa 3,457 3,299 4.8 10,498 10,266 2.2 Total $ 21,351 19,996 6.8 % $ 63,764 60,051 6.2 %", "length": 137, "numbers_raw": ["1,171", "1,059", "10.5", "3,383", "3,084", "9.7", "3,457", "3,299", "4.8", "10,498", "10,266", "2.2", "21,351", "19,996", "6.8", "63,764", "60,051", "6.2"], "numbers": [1171.0, 1059.0, 10.5, 3383.0, 3084.0, 9.7, 3457.0, 3299.0, 4.8, 10498.0, 10266.0, 2.2, 21351.0, 19996.0, 6.8, 63764.0, 60051.0, 6.2], "percents_raw": ["6.8 %", "6.2 %"], "percents": [0.068, 0.062], "currencies": ["USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 740, "tag": "div", "text_raw": "NOTE 10 ACQUISITIONS AND DIVESTITURES", "text": "NOTE 10 ACQUISITIONS AND DIVESTITURES", "length": 38, "numbers_raw": ["10"], "numbers": [10.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 742, "tag": "div", "text_raw": "There were no material acquisitions or divestitures in the fiscal first, second or third quarter of 2023.", "text": "There were no material acquisitions or divestitures in the fiscal first, second or third quarter of 2023.", "length": 105, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 744, "tag": "div", "text_raw": "On December 22, 2022, the Company completed the acquisition of Abiomed, a leading, first-to-market provider of cardiovascular medical technology with a first-in-kind portfolio for the treatment of coronary artery disease and heart failure which also has an extensive innovation pipeline of life-saving technologies. The transaction broadens the Companys position as a growing cardiovascular innovator, advancing the standard of care in heart failure and recovery, one of healthcares largest areas of unmet need. The transaction was accounted for as a business combination and the results of operations were included in the MedTech segment as of the date of the acquisition. The acquisition was completed through a tender offer for all outstanding shares. The consideration paid in the acquisition consisted of an upfront payment of $ 380.00 per share in cash, amounting to $ 17.1 billion, net of cash acquired, as well as a non-tradeable contingent value right (CVR) entitling the holder to receive up to $ 35.00 per share in cash (which with respect to the CVRs total approximately $ 1.6 billion in the aggregate) if certain commercial and clinical milestones are achieved. The corresponding enterprise value (without taking into account the CVRs) of approximately $ 16.5 billion includes cash, cash equivalents and marketable securities acquired.", "text": "On December 22, 2022, the Company completed the acquisition of Abiomed, a leading, first-to-market provider of cardiovascular medical technology with a first-in-kind portfolio for the treatment of coronary artery disease and heart failure which also has an extensive innovation pipeline of life-saving technologies.", "length": 315, "numbers_raw": ["22", "202", "2"], "numbers": [22.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 744, "tag": "div", "text_raw": "On December 22, 2022, the Company completed the acquisition of Abiomed, a leading, first-to-market provider of cardiovascular medical technology with a first-in-kind portfolio for the treatment of coronary artery disease and heart failure which also has an extensive innovation pipeline of life-saving technologies. The transaction broadens the Companys position as a growing cardiovascular innovator, advancing the standard of care in heart failure and recovery, one of healthcares largest areas of unmet need. The transaction was accounted for as a business combination and the results of operations were included in the MedTech segment as of the date of the acquisition. The acquisition was completed through a tender offer for all outstanding shares. The consideration paid in the acquisition consisted of an upfront payment of $ 380.00 per share in cash, amounting to $ 17.1 billion, net of cash acquired, as well as a non-tradeable contingent value right (CVR) entitling the holder to receive up to $ 35.00 per share in cash (which with respect to the CVRs total approximately $ 1.6 billion in the aggregate) if certain commercial and clinical milestones are achieved. The corresponding enterprise value (without taking into account the CVRs) of approximately $ 16.5 billion includes cash, cash equivalents and marketable securities acquired.", "text": "The transaction broadens the Companys position as a growing cardiovascular innovator, advancing the standard of care in heart failure and recovery, one of healthcares largest areas of unmet need.", "length": 197, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 744, "tag": "div", "text_raw": "On December 22, 2022, the Company completed the acquisition of Abiomed, a leading, first-to-market provider of cardiovascular medical technology with a first-in-kind portfolio for the treatment of coronary artery disease and heart failure which also has an extensive innovation pipeline of life-saving technologies. The transaction broadens the Companys position as a growing cardiovascular innovator, advancing the standard of care in heart failure and recovery, one of healthcares largest areas of unmet need. The transaction was accounted for as a business combination and the results of operations were included in the MedTech segment as of the date of the acquisition. The acquisition was completed through a tender offer for all outstanding shares. The consideration paid in the acquisition consisted of an upfront payment of $ 380.00 per share in cash, amounting to $ 17.1 billion, net of cash acquired, as well as a non-tradeable contingent value right (CVR) entitling the holder to receive up to $ 35.00 per share in cash (which with respect to the CVRs total approximately $ 1.6 billion in the aggregate) if certain commercial and clinical milestones are achieved. The corresponding enterprise value (without taking into account the CVRs) of approximately $ 16.5 billion includes cash, cash equivalents and marketable securities acquired.", "text": "The transaction was accounted for as a business combination and the results of operations were included in the MedTech segment as of the date of the acquisition.", "length": 161, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 744, "tag": "div", "text_raw": "On December 22, 2022, the Company completed the acquisition of Abiomed, a leading, first-to-market provider of cardiovascular medical technology with a first-in-kind portfolio for the treatment of coronary artery disease and heart failure which also has an extensive innovation pipeline of life-saving technologies. The transaction broadens the Companys position as a growing cardiovascular innovator, advancing the standard of care in heart failure and recovery, one of healthcares largest areas of unmet need. The transaction was accounted for as a business combination and the results of operations were included in the MedTech segment as of the date of the acquisition. The acquisition was completed through a tender offer for all outstanding shares. The consideration paid in the acquisition consisted of an upfront payment of $ 380.00 per share in cash, amounting to $ 17.1 billion, net of cash acquired, as well as a non-tradeable contingent value right (CVR) entitling the holder to receive up to $ 35.00 per share in cash (which with respect to the CVRs total approximately $ 1.6 billion in the aggregate) if certain commercial and clinical milestones are achieved. The corresponding enterprise value (without taking into account the CVRs) of approximately $ 16.5 billion includes cash, cash equivalents and marketable securities acquired.", "text": "The acquisition was completed through a tender offer for all outstanding shares.", "length": 80, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 744, "tag": "div", "text_raw": "On December 22, 2022, the Company completed the acquisition of Abiomed, a leading, first-to-market provider of cardiovascular medical technology with a first-in-kind portfolio for the treatment of coronary artery disease and heart failure which also has an extensive innovation pipeline of life-saving technologies. The transaction broadens the Companys position as a growing cardiovascular innovator, advancing the standard of care in heart failure and recovery, one of healthcares largest areas of unmet need. The transaction was accounted for as a business combination and the results of operations were included in the MedTech segment as of the date of the acquisition. The acquisition was completed through a tender offer for all outstanding shares. The consideration paid in the acquisition consisted of an upfront payment of $ 380.00 per share in cash, amounting to $ 17.1 billion, net of cash acquired, as well as a non-tradeable contingent value right (CVR) entitling the holder to receive up to $ 35.00 per share in cash (which with respect to the CVRs total approximately $ 1.6 billion in the aggregate) if certain commercial and clinical milestones are achieved. The corresponding enterprise value (without taking into account the CVRs) of approximately $ 16.5 billion includes cash, cash equivalents and marketable securities acquired.", "text": "The consideration paid in the acquisition consisted of an upfront payment of $ 380.00 per share in cash, amounting to $ 17.1 billion, net of cash acquired, as well as a non-tradeable contingent value right (CVR) entitling the holder to receive up to $ 35.00 per share in cash (which with respect to the CVRs total approximately $ 1.6 billion in the aggregate) if certain commercial and clinical milestones are achieved.", "length": 419, "numbers_raw": ["380.00", "17.1 billion", "35.00", "1.6 billion"], "numbers": [380.0, 17100000000.000002, 35.0, 1600000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 744, "tag": "div", "text_raw": "On December 22, 2022, the Company completed the acquisition of Abiomed, a leading, first-to-market provider of cardiovascular medical technology with a first-in-kind portfolio for the treatment of coronary artery disease and heart failure which also has an extensive innovation pipeline of life-saving technologies. The transaction broadens the Companys position as a growing cardiovascular innovator, advancing the standard of care in heart failure and recovery, one of healthcares largest areas of unmet need. The transaction was accounted for as a business combination and the results of operations were included in the MedTech segment as of the date of the acquisition. The acquisition was completed through a tender offer for all outstanding shares. The consideration paid in the acquisition consisted of an upfront payment of $ 380.00 per share in cash, amounting to $ 17.1 billion, net of cash acquired, as well as a non-tradeable contingent value right (CVR) entitling the holder to receive up to $ 35.00 per share in cash (which with respect to the CVRs total approximately $ 1.6 billion in the aggregate) if certain commercial and clinical milestones are achieved. The corresponding enterprise value (without taking into account the CVRs) of approximately $ 16.5 billion includes cash, cash equivalents and marketable securities acquired.", "text": "The corresponding enterprise value (without taking into account the CVRs) of approximately $ 16.5 billion includes cash, cash equivalents and marketable securities acquired.", "length": 173, "numbers_raw": ["16.5 billion"], "numbers": [16500000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 745, "tag": "div", "text_raw": "The milestones of the CVR consist of:", "text": "The milestones of the CVR consist of:", "length": 37, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 746, "tag": "div", "text_raw": "a. $ 17.50 per share, payable if net sales for Abiomed products exceeds $ 3.7 billion during Johnson & Johnsons fiscal second quarter of 2027 through fiscal first quarter of 2028, or if this threshold is not met during this period and is subsequently met during any rolling four quarter period up to the end of Johnson & Johnsons fiscal first quarter of 2029, $ 8.75 per share;", "text": "$ 17.50 per share, payable if net sales for Abiomed products exceeds $ 3.7 billion during Johnson & Johnsons fiscal second quarter of 2027 through fiscal first quarter of 2028, or if this threshold is not met during this period and is subsequently met during any rolling four quarter period up to the end of Johnson & Johnsons fiscal first quarter of 2029, $ 8.75 per share;", "length": 376, "numbers_raw": ["17.50", "3.7 billion", "202", "7", "202", "8", "202", "9", "8.75"], "numbers": [17.5, 3700000000.0, 202.0, 7.0, 202.0, 8.0, 202.0, 9.0, 8.75], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 747, "tag": "div", "text_raw": "b. $ 7.50 per share payable upon FDA premarket application approval of the use of Impella products in ST-elevated myocardial infarction (STEMI) patients without cardiogenic shock by January 1, 2028; and", "text": "$ 7.50 per share payable upon FDA premarket application approval of the use of Impella products in ST-elevated myocardial infarction (STEMI) patients without cardiogenic shock by January 1, 2028;", "length": 195, "numbers_raw": ["7.50", "1", "202", "8"], "numbers": [7.5, 1.0, 202.0, 8.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 748, "tag": "div", "text_raw": "c. $ 10.00 per share payable upon the first publication of a Class I recommendation for the use of Impella products in high risk PCI or STEMI with or without cardiogenic shock within four years from their respective clinical endpoint publication dates, but in all cases no later than December 31, 2029.", "text": "$ 10.00 per share payable upon the first publication of a Class I recommendation for the use of Impella products in high risk PCI or STEMI with or without cardiogenic shock within four years from their respective clinical endpoint publication dates, but in all cases no later than December 31, 2029.", "length": 299, "numbers_raw": ["10.00", "31", "202", "9"], "numbers": [10.0, 31.0, 202.0, 9.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 750, "tag": "div", "text_raw": "27", "text": "27", "length": 2, "numbers_raw": ["27"], "numbers": [27.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 751, "tag": "div", "text_raw": "27", "text": "27", "length": 2, "numbers_raw": ["27"], "numbers": [27.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 752, "tag": "div", "text_raw": "27", "text": "27", "length": 2, "numbers_raw": ["27"], "numbers": [27.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 755, "tag": "div", "text_raw": "The fair value of the acquisition was initially allocated to assets acquired of $ 19.9 billion (net of $ 0.3 billion cash acquired), primarily to goodwill for $ 10.9 billion, amortizable intangible assets for $ 6.6 billion, IPR&D for $ 1.1 billion, marketable securities of $ 0.6 billion and liabilities assumed of $ 2.8 billion, which includes the fair value of the contingent consideration mentioned above for $ 0.7 billion and deferred taxes of $ 1.8 billion. The goodwill is primarily attributable to the commercial acceleration and expansion of the portfolio and is not expected to be deductible for tax purposes. The contingent consideration was recorded in Other Liabilities on the Consolidated Balance Sheet.", "text": "The fair value of the acquisition was initially allocated to assets acquired of $ 19.9 billion (net of $ 0.3 billion cash acquired), primarily to goodwill for $ 10.9 billion, amortizable intangible assets for $ 6.6 billion, IPR&D for $ 1.1 billion, marketable securities of $ 0.6 billion and liabilities assumed of $ 2.8 billion, which includes the fair value of the contingent consideration mentioned above for $ 0.7 billion and deferred taxes of $ 1.8 billion.", "length": 462, "numbers_raw": ["19.9 billion", "0.3 billion", "10.9 billion", "6.6 billion", "1.1 billion", "0.6 billion", "2.8 billion", "0.7 billion", "1.8 billion"], "numbers": [19900000000.0, 300000000.0, 10900000000.0, 6600000000.0, 1100000000.0, 600000000.0, 2800000000.0, 700000000.0, 1800000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 755, "tag": "div", "text_raw": "The fair value of the acquisition was initially allocated to assets acquired of $ 19.9 billion (net of $ 0.3 billion cash acquired), primarily to goodwill for $ 10.9 billion, amortizable intangible assets for $ 6.6 billion, IPR&D for $ 1.1 billion, marketable securities of $ 0.6 billion and liabilities assumed of $ 2.8 billion, which includes the fair value of the contingent consideration mentioned above for $ 0.7 billion and deferred taxes of $ 1.8 billion. The goodwill is primarily attributable to the commercial acceleration and expansion of the portfolio and is not expected to be deductible for tax purposes. The contingent consideration was recorded in Other Liabilities on the Consolidated Balance Sheet.", "text": "The goodwill is primarily attributable to the commercial acceleration and expansion of the portfolio and is not expected to be deductible for tax purposes.", "length": 155, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 755, "tag": "div", "text_raw": "The fair value of the acquisition was initially allocated to assets acquired of $ 19.9 billion (net of $ 0.3 billion cash acquired), primarily to goodwill for $ 10.9 billion, amortizable intangible assets for $ 6.6 billion, IPR&D for $ 1.1 billion, marketable securities of $ 0.6 billion and liabilities assumed of $ 2.8 billion, which includes the fair value of the contingent consideration mentioned above for $ 0.7 billion and deferred taxes of $ 1.8 billion. The goodwill is primarily attributable to the commercial acceleration and expansion of the portfolio and is not expected to be deductible for tax purposes. The contingent consideration was recorded in Other Liabilities on the Consolidated Balance Sheet.", "text": "The contingent consideration was recorded in Other Liabilities on the Consolidated Balance Sheet.", "length": 97, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 756, "tag": "div", "text_raw": "As the acquisition occurred in December 2022, the Company is still finalizing the allocation of the purchase price to the individual assets acquired and liabilities assumed. The allocation of the purchase price included in the current period balance sheet is based on the best estimate of management and is preliminary and subject to change. To assist management in the allocation, the Company engaged valuation specialists to prepare appraisals. The Company will finalize the amounts recognized as the information necessary to complete the analysis is obtained. The Company expects to finalize these amounts as soon as possible but no later than one year from the acquisition date. In the fiscal first quarter of 2023, there were purchase price allocation adjustments netting to approximately $ 0.1 billion with an offsetting increase to goodwill. In the fiscal second and third quarters of 2023, there were no purchase price allocation adjustments.", "text": "As the acquisition occurred in December 2022, the Company is still finalizing the allocation of the purchase price to the individual assets acquired and liabilities assumed.", "length": 173, "numbers_raw": ["202", "2"], "numbers": [202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 756, "tag": "div", "text_raw": "As the acquisition occurred in December 2022, the Company is still finalizing the allocation of the purchase price to the individual assets acquired and liabilities assumed. The allocation of the purchase price included in the current period balance sheet is based on the best estimate of management and is preliminary and subject to change. To assist management in the allocation, the Company engaged valuation specialists to prepare appraisals. The Company will finalize the amounts recognized as the information necessary to complete the analysis is obtained. The Company expects to finalize these amounts as soon as possible but no later than one year from the acquisition date. In the fiscal first quarter of 2023, there were purchase price allocation adjustments netting to approximately $ 0.1 billion with an offsetting increase to goodwill. In the fiscal second and third quarters of 2023, there were no purchase price allocation adjustments.", "text": "The allocation of the purchase price included in the current period balance sheet is based on the best estimate of management and is preliminary and subject to change.", "length": 167, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 756, "tag": "div", "text_raw": "As the acquisition occurred in December 2022, the Company is still finalizing the allocation of the purchase price to the individual assets acquired and liabilities assumed. The allocation of the purchase price included in the current period balance sheet is based on the best estimate of management and is preliminary and subject to change. To assist management in the allocation, the Company engaged valuation specialists to prepare appraisals. The Company will finalize the amounts recognized as the information necessary to complete the analysis is obtained. The Company expects to finalize these amounts as soon as possible but no later than one year from the acquisition date. In the fiscal first quarter of 2023, there were purchase price allocation adjustments netting to approximately $ 0.1 billion with an offsetting increase to goodwill. In the fiscal second and third quarters of 2023, there were no purchase price allocation adjustments.", "text": "To assist management in the allocation, the Company engaged valuation specialists to prepare appraisals.", "length": 104, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 756, "tag": "div", "text_raw": "As the acquisition occurred in December 2022, the Company is still finalizing the allocation of the purchase price to the individual assets acquired and liabilities assumed. The allocation of the purchase price included in the current period balance sheet is based on the best estimate of management and is preliminary and subject to change. To assist management in the allocation, the Company engaged valuation specialists to prepare appraisals. The Company will finalize the amounts recognized as the information necessary to complete the analysis is obtained. The Company expects to finalize these amounts as soon as possible but no later than one year from the acquisition date. In the fiscal first quarter of 2023, there were purchase price allocation adjustments netting to approximately $ 0.1 billion with an offsetting increase to goodwill. In the fiscal second and third quarters of 2023, there were no purchase price allocation adjustments.", "text": "The Company will finalize the amounts recognized as the information necessary to complete the analysis is obtained.", "length": 115, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 756, "tag": "div", "text_raw": "As the acquisition occurred in December 2022, the Company is still finalizing the allocation of the purchase price to the individual assets acquired and liabilities assumed. The allocation of the purchase price included in the current period balance sheet is based on the best estimate of management and is preliminary and subject to change. To assist management in the allocation, the Company engaged valuation specialists to prepare appraisals. The Company will finalize the amounts recognized as the information necessary to complete the analysis is obtained. The Company expects to finalize these amounts as soon as possible but no later than one year from the acquisition date. In the fiscal first quarter of 2023, there were purchase price allocation adjustments netting to approximately $ 0.1 billion with an offsetting increase to goodwill. In the fiscal second and third quarters of 2023, there were no purchase price allocation adjustments.", "text": "The Company expects to finalize these amounts as soon as possible but no later than one year from the acquisition date.", "length": 119, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 756, "tag": "div", "text_raw": "As the acquisition occurred in December 2022, the Company is still finalizing the allocation of the purchase price to the individual assets acquired and liabilities assumed. The allocation of the purchase price included in the current period balance sheet is based on the best estimate of management and is preliminary and subject to change. To assist management in the allocation, the Company engaged valuation specialists to prepare appraisals. The Company will finalize the amounts recognized as the information necessary to complete the analysis is obtained. The Company expects to finalize these amounts as soon as possible but no later than one year from the acquisition date. In the fiscal first quarter of 2023, there were purchase price allocation adjustments netting to approximately $ 0.1 billion with an offsetting increase to goodwill. In the fiscal second and third quarters of 2023, there were no purchase price allocation adjustments.", "text": "In the fiscal first quarter of 2023, there were purchase price allocation adjustments netting to approximately $ 0.1 billion with an offsetting increase to goodwill.", "length": 165, "numbers_raw": ["202", "3", "0.1 billion"], "numbers": [202.0, 3.0, 100000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 756, "tag": "div", "text_raw": "As the acquisition occurred in December 2022, the Company is still finalizing the allocation of the purchase price to the individual assets acquired and liabilities assumed. The allocation of the purchase price included in the current period balance sheet is based on the best estimate of management and is preliminary and subject to change. To assist management in the allocation, the Company engaged valuation specialists to prepare appraisals. The Company will finalize the amounts recognized as the information necessary to complete the analysis is obtained. The Company expects to finalize these amounts as soon as possible but no later than one year from the acquisition date. In the fiscal first quarter of 2023, there were purchase price allocation adjustments netting to approximately $ 0.1 billion with an offsetting increase to goodwill. In the fiscal second and third quarters of 2023, there were no purchase price allocation adjustments.", "text": "In the fiscal second and third quarters of 2023, there were no purchase price allocation adjustments.", "length": 101, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 757, "tag": "div", "text_raw": "The amortizable intangible assets were primarily comprised of already in-market products of the Impella platform with an average weighted life of 14 years. The IPR&D assets were valued for technology programs for unapproved products. The value of the IPR&D was calculated using probability-adjusted cash flow projections discounted for the risk inherent in such projects. The probability of success factor ranged from 52 % to 70 %. The discount rate applied was 9.5 %.", "text": "The amortizable intangible assets were primarily comprised of already in-market products of the Impella platform with an average weighted life of 14 years.", "length": 155, "numbers_raw": ["14"], "numbers": [14.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 757, "tag": "div", "text_raw": "The amortizable intangible assets were primarily comprised of already in-market products of the Impella platform with an average weighted life of 14 years. The IPR&D assets were valued for technology programs for unapproved products. The value of the IPR&D was calculated using probability-adjusted cash flow projections discounted for the risk inherent in such projects. The probability of success factor ranged from 52 % to 70 %. The discount rate applied was 9.5 %.", "text": "The IPR&D assets were valued for technology programs for unapproved products.", "length": 77, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 757, "tag": "div", "text_raw": "The amortizable intangible assets were primarily comprised of already in-market products of the Impella platform with an average weighted life of 14 years. The IPR&D assets were valued for technology programs for unapproved products. The value of the IPR&D was calculated using probability-adjusted cash flow projections discounted for the risk inherent in such projects. The probability of success factor ranged from 52 % to 70 %. The discount rate applied was 9.5 %.", "text": "The value of the IPR&D was calculated using probability-adjusted cash flow projections discounted for the risk inherent in such projects.", "length": 137, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 757, "tag": "div", "text_raw": "The amortizable intangible assets were primarily comprised of already in-market products of the Impella platform with an average weighted life of 14 years. The IPR&D assets were valued for technology programs for unapproved products. The value of the IPR&D was calculated using probability-adjusted cash flow projections discounted for the risk inherent in such projects. The probability of success factor ranged from 52 % to 70 %. The discount rate applied was 9.5 %.", "text": "The probability of success factor ranged from 52 % to 70 %.", "length": 59, "numbers_raw": ["52", "70"], "numbers": [52.0, 70.0], "percents_raw": ["52 %", "70 %"], "percents": [0.52, 0.7], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 757, "tag": "div", "text_raw": "The amortizable intangible assets were primarily comprised of already in-market products of the Impella platform with an average weighted life of 14 years. The IPR&D assets were valued for technology programs for unapproved products. The value of the IPR&D was calculated using probability-adjusted cash flow projections discounted for the risk inherent in such projects. The probability of success factor ranged from 52 % to 70 %. The discount rate applied was 9.5 %.", "text": "The discount rate applied was 9.5 %.", "length": 36, "numbers_raw": ["9.5"], "numbers": [9.5], "percents_raw": ["9.5 %"], "percents": [0.095], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 758, "tag": "div", "text_raw": "In 2022, the Company recorded acquisition related costs before tax of approximately $ 0.3 billion, which was recorded in Other (income)/expense. In the fiscal nine months of 2023, the Company recorded acquisition related costs before tax of approximately $ 0.1 billion, which was primarily recorded in Other (income)/expense.", "text": "In 2022, the Company recorded acquisition related costs before tax of approximately $ 0.3 billion, which was recorded in Other (income)/expense.", "length": 144, "numbers_raw": ["202", "2", "0.3 billion"], "numbers": [202.0, 2.0, 300000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 758, "tag": "div", "text_raw": "In 2022, the Company recorded acquisition related costs before tax of approximately $ 0.3 billion, which was recorded in Other (income)/expense. In the fiscal nine months of 2023, the Company recorded acquisition related costs before tax of approximately $ 0.1 billion, which was primarily recorded in Other (income)/expense.", "text": "In the fiscal nine months of 2023, the Company recorded acquisition related costs before tax of approximately $ 0.1 billion, which was primarily recorded in Other (income)/expense.", "length": 180, "numbers_raw": ["202", "3", "0.1 billion"], "numbers": [202.0, 3.0, 100000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 760, "tag": "div", "text_raw": "There were no material acquisitions or divestitures in the fiscal first, second or third quarter of 2022.", "text": "There were no material acquisitions or divestitures in the fiscal first, second or third quarter of 2022.", "length": 105, "numbers_raw": ["202", "2"], "numbers": [202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 764, "tag": "div", "text_raw": "NOTE 11  LEGAL PROCEEDINGS", "text": "NOTE 11  LEGAL PROCEEDINGS", "length": 27, "numbers_raw": ["11"], "numbers": [11.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 766, "tag": "div", "text_raw": "Johnson & Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business.", "text": "Johnson & Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability;", "length": 122, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 766, "tag": "div", "text_raw": "Johnson & Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business.", "text": "indemnification and other matters;", "length": 34, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 766, "tag": "div", "text_raw": "Johnson & Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business.", "text": "and other legal proceedings that arise from time to time in the ordinary course of their business.", "length": 98, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 768, "tag": "div", "text_raw": "The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of October 1, 2023, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.", "text": "The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated.", "length": 198, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 768, "tag": "div", "text_raw": "The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of October 1, 2023, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.", "text": "As of October 1, 2023, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated.", "length": 159, "numbers_raw": ["1", "202", "3"], "numbers": [1.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 768, "tag": "div", "text_raw": "The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of October 1, 2023, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.", "text": "The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25.", "length": 221, "numbers_raw": ["450", "20", "25"], "numbers": [450.0, 20.0, 25.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 768, "tag": "div", "text_raw": "The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of October 1, 2023, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.", "text": "For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued.", "length": 219, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 768, "tag": "div", "text_raw": "The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of October 1, 2023, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.", "text": "Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments.", "length": 210, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 768, "tag": "div", "text_raw": "The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of October 1, 2023, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.", "text": "The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate;", "length": 194, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 768, "tag": "div", "text_raw": "The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of October 1, 2023, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.", "text": "scientific and legal discovery has not commenced or is not complete;", "length": 68, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 768, "tag": "div", "text_raw": "The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of October 1, 2023, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.", "text": "proceedings are in early stages;", "length": 32, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 768, "tag": "div", "text_raw": "The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of October 1, 2023, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.", "text": "matters present legal uncertainties;", "length": 36, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 768, "tag": "div", "text_raw": "The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of October 1, 2023, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.", "text": "there are significant facts in dispute;", "length": 39, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 768, "tag": "div", "text_raw": "The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of October 1, 2023, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.", "text": "procedural or jurisdictional issues;", "length": 36, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 768, "tag": "div", "text_raw": "The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of October 1, 2023, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.", "text": "the uncertainty and unpredictability of the number of potential claims;", "length": 71, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 768, "tag": "div", "text_raw": "The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of October 1, 2023, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.", "text": "ability to achieve comprehensive multi-party settlements;", "length": 57, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 768, "tag": "div", "text_raw": "The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of October 1, 2023, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.", "text": "complexity of related cross-claims and counterclaims;", "length": 53, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 768, "tag": "div", "text_raw": "The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of October 1, 2023, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.", "text": "and/or there are numerous parties involved.", "length": 43, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 768, "tag": "div", "text_raw": "The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of October 1, 2023, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.", "text": "To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.", "length": 205, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 770, "tag": "div", "text_raw": "In the Companys opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Companys balance sheet, is not expected to have a material adverse effect on the Companys financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Companys results of operations and cash flows for that period.", "text": "In the Companys opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Companys balance sheet, is not expected to have a material adverse effect on the Companys financial position.", "length": 310, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 770, "tag": "div", "text_raw": "In the Companys opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Companys balance sheet, is not expected to have a material adverse effect on the Companys financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Companys results of operations and cash flows for that period.", "text": "However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Companys results of operations and cash flows for that period.", "length": 215, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 774, "tag": "div", "text_raw": "A significant number of personal injury claims alleging that talc causes cancer have been asserted against Johnson & Johnson Consumer Inc., its successor LTL Management LLC and the Company arising out of the use of body powders containing talc, primarily JOHNSONS Baby Powder.", "text": "A significant number of personal injury claims alleging that talc causes cancer have been asserted against Johnson & Johnson Consumer Inc., its successor LTL Management LLC and the Company arising out of the use of body powders containing talc, primarily JOHNSONS Baby Powder.", "length": 277, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 776, "tag": "div", "text_raw": "In talc cases that previously have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $ 4.7 billion in Ingham v. Johnson & Johnson, et al., No. ED 207476", "text": "In talc cases that previously have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal.", "length": 203, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 776, "tag": "div", "text_raw": "In talc cases that previously have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $ 4.7 billion in Ingham v. Johnson & Johnson, et al., No. ED 207476", "text": "In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $ 4.7 billion in Ingham v.", "length": 131, "numbers_raw": ["202", "0", "201", "8", "4.7 billion"], "numbers": [202.0, 0.0, 201.0, 8.0, 4700000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 776, "tag": "div", "text_raw": "In talc cases that previously have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $ 4.7 billion in Ingham v. Johnson & Johnson, et al., No. ED 207476", "text": "Johnson & Johnson, et al., No.", "length": 30, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 776, "tag": "div", "text_raw": "In talc cases that previously have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $ 4.7 billion in Ingham v. Johnson & Johnson, et al., No. ED 207476", "text": "ED 207476", "length": 9, "numbers_raw": ["207", "476"], "numbers": [207.0, 476.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 777, "tag": "div", "text_raw": "28", "text": "28", "length": 2, "numbers_raw": ["28"], "numbers": [28.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 778, "tag": "div", "text_raw": "28", "text": "28", "length": 2, "numbers_raw": ["28"], "numbers": [28.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 779, "tag": "div", "text_raw": "28", "text": "28", "length": 2, "numbers_raw": ["28"], "numbers": [28.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 782, "tag": "div", "text_raw": "(Mo. App.), reducing the overall award to $ 2.1 billion. An application for transfer of the case to the Missouri Supreme Court was subsequently denied and in June 2021, a petition for certiorari, seeking a review of the Ingham decision by the United States Supreme Court, was denied. In June 2021, the Company paid the award, which, including interest, totaled approximately $ 2.5 billion. The facts and circumstances, including the terms of the award, were unique to the Ingham decision and not representative of other claims brought against the Company. The Company continues to believe that it has strong legal grounds to contest the other talc verdicts that it has appealed. Notwithstanding the Companys confidence in the safety of its talc products, in certain circumstances the Company has settled cases.", "text": "App.), reducing the overall award to $ 2.1 billion.", "length": 51, "numbers_raw": ["2.1 billion"], "numbers": [2100000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 782, "tag": "div", "text_raw": "(Mo. App.), reducing the overall award to $ 2.1 billion. An application for transfer of the case to the Missouri Supreme Court was subsequently denied and in June 2021, a petition for certiorari, seeking a review of the Ingham decision by the United States Supreme Court, was denied. In June 2021, the Company paid the award, which, including interest, totaled approximately $ 2.5 billion. The facts and circumstances, including the terms of the award, were unique to the Ingham decision and not representative of other claims brought against the Company. The Company continues to believe that it has strong legal grounds to contest the other talc verdicts that it has appealed. Notwithstanding the Companys confidence in the safety of its talc products, in certain circumstances the Company has settled cases.", "text": "An application for transfer of the case to the Missouri Supreme Court was subsequently denied and in June 2021, a petition for certiorari, seeking a review of the Ingham decision by the United States Supreme Court, was denied.", "length": 226, "numbers_raw": ["202", "1"], "numbers": [202.0, 1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 782, "tag": "div", "text_raw": "(Mo. App.), reducing the overall award to $ 2.1 billion. An application for transfer of the case to the Missouri Supreme Court was subsequently denied and in June 2021, a petition for certiorari, seeking a review of the Ingham decision by the United States Supreme Court, was denied. In June 2021, the Company paid the award, which, including interest, totaled approximately $ 2.5 billion. The facts and circumstances, including the terms of the award, were unique to the Ingham decision and not representative of other claims brought against the Company. The Company continues to believe that it has strong legal grounds to contest the other talc verdicts that it has appealed. Notwithstanding the Companys confidence in the safety of its talc products, in certain circumstances the Company has settled cases.", "text": "In June 2021, the Company paid the award, which, including interest, totaled approximately $ 2.5 billion.", "length": 105, "numbers_raw": ["202", "1", "2.5 billion"], "numbers": [202.0, 1.0, 2500000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 782, "tag": "div", "text_raw": "(Mo. App.), reducing the overall award to $ 2.1 billion. An application for transfer of the case to the Missouri Supreme Court was subsequently denied and in June 2021, a petition for certiorari, seeking a review of the Ingham decision by the United States Supreme Court, was denied. In June 2021, the Company paid the award, which, including interest, totaled approximately $ 2.5 billion. The facts and circumstances, including the terms of the award, were unique to the Ingham decision and not representative of other claims brought against the Company. The Company continues to believe that it has strong legal grounds to contest the other talc verdicts that it has appealed. Notwithstanding the Companys confidence in the safety of its talc products, in certain circumstances the Company has settled cases.", "text": "The facts and circumstances, including the terms of the award, were unique to the Ingham decision and not representative of other claims brought against the Company.", "length": 165, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 782, "tag": "div", "text_raw": "(Mo. App.), reducing the overall award to $ 2.1 billion. An application for transfer of the case to the Missouri Supreme Court was subsequently denied and in June 2021, a petition for certiorari, seeking a review of the Ingham decision by the United States Supreme Court, was denied. In June 2021, the Company paid the award, which, including interest, totaled approximately $ 2.5 billion. The facts and circumstances, including the terms of the award, were unique to the Ingham decision and not representative of other claims brought against the Company. The Company continues to believe that it has strong legal grounds to contest the other talc verdicts that it has appealed. Notwithstanding the Companys confidence in the safety of its talc products, in certain circumstances the Company has settled cases.", "text": "The Company continues to believe that it has strong legal grounds to contest the other talc verdicts that it has appealed.", "length": 122, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 782, "tag": "div", "text_raw": "(Mo. App.), reducing the overall award to $ 2.1 billion. An application for transfer of the case to the Missouri Supreme Court was subsequently denied and in June 2021, a petition for certiorari, seeking a review of the Ingham decision by the United States Supreme Court, was denied. In June 2021, the Company paid the award, which, including interest, totaled approximately $ 2.5 billion. The facts and circumstances, including the terms of the award, were unique to the Ingham decision and not representative of other claims brought against the Company. The Company continues to believe that it has strong legal grounds to contest the other talc verdicts that it has appealed. Notwithstanding the Companys confidence in the safety of its talc products, in certain circumstances the Company has settled cases.", "text": "Notwithstanding the Companys confidence in the safety of its talc products, in certain circumstances the Company has settled cases.", "length": 132, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 784, "tag": "div", "text_raw": "In October 2021, Johnson & Johnson Consumer Inc. (Old JJCI) implemented a corporate restructuring (the 2021 Corporate Restructuring). As a result of that restructuring, Old JJCI ceased to exist and three new entities were created: (a) LTL Management LLC, a North Carolina limited liability company (LTL or Debtor); (b) Royalty A&M LLC, a North Carolina limited liability company and a direct subsidiary of LTL (RAM); and (c) the Debtors direct parent, Johnson & Johnson Consumer Inc., a New Jersey company (New JJCI). The Debtor received certain of Old JJCIs assets and became solely responsible for the talc-related liabilities of Old JJCI, including all liabilities related in any way to injury or damage, or alleged injury or damage, sustained or incurred in the purchase or use of, or exposure to, talc, including talc contained in any product, or to the risk of, or responsibility for, any such damage or injury, except for any liabilities for which the exclusive remedy is provided under a workers compensation statute or act (the Talc-Related Liabilities).", "text": "In October 2021, Johnson & Johnson Consumer Inc.", "length": 48, "numbers_raw": ["202", "1"], "numbers": [202.0, 1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 784, "tag": "div", "text_raw": "In October 2021, Johnson & Johnson Consumer Inc. (Old JJCI) implemented a corporate restructuring (the 2021 Corporate Restructuring). As a result of that restructuring, Old JJCI ceased to exist and three new entities were created: (a) LTL Management LLC, a North Carolina limited liability company (LTL or Debtor); (b) Royalty A&M LLC, a North Carolina limited liability company and a direct subsidiary of LTL (RAM); and (c) the Debtors direct parent, Johnson & Johnson Consumer Inc., a New Jersey company (New JJCI). The Debtor received certain of Old JJCIs assets and became solely responsible for the talc-related liabilities of Old JJCI, including all liabilities related in any way to injury or damage, or alleged injury or damage, sustained or incurred in the purchase or use of, or exposure to, talc, including talc contained in any product, or to the risk of, or responsibility for, any such damage or injury, except for any liabilities for which the exclusive remedy is provided under a workers compensation statute or act (the Talc-Related Liabilities).", "text": "(Old JJCI) implemented a corporate restructuring (the 2021 Corporate Restructuring).", "length": 84, "numbers_raw": ["202", "1"], "numbers": [202.0, 1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 784, "tag": "div", "text_raw": "In October 2021, Johnson & Johnson Consumer Inc. (Old JJCI) implemented a corporate restructuring (the 2021 Corporate Restructuring). As a result of that restructuring, Old JJCI ceased to exist and three new entities were created: (a) LTL Management LLC, a North Carolina limited liability company (LTL or Debtor); (b) Royalty A&M LLC, a North Carolina limited liability company and a direct subsidiary of LTL (RAM); and (c) the Debtors direct parent, Johnson & Johnson Consumer Inc., a New Jersey company (New JJCI). The Debtor received certain of Old JJCIs assets and became solely responsible for the talc-related liabilities of Old JJCI, including all liabilities related in any way to injury or damage, or alleged injury or damage, sustained or incurred in the purchase or use of, or exposure to, talc, including talc contained in any product, or to the risk of, or responsibility for, any such damage or injury, except for any liabilities for which the exclusive remedy is provided under a workers compensation statute or act (the Talc-Related Liabilities).", "text": "As a result of that restructuring, Old JJCI ceased to exist and three new entities were created:", "length": 96, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 784, "tag": "div", "text_raw": "In October 2021, Johnson & Johnson Consumer Inc. (Old JJCI) implemented a corporate restructuring (the 2021 Corporate Restructuring). As a result of that restructuring, Old JJCI ceased to exist and three new entities were created: (a) LTL Management LLC, a North Carolina limited liability company (LTL or Debtor); (b) Royalty A&M LLC, a North Carolina limited liability company and a direct subsidiary of LTL (RAM); and (c) the Debtors direct parent, Johnson & Johnson Consumer Inc., a New Jersey company (New JJCI). The Debtor received certain of Old JJCIs assets and became solely responsible for the talc-related liabilities of Old JJCI, including all liabilities related in any way to injury or damage, or alleged injury or damage, sustained or incurred in the purchase or use of, or exposure to, talc, including talc contained in any product, or to the risk of, or responsibility for, any such damage or injury, except for any liabilities for which the exclusive remedy is provided under a workers compensation statute or act (the Talc-Related Liabilities).", "text": "(a) LTL Management LLC, a North Carolina limited liability company (LTL or Debtor);", "length": 83, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 784, "tag": "div", "text_raw": "In October 2021, Johnson & Johnson Consumer Inc. (Old JJCI) implemented a corporate restructuring (the 2021 Corporate Restructuring). As a result of that restructuring, Old JJCI ceased to exist and three new entities were created: (a) LTL Management LLC, a North Carolina limited liability company (LTL or Debtor); (b) Royalty A&M LLC, a North Carolina limited liability company and a direct subsidiary of LTL (RAM); and (c) the Debtors direct parent, Johnson & Johnson Consumer Inc., a New Jersey company (New JJCI). The Debtor received certain of Old JJCIs assets and became solely responsible for the talc-related liabilities of Old JJCI, including all liabilities related in any way to injury or damage, or alleged injury or damage, sustained or incurred in the purchase or use of, or exposure to, talc, including talc contained in any product, or to the risk of, or responsibility for, any such damage or injury, except for any liabilities for which the exclusive remedy is provided under a workers compensation statute or act (the Talc-Related Liabilities).", "text": "(b) Royalty A&M LLC, a North Carolina limited liability company and a direct subsidiary of LTL (RAM);", "length": 101, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 784, "tag": "div", "text_raw": "In October 2021, Johnson & Johnson Consumer Inc. (Old JJCI) implemented a corporate restructuring (the 2021 Corporate Restructuring). As a result of that restructuring, Old JJCI ceased to exist and three new entities were created: (a) LTL Management LLC, a North Carolina limited liability company (LTL or Debtor); (b) Royalty A&M LLC, a North Carolina limited liability company and a direct subsidiary of LTL (RAM); and (c) the Debtors direct parent, Johnson & Johnson Consumer Inc., a New Jersey company (New JJCI). The Debtor received certain of Old JJCIs assets and became solely responsible for the talc-related liabilities of Old JJCI, including all liabilities related in any way to injury or damage, or alleged injury or damage, sustained or incurred in the purchase or use of, or exposure to, talc, including talc contained in any product, or to the risk of, or responsibility for, any such damage or injury, except for any liabilities for which the exclusive remedy is provided under a workers compensation statute or act (the Talc-Related Liabilities).", "text": "and (c) the Debtors direct parent, Johnson & Johnson Consumer Inc., a New Jersey company (New JJCI).", "length": 101, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 784, "tag": "div", "text_raw": "In October 2021, Johnson & Johnson Consumer Inc. (Old JJCI) implemented a corporate restructuring (the 2021 Corporate Restructuring). As a result of that restructuring, Old JJCI ceased to exist and three new entities were created: (a) LTL Management LLC, a North Carolina limited liability company (LTL or Debtor); (b) Royalty A&M LLC, a North Carolina limited liability company and a direct subsidiary of LTL (RAM); and (c) the Debtors direct parent, Johnson & Johnson Consumer Inc., a New Jersey company (New JJCI). The Debtor received certain of Old JJCIs assets and became solely responsible for the talc-related liabilities of Old JJCI, including all liabilities related in any way to injury or damage, or alleged injury or damage, sustained or incurred in the purchase or use of, or exposure to, talc, including talc contained in any product, or to the risk of, or responsibility for, any such damage or injury, except for any liabilities for which the exclusive remedy is provided under a workers compensation statute or act (the Talc-Related Liabilities).", "text": "The Debtor received certain of Old JJCIs assets and became solely responsible for the talc-related liabilities of Old JJCI, including all liabilities related in any way to injury or damage, or alleged injury or damage, sustained or incurred in the purchase or use of, or exposure to, talc, including talc contained in any product, or to the risk of, or responsibility for, any such damage or injury, except for any liabilities for which the exclusive remedy is provided under a workers compensation statute or act (the Talc-Related Liabilities).", "length": 547, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 786, "tag": "div", "text_raw": "In October 2021, notwithstanding the Companys confidence in the safety of its talc products, the Debtor filed a voluntary petition with the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division, seeking relief under chapter 11 of the Bankruptcy Code (the LTL Bankruptcy Case). All litigation against LTL, Old JJCI, New JJCI, the Company, other of their corporate affiliates, identified retailers, insurance companies, and certain other parties (the Protected Parties) was stayed, although LTL did agree to lift the stay on a small number of appeals where appeal bonds had been filed. The LTL Bankruptcy Case was transferred to the United States Bankruptcy Court for the District of New Jersey. Claimants filed motions to dismiss the LTL Bankruptcy Case and, following a multiple day hearing, the New Jersey Bankruptcy Court denied those motions in March 2022.", "text": "In October 2021, notwithstanding the Companys confidence in the safety of its talc products, the Debtor filed a voluntary petition with the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division, seeking relief under chapter 11 of the Bankruptcy Code (the LTL Bankruptcy Case).", "length": 317, "numbers_raw": ["202", "1", "11"], "numbers": [202.0, 1.0, 11.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 786, "tag": "div", "text_raw": "In October 2021, notwithstanding the Companys confidence in the safety of its talc products, the Debtor filed a voluntary petition with the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division, seeking relief under chapter 11 of the Bankruptcy Code (the LTL Bankruptcy Case). All litigation against LTL, Old JJCI, New JJCI, the Company, other of their corporate affiliates, identified retailers, insurance companies, and certain other parties (the Protected Parties) was stayed, although LTL did agree to lift the stay on a small number of appeals where appeal bonds had been filed. The LTL Bankruptcy Case was transferred to the United States Bankruptcy Court for the District of New Jersey. Claimants filed motions to dismiss the LTL Bankruptcy Case and, following a multiple day hearing, the New Jersey Bankruptcy Court denied those motions in March 2022.", "text": "All litigation against LTL, Old JJCI, New JJCI, the Company, other of their corporate affiliates, identified retailers, insurance companies, and certain other parties (the Protected Parties) was stayed, although LTL did agree to lift the stay on a small number of appeals where appeal bonds had been filed.", "length": 306, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 786, "tag": "div", "text_raw": "In October 2021, notwithstanding the Companys confidence in the safety of its talc products, the Debtor filed a voluntary petition with the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division, seeking relief under chapter 11 of the Bankruptcy Code (the LTL Bankruptcy Case). All litigation against LTL, Old JJCI, New JJCI, the Company, other of their corporate affiliates, identified retailers, insurance companies, and certain other parties (the Protected Parties) was stayed, although LTL did agree to lift the stay on a small number of appeals where appeal bonds had been filed. The LTL Bankruptcy Case was transferred to the United States Bankruptcy Court for the District of New Jersey. Claimants filed motions to dismiss the LTL Bankruptcy Case and, following a multiple day hearing, the New Jersey Bankruptcy Court denied those motions in March 2022.", "text": "The LTL Bankruptcy Case was transferred to the United States Bankruptcy Court for the District of New Jersey.", "length": 109, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 786, "tag": "div", "text_raw": "In October 2021, notwithstanding the Companys confidence in the safety of its talc products, the Debtor filed a voluntary petition with the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division, seeking relief under chapter 11 of the Bankruptcy Code (the LTL Bankruptcy Case). All litigation against LTL, Old JJCI, New JJCI, the Company, other of their corporate affiliates, identified retailers, insurance companies, and certain other parties (the Protected Parties) was stayed, although LTL did agree to lift the stay on a small number of appeals where appeal bonds had been filed. The LTL Bankruptcy Case was transferred to the United States Bankruptcy Court for the District of New Jersey. Claimants filed motions to dismiss the LTL Bankruptcy Case and, following a multiple day hearing, the New Jersey Bankruptcy Court denied those motions in March 2022.", "text": "Claimants filed motions to dismiss the LTL Bankruptcy Case and, following a multiple day hearing, the New Jersey Bankruptcy Court denied those motions in March 2022.", "length": 165, "numbers_raw": ["202", "2"], "numbers": [202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 788, "tag": "div", "text_raw": "The claimants subsequently filed notices of appeal as to the denial of the motions to dismiss the LTL Bankruptcy Case and the extension of the stay to the Protected Parties. On January 30, 2023, the Third Circuit reversed the Bankruptcy Courts ruling and remanded to the Bankruptcy Court to dismiss the LTL bankruptcy.", "text": "The claimants subsequently filed notices of appeal as to the denial of the motions to dismiss the LTL Bankruptcy Case and the extension of the stay to the Protected Parties.", "length": 173, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 788, "tag": "div", "text_raw": "The claimants subsequently filed notices of appeal as to the denial of the motions to dismiss the LTL Bankruptcy Case and the extension of the stay to the Protected Parties. On January 30, 2023, the Third Circuit reversed the Bankruptcy Courts ruling and remanded to the Bankruptcy Court to dismiss the LTL bankruptcy.", "text": "On January 30, 2023, the Third Circuit reversed the Bankruptcy Courts ruling and remanded to the Bankruptcy Court to dismiss the LTL bankruptcy.", "length": 145, "numbers_raw": ["30", "202", "3"], "numbers": [30.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 790, "tag": "div", "text_raw": "LTL filed a petition for rehearing of the Third Circuits decision, which was denied in March 2023. LTL subsequently filed a motion in the Third Circuit to stay the mandate directing the New Jersey Bankruptcy Court to dismiss the LTL bankruptcy pending filing and disposition of a petition for writ of certiorari to the United States Supreme Court. The Third Circuit denied the motion to stay the mandate and issued the mandate.", "text": "LTL filed a petition for rehearing of the Third Circuits decision, which was denied in March 2023.", "length": 99, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 790, "tag": "div", "text_raw": "LTL filed a petition for rehearing of the Third Circuits decision, which was denied in March 2023. LTL subsequently filed a motion in the Third Circuit to stay the mandate directing the New Jersey Bankruptcy Court to dismiss the LTL bankruptcy pending filing and disposition of a petition for writ of certiorari to the United States Supreme Court. The Third Circuit denied the motion to stay the mandate and issued the mandate.", "text": "LTL subsequently filed a motion in the Third Circuit to stay the mandate directing the New Jersey Bankruptcy Court to dismiss the LTL bankruptcy pending filing and disposition of a petition for writ of certiorari to the United States Supreme Court.", "length": 248, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 790, "tag": "div", "text_raw": "LTL filed a petition for rehearing of the Third Circuits decision, which was denied in March 2023. LTL subsequently filed a motion in the Third Circuit to stay the mandate directing the New Jersey Bankruptcy Court to dismiss the LTL bankruptcy pending filing and disposition of a petition for writ of certiorari to the United States Supreme Court. The Third Circuit denied the motion to stay the mandate and issued the mandate.", "text": "The Third Circuit denied the motion to stay the mandate and issued the mandate.", "length": 79, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 792, "tag": "div", "text_raw": "In April 2023, the New Jersey Bankruptcy Court dismissed the LTL Bankruptcy Case, effectively lifting the stay as to all parties and returning the talc litigation to the tort system. LTL re-filed in the United States Bankruptcy Court for the District of New Jersey seeking relief under chapter 11 of the Bankruptcy Code (the LTL 2 Bankruptcy Case). As a result of the new filing, all talc claims against LTL were again automatically stayed pursuant to section 362 of the Bankruptcy Code. Additionally, the New Jersey Bankruptcy Court issued a temporary restraining order staying all litigation as to LTL, Old JJCI, New JJCI, the Company, identified retailers, and certain other parties (the New Protected Parties).", "text": "In April 2023, the New Jersey Bankruptcy Court dismissed the LTL Bankruptcy Case, effectively lifting the stay as to all parties and returning the talc litigation to the tort system.", "length": 182, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 792, "tag": "div", "text_raw": "In April 2023, the New Jersey Bankruptcy Court dismissed the LTL Bankruptcy Case, effectively lifting the stay as to all parties and returning the talc litigation to the tort system. LTL re-filed in the United States Bankruptcy Court for the District of New Jersey seeking relief under chapter 11 of the Bankruptcy Code (the LTL 2 Bankruptcy Case). As a result of the new filing, all talc claims against LTL were again automatically stayed pursuant to section 362 of the Bankruptcy Code. Additionally, the New Jersey Bankruptcy Court issued a temporary restraining order staying all litigation as to LTL, Old JJCI, New JJCI, the Company, identified retailers, and certain other parties (the New Protected Parties).", "text": "LTL re-filed in the United States Bankruptcy Court for the District of New Jersey seeking relief under chapter 11 of the Bankruptcy Code (the LTL 2 Bankruptcy Case).", "length": 165, "numbers_raw": ["11", "2"], "numbers": [11.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 792, "tag": "div", "text_raw": "In April 2023, the New Jersey Bankruptcy Court dismissed the LTL Bankruptcy Case, effectively lifting the stay as to all parties and returning the talc litigation to the tort system. LTL re-filed in the United States Bankruptcy Court for the District of New Jersey seeking relief under chapter 11 of the Bankruptcy Code (the LTL 2 Bankruptcy Case). As a result of the new filing, all talc claims against LTL were again automatically stayed pursuant to section 362 of the Bankruptcy Code. Additionally, the New Jersey Bankruptcy Court issued a temporary restraining order staying all litigation as to LTL, Old JJCI, New JJCI, the Company, identified retailers, and certain other parties (the New Protected Parties).", "text": "As a result of the new filing, all talc claims against LTL were again automatically stayed pursuant to section 362 of the Bankruptcy Code.", "length": 138, "numbers_raw": ["362"], "numbers": [362.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 792, "tag": "div", "text_raw": "In April 2023, the New Jersey Bankruptcy Court dismissed the LTL Bankruptcy Case, effectively lifting the stay as to all parties and returning the talc litigation to the tort system. LTL re-filed in the United States Bankruptcy Court for the District of New Jersey seeking relief under chapter 11 of the Bankruptcy Code (the LTL 2 Bankruptcy Case). As a result of the new filing, all talc claims against LTL were again automatically stayed pursuant to section 362 of the Bankruptcy Code. Additionally, the New Jersey Bankruptcy Court issued a temporary restraining order staying all litigation as to LTL, Old JJCI, New JJCI, the Company, identified retailers, and certain other parties (the New Protected Parties).", "text": "Additionally, the New Jersey Bankruptcy Court issued a temporary restraining order staying all litigation as to LTL, Old JJCI, New JJCI, the Company, identified retailers, and certain other parties (the New Protected Parties).", "length": 226, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 794, "tag": "div", "text_raw": "Also in April 2023, the New Jersey Bankruptcy Court issued a decision that granted limited injunctive relief to the Company and the New Protected Parties (the LTL 2 Preliminary Injunction). The LTL 2 Preliminary Injunction remained in force until late August 2023, following the Bankruptcy Courts extension of the initial LTL 2 Preliminary Injunction in June 2023. Under the LTL 2 Preliminary Injunction, except for in those cases filed in the federal court ovarian cancer multi-district litigation, discovery in all personal injury and wrongful death matters was permitted to proceed. No trials could occur in any of the personal injury and wrongful death matters except for the Valadez trial after the Bankruptcy Court partially lifted the stay for Valadez and allowed it to proceed to trial. In July 2023, the jury returned a verdict in favor of Valadez for $ 18.8 million in compensatory damages but declined to award punitive damages. The Company will appeal.", "text": "Also in April 2023, the New Jersey Bankruptcy Court issued a decision that granted limited injunctive relief to the Company and the New Protected Parties (the LTL 2 Preliminary Injunction).", "length": 189, "numbers_raw": ["202", "3", "2"], "numbers": [202.0, 3.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 794, "tag": "div", "text_raw": "Also in April 2023, the New Jersey Bankruptcy Court issued a decision that granted limited injunctive relief to the Company and the New Protected Parties (the LTL 2 Preliminary Injunction). The LTL 2 Preliminary Injunction remained in force until late August 2023, following the Bankruptcy Courts extension of the initial LTL 2 Preliminary Injunction in June 2023. Under the LTL 2 Preliminary Injunction, except for in those cases filed in the federal court ovarian cancer multi-district litigation, discovery in all personal injury and wrongful death matters was permitted to proceed. No trials could occur in any of the personal injury and wrongful death matters except for the Valadez trial after the Bankruptcy Court partially lifted the stay for Valadez and allowed it to proceed to trial. In July 2023, the jury returned a verdict in favor of Valadez for $ 18.8 million in compensatory damages but declined to award punitive damages. The Company will appeal.", "text": "The LTL 2 Preliminary Injunction remained in force until late August 2023, following the Bankruptcy Courts extension of the initial LTL 2 Preliminary Injunction in June 2023.", "length": 175, "numbers_raw": ["2", "202", "3", "2", "202", "3"], "numbers": [2.0, 202.0, 3.0, 2.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 794, "tag": "div", "text_raw": "Also in April 2023, the New Jersey Bankruptcy Court issued a decision that granted limited injunctive relief to the Company and the New Protected Parties (the LTL 2 Preliminary Injunction). The LTL 2 Preliminary Injunction remained in force until late August 2023, following the Bankruptcy Courts extension of the initial LTL 2 Preliminary Injunction in June 2023. Under the LTL 2 Preliminary Injunction, except for in those cases filed in the federal court ovarian cancer multi-district litigation, discovery in all personal injury and wrongful death matters was permitted to proceed. No trials could occur in any of the personal injury and wrongful death matters except for the Valadez trial after the Bankruptcy Court partially lifted the stay for Valadez and allowed it to proceed to trial. In July 2023, the jury returned a verdict in favor of Valadez for $ 18.8 million in compensatory damages but declined to award punitive damages. The Company will appeal.", "text": "Under the LTL 2 Preliminary Injunction, except for in those cases filed in the federal court ovarian cancer multi-district litigation, discovery in all personal injury and wrongful death matters was permitted to proceed.", "length": 220, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 794, "tag": "div", "text_raw": "Also in April 2023, the New Jersey Bankruptcy Court issued a decision that granted limited injunctive relief to the Company and the New Protected Parties (the LTL 2 Preliminary Injunction). The LTL 2 Preliminary Injunction remained in force until late August 2023, following the Bankruptcy Courts extension of the initial LTL 2 Preliminary Injunction in June 2023. Under the LTL 2 Preliminary Injunction, except for in those cases filed in the federal court ovarian cancer multi-district litigation, discovery in all personal injury and wrongful death matters was permitted to proceed. No trials could occur in any of the personal injury and wrongful death matters except for the Valadez trial after the Bankruptcy Court partially lifted the stay for Valadez and allowed it to proceed to trial. In July 2023, the jury returned a verdict in favor of Valadez for $ 18.8 million in compensatory damages but declined to award punitive damages. The Company will appeal.", "text": "No trials could occur in any of the personal injury and wrongful death matters except for the Valadez trial after the Bankruptcy Court partially lifted the stay for Valadez and allowed it to proceed to trial.", "length": 208, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 794, "tag": "div", "text_raw": "Also in April 2023, the New Jersey Bankruptcy Court issued a decision that granted limited injunctive relief to the Company and the New Protected Parties (the LTL 2 Preliminary Injunction). The LTL 2 Preliminary Injunction remained in force until late August 2023, following the Bankruptcy Courts extension of the initial LTL 2 Preliminary Injunction in June 2023. Under the LTL 2 Preliminary Injunction, except for in those cases filed in the federal court ovarian cancer multi-district litigation, discovery in all personal injury and wrongful death matters was permitted to proceed. No trials could occur in any of the personal injury and wrongful death matters except for the Valadez trial after the Bankruptcy Court partially lifted the stay for Valadez and allowed it to proceed to trial. In July 2023, the jury returned a verdict in favor of Valadez for $ 18.8 million in compensatory damages but declined to award punitive damages. The Company will appeal.", "text": "In July 2023, the jury returned a verdict in favor of Valadez for $ 18.8 million in compensatory damages but declined to award punitive damages.", "length": 144, "numbers_raw": ["202", "3", "18.8 million"], "numbers": [202.0, 3.0, 18800000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 796, "tag": "div", "text_raw": "Furthermore, in April 2023, the Talc Claimants' Committee filed a motion to dismiss the LTL 2 Bankruptcy followed by similar motions from other claimants. Hearings on the motions to dismiss occurred in June 2023. On July 28, 2023, the court dismissed the LTL 2 Bankruptcy case and, the same day, the Company stated its intent to appeal the decision and to continue its efforts to obtain a resolution of the talc claims. In September 2023, the Bankruptcy Court entered an order granting LTL leave to seek a direct appeal to the Third Circuit Court of Appeals. On October 20, 2023, the Third Circuit granted LTLs petition for a direct appeal. Since the dismissal of the LTL 2 Bankruptcy case, litigation in the tort system has reactivated.", "text": "Furthermore, in April 2023, the Talc Claimants' Committee filed a motion to dismiss the LTL 2 Bankruptcy followed by similar motions from other claimants.", "length": 154, "numbers_raw": ["202", "3", "2"], "numbers": [202.0, 3.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 796, "tag": "div", "text_raw": "Furthermore, in April 2023, the Talc Claimants' Committee filed a motion to dismiss the LTL 2 Bankruptcy followed by similar motions from other claimants. Hearings on the motions to dismiss occurred in June 2023. On July 28, 2023, the court dismissed the LTL 2 Bankruptcy case and, the same day, the Company stated its intent to appeal the decision and to continue its efforts to obtain a resolution of the talc claims. In September 2023, the Bankruptcy Court entered an order granting LTL leave to seek a direct appeal to the Third Circuit Court of Appeals. On October 20, 2023, the Third Circuit granted LTLs petition for a direct appeal. Since the dismissal of the LTL 2 Bankruptcy case, litigation in the tort system has reactivated.", "text": "Hearings on the motions to dismiss occurred in June 2023.", "length": 57, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 796, "tag": "div", "text_raw": "Furthermore, in April 2023, the Talc Claimants' Committee filed a motion to dismiss the LTL 2 Bankruptcy followed by similar motions from other claimants. Hearings on the motions to dismiss occurred in June 2023. On July 28, 2023, the court dismissed the LTL 2 Bankruptcy case and, the same day, the Company stated its intent to appeal the decision and to continue its efforts to obtain a resolution of the talc claims. In September 2023, the Bankruptcy Court entered an order granting LTL leave to seek a direct appeal to the Third Circuit Court of Appeals. On October 20, 2023, the Third Circuit granted LTLs petition for a direct appeal. Since the dismissal of the LTL 2 Bankruptcy case, litigation in the tort system has reactivated.", "text": "On July 28, 2023, the court dismissed the LTL 2 Bankruptcy case and, the same day, the Company stated its intent to appeal the decision and to continue its efforts to obtain a resolution of the talc claims.", "length": 206, "numbers_raw": ["28", "202", "3", "2"], "numbers": [28.0, 202.0, 3.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 796, "tag": "div", "text_raw": "Furthermore, in April 2023, the Talc Claimants' Committee filed a motion to dismiss the LTL 2 Bankruptcy followed by similar motions from other claimants. Hearings on the motions to dismiss occurred in June 2023. On July 28, 2023, the court dismissed the LTL 2 Bankruptcy case and, the same day, the Company stated its intent to appeal the decision and to continue its efforts to obtain a resolution of the talc claims. In September 2023, the Bankruptcy Court entered an order granting LTL leave to seek a direct appeal to the Third Circuit Court of Appeals. On October 20, 2023, the Third Circuit granted LTLs petition for a direct appeal. Since the dismissal of the LTL 2 Bankruptcy case, litigation in the tort system has reactivated.", "text": "In September 2023, the Bankruptcy Court entered an order granting LTL leave to seek a direct appeal to the Third Circuit Court of Appeals.", "length": 138, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 796, "tag": "div", "text_raw": "Furthermore, in April 2023, the Talc Claimants' Committee filed a motion to dismiss the LTL 2 Bankruptcy followed by similar motions from other claimants. Hearings on the motions to dismiss occurred in June 2023. On July 28, 2023, the court dismissed the LTL 2 Bankruptcy case and, the same day, the Company stated its intent to appeal the decision and to continue its efforts to obtain a resolution of the talc claims. In September 2023, the Bankruptcy Court entered an order granting LTL leave to seek a direct appeal to the Third Circuit Court of Appeals. On October 20, 2023, the Third Circuit granted LTLs petition for a direct appeal. Since the dismissal of the LTL 2 Bankruptcy case, litigation in the tort system has reactivated.", "text": "On October 20, 2023, the Third Circuit granted LTLs petition for a direct appeal.", "length": 82, "numbers_raw": ["20", "202", "3"], "numbers": [20.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 796, "tag": "div", "text_raw": "Furthermore, in April 2023, the Talc Claimants' Committee filed a motion to dismiss the LTL 2 Bankruptcy followed by similar motions from other claimants. Hearings on the motions to dismiss occurred in June 2023. On July 28, 2023, the court dismissed the LTL 2 Bankruptcy case and, the same day, the Company stated its intent to appeal the decision and to continue its efforts to obtain a resolution of the talc claims. In September 2023, the Bankruptcy Court entered an order granting LTL leave to seek a direct appeal to the Third Circuit Court of Appeals. On October 20, 2023, the Third Circuit granted LTLs petition for a direct appeal. Since the dismissal of the LTL 2 Bankruptcy case, litigation in the tort system has reactivated.", "text": "Since the dismissal of the LTL 2 Bankruptcy case, litigation in the tort system has reactivated.", "length": 96, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 798, "tag": "div", "text_raw": "In the original bankruptcy case, the Company agreed to provide funding to LTL for the payment of amounts the New Jersey Bankruptcy Court determines are owed by LTL and the establishment of a $ 2 billion trust in furtherance of this purpose. The", "text": "In the original bankruptcy case, the Company agreed to provide funding to LTL for the payment of amounts the New Jersey Bankruptcy Court determines are owed by LTL and the establishment of a $ 2 billion trust in furtherance of this purpose.", "length": 240, "numbers_raw": ["2 billion"], "numbers": [2000000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 799, "tag": "div", "text_raw": "29", "text": "29", "length": 2, "numbers_raw": ["29"], "numbers": [29.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 800, "tag": "div", "text_raw": "29", "text": "29", "length": 2, "numbers_raw": ["29"], "numbers": [29.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 801, "tag": "div", "text_raw": "29", "text": "29", "length": 2, "numbers_raw": ["29"], "numbers": [29.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 804, "tag": "div", "text_raw": "Company established a reserve for approximately $ 2 billion in connection with the aforementioned trust. During the bankruptcy proceedings LTL had been de-consolidated by the Company. In the LTL 2 Bankruptcy Case, the Company had agreed to contribute an additional amount which, when added to the prior $ 2 billion, would be a total reserve of approximately $ 9 billion payable over 25 years (nominal value approximately $ 12 billion discounted at a rate of 4.41 %), to resolve all the current and future talc claims. The approximate $ 9 billion reserve, of which approximately one-third is recorded as a current liability, remains the Companys best estimate of probable loss after the dismissal.", "text": "Company established a reserve for approximately $ 2 billion in connection with the aforementioned trust.", "length": 104, "numbers_raw": ["2 billion"], "numbers": [2000000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 804, "tag": "div", "text_raw": "Company established a reserve for approximately $ 2 billion in connection with the aforementioned trust. During the bankruptcy proceedings LTL had been de-consolidated by the Company. In the LTL 2 Bankruptcy Case, the Company had agreed to contribute an additional amount which, when added to the prior $ 2 billion, would be a total reserve of approximately $ 9 billion payable over 25 years (nominal value approximately $ 12 billion discounted at a rate of 4.41 %), to resolve all the current and future talc claims. The approximate $ 9 billion reserve, of which approximately one-third is recorded as a current liability, remains the Companys best estimate of probable loss after the dismissal.", "text": "During the bankruptcy proceedings LTL had been de-consolidated by the Company.", "length": 78, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 804, "tag": "div", "text_raw": "Company established a reserve for approximately $ 2 billion in connection with the aforementioned trust. During the bankruptcy proceedings LTL had been de-consolidated by the Company. In the LTL 2 Bankruptcy Case, the Company had agreed to contribute an additional amount which, when added to the prior $ 2 billion, would be a total reserve of approximately $ 9 billion payable over 25 years (nominal value approximately $ 12 billion discounted at a rate of 4.41 %), to resolve all the current and future talc claims. The approximate $ 9 billion reserve, of which approximately one-third is recorded as a current liability, remains the Companys best estimate of probable loss after the dismissal.", "text": "In the LTL 2 Bankruptcy Case, the Company had agreed to contribute an additional amount which, when added to the prior $ 2 billion, would be a total reserve of approximately $ 9 billion payable over 25 years (nominal value approximately $ 12 billion discounted at a rate of 4.41 %), to resolve all the current and future talc claims.", "length": 333, "numbers_raw": ["2", "2 billion", "9 billion", "25", "12 billion", "4.41"], "numbers": [2.0, 2000000000.0, 9000000000.0, 25.0, 12000000000.0, 4.41], "percents_raw": ["4.41 %"], "percents": [0.0441], "currencies": ["USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 804, "tag": "div", "text_raw": "Company established a reserve for approximately $ 2 billion in connection with the aforementioned trust. During the bankruptcy proceedings LTL had been de-consolidated by the Company. In the LTL 2 Bankruptcy Case, the Company had agreed to contribute an additional amount which, when added to the prior $ 2 billion, would be a total reserve of approximately $ 9 billion payable over 25 years (nominal value approximately $ 12 billion discounted at a rate of 4.41 %), to resolve all the current and future talc claims. The approximate $ 9 billion reserve, of which approximately one-third is recorded as a current liability, remains the Companys best estimate of probable loss after the dismissal.", "text": "The approximate $ 9 billion reserve, of which approximately one-third is recorded as a current liability, remains the Companys best estimate of probable loss after the dismissal.", "length": 179, "numbers_raw": ["9 billion"], "numbers": [9000000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 806, "tag": "div", "text_raw": "The parties have not yet reached a resolution of all talc matters and the Company is unable to estimate the possible loss or range of loss beyond the amount accrued.", "text": "The parties have not yet reached a resolution of all talc matters and the Company is unable to estimate the possible loss or range of loss beyond the amount accrued.", "length": 165, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 808, "tag": "div", "text_raw": "A class action advancing claims relating to industrial talc was filed against the Company and others in New Jersey state court in May 2022 (the Edley Class Action). The Edley Class Action asserts, among other things, that the Company fraudulently defended past asbestos personal injury lawsuits arising from exposure to industrial talc mined, milled, and manufactured before January 6, 1989 by the Companys then wholly owned subsidiary, Windsor Minerals, Inc., which is currently a debtor in the Imerys Bankruptcy described hereafter. The Company removed the Edley Class Action to federal court in the District of New Jersey. In October 2022, the Company filed motions to dismiss and to deny certification of a class to pursue the Edley Class Action in the New Jersey District Court. Argument on the motions is scheduled for November 2023.", "text": "A class action advancing claims relating to industrial talc was filed against the Company and others in New Jersey state court in May 2022 (the Edley Class Action).", "length": 164, "numbers_raw": ["202", "2"], "numbers": [202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 808, "tag": "div", "text_raw": "A class action advancing claims relating to industrial talc was filed against the Company and others in New Jersey state court in May 2022 (the Edley Class Action). The Edley Class Action asserts, among other things, that the Company fraudulently defended past asbestos personal injury lawsuits arising from exposure to industrial talc mined, milled, and manufactured before January 6, 1989 by the Companys then wholly owned subsidiary, Windsor Minerals, Inc., which is currently a debtor in the Imerys Bankruptcy described hereafter. The Company removed the Edley Class Action to federal court in the District of New Jersey. In October 2022, the Company filed motions to dismiss and to deny certification of a class to pursue the Edley Class Action in the New Jersey District Court. Argument on the motions is scheduled for November 2023.", "text": "The Edley Class Action asserts, among other things, that the Company fraudulently defended past asbestos personal injury lawsuits arising from exposure to industrial talc mined, milled, and manufactured before January 6, 1989 by the Companys then wholly owned subsidiary, Windsor Minerals, Inc., which is currently a debtor in the Imerys Bankruptcy described hereafter.", "length": 370, "numbers_raw": ["6", "198", "9"], "numbers": [6.0, 198.0, 9.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 808, "tag": "div", "text_raw": "A class action advancing claims relating to industrial talc was filed against the Company and others in New Jersey state court in May 2022 (the Edley Class Action). The Edley Class Action asserts, among other things, that the Company fraudulently defended past asbestos personal injury lawsuits arising from exposure to industrial talc mined, milled, and manufactured before January 6, 1989 by the Companys then wholly owned subsidiary, Windsor Minerals, Inc., which is currently a debtor in the Imerys Bankruptcy described hereafter. The Company removed the Edley Class Action to federal court in the District of New Jersey. In October 2022, the Company filed motions to dismiss and to deny certification of a class to pursue the Edley Class Action in the New Jersey District Court. Argument on the motions is scheduled for November 2023.", "text": "The Company removed the Edley Class Action to federal court in the District of New Jersey.", "length": 90, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 808, "tag": "div", "text_raw": "A class action advancing claims relating to industrial talc was filed against the Company and others in New Jersey state court in May 2022 (the Edley Class Action). The Edley Class Action asserts, among other things, that the Company fraudulently defended past asbestos personal injury lawsuits arising from exposure to industrial talc mined, milled, and manufactured before January 6, 1989 by the Companys then wholly owned subsidiary, Windsor Minerals, Inc., which is currently a debtor in the Imerys Bankruptcy described hereafter. The Company removed the Edley Class Action to federal court in the District of New Jersey. In October 2022, the Company filed motions to dismiss and to deny certification of a class to pursue the Edley Class Action in the New Jersey District Court. Argument on the motions is scheduled for November 2023.", "text": "In October 2022, the Company filed motions to dismiss and to deny certification of a class to pursue the Edley Class Action in the New Jersey District Court.", "length": 157, "numbers_raw": ["202", "2"], "numbers": [202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 808, "tag": "div", "text_raw": "A class action advancing claims relating to industrial talc was filed against the Company and others in New Jersey state court in May 2022 (the Edley Class Action). The Edley Class Action asserts, among other things, that the Company fraudulently defended past asbestos personal injury lawsuits arising from exposure to industrial talc mined, milled, and manufactured before January 6, 1989 by the Companys then wholly owned subsidiary, Windsor Minerals, Inc., which is currently a debtor in the Imerys Bankruptcy described hereafter. The Company removed the Edley Class Action to federal court in the District of New Jersey. In October 2022, the Company filed motions to dismiss and to deny certification of a class to pursue the Edley Class Action in the New Jersey District Court. Argument on the motions is scheduled for November 2023.", "text": "Argument on the motions is scheduled for November 2023.", "length": 55, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 810, "tag": "div", "text_raw": "In February 2019, the Companys talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary petition for relief under chapter 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imeryss potential liability for personal injury from exposure to talcum powder sold by Imerys. In its bankruptcy, Imerys alleges it has claims against the Company for indemnification and rights to joint insurance proceeds. In its bankruptcy, Imerys proposed a chapter 11 plan (the Imerys Plan) that contemplated all talc-related claims against it being channeled to a trust along with its alleged indemnification rights against the Company. Following confirmation and consummation of the plan, the trust would pay talc claims pursuant to proposed trust distribution procedures and then seek indemnification from the Company.", "text": "In February 2019, the Companys talc supplier, Imerys Talc America, Inc.", "length": 72, "numbers_raw": ["201", "9"], "numbers": [201.0, 9.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 810, "tag": "div", "text_raw": "In February 2019, the Companys talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary petition for relief under chapter 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imeryss potential liability for personal injury from exposure to talcum powder sold by Imerys. In its bankruptcy, Imerys alleges it has claims against the Company for indemnification and rights to joint insurance proceeds. In its bankruptcy, Imerys proposed a chapter 11 plan (the Imerys Plan) that contemplated all talc-related claims against it being channeled to a trust along with its alleged indemnification rights against the Company. Following confirmation and consummation of the plan, the trust would pay talc claims pursuant to proposed trust distribution procedures and then seek indemnification from the Company.", "text": "and two of its affiliates, Imerys Talc Vermont, Inc.", "length": 52, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 810, "tag": "div", "text_raw": "In February 2019, the Companys talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary petition for relief under chapter 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imeryss potential liability for personal injury from exposure to talcum powder sold by Imerys. In its bankruptcy, Imerys alleges it has claims against the Company for indemnification and rights to joint insurance proceeds. In its bankruptcy, Imerys proposed a chapter 11 plan (the Imerys Plan) that contemplated all talc-related claims against it being channeled to a trust along with its alleged indemnification rights against the Company. Following confirmation and consummation of the plan, the trust would pay talc claims pursuant to proposed trust distribution procedures and then seek indemnification from the Company.", "text": "(collectively, Imerys) filed a voluntary petition for relief under chapter 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy).", "length": 213, "numbers_raw": ["11"], "numbers": [11.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 810, "tag": "div", "text_raw": "In February 2019, the Companys talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary petition for relief under chapter 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imeryss potential liability for personal injury from exposure to talcum powder sold by Imerys. In its bankruptcy, Imerys alleges it has claims against the Company for indemnification and rights to joint insurance proceeds. In its bankruptcy, Imerys proposed a chapter 11 plan (the Imerys Plan) that contemplated all talc-related claims against it being channeled to a trust along with its alleged indemnification rights against the Company. Following confirmation and consummation of the plan, the trust would pay talc claims pursuant to proposed trust distribution procedures and then seek indemnification from the Company.", "text": "The Imerys Bankruptcy relates to Imeryss potential liability for personal injury from exposure to talcum powder sold by Imerys.", "length": 128, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 810, "tag": "div", "text_raw": "In February 2019, the Companys talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary petition for relief under chapter 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imeryss potential liability for personal injury from exposure to talcum powder sold by Imerys. In its bankruptcy, Imerys alleges it has claims against the Company for indemnification and rights to joint insurance proceeds. In its bankruptcy, Imerys proposed a chapter 11 plan (the Imerys Plan) that contemplated all talc-related claims against it being channeled to a trust along with its alleged indemnification rights against the Company. Following confirmation and consummation of the plan, the trust would pay talc claims pursuant to proposed trust distribution procedures and then seek indemnification from the Company.", "text": "In its bankruptcy, Imerys alleges it has claims against the Company for indemnification and rights to joint insurance proceeds.", "length": 127, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 810, "tag": "div", "text_raw": "In February 2019, the Companys talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary petition for relief under chapter 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imeryss potential liability for personal injury from exposure to talcum powder sold by Imerys. In its bankruptcy, Imerys alleges it has claims against the Company for indemnification and rights to joint insurance proceeds. In its bankruptcy, Imerys proposed a chapter 11 plan (the Imerys Plan) that contemplated all talc-related claims against it being channeled to a trust along with its alleged indemnification rights against the Company. Following confirmation and consummation of the plan, the trust would pay talc claims pursuant to proposed trust distribution procedures and then seek indemnification from the Company.", "text": "In its bankruptcy, Imerys proposed a chapter 11 plan (the Imerys Plan) that contemplated all talc-related claims against it being channeled to a trust along with its alleged indemnification rights against the Company.", "length": 217, "numbers_raw": ["11"], "numbers": [11.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 810, "tag": "div", "text_raw": "In February 2019, the Companys talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary petition for relief under chapter 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imeryss potential liability for personal injury from exposure to talcum powder sold by Imerys. In its bankruptcy, Imerys alleges it has claims against the Company for indemnification and rights to joint insurance proceeds. In its bankruptcy, Imerys proposed a chapter 11 plan (the Imerys Plan) that contemplated all talc-related claims against it being channeled to a trust along with its alleged indemnification rights against the Company. Following confirmation and consummation of the plan, the trust would pay talc claims pursuant to proposed trust distribution procedures and then seek indemnification from the Company.", "text": "Following confirmation and consummation of the plan, the trust would pay talc claims pursuant to proposed trust distribution procedures and then seek indemnification from the Company.", "length": 183, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 812, "tag": "div", "text_raw": "In February 2021, Cyprus Mines Corporation (Cyprus), which had owned certain Imerys talc mines, filed a voluntary petition for relief under chapter 11 of the Bankruptcy Code and filed its Disclosure Statement and Plan (the Cyprus Plan). The Cyprus Plan contemplates a settlement with Imerys and talc claimants where Cyprus would make a monetary contribution to a trust established under the Imerys Plan in exchange for an injunction against talc claims asserted against it and certain affiliated parties.", "text": "In February 2021, Cyprus Mines Corporation (Cyprus), which had owned certain Imerys talc mines, filed a voluntary petition for relief under chapter 11 of the Bankruptcy Code and filed its Disclosure Statement and Plan (the Cyprus Plan).", "length": 236, "numbers_raw": ["202", "1", "11"], "numbers": [202.0, 1.0, 11.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 812, "tag": "div", "text_raw": "In February 2021, Cyprus Mines Corporation (Cyprus), which had owned certain Imerys talc mines, filed a voluntary petition for relief under chapter 11 of the Bankruptcy Code and filed its Disclosure Statement and Plan (the Cyprus Plan). The Cyprus Plan contemplates a settlement with Imerys and talc claimants where Cyprus would make a monetary contribution to a trust established under the Imerys Plan in exchange for an injunction against talc claims asserted against it and certain affiliated parties.", "text": "The Cyprus Plan contemplates a settlement with Imerys and talc claimants where Cyprus would make a monetary contribution to a trust established under the Imerys Plan in exchange for an injunction against talc claims asserted against it and certain affiliated parties.", "length": 267, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 814, "tag": "div", "text_raw": "The Imerys Plan proceeded to solicitation in early 2021. However, the Imerys Plan did not receive the requisite number of votes to be confirmed after the Bankruptcy Court ruled certain votes cast in favor of the Imerys Plan should be disregarded. Imerys subsequently canceled its confirmation hearing.", "text": "The Imerys Plan proceeded to solicitation in early 2021.", "length": 56, "numbers_raw": ["202", "1"], "numbers": [202.0, 1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 814, "tag": "div", "text_raw": "The Imerys Plan proceeded to solicitation in early 2021. However, the Imerys Plan did not receive the requisite number of votes to be confirmed after the Bankruptcy Court ruled certain votes cast in favor of the Imerys Plan should be disregarded. Imerys subsequently canceled its confirmation hearing.", "text": "However, the Imerys Plan did not receive the requisite number of votes to be confirmed after the Bankruptcy Court ruled certain votes cast in favor of the Imerys Plan should be disregarded.", "length": 189, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 814, "tag": "div", "text_raw": "The Imerys Plan proceeded to solicitation in early 2021. However, the Imerys Plan did not receive the requisite number of votes to be confirmed after the Bankruptcy Court ruled certain votes cast in favor of the Imerys Plan should be disregarded. Imerys subsequently canceled its confirmation hearing.", "text": "Imerys subsequently canceled its confirmation hearing.", "length": 54, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 816, "tag": "div", "text_raw": "Imerys, the Imerys Tort Claimants Committee, and the Imerys Future Claimants Representative, along with Cyprus, the Cyprus Tort Claimants Committee, and the Cyprus Future Claimants Representative (collectively the Mediation Parties) have been engaged in mediation since shortly after the confirmation hearing was cancelled in October 2021. In September 2023, the Bankruptcy Court entered an order extending the term of the mediation among the Mediation Parties through the end of December 2023. The Bankruptcy Court also authorized Imerys and Cyprus to proceed with mediation with certain of their insurers.", "text": "Imerys, the Imerys Tort Claimants Committee, and the Imerys Future Claimants Representative, along with Cyprus, the Cyprus Tort Claimants Committee, and the Cyprus Future Claimants Representative (collectively the Mediation Parties) have been engaged in mediation since shortly after the confirmation hearing was cancelled in October 2021.", "length": 343, "numbers_raw": ["202", "1"], "numbers": [202.0, 1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 816, "tag": "div", "text_raw": "Imerys, the Imerys Tort Claimants Committee, and the Imerys Future Claimants Representative, along with Cyprus, the Cyprus Tort Claimants Committee, and the Cyprus Future Claimants Representative (collectively the Mediation Parties) have been engaged in mediation since shortly after the confirmation hearing was cancelled in October 2021. In September 2023, the Bankruptcy Court entered an order extending the term of the mediation among the Mediation Parties through the end of December 2023. The Bankruptcy Court also authorized Imerys and Cyprus to proceed with mediation with certain of their insurers.", "text": "In September 2023, the Bankruptcy Court entered an order extending the term of the mediation among the Mediation Parties through the end of December 2023.", "length": 154, "numbers_raw": ["202", "3", "202", "3"], "numbers": [202.0, 3.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 816, "tag": "div", "text_raw": "Imerys, the Imerys Tort Claimants Committee, and the Imerys Future Claimants Representative, along with Cyprus, the Cyprus Tort Claimants Committee, and the Cyprus Future Claimants Representative (collectively the Mediation Parties) have been engaged in mediation since shortly after the confirmation hearing was cancelled in October 2021. In September 2023, the Bankruptcy Court entered an order extending the term of the mediation among the Mediation Parties through the end of December 2023. The Bankruptcy Court also authorized Imerys and Cyprus to proceed with mediation with certain of their insurers.", "text": "The Bankruptcy Court also authorized Imerys and Cyprus to proceed with mediation with certain of their insurers.", "length": 112, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 818, "tag": "div", "text_raw": "In September 2023, Imerys and Cyprus filed amended plans of reorganization. The amended plans contemplate a similar construct as the prior Imerys and Cyprus Plans, including all talc claims against Imerys and Cyprus (and certain other protected parties) being channeled to a trust along with Imeryss and Cypruss alleged indemnification rights against the Company. Imerys and Cyprus have not yet filed disclosure statements for their respective chapter 11 plans.", "text": "In September 2023, Imerys and Cyprus filed amended plans of reorganization.", "length": 75, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 818, "tag": "div", "text_raw": "In September 2023, Imerys and Cyprus filed amended plans of reorganization. The amended plans contemplate a similar construct as the prior Imerys and Cyprus Plans, including all talc claims against Imerys and Cyprus (and certain other protected parties) being channeled to a trust along with Imeryss and Cypruss alleged indemnification rights against the Company. Imerys and Cyprus have not yet filed disclosure statements for their respective chapter 11 plans.", "text": "The amended plans contemplate a similar construct as the prior Imerys and Cyprus Plans, including all talc claims against Imerys and Cyprus (and certain other protected parties) being channeled to a trust along with Imeryss and Cypruss alleged indemnification rights against the Company.", "length": 289, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 818, "tag": "div", "text_raw": "In September 2023, Imerys and Cyprus filed amended plans of reorganization. The amended plans contemplate a similar construct as the prior Imerys and Cyprus Plans, including all talc claims against Imerys and Cyprus (and certain other protected parties) being channeled to a trust along with Imeryss and Cypruss alleged indemnification rights against the Company. Imerys and Cyprus have not yet filed disclosure statements for their respective chapter 11 plans.", "text": "Imerys and Cyprus have not yet filed disclosure statements for their respective chapter 11 plans.", "length": 97, "numbers_raw": ["11"], "numbers": [11.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 820, "tag": "div", "text_raw": "In February 2018, a securities class action lawsuit was filed against the Company and certain named officers in the United States District Court for the District of New Jersey, alleging that the Company violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSONS Baby Powder, and that purchasers of the Companys shares suffered losses as a result. In April 2019, the Company moved to dismiss the complaint. In December 2019, the Court denied, in part, the motion to dismiss. In April 2021, briefing on Plaintiffs motion for class certification was completed. The case was stayed in May 2022 pursuant to the LTL Bankruptcy Case and was reopened in May 2023. Fact discovery is proceeding and scheduled to be completed by December 2023.", "text": "In February 2018, a securities class action lawsuit was filed against the Company and certain named officers in the United States District Court for the District of New Jersey, alleging that the Company violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSONS Baby Powder, and that purchasers of the Companys shares suffered losses as a result.", "length": 432, "numbers_raw": ["201", "8"], "numbers": [201.0, 8.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 820, "tag": "div", "text_raw": "In February 2018, a securities class action lawsuit was filed against the Company and certain named officers in the United States District Court for the District of New Jersey, alleging that the Company violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSONS Baby Powder, and that purchasers of the Companys shares suffered losses as a result. In April 2019, the Company moved to dismiss the complaint. In December 2019, the Court denied, in part, the motion to dismiss. In April 2021, briefing on Plaintiffs motion for class certification was completed. The case was stayed in May 2022 pursuant to the LTL Bankruptcy Case and was reopened in May 2023. Fact discovery is proceeding and scheduled to be completed by December 2023.", "text": "In April 2019, the Company moved to dismiss the complaint.", "length": 58, "numbers_raw": ["201", "9"], "numbers": [201.0, 9.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 820, "tag": "div", "text_raw": "In February 2018, a securities class action lawsuit was filed against the Company and certain named officers in the United States District Court for the District of New Jersey, alleging that the Company violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSONS Baby Powder, and that purchasers of the Companys shares suffered losses as a result. In April 2019, the Company moved to dismiss the complaint. In December 2019, the Court denied, in part, the motion to dismiss. In April 2021, briefing on Plaintiffs motion for class certification was completed. The case was stayed in May 2022 pursuant to the LTL Bankruptcy Case and was reopened in May 2023. Fact discovery is proceeding and scheduled to be completed by December 2023.", "text": "In December 2019, the Court denied, in part, the motion to dismiss.", "length": 67, "numbers_raw": ["201", "9"], "numbers": [201.0, 9.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 820, "tag": "div", "text_raw": "In February 2018, a securities class action lawsuit was filed against the Company and certain named officers in the United States District Court for the District of New Jersey, alleging that the Company violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSONS Baby Powder, and that purchasers of the Companys shares suffered losses as a result. In April 2019, the Company moved to dismiss the complaint. In December 2019, the Court denied, in part, the motion to dismiss. In April 2021, briefing on Plaintiffs motion for class certification was completed. The case was stayed in May 2022 pursuant to the LTL Bankruptcy Case and was reopened in May 2023. Fact discovery is proceeding and scheduled to be completed by December 2023.", "text": "In April 2021, briefing on Plaintiffs motion for class certification was completed.", "length": 84, "numbers_raw": ["202", "1"], "numbers": [202.0, 1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 820, "tag": "div", "text_raw": "In February 2018, a securities class action lawsuit was filed against the Company and certain named officers in the United States District Court for the District of New Jersey, alleging that the Company violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSONS Baby Powder, and that purchasers of the Companys shares suffered losses as a result. In April 2019, the Company moved to dismiss the complaint. In December 2019, the Court denied, in part, the motion to dismiss. In April 2021, briefing on Plaintiffs motion for class certification was completed. The case was stayed in May 2022 pursuant to the LTL Bankruptcy Case and was reopened in May 2023. Fact discovery is proceeding and scheduled to be completed by December 2023.", "text": "The case was stayed in May 2022 pursuant to the LTL Bankruptcy Case and was reopened in May 2023.", "length": 97, "numbers_raw": ["202", "2", "202", "3"], "numbers": [202.0, 2.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 820, "tag": "div", "text_raw": "In February 2018, a securities class action lawsuit was filed against the Company and certain named officers in the United States District Court for the District of New Jersey, alleging that the Company violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSONS Baby Powder, and that purchasers of the Companys shares suffered losses as a result. In April 2019, the Company moved to dismiss the complaint. In December 2019, the Court denied, in part, the motion to dismiss. In April 2021, briefing on Plaintiffs motion for class certification was completed. The case was stayed in May 2022 pursuant to the LTL Bankruptcy Case and was reopened in May 2023. Fact discovery is proceeding and scheduled to be completed by December 2023.", "text": "Fact discovery is proceeding and scheduled to be completed by December 2023.", "length": 76, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 822, "tag": "div", "text_raw": "A lawsuit was brought against the Company in the Superior Court of California for the County of San Diego alleging violations of Californias Consumer Legal Remedies Act (CLRA) relating to JOHNSONS Baby Powder. In that lawsuit, the plaintiffs allege that the Company violated the CLRA by failing to provide required Proposition 65 warnings. In July 2019, the Company filed a notice of removal to the United States District Court for the Southern District of California and plaintiffs filed a second amended complaint shortly thereafter. In October 2019, the Company moved to dismiss the second amended complaint for", "text": "A lawsuit was brought against the Company in the Superior Court of California for the County of San Diego alleging violations of Californias Consumer Legal Remedies Act (CLRA) relating to JOHNSONS Baby Powder.", "length": 211, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 822, "tag": "div", "text_raw": "A lawsuit was brought against the Company in the Superior Court of California for the County of San Diego alleging violations of Californias Consumer Legal Remedies Act (CLRA) relating to JOHNSONS Baby Powder. In that lawsuit, the plaintiffs allege that the Company violated the CLRA by failing to provide required Proposition 65 warnings. In July 2019, the Company filed a notice of removal to the United States District Court for the Southern District of California and plaintiffs filed a second amended complaint shortly thereafter. In October 2019, the Company moved to dismiss the second amended complaint for", "text": "In that lawsuit, the plaintiffs allege that the Company violated the CLRA by failing to provide required Proposition 65 warnings.", "length": 129, "numbers_raw": ["65"], "numbers": [65.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 822, "tag": "div", "text_raw": "A lawsuit was brought against the Company in the Superior Court of California for the County of San Diego alleging violations of Californias Consumer Legal Remedies Act (CLRA) relating to JOHNSONS Baby Powder. In that lawsuit, the plaintiffs allege that the Company violated the CLRA by failing to provide required Proposition 65 warnings. In July 2019, the Company filed a notice of removal to the United States District Court for the Southern District of California and plaintiffs filed a second amended complaint shortly thereafter. In October 2019, the Company moved to dismiss the second amended complaint for", "text": "In July 2019, the Company filed a notice of removal to the United States District Court for the Southern District of California and plaintiffs filed a second amended complaint shortly thereafter.", "length": 195, "numbers_raw": ["201", "9"], "numbers": [201.0, 9.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 822, "tag": "div", "text_raw": "A lawsuit was brought against the Company in the Superior Court of California for the County of San Diego alleging violations of Californias Consumer Legal Remedies Act (CLRA) relating to JOHNSONS Baby Powder. In that lawsuit, the plaintiffs allege that the Company violated the CLRA by failing to provide required Proposition 65 warnings. In July 2019, the Company filed a notice of removal to the United States District Court for the Southern District of California and plaintiffs filed a second amended complaint shortly thereafter. In October 2019, the Company moved to dismiss the second amended complaint for", "text": "In October 2019, the Company moved to dismiss the second amended complaint for", "length": 78, "numbers_raw": ["201", "9"], "numbers": [201.0, 9.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 823, "tag": "div", "text_raw": "30", "text": "30", "length": 2, "numbers_raw": ["30"], "numbers": [30.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 824, "tag": "div", "text_raw": "30", "text": "30", "length": 2, "numbers_raw": ["30"], "numbers": [30.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 825, "tag": "div", "text_raw": "30", "text": "30", "length": 2, "numbers_raw": ["30"], "numbers": [30.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 828, "tag": "div", "text_raw": "failure to state a claim upon which relief may be granted. In response to those motions, plaintiffs filed a third amended complaint. In December 2019, the Company moved to dismiss the third amended complaint for failure to state a claim upon which relief may be granted. In April 2020, the Court granted the motion to dismiss but granted leave to amend. In May 2020, plaintiffs filed a Fourth Amended Complaint but indicated that they would be filing a motion for leave to file a fifth amended complaint. Plaintiffs filed a Fifth Amended Complaint in August 2020. The Company moved to dismiss the Fifth Amended Complaint for failure to state a claim upon which relief may be granted. In January 2021, the Court issued an Order and opinion ruling in the Companys favor and granting the motion to dismiss with prejudice. In February 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit. Plaintiffs filed their opening brief in July 2021. The company filed its responsive brief in October 2021. After the Notice of Suggestion of Bankruptcy was filed with the Ninth Circuit, a stay was imposed, and the Court held the reply deadline in abeyance. In September 2023, the stay lifted. The deadline for Plaintiff's reply brief has not yet been set.", "text": "failure to state a claim upon which relief may be granted.", "length": 58, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 828, "tag": "div", "text_raw": "failure to state a claim upon which relief may be granted. In response to those motions, plaintiffs filed a third amended complaint. In December 2019, the Company moved to dismiss the third amended complaint for failure to state a claim upon which relief may be granted. In April 2020, the Court granted the motion to dismiss but granted leave to amend. In May 2020, plaintiffs filed a Fourth Amended Complaint but indicated that they would be filing a motion for leave to file a fifth amended complaint. Plaintiffs filed a Fifth Amended Complaint in August 2020. The Company moved to dismiss the Fifth Amended Complaint for failure to state a claim upon which relief may be granted. In January 2021, the Court issued an Order and opinion ruling in the Companys favor and granting the motion to dismiss with prejudice. In February 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit. Plaintiffs filed their opening brief in July 2021. The company filed its responsive brief in October 2021. After the Notice of Suggestion of Bankruptcy was filed with the Ninth Circuit, a stay was imposed, and the Court held the reply deadline in abeyance. In September 2023, the stay lifted. The deadline for Plaintiff's reply brief has not yet been set.", "text": "In response to those motions, plaintiffs filed a third amended complaint.", "length": 73, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 828, "tag": "div", "text_raw": "failure to state a claim upon which relief may be granted. In response to those motions, plaintiffs filed a third amended complaint. In December 2019, the Company moved to dismiss the third amended complaint for failure to state a claim upon which relief may be granted. In April 2020, the Court granted the motion to dismiss but granted leave to amend. In May 2020, plaintiffs filed a Fourth Amended Complaint but indicated that they would be filing a motion for leave to file a fifth amended complaint. Plaintiffs filed a Fifth Amended Complaint in August 2020. The Company moved to dismiss the Fifth Amended Complaint for failure to state a claim upon which relief may be granted. In January 2021, the Court issued an Order and opinion ruling in the Companys favor and granting the motion to dismiss with prejudice. In February 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit. Plaintiffs filed their opening brief in July 2021. The company filed its responsive brief in October 2021. After the Notice of Suggestion of Bankruptcy was filed with the Ninth Circuit, a stay was imposed, and the Court held the reply deadline in abeyance. In September 2023, the stay lifted. The deadline for Plaintiff's reply brief has not yet been set.", "text": "In December 2019, the Company moved to dismiss the third amended complaint for failure to state a claim upon which relief may be granted.", "length": 137, "numbers_raw": ["201", "9"], "numbers": [201.0, 9.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 828, "tag": "div", "text_raw": "failure to state a claim upon which relief may be granted. In response to those motions, plaintiffs filed a third amended complaint. In December 2019, the Company moved to dismiss the third amended complaint for failure to state a claim upon which relief may be granted. In April 2020, the Court granted the motion to dismiss but granted leave to amend. In May 2020, plaintiffs filed a Fourth Amended Complaint but indicated that they would be filing a motion for leave to file a fifth amended complaint. Plaintiffs filed a Fifth Amended Complaint in August 2020. The Company moved to dismiss the Fifth Amended Complaint for failure to state a claim upon which relief may be granted. In January 2021, the Court issued an Order and opinion ruling in the Companys favor and granting the motion to dismiss with prejudice. In February 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit. Plaintiffs filed their opening brief in July 2021. The company filed its responsive brief in October 2021. After the Notice of Suggestion of Bankruptcy was filed with the Ninth Circuit, a stay was imposed, and the Court held the reply deadline in abeyance. In September 2023, the stay lifted. The deadline for Plaintiff's reply brief has not yet been set.", "text": "In April 2020, the Court granted the motion to dismiss but granted leave to amend.", "length": 82, "numbers_raw": ["202", "0"], "numbers": [202.0, 0.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 828, "tag": "div", "text_raw": "failure to state a claim upon which relief may be granted. In response to those motions, plaintiffs filed a third amended complaint. In December 2019, the Company moved to dismiss the third amended complaint for failure to state a claim upon which relief may be granted. In April 2020, the Court granted the motion to dismiss but granted leave to amend. In May 2020, plaintiffs filed a Fourth Amended Complaint but indicated that they would be filing a motion for leave to file a fifth amended complaint. Plaintiffs filed a Fifth Amended Complaint in August 2020. The Company moved to dismiss the Fifth Amended Complaint for failure to state a claim upon which relief may be granted. In January 2021, the Court issued an Order and opinion ruling in the Companys favor and granting the motion to dismiss with prejudice. In February 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit. Plaintiffs filed their opening brief in July 2021. The company filed its responsive brief in October 2021. After the Notice of Suggestion of Bankruptcy was filed with the Ninth Circuit, a stay was imposed, and the Court held the reply deadline in abeyance. In September 2023, the stay lifted. The deadline for Plaintiff's reply brief has not yet been set.", "text": "In May 2020, plaintiffs filed a Fourth Amended Complaint but indicated that they would be filing a motion for leave to file a fifth amended complaint.", "length": 150, "numbers_raw": ["202", "0"], "numbers": [202.0, 0.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 828, "tag": "div", "text_raw": "failure to state a claim upon which relief may be granted. In response to those motions, plaintiffs filed a third amended complaint. In December 2019, the Company moved to dismiss the third amended complaint for failure to state a claim upon which relief may be granted. In April 2020, the Court granted the motion to dismiss but granted leave to amend. In May 2020, plaintiffs filed a Fourth Amended Complaint but indicated that they would be filing a motion for leave to file a fifth amended complaint. Plaintiffs filed a Fifth Amended Complaint in August 2020. The Company moved to dismiss the Fifth Amended Complaint for failure to state a claim upon which relief may be granted. In January 2021, the Court issued an Order and opinion ruling in the Companys favor and granting the motion to dismiss with prejudice. In February 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit. Plaintiffs filed their opening brief in July 2021. The company filed its responsive brief in October 2021. After the Notice of Suggestion of Bankruptcy was filed with the Ninth Circuit, a stay was imposed, and the Court held the reply deadline in abeyance. In September 2023, the stay lifted. The deadline for Plaintiff's reply brief has not yet been set.", "text": "Plaintiffs filed a Fifth Amended Complaint in August 2020.", "length": 58, "numbers_raw": ["202", "0"], "numbers": [202.0, 0.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 828, "tag": "div", "text_raw": "failure to state a claim upon which relief may be granted. In response to those motions, plaintiffs filed a third amended complaint. In December 2019, the Company moved to dismiss the third amended complaint for failure to state a claim upon which relief may be granted. In April 2020, the Court granted the motion to dismiss but granted leave to amend. In May 2020, plaintiffs filed a Fourth Amended Complaint but indicated that they would be filing a motion for leave to file a fifth amended complaint. Plaintiffs filed a Fifth Amended Complaint in August 2020. The Company moved to dismiss the Fifth Amended Complaint for failure to state a claim upon which relief may be granted. In January 2021, the Court issued an Order and opinion ruling in the Companys favor and granting the motion to dismiss with prejudice. In February 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit. Plaintiffs filed their opening brief in July 2021. The company filed its responsive brief in October 2021. After the Notice of Suggestion of Bankruptcy was filed with the Ninth Circuit, a stay was imposed, and the Court held the reply deadline in abeyance. In September 2023, the stay lifted. The deadline for Plaintiff's reply brief has not yet been set.", "text": "The Company moved to dismiss the Fifth Amended Complaint for failure to state a claim upon which relief may be granted.", "length": 119, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 828, "tag": "div", "text_raw": "failure to state a claim upon which relief may be granted. In response to those motions, plaintiffs filed a third amended complaint. In December 2019, the Company moved to dismiss the third amended complaint for failure to state a claim upon which relief may be granted. In April 2020, the Court granted the motion to dismiss but granted leave to amend. In May 2020, plaintiffs filed a Fourth Amended Complaint but indicated that they would be filing a motion for leave to file a fifth amended complaint. Plaintiffs filed a Fifth Amended Complaint in August 2020. The Company moved to dismiss the Fifth Amended Complaint for failure to state a claim upon which relief may be granted. In January 2021, the Court issued an Order and opinion ruling in the Companys favor and granting the motion to dismiss with prejudice. In February 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit. Plaintiffs filed their opening brief in July 2021. The company filed its responsive brief in October 2021. After the Notice of Suggestion of Bankruptcy was filed with the Ninth Circuit, a stay was imposed, and the Court held the reply deadline in abeyance. In September 2023, the stay lifted. The deadline for Plaintiff's reply brief has not yet been set.", "text": "In January 2021, the Court issued an Order and opinion ruling in the Companys favor and granting the motion to dismiss with prejudice.", "length": 135, "numbers_raw": ["202", "1"], "numbers": [202.0, 1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 828, "tag": "div", "text_raw": "failure to state a claim upon which relief may be granted. In response to those motions, plaintiffs filed a third amended complaint. In December 2019, the Company moved to dismiss the third amended complaint for failure to state a claim upon which relief may be granted. In April 2020, the Court granted the motion to dismiss but granted leave to amend. In May 2020, plaintiffs filed a Fourth Amended Complaint but indicated that they would be filing a motion for leave to file a fifth amended complaint. Plaintiffs filed a Fifth Amended Complaint in August 2020. The Company moved to dismiss the Fifth Amended Complaint for failure to state a claim upon which relief may be granted. In January 2021, the Court issued an Order and opinion ruling in the Companys favor and granting the motion to dismiss with prejudice. In February 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit. Plaintiffs filed their opening brief in July 2021. The company filed its responsive brief in October 2021. After the Notice of Suggestion of Bankruptcy was filed with the Ninth Circuit, a stay was imposed, and the Court held the reply deadline in abeyance. In September 2023, the stay lifted. The deadline for Plaintiff's reply brief has not yet been set.", "text": "In February 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit.", "length": 77, "numbers_raw": ["202", "1"], "numbers": [202.0, 1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 828, "tag": "div", "text_raw": "failure to state a claim upon which relief may be granted. In response to those motions, plaintiffs filed a third amended complaint. In December 2019, the Company moved to dismiss the third amended complaint for failure to state a claim upon which relief may be granted. In April 2020, the Court granted the motion to dismiss but granted leave to amend. In May 2020, plaintiffs filed a Fourth Amended Complaint but indicated that they would be filing a motion for leave to file a fifth amended complaint. Plaintiffs filed a Fifth Amended Complaint in August 2020. The Company moved to dismiss the Fifth Amended Complaint for failure to state a claim upon which relief may be granted. In January 2021, the Court issued an Order and opinion ruling in the Companys favor and granting the motion to dismiss with prejudice. In February 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit. Plaintiffs filed their opening brief in July 2021. The company filed its responsive brief in October 2021. After the Notice of Suggestion of Bankruptcy was filed with the Ninth Circuit, a stay was imposed, and the Court held the reply deadline in abeyance. In September 2023, the stay lifted. The deadline for Plaintiff's reply brief has not yet been set.", "text": "Plaintiffs filed their opening brief in July 2021.", "length": 50, "numbers_raw": ["202", "1"], "numbers": [202.0, 1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 828, "tag": "div", "text_raw": "failure to state a claim upon which relief may be granted. In response to those motions, plaintiffs filed a third amended complaint. In December 2019, the Company moved to dismiss the third amended complaint for failure to state a claim upon which relief may be granted. In April 2020, the Court granted the motion to dismiss but granted leave to amend. In May 2020, plaintiffs filed a Fourth Amended Complaint but indicated that they would be filing a motion for leave to file a fifth amended complaint. Plaintiffs filed a Fifth Amended Complaint in August 2020. The Company moved to dismiss the Fifth Amended Complaint for failure to state a claim upon which relief may be granted. In January 2021, the Court issued an Order and opinion ruling in the Companys favor and granting the motion to dismiss with prejudice. In February 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit. Plaintiffs filed their opening brief in July 2021. The company filed its responsive brief in October 2021. After the Notice of Suggestion of Bankruptcy was filed with the Ninth Circuit, a stay was imposed, and the Court held the reply deadline in abeyance. In September 2023, the stay lifted. The deadline for Plaintiff's reply brief has not yet been set.", "text": "The company filed its responsive brief in October 2021.", "length": 55, "numbers_raw": ["202", "1"], "numbers": [202.0, 1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 828, "tag": "div", "text_raw": "failure to state a claim upon which relief may be granted. In response to those motions, plaintiffs filed a third amended complaint. In December 2019, the Company moved to dismiss the third amended complaint for failure to state a claim upon which relief may be granted. In April 2020, the Court granted the motion to dismiss but granted leave to amend. In May 2020, plaintiffs filed a Fourth Amended Complaint but indicated that they would be filing a motion for leave to file a fifth amended complaint. Plaintiffs filed a Fifth Amended Complaint in August 2020. The Company moved to dismiss the Fifth Amended Complaint for failure to state a claim upon which relief may be granted. In January 2021, the Court issued an Order and opinion ruling in the Companys favor and granting the motion to dismiss with prejudice. In February 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit. Plaintiffs filed their opening brief in July 2021. The company filed its responsive brief in October 2021. After the Notice of Suggestion of Bankruptcy was filed with the Ninth Circuit, a stay was imposed, and the Court held the reply deadline in abeyance. In September 2023, the stay lifted. The deadline for Plaintiff's reply brief has not yet been set.", "text": "After the Notice of Suggestion of Bankruptcy was filed with the Ninth Circuit, a stay was imposed, and the Court held the reply deadline in abeyance.", "length": 149, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 828, "tag": "div", "text_raw": "failure to state a claim upon which relief may be granted. In response to those motions, plaintiffs filed a third amended complaint. In December 2019, the Company moved to dismiss the third amended complaint for failure to state a claim upon which relief may be granted. In April 2020, the Court granted the motion to dismiss but granted leave to amend. In May 2020, plaintiffs filed a Fourth Amended Complaint but indicated that they would be filing a motion for leave to file a fifth amended complaint. Plaintiffs filed a Fifth Amended Complaint in August 2020. The Company moved to dismiss the Fifth Amended Complaint for failure to state a claim upon which relief may be granted. In January 2021, the Court issued an Order and opinion ruling in the Companys favor and granting the motion to dismiss with prejudice. In February 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit. Plaintiffs filed their opening brief in July 2021. The company filed its responsive brief in October 2021. After the Notice of Suggestion of Bankruptcy was filed with the Ninth Circuit, a stay was imposed, and the Court held the reply deadline in abeyance. In September 2023, the stay lifted. The deadline for Plaintiff's reply brief has not yet been set.", "text": "In September 2023, the stay lifted.", "length": 35, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 828, "tag": "div", "text_raw": "failure to state a claim upon which relief may be granted. In response to those motions, plaintiffs filed a third amended complaint. In December 2019, the Company moved to dismiss the third amended complaint for failure to state a claim upon which relief may be granted. In April 2020, the Court granted the motion to dismiss but granted leave to amend. In May 2020, plaintiffs filed a Fourth Amended Complaint but indicated that they would be filing a motion for leave to file a fifth amended complaint. Plaintiffs filed a Fifth Amended Complaint in August 2020. The Company moved to dismiss the Fifth Amended Complaint for failure to state a claim upon which relief may be granted. In January 2021, the Court issued an Order and opinion ruling in the Companys favor and granting the motion to dismiss with prejudice. In February 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit. Plaintiffs filed their opening brief in July 2021. The company filed its responsive brief in October 2021. After the Notice of Suggestion of Bankruptcy was filed with the Ninth Circuit, a stay was imposed, and the Court held the reply deadline in abeyance. In September 2023, the stay lifted. The deadline for Plaintiff's reply brief has not yet been set.", "text": "The deadline for Plaintiff's reply brief has not yet been set.", "length": 62, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 830, "tag": "div", "text_raw": "In June 2014, the Mississippi Attorney General filed a complaint in Chancery Court of The First Judicial District of Hinds County, Mississippi against the Company and Johnson & Johnson Consumer Companies, Inc. (now known as Johnson & Johnson Consumer Inc.) (collectively, JJCI). The complaint alleges that JJCI violated the Mississippi Consumer Protection Act by failing to disclose alleged health risks associated with female consumers use of talc contained in JOHNSONS Baby Powder and JOHNSONS Shower to Shower (a product divested in 2012) and seeks injunctive and monetary relief. In February 2022, the trial court set the case for trial to begin in February 2023. However, in October 2022, the LTL bankruptcy court issued an order staying the case. In March 2023, the Third Circuit issued the mandate to dismiss the LTL Bankruptcy Case and in April 2023, the New Jersey Bankruptcy Court dismissed the LTL Bankruptcy Case, effectively lifting the stay as to this matter. The State requested a new trial setting. Later in April 2023, the trial court set a new trial date in April 2024. The parties are currently engaged in expert work, extensive discovery, and preparations for the upcoming trial.", "text": "In June 2014, the Mississippi Attorney General filed a complaint in Chancery Court of The First Judicial District of Hinds County, Mississippi against the Company and Johnson & Johnson Consumer Companies, Inc.", "length": 209, "numbers_raw": ["201", "4"], "numbers": [201.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 830, "tag": "div", "text_raw": "In June 2014, the Mississippi Attorney General filed a complaint in Chancery Court of The First Judicial District of Hinds County, Mississippi against the Company and Johnson & Johnson Consumer Companies, Inc. (now known as Johnson & Johnson Consumer Inc.) (collectively, JJCI). The complaint alleges that JJCI violated the Mississippi Consumer Protection Act by failing to disclose alleged health risks associated with female consumers use of talc contained in JOHNSONS Baby Powder and JOHNSONS Shower to Shower (a product divested in 2012) and seeks injunctive and monetary relief. In February 2022, the trial court set the case for trial to begin in February 2023. However, in October 2022, the LTL bankruptcy court issued an order staying the case. In March 2023, the Third Circuit issued the mandate to dismiss the LTL Bankruptcy Case and in April 2023, the New Jersey Bankruptcy Court dismissed the LTL Bankruptcy Case, effectively lifting the stay as to this matter. The State requested a new trial setting. Later in April 2023, the trial court set a new trial date in April 2024. The parties are currently engaged in expert work, extensive discovery, and preparations for the upcoming trial.", "text": "(now known as Johnson & Johnson Consumer Inc.) (collectively, JJCI).", "length": 68, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 830, "tag": "div", "text_raw": "In June 2014, the Mississippi Attorney General filed a complaint in Chancery Court of The First Judicial District of Hinds County, Mississippi against the Company and Johnson & Johnson Consumer Companies, Inc. (now known as Johnson & Johnson Consumer Inc.) (collectively, JJCI). The complaint alleges that JJCI violated the Mississippi Consumer Protection Act by failing to disclose alleged health risks associated with female consumers use of talc contained in JOHNSONS Baby Powder and JOHNSONS Shower to Shower (a product divested in 2012) and seeks injunctive and monetary relief. In February 2022, the trial court set the case for trial to begin in February 2023. However, in October 2022, the LTL bankruptcy court issued an order staying the case. In March 2023, the Third Circuit issued the mandate to dismiss the LTL Bankruptcy Case and in April 2023, the New Jersey Bankruptcy Court dismissed the LTL Bankruptcy Case, effectively lifting the stay as to this matter. The State requested a new trial setting. Later in April 2023, the trial court set a new trial date in April 2024. The parties are currently engaged in expert work, extensive discovery, and preparations for the upcoming trial.", "text": "The complaint alleges that JJCI violated the Mississippi Consumer Protection Act by failing to disclose alleged health risks associated with female consumers use of talc contained in JOHNSONS Baby Powder and JOHNSONS Shower to Shower (a product divested in 2012) and seeks injunctive and monetary relief.", "length": 307, "numbers_raw": ["201", "2"], "numbers": [201.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 830, "tag": "div", "text_raw": "In June 2014, the Mississippi Attorney General filed a complaint in Chancery Court of The First Judicial District of Hinds County, Mississippi against the Company and Johnson & Johnson Consumer Companies, Inc. (now known as Johnson & Johnson Consumer Inc.) (collectively, JJCI). The complaint alleges that JJCI violated the Mississippi Consumer Protection Act by failing to disclose alleged health risks associated with female consumers use of talc contained in JOHNSONS Baby Powder and JOHNSONS Shower to Shower (a product divested in 2012) and seeks injunctive and monetary relief. In February 2022, the trial court set the case for trial to begin in February 2023. However, in October 2022, the LTL bankruptcy court issued an order staying the case. In March 2023, the Third Circuit issued the mandate to dismiss the LTL Bankruptcy Case and in April 2023, the New Jersey Bankruptcy Court dismissed the LTL Bankruptcy Case, effectively lifting the stay as to this matter. The State requested a new trial setting. Later in April 2023, the trial court set a new trial date in April 2024. The parties are currently engaged in expert work, extensive discovery, and preparations for the upcoming trial.", "text": "In February 2022, the trial court set the case for trial to begin in February 2023.", "length": 83, "numbers_raw": ["202", "2", "202", "3"], "numbers": [202.0, 2.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 830, "tag": "div", "text_raw": "In June 2014, the Mississippi Attorney General filed a complaint in Chancery Court of The First Judicial District of Hinds County, Mississippi against the Company and Johnson & Johnson Consumer Companies, Inc. (now known as Johnson & Johnson Consumer Inc.) (collectively, JJCI). The complaint alleges that JJCI violated the Mississippi Consumer Protection Act by failing to disclose alleged health risks associated with female consumers use of talc contained in JOHNSONS Baby Powder and JOHNSONS Shower to Shower (a product divested in 2012) and seeks injunctive and monetary relief. In February 2022, the trial court set the case for trial to begin in February 2023. However, in October 2022, the LTL bankruptcy court issued an order staying the case. In March 2023, the Third Circuit issued the mandate to dismiss the LTL Bankruptcy Case and in April 2023, the New Jersey Bankruptcy Court dismissed the LTL Bankruptcy Case, effectively lifting the stay as to this matter. The State requested a new trial setting. Later in April 2023, the trial court set a new trial date in April 2024. The parties are currently engaged in expert work, extensive discovery, and preparations for the upcoming trial.", "text": "However, in October 2022, the LTL bankruptcy court issued an order staying the case.", "length": 84, "numbers_raw": ["202", "2"], "numbers": [202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 830, "tag": "div", "text_raw": "In June 2014, the Mississippi Attorney General filed a complaint in Chancery Court of The First Judicial District of Hinds County, Mississippi against the Company and Johnson & Johnson Consumer Companies, Inc. (now known as Johnson & Johnson Consumer Inc.) (collectively, JJCI). The complaint alleges that JJCI violated the Mississippi Consumer Protection Act by failing to disclose alleged health risks associated with female consumers use of talc contained in JOHNSONS Baby Powder and JOHNSONS Shower to Shower (a product divested in 2012) and seeks injunctive and monetary relief. In February 2022, the trial court set the case for trial to begin in February 2023. However, in October 2022, the LTL bankruptcy court issued an order staying the case. In March 2023, the Third Circuit issued the mandate to dismiss the LTL Bankruptcy Case and in April 2023, the New Jersey Bankruptcy Court dismissed the LTL Bankruptcy Case, effectively lifting the stay as to this matter. The State requested a new trial setting. Later in April 2023, the trial court set a new trial date in April 2024. The parties are currently engaged in expert work, extensive discovery, and preparations for the upcoming trial.", "text": "In March 2023, the Third Circuit issued the mandate to dismiss the LTL Bankruptcy Case and in April 2023, the New Jersey Bankruptcy Court dismissed the LTL Bankruptcy Case, effectively lifting the stay as to this matter.", "length": 220, "numbers_raw": ["202", "3", "202", "3"], "numbers": [202.0, 3.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 830, "tag": "div", "text_raw": "In June 2014, the Mississippi Attorney General filed a complaint in Chancery Court of The First Judicial District of Hinds County, Mississippi against the Company and Johnson & Johnson Consumer Companies, Inc. (now known as Johnson & Johnson Consumer Inc.) (collectively, JJCI). The complaint alleges that JJCI violated the Mississippi Consumer Protection Act by failing to disclose alleged health risks associated with female consumers use of talc contained in JOHNSONS Baby Powder and JOHNSONS Shower to Shower (a product divested in 2012) and seeks injunctive and monetary relief. In February 2022, the trial court set the case for trial to begin in February 2023. However, in October 2022, the LTL bankruptcy court issued an order staying the case. In March 2023, the Third Circuit issued the mandate to dismiss the LTL Bankruptcy Case and in April 2023, the New Jersey Bankruptcy Court dismissed the LTL Bankruptcy Case, effectively lifting the stay as to this matter. The State requested a new trial setting. Later in April 2023, the trial court set a new trial date in April 2024. The parties are currently engaged in expert work, extensive discovery, and preparations for the upcoming trial.", "text": "The State requested a new trial setting.", "length": 40, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 830, "tag": "div", "text_raw": "In June 2014, the Mississippi Attorney General filed a complaint in Chancery Court of The First Judicial District of Hinds County, Mississippi against the Company and Johnson & Johnson Consumer Companies, Inc. (now known as Johnson & Johnson Consumer Inc.) (collectively, JJCI). The complaint alleges that JJCI violated the Mississippi Consumer Protection Act by failing to disclose alleged health risks associated with female consumers use of talc contained in JOHNSONS Baby Powder and JOHNSONS Shower to Shower (a product divested in 2012) and seeks injunctive and monetary relief. In February 2022, the trial court set the case for trial to begin in February 2023. However, in October 2022, the LTL bankruptcy court issued an order staying the case. In March 2023, the Third Circuit issued the mandate to dismiss the LTL Bankruptcy Case and in April 2023, the New Jersey Bankruptcy Court dismissed the LTL Bankruptcy Case, effectively lifting the stay as to this matter. The State requested a new trial setting. Later in April 2023, the trial court set a new trial date in April 2024. The parties are currently engaged in expert work, extensive discovery, and preparations for the upcoming trial.", "text": "Later in April 2023, the trial court set a new trial date in April 2024.", "length": 72, "numbers_raw": ["202", "3", "202", "4"], "numbers": [202.0, 3.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 830, "tag": "div", "text_raw": "In June 2014, the Mississippi Attorney General filed a complaint in Chancery Court of The First Judicial District of Hinds County, Mississippi against the Company and Johnson & Johnson Consumer Companies, Inc. (now known as Johnson & Johnson Consumer Inc.) (collectively, JJCI). The complaint alleges that JJCI violated the Mississippi Consumer Protection Act by failing to disclose alleged health risks associated with female consumers use of talc contained in JOHNSONS Baby Powder and JOHNSONS Shower to Shower (a product divested in 2012) and seeks injunctive and monetary relief. In February 2022, the trial court set the case for trial to begin in February 2023. However, in October 2022, the LTL bankruptcy court issued an order staying the case. In March 2023, the Third Circuit issued the mandate to dismiss the LTL Bankruptcy Case and in April 2023, the New Jersey Bankruptcy Court dismissed the LTL Bankruptcy Case, effectively lifting the stay as to this matter. The State requested a new trial setting. Later in April 2023, the trial court set a new trial date in April 2024. The parties are currently engaged in expert work, extensive discovery, and preparations for the upcoming trial.", "text": "The parties are currently engaged in expert work, extensive discovery, and preparations for the upcoming trial.", "length": 111, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 832, "tag": "div", "text_raw": "In January 2020, the State of New Mexico filed a consumer protection case alleging that the Company deceptively marketed and sold its talcum powder products by making misrepresentations about the safety of the products and the presence of carcinogens, including asbestos. In March 2022, the New Mexico court denied the Companys motion to compel the State of New Mexico to engage in discovery of state agencies and denied the Companys request for interlocutory appeal of that decision. The Company then filed a Petition for Writ of Superintending Control and a Request for a Stay to the New Mexico Supreme Court on the issue of the State of New Mexicos discovery obligations. In April 2022, in view of the efforts to resolve talc-related claims in the LTL Bankruptcy Case, the Company and the State agreed to a 60-day stay of all matters except for the pending writ before the New Mexico Supreme Court, which expired in June 2022. Thereafter, the Company moved to enjoin prosecution of the case in the LTL Bankruptcy Case. In October 2022, the bankruptcy court issued an order staying the case. In December 2022, the State filed an appeal to the Third Circuit concerning the stay order. Separately, in September 2022, the New Mexico Supreme Court granted the Company's request for a stay pending further briefing on the scope of the State of New Mexicos discovery obligations. In March 2023, the Third Circuit issued the mandate to dismiss the LTL Bankruptcy Case and in April 2023, the New Jersey Bankruptcy Court dismissed the LTL Bankruptcy Case, effectively lifting the stay as to this matter. However, this case remains stayed as a result of the New Mexico Supreme Courts stay until such time as the Supreme Court issues an order concerning the State of New Mexicos discovery obligations.", "text": "In January 2020, the State of New Mexico filed a consumer protection case alleging that the Company deceptively marketed and sold its talcum powder products by making misrepresentations about the safety of the products and the presence of carcinogens, including asbestos.", "length": 271, "numbers_raw": ["202", "0"], "numbers": [202.0, 0.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 832, "tag": "div", "text_raw": "In January 2020, the State of New Mexico filed a consumer protection case alleging that the Company deceptively marketed and sold its talcum powder products by making misrepresentations about the safety of the products and the presence of carcinogens, including asbestos. In March 2022, the New Mexico court denied the Companys motion to compel the State of New Mexico to engage in discovery of state agencies and denied the Companys request for interlocutory appeal of that decision. The Company then filed a Petition for Writ of Superintending Control and a Request for a Stay to the New Mexico Supreme Court on the issue of the State of New Mexicos discovery obligations. In April 2022, in view of the efforts to resolve talc-related claims in the LTL Bankruptcy Case, the Company and the State agreed to a 60-day stay of all matters except for the pending writ before the New Mexico Supreme Court, which expired in June 2022. Thereafter, the Company moved to enjoin prosecution of the case in the LTL Bankruptcy Case. In October 2022, the bankruptcy court issued an order staying the case. In December 2022, the State filed an appeal to the Third Circuit concerning the stay order. Separately, in September 2022, the New Mexico Supreme Court granted the Company's request for a stay pending further briefing on the scope of the State of New Mexicos discovery obligations. In March 2023, the Third Circuit issued the mandate to dismiss the LTL Bankruptcy Case and in April 2023, the New Jersey Bankruptcy Court dismissed the LTL Bankruptcy Case, effectively lifting the stay as to this matter. However, this case remains stayed as a result of the New Mexico Supreme Courts stay until such time as the Supreme Court issues an order concerning the State of New Mexicos discovery obligations.", "text": "In March 2022, the New Mexico court denied the Companys motion to compel the State of New Mexico to engage in discovery of state agencies and denied the Companys request for interlocutory appeal of that decision.", "length": 214, "numbers_raw": ["202", "2"], "numbers": [202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 832, "tag": "div", "text_raw": "In January 2020, the State of New Mexico filed a consumer protection case alleging that the Company deceptively marketed and sold its talcum powder products by making misrepresentations about the safety of the products and the presence of carcinogens, including asbestos. In March 2022, the New Mexico court denied the Companys motion to compel the State of New Mexico to engage in discovery of state agencies and denied the Companys request for interlocutory appeal of that decision. The Company then filed a Petition for Writ of Superintending Control and a Request for a Stay to the New Mexico Supreme Court on the issue of the State of New Mexicos discovery obligations. In April 2022, in view of the efforts to resolve talc-related claims in the LTL Bankruptcy Case, the Company and the State agreed to a 60-day stay of all matters except for the pending writ before the New Mexico Supreme Court, which expired in June 2022. Thereafter, the Company moved to enjoin prosecution of the case in the LTL Bankruptcy Case. In October 2022, the bankruptcy court issued an order staying the case. In December 2022, the State filed an appeal to the Third Circuit concerning the stay order. Separately, in September 2022, the New Mexico Supreme Court granted the Company's request for a stay pending further briefing on the scope of the State of New Mexicos discovery obligations. In March 2023, the Third Circuit issued the mandate to dismiss the LTL Bankruptcy Case and in April 2023, the New Jersey Bankruptcy Court dismissed the LTL Bankruptcy Case, effectively lifting the stay as to this matter. However, this case remains stayed as a result of the New Mexico Supreme Courts stay until such time as the Supreme Court issues an order concerning the State of New Mexicos discovery obligations.", "text": "The Company then filed a Petition for Writ of Superintending Control and a Request for a Stay to the New Mexico Supreme Court on the issue of the State of New Mexicos discovery obligations.", "length": 190, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 832, "tag": "div", "text_raw": "In January 2020, the State of New Mexico filed a consumer protection case alleging that the Company deceptively marketed and sold its talcum powder products by making misrepresentations about the safety of the products and the presence of carcinogens, including asbestos. In March 2022, the New Mexico court denied the Companys motion to compel the State of New Mexico to engage in discovery of state agencies and denied the Companys request for interlocutory appeal of that decision. The Company then filed a Petition for Writ of Superintending Control and a Request for a Stay to the New Mexico Supreme Court on the issue of the State of New Mexicos discovery obligations. In April 2022, in view of the efforts to resolve talc-related claims in the LTL Bankruptcy Case, the Company and the State agreed to a 60-day stay of all matters except for the pending writ before the New Mexico Supreme Court, which expired in June 2022. Thereafter, the Company moved to enjoin prosecution of the case in the LTL Bankruptcy Case. In October 2022, the bankruptcy court issued an order staying the case. In December 2022, the State filed an appeal to the Third Circuit concerning the stay order. Separately, in September 2022, the New Mexico Supreme Court granted the Company's request for a stay pending further briefing on the scope of the State of New Mexicos discovery obligations. In March 2023, the Third Circuit issued the mandate to dismiss the LTL Bankruptcy Case and in April 2023, the New Jersey Bankruptcy Court dismissed the LTL Bankruptcy Case, effectively lifting the stay as to this matter. However, this case remains stayed as a result of the New Mexico Supreme Courts stay until such time as the Supreme Court issues an order concerning the State of New Mexicos discovery obligations.", "text": "In April 2022, in view of the efforts to resolve talc-related claims in the LTL Bankruptcy Case, the Company and the State agreed to a 60-day stay of all matters except for the pending writ before the New Mexico Supreme Court, which expired in June 2022.", "length": 254, "numbers_raw": ["202", "2", "60", "202", "2"], "numbers": [202.0, 2.0, 60.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 832, "tag": "div", "text_raw": "In January 2020, the State of New Mexico filed a consumer protection case alleging that the Company deceptively marketed and sold its talcum powder products by making misrepresentations about the safety of the products and the presence of carcinogens, including asbestos. In March 2022, the New Mexico court denied the Companys motion to compel the State of New Mexico to engage in discovery of state agencies and denied the Companys request for interlocutory appeal of that decision. The Company then filed a Petition for Writ of Superintending Control and a Request for a Stay to the New Mexico Supreme Court on the issue of the State of New Mexicos discovery obligations. In April 2022, in view of the efforts to resolve talc-related claims in the LTL Bankruptcy Case, the Company and the State agreed to a 60-day stay of all matters except for the pending writ before the New Mexico Supreme Court, which expired in June 2022. Thereafter, the Company moved to enjoin prosecution of the case in the LTL Bankruptcy Case. In October 2022, the bankruptcy court issued an order staying the case. In December 2022, the State filed an appeal to the Third Circuit concerning the stay order. Separately, in September 2022, the New Mexico Supreme Court granted the Company's request for a stay pending further briefing on the scope of the State of New Mexicos discovery obligations. In March 2023, the Third Circuit issued the mandate to dismiss the LTL Bankruptcy Case and in April 2023, the New Jersey Bankruptcy Court dismissed the LTL Bankruptcy Case, effectively lifting the stay as to this matter. However, this case remains stayed as a result of the New Mexico Supreme Courts stay until such time as the Supreme Court issues an order concerning the State of New Mexicos discovery obligations.", "text": "Thereafter, the Company moved to enjoin prosecution of the case in the LTL Bankruptcy Case.", "length": 91, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 832, "tag": "div", "text_raw": "In January 2020, the State of New Mexico filed a consumer protection case alleging that the Company deceptively marketed and sold its talcum powder products by making misrepresentations about the safety of the products and the presence of carcinogens, including asbestos. In March 2022, the New Mexico court denied the Companys motion to compel the State of New Mexico to engage in discovery of state agencies and denied the Companys request for interlocutory appeal of that decision. The Company then filed a Petition for Writ of Superintending Control and a Request for a Stay to the New Mexico Supreme Court on the issue of the State of New Mexicos discovery obligations. In April 2022, in view of the efforts to resolve talc-related claims in the LTL Bankruptcy Case, the Company and the State agreed to a 60-day stay of all matters except for the pending writ before the New Mexico Supreme Court, which expired in June 2022. Thereafter, the Company moved to enjoin prosecution of the case in the LTL Bankruptcy Case. In October 2022, the bankruptcy court issued an order staying the case. In December 2022, the State filed an appeal to the Third Circuit concerning the stay order. Separately, in September 2022, the New Mexico Supreme Court granted the Company's request for a stay pending further briefing on the scope of the State of New Mexicos discovery obligations. In March 2023, the Third Circuit issued the mandate to dismiss the LTL Bankruptcy Case and in April 2023, the New Jersey Bankruptcy Court dismissed the LTL Bankruptcy Case, effectively lifting the stay as to this matter. However, this case remains stayed as a result of the New Mexico Supreme Courts stay until such time as the Supreme Court issues an order concerning the State of New Mexicos discovery obligations.", "text": "In October 2022, the bankruptcy court issued an order staying the case.", "length": 71, "numbers_raw": ["202", "2"], "numbers": [202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 832, "tag": "div", "text_raw": "In January 2020, the State of New Mexico filed a consumer protection case alleging that the Company deceptively marketed and sold its talcum powder products by making misrepresentations about the safety of the products and the presence of carcinogens, including asbestos. In March 2022, the New Mexico court denied the Companys motion to compel the State of New Mexico to engage in discovery of state agencies and denied the Companys request for interlocutory appeal of that decision. The Company then filed a Petition for Writ of Superintending Control and a Request for a Stay to the New Mexico Supreme Court on the issue of the State of New Mexicos discovery obligations. In April 2022, in view of the efforts to resolve talc-related claims in the LTL Bankruptcy Case, the Company and the State agreed to a 60-day stay of all matters except for the pending writ before the New Mexico Supreme Court, which expired in June 2022. Thereafter, the Company moved to enjoin prosecution of the case in the LTL Bankruptcy Case. In October 2022, the bankruptcy court issued an order staying the case. In December 2022, the State filed an appeal to the Third Circuit concerning the stay order. Separately, in September 2022, the New Mexico Supreme Court granted the Company's request for a stay pending further briefing on the scope of the State of New Mexicos discovery obligations. In March 2023, the Third Circuit issued the mandate to dismiss the LTL Bankruptcy Case and in April 2023, the New Jersey Bankruptcy Court dismissed the LTL Bankruptcy Case, effectively lifting the stay as to this matter. However, this case remains stayed as a result of the New Mexico Supreme Courts stay until such time as the Supreme Court issues an order concerning the State of New Mexicos discovery obligations.", "text": "In December 2022, the State filed an appeal to the Third Circuit concerning the stay order.", "length": 91, "numbers_raw": ["202", "2"], "numbers": [202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 832, "tag": "div", "text_raw": "In January 2020, the State of New Mexico filed a consumer protection case alleging that the Company deceptively marketed and sold its talcum powder products by making misrepresentations about the safety of the products and the presence of carcinogens, including asbestos. In March 2022, the New Mexico court denied the Companys motion to compel the State of New Mexico to engage in discovery of state agencies and denied the Companys request for interlocutory appeal of that decision. The Company then filed a Petition for Writ of Superintending Control and a Request for a Stay to the New Mexico Supreme Court on the issue of the State of New Mexicos discovery obligations. In April 2022, in view of the efforts to resolve talc-related claims in the LTL Bankruptcy Case, the Company and the State agreed to a 60-day stay of all matters except for the pending writ before the New Mexico Supreme Court, which expired in June 2022. Thereafter, the Company moved to enjoin prosecution of the case in the LTL Bankruptcy Case. In October 2022, the bankruptcy court issued an order staying the case. In December 2022, the State filed an appeal to the Third Circuit concerning the stay order. Separately, in September 2022, the New Mexico Supreme Court granted the Company's request for a stay pending further briefing on the scope of the State of New Mexicos discovery obligations. In March 2023, the Third Circuit issued the mandate to dismiss the LTL Bankruptcy Case and in April 2023, the New Jersey Bankruptcy Court dismissed the LTL Bankruptcy Case, effectively lifting the stay as to this matter. However, this case remains stayed as a result of the New Mexico Supreme Courts stay until such time as the Supreme Court issues an order concerning the State of New Mexicos discovery obligations.", "text": "Separately, in September 2022, the New Mexico Supreme Court granted the Company's request for a stay pending further briefing on the scope of the State of New Mexicos discovery obligations.", "length": 190, "numbers_raw": ["202", "2"], "numbers": [202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 832, "tag": "div", "text_raw": "In January 2020, the State of New Mexico filed a consumer protection case alleging that the Company deceptively marketed and sold its talcum powder products by making misrepresentations about the safety of the products and the presence of carcinogens, including asbestos. In March 2022, the New Mexico court denied the Companys motion to compel the State of New Mexico to engage in discovery of state agencies and denied the Companys request for interlocutory appeal of that decision. The Company then filed a Petition for Writ of Superintending Control and a Request for a Stay to the New Mexico Supreme Court on the issue of the State of New Mexicos discovery obligations. In April 2022, in view of the efforts to resolve talc-related claims in the LTL Bankruptcy Case, the Company and the State agreed to a 60-day stay of all matters except for the pending writ before the New Mexico Supreme Court, which expired in June 2022. Thereafter, the Company moved to enjoin prosecution of the case in the LTL Bankruptcy Case. In October 2022, the bankruptcy court issued an order staying the case. In December 2022, the State filed an appeal to the Third Circuit concerning the stay order. Separately, in September 2022, the New Mexico Supreme Court granted the Company's request for a stay pending further briefing on the scope of the State of New Mexicos discovery obligations. In March 2023, the Third Circuit issued the mandate to dismiss the LTL Bankruptcy Case and in April 2023, the New Jersey Bankruptcy Court dismissed the LTL Bankruptcy Case, effectively lifting the stay as to this matter. However, this case remains stayed as a result of the New Mexico Supreme Courts stay until such time as the Supreme Court issues an order concerning the State of New Mexicos discovery obligations.", "text": "In March 2023, the Third Circuit issued the mandate to dismiss the LTL Bankruptcy Case and in April 2023, the New Jersey Bankruptcy Court dismissed the LTL Bankruptcy Case, effectively lifting the stay as to this matter.", "length": 220, "numbers_raw": ["202", "3", "202", "3"], "numbers": [202.0, 3.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 832, "tag": "div", "text_raw": "In January 2020, the State of New Mexico filed a consumer protection case alleging that the Company deceptively marketed and sold its talcum powder products by making misrepresentations about the safety of the products and the presence of carcinogens, including asbestos. In March 2022, the New Mexico court denied the Companys motion to compel the State of New Mexico to engage in discovery of state agencies and denied the Companys request for interlocutory appeal of that decision. The Company then filed a Petition for Writ of Superintending Control and a Request for a Stay to the New Mexico Supreme Court on the issue of the State of New Mexicos discovery obligations. In April 2022, in view of the efforts to resolve talc-related claims in the LTL Bankruptcy Case, the Company and the State agreed to a 60-day stay of all matters except for the pending writ before the New Mexico Supreme Court, which expired in June 2022. Thereafter, the Company moved to enjoin prosecution of the case in the LTL Bankruptcy Case. In October 2022, the bankruptcy court issued an order staying the case. In December 2022, the State filed an appeal to the Third Circuit concerning the stay order. Separately, in September 2022, the New Mexico Supreme Court granted the Company's request for a stay pending further briefing on the scope of the State of New Mexicos discovery obligations. In March 2023, the Third Circuit issued the mandate to dismiss the LTL Bankruptcy Case and in April 2023, the New Jersey Bankruptcy Court dismissed the LTL Bankruptcy Case, effectively lifting the stay as to this matter. However, this case remains stayed as a result of the New Mexico Supreme Courts stay until such time as the Supreme Court issues an order concerning the State of New Mexicos discovery obligations.", "text": "However, this case remains stayed as a result of the New Mexico Supreme Courts stay until such time as the Supreme Court issues an order concerning the State of New Mexicos discovery obligations.", "length": 197, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 834, "tag": "div", "text_raw": "Forty-two states and the District of Columbia (including Mississippi and New Mexico) have commenced a joint investigation into the Companys marketing of its talcum powder products. At this time, the multi-state group has not asserted any claims against the Company. Five states have issued Civil Investigative Demands seeking documents and other information. The Company has produced documents to Arizona, North Carolina, Texas, and Washington and entered into confidentiality agreements. The Company has not received any follow up requests from those states. In March 2022, each of the forty-two states agreed to mediation of their claims in the LTL Bankruptcy Case. In July 2022, New Mexico and Mississippi indicated they would no longer voluntarily submit to further mediation in the LTL Bankruptcy and would proceed with their respective cases in state court. In March 2023, the mediation was terminated. The Company continues to engage the states on potential resolution of claims. The unique procedural history and status of the New Mexico and Mississippi matters specifically have been discussed above.", "text": "Forty-two states and the District of Columbia (including Mississippi and New Mexico) have commenced a joint investigation into the Companys marketing of its talcum powder products.", "length": 181, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 834, "tag": "div", "text_raw": "Forty-two states and the District of Columbia (including Mississippi and New Mexico) have commenced a joint investigation into the Companys marketing of its talcum powder products. At this time, the multi-state group has not asserted any claims against the Company. Five states have issued Civil Investigative Demands seeking documents and other information. The Company has produced documents to Arizona, North Carolina, Texas, and Washington and entered into confidentiality agreements. The Company has not received any follow up requests from those states. In March 2022, each of the forty-two states agreed to mediation of their claims in the LTL Bankruptcy Case. In July 2022, New Mexico and Mississippi indicated they would no longer voluntarily submit to further mediation in the LTL Bankruptcy and would proceed with their respective cases in state court. In March 2023, the mediation was terminated. The Company continues to engage the states on potential resolution of claims. The unique procedural history and status of the New Mexico and Mississippi matters specifically have been discussed above.", "text": "At this time, the multi-state group has not asserted any claims against the Company.", "length": 84, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 834, "tag": "div", "text_raw": "Forty-two states and the District of Columbia (including Mississippi and New Mexico) have commenced a joint investigation into the Companys marketing of its talcum powder products. At this time, the multi-state group has not asserted any claims against the Company. Five states have issued Civil Investigative Demands seeking documents and other information. The Company has produced documents to Arizona, North Carolina, Texas, and Washington and entered into confidentiality agreements. The Company has not received any follow up requests from those states. In March 2022, each of the forty-two states agreed to mediation of their claims in the LTL Bankruptcy Case. In July 2022, New Mexico and Mississippi indicated they would no longer voluntarily submit to further mediation in the LTL Bankruptcy and would proceed with their respective cases in state court. In March 2023, the mediation was terminated. The Company continues to engage the states on potential resolution of claims. The unique procedural history and status of the New Mexico and Mississippi matters specifically have been discussed above.", "text": "Five states have issued Civil Investigative Demands seeking documents and other information.", "length": 92, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 834, "tag": "div", "text_raw": "Forty-two states and the District of Columbia (including Mississippi and New Mexico) have commenced a joint investigation into the Companys marketing of its talcum powder products. At this time, the multi-state group has not asserted any claims against the Company. Five states have issued Civil Investigative Demands seeking documents and other information. The Company has produced documents to Arizona, North Carolina, Texas, and Washington and entered into confidentiality agreements. The Company has not received any follow up requests from those states. In March 2022, each of the forty-two states agreed to mediation of their claims in the LTL Bankruptcy Case. In July 2022, New Mexico and Mississippi indicated they would no longer voluntarily submit to further mediation in the LTL Bankruptcy and would proceed with their respective cases in state court. In March 2023, the mediation was terminated. The Company continues to engage the states on potential resolution of claims. The unique procedural history and status of the New Mexico and Mississippi matters specifically have been discussed above.", "text": "The Company has produced documents to Arizona, North Carolina, Texas, and Washington and entered into confidentiality agreements.", "length": 129, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 834, "tag": "div", "text_raw": "Forty-two states and the District of Columbia (including Mississippi and New Mexico) have commenced a joint investigation into the Companys marketing of its talcum powder products. At this time, the multi-state group has not asserted any claims against the Company. Five states have issued Civil Investigative Demands seeking documents and other information. The Company has produced documents to Arizona, North Carolina, Texas, and Washington and entered into confidentiality agreements. The Company has not received any follow up requests from those states. In March 2022, each of the forty-two states agreed to mediation of their claims in the LTL Bankruptcy Case. In July 2022, New Mexico and Mississippi indicated they would no longer voluntarily submit to further mediation in the LTL Bankruptcy and would proceed with their respective cases in state court. In March 2023, the mediation was terminated. The Company continues to engage the states on potential resolution of claims. The unique procedural history and status of the New Mexico and Mississippi matters specifically have been discussed above.", "text": "The Company has not received any follow up requests from those states.", "length": 70, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 834, "tag": "div", "text_raw": "Forty-two states and the District of Columbia (including Mississippi and New Mexico) have commenced a joint investigation into the Companys marketing of its talcum powder products. At this time, the multi-state group has not asserted any claims against the Company. Five states have issued Civil Investigative Demands seeking documents and other information. The Company has produced documents to Arizona, North Carolina, Texas, and Washington and entered into confidentiality agreements. The Company has not received any follow up requests from those states. In March 2022, each of the forty-two states agreed to mediation of their claims in the LTL Bankruptcy Case. In July 2022, New Mexico and Mississippi indicated they would no longer voluntarily submit to further mediation in the LTL Bankruptcy and would proceed with their respective cases in state court. In March 2023, the mediation was terminated. The Company continues to engage the states on potential resolution of claims. The unique procedural history and status of the New Mexico and Mississippi matters specifically have been discussed above.", "text": "In March 2022, each of the forty-two states agreed to mediation of their claims in the LTL Bankruptcy Case.", "length": 107, "numbers_raw": ["202", "2"], "numbers": [202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 834, "tag": "div", "text_raw": "Forty-two states and the District of Columbia (including Mississippi and New Mexico) have commenced a joint investigation into the Companys marketing of its talcum powder products. At this time, the multi-state group has not asserted any claims against the Company. Five states have issued Civil Investigative Demands seeking documents and other information. The Company has produced documents to Arizona, North Carolina, Texas, and Washington and entered into confidentiality agreements. The Company has not received any follow up requests from those states. In March 2022, each of the forty-two states agreed to mediation of their claims in the LTL Bankruptcy Case. In July 2022, New Mexico and Mississippi indicated they would no longer voluntarily submit to further mediation in the LTL Bankruptcy and would proceed with their respective cases in state court. In March 2023, the mediation was terminated. The Company continues to engage the states on potential resolution of claims. The unique procedural history and status of the New Mexico and Mississippi matters specifically have been discussed above.", "text": "In July 2022, New Mexico and Mississippi indicated they would no longer voluntarily submit to further mediation in the LTL Bankruptcy and would proceed with their respective cases in state court.", "length": 195, "numbers_raw": ["202", "2"], "numbers": [202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 834, "tag": "div", "text_raw": "Forty-two states and the District of Columbia (including Mississippi and New Mexico) have commenced a joint investigation into the Companys marketing of its talcum powder products. At this time, the multi-state group has not asserted any claims against the Company. Five states have issued Civil Investigative Demands seeking documents and other information. The Company has produced documents to Arizona, North Carolina, Texas, and Washington and entered into confidentiality agreements. The Company has not received any follow up requests from those states. In March 2022, each of the forty-two states agreed to mediation of their claims in the LTL Bankruptcy Case. In July 2022, New Mexico and Mississippi indicated they would no longer voluntarily submit to further mediation in the LTL Bankruptcy and would proceed with their respective cases in state court. In March 2023, the mediation was terminated. The Company continues to engage the states on potential resolution of claims. The unique procedural history and status of the New Mexico and Mississippi matters specifically have been discussed above.", "text": "In March 2023, the mediation was terminated.", "length": 44, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 834, "tag": "div", "text_raw": "Forty-two states and the District of Columbia (including Mississippi and New Mexico) have commenced a joint investigation into the Companys marketing of its talcum powder products. At this time, the multi-state group has not asserted any claims against the Company. Five states have issued Civil Investigative Demands seeking documents and other information. The Company has produced documents to Arizona, North Carolina, Texas, and Washington and entered into confidentiality agreements. The Company has not received any follow up requests from those states. In March 2022, each of the forty-two states agreed to mediation of their claims in the LTL Bankruptcy Case. In July 2022, New Mexico and Mississippi indicated they would no longer voluntarily submit to further mediation in the LTL Bankruptcy and would proceed with their respective cases in state court. In March 2023, the mediation was terminated. The Company continues to engage the states on potential resolution of claims. The unique procedural history and status of the New Mexico and Mississippi matters specifically have been discussed above.", "text": "The Company continues to engage the states on potential resolution of claims.", "length": 77, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 834, "tag": "div", "text_raw": "Forty-two states and the District of Columbia (including Mississippi and New Mexico) have commenced a joint investigation into the Companys marketing of its talcum powder products. At this time, the multi-state group has not asserted any claims against the Company. Five states have issued Civil Investigative Demands seeking documents and other information. The Company has produced documents to Arizona, North Carolina, Texas, and Washington and entered into confidentiality agreements. The Company has not received any follow up requests from those states. In March 2022, each of the forty-two states agreed to mediation of their claims in the LTL Bankruptcy Case. In July 2022, New Mexico and Mississippi indicated they would no longer voluntarily submit to further mediation in the LTL Bankruptcy and would proceed with their respective cases in state court. In March 2023, the mediation was terminated. The Company continues to engage the states on potential resolution of claims. The unique procedural history and status of the New Mexico and Mississippi matters specifically have been discussed above.", "text": "The unique procedural history and status of the New Mexico and Mississippi matters specifically have been discussed above.", "length": 122, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 836, "tag": "div", "text_raw": "In addition, the Company has received inquiries, subpoenas, and requests to produce documents regarding talc matters and the LTL Bankruptcy Case from various governmental authorities. The Company has produced documents and responded to inquiries, and will continue to cooperate with government inquiries.", "text": "In addition, the Company has received inquiries, subpoenas, and requests to produce documents regarding talc matters and the LTL Bankruptcy Case from various governmental authorities.", "length": 183, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 836, "tag": "div", "text_raw": "In addition, the Company has received inquiries, subpoenas, and requests to produce documents regarding talc matters and the LTL Bankruptcy Case from various governmental authorities. The Company has produced documents and responded to inquiries, and will continue to cooperate with government inquiries.", "text": "The Company has produced documents and responded to inquiries, and will continue to cooperate with government inquiries.", "length": 120, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 841, "tag": "div", "text_raw": "Beginning in 2014 and continuing to the present, the Company and Janssen Pharmaceuticals, Inc. (JPI), along with other pharmaceutical companies, have been named in close to 3,500 lawsuits related to the marketing of opioids, including DURAGESIC, NUCYNTA and NUCYNTA ER. The majority of the cases have been filed by state and local governments. Similar lawsuits have also been filed by private plaintiffs and organizations, including but not limited to the following: individual plaintiffs on behalf of children born with Neonatal Abstinence Syndrome (NAS); hospitals; and health insurers/payors.", "text": "Beginning in 2014 and continuing to the present, the Company and Janssen Pharmaceuticals, Inc.", "length": 94, "numbers_raw": ["201", "4"], "numbers": [201.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 841, "tag": "div", "text_raw": "Beginning in 2014 and continuing to the present, the Company and Janssen Pharmaceuticals, Inc. (JPI), along with other pharmaceutical companies, have been named in close to 3,500 lawsuits related to the marketing of opioids, including DURAGESIC, NUCYNTA and NUCYNTA ER. The majority of the cases have been filed by state and local governments. Similar lawsuits have also been filed by private plaintiffs and organizations, including but not limited to the following: individual plaintiffs on behalf of children born with Neonatal Abstinence Syndrome (NAS); hospitals; and health insurers/payors.", "text": "(JPI), along with other pharmaceutical companies, have been named in close to 3,500 lawsuits related to the marketing of opioids, including DURAGESIC, NUCYNTA and NUCYNTA ER.", "length": 174, "numbers_raw": ["3,500"], "numbers": [3500.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 841, "tag": "div", "text_raw": "Beginning in 2014 and continuing to the present, the Company and Janssen Pharmaceuticals, Inc. (JPI), along with other pharmaceutical companies, have been named in close to 3,500 lawsuits related to the marketing of opioids, including DURAGESIC, NUCYNTA and NUCYNTA ER. The majority of the cases have been filed by state and local governments. Similar lawsuits have also been filed by private plaintiffs and organizations, including but not limited to the following: individual plaintiffs on behalf of children born with Neonatal Abstinence Syndrome (NAS); hospitals; and health insurers/payors.", "text": "The majority of the cases have been filed by state and local governments.", "length": 73, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 841, "tag": "div", "text_raw": "Beginning in 2014 and continuing to the present, the Company and Janssen Pharmaceuticals, Inc. (JPI), along with other pharmaceutical companies, have been named in close to 3,500 lawsuits related to the marketing of opioids, including DURAGESIC, NUCYNTA and NUCYNTA ER. The majority of the cases have been filed by state and local governments. Similar lawsuits have also been filed by private plaintiffs and organizations, including but not limited to the following: individual plaintiffs on behalf of children born with Neonatal Abstinence Syndrome (NAS); hospitals; and health insurers/payors.", "text": "Similar lawsuits have also been filed by private plaintiffs and organizations, including but not limited to the following:", "length": 122, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 841, "tag": "div", "text_raw": "Beginning in 2014 and continuing to the present, the Company and Janssen Pharmaceuticals, Inc. (JPI), along with other pharmaceutical companies, have been named in close to 3,500 lawsuits related to the marketing of opioids, including DURAGESIC, NUCYNTA and NUCYNTA ER. The majority of the cases have been filed by state and local governments. Similar lawsuits have also been filed by private plaintiffs and organizations, including but not limited to the following: individual plaintiffs on behalf of children born with Neonatal Abstinence Syndrome (NAS); hospitals; and health insurers/payors.", "text": "individual plaintiffs on behalf of children born with Neonatal Abstinence Syndrome (NAS);", "length": 89, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 842, "tag": "div", "text_raw": "31", "text": "31", "length": 2, "numbers_raw": ["31"], "numbers": [31.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 843, "tag": "div", "text_raw": "31", "text": "31", "length": 2, "numbers_raw": ["31"], "numbers": [31.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 844, "tag": "div", "text_raw": "31", "text": "31", "length": 2, "numbers_raw": ["31"], "numbers": [31.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 848, "tag": "div", "text_raw": "To date, the Company and JPI have litigated two of the cases to judgment and have prevailed in both, either at trial or on appeal.", "text": "To date, the Company and JPI have litigated two of the cases to judgment and have prevailed in both, either at trial or on appeal.", "length": 130, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 850, "tag": "div", "text_raw": "In October 2019, the Company announced a proposed agreement in principle with a negotiating committee of state Attorneys General to settle all remaining government opioid litigation claims nationwide. Under the final national settlement agreement, which was announced in July 2021, the Company agreed to pay up to $ 5.0 billion to resolve all opioid lawsuits and future opioid claims by states, cities, counties, local school districts and other special districts, and tribal governments, contingent on sufficient participation by eligible government entities, and with credits back for entities that declined or were ineligible to participate. In July 2021, the Company announced that the terms of the agreement to settle the state and subdivision claims had been finalized and approximately 60 % of the all-in settlement was paid by the third fiscal quarter of 2023. The expected payment schedule provides that approximately $ 0.6 billion of payments are to be paid by the end of the third fiscal quarter of 2024. The agreement is not an admission of liability or wrongdoing, and it provides for the release of all opioid-related claims against the Company, JPI, and their affiliates (including the Companys former subsidiaries Tasmanian Alkaloids Pty, Ltd. and Noramco, Inc.). As of September 2023, the Company and JPI have settled or otherwise resolved the opioid claims advanced by all government entity claimants except the State of Washington and its subdivisions, the City of Baltimore, a number of school districts and other special district claimants, and a handful of others.", "text": "In October 2019, the Company announced a proposed agreement in principle with a negotiating committee of state Attorneys General to settle all remaining government opioid litigation claims nationwide.", "length": 200, "numbers_raw": ["201", "9"], "numbers": [201.0, 9.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 850, "tag": "div", "text_raw": "In October 2019, the Company announced a proposed agreement in principle with a negotiating committee of state Attorneys General to settle all remaining government opioid litigation claims nationwide. Under the final national settlement agreement, which was announced in July 2021, the Company agreed to pay up to $ 5.0 billion to resolve all opioid lawsuits and future opioid claims by states, cities, counties, local school districts and other special districts, and tribal governments, contingent on sufficient participation by eligible government entities, and with credits back for entities that declined or were ineligible to participate. In July 2021, the Company announced that the terms of the agreement to settle the state and subdivision claims had been finalized and approximately 60 % of the all-in settlement was paid by the third fiscal quarter of 2023. The expected payment schedule provides that approximately $ 0.6 billion of payments are to be paid by the end of the third fiscal quarter of 2024. The agreement is not an admission of liability or wrongdoing, and it provides for the release of all opioid-related claims against the Company, JPI, and their affiliates (including the Companys former subsidiaries Tasmanian Alkaloids Pty, Ltd. and Noramco, Inc.). As of September 2023, the Company and JPI have settled or otherwise resolved the opioid claims advanced by all government entity claimants except the State of Washington and its subdivisions, the City of Baltimore, a number of school districts and other special district claimants, and a handful of others.", "text": "Under the final national settlement agreement, which was announced in July 2021, the Company agreed to pay up to $ 5.0 billion to resolve all opioid lawsuits and future opioid claims by states, cities, counties, local school districts and other special districts, and tribal governments, contingent on sufficient participation by eligible government entities, and with credits back for entities that declined or were ineligible to participate.", "length": 443, "numbers_raw": ["202", "1", "5.0 billion"], "numbers": [202.0, 1.0, 5000000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 850, "tag": "div", "text_raw": "In October 2019, the Company announced a proposed agreement in principle with a negotiating committee of state Attorneys General to settle all remaining government opioid litigation claims nationwide. Under the final national settlement agreement, which was announced in July 2021, the Company agreed to pay up to $ 5.0 billion to resolve all opioid lawsuits and future opioid claims by states, cities, counties, local school districts and other special districts, and tribal governments, contingent on sufficient participation by eligible government entities, and with credits back for entities that declined or were ineligible to participate. In July 2021, the Company announced that the terms of the agreement to settle the state and subdivision claims had been finalized and approximately 60 % of the all-in settlement was paid by the third fiscal quarter of 2023. The expected payment schedule provides that approximately $ 0.6 billion of payments are to be paid by the end of the third fiscal quarter of 2024. The agreement is not an admission of liability or wrongdoing, and it provides for the release of all opioid-related claims against the Company, JPI, and their affiliates (including the Companys former subsidiaries Tasmanian Alkaloids Pty, Ltd. and Noramco, Inc.). As of September 2023, the Company and JPI have settled or otherwise resolved the opioid claims advanced by all government entity claimants except the State of Washington and its subdivisions, the City of Baltimore, a number of school districts and other special district claimants, and a handful of others.", "text": "In July 2021, the Company announced that the terms of the agreement to settle the state and subdivision claims had been finalized and approximately 60 % of the all-in settlement was paid by the third fiscal quarter of 2023.", "length": 223, "numbers_raw": ["202", "1", "60", "202", "3"], "numbers": [202.0, 1.0, 60.0, 202.0, 3.0], "percents_raw": ["60 %"], "percents": [0.6], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 850, "tag": "div", "text_raw": "In October 2019, the Company announced a proposed agreement in principle with a negotiating committee of state Attorneys General to settle all remaining government opioid litigation claims nationwide. Under the final national settlement agreement, which was announced in July 2021, the Company agreed to pay up to $ 5.0 billion to resolve all opioid lawsuits and future opioid claims by states, cities, counties, local school districts and other special districts, and tribal governments, contingent on sufficient participation by eligible government entities, and with credits back for entities that declined or were ineligible to participate. In July 2021, the Company announced that the terms of the agreement to settle the state and subdivision claims had been finalized and approximately 60 % of the all-in settlement was paid by the third fiscal quarter of 2023. The expected payment schedule provides that approximately $ 0.6 billion of payments are to be paid by the end of the third fiscal quarter of 2024. The agreement is not an admission of liability or wrongdoing, and it provides for the release of all opioid-related claims against the Company, JPI, and their affiliates (including the Companys former subsidiaries Tasmanian Alkaloids Pty, Ltd. and Noramco, Inc.). As of September 2023, the Company and JPI have settled or otherwise resolved the opioid claims advanced by all government entity claimants except the State of Washington and its subdivisions, the City of Baltimore, a number of school districts and other special district claimants, and a handful of others.", "text": "The expected payment schedule provides that approximately $ 0.6 billion of payments are to be paid by the end of the third fiscal quarter of 2024.", "length": 146, "numbers_raw": ["0.6 billion", "202", "4"], "numbers": [600000000.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 850, "tag": "div", "text_raw": "In October 2019, the Company announced a proposed agreement in principle with a negotiating committee of state Attorneys General to settle all remaining government opioid litigation claims nationwide. Under the final national settlement agreement, which was announced in July 2021, the Company agreed to pay up to $ 5.0 billion to resolve all opioid lawsuits and future opioid claims by states, cities, counties, local school districts and other special districts, and tribal governments, contingent on sufficient participation by eligible government entities, and with credits back for entities that declined or were ineligible to participate. In July 2021, the Company announced that the terms of the agreement to settle the state and subdivision claims had been finalized and approximately 60 % of the all-in settlement was paid by the third fiscal quarter of 2023. The expected payment schedule provides that approximately $ 0.6 billion of payments are to be paid by the end of the third fiscal quarter of 2024. The agreement is not an admission of liability or wrongdoing, and it provides for the release of all opioid-related claims against the Company, JPI, and their affiliates (including the Companys former subsidiaries Tasmanian Alkaloids Pty, Ltd. and Noramco, Inc.). As of September 2023, the Company and JPI have settled or otherwise resolved the opioid claims advanced by all government entity claimants except the State of Washington and its subdivisions, the City of Baltimore, a number of school districts and other special district claimants, and a handful of others.", "text": "The agreement is not an admission of liability or wrongdoing, and it provides for the release of all opioid-related claims against the Company, JPI, and their affiliates (including the Companys former subsidiaries Tasmanian Alkaloids Pty, Ltd.", "length": 244, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 850, "tag": "div", "text_raw": "In October 2019, the Company announced a proposed agreement in principle with a negotiating committee of state Attorneys General to settle all remaining government opioid litigation claims nationwide. Under the final national settlement agreement, which was announced in July 2021, the Company agreed to pay up to $ 5.0 billion to resolve all opioid lawsuits and future opioid claims by states, cities, counties, local school districts and other special districts, and tribal governments, contingent on sufficient participation by eligible government entities, and with credits back for entities that declined or were ineligible to participate. In July 2021, the Company announced that the terms of the agreement to settle the state and subdivision claims had been finalized and approximately 60 % of the all-in settlement was paid by the third fiscal quarter of 2023. The expected payment schedule provides that approximately $ 0.6 billion of payments are to be paid by the end of the third fiscal quarter of 2024. The agreement is not an admission of liability or wrongdoing, and it provides for the release of all opioid-related claims against the Company, JPI, and their affiliates (including the Companys former subsidiaries Tasmanian Alkaloids Pty, Ltd. and Noramco, Inc.). As of September 2023, the Company and JPI have settled or otherwise resolved the opioid claims advanced by all government entity claimants except the State of Washington and its subdivisions, the City of Baltimore, a number of school districts and other special district claimants, and a handful of others.", "text": "As of September 2023, the Company and JPI have settled or otherwise resolved the opioid claims advanced by all government entity claimants except the State of Washington and its subdivisions, the City of Baltimore, a number of school districts and other special district claimants, and a handful of others.", "length": 306, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 852, "tag": "div", "text_raw": "The Company and JPI continue to defend the cases brought by the remaining government entity litigants as well as the cases brought by private litigants, including NAS claimants, hospitals, and health insurers/payors. Counting the private litigant cases, there are approximately 35 remaining opioid cases against the Company and JPI in various state courts, 430 remaining cases in the Ohio MDL, and 3 additional cases in other federal courts. Some of these cases have been dismissed and are being appealed by the plaintiffs; a handful of others are scheduled for trial in 2024 or 2025.", "text": "The Company and JPI continue to defend the cases brought by the remaining government entity litigants as well as the cases brought by private litigants, including NAS claimants, hospitals, and health insurers/payors.", "length": 216, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 852, "tag": "div", "text_raw": "The Company and JPI continue to defend the cases brought by the remaining government entity litigants as well as the cases brought by private litigants, including NAS claimants, hospitals, and health insurers/payors. Counting the private litigant cases, there are approximately 35 remaining opioid cases against the Company and JPI in various state courts, 430 remaining cases in the Ohio MDL, and 3 additional cases in other federal courts. Some of these cases have been dismissed and are being appealed by the plaintiffs; a handful of others are scheduled for trial in 2024 or 2025.", "text": "Counting the private litigant cases, there are approximately 35 remaining opioid cases against the Company and JPI in various state courts, 430 remaining cases in the Ohio MDL, and 3 additional cases in other federal courts.", "length": 224, "numbers_raw": ["35", "430", "3"], "numbers": [35.0, 430.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 852, "tag": "div", "text_raw": "The Company and JPI continue to defend the cases brought by the remaining government entity litigants as well as the cases brought by private litigants, including NAS claimants, hospitals, and health insurers/payors. Counting the private litigant cases, there are approximately 35 remaining opioid cases against the Company and JPI in various state courts, 430 remaining cases in the Ohio MDL, and 3 additional cases in other federal courts. Some of these cases have been dismissed and are being appealed by the plaintiffs; a handful of others are scheduled for trial in 2024 or 2025.", "text": "Some of these cases have been dismissed and are being appealed by the plaintiffs;", "length": 81, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 852, "tag": "div", "text_raw": "The Company and JPI continue to defend the cases brought by the remaining government entity litigants as well as the cases brought by private litigants, including NAS claimants, hospitals, and health insurers/payors. Counting the private litigant cases, there are approximately 35 remaining opioid cases against the Company and JPI in various state courts, 430 remaining cases in the Ohio MDL, and 3 additional cases in other federal courts. Some of these cases have been dismissed and are being appealed by the plaintiffs; a handful of others are scheduled for trial in 2024 or 2025.", "text": "a handful of others are scheduled for trial in 2024 or 2025.", "length": 60, "numbers_raw": ["202", "4", "202", "5"], "numbers": [202.0, 4.0, 202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 854, "tag": "div", "text_raw": "In addition, the Province of British Columbia filed suit against the Company and its Canadian affiliate Janssen Inc., and many other industry members, in Canada, and is seeking to have that action certified as an opt in class action on behalf of other provincial/territorial and the federal governments in Canada. Additional proposed class actions have been filed in Canada against the Company and Janssen Inc., and many other industry members, by and on behalf of people who used opioids (for personal injuries), municipalities and First Nations bands. These actions allege a variety of claims related to opioid marketing practices, including false advertising, unfair competition, public nuisance, consumer fraud violations, deceptive acts and practices, false claims and unjust enrichment. An adverse judgment in any of these lawsuits could result in the imposition of large monetary penalties and significant damages including, punitive damages, cost of abatement, substantial fines, equitable remedies and other sanctions.", "text": "In addition, the Province of British Columbia filed suit against the Company and its Canadian affiliate Janssen Inc., and many other industry members, in Canada, and is seeking to have that action certified as an opt in class action on behalf of other provincial/territorial and the federal governments in Canada.", "length": 313, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 854, "tag": "div", "text_raw": "In addition, the Province of British Columbia filed suit against the Company and its Canadian affiliate Janssen Inc., and many other industry members, in Canada, and is seeking to have that action certified as an opt in class action on behalf of other provincial/territorial and the federal governments in Canada. Additional proposed class actions have been filed in Canada against the Company and Janssen Inc., and many other industry members, by and on behalf of people who used opioids (for personal injuries), municipalities and First Nations bands. These actions allege a variety of claims related to opioid marketing practices, including false advertising, unfair competition, public nuisance, consumer fraud violations, deceptive acts and practices, false claims and unjust enrichment. An adverse judgment in any of these lawsuits could result in the imposition of large monetary penalties and significant damages including, punitive damages, cost of abatement, substantial fines, equitable remedies and other sanctions.", "text": "Additional proposed class actions have been filed in Canada against the Company and Janssen Inc., and many other industry members, by and on behalf of people who used opioids (for personal injuries), municipalities and First Nations bands.", "length": 239, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 854, "tag": "div", "text_raw": "In addition, the Province of British Columbia filed suit against the Company and its Canadian affiliate Janssen Inc., and many other industry members, in Canada, and is seeking to have that action certified as an opt in class action on behalf of other provincial/territorial and the federal governments in Canada. Additional proposed class actions have been filed in Canada against the Company and Janssen Inc., and many other industry members, by and on behalf of people who used opioids (for personal injuries), municipalities and First Nations bands. These actions allege a variety of claims related to opioid marketing practices, including false advertising, unfair competition, public nuisance, consumer fraud violations, deceptive acts and practices, false claims and unjust enrichment. An adverse judgment in any of these lawsuits could result in the imposition of large monetary penalties and significant damages including, punitive damages, cost of abatement, substantial fines, equitable remedies and other sanctions.", "text": "These actions allege a variety of claims related to opioid marketing practices, including false advertising, unfair competition, public nuisance, consumer fraud violations, deceptive acts and practices, false claims and unjust enrichment.", "length": 238, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 854, "tag": "div", "text_raw": "In addition, the Province of British Columbia filed suit against the Company and its Canadian affiliate Janssen Inc., and many other industry members, in Canada, and is seeking to have that action certified as an opt in class action on behalf of other provincial/territorial and the federal governments in Canada. Additional proposed class actions have been filed in Canada against the Company and Janssen Inc., and many other industry members, by and on behalf of people who used opioids (for personal injuries), municipalities and First Nations bands. These actions allege a variety of claims related to opioid marketing practices, including false advertising, unfair competition, public nuisance, consumer fraud violations, deceptive acts and practices, false claims and unjust enrichment. An adverse judgment in any of these lawsuits could result in the imposition of large monetary penalties and significant damages including, punitive damages, cost of abatement, substantial fines, equitable remedies and other sanctions.", "text": "An adverse judgment in any of these lawsuits could result in the imposition of large monetary penalties and significant damages including, punitive damages, cost of abatement, substantial fines, equitable remedies and other sanctions.", "length": 234, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 856, "tag": "div", "text_raw": "From June 2017 through December 2019, the Companys Board of Directors received a series of shareholder demand letters alleging breaches of fiduciary duties related to the marketing of opioids. The Board retained independent counsel to investigate the allegations in the demands, and in April 2020, independent counsel delivered a report to the Board recommending that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of related derivative litigation. The Board unanimously adopted the recommendations of the independent counsels report.", "text": "From June 2017 through December 2019, the Companys Board of Directors received a series of shareholder demand letters alleging breaches of fiduciary duties related to the marketing of opioids.", "length": 193, "numbers_raw": ["201", "7", "201", "9"], "numbers": [201.0, 7.0, 201.0, 9.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 856, "tag": "div", "text_raw": "From June 2017 through December 2019, the Companys Board of Directors received a series of shareholder demand letters alleging breaches of fiduciary duties related to the marketing of opioids. The Board retained independent counsel to investigate the allegations in the demands, and in April 2020, independent counsel delivered a report to the Board recommending that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of related derivative litigation. The Board unanimously adopted the recommendations of the independent counsels report.", "text": "The Board retained independent counsel to investigate the allegations in the demands, and in April 2020, independent counsel delivered a report to the Board recommending that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of related derivative litigation.", "length": 324, "numbers_raw": ["202", "0"], "numbers": [202.0, 0.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 856, "tag": "div", "text_raw": "From June 2017 through December 2019, the Companys Board of Directors received a series of shareholder demand letters alleging breaches of fiduciary duties related to the marketing of opioids. The Board retained independent counsel to investigate the allegations in the demands, and in April 2020, independent counsel delivered a report to the Board recommending that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of related derivative litigation. The Board unanimously adopted the recommendations of the independent counsels report.", "text": "The Board unanimously adopted the recommendations of the independent counsels report.", "length": 86, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 858, "tag": "div", "text_raw": "In November 2019, one of the shareholders who sent a demand filed a derivative complaint against the Company as the nominal defendant and certain current and former directors and officers as defendants in the Superior Court of New Jersey. The complaint alleges breaches of fiduciary duties related to the marketing of opioids, and that the Company has suffered damages as a result of those alleged breaches. A series of additional derivative complaints making similar allegations against the same and similar defendants were filed in New Jersey state and federal courts in 2019 and 2020. By 2022, all but two state court cases had been voluntarily dismissed. In February 2022, the state court granted the Companys motion to dismiss one of the two cases, and the shareholder that brought the second case filed a notice of dismissal. The shareholder whose complaint was dismissed filed a motion for reconsideration. In May 2022, the state court held oral argument on the motion for reconsideration and subsequently denied the motion. The shareholder has appealed the state courts dismissal order.", "text": "In November 2019, one of the shareholders who sent a demand filed a derivative complaint against the Company as the nominal defendant and certain current and former directors and officers as defendants in the Superior Court of New Jersey.", "length": 238, "numbers_raw": ["201", "9"], "numbers": [201.0, 9.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 858, "tag": "div", "text_raw": "In November 2019, one of the shareholders who sent a demand filed a derivative complaint against the Company as the nominal defendant and certain current and former directors and officers as defendants in the Superior Court of New Jersey. The complaint alleges breaches of fiduciary duties related to the marketing of opioids, and that the Company has suffered damages as a result of those alleged breaches. A series of additional derivative complaints making similar allegations against the same and similar defendants were filed in New Jersey state and federal courts in 2019 and 2020. By 2022, all but two state court cases had been voluntarily dismissed. In February 2022, the state court granted the Companys motion to dismiss one of the two cases, and the shareholder that brought the second case filed a notice of dismissal. The shareholder whose complaint was dismissed filed a motion for reconsideration. In May 2022, the state court held oral argument on the motion for reconsideration and subsequently denied the motion. The shareholder has appealed the state courts dismissal order.", "text": "The complaint alleges breaches of fiduciary duties related to the marketing of opioids, and that the Company has suffered damages as a result of those alleged breaches.", "length": 168, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 858, "tag": "div", "text_raw": "In November 2019, one of the shareholders who sent a demand filed a derivative complaint against the Company as the nominal defendant and certain current and former directors and officers as defendants in the Superior Court of New Jersey. The complaint alleges breaches of fiduciary duties related to the marketing of opioids, and that the Company has suffered damages as a result of those alleged breaches. A series of additional derivative complaints making similar allegations against the same and similar defendants were filed in New Jersey state and federal courts in 2019 and 2020. By 2022, all but two state court cases had been voluntarily dismissed. In February 2022, the state court granted the Companys motion to dismiss one of the two cases, and the shareholder that brought the second case filed a notice of dismissal. The shareholder whose complaint was dismissed filed a motion for reconsideration. In May 2022, the state court held oral argument on the motion for reconsideration and subsequently denied the motion. The shareholder has appealed the state courts dismissal order.", "text": "A series of additional derivative complaints making similar allegations against the same and similar defendants were filed in New Jersey state and federal courts in 2019 and 2020.", "length": 179, "numbers_raw": ["201", "9", "202", "0"], "numbers": [201.0, 9.0, 202.0, 0.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 858, "tag": "div", "text_raw": "In November 2019, one of the shareholders who sent a demand filed a derivative complaint against the Company as the nominal defendant and certain current and former directors and officers as defendants in the Superior Court of New Jersey. The complaint alleges breaches of fiduciary duties related to the marketing of opioids, and that the Company has suffered damages as a result of those alleged breaches. A series of additional derivative complaints making similar allegations against the same and similar defendants were filed in New Jersey state and federal courts in 2019 and 2020. By 2022, all but two state court cases had been voluntarily dismissed. In February 2022, the state court granted the Companys motion to dismiss one of the two cases, and the shareholder that brought the second case filed a notice of dismissal. The shareholder whose complaint was dismissed filed a motion for reconsideration. In May 2022, the state court held oral argument on the motion for reconsideration and subsequently denied the motion. The shareholder has appealed the state courts dismissal order.", "text": "By 2022, all but two state court cases had been voluntarily dismissed.", "length": 70, "numbers_raw": ["202", "2"], "numbers": [202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 858, "tag": "div", "text_raw": "In November 2019, one of the shareholders who sent a demand filed a derivative complaint against the Company as the nominal defendant and certain current and former directors and officers as defendants in the Superior Court of New Jersey. The complaint alleges breaches of fiduciary duties related to the marketing of opioids, and that the Company has suffered damages as a result of those alleged breaches. A series of additional derivative complaints making similar allegations against the same and similar defendants were filed in New Jersey state and federal courts in 2019 and 2020. By 2022, all but two state court cases had been voluntarily dismissed. In February 2022, the state court granted the Companys motion to dismiss one of the two cases, and the shareholder that brought the second case filed a notice of dismissal. The shareholder whose complaint was dismissed filed a motion for reconsideration. In May 2022, the state court held oral argument on the motion for reconsideration and subsequently denied the motion. The shareholder has appealed the state courts dismissal order.", "text": "In February 2022, the state court granted the Companys motion to dismiss one of the two cases, and the shareholder that brought the second case filed a notice of dismissal.", "length": 173, "numbers_raw": ["202", "2"], "numbers": [202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 858, "tag": "div", "text_raw": "In November 2019, one of the shareholders who sent a demand filed a derivative complaint against the Company as the nominal defendant and certain current and former directors and officers as defendants in the Superior Court of New Jersey. The complaint alleges breaches of fiduciary duties related to the marketing of opioids, and that the Company has suffered damages as a result of those alleged breaches. A series of additional derivative complaints making similar allegations against the same and similar defendants were filed in New Jersey state and federal courts in 2019 and 2020. By 2022, all but two state court cases had been voluntarily dismissed. In February 2022, the state court granted the Companys motion to dismiss one of the two cases, and the shareholder that brought the second case filed a notice of dismissal. The shareholder whose complaint was dismissed filed a motion for reconsideration. In May 2022, the state court held oral argument on the motion for reconsideration and subsequently denied the motion. The shareholder has appealed the state courts dismissal order.", "text": "The shareholder whose complaint was dismissed filed a motion for reconsideration.", "length": 81, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 858, "tag": "div", "text_raw": "In November 2019, one of the shareholders who sent a demand filed a derivative complaint against the Company as the nominal defendant and certain current and former directors and officers as defendants in the Superior Court of New Jersey. The complaint alleges breaches of fiduciary duties related to the marketing of opioids, and that the Company has suffered damages as a result of those alleged breaches. A series of additional derivative complaints making similar allegations against the same and similar defendants were filed in New Jersey state and federal courts in 2019 and 2020. By 2022, all but two state court cases had been voluntarily dismissed. In February 2022, the state court granted the Companys motion to dismiss one of the two cases, and the shareholder that brought the second case filed a notice of dismissal. The shareholder whose complaint was dismissed filed a motion for reconsideration. In May 2022, the state court held oral argument on the motion for reconsideration and subsequently denied the motion. The shareholder has appealed the state courts dismissal order.", "text": "In May 2022, the state court held oral argument on the motion for reconsideration and subsequently denied the motion.", "length": 117, "numbers_raw": ["202", "2"], "numbers": [202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 858, "tag": "div", "text_raw": "In November 2019, one of the shareholders who sent a demand filed a derivative complaint against the Company as the nominal defendant and certain current and former directors and officers as defendants in the Superior Court of New Jersey. The complaint alleges breaches of fiduciary duties related to the marketing of opioids, and that the Company has suffered damages as a result of those alleged breaches. A series of additional derivative complaints making similar allegations against the same and similar defendants were filed in New Jersey state and federal courts in 2019 and 2020. By 2022, all but two state court cases had been voluntarily dismissed. In February 2022, the state court granted the Companys motion to dismiss one of the two cases, and the shareholder that brought the second case filed a notice of dismissal. The shareholder whose complaint was dismissed filed a motion for reconsideration. In May 2022, the state court held oral argument on the motion for reconsideration and subsequently denied the motion. The shareholder has appealed the state courts dismissal order.", "text": "The shareholder has appealed the state courts dismissal order.", "length": 63, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 862, "tag": "div", "text_raw": "The Company and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available.", "text": "The Company and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products.", "length": 135, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 862, "tag": "div", "text_raw": "The Company and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available.", "text": "Claimants in these cases seek substantial compensatory and, where available, punitive damages.", "length": 94, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 862, "tag": "div", "text_raw": "The Company and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available.", "text": "While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation.", "length": 121, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 862, "tag": "div", "text_raw": "The Company and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available.", "text": "From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances.", "length": 135, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 862, "tag": "div", "text_raw": "The Company and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available.", "text": "The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25.", "length": 221, "numbers_raw": ["450", "20", "25"], "numbers": [450.0, 20.0, 25.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 862, "tag": "div", "text_raw": "The Company and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available.", "text": "The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated.", "length": 150, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 862, "tag": "div", "text_raw": "The Company and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available.", "text": "For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses.", "length": 151, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 862, "tag": "div", "text_raw": "The Company and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available.", "text": "Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns.", "length": 186, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 862, "tag": "div", "text_raw": "The Company and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available.", "text": "Changes to the accruals may be required in the future as additional information becomes available.", "length": 98, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 863, "tag": "div", "text_raw": "32", "text": "32", "length": 2, "numbers_raw": ["32"], "numbers": [32.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 864, "tag": "div", "text_raw": "32", "text": "32", "length": 2, "numbers_raw": ["32"], "numbers": [32.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 865, "tag": "div", "text_raw": "32", "text": "32", "length": 2, "numbers_raw": ["32"], "numbers": [32.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 869, "tag": "div", "text_raw": "The table below contains the most significant of these cases and provides the approximate number of plaintiffs in the United States with direct claims in pending lawsuits regarding injuries allegedly due to the relevant product or product category as of October 1, 2023:", "text": "The table below contains the most significant of these cases and provides the approximate number of plaintiffs in the United States with direct claims in pending lawsuits regarding injuries allegedly due to the relevant product or product category as of October 1, 2023:", "length": 270, "numbers_raw": ["1", "202", "3"], "numbers": [1.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 871, "tag": "div", "text_raw": "Product or product category Number of Plaintiffs Body powders containing talc, primarily JOHNSONS Baby Powder 52,220 DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System 160 PINNACLE Acetabular Cup System 930 Pelvic meshes 6,960 ETHICON PHYSIOMESH Flexible Composite Mesh 720 RISPERDAL 220 ELMIRON 2,150", "text": "Product or product category Number of Plaintiffs Body powders containing talc, primarily JOHNSONS Baby Powder 52,220 DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System 160 PINNACLE Acetabular Cup System 930 Pelvic meshes 6,960 ETHICON PHYSIOMESH Flexible Composite Mesh 720 RISPERDAL 220 ELMIRON 2,150", "length": 319, "numbers_raw": ["52,220", "160", "930", "6,960", "720", "220", "2,150"], "numbers": [52220.0, 160.0, 930.0, 6960.0, 720.0, 220.0, 2150.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 873, "tag": "div", "text_raw": "The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed. There may be additional claims that have not yet been filed.", "text": "The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed.", "length": 135, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 873, "tag": "div", "text_raw": "The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed. There may be additional claims that have not yet been filed.", "text": "There may be additional claims that have not yet been filed.", "length": 60, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 877, "tag": "div", "text_raw": "DePuy ASR XL Acetabular System and ASR Hip Resurfacing System", "text": "DePuy ASR XL Acetabular System and ASR Hip Resurfacing System", "length": 61, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 878, "tag": "div", "text_raw": "In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR XL Acetabular System and DePuy ASR Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and the Company. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 2013 and prior to February 15, 2017. This settlement program has resolved more than 10,000 claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle the class actions filed in that country. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation.", "text": "In August 2010, DePuy Orthopaedics, Inc.", "length": 40, "numbers_raw": ["201", "0"], "numbers": [201.0, 0.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 878, "tag": "div", "text_raw": "In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR XL Acetabular System and DePuy ASR Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and the Company. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 2013 and prior to February 15, 2017. This settlement program has resolved more than 10,000 claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle the class actions filed in that country. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation.", "text": "(DePuy) announced a worldwide voluntary recall of its ASR XL Acetabular System and DePuy ASR Hip Resurfacing System (ASR Hip) used in hip replacement surgery.", "length": 158, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 878, "tag": "div", "text_raw": "In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR XL Acetabular System and DePuy ASR Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and the Company. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 2013 and prior to February 15, 2017. This settlement program has resolved more than 10,000 claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle the class actions filed in that country. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation.", "text": "Claims for personal injury have been made against DePuy and the Company.", "length": 72, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 878, "tag": "div", "text_raw": "In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR XL Acetabular System and DePuy ASR Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and the Company. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 2013 and prior to February 15, 2017. This settlement program has resolved more than 10,000 claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle the class actions filed in that country. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation.", "text": "Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio.", "length": 172, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 878, "tag": "div", "text_raw": "In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR XL Acetabular System and DePuy ASR Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and the Company. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 2013 and prior to February 15, 2017. This settlement program has resolved more than 10,000 claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle the class actions filed in that country. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation.", "text": "Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany, India and Italy.", "length": 160, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 878, "tag": "div", "text_raw": "In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR XL Acetabular System and DePuy ASR Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and the Company. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 2013 and prior to February 15, 2017. This settlement program has resolved more than 10,000 claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle the class actions filed in that country. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation.", "text": "In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 2013.", "length": 301, "numbers_raw": ["201", "3", "201", "3"], "numbers": [201.0, 3.0, 201.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 878, "tag": "div", "text_raw": "In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR XL Acetabular System and DePuy ASR Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and the Company. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 2013 and prior to February 15, 2017. This settlement program has resolved more than 10,000 claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle the class actions filed in that country. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation.", "text": "DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 2013 and prior to February 15, 2017.", "length": 219, "numbers_raw": ["201", "5", "201", "7", "201", "3", "15", "201", "7"], "numbers": [201.0, 5.0, 201.0, 7.0, 201.0, 3.0, 15.0, 201.0, 7.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 878, "tag": "div", "text_raw": "In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR XL Acetabular System and DePuy ASR Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and the Company. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 2013 and prior to February 15, 2017. This settlement program has resolved more than 10,000 claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle the class actions filed in that country. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation.", "text": "This settlement program has resolved more than 10,000 claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States.", "length": 154, "numbers_raw": ["10,000"], "numbers": [10000.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 878, "tag": "div", "text_raw": "In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR XL Acetabular System and DePuy ASR Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and the Company. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 2013 and prior to February 15, 2017. This settlement program has resolved more than 10,000 claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle the class actions filed in that country. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation.", "text": "However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States.", "length": 131, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 878, "tag": "div", "text_raw": "In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR XL Acetabular System and DePuy ASR Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and the Company. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 2013 and prior to February 15, 2017. This settlement program has resolved more than 10,000 claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle the class actions filed in that country. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation.", "text": "In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country.", "length": 129, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 878, "tag": "div", "text_raw": "In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR XL Acetabular System and DePuy ASR Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and the Company. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 2013 and prior to February 15, 2017. This settlement program has resolved more than 10,000 claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle the class actions filed in that country. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation.", "text": "In Canada, the Company has reached agreements to settle the class actions filed in that country.", "length": 96, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 878, "tag": "div", "text_raw": "In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR XL Acetabular System and DePuy ASR Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and the Company. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 2013 and prior to February 15, 2017. This settlement program has resolved more than 10,000 claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle the class actions filed in that country. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation.", "text": "The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis.", "length": 137, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 878, "tag": "div", "text_raw": "In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR XL Acetabular System and DePuy ASR Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and the Company. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 2013 and prior to February 15, 2017. This settlement program has resolved more than 10,000 claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle the class actions filed in that country. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation.", "text": "The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation.", "length": 153, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 880, "tag": "div", "text_raw": "DePuy PINNACLE Acetabular Cup System", "text": "DePuy PINNACLE Acetabular Cup System", "length": 36, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 881, "tag": "div", "text_raw": "Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and the Company (collectively, DePuy) relating to the PINNACLE Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Most cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas (Texas MDL). Beginning on June 1, 2022, the Judicial Panel on Multidistrict Litigation ceased transfer of new cases into the Texas MDL, and there are now cases pending in federal court outside the Texas MDL. Litigation also has been filed in state courts and in countries outside of the United States. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE Acetabular Cup System and the related settlement program.", "text": "Claims for personal injury have also been made against DePuy Orthopaedics, Inc.", "length": 79, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 881, "tag": "div", "text_raw": "Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and the Company (collectively, DePuy) relating to the PINNACLE Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Most cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas (Texas MDL). Beginning on June 1, 2022, the Judicial Panel on Multidistrict Litigation ceased transfer of new cases into the Texas MDL, and there are now cases pending in federal court outside the Texas MDL. Litigation also has been filed in state courts and in countries outside of the United States. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE Acetabular Cup System and the related settlement program.", "text": "and the Company (collectively, DePuy) relating to the PINNACLE Acetabular Cup System used in hip replacement surgery.", "length": 117, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 881, "tag": "div", "text_raw": "Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and the Company (collectively, DePuy) relating to the PINNACLE Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Most cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas (Texas MDL). Beginning on June 1, 2022, the Judicial Panel on Multidistrict Litigation ceased transfer of new cases into the Texas MDL, and there are now cases pending in federal court outside the Texas MDL. Litigation also has been filed in state courts and in countries outside of the United States. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE Acetabular Cup System and the related settlement program.", "text": "Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases.", "length": 166, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 881, "tag": "div", "text_raw": "Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and the Company (collectively, DePuy) relating to the PINNACLE Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Most cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas (Texas MDL). Beginning on June 1, 2022, the Judicial Panel on Multidistrict Litigation ceased transfer of new cases into the Texas MDL, and there are now cases pending in federal court outside the Texas MDL. Litigation also has been filed in state courts and in countries outside of the United States. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE Acetabular Cup System and the related settlement program.", "text": "Most cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas (Texas MDL).", "length": 190, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 881, "tag": "div", "text_raw": "Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and the Company (collectively, DePuy) relating to the PINNACLE Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Most cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas (Texas MDL). Beginning on June 1, 2022, the Judicial Panel on Multidistrict Litigation ceased transfer of new cases into the Texas MDL, and there are now cases pending in federal court outside the Texas MDL. Litigation also has been filed in state courts and in countries outside of the United States. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE Acetabular Cup System and the related settlement program.", "text": "Beginning on June 1, 2022, the Judicial Panel on Multidistrict Litigation ceased transfer of new cases into the Texas MDL, and there are now cases pending in federal court outside the Texas MDL.", "length": 194, "numbers_raw": ["1", "202", "2"], "numbers": [1.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 881, "tag": "div", "text_raw": "Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and the Company (collectively, DePuy) relating to the PINNACLE Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Most cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas (Texas MDL). Beginning on June 1, 2022, the Judicial Panel on Multidistrict Litigation ceased transfer of new cases into the Texas MDL, and there are now cases pending in federal court outside the Texas MDL. Litigation also has been filed in state courts and in countries outside of the United States. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE Acetabular Cup System and the related settlement program.", "text": "Litigation also has been filed in state courts and in countries outside of the United States.", "length": 93, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 881, "tag": "div", "text_raw": "Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and the Company (collectively, DePuy) relating to the PINNACLE Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Most cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas (Texas MDL). Beginning on June 1, 2022, the Judicial Panel on Multidistrict Litigation ceased transfer of new cases into the Texas MDL, and there are now cases pending in federal court outside the Texas MDL. Litigation also has been filed in state courts and in countries outside of the United States. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE Acetabular Cup System and the related settlement program.", "text": "During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases.", "length": 110, "numbers_raw": ["201", "9"], "numbers": [201.0, 9.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 881, "tag": "div", "text_raw": "Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and the Company (collectively, DePuy) relating to the PINNACLE Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Most cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas (Texas MDL). Beginning on June 1, 2022, the Judicial Panel on Multidistrict Litigation ceased transfer of new cases into the Texas MDL, and there are now cases pending in federal court outside the Texas MDL. Litigation also has been filed in state courts and in countries outside of the United States. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE Acetabular Cup System and the related settlement program.", "text": "As part of the settlement program, adverse verdicts have been settled.", "length": 70, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 881, "tag": "div", "text_raw": "Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and the Company (collectively, DePuy) relating to the PINNACLE Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Most cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas (Texas MDL). Beginning on June 1, 2022, the Judicial Panel on Multidistrict Litigation ceased transfer of new cases into the Texas MDL, and there are now cases pending in federal court outside the Texas MDL. Litigation also has been filed in state courts and in countries outside of the United States. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE Acetabular Cup System and the related settlement program.", "text": "The Company has established an accrual for product liability litigation associated with the PINNACLE Acetabular Cup System and the related settlement program.", "length": 158, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 885, "tag": "div", "text_raw": "Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company arising out of Ethicons pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. In March 2021, the MDL Court entered an order closing the MDL. The MDL Court has remanded cases for trial to the jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved the majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Companys accruals. In addition, class actions and individual", "text": "Claims for personal injury have been made against Ethicon, Inc.", "length": 63, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 885, "tag": "div", "text_raw": "Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company arising out of Ethicons pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. In March 2021, the MDL Court entered an order closing the MDL. The MDL Court has remanded cases for trial to the jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved the majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Companys accruals. In addition, class actions and individual", "text": "(Ethicon) and the Company arising out of Ethicons pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse.", "length": 139, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 885, "tag": "div", "text_raw": "Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company arising out of Ethicons pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. In March 2021, the MDL Court entered an order closing the MDL. The MDL Court has remanded cases for trial to the jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved the majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Companys accruals. In addition, class actions and individual", "text": "The Company continues to receive information with respect to potential costs and additional cases.", "length": 98, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 885, "tag": "div", "text_raw": "Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company arising out of Ethicons pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. In March 2021, the MDL Court entered an order closing the MDL. The MDL Court has remanded cases for trial to the jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved the majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Companys accruals. In addition, class actions and individual", "text": "Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia.", "length": 186, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 885, "tag": "div", "text_raw": "Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company arising out of Ethicons pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. In March 2021, the MDL Court entered an order closing the MDL. The MDL Court has remanded cases for trial to the jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved the majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Companys accruals. In addition, class actions and individual", "text": "In March 2021, the MDL Court entered an order closing the MDL.", "length": 62, "numbers_raw": ["202", "1"], "numbers": [202.0, 1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 885, "tag": "div", "text_raw": "Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company arising out of Ethicons pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. In March 2021, the MDL Court entered an order closing the MDL. The MDL Court has remanded cases for trial to the jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved the majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Companys accruals. In addition, class actions and individual", "text": "The MDL Court has remanded cases for trial to the jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL.", "length": 184, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 885, "tag": "div", "text_raw": "Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company arising out of Ethicons pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. In March 2021, the MDL Court entered an order closing the MDL. The MDL Court has remanded cases for trial to the jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved the majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Companys accruals. In addition, class actions and individual", "text": "The Company has settled or otherwise resolved the majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Companys accruals.", "length": 208, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 885, "tag": "div", "text_raw": "Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company arising out of Ethicons pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. In March 2021, the MDL Court entered an order closing the MDL. The MDL Court has remanded cases for trial to the jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved the majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Companys accruals. In addition, class actions and individual", "text": "In addition, class actions and individual", "length": 41, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 886, "tag": "div", "text_raw": "33", "text": "33", "length": 2, "numbers_raw": ["33"], "numbers": [33.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 887, "tag": "div", "text_raw": "33", "text": "33", "length": 2, "numbers_raw": ["33"], "numbers": [33.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 888, "tag": "div", "text_raw": "33", "text": "33", "length": 2, "numbers_raw": ["33"], "numbers": [33.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 891, "tag": "div", "text_raw": "personal injury cases or claims seeking damages for alleged injury resulting from Ethicons pelvic mesh devices have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands, Belgium, France, Ireland, Italy, Spain and Slovenia and class actions in Israel, Australia, Canada and South Africa. In November 2019, the Federal Court of Australia issued a judgment regarding its findings with respect to liability in relation to the three Lead Applicants and generally in relation to the design, manufacture, pre- and post-market assessments and testing, and supply and promotion of the devices in Australia used to treat stress urinary incontinence and pelvic organ prolapse. In September 2022, after exhausting its appeals, the Company reached an in-principle agreement to resolve the two pelvic mesh class actions in Australia and in March 2023 the Federal Court approved the settlement. The class actions in Canada were discontinued in 2020 as a result of a settlement of a group of cases and an agreement to resolve the Israeli class action was reached in May 2021. The parties in the Israeli class action are currently finalizing the terms of the settlement. A motion to approve the settlement was filed with the Court. The Company has established accruals with respect to product liability litigation associated with Ethicons pelvic mesh products.", "text": "personal injury cases or claims seeking damages for alleged injury resulting from Ethicons pelvic mesh devices have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands, Belgium, France, Ireland, Italy, Spain and Slovenia and class actions in Israel, Australia, Canada and South Africa.", "length": 366, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 891, "tag": "div", "text_raw": "personal injury cases or claims seeking damages for alleged injury resulting from Ethicons pelvic mesh devices have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands, Belgium, France, Ireland, Italy, Spain and Slovenia and class actions in Israel, Australia, Canada and South Africa. In November 2019, the Federal Court of Australia issued a judgment regarding its findings with respect to liability in relation to the three Lead Applicants and generally in relation to the design, manufacture, pre- and post-market assessments and testing, and supply and promotion of the devices in Australia used to treat stress urinary incontinence and pelvic organ prolapse. In September 2022, after exhausting its appeals, the Company reached an in-principle agreement to resolve the two pelvic mesh class actions in Australia and in March 2023 the Federal Court approved the settlement. The class actions in Canada were discontinued in 2020 as a result of a settlement of a group of cases and an agreement to resolve the Israeli class action was reached in May 2021. The parties in the Israeli class action are currently finalizing the terms of the settlement. A motion to approve the settlement was filed with the Court. The Company has established accruals with respect to product liability litigation associated with Ethicons pelvic mesh products.", "text": "In November 2019, the Federal Court of Australia issued a judgment regarding its findings with respect to liability in relation to the three Lead Applicants and generally in relation to the design, manufacture, pre- and post-market assessments and testing, and supply and promotion of the devices in Australia used to treat stress urinary incontinence and pelvic organ prolapse.", "length": 378, "numbers_raw": ["201", "9"], "numbers": [201.0, 9.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 891, "tag": "div", "text_raw": "personal injury cases or claims seeking damages for alleged injury resulting from Ethicons pelvic mesh devices have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands, Belgium, France, Ireland, Italy, Spain and Slovenia and class actions in Israel, Australia, Canada and South Africa. In November 2019, the Federal Court of Australia issued a judgment regarding its findings with respect to liability in relation to the three Lead Applicants and generally in relation to the design, manufacture, pre- and post-market assessments and testing, and supply and promotion of the devices in Australia used to treat stress urinary incontinence and pelvic organ prolapse. In September 2022, after exhausting its appeals, the Company reached an in-principle agreement to resolve the two pelvic mesh class actions in Australia and in March 2023 the Federal Court approved the settlement. The class actions in Canada were discontinued in 2020 as a result of a settlement of a group of cases and an agreement to resolve the Israeli class action was reached in May 2021. The parties in the Israeli class action are currently finalizing the terms of the settlement. A motion to approve the settlement was filed with the Court. The Company has established accruals with respect to product liability litigation associated with Ethicons pelvic mesh products.", "text": "In September 2022, after exhausting its appeals, the Company reached an in-principle agreement to resolve the two pelvic mesh class actions in Australia and in March 2023 the Federal Court approved the settlement.", "length": 213, "numbers_raw": ["202", "2", "202", "3"], "numbers": [202.0, 2.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 891, "tag": "div", "text_raw": "personal injury cases or claims seeking damages for alleged injury resulting from Ethicons pelvic mesh devices have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands, Belgium, France, Ireland, Italy, Spain and Slovenia and class actions in Israel, Australia, Canada and South Africa. In November 2019, the Federal Court of Australia issued a judgment regarding its findings with respect to liability in relation to the three Lead Applicants and generally in relation to the design, manufacture, pre- and post-market assessments and testing, and supply and promotion of the devices in Australia used to treat stress urinary incontinence and pelvic organ prolapse. In September 2022, after exhausting its appeals, the Company reached an in-principle agreement to resolve the two pelvic mesh class actions in Australia and in March 2023 the Federal Court approved the settlement. The class actions in Canada were discontinued in 2020 as a result of a settlement of a group of cases and an agreement to resolve the Israeli class action was reached in May 2021. The parties in the Israeli class action are currently finalizing the terms of the settlement. A motion to approve the settlement was filed with the Court. The Company has established accruals with respect to product liability litigation associated with Ethicons pelvic mesh products.", "text": "The class actions in Canada were discontinued in 2020 as a result of a settlement of a group of cases and an agreement to resolve the Israeli class action was reached in May 2021.", "length": 179, "numbers_raw": ["202", "0", "202", "1"], "numbers": [202.0, 0.0, 202.0, 1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 891, "tag": "div", "text_raw": "personal injury cases or claims seeking damages for alleged injury resulting from Ethicons pelvic mesh devices have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands, Belgium, France, Ireland, Italy, Spain and Slovenia and class actions in Israel, Australia, Canada and South Africa. In November 2019, the Federal Court of Australia issued a judgment regarding its findings with respect to liability in relation to the three Lead Applicants and generally in relation to the design, manufacture, pre- and post-market assessments and testing, and supply and promotion of the devices in Australia used to treat stress urinary incontinence and pelvic organ prolapse. In September 2022, after exhausting its appeals, the Company reached an in-principle agreement to resolve the two pelvic mesh class actions in Australia and in March 2023 the Federal Court approved the settlement. The class actions in Canada were discontinued in 2020 as a result of a settlement of a group of cases and an agreement to resolve the Israeli class action was reached in May 2021. The parties in the Israeli class action are currently finalizing the terms of the settlement. A motion to approve the settlement was filed with the Court. The Company has established accruals with respect to product liability litigation associated with Ethicons pelvic mesh products.", "text": "The parties in the Israeli class action are currently finalizing the terms of the settlement.", "length": 93, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 891, "tag": "div", "text_raw": "personal injury cases or claims seeking damages for alleged injury resulting from Ethicons pelvic mesh devices have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands, Belgium, France, Ireland, Italy, Spain and Slovenia and class actions in Israel, Australia, Canada and South Africa. In November 2019, the Federal Court of Australia issued a judgment regarding its findings with respect to liability in relation to the three Lead Applicants and generally in relation to the design, manufacture, pre- and post-market assessments and testing, and supply and promotion of the devices in Australia used to treat stress urinary incontinence and pelvic organ prolapse. In September 2022, after exhausting its appeals, the Company reached an in-principle agreement to resolve the two pelvic mesh class actions in Australia and in March 2023 the Federal Court approved the settlement. The class actions in Canada were discontinued in 2020 as a result of a settlement of a group of cases and an agreement to resolve the Israeli class action was reached in May 2021. The parties in the Israeli class action are currently finalizing the terms of the settlement. A motion to approve the settlement was filed with the Court. The Company has established accruals with respect to product liability litigation associated with Ethicons pelvic mesh products.", "text": "A motion to approve the settlement was filed with the Court.", "length": 60, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 891, "tag": "div", "text_raw": "personal injury cases or claims seeking damages for alleged injury resulting from Ethicons pelvic mesh devices have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands, Belgium, France, Ireland, Italy, Spain and Slovenia and class actions in Israel, Australia, Canada and South Africa. In November 2019, the Federal Court of Australia issued a judgment regarding its findings with respect to liability in relation to the three Lead Applicants and generally in relation to the design, manufacture, pre- and post-market assessments and testing, and supply and promotion of the devices in Australia used to treat stress urinary incontinence and pelvic organ prolapse. In September 2022, after exhausting its appeals, the Company reached an in-principle agreement to resolve the two pelvic mesh class actions in Australia and in March 2023 the Federal Court approved the settlement. The class actions in Canada were discontinued in 2020 as a result of a settlement of a group of cases and an agreement to resolve the Israeli class action was reached in May 2021. The parties in the Israeli class action are currently finalizing the terms of the settlement. A motion to approve the settlement was filed with the Court. The Company has established accruals with respect to product liability litigation associated with Ethicons pelvic mesh products.", "text": "The Company has established accruals with respect to product liability litigation associated with Ethicons pelvic mesh products.", "length": 129, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 894, "tag": "div", "text_raw": "Following a June 2016 worldwide market withdrawal of Ethicon Physiomesh Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending in two New Jersey MCLs formed for Proceed/Proceed Ventral Patch and Prolene Hernia systems, and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately 3,600 Physiomesh cases (covering approximately 4,300 plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes 3,729 cases in the MDL and MCL. All deadlines and trial settings in those proceedings are currently stayed pending the completion of the settlement agreement. Of the cases subject to the MSA, 3,390 have been dismissed with prejudice. Ethicon has received releases from 3,584 plaintiffs, and releases continue to be submitted as part of the settlement process. Post-settlement cases in the Physiomesh MDL and MCL are subject to docket control orders requiring early expert reports and discovery requirements. In May 2023, Ethicon entered an additional settlement to resolve the claims of 292 Physiomesh claimants. That settlement is proceeding, and releases are being returned. There are three cases in the MDL and two in the MCL which are not included in either settlement and which remain subject to the docket control orders.", "text": "Following a June 2016 worldwide market withdrawal of Ethicon Physiomesh Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc.", "length": 173, "numbers_raw": ["201", "6"], "numbers": [201.0, 6.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 894, "tag": "div", "text_raw": "Following a June 2016 worldwide market withdrawal of Ethicon Physiomesh Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending in two New Jersey MCLs formed for Proceed/Proceed Ventral Patch and Prolene Hernia systems, and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately 3,600 Physiomesh cases (covering approximately 4,300 plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes 3,729 cases in the MDL and MCL. All deadlines and trial settings in those proceedings are currently stayed pending the completion of the settlement agreement. Of the cases subject to the MSA, 3,390 have been dismissed with prejudice. Ethicon has received releases from 3,584 plaintiffs, and releases continue to be submitted as part of the settlement process. Post-settlement cases in the Physiomesh MDL and MCL are subject to docket control orders requiring early expert reports and discovery requirements. In May 2023, Ethicon entered an additional settlement to resolve the claims of 292 Physiomesh claimants. That settlement is proceeding, and releases are being returned. There are three cases in the MDL and two in the MCL which are not included in either settlement and which remain subject to the docket control orders.", "text": "(Ethicon) and the Company alleging personal injury arising out of the use of this hernia mesh device.", "length": 101, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 894, "tag": "div", "text_raw": "Following a June 2016 worldwide market withdrawal of Ethicon Physiomesh Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending in two New Jersey MCLs formed for Proceed/Proceed Ventral Patch and Prolene Hernia systems, and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately 3,600 Physiomesh cases (covering approximately 4,300 plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes 3,729 cases in the MDL and MCL. All deadlines and trial settings in those proceedings are currently stayed pending the completion of the settlement agreement. Of the cases subject to the MSA, 3,390 have been dismissed with prejudice. Ethicon has received releases from 3,584 plaintiffs, and releases continue to be submitted as part of the settlement process. Post-settlement cases in the Physiomesh MDL and MCL are subject to docket control orders requiring early expert reports and discovery requirements. In May 2023, Ethicon entered an additional settlement to resolve the claims of 292 Physiomesh claimants. That settlement is proceeding, and releases are being returned. There are three cases in the MDL and two in the MCL which are not included in either settlement and which remain subject to the docket control orders.", "text": "Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia.", "length": 181, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 894, "tag": "div", "text_raw": "Following a June 2016 worldwide market withdrawal of Ethicon Physiomesh Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending in two New Jersey MCLs formed for Proceed/Proceed Ventral Patch and Prolene Hernia systems, and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately 3,600 Physiomesh cases (covering approximately 4,300 plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes 3,729 cases in the MDL and MCL. All deadlines and trial settings in those proceedings are currently stayed pending the completion of the settlement agreement. Of the cases subject to the MSA, 3,390 have been dismissed with prejudice. Ethicon has received releases from 3,584 plaintiffs, and releases continue to be submitted as part of the settlement process. Post-settlement cases in the Physiomesh MDL and MCL are subject to docket control orders requiring early expert reports and discovery requirements. In May 2023, Ethicon entered an additional settlement to resolve the claims of 292 Physiomesh claimants. That settlement is proceeding, and releases are being returned. There are three cases in the MDL and two in the MCL which are not included in either settlement and which remain subject to the docket control orders.", "text": "A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey.", "length": 143, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 894, "tag": "div", "text_raw": "Following a June 2016 worldwide market withdrawal of Ethicon Physiomesh Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending in two New Jersey MCLs formed for Proceed/Proceed Ventral Patch and Prolene Hernia systems, and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately 3,600 Physiomesh cases (covering approximately 4,300 plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes 3,729 cases in the MDL and MCL. All deadlines and trial settings in those proceedings are currently stayed pending the completion of the settlement agreement. Of the cases subject to the MSA, 3,390 have been dismissed with prejudice. Ethicon has received releases from 3,584 plaintiffs, and releases continue to be submitted as part of the settlement process. Post-settlement cases in the Physiomesh MDL and MCL are subject to docket control orders requiring early expert reports and discovery requirements. In May 2023, Ethicon entered an additional settlement to resolve the claims of 292 Physiomesh claimants. That settlement is proceeding, and releases are being returned. There are three cases in the MDL and two in the MCL which are not included in either settlement and which remain subject to the docket control orders.", "text": "In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R.", "length": 233, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 894, "tag": "div", "text_raw": "Following a June 2016 worldwide market withdrawal of Ethicon Physiomesh Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending in two New Jersey MCLs formed for Proceed/Proceed Ventral Patch and Prolene Hernia systems, and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately 3,600 Physiomesh cases (covering approximately 4,300 plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes 3,729 cases in the MDL and MCL. All deadlines and trial settings in those proceedings are currently stayed pending the completion of the settlement agreement. Of the cases subject to the MSA, 3,390 have been dismissed with prejudice. Ethicon has received releases from 3,584 plaintiffs, and releases continue to be submitted as part of the settlement process. Post-settlement cases in the Physiomesh MDL and MCL are subject to docket control orders requiring early expert reports and discovery requirements. In May 2023, Ethicon entered an additional settlement to resolve the claims of 292 Physiomesh claimants. That settlement is proceeding, and releases are being returned. There are three cases in the MDL and two in the MCL which are not included in either settlement and which remain subject to the docket control orders.", "text": "Bard, Inc., and lawsuits pending in two New Jersey MCLs formed for Proceed/Proceed Ventral Patch and Prolene Hernia systems, and lawsuits pending outside the United States.", "length": 172, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 894, "tag": "div", "text_raw": "Following a June 2016 worldwide market withdrawal of Ethicon Physiomesh Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending in two New Jersey MCLs formed for Proceed/Proceed Ventral Patch and Prolene Hernia systems, and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately 3,600 Physiomesh cases (covering approximately 4,300 plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes 3,729 cases in the MDL and MCL. All deadlines and trial settings in those proceedings are currently stayed pending the completion of the settlement agreement. Of the cases subject to the MSA, 3,390 have been dismissed with prejudice. Ethicon has received releases from 3,584 plaintiffs, and releases continue to be submitted as part of the settlement process. Post-settlement cases in the Physiomesh MDL and MCL are subject to docket control orders requiring early expert reports and discovery requirements. In May 2023, Ethicon entered an additional settlement to resolve the claims of 292 Physiomesh claimants. That settlement is proceeding, and releases are being returned. There are three cases in the MDL and two in the MCL which are not included in either settlement and which remain subject to the docket control orders.", "text": "In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately 3,600 Physiomesh cases (covering approximately 4,300 plaintiffs) pending in the MDL and MCL at that time.", "length": 213, "numbers_raw": ["202", "1", "3,600", "4,300"], "numbers": [202.0, 1.0, 3600.0, 4300.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 894, "tag": "div", "text_raw": "Following a June 2016 worldwide market withdrawal of Ethicon Physiomesh Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending in two New Jersey MCLs formed for Proceed/Proceed Ventral Patch and Prolene Hernia systems, and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately 3,600 Physiomesh cases (covering approximately 4,300 plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes 3,729 cases in the MDL and MCL. All deadlines and trial settings in those proceedings are currently stayed pending the completion of the settlement agreement. Of the cases subject to the MSA, 3,390 have been dismissed with prejudice. Ethicon has received releases from 3,584 plaintiffs, and releases continue to be submitted as part of the settlement process. Post-settlement cases in the Physiomesh MDL and MCL are subject to docket control orders requiring early expert reports and discovery requirements. In May 2023, Ethicon entered an additional settlement to resolve the claims of 292 Physiomesh claimants. That settlement is proceeding, and releases are being returned. There are three cases in the MDL and two in the MCL which are not included in either settlement and which remain subject to the docket control orders.", "text": "A master settlement agreement (MSA) was entered into in September 2021 and includes 3,729 cases in the MDL and MCL.", "length": 115, "numbers_raw": ["202", "1", "3,729"], "numbers": [202.0, 1.0, 3729.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 894, "tag": "div", "text_raw": "Following a June 2016 worldwide market withdrawal of Ethicon Physiomesh Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending in two New Jersey MCLs formed for Proceed/Proceed Ventral Patch and Prolene Hernia systems, and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately 3,600 Physiomesh cases (covering approximately 4,300 plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes 3,729 cases in the MDL and MCL. All deadlines and trial settings in those proceedings are currently stayed pending the completion of the settlement agreement. Of the cases subject to the MSA, 3,390 have been dismissed with prejudice. Ethicon has received releases from 3,584 plaintiffs, and releases continue to be submitted as part of the settlement process. Post-settlement cases in the Physiomesh MDL and MCL are subject to docket control orders requiring early expert reports and discovery requirements. In May 2023, Ethicon entered an additional settlement to resolve the claims of 292 Physiomesh claimants. That settlement is proceeding, and releases are being returned. There are three cases in the MDL and two in the MCL which are not included in either settlement and which remain subject to the docket control orders.", "text": "All deadlines and trial settings in those proceedings are currently stayed pending the completion of the settlement agreement.", "length": 126, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 894, "tag": "div", "text_raw": "Following a June 2016 worldwide market withdrawal of Ethicon Physiomesh Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending in two New Jersey MCLs formed for Proceed/Proceed Ventral Patch and Prolene Hernia systems, and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately 3,600 Physiomesh cases (covering approximately 4,300 plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes 3,729 cases in the MDL and MCL. All deadlines and trial settings in those proceedings are currently stayed pending the completion of the settlement agreement. Of the cases subject to the MSA, 3,390 have been dismissed with prejudice. Ethicon has received releases from 3,584 plaintiffs, and releases continue to be submitted as part of the settlement process. Post-settlement cases in the Physiomesh MDL and MCL are subject to docket control orders requiring early expert reports and discovery requirements. In May 2023, Ethicon entered an additional settlement to resolve the claims of 292 Physiomesh claimants. That settlement is proceeding, and releases are being returned. There are three cases in the MDL and two in the MCL which are not included in either settlement and which remain subject to the docket control orders.", "text": "Of the cases subject to the MSA, 3,390 have been dismissed with prejudice.", "length": 74, "numbers_raw": ["3,390"], "numbers": [3390.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 894, "tag": "div", "text_raw": "Following a June 2016 worldwide market withdrawal of Ethicon Physiomesh Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending in two New Jersey MCLs formed for Proceed/Proceed Ventral Patch and Prolene Hernia systems, and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately 3,600 Physiomesh cases (covering approximately 4,300 plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes 3,729 cases in the MDL and MCL. All deadlines and trial settings in those proceedings are currently stayed pending the completion of the settlement agreement. Of the cases subject to the MSA, 3,390 have been dismissed with prejudice. Ethicon has received releases from 3,584 plaintiffs, and releases continue to be submitted as part of the settlement process. Post-settlement cases in the Physiomesh MDL and MCL are subject to docket control orders requiring early expert reports and discovery requirements. In May 2023, Ethicon entered an additional settlement to resolve the claims of 292 Physiomesh claimants. That settlement is proceeding, and releases are being returned. There are three cases in the MDL and two in the MCL which are not included in either settlement and which remain subject to the docket control orders.", "text": "Ethicon has received releases from 3,584 plaintiffs, and releases continue to be submitted as part of the settlement process.", "length": 125, "numbers_raw": ["3,584"], "numbers": [3584.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 894, "tag": "div", "text_raw": "Following a June 2016 worldwide market withdrawal of Ethicon Physiomesh Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending in two New Jersey MCLs formed for Proceed/Proceed Ventral Patch and Prolene Hernia systems, and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately 3,600 Physiomesh cases (covering approximately 4,300 plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes 3,729 cases in the MDL and MCL. All deadlines and trial settings in those proceedings are currently stayed pending the completion of the settlement agreement. Of the cases subject to the MSA, 3,390 have been dismissed with prejudice. Ethicon has received releases from 3,584 plaintiffs, and releases continue to be submitted as part of the settlement process. Post-settlement cases in the Physiomesh MDL and MCL are subject to docket control orders requiring early expert reports and discovery requirements. In May 2023, Ethicon entered an additional settlement to resolve the claims of 292 Physiomesh claimants. That settlement is proceeding, and releases are being returned. There are three cases in the MDL and two in the MCL which are not included in either settlement and which remain subject to the docket control orders.", "text": "Post-settlement cases in the Physiomesh MDL and MCL are subject to docket control orders requiring early expert reports and discovery requirements.", "length": 147, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 894, "tag": "div", "text_raw": "Following a June 2016 worldwide market withdrawal of Ethicon Physiomesh Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending in two New Jersey MCLs formed for Proceed/Proceed Ventral Patch and Prolene Hernia systems, and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately 3,600 Physiomesh cases (covering approximately 4,300 plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes 3,729 cases in the MDL and MCL. All deadlines and trial settings in those proceedings are currently stayed pending the completion of the settlement agreement. Of the cases subject to the MSA, 3,390 have been dismissed with prejudice. Ethicon has received releases from 3,584 plaintiffs, and releases continue to be submitted as part of the settlement process. Post-settlement cases in the Physiomesh MDL and MCL are subject to docket control orders requiring early expert reports and discovery requirements. In May 2023, Ethicon entered an additional settlement to resolve the claims of 292 Physiomesh claimants. That settlement is proceeding, and releases are being returned. There are three cases in the MDL and two in the MCL which are not included in either settlement and which remain subject to the docket control orders.", "text": "In May 2023, Ethicon entered an additional settlement to resolve the claims of 292 Physiomesh claimants.", "length": 104, "numbers_raw": ["202", "3", "292"], "numbers": [202.0, 3.0, 292.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 894, "tag": "div", "text_raw": "Following a June 2016 worldwide market withdrawal of Ethicon Physiomesh Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending in two New Jersey MCLs formed for Proceed/Proceed Ventral Patch and Prolene Hernia systems, and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately 3,600 Physiomesh cases (covering approximately 4,300 plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes 3,729 cases in the MDL and MCL. All deadlines and trial settings in those proceedings are currently stayed pending the completion of the settlement agreement. Of the cases subject to the MSA, 3,390 have been dismissed with prejudice. Ethicon has received releases from 3,584 plaintiffs, and releases continue to be submitted as part of the settlement process. Post-settlement cases in the Physiomesh MDL and MCL are subject to docket control orders requiring early expert reports and discovery requirements. In May 2023, Ethicon entered an additional settlement to resolve the claims of 292 Physiomesh claimants. That settlement is proceeding, and releases are being returned. There are three cases in the MDL and two in the MCL which are not included in either settlement and which remain subject to the docket control orders.", "text": "That settlement is proceeding, and releases are being returned.", "length": 63, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 894, "tag": "div", "text_raw": "Following a June 2016 worldwide market withdrawal of Ethicon Physiomesh Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending in two New Jersey MCLs formed for Proceed/Proceed Ventral Patch and Prolene Hernia systems, and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately 3,600 Physiomesh cases (covering approximately 4,300 plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes 3,729 cases in the MDL and MCL. All deadlines and trial settings in those proceedings are currently stayed pending the completion of the settlement agreement. Of the cases subject to the MSA, 3,390 have been dismissed with prejudice. Ethicon has received releases from 3,584 plaintiffs, and releases continue to be submitted as part of the settlement process. Post-settlement cases in the Physiomesh MDL and MCL are subject to docket control orders requiring early expert reports and discovery requirements. In May 2023, Ethicon entered an additional settlement to resolve the claims of 292 Physiomesh claimants. That settlement is proceeding, and releases are being returned. There are three cases in the MDL and two in the MCL which are not included in either settlement and which remain subject to the docket control orders.", "text": "There are three cases in the MDL and two in the MCL which are not included in either settlement and which remain subject to the docket control orders.", "length": 150, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 896, "tag": "div", "text_raw": "Claims have also been filed against Ethicon and the Company alleging personal injuries arising from the PROCEED Mesh and PROCEED Ventral Patch hernia mesh products. In March 2019, the New Jersey Supreme Court entered an order consolidating these cases pending in New Jersey as an MCL in Atlantic County Superior Court. Additional cases have been filed in various federal and state courts in the United States, and in jurisdictions outside the United States.", "text": "Claims have also been filed against Ethicon and the Company alleging personal injuries arising from the PROCEED Mesh and PROCEED Ventral Patch hernia mesh products.", "length": 164, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 896, "tag": "div", "text_raw": "Claims have also been filed against Ethicon and the Company alleging personal injuries arising from the PROCEED Mesh and PROCEED Ventral Patch hernia mesh products. In March 2019, the New Jersey Supreme Court entered an order consolidating these cases pending in New Jersey as an MCL in Atlantic County Superior Court. Additional cases have been filed in various federal and state courts in the United States, and in jurisdictions outside the United States.", "text": "In March 2019, the New Jersey Supreme Court entered an order consolidating these cases pending in New Jersey as an MCL in Atlantic County Superior Court.", "length": 153, "numbers_raw": ["201", "9"], "numbers": [201.0, 9.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 896, "tag": "div", "text_raw": "Claims have also been filed against Ethicon and the Company alleging personal injuries arising from the PROCEED Mesh and PROCEED Ventral Patch hernia mesh products. In March 2019, the New Jersey Supreme Court entered an order consolidating these cases pending in New Jersey as an MCL in Atlantic County Superior Court. Additional cases have been filed in various federal and state courts in the United States, and in jurisdictions outside the United States.", "text": "Additional cases have been filed in various federal and state courts in the United States, and in jurisdictions outside the United States.", "length": 138, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 898, "tag": "div", "text_raw": "Ethicon and the Company also have been subject to claims for personal injuries arising from the PROLENE Polypropylene Hernia System. In January 2020, the New Jersey Supreme Court created an MCL in Atlantic County Superior Court to handle such cases. Cases involving this product have also been filed in other federal and state courts in the United States.", "text": "Ethicon and the Company also have been subject to claims for personal injuries arising from the PROLENE Polypropylene Hernia System.", "length": 132, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 898, "tag": "div", "text_raw": "Ethicon and the Company also have been subject to claims for personal injuries arising from the PROLENE Polypropylene Hernia System. In January 2020, the New Jersey Supreme Court created an MCL in Atlantic County Superior Court to handle such cases. Cases involving this product have also been filed in other federal and state courts in the United States.", "text": "In January 2020, the New Jersey Supreme Court created an MCL in Atlantic County Superior Court to handle such cases.", "length": 116, "numbers_raw": ["202", "0"], "numbers": [202.0, 0.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 898, "tag": "div", "text_raw": "Ethicon and the Company also have been subject to claims for personal injuries arising from the PROLENE Polypropylene Hernia System. In January 2020, the New Jersey Supreme Court created an MCL in Atlantic County Superior Court to handle such cases. Cases involving this product have also been filed in other federal and state courts in the United States.", "text": "Cases involving this product have also been filed in other federal and state courts in the United States.", "length": 105, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 900, "tag": "div", "text_raw": "In October 2022, an agreement in principle, subject to various conditions, was reached to settle the majority of the pending cases involving Proceed, Proceed Ventral Patch, Prolene Hernia System and related multi-layered mesh products, as well as a number of unfiled claims. All litigation activities in the two New Jersey MCLs are stayed pending effectuation of the proposed settlement. Future cases that are filed in the New Jersey MCLs will be subject to docket control orders requiring early expert reports and discovery requirements.", "text": "In October 2022, an agreement in principle, subject to various conditions, was reached to settle the majority of the pending cases involving Proceed, Proceed Ventral Patch, Prolene Hernia System and related multi-layered mesh products, as well as a number of unfiled claims.", "length": 274, "numbers_raw": ["202", "2"], "numbers": [202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 900, "tag": "div", "text_raw": "In October 2022, an agreement in principle, subject to various conditions, was reached to settle the majority of the pending cases involving Proceed, Proceed Ventral Patch, Prolene Hernia System and related multi-layered mesh products, as well as a number of unfiled claims. All litigation activities in the two New Jersey MCLs are stayed pending effectuation of the proposed settlement. Future cases that are filed in the New Jersey MCLs will be subject to docket control orders requiring early expert reports and discovery requirements.", "text": "All litigation activities in the two New Jersey MCLs are stayed pending effectuation of the proposed settlement.", "length": 112, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 900, "tag": "div", "text_raw": "In October 2022, an agreement in principle, subject to various conditions, was reached to settle the majority of the pending cases involving Proceed, Proceed Ventral Patch, Prolene Hernia System and related multi-layered mesh products, as well as a number of unfiled claims. All litigation activities in the two New Jersey MCLs are stayed pending effectuation of the proposed settlement. Future cases that are filed in the New Jersey MCLs will be subject to docket control orders requiring early expert reports and discovery requirements.", "text": "Future cases that are filed in the New Jersey MCLs will be subject to docket control orders requiring early expert reports and discovery requirements.", "length": 150, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 902, "tag": "div", "text_raw": "The Company has established accruals with respect to product liability litigation associated with Ethicon Physiomesh Flexible Composite Mesh, PROCEED Mesh and PROCEED Ventral Patch, and PROLENE Polypropylene Hernia System products.", "text": "The Company has established accruals with respect to product liability litigation associated with Ethicon Physiomesh Flexible Composite Mesh, PROCEED Mesh and PROCEED Ventral Patch, and PROLENE Polypropylene Hernia System products.", "length": 231, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 907, "tag": "div", "text_raw": "Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and the Company arising out of the use of RISPERDAL, and related compounds, indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism. Lawsuits primarily have been filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a verdict in October 2019 of $ 8.0 billion of punitive damages related to one plaintiff, which the trial judge reduced to $ 6.8 million in January 2020. In September 2021, the Company entered into a settlement in principle with", "text": "Claims for personal injury have been made against Janssen Pharmaceuticals, Inc.", "length": 79, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 907, "tag": "div", "text_raw": "Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and the Company arising out of the use of RISPERDAL, and related compounds, indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism. Lawsuits primarily have been filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a verdict in October 2019 of $ 8.0 billion of punitive damages related to one plaintiff, which the trial judge reduced to $ 6.8 million in January 2020. In September 2021, the Company entered into a settlement in principle with", "text": "and the Company arising out of the use of RISPERDAL, and related compounds, indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism.", "length": 227, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 907, "tag": "div", "text_raw": "Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and the Company arising out of the use of RISPERDAL, and related compounds, indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism. Lawsuits primarily have been filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a verdict in October 2019 of $ 8.0 billion of punitive damages related to one plaintiff, which the trial judge reduced to $ 6.8 million in January 2020. In September 2021, the Company entered into a settlement in principle with", "text": "Lawsuits primarily have been filed in state courts in Pennsylvania, California, and Missouri.", "length": 93, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 907, "tag": "div", "text_raw": "Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and the Company arising out of the use of RISPERDAL, and related compounds, indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism. Lawsuits primarily have been filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a verdict in October 2019 of $ 8.0 billion of punitive damages related to one plaintiff, which the trial judge reduced to $ 6.8 million in January 2020. In September 2021, the Company entered into a settlement in principle with", "text": "Other actions are pending in various courts in the United States and Canada.", "length": 76, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 907, "tag": "div", "text_raw": "Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and the Company arising out of the use of RISPERDAL, and related compounds, indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism. Lawsuits primarily have been filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a verdict in October 2019 of $ 8.0 billion of punitive damages related to one plaintiff, which the trial judge reduced to $ 6.8 million in January 2020. In September 2021, the Company entered into a settlement in principle with", "text": "Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases.", "length": 166, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 907, "tag": "div", "text_raw": "Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and the Company arising out of the use of RISPERDAL, and related compounds, indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism. Lawsuits primarily have been filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a verdict in October 2019 of $ 8.0 billion of punitive damages related to one plaintiff, which the trial judge reduced to $ 6.8 million in January 2020. In September 2021, the Company entered into a settlement in principle with", "text": "The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a verdict in October 2019 of $ 8.0 billion of punitive damages related to one plaintiff, which the trial judge reduced to $ 6.8 million in January 2020.", "length": 274, "numbers_raw": ["201", "9", "8.0 billion", "6.8 million", "202", "0"], "numbers": [201.0, 9.0, 8000000000.0, 6800000.0, 202.0, 0.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 907, "tag": "div", "text_raw": "Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and the Company arising out of the use of RISPERDAL, and related compounds, indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism. Lawsuits primarily have been filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a verdict in October 2019 of $ 8.0 billion of punitive damages related to one plaintiff, which the trial judge reduced to $ 6.8 million in January 2020. In September 2021, the Company entered into a settlement in principle with", "text": "In September 2021, the Company entered into a settlement in principle with", "length": 74, "numbers_raw": ["202", "1"], "numbers": [202.0, 1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 908, "tag": "div", "text_raw": "34", "text": "34", "length": 2, "numbers_raw": ["34"], "numbers": [34.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 909, "tag": "div", "text_raw": "34", "text": "34", "length": 2, "numbers_raw": ["34"], "numbers": [34.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 910, "tag": "div", "text_raw": "34", "text": "34", "length": 2, "numbers_raw": ["34"], "numbers": [34.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 913, "tag": "div", "text_raw": "the counsel representing plaintiffs in this matter and in substantially all of the outstanding cases in the United States. The costs associated with this and other settlements are reflected in the Companys accruals.", "text": "the counsel representing plaintiffs in this matter and in substantially all of the outstanding cases in the United States.", "length": 122, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 913, "tag": "div", "text_raw": "the counsel representing plaintiffs in this matter and in substantially all of the outstanding cases in the United States. The costs associated with this and other settlements are reflected in the Companys accruals.", "text": "The costs associated with this and other settlements are reflected in the Companys accruals.", "length": 93, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 916, "tag": "div", "text_raw": "Claims for personal injury have been made against a number of Johnson & Johnson companies, including Janssen Pharmaceuticals, Inc. and the Company, arising out of the use of ELMIRON, a prescription medication indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, lawsuits filed in federal courts in the United States, including putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New Jersey. In addition, cases have been filed in various state courts of New Jersey, which have been coordinated in a multi-county litigation in Bergen County, as well as the Court of Common Pleas in Philadelphia, which have been coordinated and granted mass tort designation. In addition, three class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established accruals for defense and indemnity costs associated with ELMIRON related product liability litigation.", "text": "Claims for personal injury have been made against a number of Johnson & Johnson companies, including Janssen Pharmaceuticals, Inc.", "length": 130, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 916, "tag": "div", "text_raw": "Claims for personal injury have been made against a number of Johnson & Johnson companies, including Janssen Pharmaceuticals, Inc. and the Company, arising out of the use of ELMIRON, a prescription medication indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, lawsuits filed in federal courts in the United States, including putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New Jersey. In addition, cases have been filed in various state courts of New Jersey, which have been coordinated in a multi-county litigation in Bergen County, as well as the Court of Common Pleas in Philadelphia, which have been coordinated and granted mass tort designation. In addition, three class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established accruals for defense and indemnity costs associated with ELMIRON related product liability litigation.", "text": "and the Company, arising out of the use of ELMIRON, a prescription medication indicated for the relief of bladder pain or discomfort associated with interstitial cystitis.", "length": 171, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 916, "tag": "div", "text_raw": "Claims for personal injury have been made against a number of Johnson & Johnson companies, including Janssen Pharmaceuticals, Inc. and the Company, arising out of the use of ELMIRON, a prescription medication indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, lawsuits filed in federal courts in the United States, including putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New Jersey. In addition, cases have been filed in various state courts of New Jersey, which have been coordinated in a multi-county litigation in Bergen County, as well as the Court of Common Pleas in Philadelphia, which have been coordinated and granted mass tort designation. In addition, three class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established accruals for defense and indemnity costs associated with ELMIRON related product liability litigation.", "text": "These lawsuits, which allege that ELMIRON contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States.", "length": 192, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 916, "tag": "div", "text_raw": "Claims for personal injury have been made against a number of Johnson & Johnson companies, including Janssen Pharmaceuticals, Inc. and the Company, arising out of the use of ELMIRON, a prescription medication indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, lawsuits filed in federal courts in the United States, including putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New Jersey. In addition, cases have been filed in various state courts of New Jersey, which have been coordinated in a multi-county litigation in Bergen County, as well as the Court of Common Pleas in Philadelphia, which have been coordinated and granted mass tort designation. In addition, three class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established accruals for defense and indemnity costs associated with ELMIRON related product liability litigation.", "text": "In December 2020, lawsuits filed in federal courts in the United States, including putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New Jersey.", "length": 252, "numbers_raw": ["202", "0"], "numbers": [202.0, 0.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 916, "tag": "div", "text_raw": "Claims for personal injury have been made against a number of Johnson & Johnson companies, including Janssen Pharmaceuticals, Inc. and the Company, arising out of the use of ELMIRON, a prescription medication indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, lawsuits filed in federal courts in the United States, including putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New Jersey. In addition, cases have been filed in various state courts of New Jersey, which have been coordinated in a multi-county litigation in Bergen County, as well as the Court of Common Pleas in Philadelphia, which have been coordinated and granted mass tort designation. In addition, three class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established accruals for defense and indemnity costs associated with ELMIRON related product liability litigation.", "text": "In addition, cases have been filed in various state courts of New Jersey, which have been coordinated in a multi-county litigation in Bergen County, as well as the Court of Common Pleas in Philadelphia, which have been coordinated and granted mass tort designation.", "length": 265, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 916, "tag": "div", "text_raw": "Claims for personal injury have been made against a number of Johnson & Johnson companies, including Janssen Pharmaceuticals, Inc. and the Company, arising out of the use of ELMIRON, a prescription medication indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, lawsuits filed in federal courts in the United States, including putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New Jersey. In addition, cases have been filed in various state courts of New Jersey, which have been coordinated in a multi-county litigation in Bergen County, as well as the Court of Common Pleas in Philadelphia, which have been coordinated and granted mass tort designation. In addition, three class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established accruals for defense and indemnity costs associated with ELMIRON related product liability litigation.", "text": "In addition, three class action lawsuits have been filed in Canada.", "length": 67, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 916, "tag": "div", "text_raw": "Claims for personal injury have been made against a number of Johnson & Johnson companies, including Janssen Pharmaceuticals, Inc. and the Company, arising out of the use of ELMIRON, a prescription medication indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, lawsuits filed in federal courts in the United States, including putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New Jersey. In addition, cases have been filed in various state courts of New Jersey, which have been coordinated in a multi-county litigation in Bergen County, as well as the Court of Common Pleas in Philadelphia, which have been coordinated and granted mass tort designation. In addition, three class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established accruals for defense and indemnity costs associated with ELMIRON related product liability litigation.", "text": "Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases.", "length": 166, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 916, "tag": "div", "text_raw": "Claims for personal injury have been made against a number of Johnson & Johnson companies, including Janssen Pharmaceuticals, Inc. and the Company, arising out of the use of ELMIRON, a prescription medication indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, lawsuits filed in federal courts in the United States, including putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New Jersey. In addition, cases have been filed in various state courts of New Jersey, which have been coordinated in a multi-county litigation in Bergen County, as well as the Court of Common Pleas in Philadelphia, which have been coordinated and granted mass tort designation. In addition, three class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established accruals for defense and indemnity costs associated with ELMIRON related product liability litigation.", "text": "The Company has established accruals for defense and indemnity costs associated with ELMIRON related product liability litigation.", "length": 130, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 920, "tag": "div", "text_raw": "Certain subsidiaries of the Company are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the coverage and/or validity of the patents on various products and allegations that certain of the Companys products infringe the patents of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset.", "text": "Certain subsidiaries of the Company are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses.", "length": 201, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 920, "tag": "div", "text_raw": "Certain subsidiaries of the Company are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the coverage and/or validity of the patents on various products and allegations that certain of the Companys products infringe the patents of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset.", "text": "Many of these matters involve challenges to the coverage and/or validity of the patents on various products and allegations that certain of the Companys products infringe the patents of third parties.", "length": 201, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 920, "tag": "div", "text_raw": "Certain subsidiaries of the Company are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the coverage and/or validity of the patents on various products and allegations that certain of the Companys products infringe the patents of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset.", "text": "Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters.", "length": 210, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 920, "tag": "div", "text_raw": "Certain subsidiaries of the Company are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the coverage and/or validity of the patents on various products and allegations that certain of the Companys products infringe the patents of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset.", "text": "A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset.", "length": 310, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 922, "tag": "div", "text_raw": "Innovative Medicine - Litigation Against Filers of Abbreviated New Drug Applications (ANDAs)", "text": "Innovative Medicine - Litigation Against Filers of Abbreviated New Drug Applications (ANDAs)", "length": 92, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 924, "tag": "div", "text_raw": "The Companys subsidiaries have brought lawsuits against generic companies that have filed ANDAs with the U.S. FDA (or similar lawsuits outside of the United States) seeking to market generic versions of products sold by various subsidiaries of the Company prior to expiration of the applicable patents covering those products. These lawsuits typically include allegations of non-infringement and/or invalidity of patents listed in FDAs publication Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book). In each of these lawsuits, the Companys subsidiaries are seeking an order enjoining the defendant from marketing a generic version of a product before the expiration of the relevant patents (Orange Book Listed Patents). In the event the Companys subsidiaries are not successful in an action, or any automatic statutory stay expires before the court rulings are obtained, the generic companies involved would have the ability, upon regulatory approval, to introduce generic versions of their products to the market, resulting in the potential for substantial market share and revenue losses for the applicable products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, the Companys subsidiaries may settle these types of actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents.", "text": "The Companys subsidiaries have brought lawsuits against generic companies that have filed ANDAs with the U.S.", "length": 110, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 924, "tag": "div", "text_raw": "The Companys subsidiaries have brought lawsuits against generic companies that have filed ANDAs with the U.S. FDA (or similar lawsuits outside of the United States) seeking to market generic versions of products sold by various subsidiaries of the Company prior to expiration of the applicable patents covering those products. These lawsuits typically include allegations of non-infringement and/or invalidity of patents listed in FDAs publication Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book). In each of these lawsuits, the Companys subsidiaries are seeking an order enjoining the defendant from marketing a generic version of a product before the expiration of the relevant patents (Orange Book Listed Patents). In the event the Companys subsidiaries are not successful in an action, or any automatic statutory stay expires before the court rulings are obtained, the generic companies involved would have the ability, upon regulatory approval, to introduce generic versions of their products to the market, resulting in the potential for substantial market share and revenue losses for the applicable products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, the Companys subsidiaries may settle these types of actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents.", "text": "FDA (or similar lawsuits outside of the United States) seeking to market generic versions of products sold by various subsidiaries of the Company prior to expiration of the applicable patents covering those products.", "length": 216, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 924, "tag": "div", "text_raw": "The Companys subsidiaries have brought lawsuits against generic companies that have filed ANDAs with the U.S. FDA (or similar lawsuits outside of the United States) seeking to market generic versions of products sold by various subsidiaries of the Company prior to expiration of the applicable patents covering those products. These lawsuits typically include allegations of non-infringement and/or invalidity of patents listed in FDAs publication Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book). In each of these lawsuits, the Companys subsidiaries are seeking an order enjoining the defendant from marketing a generic version of a product before the expiration of the relevant patents (Orange Book Listed Patents). In the event the Companys subsidiaries are not successful in an action, or any automatic statutory stay expires before the court rulings are obtained, the generic companies involved would have the ability, upon regulatory approval, to introduce generic versions of their products to the market, resulting in the potential for substantial market share and revenue losses for the applicable products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, the Companys subsidiaries may settle these types of actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents.", "text": "These lawsuits typically include allegations of non-infringement and/or invalidity of patents listed in FDAs publication Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book).", "length": 224, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 924, "tag": "div", "text_raw": "The Companys subsidiaries have brought lawsuits against generic companies that have filed ANDAs with the U.S. FDA (or similar lawsuits outside of the United States) seeking to market generic versions of products sold by various subsidiaries of the Company prior to expiration of the applicable patents covering those products. These lawsuits typically include allegations of non-infringement and/or invalidity of patents listed in FDAs publication Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book). In each of these lawsuits, the Companys subsidiaries are seeking an order enjoining the defendant from marketing a generic version of a product before the expiration of the relevant patents (Orange Book Listed Patents). In the event the Companys subsidiaries are not successful in an action, or any automatic statutory stay expires before the court rulings are obtained, the generic companies involved would have the ability, upon regulatory approval, to introduce generic versions of their products to the market, resulting in the potential for substantial market share and revenue losses for the applicable products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, the Companys subsidiaries may settle these types of actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents.", "text": "In each of these lawsuits, the Companys subsidiaries are seeking an order enjoining the defendant from marketing a generic version of a product before the expiration of the relevant patents (Orange Book Listed Patents).", "length": 220, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 924, "tag": "div", "text_raw": "The Companys subsidiaries have brought lawsuits against generic companies that have filed ANDAs with the U.S. FDA (or similar lawsuits outside of the United States) seeking to market generic versions of products sold by various subsidiaries of the Company prior to expiration of the applicable patents covering those products. These lawsuits typically include allegations of non-infringement and/or invalidity of patents listed in FDAs publication Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book). In each of these lawsuits, the Companys subsidiaries are seeking an order enjoining the defendant from marketing a generic version of a product before the expiration of the relevant patents (Orange Book Listed Patents). In the event the Companys subsidiaries are not successful in an action, or any automatic statutory stay expires before the court rulings are obtained, the generic companies involved would have the ability, upon regulatory approval, to introduce generic versions of their products to the market, resulting in the potential for substantial market share and revenue losses for the applicable products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, the Companys subsidiaries may settle these types of actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents.", "text": "In the event the Companys subsidiaries are not successful in an action, or any automatic statutory stay expires before the court rulings are obtained, the generic companies involved would have the ability, upon regulatory approval, to introduce generic versions of their products to the market, resulting in the potential for substantial market share and revenue losses for the applicable products, and which may result in a non-cash impairment charge in any associated intangible asset.", "length": 488, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 924, "tag": "div", "text_raw": "The Companys subsidiaries have brought lawsuits against generic companies that have filed ANDAs with the U.S. FDA (or similar lawsuits outside of the United States) seeking to market generic versions of products sold by various subsidiaries of the Company prior to expiration of the applicable patents covering those products. These lawsuits typically include allegations of non-infringement and/or invalidity of patents listed in FDAs publication Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book). In each of these lawsuits, the Companys subsidiaries are seeking an order enjoining the defendant from marketing a generic version of a product before the expiration of the relevant patents (Orange Book Listed Patents). In the event the Companys subsidiaries are not successful in an action, or any automatic statutory stay expires before the court rulings are obtained, the generic companies involved would have the ability, upon regulatory approval, to introduce generic versions of their products to the market, resulting in the potential for substantial market share and revenue losses for the applicable products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, the Companys subsidiaries may settle these types of actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents.", "text": "In addition, from time to time, the Companys subsidiaries may settle these types of actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents.", "length": 250, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 926, "tag": "div", "text_raw": "The Inter Partes Review (IPR) process with the United States Patent and Trademark Office (USPTO), created under the 2011 America Invents Act, is also being used at times by generic companies in conjunction with ANDAs and lawsuits to challenge the applicable patents.", "text": "The Inter Partes Review (IPR) process with the United States Patent and Trademark Office (USPTO), created under the 2011 America Invents Act, is also being used at times by generic companies in conjunction with ANDAs and lawsuits to challenge the applicable patents.", "length": 266, "numbers_raw": ["201", "1"], "numbers": [201.0, 1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 929, "tag": "div", "text_raw": "Beginning in March 2021, Janssen Pharmaceuticals, Inc.; Bayer Pharma AG; Bayer AG; and Bayer Intellectual Property GmbH filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of XARELTO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Dr. Reddys Laboratories, Inc.; Dr. Reddys Laboratories, Ltd.; Lupin Limited; Lupin Pharmaceuticals, Inc.; Taro Pharmaceutical Industries Ltd.; Taro Pharmaceuticals U.S.A., Inc.; Teva Pharmaceuticals USA, Inc.; Mylan Pharmaceuticals Inc.; Mylan Inc.; Mankind Pharma Limited; Apotex Inc.; Apotex Corp.; Biocon Pharma Limited; Biocon Limited; Biocon Pharma, Inc.; Auson Pharmaceuticals Inc.; Macleods Pharmaceuticals Ltd; Macleods Pharma USA, Inc.; Indoco Remedies Limited; and FPP Holding Company LLC. The following U.S. patents are included in one or more cases: 9,539,218 and 10,828,310. In August 2023, the Company entered into a confidential settlement agreement with Biocon Pharma Limited, Biocon Limited and Biocon Pharma, Inc.", "text": "Beginning in March 2021, Janssen Pharmaceuticals, Inc.;", "length": 55, "numbers_raw": ["202", "1"], "numbers": [202.0, 1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 929, "tag": "div", "text_raw": "Beginning in March 2021, Janssen Pharmaceuticals, Inc.; Bayer Pharma AG; Bayer AG; and Bayer Intellectual Property GmbH filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of XARELTO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Dr. Reddys Laboratories, Inc.; Dr. Reddys Laboratories, Ltd.; Lupin Limited; Lupin Pharmaceuticals, Inc.; Taro Pharmaceutical Industries Ltd.; Taro Pharmaceuticals U.S.A., Inc.; Teva Pharmaceuticals USA, Inc.; Mylan Pharmaceuticals Inc.; Mylan Inc.; Mankind Pharma Limited; Apotex Inc.; Apotex Corp.; Biocon Pharma Limited; Biocon Limited; Biocon Pharma, Inc.; Auson Pharmaceuticals Inc.; Macleods Pharmaceuticals Ltd; Macleods Pharma USA, Inc.; Indoco Remedies Limited; and FPP Holding Company LLC. The following U.S. patents are included in one or more cases: 9,539,218 and 10,828,310. In August 2023, the Company entered into a confidential settlement agreement with Biocon Pharma Limited, Biocon Limited and Biocon Pharma, Inc.", "text": "and Bayer Intellectual Property GmbH filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of XARELTO before expiration of certain Orange Book Listed Patents.", "length": 267, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 929, "tag": "div", "text_raw": "Beginning in March 2021, Janssen Pharmaceuticals, Inc.; Bayer Pharma AG; Bayer AG; and Bayer Intellectual Property GmbH filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of XARELTO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Dr. Reddys Laboratories, Inc.; Dr. Reddys Laboratories, Ltd.; Lupin Limited; Lupin Pharmaceuticals, Inc.; Taro Pharmaceutical Industries Ltd.; Taro Pharmaceuticals U.S.A., Inc.; Teva Pharmaceuticals USA, Inc.; Mylan Pharmaceuticals Inc.; Mylan Inc.; Mankind Pharma Limited; Apotex Inc.; Apotex Corp.; Biocon Pharma Limited; Biocon Limited; Biocon Pharma, Inc.; Auson Pharmaceuticals Inc.; Macleods Pharmaceuticals Ltd; Macleods Pharma USA, Inc.; Indoco Remedies Limited; and FPP Holding Company LLC. The following U.S. patents are included in one or more cases: 9,539,218 and 10,828,310. In August 2023, the Company entered into a confidential settlement agreement with Biocon Pharma Limited, Biocon Limited and Biocon Pharma, Inc.", "text": "The following entities are named defendants:", "length": 44, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 929, "tag": "div", "text_raw": "Beginning in March 2021, Janssen Pharmaceuticals, Inc.; Bayer Pharma AG; Bayer AG; and Bayer Intellectual Property GmbH filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of XARELTO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Dr. Reddys Laboratories, Inc.; Dr. Reddys Laboratories, Ltd.; Lupin Limited; Lupin Pharmaceuticals, Inc.; Taro Pharmaceutical Industries Ltd.; Taro Pharmaceuticals U.S.A., Inc.; Teva Pharmaceuticals USA, Inc.; Mylan Pharmaceuticals Inc.; Mylan Inc.; Mankind Pharma Limited; Apotex Inc.; Apotex Corp.; Biocon Pharma Limited; Biocon Limited; Biocon Pharma, Inc.; Auson Pharmaceuticals Inc.; Macleods Pharmaceuticals Ltd; Macleods Pharma USA, Inc.; Indoco Remedies Limited; and FPP Holding Company LLC. The following U.S. patents are included in one or more cases: 9,539,218 and 10,828,310. In August 2023, the Company entered into a confidential settlement agreement with Biocon Pharma Limited, Biocon Limited and Biocon Pharma, Inc.", "text": "Taro Pharmaceutical Industries Ltd.;", "length": 36, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 929, "tag": "div", "text_raw": "Beginning in March 2021, Janssen Pharmaceuticals, Inc.; Bayer Pharma AG; Bayer AG; and Bayer Intellectual Property GmbH filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of XARELTO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Dr. Reddys Laboratories, Inc.; Dr. Reddys Laboratories, Ltd.; Lupin Limited; Lupin Pharmaceuticals, Inc.; Taro Pharmaceutical Industries Ltd.; Taro Pharmaceuticals U.S.A., Inc.; Teva Pharmaceuticals USA, Inc.; Mylan Pharmaceuticals Inc.; Mylan Inc.; Mankind Pharma Limited; Apotex Inc.; Apotex Corp.; Biocon Pharma Limited; Biocon Limited; Biocon Pharma, Inc.; Auson Pharmaceuticals Inc.; Macleods Pharmaceuticals Ltd; Macleods Pharma USA, Inc.; Indoco Remedies Limited; and FPP Holding Company LLC. The following U.S. patents are included in one or more cases: 9,539,218 and 10,828,310. In August 2023, the Company entered into a confidential settlement agreement with Biocon Pharma Limited, Biocon Limited and Biocon Pharma, Inc.", "text": "Taro Pharmaceuticals U.S.A., Inc.;", "length": 34, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 929, "tag": "div", "text_raw": "Beginning in March 2021, Janssen Pharmaceuticals, Inc.; Bayer Pharma AG; Bayer AG; and Bayer Intellectual Property GmbH filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of XARELTO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Dr. Reddys Laboratories, Inc.; Dr. Reddys Laboratories, Ltd.; Lupin Limited; Lupin Pharmaceuticals, Inc.; Taro Pharmaceutical Industries Ltd.; Taro Pharmaceuticals U.S.A., Inc.; Teva Pharmaceuticals USA, Inc.; Mylan Pharmaceuticals Inc.; Mylan Inc.; Mankind Pharma Limited; Apotex Inc.; Apotex Corp.; Biocon Pharma Limited; Biocon Limited; Biocon Pharma, Inc.; Auson Pharmaceuticals Inc.; Macleods Pharmaceuticals Ltd; Macleods Pharma USA, Inc.; Indoco Remedies Limited; and FPP Holding Company LLC. The following U.S. patents are included in one or more cases: 9,539,218 and 10,828,310. In August 2023, the Company entered into a confidential settlement agreement with Biocon Pharma Limited, Biocon Limited and Biocon Pharma, Inc.", "text": "Teva Pharmaceuticals USA, Inc.;", "length": 31, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 929, "tag": "div", "text_raw": "Beginning in March 2021, Janssen Pharmaceuticals, Inc.; Bayer Pharma AG; Bayer AG; and Bayer Intellectual Property GmbH filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of XARELTO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Dr. Reddys Laboratories, Inc.; Dr. Reddys Laboratories, Ltd.; Lupin Limited; Lupin Pharmaceuticals, Inc.; Taro Pharmaceutical Industries Ltd.; Taro Pharmaceuticals U.S.A., Inc.; Teva Pharmaceuticals USA, Inc.; Mylan Pharmaceuticals Inc.; Mylan Inc.; Mankind Pharma Limited; Apotex Inc.; Apotex Corp.; Biocon Pharma Limited; Biocon Limited; Biocon Pharma, Inc.; Auson Pharmaceuticals Inc.; Macleods Pharmaceuticals Ltd; Macleods Pharma USA, Inc.; Indoco Remedies Limited; and FPP Holding Company LLC. The following U.S. patents are included in one or more cases: 9,539,218 and 10,828,310. In August 2023, the Company entered into a confidential settlement agreement with Biocon Pharma Limited, Biocon Limited and Biocon Pharma, Inc.", "text": "patents are included in one or more cases:", "length": 42, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 929, "tag": "div", "text_raw": "Beginning in March 2021, Janssen Pharmaceuticals, Inc.; Bayer Pharma AG; Bayer AG; and Bayer Intellectual Property GmbH filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of XARELTO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Dr. Reddys Laboratories, Inc.; Dr. Reddys Laboratories, Ltd.; Lupin Limited; Lupin Pharmaceuticals, Inc.; Taro Pharmaceutical Industries Ltd.; Taro Pharmaceuticals U.S.A., Inc.; Teva Pharmaceuticals USA, Inc.; Mylan Pharmaceuticals Inc.; Mylan Inc.; Mankind Pharma Limited; Apotex Inc.; Apotex Corp.; Biocon Pharma Limited; Biocon Limited; Biocon Pharma, Inc.; Auson Pharmaceuticals Inc.; Macleods Pharmaceuticals Ltd; Macleods Pharma USA, Inc.; Indoco Remedies Limited; and FPP Holding Company LLC. The following U.S. patents are included in one or more cases: 9,539,218 and 10,828,310. In August 2023, the Company entered into a confidential settlement agreement with Biocon Pharma Limited, Biocon Limited and Biocon Pharma, Inc.", "text": "9,539,218 and 10,828,310.", "length": 25, "numbers_raw": ["9,539,218", "10,828,310"], "numbers": [9539218.0, 10828310.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 929, "tag": "div", "text_raw": "Beginning in March 2021, Janssen Pharmaceuticals, Inc.; Bayer Pharma AG; Bayer AG; and Bayer Intellectual Property GmbH filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of XARELTO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Dr. Reddys Laboratories, Inc.; Dr. Reddys Laboratories, Ltd.; Lupin Limited; Lupin Pharmaceuticals, Inc.; Taro Pharmaceutical Industries Ltd.; Taro Pharmaceuticals U.S.A., Inc.; Teva Pharmaceuticals USA, Inc.; Mylan Pharmaceuticals Inc.; Mylan Inc.; Mankind Pharma Limited; Apotex Inc.; Apotex Corp.; Biocon Pharma Limited; Biocon Limited; Biocon Pharma, Inc.; Auson Pharmaceuticals Inc.; Macleods Pharmaceuticals Ltd; Macleods Pharma USA, Inc.; Indoco Remedies Limited; and FPP Holding Company LLC. The following U.S. patents are included in one or more cases: 9,539,218 and 10,828,310. In August 2023, the Company entered into a confidential settlement agreement with Biocon Pharma Limited, Biocon Limited and Biocon Pharma, Inc.", "text": "In August 2023, the Company entered into a confidential settlement agreement with Biocon Pharma Limited, Biocon Limited and Biocon Pharma, Inc.", "length": 143, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 931, "tag": "div", "text_raw": "U.S. Patent No. 10,828,310 was also under consideration by the USPTO in an IPR proceeding. In July 2023, the USPTO issued a final written decision finding the claims of the patent invalid. In September 2023, Bayer Pharma AG filed an appeal to the U.S. Court of Appeals for the Federal Circuit.", "text": "10,828,310 was also under consideration by the USPTO in an IPR proceeding.", "length": 74, "numbers_raw": ["10,828,310"], "numbers": [10828310.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 931, "tag": "div", "text_raw": "U.S. Patent No. 10,828,310 was also under consideration by the USPTO in an IPR proceeding. In July 2023, the USPTO issued a final written decision finding the claims of the patent invalid. In September 2023, Bayer Pharma AG filed an appeal to the U.S. Court of Appeals for the Federal Circuit.", "text": "In July 2023, the USPTO issued a final written decision finding the claims of the patent invalid.", "length": 97, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 931, "tag": "div", "text_raw": "U.S. Patent No. 10,828,310 was also under consideration by the USPTO in an IPR proceeding. In July 2023, the USPTO issued a final written decision finding the claims of the patent invalid. In September 2023, Bayer Pharma AG filed an appeal to the U.S. Court of Appeals for the Federal Circuit.", "text": "In September 2023, Bayer Pharma AG filed an appeal to the U.S.", "length": 62, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 931, "tag": "div", "text_raw": "U.S. Patent No. 10,828,310 was also under consideration by the USPTO in an IPR proceeding. In July 2023, the USPTO issued a final written decision finding the claims of the patent invalid. In September 2023, Bayer Pharma AG filed an appeal to the U.S. Court of Appeals for the Federal Circuit.", "text": "Court of Appeals for the Federal Circuit.", "length": 41, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 932, "tag": "div", "text_raw": "35", "text": "35", "length": 2, "numbers_raw": ["35"], "numbers": [35.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 933, "tag": "div", "text_raw": "35", "text": "35", "length": 2, "numbers_raw": ["35"], "numbers": [35.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 934, "tag": "div", "text_raw": "35", "text": "35", "length": 2, "numbers_raw": ["35"], "numbers": [35.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 939, "tag": "div", "text_raw": "Beginning in January 2023 Actelion Pharmaceuticals Ltd and Actelion Pharmaceuticals US, Inc. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of OPSUMIT before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Sun Pharmaceutical Industries Limited; Sun Pharmaceutical Industries, Inc.; Alembic Pharmaceuticals Ltd.; Alembic Pharmaceuticals, Inc.; MSN Laboratories Private Limited; MSN Pharmaceuticals Inc.; Apotex Inc.; and Apotex Corp. The following U.S. patents are included in one or more cases: 7,094,781; and 10,946,015. In September 2023, the Company entered into confidential settlement agreements with Alembic Pharmaceuticals Ltd., Alembic Pharmaceuticals, Inc., Apotex Inc. and Apotex Corp.", "text": "Beginning in January 2023 Actelion Pharmaceuticals Ltd and Actelion Pharmaceuticals US, Inc.", "length": 92, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 939, "tag": "div", "text_raw": "Beginning in January 2023 Actelion Pharmaceuticals Ltd and Actelion Pharmaceuticals US, Inc. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of OPSUMIT before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Sun Pharmaceutical Industries Limited; Sun Pharmaceutical Industries, Inc.; Alembic Pharmaceuticals Ltd.; Alembic Pharmaceuticals, Inc.; MSN Laboratories Private Limited; MSN Pharmaceuticals Inc.; Apotex Inc.; and Apotex Corp. The following U.S. patents are included in one or more cases: 7,094,781; and 10,946,015. In September 2023, the Company entered into confidential settlement agreements with Alembic Pharmaceuticals Ltd., Alembic Pharmaceuticals, Inc., Apotex Inc. and Apotex Corp.", "text": "filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of OPSUMIT before expiration of certain Orange Book Listed Patents.", "length": 230, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 939, "tag": "div", "text_raw": "Beginning in January 2023 Actelion Pharmaceuticals Ltd and Actelion Pharmaceuticals US, Inc. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of OPSUMIT before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Sun Pharmaceutical Industries Limited; Sun Pharmaceutical Industries, Inc.; Alembic Pharmaceuticals Ltd.; Alembic Pharmaceuticals, Inc.; MSN Laboratories Private Limited; MSN Pharmaceuticals Inc.; Apotex Inc.; and Apotex Corp. The following U.S. patents are included in one or more cases: 7,094,781; and 10,946,015. In September 2023, the Company entered into confidential settlement agreements with Alembic Pharmaceuticals Ltd., Alembic Pharmaceuticals, Inc., Apotex Inc. and Apotex Corp.", "text": "The following entities are named defendants:", "length": 44, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 939, "tag": "div", "text_raw": "Beginning in January 2023 Actelion Pharmaceuticals Ltd and Actelion Pharmaceuticals US, Inc. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of OPSUMIT before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Sun Pharmaceutical Industries Limited; Sun Pharmaceutical Industries, Inc.; Alembic Pharmaceuticals Ltd.; Alembic Pharmaceuticals, Inc.; MSN Laboratories Private Limited; MSN Pharmaceuticals Inc.; Apotex Inc.; and Apotex Corp. The following U.S. patents are included in one or more cases: 7,094,781; and 10,946,015. In September 2023, the Company entered into confidential settlement agreements with Alembic Pharmaceuticals Ltd., Alembic Pharmaceuticals, Inc., Apotex Inc. and Apotex Corp.", "text": "Sun Pharmaceutical Industries Limited;", "length": 38, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 939, "tag": "div", "text_raw": "Beginning in January 2023 Actelion Pharmaceuticals Ltd and Actelion Pharmaceuticals US, Inc. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of OPSUMIT before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Sun Pharmaceutical Industries Limited; Sun Pharmaceutical Industries, Inc.; Alembic Pharmaceuticals Ltd.; Alembic Pharmaceuticals, Inc.; MSN Laboratories Private Limited; MSN Pharmaceuticals Inc.; Apotex Inc.; and Apotex Corp. The following U.S. patents are included in one or more cases: 7,094,781; and 10,946,015. In September 2023, the Company entered into confidential settlement agreements with Alembic Pharmaceuticals Ltd., Alembic Pharmaceuticals, Inc., Apotex Inc. and Apotex Corp.", "text": "Sun Pharmaceutical Industries, Inc.;", "length": 36, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 939, "tag": "div", "text_raw": "Beginning in January 2023 Actelion Pharmaceuticals Ltd and Actelion Pharmaceuticals US, Inc. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of OPSUMIT before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Sun Pharmaceutical Industries Limited; Sun Pharmaceutical Industries, Inc.; Alembic Pharmaceuticals Ltd.; Alembic Pharmaceuticals, Inc.; MSN Laboratories Private Limited; MSN Pharmaceuticals Inc.; Apotex Inc.; and Apotex Corp. The following U.S. patents are included in one or more cases: 7,094,781; and 10,946,015. In September 2023, the Company entered into confidential settlement agreements with Alembic Pharmaceuticals Ltd., Alembic Pharmaceuticals, Inc., Apotex Inc. and Apotex Corp.", "text": "Alembic Pharmaceuticals, Inc.;", "length": 30, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 939, "tag": "div", "text_raw": "Beginning in January 2023 Actelion Pharmaceuticals Ltd and Actelion Pharmaceuticals US, Inc. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of OPSUMIT before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Sun Pharmaceutical Industries Limited; Sun Pharmaceutical Industries, Inc.; Alembic Pharmaceuticals Ltd.; Alembic Pharmaceuticals, Inc.; MSN Laboratories Private Limited; MSN Pharmaceuticals Inc.; Apotex Inc.; and Apotex Corp. The following U.S. patents are included in one or more cases: 7,094,781; and 10,946,015. In September 2023, the Company entered into confidential settlement agreements with Alembic Pharmaceuticals Ltd., Alembic Pharmaceuticals, Inc., Apotex Inc. and Apotex Corp.", "text": "MSN Laboratories Private Limited;", "length": 33, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 939, "tag": "div", "text_raw": "Beginning in January 2023 Actelion Pharmaceuticals Ltd and Actelion Pharmaceuticals US, Inc. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of OPSUMIT before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Sun Pharmaceutical Industries Limited; Sun Pharmaceutical Industries, Inc.; Alembic Pharmaceuticals Ltd.; Alembic Pharmaceuticals, Inc.; MSN Laboratories Private Limited; MSN Pharmaceuticals Inc.; Apotex Inc.; and Apotex Corp. The following U.S. patents are included in one or more cases: 7,094,781; and 10,946,015. In September 2023, the Company entered into confidential settlement agreements with Alembic Pharmaceuticals Ltd., Alembic Pharmaceuticals, Inc., Apotex Inc. and Apotex Corp.", "text": "patents are included in one or more cases:", "length": 42, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 939, "tag": "div", "text_raw": "Beginning in January 2023 Actelion Pharmaceuticals Ltd and Actelion Pharmaceuticals US, Inc. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of OPSUMIT before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Sun Pharmaceutical Industries Limited; Sun Pharmaceutical Industries, Inc.; Alembic Pharmaceuticals Ltd.; Alembic Pharmaceuticals, Inc.; MSN Laboratories Private Limited; MSN Pharmaceuticals Inc.; Apotex Inc.; and Apotex Corp. The following U.S. patents are included in one or more cases: 7,094,781; and 10,946,015. In September 2023, the Company entered into confidential settlement agreements with Alembic Pharmaceuticals Ltd., Alembic Pharmaceuticals, Inc., Apotex Inc. and Apotex Corp.", "text": "7,094,781;", "length": 10, "numbers_raw": ["7,094,781"], "numbers": [7094781.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 939, "tag": "div", "text_raw": "Beginning in January 2023 Actelion Pharmaceuticals Ltd and Actelion Pharmaceuticals US, Inc. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of OPSUMIT before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Sun Pharmaceutical Industries Limited; Sun Pharmaceutical Industries, Inc.; Alembic Pharmaceuticals Ltd.; Alembic Pharmaceuticals, Inc.; MSN Laboratories Private Limited; MSN Pharmaceuticals Inc.; Apotex Inc.; and Apotex Corp. The following U.S. patents are included in one or more cases: 7,094,781; and 10,946,015. In September 2023, the Company entered into confidential settlement agreements with Alembic Pharmaceuticals Ltd., Alembic Pharmaceuticals, Inc., Apotex Inc. and Apotex Corp.", "text": "and 10,946,015.", "length": 15, "numbers_raw": ["10,946,015"], "numbers": [10946015.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 939, "tag": "div", "text_raw": "Beginning in January 2023 Actelion Pharmaceuticals Ltd and Actelion Pharmaceuticals US, Inc. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of OPSUMIT before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Sun Pharmaceutical Industries Limited; Sun Pharmaceutical Industries, Inc.; Alembic Pharmaceuticals Ltd.; Alembic Pharmaceuticals, Inc.; MSN Laboratories Private Limited; MSN Pharmaceuticals Inc.; Apotex Inc.; and Apotex Corp. The following U.S. patents are included in one or more cases: 7,094,781; and 10,946,015. In September 2023, the Company entered into confidential settlement agreements with Alembic Pharmaceuticals Ltd., Alembic Pharmaceuticals, Inc., Apotex Inc. and Apotex Corp.", "text": "In September 2023, the Company entered into confidential settlement agreements with Alembic Pharmaceuticals Ltd., Alembic Pharmaceuticals, Inc., Apotex Inc.", "length": 156, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 942, "tag": "div", "text_raw": "Beginning in January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Teva Pharmaceuticals USA, Inc.; Mylan Laboratories Limited; Pharmascience Inc.; Mallinckrodt PLC; Specgx LLC; Tolmar, Inc.; and Accord Healthcare, Inc. The following U.S. patent is included in one or more cases: 9,439,906.", "text": "Beginning in January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc.", "length": 85, "numbers_raw": ["201", "8"], "numbers": [201.0, 8.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 942, "tag": "div", "text_raw": "Beginning in January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Teva Pharmaceuticals USA, Inc.; Mylan Laboratories Limited; Pharmascience Inc.; Mallinckrodt PLC; Specgx LLC; Tolmar, Inc.; and Accord Healthcare, Inc. The following U.S. patent is included in one or more cases: 9,439,906.", "text": "filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the Orange Book Listed Patent.", "length": 233, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 942, "tag": "div", "text_raw": "Beginning in January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Teva Pharmaceuticals USA, Inc.; Mylan Laboratories Limited; Pharmascience Inc.; Mallinckrodt PLC; Specgx LLC; Tolmar, Inc.; and Accord Healthcare, Inc. The following U.S. patent is included in one or more cases: 9,439,906.", "text": "The following entities are named defendants:", "length": 44, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 942, "tag": "div", "text_raw": "Beginning in January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Teva Pharmaceuticals USA, Inc.; Mylan Laboratories Limited; Pharmascience Inc.; Mallinckrodt PLC; Specgx LLC; Tolmar, Inc.; and Accord Healthcare, Inc. The following U.S. patent is included in one or more cases: 9,439,906.", "text": "Teva Pharmaceuticals USA, Inc.;", "length": 31, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 942, "tag": "div", "text_raw": "Beginning in January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Teva Pharmaceuticals USA, Inc.; Mylan Laboratories Limited; Pharmascience Inc.; Mallinckrodt PLC; Specgx LLC; Tolmar, Inc.; and Accord Healthcare, Inc. The following U.S. patent is included in one or more cases: 9,439,906.", "text": "patent is included in one or more cases:", "length": 40, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 942, "tag": "div", "text_raw": "Beginning in January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Teva Pharmaceuticals USA, Inc.; Mylan Laboratories Limited; Pharmascience Inc.; Mallinckrodt PLC; Specgx LLC; Tolmar, Inc.; and Accord Healthcare, Inc. The following U.S. patent is included in one or more cases: 9,439,906.", "text": "9,439,906.", "length": 10, "numbers_raw": ["9,439,906"], "numbers": [9439906.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 944, "tag": "div", "text_raw": "Beginning in February 2018, Janssen Inc. and Janssen Pharmaceutica NV initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against generic manufacturers who have filed ANDSs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the listed patent. The following entities are named defendants: Pharmascience Inc. and Apotex Inc. The following Canadian patent is included in one or more cases: 2,655,335.", "text": "Beginning in February 2018, Janssen Inc.", "length": 40, "numbers_raw": ["201", "8"], "numbers": [201.0, 8.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 944, "tag": "div", "text_raw": "Beginning in February 2018, Janssen Inc. and Janssen Pharmaceutica NV initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against generic manufacturers who have filed ANDSs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the listed patent. The following entities are named defendants: Pharmascience Inc. and Apotex Inc. The following Canadian patent is included in one or more cases: 2,655,335.", "text": "and Janssen Pharmaceutica NV initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against generic manufacturers who have filed ANDSs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the listed patent.", "length": 290, "numbers_raw": ["6"], "numbers": [6.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 944, "tag": "div", "text_raw": "Beginning in February 2018, Janssen Inc. and Janssen Pharmaceutica NV initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against generic manufacturers who have filed ANDSs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the listed patent. The following entities are named defendants: Pharmascience Inc. and Apotex Inc. The following Canadian patent is included in one or more cases: 2,655,335.", "text": "The following entities are named defendants:", "length": 44, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 944, "tag": "div", "text_raw": "Beginning in February 2018, Janssen Inc. and Janssen Pharmaceutica NV initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against generic manufacturers who have filed ANDSs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the listed patent. The following entities are named defendants: Pharmascience Inc. and Apotex Inc. The following Canadian patent is included in one or more cases: 2,655,335.", "text": "The following Canadian patent is included in one or more cases:", "length": 63, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 944, "tag": "div", "text_raw": "Beginning in February 2018, Janssen Inc. and Janssen Pharmaceutica NV initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against generic manufacturers who have filed ANDSs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the listed patent. The following entities are named defendants: Pharmascience Inc. and Apotex Inc. The following Canadian patent is included in one or more cases: 2,655,335.", "text": "2,655,335.", "length": 10, "numbers_raw": ["2,655,335"], "numbers": [2655335.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 947, "tag": "div", "text_raw": "Beginning in September 2020, Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, and Janssen Research & Development, LLC filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA TRINZA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Mylan Laboratories Limited; Mylan Pharmaceuticals Inc.; and Mylan Institutional LLC. The following U.S. patent is included in one or more cases: 10,143,693. In May 2023, the District Court issued a decision finding that Mylans proposed generic product infringes the asserted patent and that the patent is not invalid. Mylan has appealed the verdict.", "text": "Beginning in September 2020, Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, and Janssen Research & Development, LLC filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA TRINZA before expiration of the Orange Book Listed Patent.", "length": 357, "numbers_raw": ["202", "0"], "numbers": [202.0, 0.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 947, "tag": "div", "text_raw": "Beginning in September 2020, Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, and Janssen Research & Development, LLC filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA TRINZA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Mylan Laboratories Limited; Mylan Pharmaceuticals Inc.; and Mylan Institutional LLC. The following U.S. patent is included in one or more cases: 10,143,693. In May 2023, the District Court issued a decision finding that Mylans proposed generic product infringes the asserted patent and that the patent is not invalid. Mylan has appealed the verdict.", "text": "The following entities are named defendants:", "length": 44, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 947, "tag": "div", "text_raw": "Beginning in September 2020, Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, and Janssen Research & Development, LLC filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA TRINZA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Mylan Laboratories Limited; Mylan Pharmaceuticals Inc.; and Mylan Institutional LLC. The following U.S. patent is included in one or more cases: 10,143,693. In May 2023, the District Court issued a decision finding that Mylans proposed generic product infringes the asserted patent and that the patent is not invalid. Mylan has appealed the verdict.", "text": "patent is included in one or more cases:", "length": 40, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 947, "tag": "div", "text_raw": "Beginning in September 2020, Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, and Janssen Research & Development, LLC filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA TRINZA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Mylan Laboratories Limited; Mylan Pharmaceuticals Inc.; and Mylan Institutional LLC. The following U.S. patent is included in one or more cases: 10,143,693. In May 2023, the District Court issued a decision finding that Mylans proposed generic product infringes the asserted patent and that the patent is not invalid. Mylan has appealed the verdict.", "text": "10,143,693.", "length": 11, "numbers_raw": ["10,143,693"], "numbers": [10143693.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 947, "tag": "div", "text_raw": "Beginning in September 2020, Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, and Janssen Research & Development, LLC filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA TRINZA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Mylan Laboratories Limited; Mylan Pharmaceuticals Inc.; and Mylan Institutional LLC. The following U.S. patent is included in one or more cases: 10,143,693. In May 2023, the District Court issued a decision finding that Mylans proposed generic product infringes the asserted patent and that the patent is not invalid. Mylan has appealed the verdict.", "text": "In May 2023, the District Court issued a decision finding that Mylans proposed generic product infringes the asserted patent and that the patent is not invalid.", "length": 161, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 947, "tag": "div", "text_raw": "Beginning in September 2020, Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, and Janssen Research & Development, LLC filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA TRINZA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Mylan Laboratories Limited; Mylan Pharmaceuticals Inc.; and Mylan Institutional LLC. The following U.S. patent is included in one or more cases: 10,143,693. In May 2023, the District Court issued a decision finding that Mylans proposed generic product infringes the asserted patent and that the patent is not invalid. Mylan has appealed the verdict.", "text": "Mylan has appealed the verdict.", "length": 31, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 950, "tag": "div", "text_raw": "Beginning in November 2021, Janssen Products, L.P., Janssen Sciences Ireland Unlimited Company, Gilead Sciences, Inc. and Gilead Sciences Ireland UC filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of SYMTUZA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Lupin Limited; Lupin Pharmaceuticals, Inc.; MSN Laboratories Private Ltd.; MSN Life Sciences Private Ltd.; MSN Pharmaceuticals Inc.; Apotex Inc.; and Apotex Corp. The following U.S. patents are included in one or more cases: 10,039,718 and 10,786,518.", "text": "Beginning in November 2021, Janssen Products, L.P., Janssen Sciences Ireland Unlimited Company, Gilead Sciences, Inc.", "length": 117, "numbers_raw": ["202", "1"], "numbers": [202.0, 1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 950, "tag": "div", "text_raw": "Beginning in November 2021, Janssen Products, L.P., Janssen Sciences Ireland Unlimited Company, Gilead Sciences, Inc. and Gilead Sciences Ireland UC filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of SYMTUZA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Lupin Limited; Lupin Pharmaceuticals, Inc.; MSN Laboratories Private Ltd.; MSN Life Sciences Private Ltd.; MSN Pharmaceuticals Inc.; Apotex Inc.; and Apotex Corp. The following U.S. patents are included in one or more cases: 10,039,718 and 10,786,518.", "text": "and Gilead Sciences Ireland UC filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of SYMTUZA before expiration of certain Orange Book Listed Patents.", "length": 261, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 950, "tag": "div", "text_raw": "Beginning in November 2021, Janssen Products, L.P., Janssen Sciences Ireland Unlimited Company, Gilead Sciences, Inc. and Gilead Sciences Ireland UC filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of SYMTUZA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Lupin Limited; Lupin Pharmaceuticals, Inc.; MSN Laboratories Private Ltd.; MSN Life Sciences Private Ltd.; MSN Pharmaceuticals Inc.; Apotex Inc.; and Apotex Corp. The following U.S. patents are included in one or more cases: 10,039,718 and 10,786,518.", "text": "The following entities are named defendants:", "length": 44, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 950, "tag": "div", "text_raw": "Beginning in November 2021, Janssen Products, L.P., Janssen Sciences Ireland Unlimited Company, Gilead Sciences, Inc. and Gilead Sciences Ireland UC filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of SYMTUZA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Lupin Limited; Lupin Pharmaceuticals, Inc.; MSN Laboratories Private Ltd.; MSN Life Sciences Private Ltd.; MSN Pharmaceuticals Inc.; Apotex Inc.; and Apotex Corp. The following U.S. patents are included in one or more cases: 10,039,718 and 10,786,518.", "text": "MSN Laboratories Private Ltd.;", "length": 30, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 950, "tag": "div", "text_raw": "Beginning in November 2021, Janssen Products, L.P., Janssen Sciences Ireland Unlimited Company, Gilead Sciences, Inc. and Gilead Sciences Ireland UC filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of SYMTUZA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Lupin Limited; Lupin Pharmaceuticals, Inc.; MSN Laboratories Private Ltd.; MSN Life Sciences Private Ltd.; MSN Pharmaceuticals Inc.; Apotex Inc.; and Apotex Corp. The following U.S. patents are included in one or more cases: 10,039,718 and 10,786,518.", "text": "MSN Life Sciences Private Ltd.;", "length": 31, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 950, "tag": "div", "text_raw": "Beginning in November 2021, Janssen Products, L.P., Janssen Sciences Ireland Unlimited Company, Gilead Sciences, Inc. and Gilead Sciences Ireland UC filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of SYMTUZA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Lupin Limited; Lupin Pharmaceuticals, Inc.; MSN Laboratories Private Ltd.; MSN Life Sciences Private Ltd.; MSN Pharmaceuticals Inc.; Apotex Inc.; and Apotex Corp. The following U.S. patents are included in one or more cases: 10,039,718 and 10,786,518.", "text": "patents are included in one or more cases:", "length": 42, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 950, "tag": "div", "text_raw": "Beginning in November 2021, Janssen Products, L.P., Janssen Sciences Ireland Unlimited Company, Gilead Sciences, Inc. and Gilead Sciences Ireland UC filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of SYMTUZA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Lupin Limited; Lupin Pharmaceuticals, Inc.; MSN Laboratories Private Ltd.; MSN Life Sciences Private Ltd.; MSN Pharmaceuticals Inc.; Apotex Inc.; and Apotex Corp. The following U.S. patents are included in one or more cases: 10,039,718 and 10,786,518.", "text": "10,039,718 and 10,786,518.", "length": 26, "numbers_raw": ["10,039,718", "10,786,518"], "numbers": [10039718.0, 10786518.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 953, "tag": "div", "text_raw": "Beginning in May 2022, Aragon Pharmaceuticals, Inc., Janssen Biotech, Inc., Sloan Kettering Institute for Cancer Research and The Regents of the University of California filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of ERLEADA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Lupin Limited; Lupin Pharmaceuticals, Inc.; Zydus Worldwide DMCC; Zydus Pharmaceuticals (USA), Inc.; Zydus Lifesciences Limited; Sandoz Inc.; Eugia Pharma Specialities Limited; Aurobindo Pharma USA, Inc.; Auromedics Pharma LLC; Hetero Labs Limited Unit V; and Hetero USA, Inc. The following U.S. patents are included in one or more cases: 9,481,663; 9,884,054; 10,052,314; 10,702,508; 10,849,888; 8,445,507; 8,802,689; 9,388,159; 9,987,261; and RE49,353.", "text": "Beginning in May 2022, Aragon Pharmaceuticals, Inc., Janssen Biotech, Inc., Sloan Kettering Institute for Cancer Research and The Regents of the University of California filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of ERLEADA before expiration of certain Orange Book Listed Patents.", "length": 400, "numbers_raw": ["202", "2"], "numbers": [202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 953, "tag": "div", "text_raw": "Beginning in May 2022, Aragon Pharmaceuticals, Inc., Janssen Biotech, Inc., Sloan Kettering Institute for Cancer Research and The Regents of the University of California filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of ERLEADA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Lupin Limited; Lupin Pharmaceuticals, Inc.; Zydus Worldwide DMCC; Zydus Pharmaceuticals (USA), Inc.; Zydus Lifesciences Limited; Sandoz Inc.; Eugia Pharma Specialities Limited; Aurobindo Pharma USA, Inc.; Auromedics Pharma LLC; Hetero Labs Limited Unit V; and Hetero USA, Inc. The following U.S. patents are included in one or more cases: 9,481,663; 9,884,054; 10,052,314; 10,702,508; 10,849,888; 8,445,507; 8,802,689; 9,388,159; 9,987,261; and RE49,353.", "text": "The following entities are named defendants:", "length": 44, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 953, "tag": "div", "text_raw": "Beginning in May 2022, Aragon Pharmaceuticals, Inc., Janssen Biotech, Inc., Sloan Kettering Institute for Cancer Research and The Regents of the University of California filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of ERLEADA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Lupin Limited; Lupin Pharmaceuticals, Inc.; Zydus Worldwide DMCC; Zydus Pharmaceuticals (USA), Inc.; Zydus Lifesciences Limited; Sandoz Inc.; Eugia Pharma Specialities Limited; Aurobindo Pharma USA, Inc.; Auromedics Pharma LLC; Hetero Labs Limited Unit V; and Hetero USA, Inc. The following U.S. patents are included in one or more cases: 9,481,663; 9,884,054; 10,052,314; 10,702,508; 10,849,888; 8,445,507; 8,802,689; 9,388,159; 9,987,261; and RE49,353.", "text": "Zydus Pharmaceuticals (USA), Inc.;", "length": 34, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 953, "tag": "div", "text_raw": "Beginning in May 2022, Aragon Pharmaceuticals, Inc., Janssen Biotech, Inc., Sloan Kettering Institute for Cancer Research and The Regents of the University of California filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of ERLEADA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Lupin Limited; Lupin Pharmaceuticals, Inc.; Zydus Worldwide DMCC; Zydus Pharmaceuticals (USA), Inc.; Zydus Lifesciences Limited; Sandoz Inc.; Eugia Pharma Specialities Limited; Aurobindo Pharma USA, Inc.; Auromedics Pharma LLC; Hetero Labs Limited Unit V; and Hetero USA, Inc. The following U.S. patents are included in one or more cases: 9,481,663; 9,884,054; 10,052,314; 10,702,508; 10,849,888; 8,445,507; 8,802,689; 9,388,159; 9,987,261; and RE49,353.", "text": "Eugia Pharma Specialities Limited;", "length": 34, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 953, "tag": "div", "text_raw": "Beginning in May 2022, Aragon Pharmaceuticals, Inc., Janssen Biotech, Inc., Sloan Kettering Institute for Cancer Research and The Regents of the University of California filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of ERLEADA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Lupin Limited; Lupin Pharmaceuticals, Inc.; Zydus Worldwide DMCC; Zydus Pharmaceuticals (USA), Inc.; Zydus Lifesciences Limited; Sandoz Inc.; Eugia Pharma Specialities Limited; Aurobindo Pharma USA, Inc.; Auromedics Pharma LLC; Hetero Labs Limited Unit V; and Hetero USA, Inc. The following U.S. patents are included in one or more cases: 9,481,663; 9,884,054; 10,052,314; 10,702,508; 10,849,888; 8,445,507; 8,802,689; 9,388,159; 9,987,261; and RE49,353.", "text": "patents are included in one or more cases:", "length": 42, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 953, "tag": "div", "text_raw": "Beginning in May 2022, Aragon Pharmaceuticals, Inc., Janssen Biotech, Inc., Sloan Kettering Institute for Cancer Research and The Regents of the University of California filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of ERLEADA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Lupin Limited; Lupin Pharmaceuticals, Inc.; Zydus Worldwide DMCC; Zydus Pharmaceuticals (USA), Inc.; Zydus Lifesciences Limited; Sandoz Inc.; Eugia Pharma Specialities Limited; Aurobindo Pharma USA, Inc.; Auromedics Pharma LLC; Hetero Labs Limited Unit V; and Hetero USA, Inc. The following U.S. patents are included in one or more cases: 9,481,663; 9,884,054; 10,052,314; 10,702,508; 10,849,888; 8,445,507; 8,802,689; 9,388,159; 9,987,261; and RE49,353.", "text": "9,481,663;", "length": 10, "numbers_raw": ["9,481,663"], "numbers": [9481663.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 953, "tag": "div", "text_raw": "Beginning in May 2022, Aragon Pharmaceuticals, Inc., Janssen Biotech, Inc., Sloan Kettering Institute for Cancer Research and The Regents of the University of California filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of ERLEADA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Lupin Limited; Lupin Pharmaceuticals, Inc.; Zydus Worldwide DMCC; Zydus Pharmaceuticals (USA), Inc.; Zydus Lifesciences Limited; Sandoz Inc.; Eugia Pharma Specialities Limited; Aurobindo Pharma USA, Inc.; Auromedics Pharma LLC; Hetero Labs Limited Unit V; and Hetero USA, Inc. The following U.S. patents are included in one or more cases: 9,481,663; 9,884,054; 10,052,314; 10,702,508; 10,849,888; 8,445,507; 8,802,689; 9,388,159; 9,987,261; and RE49,353.", "text": "9,884,054;", "length": 10, "numbers_raw": ["9,884,054"], "numbers": [9884054.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 953, "tag": "div", "text_raw": "Beginning in May 2022, Aragon Pharmaceuticals, Inc., Janssen Biotech, Inc., Sloan Kettering Institute for Cancer Research and The Regents of the University of California filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of ERLEADA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Lupin Limited; Lupin Pharmaceuticals, Inc.; Zydus Worldwide DMCC; Zydus Pharmaceuticals (USA), Inc.; Zydus Lifesciences Limited; Sandoz Inc.; Eugia Pharma Specialities Limited; Aurobindo Pharma USA, Inc.; Auromedics Pharma LLC; Hetero Labs Limited Unit V; and Hetero USA, Inc. The following U.S. patents are included in one or more cases: 9,481,663; 9,884,054; 10,052,314; 10,702,508; 10,849,888; 8,445,507; 8,802,689; 9,388,159; 9,987,261; and RE49,353.", "text": "10,052,314;", "length": 11, "numbers_raw": ["10,052,314"], "numbers": [10052314.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 953, "tag": "div", "text_raw": "Beginning in May 2022, Aragon Pharmaceuticals, Inc., Janssen Biotech, Inc., Sloan Kettering Institute for Cancer Research and The Regents of the University of California filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of ERLEADA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Lupin Limited; Lupin Pharmaceuticals, Inc.; Zydus Worldwide DMCC; Zydus Pharmaceuticals (USA), Inc.; Zydus Lifesciences Limited; Sandoz Inc.; Eugia Pharma Specialities Limited; Aurobindo Pharma USA, Inc.; Auromedics Pharma LLC; Hetero Labs Limited Unit V; and Hetero USA, Inc. The following U.S. patents are included in one or more cases: 9,481,663; 9,884,054; 10,052,314; 10,702,508; 10,849,888; 8,445,507; 8,802,689; 9,388,159; 9,987,261; and RE49,353.", "text": "10,702,508;", "length": 11, "numbers_raw": ["10,702,508"], "numbers": [10702508.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 953, "tag": "div", "text_raw": "Beginning in May 2022, Aragon Pharmaceuticals, Inc., Janssen Biotech, Inc., Sloan Kettering Institute for Cancer Research and The Regents of the University of California filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of ERLEADA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Lupin Limited; Lupin Pharmaceuticals, Inc.; Zydus Worldwide DMCC; Zydus Pharmaceuticals (USA), Inc.; Zydus Lifesciences Limited; Sandoz Inc.; Eugia Pharma Specialities Limited; Aurobindo Pharma USA, Inc.; Auromedics Pharma LLC; Hetero Labs Limited Unit V; and Hetero USA, Inc. The following U.S. patents are included in one or more cases: 9,481,663; 9,884,054; 10,052,314; 10,702,508; 10,849,888; 8,445,507; 8,802,689; 9,388,159; 9,987,261; and RE49,353.", "text": "10,849,888;", "length": 11, "numbers_raw": ["10,849,888"], "numbers": [10849888.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 953, "tag": "div", "text_raw": "Beginning in May 2022, Aragon Pharmaceuticals, Inc., Janssen Biotech, Inc., Sloan Kettering Institute for Cancer Research and The Regents of the University of California filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of ERLEADA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Lupin Limited; Lupin Pharmaceuticals, Inc.; Zydus Worldwide DMCC; Zydus Pharmaceuticals (USA), Inc.; Zydus Lifesciences Limited; Sandoz Inc.; Eugia Pharma Specialities Limited; Aurobindo Pharma USA, Inc.; Auromedics Pharma LLC; Hetero Labs Limited Unit V; and Hetero USA, Inc. The following U.S. patents are included in one or more cases: 9,481,663; 9,884,054; 10,052,314; 10,702,508; 10,849,888; 8,445,507; 8,802,689; 9,388,159; 9,987,261; and RE49,353.", "text": "8,445,507;", "length": 10, "numbers_raw": ["8,445,507"], "numbers": [8445507.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 953, "tag": "div", "text_raw": "Beginning in May 2022, Aragon Pharmaceuticals, Inc., Janssen Biotech, Inc., Sloan Kettering Institute for Cancer Research and The Regents of the University of California filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of ERLEADA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Lupin Limited; Lupin Pharmaceuticals, Inc.; Zydus Worldwide DMCC; Zydus Pharmaceuticals (USA), Inc.; Zydus Lifesciences Limited; Sandoz Inc.; Eugia Pharma Specialities Limited; Aurobindo Pharma USA, Inc.; Auromedics Pharma LLC; Hetero Labs Limited Unit V; and Hetero USA, Inc. The following U.S. patents are included in one or more cases: 9,481,663; 9,884,054; 10,052,314; 10,702,508; 10,849,888; 8,445,507; 8,802,689; 9,388,159; 9,987,261; and RE49,353.", "text": "8,802,689;", "length": 10, "numbers_raw": ["8,802,689"], "numbers": [8802689.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 953, "tag": "div", "text_raw": "Beginning in May 2022, Aragon Pharmaceuticals, Inc., Janssen Biotech, Inc., Sloan Kettering Institute for Cancer Research and The Regents of the University of California filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of ERLEADA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Lupin Limited; Lupin Pharmaceuticals, Inc.; Zydus Worldwide DMCC; Zydus Pharmaceuticals (USA), Inc.; Zydus Lifesciences Limited; Sandoz Inc.; Eugia Pharma Specialities Limited; Aurobindo Pharma USA, Inc.; Auromedics Pharma LLC; Hetero Labs Limited Unit V; and Hetero USA, Inc. The following U.S. patents are included in one or more cases: 9,481,663; 9,884,054; 10,052,314; 10,702,508; 10,849,888; 8,445,507; 8,802,689; 9,388,159; 9,987,261; and RE49,353.", "text": "9,388,159;", "length": 10, "numbers_raw": ["9,388,159"], "numbers": [9388159.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 953, "tag": "div", "text_raw": "Beginning in May 2022, Aragon Pharmaceuticals, Inc., Janssen Biotech, Inc., Sloan Kettering Institute for Cancer Research and The Regents of the University of California filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of ERLEADA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Lupin Limited; Lupin Pharmaceuticals, Inc.; Zydus Worldwide DMCC; Zydus Pharmaceuticals (USA), Inc.; Zydus Lifesciences Limited; Sandoz Inc.; Eugia Pharma Specialities Limited; Aurobindo Pharma USA, Inc.; Auromedics Pharma LLC; Hetero Labs Limited Unit V; and Hetero USA, Inc. The following U.S. patents are included in one or more cases: 9,481,663; 9,884,054; 10,052,314; 10,702,508; 10,849,888; 8,445,507; 8,802,689; 9,388,159; 9,987,261; and RE49,353.", "text": "9,987,261;", "length": 10, "numbers_raw": ["9,987,261"], "numbers": [9987261.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 953, "tag": "div", "text_raw": "Beginning in May 2022, Aragon Pharmaceuticals, Inc., Janssen Biotech, Inc., Sloan Kettering Institute for Cancer Research and The Regents of the University of California filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of ERLEADA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Lupin Limited; Lupin Pharmaceuticals, Inc.; Zydus Worldwide DMCC; Zydus Pharmaceuticals (USA), Inc.; Zydus Lifesciences Limited; Sandoz Inc.; Eugia Pharma Specialities Limited; Aurobindo Pharma USA, Inc.; Auromedics Pharma LLC; Hetero Labs Limited Unit V; and Hetero USA, Inc. The following U.S. patents are included in one or more cases: 9,481,663; 9,884,054; 10,052,314; 10,702,508; 10,849,888; 8,445,507; 8,802,689; 9,388,159; 9,987,261; and RE49,353.", "text": "and RE49,353.", "length": 13, "numbers_raw": ["49,353"], "numbers": [49353.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 956, "tag": "div", "text_raw": "Beginning in November 2022, Actelion Pharmaceuticals US Inc., Actelion Pharmaceuticals Ltd and Nippon Shinyaku Co., Ltd. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of UPTRAVI intravenous before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals Inc.; Lupin Ltd.; Lupin Pharmaceuticals, Inc.; Cipla Limited; Cipla USA Inc.; MSN Laboratories Private Ltd.; and MSN Pharmaceuticals Inc. The following U.S. patents are included in one or more cases: 8,791,122 and 9,284,280.", "text": "Beginning in November 2022, Actelion Pharmaceuticals US Inc., Actelion Pharmaceuticals Ltd and Nippon Shinyaku Co., Ltd.", "length": 120, "numbers_raw": ["202", "2"], "numbers": [202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 956, "tag": "div", "text_raw": "Beginning in November 2022, Actelion Pharmaceuticals US Inc., Actelion Pharmaceuticals Ltd and Nippon Shinyaku Co., Ltd. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of UPTRAVI intravenous before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals Inc.; Lupin Ltd.; Lupin Pharmaceuticals, Inc.; Cipla Limited; Cipla USA Inc.; MSN Laboratories Private Ltd.; and MSN Pharmaceuticals Inc. The following U.S. patents are included in one or more cases: 8,791,122 and 9,284,280.", "text": "filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of UPTRAVI intravenous before expiration of certain Orange Book Listed Patents.", "length": 242, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 956, "tag": "div", "text_raw": "Beginning in November 2022, Actelion Pharmaceuticals US Inc., Actelion Pharmaceuticals Ltd and Nippon Shinyaku Co., Ltd. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of UPTRAVI intravenous before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals Inc.; Lupin Ltd.; Lupin Pharmaceuticals, Inc.; Cipla Limited; Cipla USA Inc.; MSN Laboratories Private Ltd.; and MSN Pharmaceuticals Inc. The following U.S. patents are included in one or more cases: 8,791,122 and 9,284,280.", "text": "The following entities are named defendants:", "length": 44, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 956, "tag": "div", "text_raw": "Beginning in November 2022, Actelion Pharmaceuticals US Inc., Actelion Pharmaceuticals Ltd and Nippon Shinyaku Co., Ltd. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of UPTRAVI intravenous before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals Inc.; Lupin Ltd.; Lupin Pharmaceuticals, Inc.; Cipla Limited; Cipla USA Inc.; MSN Laboratories Private Ltd.; and MSN Pharmaceuticals Inc. The following U.S. patents are included in one or more cases: 8,791,122 and 9,284,280.", "text": "Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals Inc.;", "length": 62, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 956, "tag": "div", "text_raw": "Beginning in November 2022, Actelion Pharmaceuticals US Inc., Actelion Pharmaceuticals Ltd and Nippon Shinyaku Co., Ltd. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of UPTRAVI intravenous before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals Inc.; Lupin Ltd.; Lupin Pharmaceuticals, Inc.; Cipla Limited; Cipla USA Inc.; MSN Laboratories Private Ltd.; and MSN Pharmaceuticals Inc. The following U.S. patents are included in one or more cases: 8,791,122 and 9,284,280.", "text": "MSN Laboratories Private Ltd.;", "length": 30, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 956, "tag": "div", "text_raw": "Beginning in November 2022, Actelion Pharmaceuticals US Inc., Actelion Pharmaceuticals Ltd and Nippon Shinyaku Co., Ltd. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of UPTRAVI intravenous before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals Inc.; Lupin Ltd.; Lupin Pharmaceuticals, Inc.; Cipla Limited; Cipla USA Inc.; MSN Laboratories Private Ltd.; and MSN Pharmaceuticals Inc. The following U.S. patents are included in one or more cases: 8,791,122 and 9,284,280.", "text": "patents are included in one or more cases:", "length": 42, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 956, "tag": "div", "text_raw": "Beginning in November 2022, Actelion Pharmaceuticals US Inc., Actelion Pharmaceuticals Ltd and Nippon Shinyaku Co., Ltd. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of UPTRAVI intravenous before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals Inc.; Lupin Ltd.; Lupin Pharmaceuticals, Inc.; Cipla Limited; Cipla USA Inc.; MSN Laboratories Private Ltd.; and MSN Pharmaceuticals Inc. The following U.S. patents are included in one or more cases: 8,791,122 and 9,284,280.", "text": "8,791,122 and 9,284,280.", "length": 24, "numbers_raw": ["8,791,122", "9,284,280"], "numbers": [8791122.0, 9284280.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 959, "tag": "div", "text_raw": "Beginning in May 2023, Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica NV filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions", "text": "Beginning in May 2023, Janssen Pharmaceuticals, Inc.", "length": 52, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 959, "tag": "div", "text_raw": "Beginning in May 2023, Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica NV filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions", "text": "and Janssen Pharmaceutica NV filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions", "length": 191, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 960, "tag": "div", "text_raw": "36", "text": "36", "length": 2, "numbers_raw": ["36"], "numbers": [36.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 961, "tag": "div", "text_raw": "36", "text": "36", "length": 2, "numbers_raw": ["36"], "numbers": [36.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 962, "tag": "div", "text_raw": "36", "text": "36", "length": 2, "numbers_raw": ["36"], "numbers": [36.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 965, "tag": "div", "text_raw": "of SPRAVATO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Sandoz Inc.; Hikma Pharmaceuticals Inc. USA; Hikma Pharmaceuticals PLC; Westward Columbus Inc. (Westward); Alkem Laboratories Ltd; and Ascend Laboratories, LLC (Ascend). The following U.S. patents are included in one or more cases: 10,869,844; 11,173,134; 11,311,500; and 11,446,260. In June 2023, Westward and Ascend were dismissed from the suit .", "text": "of SPRAVATO before expiration of certain Orange Book Listed Patents.", "length": 68, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 965, "tag": "div", "text_raw": "of SPRAVATO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Sandoz Inc.; Hikma Pharmaceuticals Inc. USA; Hikma Pharmaceuticals PLC; Westward Columbus Inc. (Westward); Alkem Laboratories Ltd; and Ascend Laboratories, LLC (Ascend). The following U.S. patents are included in one or more cases: 10,869,844; 11,173,134; 11,311,500; and 11,446,260. In June 2023, Westward and Ascend were dismissed from the suit .", "text": "The following entities are named defendants:", "length": 44, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 965, "tag": "div", "text_raw": "of SPRAVATO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Sandoz Inc.; Hikma Pharmaceuticals Inc. USA; Hikma Pharmaceuticals PLC; Westward Columbus Inc. (Westward); Alkem Laboratories Ltd; and Ascend Laboratories, LLC (Ascend). The following U.S. patents are included in one or more cases: 10,869,844; 11,173,134; 11,311,500; and 11,446,260. In June 2023, Westward and Ascend were dismissed from the suit .", "text": "and Ascend Laboratories, LLC (Ascend).", "length": 38, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 965, "tag": "div", "text_raw": "of SPRAVATO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Sandoz Inc.; Hikma Pharmaceuticals Inc. USA; Hikma Pharmaceuticals PLC; Westward Columbus Inc. (Westward); Alkem Laboratories Ltd; and Ascend Laboratories, LLC (Ascend). The following U.S. patents are included in one or more cases: 10,869,844; 11,173,134; 11,311,500; and 11,446,260. In June 2023, Westward and Ascend were dismissed from the suit .", "text": "patents are included in one or more cases:", "length": 42, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 965, "tag": "div", "text_raw": "of SPRAVATO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Sandoz Inc.; Hikma Pharmaceuticals Inc. USA; Hikma Pharmaceuticals PLC; Westward Columbus Inc. (Westward); Alkem Laboratories Ltd; and Ascend Laboratories, LLC (Ascend). The following U.S. patents are included in one or more cases: 10,869,844; 11,173,134; 11,311,500; and 11,446,260. In June 2023, Westward and Ascend were dismissed from the suit .", "text": "10,869,844;", "length": 11, "numbers_raw": ["10,869,844"], "numbers": [10869844.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 965, "tag": "div", "text_raw": "of SPRAVATO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Sandoz Inc.; Hikma Pharmaceuticals Inc. USA; Hikma Pharmaceuticals PLC; Westward Columbus Inc. (Westward); Alkem Laboratories Ltd; and Ascend Laboratories, LLC (Ascend). The following U.S. patents are included in one or more cases: 10,869,844; 11,173,134; 11,311,500; and 11,446,260. In June 2023, Westward and Ascend were dismissed from the suit .", "text": "11,173,134;", "length": 11, "numbers_raw": ["11,173,134"], "numbers": [11173134.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 965, "tag": "div", "text_raw": "of SPRAVATO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Sandoz Inc.; Hikma Pharmaceuticals Inc. USA; Hikma Pharmaceuticals PLC; Westward Columbus Inc. (Westward); Alkem Laboratories Ltd; and Ascend Laboratories, LLC (Ascend). The following U.S. patents are included in one or more cases: 10,869,844; 11,173,134; 11,311,500; and 11,446,260. In June 2023, Westward and Ascend were dismissed from the suit .", "text": "11,311,500;", "length": 11, "numbers_raw": ["11,311,500"], "numbers": [11311500.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 965, "tag": "div", "text_raw": "of SPRAVATO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Sandoz Inc.; Hikma Pharmaceuticals Inc. USA; Hikma Pharmaceuticals PLC; Westward Columbus Inc. (Westward); Alkem Laboratories Ltd; and Ascend Laboratories, LLC (Ascend). The following U.S. patents are included in one or more cases: 10,869,844; 11,173,134; 11,311,500; and 11,446,260. In June 2023, Westward and Ascend were dismissed from the suit .", "text": "and 11,446,260.", "length": 15, "numbers_raw": ["11,446,260"], "numbers": [11446260.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 965, "tag": "div", "text_raw": "of SPRAVATO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Sandoz Inc.; Hikma Pharmaceuticals Inc. USA; Hikma Pharmaceuticals PLC; Westward Columbus Inc. (Westward); Alkem Laboratories Ltd; and Ascend Laboratories, LLC (Ascend). The following U.S. patents are included in one or more cases: 10,869,844; 11,173,134; 11,311,500; and 11,446,260. In June 2023, Westward and Ascend were dismissed from the suit .", "text": "In June 2023, Westward and Ascend were dismissed from the suit .", "length": 64, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 969, "tag": "div", "text_raw": "Like other companies in the pharmaceutical and medical technologies industries, the Company and certain of its subsidiaries are subject to extensive regulation by national, state and local government agencies in the United States and other countries in which they operate. Such regulation has been the basis of government investigations and litigations. The most significant litigation brought by, and investigations conducted by, government agencies are listed below. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from government investigations or litigation.", "text": "Like other companies in the pharmaceutical and medical technologies industries, the Company and certain of its subsidiaries are subject to extensive regulation by national, state and local government agencies in the United States and other countries in which they operate.", "length": 272, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 969, "tag": "div", "text_raw": "Like other companies in the pharmaceutical and medical technologies industries, the Company and certain of its subsidiaries are subject to extensive regulation by national, state and local government agencies in the United States and other countries in which they operate. Such regulation has been the basis of government investigations and litigations. The most significant litigation brought by, and investigations conducted by, government agencies are listed below. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from government investigations or litigation.", "text": "Such regulation has been the basis of government investigations and litigations.", "length": 80, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 969, "tag": "div", "text_raw": "Like other companies in the pharmaceutical and medical technologies industries, the Company and certain of its subsidiaries are subject to extensive regulation by national, state and local government agencies in the United States and other countries in which they operate. Such regulation has been the basis of government investigations and litigations. The most significant litigation brought by, and investigations conducted by, government agencies are listed below. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from government investigations or litigation.", "text": "The most significant litigation brought by, and investigations conducted by, government agencies are listed below.", "length": 114, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 969, "tag": "div", "text_raw": "Like other companies in the pharmaceutical and medical technologies industries, the Company and certain of its subsidiaries are subject to extensive regulation by national, state and local government agencies in the United States and other countries in which they operate. Such regulation has been the basis of government investigations and litigations. The most significant litigation brought by, and investigations conducted by, government agencies are listed below. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from government investigations or litigation.", "text": "It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from government investigations or litigation.", "length": 151, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 973, "tag": "div", "text_raw": "In July 2018, the Public Prosecution Service in Rio de Janeiro and representatives from the Brazilian antitrust authority CADE inspected the offices of more than 30 companies including Johnson & Johnson do Brasil Indstria e Comrcio de Produtos para Sade Ltda. The authorities appear to be investigating allegations of possible anti-competitive behavior and possible improper payments in the medical device industry. The Company continues to respond to inquiries regarding the Foreign Corrupt Practices Act from the United States Department of Justice and the United States Securities and Exchange Commission.", "text": "In July 2018, the Public Prosecution Service in Rio de Janeiro and representatives from the Brazilian antitrust authority CADE inspected the offices of more than 30 companies including Johnson & Johnson do Brasil Indstria e Comrcio de Produtos para Sade Ltda.", "length": 262, "numbers_raw": ["201", "8", "30"], "numbers": [201.0, 8.0, 30.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 973, "tag": "div", "text_raw": "In July 2018, the Public Prosecution Service in Rio de Janeiro and representatives from the Brazilian antitrust authority CADE inspected the offices of more than 30 companies including Johnson & Johnson do Brasil Indstria e Comrcio de Produtos para Sade Ltda. The authorities appear to be investigating allegations of possible anti-competitive behavior and possible improper payments in the medical device industry. The Company continues to respond to inquiries regarding the Foreign Corrupt Practices Act from the United States Department of Justice and the United States Securities and Exchange Commission.", "text": "The authorities appear to be investigating allegations of possible anti-competitive behavior and possible improper payments in the medical device industry.", "length": 155, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 973, "tag": "div", "text_raw": "In July 2018, the Public Prosecution Service in Rio de Janeiro and representatives from the Brazilian antitrust authority CADE inspected the offices of more than 30 companies including Johnson & Johnson do Brasil Indstria e Comrcio de Produtos para Sade Ltda. The authorities appear to be investigating allegations of possible anti-competitive behavior and possible improper payments in the medical device industry. The Company continues to respond to inquiries regarding the Foreign Corrupt Practices Act from the United States Department of Justice and the United States Securities and Exchange Commission.", "text": "The Company continues to respond to inquiries regarding the Foreign Corrupt Practices Act from the United States Department of Justice and the United States Securities and Exchange Commission.", "length": 192, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 975, "tag": "div", "text_raw": "In July 2023, the U.S. Department of Justice (DOJ) issued Civil Investigative Demands to the Company, Johnson & Johnson Surgical Vision, Inc., and Johnson & Johnson Vision Care, Inc. (collectively, J&J Vision) in connection with a civil investigation under the False Claims Act relating to free or discounted intraocular lenses and equipment used in eye surgery, such as phacoemulsification and laser systems. J&J Vision has begun producing documents and information responsive to the Civil Investigative Demands. J&J Vision is in ongoing discussions with the DOJ regarding its inquiry.", "text": "In July 2023, the U.S.", "length": 22, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 975, "tag": "div", "text_raw": "In July 2023, the U.S. Department of Justice (DOJ) issued Civil Investigative Demands to the Company, Johnson & Johnson Surgical Vision, Inc., and Johnson & Johnson Vision Care, Inc. (collectively, J&J Vision) in connection with a civil investigation under the False Claims Act relating to free or discounted intraocular lenses and equipment used in eye surgery, such as phacoemulsification and laser systems. J&J Vision has begun producing documents and information responsive to the Civil Investigative Demands. J&J Vision is in ongoing discussions with the DOJ regarding its inquiry.", "text": "Department of Justice (DOJ) issued Civil Investigative Demands to the Company, Johnson & Johnson Surgical Vision, Inc., and Johnson & Johnson Vision Care, Inc.", "length": 161, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 975, "tag": "div", "text_raw": "In July 2023, the U.S. Department of Justice (DOJ) issued Civil Investigative Demands to the Company, Johnson & Johnson Surgical Vision, Inc., and Johnson & Johnson Vision Care, Inc. (collectively, J&J Vision) in connection with a civil investigation under the False Claims Act relating to free or discounted intraocular lenses and equipment used in eye surgery, such as phacoemulsification and laser systems. J&J Vision has begun producing documents and information responsive to the Civil Investigative Demands. J&J Vision is in ongoing discussions with the DOJ regarding its inquiry.", "text": "(collectively, J&J Vision) in connection with a civil investigation under the False Claims Act relating to free or discounted intraocular lenses and equipment used in eye surgery, such as phacoemulsification and laser systems.", "length": 228, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 975, "tag": "div", "text_raw": "In July 2023, the U.S. Department of Justice (DOJ) issued Civil Investigative Demands to the Company, Johnson & Johnson Surgical Vision, Inc., and Johnson & Johnson Vision Care, Inc. (collectively, J&J Vision) in connection with a civil investigation under the False Claims Act relating to free or discounted intraocular lenses and equipment used in eye surgery, such as phacoemulsification and laser systems. J&J Vision has begun producing documents and information responsive to the Civil Investigative Demands. J&J Vision is in ongoing discussions with the DOJ regarding its inquiry.", "text": "J&J Vision has begun producing documents and information responsive to the Civil Investigative Demands.", "length": 103, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 975, "tag": "div", "text_raw": "In July 2023, the U.S. Department of Justice (DOJ) issued Civil Investigative Demands to the Company, Johnson & Johnson Surgical Vision, Inc., and Johnson & Johnson Vision Care, Inc. (collectively, J&J Vision) in connection with a civil investigation under the False Claims Act relating to free or discounted intraocular lenses and equipment used in eye surgery, such as phacoemulsification and laser systems. J&J Vision has begun producing documents and information responsive to the Civil Investigative Demands. J&J Vision is in ongoing discussions with the DOJ regarding its inquiry.", "text": "J&J Vision is in ongoing discussions with the DOJ regarding its inquiry.", "length": 72, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 979, "tag": "div", "text_raw": "In July 2016, the Company and Janssen Products, LP were served with a qui tam complaint pursuant to the False Claims Act filed in the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA and INTELENCE, and anti-kickback violations in connection with the promotion of these products. The complaint was filed under seal in December 2012. The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the relators. The Court denied summary judgment on all claims in December 2021. Daubert motions were granted in part and denied in part in January 2022, and the case is proceeding to trial. Trial is scheduled for May 2024.", "text": "In July 2016, the Company and Janssen Products, LP were served with a qui tam complaint pursuant to the False Claims Act filed in the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA and INTELENCE, and anti-kickback violations in connection with the promotion of these products.", "length": 352, "numbers_raw": ["201", "6"], "numbers": [201.0, 6.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 979, "tag": "div", "text_raw": "In July 2016, the Company and Janssen Products, LP were served with a qui tam complaint pursuant to the False Claims Act filed in the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA and INTELENCE, and anti-kickback violations in connection with the promotion of these products. The complaint was filed under seal in December 2012. The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the relators. The Court denied summary judgment on all claims in December 2021. Daubert motions were granted in part and denied in part in January 2022, and the case is proceeding to trial. Trial is scheduled for May 2024.", "text": "The complaint was filed under seal in December 2012.", "length": 52, "numbers_raw": ["201", "2"], "numbers": [201.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 979, "tag": "div", "text_raw": "In July 2016, the Company and Janssen Products, LP were served with a qui tam complaint pursuant to the False Claims Act filed in the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA and INTELENCE, and anti-kickback violations in connection with the promotion of these products. The complaint was filed under seal in December 2012. The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the relators. The Court denied summary judgment on all claims in December 2021. Daubert motions were granted in part and denied in part in January 2022, and the case is proceeding to trial. Trial is scheduled for May 2024.", "text": "The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the relators.", "length": 114, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 979, "tag": "div", "text_raw": "In July 2016, the Company and Janssen Products, LP were served with a qui tam complaint pursuant to the False Claims Act filed in the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA and INTELENCE, and anti-kickback violations in connection with the promotion of these products. The complaint was filed under seal in December 2012. The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the relators. The Court denied summary judgment on all claims in December 2021. Daubert motions were granted in part and denied in part in January 2022, and the case is proceeding to trial. Trial is scheduled for May 2024.", "text": "The Court denied summary judgment on all claims in December 2021.", "length": 65, "numbers_raw": ["202", "1"], "numbers": [202.0, 1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 979, "tag": "div", "text_raw": "In July 2016, the Company and Janssen Products, LP were served with a qui tam complaint pursuant to the False Claims Act filed in the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA and INTELENCE, and anti-kickback violations in connection with the promotion of these products. The complaint was filed under seal in December 2012. The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the relators. The Court denied summary judgment on all claims in December 2021. Daubert motions were granted in part and denied in part in January 2022, and the case is proceeding to trial. Trial is scheduled for May 2024.", "text": "Daubert motions were granted in part and denied in part in January 2022, and the case is proceeding to trial.", "length": 109, "numbers_raw": ["202", "2"], "numbers": [202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 979, "tag": "div", "text_raw": "In July 2016, the Company and Janssen Products, LP were served with a qui tam complaint pursuant to the False Claims Act filed in the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA and INTELENCE, and anti-kickback violations in connection with the promotion of these products. The complaint was filed under seal in December 2012. The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the relators. The Court denied summary judgment on all claims in December 2021. Daubert motions were granted in part and denied in part in January 2022, and the case is proceeding to trial. Trial is scheduled for May 2024.", "text": "Trial is scheduled for May 2024.", "length": 32, "numbers_raw": ["202", "4"], "numbers": [202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 981, "tag": "div", "text_raw": "In March 2017, Janssen Biotech, Inc. (JBI) received a Civil Investigative Demand from the United States Department of Justice regarding a False Claims Act investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that purchased REMICADE or SIMPONI ARIA. In August 2019, the United States Department of Justice notified JBI that it was closing the investigation. Subsequently, the United States District Court for the District of Massachusetts unsealed a qui tam False Claims Act complaint, which was served on the Company. The Department of Justice had declined to intervene in the qui tam lawsuit in August 2019. The Company filed a motion to dismiss, which was granted in part and denied in part. Discovery is underway.", "text": "In March 2017, Janssen Biotech, Inc.", "length": 36, "numbers_raw": ["201", "7"], "numbers": [201.0, 7.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 981, "tag": "div", "text_raw": "In March 2017, Janssen Biotech, Inc. (JBI) received a Civil Investigative Demand from the United States Department of Justice regarding a False Claims Act investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that purchased REMICADE or SIMPONI ARIA. In August 2019, the United States Department of Justice notified JBI that it was closing the investigation. Subsequently, the United States District Court for the District of Massachusetts unsealed a qui tam False Claims Act complaint, which was served on the Company. The Department of Justice had declined to intervene in the qui tam lawsuit in August 2019. The Company filed a motion to dismiss, which was granted in part and denied in part. Discovery is underway.", "text": "(JBI) received a Civil Investigative Demand from the United States Department of Justice regarding a False Claims Act investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that purchased REMICADE or SIMPONI ARIA.", "length": 272, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 981, "tag": "div", "text_raw": "In March 2017, Janssen Biotech, Inc. (JBI) received a Civil Investigative Demand from the United States Department of Justice regarding a False Claims Act investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that purchased REMICADE or SIMPONI ARIA. In August 2019, the United States Department of Justice notified JBI that it was closing the investigation. Subsequently, the United States District Court for the District of Massachusetts unsealed a qui tam False Claims Act complaint, which was served on the Company. The Department of Justice had declined to intervene in the qui tam lawsuit in August 2019. The Company filed a motion to dismiss, which was granted in part and denied in part. Discovery is underway.", "text": "In August 2019, the United States Department of Justice notified JBI that it was closing the investigation.", "length": 107, "numbers_raw": ["201", "9"], "numbers": [201.0, 9.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 981, "tag": "div", "text_raw": "In March 2017, Janssen Biotech, Inc. (JBI) received a Civil Investigative Demand from the United States Department of Justice regarding a False Claims Act investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that purchased REMICADE or SIMPONI ARIA. In August 2019, the United States Department of Justice notified JBI that it was closing the investigation. Subsequently, the United States District Court for the District of Massachusetts unsealed a qui tam False Claims Act complaint, which was served on the Company. The Department of Justice had declined to intervene in the qui tam lawsuit in August 2019. The Company filed a motion to dismiss, which was granted in part and denied in part. Discovery is underway.", "text": "Subsequently, the United States District Court for the District of Massachusetts unsealed a qui tam False Claims Act complaint, which was served on the Company.", "length": 160, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 981, "tag": "div", "text_raw": "In March 2017, Janssen Biotech, Inc. (JBI) received a Civil Investigative Demand from the United States Department of Justice regarding a False Claims Act investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that purchased REMICADE or SIMPONI ARIA. In August 2019, the United States Department of Justice notified JBI that it was closing the investigation. Subsequently, the United States District Court for the District of Massachusetts unsealed a qui tam False Claims Act complaint, which was served on the Company. The Department of Justice had declined to intervene in the qui tam lawsuit in August 2019. The Company filed a motion to dismiss, which was granted in part and denied in part. Discovery is underway.", "text": "The Department of Justice had declined to intervene in the qui tam lawsuit in August 2019.", "length": 90, "numbers_raw": ["201", "9"], "numbers": [201.0, 9.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 981, "tag": "div", "text_raw": "In March 2017, Janssen Biotech, Inc. (JBI) received a Civil Investigative Demand from the United States Department of Justice regarding a False Claims Act investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that purchased REMICADE or SIMPONI ARIA. In August 2019, the United States Department of Justice notified JBI that it was closing the investigation. Subsequently, the United States District Court for the District of Massachusetts unsealed a qui tam False Claims Act complaint, which was served on the Company. The Department of Justice had declined to intervene in the qui tam lawsuit in August 2019. The Company filed a motion to dismiss, which was granted in part and denied in part. Discovery is underway.", "text": "The Company filed a motion to dismiss, which was granted in part and denied in part.", "length": 84, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 983, "tag": "div", "text_raw": "From time to time, the Company has received requests from a variety of United States Congressional Committees to produce information relevant to ongoing congressional inquiries. It is the policy of Johnson & Johnson to cooperate with these inquiries by producing the requested information.", "text": "From time to time, the Company has received requests from a variety of United States Congressional Committees to produce information relevant to ongoing congressional inquiries.", "length": 177, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 983, "tag": "div", "text_raw": "From time to time, the Company has received requests from a variety of United States Congressional Committees to produce information relevant to ongoing congressional inquiries. It is the policy of Johnson & Johnson to cooperate with these inquiries by producing the requested information.", "text": "It is the policy of Johnson & Johnson to cooperate with these inquiries by producing the requested information.", "length": 111, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 987, "tag": "div", "text_raw": "The Company or its subsidiaries are also parties to various proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as Superfund, and comparable state, local or foreign laws in which the primary relief sought is the Companys agreement to implement remediation activities at designated hazardous waste sites or to reimburse the government or third parties for the costs they have incurred in performing remediation as such sites.", "text": "The Company or its subsidiaries are also parties to various proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as Superfund, and comparable state, local or foreign laws in which the primary relief sought is the Companys agreement to implement remediation activities at designated hazardous waste sites or to reimburse the government or third parties for the costs they have incurred in performing remediation as such sites.", "length": 489, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 989, "tag": "div", "text_raw": "In October 2017, certain United States service members and their families brought a complaint against a number of pharmaceutical and medical devices companies, including Johnson & Johnson and certain of its subsidiaries in United States District Court for the District of Columbia, alleging that the defendants violated the United States Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health. In July 2020, the District Court dismissed the complaint. In January 2022, the United States Court of Appeals for the District of Columbia Circuit reversed the District Courts decision. In June 2023, defendants filed a petition for a writ of certiorari to the United States Supreme Court.", "text": "In October 2017, certain United States service members and their families brought a complaint against a number of pharmaceutical and medical devices companies, including Johnson & Johnson and certain of its subsidiaries in United States District Court for the District of Columbia, alleging that the defendants violated the United States Anti-Terrorism Act.", "length": 357, "numbers_raw": ["201", "7"], "numbers": [201.0, 7.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 989, "tag": "div", "text_raw": "In October 2017, certain United States service members and their families brought a complaint against a number of pharmaceutical and medical devices companies, including Johnson & Johnson and certain of its subsidiaries in United States District Court for the District of Columbia, alleging that the defendants violated the United States Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health. In July 2020, the District Court dismissed the complaint. In January 2022, the United States Court of Appeals for the District of Columbia Circuit reversed the District Courts decision. In June 2023, defendants filed a petition for a writ of certiorari to the United States Supreme Court.", "text": "The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health.", "length": 207, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 989, "tag": "div", "text_raw": "In October 2017, certain United States service members and their families brought a complaint against a number of pharmaceutical and medical devices companies, including Johnson & Johnson and certain of its subsidiaries in United States District Court for the District of Columbia, alleging that the defendants violated the United States Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health. In July 2020, the District Court dismissed the complaint. In January 2022, the United States Court of Appeals for the District of Columbia Circuit reversed the District Courts decision. In June 2023, defendants filed a petition for a writ of certiorari to the United States Supreme Court.", "text": "In July 2020, the District Court dismissed the complaint.", "length": 57, "numbers_raw": ["202", "0"], "numbers": [202.0, 0.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 989, "tag": "div", "text_raw": "In October 2017, certain United States service members and their families brought a complaint against a number of pharmaceutical and medical devices companies, including Johnson & Johnson and certain of its subsidiaries in United States District Court for the District of Columbia, alleging that the defendants violated the United States Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health. In July 2020, the District Court dismissed the complaint. In January 2022, the United States Court of Appeals for the District of Columbia Circuit reversed the District Courts decision. In June 2023, defendants filed a petition for a writ of certiorari to the United States Supreme Court.", "text": "In January 2022, the United States Court of Appeals for the District of Columbia Circuit reversed the District Courts decision.", "length": 128, "numbers_raw": ["202", "2"], "numbers": [202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 989, "tag": "div", "text_raw": "In October 2017, certain United States service members and their families brought a complaint against a number of pharmaceutical and medical devices companies, including Johnson & Johnson and certain of its subsidiaries in United States District Court for the District of Columbia, alleging that the defendants violated the United States Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health. In July 2020, the District Court dismissed the complaint. In January 2022, the United States Court of Appeals for the District of Columbia Circuit reversed the District Courts decision. In June 2023, defendants filed a petition for a writ of certiorari to the United States Supreme Court.", "text": "In June 2023, defendants filed a petition for a writ of certiorari to the United States Supreme Court.", "length": 102, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 991, "tag": "div", "text_raw": "37", "text": "37", "length": 2, "numbers_raw": ["37"], "numbers": [37.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 992, "tag": "div", "text_raw": "37", "text": "37", "length": 2, "numbers_raw": ["37"], "numbers": [37.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 993, "tag": "div", "text_raw": "37", "text": "37", "length": 2, "numbers_raw": ["37"], "numbers": [37.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 998, "tag": "div", "text_raw": "In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against the Company, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware. The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicons acquisition of Auris in 2019. The complaint seeks damages and other relief. In December 2021, the Court granted in part and denied in part defendants motion to dismiss certain causes of action. All claims against the individual defendants were dismissed. The trial is scheduled for January 2024.", "text": "In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc.", "length": 128, "numbers_raw": ["202", "0"], "numbers": [202.0, 0.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 998, "tag": "div", "text_raw": "In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against the Company, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware. The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicons acquisition of Auris in 2019. The complaint seeks damages and other relief. In December 2021, the Court granted in part and denied in part defendants motion to dismiss certain causes of action. All claims against the individual defendants were dismissed. The trial is scheduled for January 2024.", "text": "(Auris), filed a complaint against the Company, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware.", "length": 177, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 998, "tag": "div", "text_raw": "In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against the Company, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware. The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicons acquisition of Auris in 2019. The complaint seeks damages and other relief. In December 2021, the Court granted in part and denied in part defendants motion to dismiss certain causes of action. All claims against the individual defendants were dismissed. The trial is scheduled for January 2024.", "text": "The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicons acquisition of Auris in 2019.", "length": 150, "numbers_raw": ["201", "9"], "numbers": [201.0, 9.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 998, "tag": "div", "text_raw": "In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against the Company, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware. The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicons acquisition of Auris in 2019. The complaint seeks damages and other relief. In December 2021, the Court granted in part and denied in part defendants motion to dismiss certain causes of action. All claims against the individual defendants were dismissed. The trial is scheduled for January 2024.", "text": "The complaint seeks damages and other relief.", "length": 45, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 998, "tag": "div", "text_raw": "In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against the Company, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware. The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicons acquisition of Auris in 2019. The complaint seeks damages and other relief. In December 2021, the Court granted in part and denied in part defendants motion to dismiss certain causes of action. All claims against the individual defendants were dismissed. The trial is scheduled for January 2024.", "text": "In December 2021, the Court granted in part and denied in part defendants motion to dismiss certain causes of action.", "length": 118, "numbers_raw": ["202", "1"], "numbers": [202.0, 1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 998, "tag": "div", "text_raw": "In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against the Company, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware. The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicons acquisition of Auris in 2019. The complaint seeks damages and other relief. In December 2021, the Court granted in part and denied in part defendants motion to dismiss certain causes of action. All claims against the individual defendants were dismissed. The trial is scheduled for January 2024.", "text": "All claims against the individual defendants were dismissed.", "length": 60, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 998, "tag": "div", "text_raw": "In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against the Company, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware. The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicons acquisition of Auris in 2019. The complaint seeks damages and other relief. In December 2021, the Court granted in part and denied in part defendants motion to dismiss certain causes of action. All claims against the individual defendants were dismissed. The trial is scheduled for January 2024.", "text": "The trial is scheduled for January 2024.", "length": 40, "numbers_raw": ["202", "4"], "numbers": [202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1002, "tag": "div", "text_raw": "In June 2019, the United States Federal Trade Commission (FTC) issued a Civil Investigative Demand to the Company and Janssen Biotech, Inc. (collectively, Janssen) in connection with its investigation of whether Janssens REMICADE contracting practices violate federal antitrust laws. The Company has produced documents and information responsive to the Civil Investigative Demand. Janssen is in ongoing discussions with the FTC staff regarding its inquiry.", "text": "In June 2019, the United States Federal Trade Commission (FTC) issued a Civil Investigative Demand to the Company and Janssen Biotech, Inc.", "length": 139, "numbers_raw": ["201", "9"], "numbers": [201.0, 9.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1002, "tag": "div", "text_raw": "In June 2019, the United States Federal Trade Commission (FTC) issued a Civil Investigative Demand to the Company and Janssen Biotech, Inc. (collectively, Janssen) in connection with its investigation of whether Janssens REMICADE contracting practices violate federal antitrust laws. The Company has produced documents and information responsive to the Civil Investigative Demand. Janssen is in ongoing discussions with the FTC staff regarding its inquiry.", "text": "(collectively, Janssen) in connection with its investigation of whether Janssens REMICADE contracting practices violate federal antitrust laws.", "length": 144, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1002, "tag": "div", "text_raw": "In June 2019, the United States Federal Trade Commission (FTC) issued a Civil Investigative Demand to the Company and Janssen Biotech, Inc. (collectively, Janssen) in connection with its investigation of whether Janssens REMICADE contracting practices violate federal antitrust laws. The Company has produced documents and information responsive to the Civil Investigative Demand. Janssen is in ongoing discussions with the FTC staff regarding its inquiry.", "text": "The Company has produced documents and information responsive to the Civil Investigative Demand.", "length": 96, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1002, "tag": "div", "text_raw": "In June 2019, the United States Federal Trade Commission (FTC) issued a Civil Investigative Demand to the Company and Janssen Biotech, Inc. (collectively, Janssen) in connection with its investigation of whether Janssens REMICADE contracting practices violate federal antitrust laws. The Company has produced documents and information responsive to the Civil Investigative Demand. Janssen is in ongoing discussions with the FTC staff regarding its inquiry.", "text": "Janssen is in ongoing discussions with the FTC staff regarding its inquiry.", "length": 75, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1004, "tag": "div", "text_raw": "In February 2022, the United States Federal Trade Commission (FTC) issued Civil Investigative Demands to Johnson & Johnson and Janssen Biotech, Inc. (collectively, Janssen) in connection with its investigation of whether advertising practices for REMICADE violate federal law. Janssen has produced documents and information responsive to the Civil Investigative Demands. Janssen is in ongoing discussions with the FTC staff regarding the inquiry.", "text": "In February 2022, the United States Federal Trade Commission (FTC) issued Civil Investigative Demands to Johnson & Johnson and Janssen Biotech, Inc.", "length": 148, "numbers_raw": ["202", "2"], "numbers": [202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1004, "tag": "div", "text_raw": "In February 2022, the United States Federal Trade Commission (FTC) issued Civil Investigative Demands to Johnson & Johnson and Janssen Biotech, Inc. (collectively, Janssen) in connection with its investigation of whether advertising practices for REMICADE violate federal law. Janssen has produced documents and information responsive to the Civil Investigative Demands. Janssen is in ongoing discussions with the FTC staff regarding the inquiry.", "text": "(collectively, Janssen) in connection with its investigation of whether advertising practices for REMICADE violate federal law.", "length": 127, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1004, "tag": "div", "text_raw": "In February 2022, the United States Federal Trade Commission (FTC) issued Civil Investigative Demands to Johnson & Johnson and Janssen Biotech, Inc. (collectively, Janssen) in connection with its investigation of whether advertising practices for REMICADE violate federal law. Janssen has produced documents and information responsive to the Civil Investigative Demands. Janssen is in ongoing discussions with the FTC staff regarding the inquiry.", "text": "Janssen has produced documents and information responsive to the Civil Investigative Demands.", "length": 93, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1004, "tag": "div", "text_raw": "In February 2022, the United States Federal Trade Commission (FTC) issued Civil Investigative Demands to Johnson & Johnson and Janssen Biotech, Inc. (collectively, Janssen) in connection with its investigation of whether advertising practices for REMICADE violate federal law. Janssen has produced documents and information responsive to the Civil Investigative Demands. Janssen is in ongoing discussions with the FTC staff regarding the inquiry.", "text": "Janssen is in ongoing discussions with the FTC staff regarding the inquiry.", "length": 75, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1006, "tag": "div", "text_raw": "In June 2022, Genmab A/S filed a Notice for Arbitration with International Institute for Conflict Prevention and Resolution (CPR) against Janssen Biotech, Inc. seeking milestones and an extended royalty term for Darzalex FASPRO. In April 2023, the Arbitration Panel ruled in Janssen's favor and dismissed Genmab's claims. Genmab appealed that award and oral arguments are scheduled for November 2023.", "text": "In June 2022, Genmab A/S filed a Notice for Arbitration with International Institute for Conflict Prevention and Resolution (CPR) against Janssen Biotech, Inc.", "length": 159, "numbers_raw": ["202", "2"], "numbers": [202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1006, "tag": "div", "text_raw": "In June 2022, Genmab A/S filed a Notice for Arbitration with International Institute for Conflict Prevention and Resolution (CPR) against Janssen Biotech, Inc. seeking milestones and an extended royalty term for Darzalex FASPRO. In April 2023, the Arbitration Panel ruled in Janssen's favor and dismissed Genmab's claims. Genmab appealed that award and oral arguments are scheduled for November 2023.", "text": "seeking milestones and an extended royalty term for Darzalex FASPRO.", "length": 68, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1006, "tag": "div", "text_raw": "In June 2022, Genmab A/S filed a Notice for Arbitration with International Institute for Conflict Prevention and Resolution (CPR) against Janssen Biotech, Inc. seeking milestones and an extended royalty term for Darzalex FASPRO. In April 2023, the Arbitration Panel ruled in Janssen's favor and dismissed Genmab's claims. Genmab appealed that award and oral arguments are scheduled for November 2023.", "text": "In April 2023, the Arbitration Panel ruled in Janssen's favor and dismissed Genmab's claims.", "length": 92, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1006, "tag": "div", "text_raw": "In June 2022, Genmab A/S filed a Notice for Arbitration with International Institute for Conflict Prevention and Resolution (CPR) against Janssen Biotech, Inc. seeking milestones and an extended royalty term for Darzalex FASPRO. In April 2023, the Arbitration Panel ruled in Janssen's favor and dismissed Genmab's claims. Genmab appealed that award and oral arguments are scheduled for November 2023.", "text": "Genmab appealed that award and oral arguments are scheduled for November 2023.", "length": 78, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1008, "tag": "div", "text_raw": "In October 2018, two separate putative class actions were filed against Actelion Pharmaceutical Ltd., Actelion Pharmaceuticals U.S., Inc., and Actelion Clinical Research, Inc. (collectively Actelion) in United States District Court for the District of Maryland and United States District Court for the District of Columbia. The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with samples of TRACLEER. TRACLEER is subject to a Risk Evaluation and Mitigation Strategy required by the U.S. Food and Drug Administration, which imposes restrictions on distribution of the product. In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland.", "text": "In October 2018, two separate putative class actions were filed against Actelion Pharmaceutical Ltd., Actelion Pharmaceuticals U.S., Inc., and Actelion Clinical Research, Inc.", "length": 175, "numbers_raw": ["201", "8"], "numbers": [201.0, 8.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1008, "tag": "div", "text_raw": "In October 2018, two separate putative class actions were filed against Actelion Pharmaceutical Ltd., Actelion Pharmaceuticals U.S., Inc., and Actelion Clinical Research, Inc. (collectively Actelion) in United States District Court for the District of Maryland and United States District Court for the District of Columbia. The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with samples of TRACLEER. TRACLEER is subject to a Risk Evaluation and Mitigation Strategy required by the U.S. Food and Drug Administration, which imposes restrictions on distribution of the product. In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland.", "text": "(collectively Actelion) in United States District Court for the District of Maryland and United States District Court for the District of Columbia.", "length": 147, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1008, "tag": "div", "text_raw": "In October 2018, two separate putative class actions were filed against Actelion Pharmaceutical Ltd., Actelion Pharmaceuticals U.S., Inc., and Actelion Clinical Research, Inc. (collectively Actelion) in United States District Court for the District of Maryland and United States District Court for the District of Columbia. The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with samples of TRACLEER. TRACLEER is subject to a Risk Evaluation and Mitigation Strategy required by the U.S. Food and Drug Administration, which imposes restrictions on distribution of the product. In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland.", "text": "The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with samples of TRACLEER.", "length": 195, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1008, "tag": "div", "text_raw": "In October 2018, two separate putative class actions were filed against Actelion Pharmaceutical Ltd., Actelion Pharmaceuticals U.S., Inc., and Actelion Clinical Research, Inc. (collectively Actelion) in United States District Court for the District of Maryland and United States District Court for the District of Columbia. The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with samples of TRACLEER. TRACLEER is subject to a Risk Evaluation and Mitigation Strategy required by the U.S. Food and Drug Administration, which imposes restrictions on distribution of the product. In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland.", "text": "TRACLEER is subject to a Risk Evaluation and Mitigation Strategy required by the U.S.", "length": 85, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1008, "tag": "div", "text_raw": "In October 2018, two separate putative class actions were filed against Actelion Pharmaceutical Ltd., Actelion Pharmaceuticals U.S., Inc., and Actelion Clinical Research, Inc. (collectively Actelion) in United States District Court for the District of Maryland and United States District Court for the District of Columbia. The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with samples of TRACLEER. TRACLEER is subject to a Risk Evaluation and Mitigation Strategy required by the U.S. Food and Drug Administration, which imposes restrictions on distribution of the product. In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland.", "text": "Food and Drug Administration, which imposes restrictions on distribution of the product.", "length": 88, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1008, "tag": "div", "text_raw": "In October 2018, two separate putative class actions were filed against Actelion Pharmaceutical Ltd., Actelion Pharmaceuticals U.S., Inc., and Actelion Clinical Research, Inc. (collectively Actelion) in United States District Court for the District of Maryland and United States District Court for the District of Columbia. The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with samples of TRACLEER. TRACLEER is subject to a Risk Evaluation and Mitigation Strategy required by the U.S. Food and Drug Administration, which imposes restrictions on distribution of the product. In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland.", "text": "In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland.", "length": 172, "numbers_raw": ["201", "9"], "numbers": [201.0, 9.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1010, "tag": "div", "text_raw": "In June 2022, Janssen Pharmaceuticals, Inc. filed a Demand for Arbitration against Emergent Biosolutions Inc. et al (EBSI) with the American Arbitration Association, alleging that EBSI breached the parties Manufacturing Services Agreement for the Companys COVID-19 vaccine. In July 2022, Emergent filed its answering statement and counterclaims. The hearing is scheduled for July 2024.", "text": "In June 2022, Janssen Pharmaceuticals, Inc.", "length": 43, "numbers_raw": ["202", "2"], "numbers": [202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1010, "tag": "div", "text_raw": "In June 2022, Janssen Pharmaceuticals, Inc. filed a Demand for Arbitration against Emergent Biosolutions Inc. et al (EBSI) with the American Arbitration Association, alleging that EBSI breached the parties Manufacturing Services Agreement for the Companys COVID-19 vaccine. In July 2022, Emergent filed its answering statement and counterclaims. The hearing is scheduled for July 2024.", "text": "filed a Demand for Arbitration against Emergent Biosolutions Inc.", "length": 65, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1010, "tag": "div", "text_raw": "In June 2022, Janssen Pharmaceuticals, Inc. filed a Demand for Arbitration against Emergent Biosolutions Inc. et al (EBSI) with the American Arbitration Association, alleging that EBSI breached the parties Manufacturing Services Agreement for the Companys COVID-19 vaccine. In July 2022, Emergent filed its answering statement and counterclaims. The hearing is scheduled for July 2024.", "text": "et al (EBSI) with the American Arbitration Association, alleging that EBSI breached the parties Manufacturing Services Agreement for the Companys COVID-19 vaccine.", "length": 165, "numbers_raw": ["19"], "numbers": [19.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1010, "tag": "div", "text_raw": "In June 2022, Janssen Pharmaceuticals, Inc. filed a Demand for Arbitration against Emergent Biosolutions Inc. et al (EBSI) with the American Arbitration Association, alleging that EBSI breached the parties Manufacturing Services Agreement for the Companys COVID-19 vaccine. In July 2022, Emergent filed its answering statement and counterclaims. The hearing is scheduled for July 2024.", "text": "In July 2022, Emergent filed its answering statement and counterclaims.", "length": 71, "numbers_raw": ["202", "2"], "numbers": [202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1010, "tag": "div", "text_raw": "In June 2022, Janssen Pharmaceuticals, Inc. filed a Demand for Arbitration against Emergent Biosolutions Inc. et al (EBSI) with the American Arbitration Association, alleging that EBSI breached the parties Manufacturing Services Agreement for the Companys COVID-19 vaccine. In July 2022, Emergent filed its answering statement and counterclaims. The hearing is scheduled for July 2024.", "text": "The hearing is scheduled for July 2024.", "length": 39, "numbers_raw": ["202", "4"], "numbers": [202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1012, "tag": "div", "text_raw": "38", "text": "38", "length": 2, "numbers_raw": ["38"], "numbers": [38.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1013, "tag": "div", "text_raw": "38", "text": "38", "length": 2, "numbers_raw": ["38"], "numbers": [38.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1014, "tag": "div", "text_raw": "38", "text": "38", "length": 2, "numbers_raw": ["38"], "numbers": [38.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1019, "tag": "div", "text_raw": "NOTE 12 KENVUE SEPARATION", "text": "NOTE 12 KENVUE SEPARATION", "length": 26, "numbers_raw": ["12"], "numbers": [12.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1021, "tag": "div", "text_raw": "On May 8, 2023, Kenvue, completed an initial public offering (the IPO) resulting in the issuance of 198,734,444 shares of its common stock, par value $ 0.01 per share (the Kenvue Common Stock), at an initial public offering of $ 22.00 per share for net proceeds of $ 4.2 billion. The excess of the net proceeds from the IPO over the net book value of the Johnson & Johnson divested interest was $ 2.5 billion and was recorded to additional paid-in capital. As of the closing of the IPO, Johnson & Johnson owned approximately 89.6 % of the total outstanding shares of Kenvue Common Stock and at July 2, 2023, the non-controlling interest of $ 1.3 billion associated with Kenvue was reflected in equity attributable to non-controlling interests in the consolidated balance sheet in the fiscal second quarter.", "text": "On May 8, 2023, Kenvue, completed an initial public offering (the IPO) resulting in the issuance of 198,734,444 shares of its common stock, par value $ 0.01 per share (the Kenvue Common Stock), at an initial public offering of $ 22.00 per share for net proceeds of $ 4.2 billion.", "length": 281, "numbers_raw": ["8", "202", "3", "198,734,444", "0.01", "22.00", "4.2 billion"], "numbers": [8.0, 202.0, 3.0, 198734444.0, 0.01, 22.0, 4200000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1021, "tag": "div", "text_raw": "On May 8, 2023, Kenvue, completed an initial public offering (the IPO) resulting in the issuance of 198,734,444 shares of its common stock, par value $ 0.01 per share (the Kenvue Common Stock), at an initial public offering of $ 22.00 per share for net proceeds of $ 4.2 billion. The excess of the net proceeds from the IPO over the net book value of the Johnson & Johnson divested interest was $ 2.5 billion and was recorded to additional paid-in capital. As of the closing of the IPO, Johnson & Johnson owned approximately 89.6 % of the total outstanding shares of Kenvue Common Stock and at July 2, 2023, the non-controlling interest of $ 1.3 billion associated with Kenvue was reflected in equity attributable to non-controlling interests in the consolidated balance sheet in the fiscal second quarter.", "text": "The excess of the net proceeds from the IPO over the net book value of the Johnson & Johnson divested interest was $ 2.5 billion and was recorded to additional paid-in capital.", "length": 176, "numbers_raw": ["2.5 billion"], "numbers": [2500000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1021, "tag": "div", "text_raw": "On May 8, 2023, Kenvue, completed an initial public offering (the IPO) resulting in the issuance of 198,734,444 shares of its common stock, par value $ 0.01 per share (the Kenvue Common Stock), at an initial public offering of $ 22.00 per share for net proceeds of $ 4.2 billion. The excess of the net proceeds from the IPO over the net book value of the Johnson & Johnson divested interest was $ 2.5 billion and was recorded to additional paid-in capital. As of the closing of the IPO, Johnson & Johnson owned approximately 89.6 % of the total outstanding shares of Kenvue Common Stock and at July 2, 2023, the non-controlling interest of $ 1.3 billion associated with Kenvue was reflected in equity attributable to non-controlling interests in the consolidated balance sheet in the fiscal second quarter.", "text": "As of the closing of the IPO, Johnson & Johnson owned approximately 89.6 % of the total outstanding shares of Kenvue Common Stock and at July 2, 2023, the non-controlling interest of $ 1.3 billion associated with Kenvue was reflected in equity attributable to non-controlling interests in the consolidated balance sheet in the fiscal second quarter.", "length": 349, "numbers_raw": ["89.6", "2", "202", "3", "1.3 billion"], "numbers": [89.6, 2.0, 202.0, 3.0, 1300000000.0], "percents_raw": ["89.6 %"], "percents": [0.8959999999999999], "currencies": ["USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 1023, "tag": "div", "text_raw": "On August 23, 2023, Johnson & Johnson completed the disposition of an additional 80.1 % ownership of Kenvue Common Stock through an exchange offer, which resulted in Johnson & Johnson acquiring 190,955,436 shares of the Companys common stock in exchange for 1,533,830,450 shares of Kenvue Common Stock. The $ 31.4 billion of Johnson & Johnson common stock received in the exchange offer is recorded in Treasury stock. Following the exchange offer, the Company owns 9.5 % of the total outstanding shares of Kenvue Common Stock that was recorded in other assets within continuing operations at the fair market value of $ 4.3 billion as of August 23, 2023.", "text": "On August 23, 2023, Johnson & Johnson completed the disposition of an additional 80.1 % ownership of Kenvue Common Stock through an exchange offer, which resulted in Johnson & Johnson acquiring 190,955,436 shares of the Companys common stock in exchange for 1,533,830,450 shares of Kenvue Common Stock.", "length": 303, "numbers_raw": ["23", "202", "3", "80.1", "190,955,436", "1,533,830,450"], "numbers": [23.0, 202.0, 3.0, 80.1, 190955436.0, 1533830450.0], "percents_raw": ["80.1 %"], "percents": [0.8009999999999999], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1023, "tag": "div", "text_raw": "On August 23, 2023, Johnson & Johnson completed the disposition of an additional 80.1 % ownership of Kenvue Common Stock through an exchange offer, which resulted in Johnson & Johnson acquiring 190,955,436 shares of the Companys common stock in exchange for 1,533,830,450 shares of Kenvue Common Stock. The $ 31.4 billion of Johnson & Johnson common stock received in the exchange offer is recorded in Treasury stock. Following the exchange offer, the Company owns 9.5 % of the total outstanding shares of Kenvue Common Stock that was recorded in other assets within continuing operations at the fair market value of $ 4.3 billion as of August 23, 2023.", "text": "The $ 31.4 billion of Johnson & Johnson common stock received in the exchange offer is recorded in Treasury stock.", "length": 114, "numbers_raw": ["31.4 billion"], "numbers": [31400000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1023, "tag": "div", "text_raw": "On August 23, 2023, Johnson & Johnson completed the disposition of an additional 80.1 % ownership of Kenvue Common Stock through an exchange offer, which resulted in Johnson & Johnson acquiring 190,955,436 shares of the Companys common stock in exchange for 1,533,830,450 shares of Kenvue Common Stock. The $ 31.4 billion of Johnson & Johnson common stock received in the exchange offer is recorded in Treasury stock. Following the exchange offer, the Company owns 9.5 % of the total outstanding shares of Kenvue Common Stock that was recorded in other assets within continuing operations at the fair market value of $ 4.3 billion as of August 23, 2023.", "text": "Following the exchange offer, the Company owns 9.5 % of the total outstanding shares of Kenvue Common Stock that was recorded in other assets within continuing operations at the fair market value of $ 4.3 billion as of August 23, 2023.", "length": 235, "numbers_raw": ["9.5", "4.3 billion", "23", "202", "3"], "numbers": [9.5, 4300000000.0, 23.0, 202.0, 3.0], "percents_raw": ["9.5 %"], "percents": [0.095], "currencies": ["USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 1025, "tag": "div", "text_raw": "Johnson & Johnson divested net assets of $ 11.6 billion as of August 23, 2023, and the accumulated other comprehensive loss attributable to the Consumer Health business at that date was $ 4.3 billion. Additionally, at the date of the exchange offer, Johnson & Johnson decreased the non-controlling interest by $ 1.2 billion to record the deconsolidation of Kenvue. This resulted in a non-cash gain on the exchange offer of $ 21.0 billion that was recorded in Net earnings from discontinued operations, net of taxes in the consolidated statements of earnings for the fiscal third quarter of 2023. This one-time gain includes a gain of $ 2.8 billion on the Kenvue Common Stock retained by Johnson & Johnson. The gain on the exchange offer qualifies as a tax-free transaction for U.S. federal income tax purposes.", "text": "Johnson & Johnson divested net assets of $ 11.6 billion as of August 23, 2023, and the accumulated other comprehensive loss attributable to the Consumer Health business at that date was $ 4.3 billion.", "length": 200, "numbers_raw": ["11.6 billion", "23", "202", "3", "4.3 billion"], "numbers": [11600000000.0, 23.0, 202.0, 3.0, 4300000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1025, "tag": "div", "text_raw": "Johnson & Johnson divested net assets of $ 11.6 billion as of August 23, 2023, and the accumulated other comprehensive loss attributable to the Consumer Health business at that date was $ 4.3 billion. Additionally, at the date of the exchange offer, Johnson & Johnson decreased the non-controlling interest by $ 1.2 billion to record the deconsolidation of Kenvue. This resulted in a non-cash gain on the exchange offer of $ 21.0 billion that was recorded in Net earnings from discontinued operations, net of taxes in the consolidated statements of earnings for the fiscal third quarter of 2023. This one-time gain includes a gain of $ 2.8 billion on the Kenvue Common Stock retained by Johnson & Johnson. The gain on the exchange offer qualifies as a tax-free transaction for U.S. federal income tax purposes.", "text": "Additionally, at the date of the exchange offer, Johnson & Johnson decreased the non-controlling interest by $ 1.2 billion to record the deconsolidation of Kenvue.", "length": 163, "numbers_raw": ["1.2 billion"], "numbers": [1200000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1025, "tag": "div", "text_raw": "Johnson & Johnson divested net assets of $ 11.6 billion as of August 23, 2023, and the accumulated other comprehensive loss attributable to the Consumer Health business at that date was $ 4.3 billion. Additionally, at the date of the exchange offer, Johnson & Johnson decreased the non-controlling interest by $ 1.2 billion to record the deconsolidation of Kenvue. This resulted in a non-cash gain on the exchange offer of $ 21.0 billion that was recorded in Net earnings from discontinued operations, net of taxes in the consolidated statements of earnings for the fiscal third quarter of 2023. This one-time gain includes a gain of $ 2.8 billion on the Kenvue Common Stock retained by Johnson & Johnson. The gain on the exchange offer qualifies as a tax-free transaction for U.S. federal income tax purposes.", "text": "This resulted in a non-cash gain on the exchange offer of $ 21.0 billion that was recorded in Net earnings from discontinued operations, net of taxes in the consolidated statements of earnings for the fiscal third quarter of 2023.", "length": 230, "numbers_raw": ["21.0 billion", "202", "3"], "numbers": [21000000000.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1025, "tag": "div", "text_raw": "Johnson & Johnson divested net assets of $ 11.6 billion as of August 23, 2023, and the accumulated other comprehensive loss attributable to the Consumer Health business at that date was $ 4.3 billion. Additionally, at the date of the exchange offer, Johnson & Johnson decreased the non-controlling interest by $ 1.2 billion to record the deconsolidation of Kenvue. This resulted in a non-cash gain on the exchange offer of $ 21.0 billion that was recorded in Net earnings from discontinued operations, net of taxes in the consolidated statements of earnings for the fiscal third quarter of 2023. This one-time gain includes a gain of $ 2.8 billion on the Kenvue Common Stock retained by Johnson & Johnson. The gain on the exchange offer qualifies as a tax-free transaction for U.S. federal income tax purposes.", "text": "This one-time gain includes a gain of $ 2.8 billion on the Kenvue Common Stock retained by Johnson & Johnson.", "length": 109, "numbers_raw": ["2.8 billion"], "numbers": [2800000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1025, "tag": "div", "text_raw": "Johnson & Johnson divested net assets of $ 11.6 billion as of August 23, 2023, and the accumulated other comprehensive loss attributable to the Consumer Health business at that date was $ 4.3 billion. Additionally, at the date of the exchange offer, Johnson & Johnson decreased the non-controlling interest by $ 1.2 billion to record the deconsolidation of Kenvue. This resulted in a non-cash gain on the exchange offer of $ 21.0 billion that was recorded in Net earnings from discontinued operations, net of taxes in the consolidated statements of earnings for the fiscal third quarter of 2023. This one-time gain includes a gain of $ 2.8 billion on the Kenvue Common Stock retained by Johnson & Johnson. The gain on the exchange offer qualifies as a tax-free transaction for U.S. federal income tax purposes.", "text": "The gain on the exchange offer qualifies as a tax-free transaction for U.S.", "length": 75, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1027, "tag": "div", "text_raw": "Also in connection with the separation, Johnson & Johnson and Kenvue entered into a separation agreement and also entered into various other agreements that provide for certain transactions to effect the transfer of the assets and liabilities of the Consumer Health business to Kenvue and to govern various interim and ongoing relationships between Kenvue and Johnson & Johnson following the completion of the Kenvue IPO, including transition services agreements (TSAs), transition manufacturing agreements (TMAs), trademark agreements, intellectual property agreements, an employee matters agreement, and a tax matters agreement. Under the TSAs, Johnson & Johnson will provide Kenvue various services and, similarly, Kenvue will provide Johnson & Johnson various services. The provision of services under the TSAs generally will terminate within 24 months following the Kenvue IPO. Additionally, Johnson & Johnson and Kenvue entered into TMAs pursuant to which Johnson & Johnson will manufacture and supply to Kenvue certain products and, similarly, Kenvue will manufacture and supply to Johnson & Johnson certain products. The terms of the TMAs range in initial duration from 3 months to 5 years.", "text": "Also in connection with the separation, Johnson & Johnson and Kenvue entered into a separation agreement and also entered into various other agreements that provide for certain transactions to effect the transfer of the assets and liabilities of the Consumer Health business to Kenvue and to govern various interim and ongoing relationships between Kenvue and Johnson & Johnson following the completion of the Kenvue IPO, including transition services agreements (TSAs), transition manufacturing agreements (TMAs), trademark agreements, intellectual property agreements, an employee matters agreement, and a tax matters agreement.", "length": 630, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1027, "tag": "div", "text_raw": "Also in connection with the separation, Johnson & Johnson and Kenvue entered into a separation agreement and also entered into various other agreements that provide for certain transactions to effect the transfer of the assets and liabilities of the Consumer Health business to Kenvue and to govern various interim and ongoing relationships between Kenvue and Johnson & Johnson following the completion of the Kenvue IPO, including transition services agreements (TSAs), transition manufacturing agreements (TMAs), trademark agreements, intellectual property agreements, an employee matters agreement, and a tax matters agreement. Under the TSAs, Johnson & Johnson will provide Kenvue various services and, similarly, Kenvue will provide Johnson & Johnson various services. The provision of services under the TSAs generally will terminate within 24 months following the Kenvue IPO. Additionally, Johnson & Johnson and Kenvue entered into TMAs pursuant to which Johnson & Johnson will manufacture and supply to Kenvue certain products and, similarly, Kenvue will manufacture and supply to Johnson & Johnson certain products. The terms of the TMAs range in initial duration from 3 months to 5 years.", "text": "Under the TSAs, Johnson & Johnson will provide Kenvue various services and, similarly, Kenvue will provide Johnson & Johnson various services.", "length": 142, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1027, "tag": "div", "text_raw": "Also in connection with the separation, Johnson & Johnson and Kenvue entered into a separation agreement and also entered into various other agreements that provide for certain transactions to effect the transfer of the assets and liabilities of the Consumer Health business to Kenvue and to govern various interim and ongoing relationships between Kenvue and Johnson & Johnson following the completion of the Kenvue IPO, including transition services agreements (TSAs), transition manufacturing agreements (TMAs), trademark agreements, intellectual property agreements, an employee matters agreement, and a tax matters agreement. Under the TSAs, Johnson & Johnson will provide Kenvue various services and, similarly, Kenvue will provide Johnson & Johnson various services. The provision of services under the TSAs generally will terminate within 24 months following the Kenvue IPO. Additionally, Johnson & Johnson and Kenvue entered into TMAs pursuant to which Johnson & Johnson will manufacture and supply to Kenvue certain products and, similarly, Kenvue will manufacture and supply to Johnson & Johnson certain products. The terms of the TMAs range in initial duration from 3 months to 5 years.", "text": "The provision of services under the TSAs generally will terminate within 24 months following the Kenvue IPO.", "length": 108, "numbers_raw": ["24 m"], "numbers": [24000000.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1027, "tag": "div", "text_raw": "Also in connection with the separation, Johnson & Johnson and Kenvue entered into a separation agreement and also entered into various other agreements that provide for certain transactions to effect the transfer of the assets and liabilities of the Consumer Health business to Kenvue and to govern various interim and ongoing relationships between Kenvue and Johnson & Johnson following the completion of the Kenvue IPO, including transition services agreements (TSAs), transition manufacturing agreements (TMAs), trademark agreements, intellectual property agreements, an employee matters agreement, and a tax matters agreement. Under the TSAs, Johnson & Johnson will provide Kenvue various services and, similarly, Kenvue will provide Johnson & Johnson various services. The provision of services under the TSAs generally will terminate within 24 months following the Kenvue IPO. Additionally, Johnson & Johnson and Kenvue entered into TMAs pursuant to which Johnson & Johnson will manufacture and supply to Kenvue certain products and, similarly, Kenvue will manufacture and supply to Johnson & Johnson certain products. The terms of the TMAs range in initial duration from 3 months to 5 years.", "text": "Additionally, Johnson & Johnson and Kenvue entered into TMAs pursuant to which Johnson & Johnson will manufacture and supply to Kenvue certain products and, similarly, Kenvue will manufacture and supply to Johnson & Johnson certain products.", "length": 241, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1027, "tag": "div", "text_raw": "Also in connection with the separation, Johnson & Johnson and Kenvue entered into a separation agreement and also entered into various other agreements that provide for certain transactions to effect the transfer of the assets and liabilities of the Consumer Health business to Kenvue and to govern various interim and ongoing relationships between Kenvue and Johnson & Johnson following the completion of the Kenvue IPO, including transition services agreements (TSAs), transition manufacturing agreements (TMAs), trademark agreements, intellectual property agreements, an employee matters agreement, and a tax matters agreement. Under the TSAs, Johnson & Johnson will provide Kenvue various services and, similarly, Kenvue will provide Johnson & Johnson various services. The provision of services under the TSAs generally will terminate within 24 months following the Kenvue IPO. Additionally, Johnson & Johnson and Kenvue entered into TMAs pursuant to which Johnson & Johnson will manufacture and supply to Kenvue certain products and, similarly, Kenvue will manufacture and supply to Johnson & Johnson certain products. The terms of the TMAs range in initial duration from 3 months to 5 years.", "text": "The terms of the TMAs range in initial duration from 3 months to 5 years.", "length": 73, "numbers_raw": ["3 m", "5"], "numbers": [3000000.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1029, "tag": "div", "text_raw": "Amounts related to the TSAs and TMAs included in the consolidated statements of earnings were immaterial for the fiscal third quarter and fiscal nine months ended October 1, 2023. Additionally, the amounts due to and from Kenvue for the above agreements was not material as of October 1, 2023.", "text": "Amounts related to the TSAs and TMAs included in the consolidated statements of earnings were immaterial for the fiscal third quarter and fiscal nine months ended October 1, 2023.", "length": 179, "numbers_raw": ["1", "202", "3"], "numbers": [1.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1029, "tag": "div", "text_raw": "Amounts related to the TSAs and TMAs included in the consolidated statements of earnings were immaterial for the fiscal third quarter and fiscal nine months ended October 1, 2023. Additionally, the amounts due to and from Kenvue for the above agreements was not material as of October 1, 2023.", "text": "Additionally, the amounts due to and from Kenvue for the above agreements was not material as of October 1, 2023.", "length": 113, "numbers_raw": ["1", "202", "3"], "numbers": [1.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1031, "tag": "div", "text_raw": "The results of the Consumer Health business (previously reported as a separate business segment), as well as the associated gain, have been reflected as discontinued operations in the Companys consolidated statements of earnings as Net earnings from discontinued operations, net of taxes through August 23, 2023, the date of the exchange offer. Prior periods have been recast to reflect this presentation. As a result of the separation of Kenvue, Johnson & Johnson incurred separation costs of $ 330 million and $ 912 million in the fiscal third quarter and fiscal nine months ended October 1, 2023, respectively, and $ 249 million and $ 619 million in the fiscal third quarter and fiscal nine months ended October 2, 2022, respectively, which are also included in Net earnings from discontinued operations, net of taxes. These costs were primarily related to external advisory, legal, accounting, contractor and other incremental costs directly related to separation activities. As of January 1, 2023, the assets and liabilities associated with the Consumer Health business were classified as assets and liabilities of discontinued operations in the consolidated balance sheets.", "text": "The results of the Consumer Health business (previously reported as a separate business segment), as well as the associated gain, have been reflected as discontinued operations in the Companys consolidated statements of earnings as Net earnings from discontinued operations, net of taxes through August 23, 2023, the date of the exchange offer.", "length": 345, "numbers_raw": ["23", "202", "3"], "numbers": [23.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1031, "tag": "div", "text_raw": "The results of the Consumer Health business (previously reported as a separate business segment), as well as the associated gain, have been reflected as discontinued operations in the Companys consolidated statements of earnings as Net earnings from discontinued operations, net of taxes through August 23, 2023, the date of the exchange offer. Prior periods have been recast to reflect this presentation. As a result of the separation of Kenvue, Johnson & Johnson incurred separation costs of $ 330 million and $ 912 million in the fiscal third quarter and fiscal nine months ended October 1, 2023, respectively, and $ 249 million and $ 619 million in the fiscal third quarter and fiscal nine months ended October 2, 2022, respectively, which are also included in Net earnings from discontinued operations, net of taxes. These costs were primarily related to external advisory, legal, accounting, contractor and other incremental costs directly related to separation activities. As of January 1, 2023, the assets and liabilities associated with the Consumer Health business were classified as assets and liabilities of discontinued operations in the consolidated balance sheets.", "text": "Prior periods have been recast to reflect this presentation.", "length": 60, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1031, "tag": "div", "text_raw": "The results of the Consumer Health business (previously reported as a separate business segment), as well as the associated gain, have been reflected as discontinued operations in the Companys consolidated statements of earnings as Net earnings from discontinued operations, net of taxes through August 23, 2023, the date of the exchange offer. Prior periods have been recast to reflect this presentation. As a result of the separation of Kenvue, Johnson & Johnson incurred separation costs of $ 330 million and $ 912 million in the fiscal third quarter and fiscal nine months ended October 1, 2023, respectively, and $ 249 million and $ 619 million in the fiscal third quarter and fiscal nine months ended October 2, 2022, respectively, which are also included in Net earnings from discontinued operations, net of taxes. These costs were primarily related to external advisory, legal, accounting, contractor and other incremental costs directly related to separation activities. As of January 1, 2023, the assets and liabilities associated with the Consumer Health business were classified as assets and liabilities of discontinued operations in the consolidated balance sheets.", "text": "As a result of the separation of Kenvue, Johnson & Johnson incurred separation costs of $ 330 million and $ 912 million in the fiscal third quarter and fiscal nine months ended October 1, 2023, respectively, and $ 249 million and $ 619 million in the fiscal third quarter and fiscal nine months ended October 2, 2022, respectively, which are also included in Net earnings from discontinued operations, net of taxes.", "length": 415, "numbers_raw": ["330 million", "912 million", "1", "202", "3", "249 million", "619 million", "2", "202", "2"], "numbers": [330000000.0, 912000000.0, 1.0, 202.0, 3.0, 249000000.0, 619000000.0, 2.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1031, "tag": "div", "text_raw": "The results of the Consumer Health business (previously reported as a separate business segment), as well as the associated gain, have been reflected as discontinued operations in the Companys consolidated statements of earnings as Net earnings from discontinued operations, net of taxes through August 23, 2023, the date of the exchange offer. Prior periods have been recast to reflect this presentation. As a result of the separation of Kenvue, Johnson & Johnson incurred separation costs of $ 330 million and $ 912 million in the fiscal third quarter and fiscal nine months ended October 1, 2023, respectively, and $ 249 million and $ 619 million in the fiscal third quarter and fiscal nine months ended October 2, 2022, respectively, which are also included in Net earnings from discontinued operations, net of taxes. These costs were primarily related to external advisory, legal, accounting, contractor and other incremental costs directly related to separation activities. As of January 1, 2023, the assets and liabilities associated with the Consumer Health business were classified as assets and liabilities of discontinued operations in the consolidated balance sheets.", "text": "These costs were primarily related to external advisory, legal, accounting, contractor and other incremental costs directly related to separation activities.", "length": 157, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1031, "tag": "div", "text_raw": "The results of the Consumer Health business (previously reported as a separate business segment), as well as the associated gain, have been reflected as discontinued operations in the Companys consolidated statements of earnings as Net earnings from discontinued operations, net of taxes through August 23, 2023, the date of the exchange offer. Prior periods have been recast to reflect this presentation. As a result of the separation of Kenvue, Johnson & Johnson incurred separation costs of $ 330 million and $ 912 million in the fiscal third quarter and fiscal nine months ended October 1, 2023, respectively, and $ 249 million and $ 619 million in the fiscal third quarter and fiscal nine months ended October 2, 2022, respectively, which are also included in Net earnings from discontinued operations, net of taxes. These costs were primarily related to external advisory, legal, accounting, contractor and other incremental costs directly related to separation activities. As of January 1, 2023, the assets and liabilities associated with the Consumer Health business were classified as assets and liabilities of discontinued operations in the consolidated balance sheets.", "text": "As of January 1, 2023, the assets and liabilities associated with the Consumer Health business were classified as assets and liabilities of discontinued operations in the consolidated balance sheets.", "length": 199, "numbers_raw": ["1", "202", "3"], "numbers": [1.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1044, "tag": "div", "text_raw": "39", "text": "39", "length": 2, "numbers_raw": ["39"], "numbers": [39.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1045, "tag": "div", "text_raw": "39", "text": "39", "length": 2, "numbers_raw": ["39"], "numbers": [39.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1046, "tag": "div", "text_raw": "39", "text": "39", "length": 2, "numbers_raw": ["39"], "numbers": [39.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1051, "tag": "div", "text_raw": "Details of Net Earnings from Discontinued Operations, net of taxes are as follows:", "text": "Details of Net Earnings from Discontinued Operations, net of taxes are as follows:", "length": 82, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1053, "tag": "div", "text_raw": "Fiscal Third Quarter Ended Fiscal Nine Months Ended (Dollars in Millions) October 1, 2023 (1) October 2, 2022 October 1, 2023 (1) October 2, 2022 Sales to customers $ 2,173 3,795 10,036 11,186 Cost of products sold 911 1,635 4,369 4,812 Gross profit 1,262 2,160 5,667 6,374 Selling, marketing and administrative expenses 584 1,114 3,085 3,346 Research and development expense 24 112 258 337 Interest Income ( 37 )  ( 117 )  Interest expense, net of portion capitalized (Note 4) 67  199  Other (income) expense, net 406 267 1,018 649 Gain on separation of Kenvue ( 20,984 )  ( 20,984 )  Restructuring  17  37 Earnings from Discontinued Operations Before Provision for Taxes on Income 21,202 650 22,208 2,005 (Benefit from)/Provision for taxes on income (Note 5) ( 517 ) 502 298 727 Net earnings from Discontinued Operations 21,719 148 21,910 1,278", "text": "Fiscal Third Quarter Ended Fiscal Nine Months Ended (Dollars in Millions) October 1, 2023 (1) October 2, 2022 October 1, 2023 (1) October 2, 2022 Sales to customers $ 2,173 3,795 10,036 11,186 Cost of products sold 911 1,635 4,369 4,812 Gross profit 1,262 2,160 5,667 6,374 Selling, marketing and administrative expenses 584 1,114 3,085 3,346 Research and development expense 24 112 258 337 Interest Income ( 37 )  ( 117 )  Interest expense, net of portion capitalized (Note 4) 67  199  Other (income) expense, net 406 267 1,018 649 Gain on separation of Kenvue ( 20,984 )  ( 20,984 )  Restructuring  17  37 Earnings from Discontinued Operations Before Provision for Taxes on Income 21,202 650 22,208 2,005 (Benefit from)/Provision for taxes on income (Note 5) ( 517 ) 502 298 727 Net earnings from Discontinued Operations 21,719 148 21,910 1,278", "length": 854, "numbers_raw": ["1", "202", "3", "1", "2", "202", "2", "1", "202", "3", "1", "2", "202", "2", "2,173", "3,795", "10,036", "11,186", "911", "1,635", "4,369", "4,812", "1,262", "2,160", "5,667", "6,374", "584", "1,114", "3,085", "3,346", "24", "112", "258", "337", "37", "117", "4", "67", "199", "406", "267", "1,018", "649", "20,984", "20,984", "17", "37", "21,202", "650", "22,208", "2,005", "5", "517", "502", "298", "727", "21,719", "148", "21,910", "1,278"], "numbers": [1.0, 202.0, 3.0, 1.0, 2.0, 202.0, 2.0, 1.0, 202.0, 3.0, 1.0, 2.0, 202.0, 2.0, 2173.0, 3795.0, 10036.0, 11186.0, 911.0, 1635.0, 4369.0, 4812.0, 1262.0, 2160.0, 5667.0, 6374.0, 584.0, 1114.0, 3085.0, 3346.0, 24.0, 112.0, 258.0, 337.0, 37.0, 117.0, 4.0, 67.0, 199.0, 406.0, 267.0, 1018.0, 649.0, 20984.0, 20984.0, 17.0, 37.0, 21202.0, 650.0, 22208.0, 2005.0, 5.0, 517.0, 502.0, 298.0, 727.0, 21719.0, 148.0, 21910.0, 1278.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1054, "tag": "div", "text_raw": "October 1, 2023 (1)", "text": "October 1, 2023 (1)", "length": 19, "numbers_raw": ["1", "202", "3", "1"], "numbers": [1.0, 202.0, 3.0, 1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1055, "tag": "div", "text_raw": "October 1, 2023 (1)", "text": "October 1, 2023 (1)", "length": 19, "numbers_raw": ["1", "202", "3", "1"], "numbers": [1.0, 202.0, 3.0, 1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1057, "tag": "div", "text_raw": "(1) The Company ceased consolidating the results of the Consumer Health business on August 23, 2023, the date of the exchange offer, but continued to reflect any separation costs incurred as part of discontinued operations through the end of the fiscal third quarter.", "text": "(1) The Company ceased consolidating the results of the Consumer Health business on August 23, 2023, the date of the exchange offer, but continued to reflect any separation costs incurred as part of discontinued operations through the end of the fiscal third quarter.", "length": 267, "numbers_raw": ["1", "23", "202", "3"], "numbers": [1.0, 23.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1059, "tag": "div", "text_raw": "The following table presents depreciation, amortization and capital expenditures of the discontinued operations related to Kenvue:", "text": "The following table presents depreciation, amortization and capital expenditures of the discontinued operations related to Kenvue:", "length": 130, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1060, "tag": "div", "text_raw": "Fiscal Nine Months Ended (Dollars in Millions) October 1, 2023 October 2, 2022 Depreciation and Amortization 383 482 Capital expenditures 162 178", "text": "Fiscal Nine Months Ended (Dollars in Millions) October 1, 2023 October 2, 2022 Depreciation and Amortization 383 482 Capital expenditures 162 178", "length": 145, "numbers_raw": ["1", "202", "3", "2", "202", "2", "383", "482", "162", "178"], "numbers": [1.0, 202.0, 3.0, 2.0, 202.0, 2.0, 383.0, 482.0, 162.0, 178.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1085, "tag": "div", "text_raw": "40", "text": "40", "length": 2, "numbers_raw": ["40"], "numbers": [40.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1086, "tag": "div", "text_raw": "40", "text": "40", "length": 2, "numbers_raw": ["40"], "numbers": [40.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1087, "tag": "div", "text_raw": "40", "text": "40", "length": 2, "numbers_raw": ["40"], "numbers": [40.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1094, "tag": "div", "text_raw": "Details of assets and liabilities of discontinued operations are as follows:", "text": "Details of assets and liabilities of discontinued operations are as follows:", "length": 76, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1096, "tag": "div", "text_raw": "January 1, 2023 Assets Current assets Cash and cash equivalents $ 1,238 Accounts receivable trade, less allowances for doubtful accounts 2,121 Inventories 2,215 Prepaid expenses and other receivables 256 Total current assets of discontinued operations 5,830 Property, plant and equipment, net 1,821 Intangible assets, net 9,836 Goodwill 9,184 Deferred taxes on income 176 Other assets 390 Total noncurrent assets of discontinued operations $ 21,407 Liabilities Loans and notes payable $ 15 Accounts payable 1,814 Accrued liabilities 737 Accrued rebates, returns and promotions 838 Accrued compensation and employee related obligations 279 Accrued taxes on income ( 93 ) Total current liabilities of discontinued operations 3,590 Long-term debt 2 Deferred taxes on income 2,383 Employee related obligations 225 Other liabilities 291 Total noncurrent liabilities of discontinued operations $ 2,901", "text": "January 1, 2023 Assets Current assets Cash and cash equivalents $ 1,238 Accounts receivable trade, less allowances for doubtful accounts 2,121 Inventories 2,215 Prepaid expenses and other receivables 256 Total current assets of discontinued operations 5,830 Property, plant and equipment, net 1,821 Intangible assets, net 9,836 Goodwill 9,184 Deferred taxes on income 176 Other assets 390 Total noncurrent assets of discontinued operations $ 21,407 Liabilities Loans and notes payable $ 15 Accounts payable 1,814 Accrued liabilities 737 Accrued rebates, returns and promotions 838 Accrued compensation and employee related obligations 279 Accrued taxes on income ( 93 ) Total current liabilities of discontinued operations 3,590 Long-term debt 2 Deferred taxes on income 2,383 Employee related obligations 225 Other liabilities 291 Total noncurrent liabilities of discontinued operations $ 2,901", "length": 895, "numbers_raw": ["1", "202", "3", "1,238", "2,121", "2,215", "256", "5,830", "1,821", "9,836", "9,184", "176", "390", "21,407", "15", "1,814", "737", "838", "279", "93", "3,590", "2", "2,383", "225", "291", "2,901"], "numbers": [1.0, 202.0, 3.0, 1238.0, 2121.0, 2215.0, 256.0, 5830.0, 1821.0, 9836.0, 9184.0, 176.0, 390.0, 21407.0, 15.0, 1814.0, 737.0, 838.0, 279.0, 93.0, 3590.0, 2.0, 2383.0, 225.0, 291.0, 2901.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1097, "tag": "div", "text_raw": "41", "text": "41", "length": 2, "numbers_raw": ["41"], "numbers": [41.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1098, "tag": "div", "text_raw": "41", "text": "41", "length": 2, "numbers_raw": ["41"], "numbers": [41.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1099, "tag": "div", "text_raw": "41", "text": "41", "length": 2, "numbers_raw": ["41"], "numbers": [41.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1104, "tag": "div", "text_raw": "NOTE 13 RESTRUCTURING", "text": "NOTE 13 RESTRUCTURING", "length": 22, "numbers_raw": ["13"], "numbers": [13.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1106, "tag": "div", "text_raw": "In fiscal 2023, the Company commenced restructuring actions within its Innovative Medicine and MedTech segments. The amounts and details of the current year programs are included below.", "text": "In fiscal 2023, the Company commenced restructuring actions within its Innovative Medicine and MedTech segments.", "length": 112, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1106, "tag": "div", "text_raw": "In fiscal 2023, the Company commenced restructuring actions within its Innovative Medicine and MedTech segments. The amounts and details of the current year programs are included below.", "text": "The amounts and details of the current year programs are included below.", "length": 72, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1108, "tag": "div", "text_raw": "In fiscal 2023, the Company completed a prioritization of its research and development (R&D) investment within its Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within certain therapeutic areas. The R&D program exits are primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, hepatitis and HIV development. Pre-tax Restructuring expenses of $ 149 million in the fiscal third quarter and $ 424 million in the fiscal nine months included the termination of partnered and non-partnered development program costs and asset impairments. The estimated costs of these total activities is between $ 500 - $ 600 million and is expected to be completed in fiscal year 2024.", "text": "In fiscal 2023, the Company completed a prioritization of its research and development (R&D) investment within its Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients.", "length": 222, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1108, "tag": "div", "text_raw": "In fiscal 2023, the Company completed a prioritization of its research and development (R&D) investment within its Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within certain therapeutic areas. The R&D program exits are primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, hepatitis and HIV development. Pre-tax Restructuring expenses of $ 149 million in the fiscal third quarter and $ 424 million in the fiscal nine months included the termination of partnered and non-partnered development program costs and asset impairments. The estimated costs of these total activities is between $ 500 - $ 600 million and is expected to be completed in fiscal year 2024.", "text": "This resulted in the exit of certain programs within certain therapeutic areas.", "length": 79, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1108, "tag": "div", "text_raw": "In fiscal 2023, the Company completed a prioritization of its research and development (R&D) investment within its Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within certain therapeutic areas. The R&D program exits are primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, hepatitis and HIV development. Pre-tax Restructuring expenses of $ 149 million in the fiscal third quarter and $ 424 million in the fiscal nine months included the termination of partnered and non-partnered development program costs and asset impairments. The estimated costs of these total activities is between $ 500 - $ 600 million and is expected to be completed in fiscal year 2024.", "text": "The R&D program exits are primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, hepatitis and HIV development.", "length": 196, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1108, "tag": "div", "text_raw": "In fiscal 2023, the Company completed a prioritization of its research and development (R&D) investment within its Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within certain therapeutic areas. The R&D program exits are primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, hepatitis and HIV development. Pre-tax Restructuring expenses of $ 149 million in the fiscal third quarter and $ 424 million in the fiscal nine months included the termination of partnered and non-partnered development program costs and asset impairments. The estimated costs of these total activities is between $ 500 - $ 600 million and is expected to be completed in fiscal year 2024.", "text": "Pre-tax Restructuring expenses of $ 149 million in the fiscal third quarter and $ 424 million in the fiscal nine months included the termination of partnered and non-partnered development program costs and asset impairments.", "length": 224, "numbers_raw": ["149 million", "424 million"], "numbers": [149000000.0, 424000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1108, "tag": "div", "text_raw": "In fiscal 2023, the Company completed a prioritization of its research and development (R&D) investment within its Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within certain therapeutic areas. The R&D program exits are primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, hepatitis and HIV development. Pre-tax Restructuring expenses of $ 149 million in the fiscal third quarter and $ 424 million in the fiscal nine months included the termination of partnered and non-partnered development program costs and asset impairments. The estimated costs of these total activities is between $ 500 - $ 600 million and is expected to be completed in fiscal year 2024.", "text": "The estimated costs of these total activities is between $ 500 - $ 600 million and is expected to be completed in fiscal year 2024.", "length": 131, "numbers_raw": ["500", "600 million", "202", "4"], "numbers": [500.0, 600000000.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1110, "tag": "div", "text_raw": "In the third quarter of 2023, the Company initiated a restructuring program of its Orthopaedics franchise within its MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The pre-tax restructuring expense of $ 235 million in the fiscal third quarter and nine months primarily included inventory and instrument charges related to market and product exits. The estimated costs of the total program are between $ 700 million - $ 800 million and is expected to be completed by the end of fiscal year 2025.", "text": "In the third quarter of 2023, the Company initiated a restructuring program of its Orthopaedics franchise within its MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements.", "length": 238, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1110, "tag": "div", "text_raw": "In the third quarter of 2023, the Company initiated a restructuring program of its Orthopaedics franchise within its MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The pre-tax restructuring expense of $ 235 million in the fiscal third quarter and nine months primarily included inventory and instrument charges related to market and product exits. The estimated costs of the total program are between $ 700 million - $ 800 million and is expected to be completed by the end of fiscal year 2025.", "text": "The pre-tax restructuring expense of $ 235 million in the fiscal third quarter and nine months primarily included inventory and instrument charges related to market and product exits.", "length": 183, "numbers_raw": ["235 million"], "numbers": [235000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1110, "tag": "div", "text_raw": "In the third quarter of 2023, the Company initiated a restructuring program of its Orthopaedics franchise within its MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The pre-tax restructuring expense of $ 235 million in the fiscal third quarter and nine months primarily included inventory and instrument charges related to market and product exits. The estimated costs of the total program are between $ 700 million - $ 800 million and is expected to be completed by the end of fiscal year 2025.", "text": "The estimated costs of the total program are between $ 700 million - $ 800 million and is expected to be completed by the end of fiscal year 2025.", "length": 146, "numbers_raw": ["700 million", "800 million", "202", "5"], "numbers": [700000000.0, 800000000.0, 202.0, 5.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1112, "tag": "div", "text_raw": "The following table summarizes the restructuring expenses for 2023:", "text": "The following table summarizes the restructuring expenses for 2023:", "length": 67, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1113, "tag": "div", "text_raw": "(Pre-tax Dollars in Millions) Fiscal Third Quarter Ended Fiscal Nine Months Ended Innovative Medicine Segment (1) $ 149 424 MedTech Segment (2) 235 235 Total Programs $ 384 659", "text": "(Pre-tax Dollars in Millions) Fiscal Third Quarter Ended Fiscal Nine Months Ended Innovative Medicine Segment (1) $ 149 424 MedTech Segment (2) 235 235 Total Programs $ 384 659", "length": 176, "numbers_raw": ["1", "149", "424 M", "2", "235", "235", "384", "659"], "numbers": [1.0, 149.0, 424000000.0, 2.0, 235.0, 235.0, 384.0, 659.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1114, "tag": "div", "text_raw": "Innovative Medicine Segment (1)", "text": "Innovative Medicine Segment (1)", "length": 31, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1115, "tag": "div", "text_raw": "MedTech Segment (2)", "text": "MedTech Segment (2)", "length": 19, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1116, "tag": "div", "text_raw": "(1 ) Included in Restructuring on the Consolidated Statement of Earnings", "text": "(1 ) Included in Restructuring on the Consolidated Statement of Earnings", "length": 72, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1117, "tag": "div", "text_raw": "(2) Included $ 9 million in the Restructuring and $ 226 million in Cost of products sold on the Consolidated Statement of Earnings", "text": "(2) Included $ 9 million in the Restructuring and $ 226 million in Cost of products sold on the Consolidated Statement of Earnings", "length": 130, "numbers_raw": ["2", "9 million", "226 million"], "numbers": [2.0, 9000000.0, 226000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1119, "tag": "div", "text_raw": "42", "text": "42", "length": 2, "numbers_raw": ["42"], "numbers": [42.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1120, "tag": "div", "text_raw": "42", "text": "42", "length": 2, "numbers_raw": ["42"], "numbers": [42.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1121, "tag": "div", "text_raw": "42", "text": "42", "length": 2, "numbers_raw": ["42"], "numbers": [42.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1127, "tag": "div", "text_raw": "Item 2  MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS", "text": "Item 2  MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS", "length": 94, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1133, "tag": "div", "text_raw": "Analysis of Consolidated Sales", "text": "Analysis of Consolidated Sales", "length": 30, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1135, "tag": "div", "text_raw": "For the fiscal nine months of 2023, worldwide sales were $63.8 billion, a total increase of 6.2%, including an operational increase of 7.5% as compared to 2022 fiscal nine months sales of $60.1 billion. Currency fluctuations had a negative impact of 1.3% for the fiscal nine months of 2023. In the fiscal nine months of 2023, the net impact of acquisitions and divestitures on worldwide operational sales growth was a positive 1.5%.", "text": "For the fiscal nine months of 2023, worldwide sales were $63.8 billion, a total increase of 6.2%, including an operational increase of 7.5% as compared to 2022 fiscal nine months sales of $60.1 billion.", "length": 202, "numbers_raw": ["202", "3", "$63.8 billion", "6.2", "7.5", "202", "2", "$60.1 billion"], "numbers": [202.0, 3.0, 63800000000.0, 6.2, 7.5, 202.0, 2.0, 60100000000.0], "percents_raw": ["6.2%", "7.5%"], "percents": [0.062, 0.075], "currencies": ["USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 1135, "tag": "div", "text_raw": "For the fiscal nine months of 2023, worldwide sales were $63.8 billion, a total increase of 6.2%, including an operational increase of 7.5% as compared to 2022 fiscal nine months sales of $60.1 billion. Currency fluctuations had a negative impact of 1.3% for the fiscal nine months of 2023. In the fiscal nine months of 2023, the net impact of acquisitions and divestitures on worldwide operational sales growth was a positive 1.5%.", "text": "Currency fluctuations had a negative impact of 1.3% for the fiscal nine months of 2023.", "length": 87, "numbers_raw": ["1.3", "202", "3"], "numbers": [1.3, 202.0, 3.0], "percents_raw": ["1.3%"], "percents": [0.013000000000000001], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1135, "tag": "div", "text_raw": "For the fiscal nine months of 2023, worldwide sales were $63.8 billion, a total increase of 6.2%, including an operational increase of 7.5% as compared to 2022 fiscal nine months sales of $60.1 billion. Currency fluctuations had a negative impact of 1.3% for the fiscal nine months of 2023. In the fiscal nine months of 2023, the net impact of acquisitions and divestitures on worldwide operational sales growth was a positive 1.5%.", "text": "In the fiscal nine months of 2023, the net impact of acquisitions and divestitures on worldwide operational sales growth was a positive 1.5%.", "length": 141, "numbers_raw": ["202", "3", "1.5"], "numbers": [202.0, 3.0, 1.5], "percents_raw": ["1.5%"], "percents": [0.015], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1137, "tag": "div", "text_raw": "Sales by U.S. companies were $34.4 billion in the fiscal nine months of 2023, which represented an increase of 10.5% as compared to the prior year. In the fiscal nine months of 2023, the net impact of acquisitions and divestitures on the U.S. operational sales growth was a positive 2.5%. Sales by international companies were $29.3 billion, an increase of 1.5%, including an operational increase of 4.2%, and a negative currency impact of 2.7% as compared to the fiscal nine months sales of 2022. In the fiscal nine months of 2023, the net impact of acquisitions and divestitures on the international operational sales growth was a positive 0.5%.", "text": "companies were $34.4 billion in the fiscal nine months of 2023, which represented an increase of 10.5% as compared to the prior year.", "length": 133, "numbers_raw": ["$34.4 billion", "202", "3", "10.5"], "numbers": [34400000000.0, 202.0, 3.0, 10.5], "percents_raw": ["10.5%"], "percents": [0.105], "currencies": ["USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 1137, "tag": "div", "text_raw": "Sales by U.S. companies were $34.4 billion in the fiscal nine months of 2023, which represented an increase of 10.5% as compared to the prior year. In the fiscal nine months of 2023, the net impact of acquisitions and divestitures on the U.S. operational sales growth was a positive 2.5%. Sales by international companies were $29.3 billion, an increase of 1.5%, including an operational increase of 4.2%, and a negative currency impact of 2.7% as compared to the fiscal nine months sales of 2022. In the fiscal nine months of 2023, the net impact of acquisitions and divestitures on the international operational sales growth was a positive 0.5%.", "text": "In the fiscal nine months of 2023, the net impact of acquisitions and divestitures on the U.S.", "length": 94, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1137, "tag": "div", "text_raw": "Sales by U.S. companies were $34.4 billion in the fiscal nine months of 2023, which represented an increase of 10.5% as compared to the prior year. In the fiscal nine months of 2023, the net impact of acquisitions and divestitures on the U.S. operational sales growth was a positive 2.5%. Sales by international companies were $29.3 billion, an increase of 1.5%, including an operational increase of 4.2%, and a negative currency impact of 2.7% as compared to the fiscal nine months sales of 2022. In the fiscal nine months of 2023, the net impact of acquisitions and divestitures on the international operational sales growth was a positive 0.5%.", "text": "operational sales growth was a positive 2.5%.", "length": 45, "numbers_raw": ["2.5"], "numbers": [2.5], "percents_raw": ["2.5%"], "percents": [0.025], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1137, "tag": "div", "text_raw": "Sales by U.S. companies were $34.4 billion in the fiscal nine months of 2023, which represented an increase of 10.5% as compared to the prior year. In the fiscal nine months of 2023, the net impact of acquisitions and divestitures on the U.S. operational sales growth was a positive 2.5%. Sales by international companies were $29.3 billion, an increase of 1.5%, including an operational increase of 4.2%, and a negative currency impact of 2.7% as compared to the fiscal nine months sales of 2022. In the fiscal nine months of 2023, the net impact of acquisitions and divestitures on the international operational sales growth was a positive 0.5%.", "text": "Sales by international companies were $29.3 billion, an increase of 1.5%, including an operational increase of 4.2%, and a negative currency impact of 2.7% as compared to the fiscal nine months sales of 2022.", "length": 208, "numbers_raw": ["$29.3 billion", "1.5", "4.2", "2.7", "202", "2"], "numbers": [29300000000.0, 1.5, 4.2, 2.7, 202.0, 2.0], "percents_raw": ["1.5%", "4.2%", "2.7%"], "percents": [0.015, 0.042, 0.027000000000000003], "currencies": ["USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 1137, "tag": "div", "text_raw": "Sales by U.S. companies were $34.4 billion in the fiscal nine months of 2023, which represented an increase of 10.5% as compared to the prior year. In the fiscal nine months of 2023, the net impact of acquisitions and divestitures on the U.S. operational sales growth was a positive 2.5%. Sales by international companies were $29.3 billion, an increase of 1.5%, including an operational increase of 4.2%, and a negative currency impact of 2.7% as compared to the fiscal nine months sales of 2022. In the fiscal nine months of 2023, the net impact of acquisitions and divestitures on the international operational sales growth was a positive 0.5%.", "text": "In the fiscal nine months of 2023, the net impact of acquisitions and divestitures on the international operational sales growth was a positive 0.5%.", "length": 149, "numbers_raw": ["202", "3", "0.5"], "numbers": [202.0, 3.0, 0.5], "percents_raw": ["0.5%"], "percents": [0.005], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1139, "tag": "div", "text_raw": "In the fiscal nine months of 2023, sales by companies in Europe experienced a decline of 0.6%, which included an operational decline of 1.0% and a positive currency impact of 0.4%. In the fiscal nine months of 2023, the net impact of Covid-19 Vaccine and the loss of exclusivity of Zytiga on the European regions change in operational sales was a negative 7.9%. Sales by companies in the Western Hemisphere, excluding the U.S., achieved growth of 9.7%, which included an operational increase of 15.0%, and a negative currency impact of 5.3%. Sales by companies in the Asia-Pacific, Africa region achieved growth of 2.2%, including an operational increase of 8.7% and a negative currency impact of 6.5%.", "text": "In the fiscal nine months of 2023, sales by companies in Europe experienced a decline of 0.6%, which included an operational decline of 1.0% and a positive currency impact of 0.4%.", "length": 180, "numbers_raw": ["202", "3", "0.6", "1.0", "0.4"], "numbers": [202.0, 3.0, 0.6, 1.0, 0.4], "percents_raw": ["0.6%", "1.0%", "0.4%"], "percents": [0.006, 0.01, 0.004], "currencies": ["EUR"], "has_numbers": true, "has_percents": true}
{"idx_source": 1139, "tag": "div", "text_raw": "In the fiscal nine months of 2023, sales by companies in Europe experienced a decline of 0.6%, which included an operational decline of 1.0% and a positive currency impact of 0.4%. In the fiscal nine months of 2023, the net impact of Covid-19 Vaccine and the loss of exclusivity of Zytiga on the European regions change in operational sales was a negative 7.9%. Sales by companies in the Western Hemisphere, excluding the U.S., achieved growth of 9.7%, which included an operational increase of 15.0%, and a negative currency impact of 5.3%. Sales by companies in the Asia-Pacific, Africa region achieved growth of 2.2%, including an operational increase of 8.7% and a negative currency impact of 6.5%.", "text": "In the fiscal nine months of 2023, the net impact of Covid-19 Vaccine and the loss of exclusivity of Zytiga on the European regions change in operational sales was a negative 7.9%.", "length": 180, "numbers_raw": ["202", "3", "19", "7.9"], "numbers": [202.0, 3.0, 19.0, 7.9], "percents_raw": ["7.9%"], "percents": [0.079], "currencies": ["EUR"], "has_numbers": true, "has_percents": true}
{"idx_source": 1139, "tag": "div", "text_raw": "In the fiscal nine months of 2023, sales by companies in Europe experienced a decline of 0.6%, which included an operational decline of 1.0% and a positive currency impact of 0.4%. In the fiscal nine months of 2023, the net impact of Covid-19 Vaccine and the loss of exclusivity of Zytiga on the European regions change in operational sales was a negative 7.9%. Sales by companies in the Western Hemisphere, excluding the U.S., achieved growth of 9.7%, which included an operational increase of 15.0%, and a negative currency impact of 5.3%. Sales by companies in the Asia-Pacific, Africa region achieved growth of 2.2%, including an operational increase of 8.7% and a negative currency impact of 6.5%.", "text": "Sales by companies in the Western Hemisphere, excluding the U.S., achieved growth of 9.7%, which included an operational increase of 15.0%, and a negative currency impact of 5.3%.", "length": 179, "numbers_raw": ["9.7", "15.0", "5.3"], "numbers": [9.7, 15.0, 5.3], "percents_raw": ["9.7%", "15.0%", "5.3%"], "percents": [0.09699999999999999, 0.15, 0.053], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1139, "tag": "div", "text_raw": "In the fiscal nine months of 2023, sales by companies in Europe experienced a decline of 0.6%, which included an operational decline of 1.0% and a positive currency impact of 0.4%. In the fiscal nine months of 2023, the net impact of Covid-19 Vaccine and the loss of exclusivity of Zytiga on the European regions change in operational sales was a negative 7.9%. Sales by companies in the Western Hemisphere, excluding the U.S., achieved growth of 9.7%, which included an operational increase of 15.0%, and a negative currency impact of 5.3%. Sales by companies in the Asia-Pacific, Africa region achieved growth of 2.2%, including an operational increase of 8.7% and a negative currency impact of 6.5%.", "text": "Sales by companies in the Asia-Pacific, Africa region achieved growth of 2.2%, including an operational increase of 8.7% and a negative currency impact of 6.5%.", "length": 160, "numbers_raw": ["2.2", "8.7", "6.5"], "numbers": [2.2, 8.7, 6.5], "percents_raw": ["2.2%", "8.7%", "6.5%"], "percents": [0.022000000000000002, 0.087, 0.065], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1150, "tag": "div", "text_raw": "43", "text": "43", "length": 2, "numbers_raw": ["43"], "numbers": [43.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1151, "tag": "div", "text_raw": "43", "text": "43", "length": 2, "numbers_raw": ["43"], "numbers": [43.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1152, "tag": "div", "text_raw": "43", "text": "43", "length": 2, "numbers_raw": ["43"], "numbers": [43.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1158, "tag": "div", "text_raw": "For the fiscal third quarter of 2023, worldwide sales were $21.4 billion, a total increase of 6.8%, which included operational growth of 6.4% and a positive currency impact of 0.4% as compared to 2022 fiscal third quarter sales of $20.0 billion. In the fiscal third quarter of 2023, the net impact of acquisitions and divestitures on worldwide operational sales growth was a positive 1.5%.", "text": "For the fiscal third quarter of 2023, worldwide sales were $21.4 billion, a total increase of 6.8%, which included operational growth of 6.4% and a positive currency impact of 0.4% as compared to 2022 fiscal third quarter sales of $20.0 billion.", "length": 245, "numbers_raw": ["202", "3", "$21.4 billion", "6.8", "6.4", "0.4", "202", "2", "$20.0 billion"], "numbers": [202.0, 3.0, 21400000000.0, 6.8, 6.4, 0.4, 202.0, 2.0, 20000000000.0], "percents_raw": ["6.8%", "6.4%", "0.4%"], "percents": [0.068, 0.064, 0.004], "currencies": ["USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 1158, "tag": "div", "text_raw": "For the fiscal third quarter of 2023, worldwide sales were $21.4 billion, a total increase of 6.8%, which included operational growth of 6.4% and a positive currency impact of 0.4% as compared to 2022 fiscal third quarter sales of $20.0 billion. In the fiscal third quarter of 2023, the net impact of acquisitions and divestitures on worldwide operational sales growth was a positive 1.5%.", "text": "In the fiscal third quarter of 2023, the net impact of acquisitions and divestitures on worldwide operational sales growth was a positive 1.5%.", "length": 143, "numbers_raw": ["202", "3", "1.5"], "numbers": [202.0, 3.0, 1.5], "percents_raw": ["1.5%"], "percents": [0.015], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1160, "tag": "div", "text_raw": "Sales by U.S. companies were $12.0 billion in the fiscal third quarter of 2023, which represented an increase of 11.1% as compared to the prior year. In the fiscal third quarter of 2023, the net impact of acquisitions and divestitures on the U.S. operational sales growth was a positive 2.2%. Sales by international companies were $9.4 billion, a total increase of 1.6%, which included operational growth of 0.7% and a positive currency impact of 0.9%. In the fiscal third quarter of 2023, the net impact of acquisitions and divestitures on the international operational sales growth was a positive 0.4%.", "text": "companies were $12.0 billion in the fiscal third quarter of 2023, which represented an increase of 11.1% as compared to the prior year.", "length": 135, "numbers_raw": ["$12.0 billion", "202", "3", "11.1"], "numbers": [12000000000.0, 202.0, 3.0, 11.1], "percents_raw": ["11.1%"], "percents": [0.111], "currencies": ["USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 1160, "tag": "div", "text_raw": "Sales by U.S. companies were $12.0 billion in the fiscal third quarter of 2023, which represented an increase of 11.1% as compared to the prior year. In the fiscal third quarter of 2023, the net impact of acquisitions and divestitures on the U.S. operational sales growth was a positive 2.2%. Sales by international companies were $9.4 billion, a total increase of 1.6%, which included operational growth of 0.7% and a positive currency impact of 0.9%. In the fiscal third quarter of 2023, the net impact of acquisitions and divestitures on the international operational sales growth was a positive 0.4%.", "text": "In the fiscal third quarter of 2023, the net impact of acquisitions and divestitures on the U.S.", "length": 96, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1160, "tag": "div", "text_raw": "Sales by U.S. companies were $12.0 billion in the fiscal third quarter of 2023, which represented an increase of 11.1% as compared to the prior year. In the fiscal third quarter of 2023, the net impact of acquisitions and divestitures on the U.S. operational sales growth was a positive 2.2%. Sales by international companies were $9.4 billion, a total increase of 1.6%, which included operational growth of 0.7% and a positive currency impact of 0.9%. In the fiscal third quarter of 2023, the net impact of acquisitions and divestitures on the international operational sales growth was a positive 0.4%.", "text": "operational sales growth was a positive 2.2%.", "length": 45, "numbers_raw": ["2.2"], "numbers": [2.2], "percents_raw": ["2.2%"], "percents": [0.022000000000000002], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1160, "tag": "div", "text_raw": "Sales by U.S. companies were $12.0 billion in the fiscal third quarter of 2023, which represented an increase of 11.1% as compared to the prior year. In the fiscal third quarter of 2023, the net impact of acquisitions and divestitures on the U.S. operational sales growth was a positive 2.2%. Sales by international companies were $9.4 billion, a total increase of 1.6%, which included operational growth of 0.7% and a positive currency impact of 0.9%. In the fiscal third quarter of 2023, the net impact of acquisitions and divestitures on the international operational sales growth was a positive 0.4%.", "text": "Sales by international companies were $9.4 billion, a total increase of 1.6%, which included operational growth of 0.7% and a positive currency impact of 0.9%.", "length": 159, "numbers_raw": ["$9.4 billion", "1.6", "0.7", "0.9"], "numbers": [9400000000.0, 1.6, 0.7, 0.9], "percents_raw": ["1.6%", "0.7%", "0.9%"], "percents": [0.016, 0.006999999999999999, 0.009000000000000001], "currencies": ["USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 1160, "tag": "div", "text_raw": "Sales by U.S. companies were $12.0 billion in the fiscal third quarter of 2023, which represented an increase of 11.1% as compared to the prior year. In the fiscal third quarter of 2023, the net impact of acquisitions and divestitures on the U.S. operational sales growth was a positive 2.2%. Sales by international companies were $9.4 billion, a total increase of 1.6%, which included operational growth of 0.7% and a positive currency impact of 0.9%. In the fiscal third quarter of 2023, the net impact of acquisitions and divestitures on the international operational sales growth was a positive 0.4%.", "text": "In the fiscal third quarter of 2023, the net impact of acquisitions and divestitures on the international operational sales growth was a positive 0.4%.", "length": 151, "numbers_raw": ["202", "3", "0.4"], "numbers": [202.0, 3.0, 0.4], "percents_raw": ["0.4%"], "percents": [0.004], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1162, "tag": "div", "text_raw": "In the fiscal third quarter of 2023, sales by companies in Europe experienced a decline of 2.4%, which included an operational decline of 7.8% and a positive currency impact of 5.4%. In the fiscal third quarter of 2023, the net impact of Covid-19 Vaccine and the loss of exclusivity of Zytiga on the European regions change in operational sales was a negative 16.1%. Sales by companies in the Western Hemisphere, excluding the U.S., achieved growth of 10.5%, including operational growth of 12.8% and a negative currency impact of 2.3%. Sales by companies in the Asia-Pacific, Africa region achieved growth of 4.8%, including operational growth of 9.4% and a negative currency impact of 4.6%.", "text": "In the fiscal third quarter of 2023, sales by companies in Europe experienced a decline of 2.4%, which included an operational decline of 7.8% and a positive currency impact of 5.4%.", "length": 182, "numbers_raw": ["202", "3", "2.4", "7.8", "5.4"], "numbers": [202.0, 3.0, 2.4, 7.8, 5.4], "percents_raw": ["2.4%", "7.8%", "5.4%"], "percents": [0.024, 0.078, 0.054000000000000006], "currencies": ["EUR"], "has_numbers": true, "has_percents": true}
{"idx_source": 1162, "tag": "div", "text_raw": "In the fiscal third quarter of 2023, sales by companies in Europe experienced a decline of 2.4%, which included an operational decline of 7.8% and a positive currency impact of 5.4%. In the fiscal third quarter of 2023, the net impact of Covid-19 Vaccine and the loss of exclusivity of Zytiga on the European regions change in operational sales was a negative 16.1%. Sales by companies in the Western Hemisphere, excluding the U.S., achieved growth of 10.5%, including operational growth of 12.8% and a negative currency impact of 2.3%. Sales by companies in the Asia-Pacific, Africa region achieved growth of 4.8%, including operational growth of 9.4% and a negative currency impact of 4.6%.", "text": "In the fiscal third quarter of 2023, the net impact of Covid-19 Vaccine and the loss of exclusivity of Zytiga on the European regions change in operational sales was a negative 16.1%.", "length": 183, "numbers_raw": ["202", "3", "19", "16.1"], "numbers": [202.0, 3.0, 19.0, 16.1], "percents_raw": ["16.1%"], "percents": [0.161], "currencies": ["EUR"], "has_numbers": true, "has_percents": true}
{"idx_source": 1162, "tag": "div", "text_raw": "In the fiscal third quarter of 2023, sales by companies in Europe experienced a decline of 2.4%, which included an operational decline of 7.8% and a positive currency impact of 5.4%. In the fiscal third quarter of 2023, the net impact of Covid-19 Vaccine and the loss of exclusivity of Zytiga on the European regions change in operational sales was a negative 16.1%. Sales by companies in the Western Hemisphere, excluding the U.S., achieved growth of 10.5%, including operational growth of 12.8% and a negative currency impact of 2.3%. Sales by companies in the Asia-Pacific, Africa region achieved growth of 4.8%, including operational growth of 9.4% and a negative currency impact of 4.6%.", "text": "Sales by companies in the Western Hemisphere, excluding the U.S., achieved growth of 10.5%, including operational growth of 12.8% and a negative currency impact of 2.3%.", "length": 169, "numbers_raw": ["10.5", "12.8", "2.3"], "numbers": [10.5, 12.8, 2.3], "percents_raw": ["10.5%", "12.8%", "2.3%"], "percents": [0.105, 0.128, 0.023], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1162, "tag": "div", "text_raw": "In the fiscal third quarter of 2023, sales by companies in Europe experienced a decline of 2.4%, which included an operational decline of 7.8% and a positive currency impact of 5.4%. In the fiscal third quarter of 2023, the net impact of Covid-19 Vaccine and the loss of exclusivity of Zytiga on the European regions change in operational sales was a negative 16.1%. Sales by companies in the Western Hemisphere, excluding the U.S., achieved growth of 10.5%, including operational growth of 12.8% and a negative currency impact of 2.3%. Sales by companies in the Asia-Pacific, Africa region achieved growth of 4.8%, including operational growth of 9.4% and a negative currency impact of 4.6%.", "text": "Sales by companies in the Asia-Pacific, Africa region achieved growth of 4.8%, including operational growth of 9.4% and a negative currency impact of 4.6%.", "length": 155, "numbers_raw": ["4.8", "9.4", "4.6"], "numbers": [4.8, 9.4, 4.6], "percents_raw": ["4.8%", "9.4%", "4.6%"], "percents": [0.048, 0.094, 0.046], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1173, "tag": "div", "text_raw": "44", "text": "44", "length": 2, "numbers_raw": ["44"], "numbers": [44.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1174, "tag": "div", "text_raw": "44", "text": "44", "length": 2, "numbers_raw": ["44"], "numbers": [44.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1175, "tag": "div", "text_raw": "44", "text": "44", "length": 2, "numbers_raw": ["44"], "numbers": [44.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1180, "tag": "div", "text_raw": "Analysis of Sales by Business Segments", "text": "Analysis of Sales by Business Segments", "length": 38, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1183, "tag": "div", "text_raw": "Innovative Medicine segment sales in the fiscal nine months of 2023 were $41.0 billion, an increase of 4.2% as compared to the same period a year ago, with an operational increase of 5.1% and a negative currency impact of 0.9%. U.S. Innovative Medicine sales increased 8.8% as compared to the same period a year ago. International Innovative Medicine sales decreased by 1.2%, including operational growth of 0.8% offset by a negative currency impact of 2.0%. In the fiscal nine months of 2023, the net impact of acquisitions and divestitures on the Innovative Medicine segment operational sales growth was a negative 0.1%.", "text": "Innovative Medicine segment sales in the fiscal nine months of 2023 were $41.0 billion, an increase of 4.2% as compared to the same period a year ago, with an operational increase of 5.1% and a negative currency impact of 0.9%.", "length": 227, "numbers_raw": ["202", "3", "$41.0 billion", "4.2", "5.1", "0.9"], "numbers": [202.0, 3.0, 41000000000.0, 4.2, 5.1, 0.9], "percents_raw": ["4.2%", "5.1%", "0.9%"], "percents": [0.042, 0.051, 0.009000000000000001], "currencies": ["USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 1183, "tag": "div", "text_raw": "Innovative Medicine segment sales in the fiscal nine months of 2023 were $41.0 billion, an increase of 4.2% as compared to the same period a year ago, with an operational increase of 5.1% and a negative currency impact of 0.9%. U.S. Innovative Medicine sales increased 8.8% as compared to the same period a year ago. International Innovative Medicine sales decreased by 1.2%, including operational growth of 0.8% offset by a negative currency impact of 2.0%. In the fiscal nine months of 2023, the net impact of acquisitions and divestitures on the Innovative Medicine segment operational sales growth was a negative 0.1%.", "text": "Innovative Medicine sales increased 8.8% as compared to the same period a year ago.", "length": 83, "numbers_raw": ["8.8"], "numbers": [8.8], "percents_raw": ["8.8%"], "percents": [0.08800000000000001], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1183, "tag": "div", "text_raw": "Innovative Medicine segment sales in the fiscal nine months of 2023 were $41.0 billion, an increase of 4.2% as compared to the same period a year ago, with an operational increase of 5.1% and a negative currency impact of 0.9%. U.S. Innovative Medicine sales increased 8.8% as compared to the same period a year ago. International Innovative Medicine sales decreased by 1.2%, including operational growth of 0.8% offset by a negative currency impact of 2.0%. In the fiscal nine months of 2023, the net impact of acquisitions and divestitures on the Innovative Medicine segment operational sales growth was a negative 0.1%.", "text": "International Innovative Medicine sales decreased by 1.2%, including operational growth of 0.8% offset by a negative currency impact of 2.0%.", "length": 141, "numbers_raw": ["1.2", "0.8", "2.0"], "numbers": [1.2, 0.8, 2.0], "percents_raw": ["1.2%", "0.8%", "2.0%"], "percents": [0.012, 0.008, 0.02], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1183, "tag": "div", "text_raw": "Innovative Medicine segment sales in the fiscal nine months of 2023 were $41.0 billion, an increase of 4.2% as compared to the same period a year ago, with an operational increase of 5.1% and a negative currency impact of 0.9%. U.S. Innovative Medicine sales increased 8.8% as compared to the same period a year ago. International Innovative Medicine sales decreased by 1.2%, including operational growth of 0.8% offset by a negative currency impact of 2.0%. In the fiscal nine months of 2023, the net impact of acquisitions and divestitures on the Innovative Medicine segment operational sales growth was a negative 0.1%.", "text": "In the fiscal nine months of 2023, the net impact of acquisitions and divestitures on the Innovative Medicine segment operational sales growth was a negative 0.1%.", "length": 163, "numbers_raw": ["202", "3", "0.1"], "numbers": [202.0, 3.0, 0.1], "percents_raw": ["0.1%"], "percents": [0.001], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1185, "tag": "div", "text_raw": "Major Innovative Medicine Therapeutic Area Sales***  Fiscal Nine Months Ended", "text": "Major Innovative Medicine Therapeutic Area Sales***  Fiscal Nine Months Ended", "length": 78, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1187, "tag": "div", "text_raw": "(Dollars in Millions) October 1, 2023 October 2, 2022 Total Change Operations Change Currency Change Immunology $ 13,457 $ 12,817 5.0 % 5.9 % (0.9) % REMICADE 1,410 1,868 (24.5) (23.6) (0.9) SIMPONI/ SIMPONI ARIA 1,695 1,682 0.8 2.9 (2.1) STELARA 8,105 7,336 10.5 11.1 (0.6) TREMFYA 2,237 1,916 16.8 17.4 (0.6) Other Immunology 9 14 (36.1) (36.1)  Infectious Diseases 3,566 3,908 (8.7) (9.3) 0.6 COVID-19 VACCINE 1,073 1,490 (27.9) (29.2) 1.3 EDURANT/rilpivirine 843 718 17.5 15.8 1.7 PREZISTA/ PREZCOBIX/ REZOLSTA/ SYMTUZA 1,415 1,450 (2.4) (2.5) 0.1 Other Infectious Diseases 235 251 (6.4) (2.6) (3.8) Neuroscience 5,339 5,156 3.5 5.4 (1.9) CONCERTA/methylphenidate 603 476 26.7 30.7 (4.0) INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA 3,104 3,132 (0.9) (0.1) (0.8) SPRAVATO 483 255 88.8 88.7 0.1 Other Neuroscience (1) 1,149 1,293 (11.0) (7.1) (3.9) Oncology 13,043 12,056 8.2 9.3 (1.1) CARVYKTI 341 79 * *  DARZALEX 7,194 5,894 22.1 23.2 (1.1) ERLEADA 1,740 1,340 29.8 30.9 (1.1) IMBRUVICA 2,476 2,918 (15.2) (14.2) (1.0) ZYTIGA/ abiraterone acetate 686 1,500 (54.2) (52.6) (1.6) Other Oncology 605 324 86.5 87.4 (0.9) Pulmonary Hypertension 2,798 2,547 9.9 11.3 (1.4) OPSUMIT 1,437 1,322 8.7 9.9 (1.2) UPTRAVI 1,163 986 18.0 18.7 (0.7) Other Pulmonary Hypertension 199 239 (16.9) (11.8) (5.1) Cardiovascular / Metabolism / Other 2,834 2,916 (2.8) (2.6) (0.2) XARELTO 1,840 1,806 1.9 1.9  Other (2) 994 1,110 (10.5) (9.8) (0.7) Total Innovative Medicine Sales $ 41,037 $ 39,400 4.2 % 5.1 % (0.9) %", "text": "(Dollars in Millions) October 1, 2023 October 2, 2022 Total Change Operations Change Currency Change Immunology $ 13,457 $ 12,817 5.0 % 5.9 % (0.9) % REMICADE 1,410 1,868 (24.5) (23.6) (0.9) SIMPONI/ SIMPONI ARIA 1,695 1,682 0.8 2.9 (2.1) STELARA 8,105 7,336 10.5 11.1 (0.6) TREMFYA 2,237 1,916 16.8 17.4 (0.6) Other Immunology 9 14 (36.1) (36.1)  Infectious Diseases 3,566 3,908 (8.7) (9.3) 0.6 COVID-19 VACCINE 1,073 1,490 (27.9) (29.2) 1.3 EDURANT/rilpivirine 843 718 17.5 15.8 1.7 PREZISTA/ PREZCOBIX/ REZOLSTA/ SYMTUZA 1,415 1,450 (2.4) (2.5) 0.1 Other Infectious Diseases 235 251 (6.4) (2.6) (3.8) Neuroscience 5,339 5,156 3.5 5.4 (1.9) CONCERTA/methylphenidate 603 476 26.7 30.7 (4.0) INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA 3,104 3,132 (0.9) (0.1) (0.8) SPRAVATO 483 255 88.8 88.7 0.1 Other Neuroscience (1) 1,149 1,293 (11.0) (7.1) (3.9) Oncology 13,043 12,056 8.2 9.3 (1.1) CARVYKTI 341 79 * *  DARZALEX 7,194 5,894 22.1 23.2 (1.1) ERLEADA 1,740 1,340 29.8 30.9 (1.1) IMBRUVICA 2,476 2,918 (15.2) (14.2) (1.0) ZYTIGA/ abiraterone acetate 686 1,500 (54.2) (52.6) (1.6) Other Oncology 605 324 86.5 87.4 (0.9) Pulmonary Hypertension 2,798 2,547 9.9 11.3 (1.4) OPSUMIT 1,437 1,322 8.7 9.9 (1.2) UPTRAVI 1,163 986 18.0 18.7 (0.7) Other Pulmonary Hypertension 199 239 (16.9) (11.8) (5.1) Cardiovascular / Metabolism / Other 2,834 2,916 (2.8) (2.6) (0.2) XARELTO 1,840 1,806 1.9 1.9  Other (2) 994 1,110 (10.5) (9.8) (0.7) Total Innovative Medicine Sales $ 41,037 $ 39,400 4.2 % 5.1 % (0.9) %", "length": 1508, "numbers_raw": ["1", "202", "3", "2", "202", "2", "13,457", "12,817", "5.0", "5.9", "0.9", "1,410", "1,868", "24.5", "23.6", "0.9", "1,695", "1,682", "0.8", "2.9", "2.1", "8,105", "7,336", "10.5", "11.1", "0.6", "2,237", "1,916", "16.8", "17.4", "0.6", "9", "14", "36.1", "36.1", "3,566", "3,908", "8.7", "9.3", "0.6", "19", "1,073", "1,490", "27.9", "29.2", "1.3", "843", "718", "17.5", "15.8", "1.7", "1,415", "1,450", "2.4", "2.5", "0.1", "235", "251", "6.4", "2.6", "3.8", "5,339", "5,156", "3.5", "5.4", "1.9", "603", "476", "26.7", "30.7", "4.0", "3,104", "3,132", "0.9", "0.1", "0.8", "483", "255", "88.8", "88.7", "0.1", "1", "1,149", "1,293", "11.0", "7.1", "3.9", "13,043", "12,056", "8.2", "9.3", "1.1", "341", "79", "7,194", "5,894", "22.1", "23.2", "1.1", "1,740", "1,340", "29.8", "30.9", "1.1", "2,476", "2,918", "15.2", "14.2", "1.0", "686", "1,500", "54.2", "52.6", "1.6", "605", "324", "86.5", "87.4", "0.9", "2,798", "2,547", "9.9", "11.3", "1.4", "1,437", "1,322", "8.7", "9.9", "1.2", "1,163", "986", "18.0", "18.7", "0.7", "199", "239", "16.9", "11.8", "5.1", "2,834", "2,916", "2.8", "2.6", "0.2", "1,840", "1,806", "1.9", "1.9", "2", "994", "1,110", "10.5", "9.8", "0.7", "41,037", "39,400", "4.2", "5.1", "0.9"], "numbers": [1.0, 202.0, 3.0, 2.0, 202.0, 2.0, 13457.0, 12817.0, 5.0, 5.9, 0.9, 1410.0, 1868.0, 24.5, 23.6, 0.9, 1695.0, 1682.0, 0.8, 2.9, 2.1, 8105.0, 7336.0, 10.5, 11.1, 0.6, 2237.0, 1916.0, 16.8, 17.4, 0.6, 9.0, 14.0, 36.1, 36.1, 3566.0, 3908.0, 8.7, 9.3, 0.6, 19.0, 1073.0, 1490.0, 27.9, 29.2, 1.3, 843.0, 718.0, 17.5, 15.8, 1.7, 1415.0, 1450.0, 2.4, 2.5, 0.1, 235.0, 251.0, 6.4, 2.6, 3.8, 5339.0, 5156.0, 3.5, 5.4, 1.9, 603.0, 476.0, 26.7, 30.7, 4.0, 3104.0, 3132.0, 0.9, 0.1, 0.8, 483.0, 255.0, 88.8, 88.7, 0.1, 1.0, 1149.0, 1293.0, 11.0, 7.1, 3.9, 13043.0, 12056.0, 8.2, 9.3, 1.1, 341.0, 79.0, 7194.0, 5894.0, 22.1, 23.2, 1.1, 1740.0, 1340.0, 29.8, 30.9, 1.1, 2476.0, 2918.0, 15.2, 14.2, 1.0, 686.0, 1500.0, 54.2, 52.6, 1.6, 605.0, 324.0, 86.5, 87.4, 0.9, 2798.0, 2547.0, 9.9, 11.3, 1.4, 1437.0, 1322.0, 8.7, 9.9, 1.2, 1163.0, 986.0, 18.0, 18.7, 0.7, 199.0, 239.0, 16.9, 11.8, 5.1, 2834.0, 2916.0, 2.8, 2.6, 0.2, 1840.0, 1806.0, 1.9, 1.9, 2.0, 994.0, 1110.0, 10.5, 9.8, 0.7, 41037.0, 39400.0, 4.2, 5.1, 0.9], "percents_raw": ["5.0 %", "5.9 %", "4.2 %", "5.1 %"], "percents": [0.05, 0.059000000000000004, 0.042, 0.051], "currencies": ["EUR", "USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 1188, "tag": "div", "text_raw": "Other Neuroscience (1)", "text": "Other Neuroscience (1)", "length": 22, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": ["EUR"], "has_numbers": true, "has_percents": false}
{"idx_source": 1189, "tag": "div", "text_raw": "Other (2)", "text": "Other (2)", "length": 9, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1190, "tag": "div", "text_raw": "* Percentage greater than 100% or not meaningful", "text": "* Percentage greater than 100% or not meaningful", "length": 48, "numbers_raw": ["100"], "numbers": [100.0], "percents_raw": ["100%"], "percents": [1.0], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1191, "tag": "div", "text_raw": "**Previously referred to as Pharmaceutical", "text": "**Previously referred to as Pharmaceutical", "length": 42, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1192, "tag": "div", "text_raw": "45", "text": "45", "length": 2, "numbers_raw": ["45"], "numbers": [45.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1193, "tag": "div", "text_raw": "45", "text": "45", "length": 2, "numbers_raw": ["45"], "numbers": [45.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1194, "tag": "div", "text_raw": "45", "text": "45", "length": 2, "numbers_raw": ["45"], "numbers": [45.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1197, "tag": "div", "text_raw": "***Certain prior year amounts have been reclassified to conform to current year presentation", "text": "***Certain prior year amounts have been reclassified to conform to current year presentation", "length": 92, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1198, "tag": "div", "text_raw": "(1) Inclusive of RISPERDAL CONSTA which was previously disclosed separately", "text": "(1) Inclusive of RISPERDAL CONSTA which was previously disclosed separately", "length": 75, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1199, "tag": "div", "text_raw": "(2) Inclusive of INVOKANA which was previously disclosed separately", "text": "(2) Inclusive of INVOKANA which was previously disclosed separately", "length": 67, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1201, "tag": "div", "text_raw": "Innovative Medicine segment sales in the fiscal third quarter of 2023 were $13.9 billion, an increase of 5.1% as compared to the same period a year ago, including an operational increase of 4.3% and a positive currency impact of 0.8%. U.S. Innovative Medicine sales increased 10.9% as compared to the same period a year ago. International Innovative Medicine sales decreased by 2.3%, including an operational decline of 4.3% and a positive currency impact of 2.0%. In the fiscal third quarter of 2023, the net impact of acquisitions and divestitures on the Innovative Medicine segment operational sales growth was a negative 0.1%.", "text": "Innovative Medicine segment sales in the fiscal third quarter of 2023 were $13.9 billion, an increase of 5.1% as compared to the same period a year ago, including an operational increase of 4.3% and a positive currency impact of 0.8%.", "length": 234, "numbers_raw": ["202", "3", "$13.9 billion", "5.1", "4.3", "0.8"], "numbers": [202.0, 3.0, 13900000000.0, 5.1, 4.3, 0.8], "percents_raw": ["5.1%", "4.3%", "0.8%"], "percents": [0.051, 0.043, 0.008], "currencies": ["USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 1201, "tag": "div", "text_raw": "Innovative Medicine segment sales in the fiscal third quarter of 2023 were $13.9 billion, an increase of 5.1% as compared to the same period a year ago, including an operational increase of 4.3% and a positive currency impact of 0.8%. U.S. Innovative Medicine sales increased 10.9% as compared to the same period a year ago. International Innovative Medicine sales decreased by 2.3%, including an operational decline of 4.3% and a positive currency impact of 2.0%. In the fiscal third quarter of 2023, the net impact of acquisitions and divestitures on the Innovative Medicine segment operational sales growth was a negative 0.1%.", "text": "Innovative Medicine sales increased 10.9% as compared to the same period a year ago.", "length": 84, "numbers_raw": ["10.9"], "numbers": [10.9], "percents_raw": ["10.9%"], "percents": [0.109], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1201, "tag": "div", "text_raw": "Innovative Medicine segment sales in the fiscal third quarter of 2023 were $13.9 billion, an increase of 5.1% as compared to the same period a year ago, including an operational increase of 4.3% and a positive currency impact of 0.8%. U.S. Innovative Medicine sales increased 10.9% as compared to the same period a year ago. International Innovative Medicine sales decreased by 2.3%, including an operational decline of 4.3% and a positive currency impact of 2.0%. In the fiscal third quarter of 2023, the net impact of acquisitions and divestitures on the Innovative Medicine segment operational sales growth was a negative 0.1%.", "text": "International Innovative Medicine sales decreased by 2.3%, including an operational decline of 4.3% and a positive currency impact of 2.0%.", "length": 139, "numbers_raw": ["2.3", "4.3", "2.0"], "numbers": [2.3, 4.3, 2.0], "percents_raw": ["2.3%", "4.3%", "2.0%"], "percents": [0.023, 0.043, 0.02], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1201, "tag": "div", "text_raw": "Innovative Medicine segment sales in the fiscal third quarter of 2023 were $13.9 billion, an increase of 5.1% as compared to the same period a year ago, including an operational increase of 4.3% and a positive currency impact of 0.8%. U.S. Innovative Medicine sales increased 10.9% as compared to the same period a year ago. International Innovative Medicine sales decreased by 2.3%, including an operational decline of 4.3% and a positive currency impact of 2.0%. In the fiscal third quarter of 2023, the net impact of acquisitions and divestitures on the Innovative Medicine segment operational sales growth was a negative 0.1%.", "text": "In the fiscal third quarter of 2023, the net impact of acquisitions and divestitures on the Innovative Medicine segment operational sales growth was a negative 0.1%.", "length": 165, "numbers_raw": ["202", "3", "0.1"], "numbers": [202.0, 3.0, 0.1], "percents_raw": ["0.1%"], "percents": [0.001], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1203, "tag": "div", "text_raw": "Major Innovative Medicine Therapeutic Area Sales**  Fiscal Third Quarter Ended", "text": "Major Innovative Medicine Therapeutic Area Sales**  Fiscal Third Quarter Ended", "length": 79, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1204, "tag": "div", "text_raw": "(Dollars in Millions) October 1, 2023 October 2, 2022 Total Change Operations Change Currency Change Immunology $ 4,849 $ 4,287 13.1 % 12.4 % 0.7 % REMICADE 461 558 (17.4) (17.1) (0.3) SIMPONI/ SIMPONI ARIA 629 545 15.3 15.8 (0.5) STELARA 2,864 2,449 16.9 15.8 1.1 TREMFYA 891 729 22.2 21.5 0.7 Other Immunology 2 5 (47.1) (47.1)  Infectious Diseases 859 1,295 (33.6) (37.8) 4.2 COVID-19 VACCINE 41 489 (91.5) (97.8) 6.3 EDURANT/rilpivirine 297 245 21.0 13.3 7.7 PREZISTA/ PREZCOBIX/ REZOLSTA/ SYMTUZA 447 485 (7.8) (9.0) 1.2 Other Infectious Diseases 74 77 (3.6) (0.5) (3.1) Neuroscience 1,742 1,681 3.6 4.6 (1.0) CONCERTA/ methylphenidate 189 158 20.0 21.4 (1.4) INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA 1,029 1,031 (0.2) (0.3) 0.1 SPRAVATO 183 100 82.1 81.0 1.1 Other Neuroscience (1) 340 393 (13.2) (8.7) (4.5) Oncology 4,533 4,064 11.5 10.4 1.1 CARVYKTI 152 55 * *  DARZALEX 2,499 2,052 21.8 20.7 1.1 ERLEADA 631 490 28.7 27.0 1.7 IMBRUVICA 808 911 (11.3) (12.6) 1.3 ZYTIGA/ abiraterone acetate 214 456 (53.0) (53.2) 0.2 Other Oncology 229 100 * * * Pulmonary Hypertension 954 852 12.0 12.4 (0.4) OPSUMIT 490 441 11.2 10.9 0.3 UPTRAVI 402 333 20.7 21.1 (0.4) Other Pulmonary Hypertension 63 78 (19.8) (16.6) (3.2) Cardiovascular / Metabolism / Other 957 1,034 (7.5) (8.0) 0.5 XARELTO 625 689 (9.4) (9.4)  Other (2) 332 345 (3.8) (5.3) 1.5 Total Innovative Medicine Sales $ 13,893 $ 13,214 5.1 % 4.3 % 0.8 %", "text": "(Dollars in Millions) October 1, 2023 October 2, 2022 Total Change Operations Change Currency Change Immunology $ 4,849 $ 4,287 13.1 % 12.4 % 0.7 % REMICADE 461 558 (17.4) (17.1) (0.3) SIMPONI/ SIMPONI ARIA 629 545 15.3 15.8 (0.5) STELARA 2,864 2,449 16.9 15.8 1.1 TREMFYA 891 729 22.2 21.5 0.7 Other Immunology 2 5 (47.1) (47.1)  Infectious Diseases 859 1,295 (33.6) (37.8) 4.2 COVID-19 VACCINE 41 489 (91.5) (97.8) 6.3 EDURANT/rilpivirine 297 245 21.0 13.3 7.7 PREZISTA/ PREZCOBIX/ REZOLSTA/ SYMTUZA 447 485 (7.8) (9.0) 1.2 Other Infectious Diseases 74 77 (3.6) (0.5) (3.1) Neuroscience 1,742 1,681 3.6 4.6 (1.0) CONCERTA/ methylphenidate 189 158 20.0 21.4 (1.4) INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA 1,029 1,031 (0.2) (0.3) 0.1 SPRAVATO 183 100 82.1 81.0 1.1 Other Neuroscience (1) 340 393 (13.2) (8.7) (4.5) Oncology 4,533 4,064 11.5 10.4 1.1 CARVYKTI 152 55 * *  DARZALEX 2,499 2,052 21.8 20.7 1.1 ERLEADA 631 490 28.7 27.0 1.7 IMBRUVICA 808 911 (11.3) (12.6) 1.3 ZYTIGA/ abiraterone acetate 214 456 (53.0) (53.2) 0.2 Other Oncology 229 100 * * * Pulmonary Hypertension 954 852 12.0 12.4 (0.4) OPSUMIT 490 441 11.2 10.9 0.3 UPTRAVI 402 333 20.7 21.1 (0.4) Other Pulmonary Hypertension 63 78 (19.8) (16.6) (3.2) Cardiovascular / Metabolism / Other 957 1,034 (7.5) (8.0) 0.5 XARELTO 625 689 (9.4) (9.4)  Other (2) 332 345 (3.8) (5.3) 1.5 Total Innovative Medicine Sales $ 13,893 $ 13,214 5.1 % 4.3 % 0.8 %", "length": 1423, "numbers_raw": ["1", "202", "3", "2", "202", "2", "4,849", "4,287", "13.1", "12.4", "0.7", "461", "558", "17.4", "17.1", "0.3", "629", "545", "15.3", "15.8", "0.5", "2,864", "2,449", "16.9", "15.8", "1.1", "891", "729", "22.2", "21.5", "0.7", "2", "5", "47.1", "47.1", "859", "1,295", "33.6", "37.8", "4.2", "19", "41", "489", "91.5", "97.8", "6.3", "297", "245", "21.0", "13.3", "7.7", "447", "485", "7.8", "9.0", "1.2", "74", "77", "3.6", "0.5", "3.1", "1,742", "1,681", "3.6", "4.6", "1.0", "189", "158", "20.0", "21.4", "1.4", "1,029", "1,031", "0.2", "0.3", "0.1", "183", "100", "82.1", "81.0", "1.1", "1", "340", "393", "13.2", "8.7", "4.5", "4,533", "4,064", "11.5", "10.4", "1.1", "152", "55", "2,499", "2,052", "21.8", "20.7", "1.1", "631", "490", "28.7", "27.0", "1.7", "808", "911", "11.3", "12.6", "1.3", "214", "456", "53.0", "53.2", "0.2", "229", "100", "954", "852", "12.0", "12.4", "0.4", "490", "441", "11.2", "10.9", "0.3", "402", "333", "20.7", "21.1", "0.4", "63", "78", "19.8", "16.6", "3.2", "957", "1,034", "7.5", "8.0", "0.5", "625", "689", "9.4", "9.4", "2", "332", "345", "3.8", "5.3", "1.5", "13,893", "13,214", "5.1", "4.3", "0.8"], "numbers": [1.0, 202.0, 3.0, 2.0, 202.0, 2.0, 4849.0, 4287.0, 13.1, 12.4, 0.7, 461.0, 558.0, 17.4, 17.1, 0.3, 629.0, 545.0, 15.3, 15.8, 0.5, 2864.0, 2449.0, 16.9, 15.8, 1.1, 891.0, 729.0, 22.2, 21.5, 0.7, 2.0, 5.0, 47.1, 47.1, 859.0, 1295.0, 33.6, 37.8, 4.2, 19.0, 41.0, 489.0, 91.5, 97.8, 6.3, 297.0, 245.0, 21.0, 13.3, 7.7, 447.0, 485.0, 7.8, 9.0, 1.2, 74.0, 77.0, 3.6, 0.5, 3.1, 1742.0, 1681.0, 3.6, 4.6, 1.0, 189.0, 158.0, 20.0, 21.4, 1.4, 1029.0, 1031.0, 0.2, 0.3, 0.1, 183.0, 100.0, 82.1, 81.0, 1.1, 1.0, 340.0, 393.0, 13.2, 8.7, 4.5, 4533.0, 4064.0, 11.5, 10.4, 1.1, 152.0, 55.0, 2499.0, 2052.0, 21.8, 20.7, 1.1, 631.0, 490.0, 28.7, 27.0, 1.7, 808.0, 911.0, 11.3, 12.6, 1.3, 214.0, 456.0, 53.0, 53.2, 0.2, 229.0, 100.0, 954.0, 852.0, 12.0, 12.4, 0.4, 490.0, 441.0, 11.2, 10.9, 0.3, 402.0, 333.0, 20.7, 21.1, 0.4, 63.0, 78.0, 19.8, 16.6, 3.2, 957.0, 1034.0, 7.5, 8.0, 0.5, 625.0, 689.0, 9.4, 9.4, 2.0, 332.0, 345.0, 3.8, 5.3, 1.5, 13893.0, 13214.0, 5.1, 4.3, 0.8], "percents_raw": ["13.1 %", "12.4 %", "0.7 %", "5.1 %", "4.3 %", "0.8 %"], "percents": [0.131, 0.124, 0.006999999999999999, 0.051, 0.043, 0.008], "currencies": ["EUR", "USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 1205, "tag": "div", "text_raw": "PREZISTA/ PREZCOBIX/ REZOLSTA/ SYMTUZA", "text": "PREZISTA/ PREZCOBIX/ REZOLSTA/ SYMTUZA", "length": 38, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1206, "tag": "div", "text_raw": "INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA", "text": "INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA", "length": 49, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1207, "tag": "div", "text_raw": "Other Neuroscience (1)", "text": "Other Neuroscience (1)", "length": 22, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": ["EUR"], "has_numbers": true, "has_percents": false}
{"idx_source": 1208, "tag": "div", "text_raw": "Other (2)", "text": "Other (2)", "length": 9, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1209, "tag": "div", "text_raw": "* Percentage greater than 100% or not meaningful", "text": "* Percentage greater than 100% or not meaningful", "length": 48, "numbers_raw": ["100"], "numbers": [100.0], "percents_raw": ["100%"], "percents": [1.0], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1210, "tag": "div", "text_raw": "**Certain prior year amounts have been reclassified to conform to current year presentation", "text": "**Certain prior year amounts have been reclassified to conform to current year presentation", "length": 91, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1211, "tag": "div", "text_raw": "(1) Inclusive of RISPERDAL CONSTA which was previously disclosed separately", "text": "(1) Inclusive of RISPERDAL CONSTA which was previously disclosed separately", "length": 75, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1212, "tag": "div", "text_raw": "(2) Inclusive of INVOKANA which was previously disclosed separately", "text": "(2) Inclusive of INVOKANA which was previously disclosed separately", "length": 67, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1213, "tag": "div", "text_raw": "46", "text": "46", "length": 2, "numbers_raw": ["46"], "numbers": [46.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1214, "tag": "div", "text_raw": "46", "text": "46", "length": 2, "numbers_raw": ["46"], "numbers": [46.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1215, "tag": "div", "text_raw": "46", "text": "46", "length": 2, "numbers_raw": ["46"], "numbers": [46.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1222, "tag": "div", "text_raw": "Immunology products achieved operational growth of 12.4% as compared to the same period a year ago. Increased sales of STELARA (ustekinumab) was driven by patient mix, market growth, and continued strength in IBD. Growth of TREMFYA (guselkumab) was due to patient mix, market growth and continued strength in PsO/PsA. Additionally, SIMPONI/SIMPONI ARIA growth was driven by market growth and favorable mix. Lower sales of REMICADE (infliximab) were due to biosimilar competition.", "text": "Immunology products achieved operational growth of 12.4% as compared to the same period a year ago.", "length": 99, "numbers_raw": ["12.4"], "numbers": [12.4], "percents_raw": ["12.4%"], "percents": [0.124], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1222, "tag": "div", "text_raw": "Immunology products achieved operational growth of 12.4% as compared to the same period a year ago. Increased sales of STELARA (ustekinumab) was driven by patient mix, market growth, and continued strength in IBD. Growth of TREMFYA (guselkumab) was due to patient mix, market growth and continued strength in PsO/PsA. Additionally, SIMPONI/SIMPONI ARIA growth was driven by market growth and favorable mix. Lower sales of REMICADE (infliximab) were due to biosimilar competition.", "text": "Increased sales of STELARA (ustekinumab) was driven by patient mix, market growth, and continued strength in IBD.", "length": 113, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1222, "tag": "div", "text_raw": "Immunology products achieved operational growth of 12.4% as compared to the same period a year ago. Increased sales of STELARA (ustekinumab) was driven by patient mix, market growth, and continued strength in IBD. Growth of TREMFYA (guselkumab) was due to patient mix, market growth and continued strength in PsO/PsA. Additionally, SIMPONI/SIMPONI ARIA growth was driven by market growth and favorable mix. Lower sales of REMICADE (infliximab) were due to biosimilar competition.", "text": "Growth of TREMFYA (guselkumab) was due to patient mix, market growth and continued strength in PsO/PsA.", "length": 103, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1222, "tag": "div", "text_raw": "Immunology products achieved operational growth of 12.4% as compared to the same period a year ago. Increased sales of STELARA (ustekinumab) was driven by patient mix, market growth, and continued strength in IBD. Growth of TREMFYA (guselkumab) was due to patient mix, market growth and continued strength in PsO/PsA. Additionally, SIMPONI/SIMPONI ARIA growth was driven by market growth and favorable mix. Lower sales of REMICADE (infliximab) were due to biosimilar competition.", "text": "Additionally, SIMPONI/SIMPONI ARIA growth was driven by market growth and favorable mix.", "length": 88, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1222, "tag": "div", "text_raw": "Immunology products achieved operational growth of 12.4% as compared to the same period a year ago. Increased sales of STELARA (ustekinumab) was driven by patient mix, market growth, and continued strength in IBD. Growth of TREMFYA (guselkumab) was due to patient mix, market growth and continued strength in PsO/PsA. Additionally, SIMPONI/SIMPONI ARIA growth was driven by market growth and favorable mix. Lower sales of REMICADE (infliximab) were due to biosimilar competition.", "text": "Lower sales of REMICADE (infliximab) were due to biosimilar competition.", "length": 72, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1224, "tag": "div", "text_raw": "Biosimilar versions of REMICADE have been introduced in the United States and certain markets outside the United States and additional competitors continue to enter the market. Continued infliximab biosimilar competition will result in a further reduction in sales of REMICADE.", "text": "Biosimilar versions of REMICADE have been introduced in the United States and certain markets outside the United States and additional competitors continue to enter the market.", "length": 176, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1224, "tag": "div", "text_raw": "Biosimilar versions of REMICADE have been introduced in the United States and certain markets outside the United States and additional competitors continue to enter the market. Continued infliximab biosimilar competition will result in a further reduction in sales of REMICADE.", "text": "Continued infliximab biosimilar competition will result in a further reduction in sales of REMICADE.", "length": 100, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1226, "tag": "div", "text_raw": "The latest expiring United States composition of matter patent for STELARA (ustekinumab) expired in September 2023. STELARA (ustekinumab) U.S. sales in fiscal 2022 were approximately $6.4 billion. Third parties have filed abbreviated Biologics License Applications with the FDA seeking approval to market biosimilar versions of STELARA. In May 2023, the Company settled litigation with Amgen under the Biosimilar Price Competition and Innovation Act of 2009. As a result of the settlement and other agreements with separate third parties, the Company does not anticipate the launch of a biosimilar version of STELARA until January 1, 2025 in the United States.", "text": "The latest expiring United States composition of matter patent for STELARA (ustekinumab) expired in September 2023.", "length": 115, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1226, "tag": "div", "text_raw": "The latest expiring United States composition of matter patent for STELARA (ustekinumab) expired in September 2023. STELARA (ustekinumab) U.S. sales in fiscal 2022 were approximately $6.4 billion. Third parties have filed abbreviated Biologics License Applications with the FDA seeking approval to market biosimilar versions of STELARA. In May 2023, the Company settled litigation with Amgen under the Biosimilar Price Competition and Innovation Act of 2009. As a result of the settlement and other agreements with separate third parties, the Company does not anticipate the launch of a biosimilar version of STELARA until January 1, 2025 in the United States.", "text": "sales in fiscal 2022 were approximately $6.4 billion.", "length": 53, "numbers_raw": ["202", "2", "$6.4 billion"], "numbers": [202.0, 2.0, 6400000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1226, "tag": "div", "text_raw": "The latest expiring United States composition of matter patent for STELARA (ustekinumab) expired in September 2023. STELARA (ustekinumab) U.S. sales in fiscal 2022 were approximately $6.4 billion. Third parties have filed abbreviated Biologics License Applications with the FDA seeking approval to market biosimilar versions of STELARA. In May 2023, the Company settled litigation with Amgen under the Biosimilar Price Competition and Innovation Act of 2009. As a result of the settlement and other agreements with separate third parties, the Company does not anticipate the launch of a biosimilar version of STELARA until January 1, 2025 in the United States.", "text": "Third parties have filed abbreviated Biologics License Applications with the FDA seeking approval to market biosimilar versions of STELARA.", "length": 139, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1226, "tag": "div", "text_raw": "The latest expiring United States composition of matter patent for STELARA (ustekinumab) expired in September 2023. STELARA (ustekinumab) U.S. sales in fiscal 2022 were approximately $6.4 billion. Third parties have filed abbreviated Biologics License Applications with the FDA seeking approval to market biosimilar versions of STELARA. In May 2023, the Company settled litigation with Amgen under the Biosimilar Price Competition and Innovation Act of 2009. As a result of the settlement and other agreements with separate third parties, the Company does not anticipate the launch of a biosimilar version of STELARA until January 1, 2025 in the United States.", "text": "In May 2023, the Company settled litigation with Amgen under the Biosimilar Price Competition and Innovation Act of 2009.", "length": 121, "numbers_raw": ["202", "3", "200", "9"], "numbers": [202.0, 3.0, 200.0, 9.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1226, "tag": "div", "text_raw": "The latest expiring United States composition of matter patent for STELARA (ustekinumab) expired in September 2023. STELARA (ustekinumab) U.S. sales in fiscal 2022 were approximately $6.4 billion. Third parties have filed abbreviated Biologics License Applications with the FDA seeking approval to market biosimilar versions of STELARA. In May 2023, the Company settled litigation with Amgen under the Biosimilar Price Competition and Innovation Act of 2009. As a result of the settlement and other agreements with separate third parties, the Company does not anticipate the launch of a biosimilar version of STELARA until January 1, 2025 in the United States.", "text": "As a result of the settlement and other agreements with separate third parties, the Company does not anticipate the launch of a biosimilar version of STELARA until January 1, 2025 in the United States.", "length": 201, "numbers_raw": ["1", "202", "5"], "numbers": [1.0, 202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1228, "tag": "div", "text_raw": "Infectious disease products experienced an operational decline of 37.8% as compared to the same period a year ago primarily driven by a decline in COVID-19 vaccine revenue.", "text": "Infectious disease products experienced an operational decline of 37.8% as compared to the same period a year ago primarily driven by a decline in COVID-19 vaccine revenue.", "length": 172, "numbers_raw": ["37.8", "19"], "numbers": [37.8, 19.0], "percents_raw": ["37.8%"], "percents": [0.37799999999999995], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1230, "tag": "div", "text_raw": "Neuroscience products achieved operational sales growth of 4.6% as compared to the same period a year ago. The growth of SPRAVATO (esketamine) was driven by ongoing launches as well as increased physician confidence and patient demand. Growth was partially offset by declines in RISPERDAL/RISPERDAL CONSTA and the paliperidone long-acting injectables, due to the XEPLION loss of exclusivity in the European Union.", "text": "Neuroscience products achieved operational sales growth of 4.6% as compared to the same period a year ago.", "length": 106, "numbers_raw": ["4.6"], "numbers": [4.6], "percents_raw": ["4.6%"], "percents": [0.046], "currencies": ["EUR"], "has_numbers": true, "has_percents": true}
{"idx_source": 1230, "tag": "div", "text_raw": "Neuroscience products achieved operational sales growth of 4.6% as compared to the same period a year ago. The growth of SPRAVATO (esketamine) was driven by ongoing launches as well as increased physician confidence and patient demand. Growth was partially offset by declines in RISPERDAL/RISPERDAL CONSTA and the paliperidone long-acting injectables, due to the XEPLION loss of exclusivity in the European Union.", "text": "The growth of SPRAVATO (esketamine) was driven by ongoing launches as well as increased physician confidence and patient demand.", "length": 128, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1230, "tag": "div", "text_raw": "Neuroscience products achieved operational sales growth of 4.6% as compared to the same period a year ago. The growth of SPRAVATO (esketamine) was driven by ongoing launches as well as increased physician confidence and patient demand. Growth was partially offset by declines in RISPERDAL/RISPERDAL CONSTA and the paliperidone long-acting injectables, due to the XEPLION loss of exclusivity in the European Union.", "text": "Growth was partially offset by declines in RISPERDAL/RISPERDAL CONSTA and the paliperidone long-acting injectables, due to the XEPLION loss of exclusivity in the European Union.", "length": 177, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": ["EUR"], "has_numbers": false, "has_percents": false}
{"idx_source": 1232, "tag": "div", "text_raw": "Oncology products achieved operational sales growth of 10.4% as compared to the same period a year ago. Strong sales of DARZALEX (daratumumab) were driven by continued share gains in all regions and market growth. Growth of ERLEADA (apalutamide) was due to continued share gains and market growth in Metastatic Castrate Resistant Prostate Cancer. Sales of CARVYKTI (ciltacabtagene autoleucel) were driven by the ongoing launch, share gains and capacity improvement. Additionally, sales from the launch of TECVAYLI (teclistamab-cqyv), included in Other Oncology, contributed to the growth. Growth was partially offset by ZYTIGA (abiraterone acetate) due to loss of exclusivity and IMBRUVICA (ibrutinib) due to global competitive pressures.", "text": "Oncology products achieved operational sales growth of 10.4% as compared to the same period a year ago.", "length": 103, "numbers_raw": ["10.4"], "numbers": [10.4], "percents_raw": ["10.4%"], "percents": [0.10400000000000001], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1232, "tag": "div", "text_raw": "Oncology products achieved operational sales growth of 10.4% as compared to the same period a year ago. Strong sales of DARZALEX (daratumumab) were driven by continued share gains in all regions and market growth. Growth of ERLEADA (apalutamide) was due to continued share gains and market growth in Metastatic Castrate Resistant Prostate Cancer. Sales of CARVYKTI (ciltacabtagene autoleucel) were driven by the ongoing launch, share gains and capacity improvement. Additionally, sales from the launch of TECVAYLI (teclistamab-cqyv), included in Other Oncology, contributed to the growth. Growth was partially offset by ZYTIGA (abiraterone acetate) due to loss of exclusivity and IMBRUVICA (ibrutinib) due to global competitive pressures.", "text": "Strong sales of DARZALEX (daratumumab) were driven by continued share gains in all regions and market growth.", "length": 109, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1232, "tag": "div", "text_raw": "Oncology products achieved operational sales growth of 10.4% as compared to the same period a year ago. Strong sales of DARZALEX (daratumumab) were driven by continued share gains in all regions and market growth. Growth of ERLEADA (apalutamide) was due to continued share gains and market growth in Metastatic Castrate Resistant Prostate Cancer. Sales of CARVYKTI (ciltacabtagene autoleucel) were driven by the ongoing launch, share gains and capacity improvement. Additionally, sales from the launch of TECVAYLI (teclistamab-cqyv), included in Other Oncology, contributed to the growth. Growth was partially offset by ZYTIGA (abiraterone acetate) due to loss of exclusivity and IMBRUVICA (ibrutinib) due to global competitive pressures.", "text": "Growth of ERLEADA (apalutamide) was due to continued share gains and market growth in Metastatic Castrate Resistant Prostate Cancer.", "length": 132, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1232, "tag": "div", "text_raw": "Oncology products achieved operational sales growth of 10.4% as compared to the same period a year ago. Strong sales of DARZALEX (daratumumab) were driven by continued share gains in all regions and market growth. Growth of ERLEADA (apalutamide) was due to continued share gains and market growth in Metastatic Castrate Resistant Prostate Cancer. Sales of CARVYKTI (ciltacabtagene autoleucel) were driven by the ongoing launch, share gains and capacity improvement. Additionally, sales from the launch of TECVAYLI (teclistamab-cqyv), included in Other Oncology, contributed to the growth. Growth was partially offset by ZYTIGA (abiraterone acetate) due to loss of exclusivity and IMBRUVICA (ibrutinib) due to global competitive pressures.", "text": "Sales of CARVYKTI (ciltacabtagene autoleucel) were driven by the ongoing launch, share gains and capacity improvement.", "length": 118, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1232, "tag": "div", "text_raw": "Oncology products achieved operational sales growth of 10.4% as compared to the same period a year ago. Strong sales of DARZALEX (daratumumab) were driven by continued share gains in all regions and market growth. Growth of ERLEADA (apalutamide) was due to continued share gains and market growth in Metastatic Castrate Resistant Prostate Cancer. Sales of CARVYKTI (ciltacabtagene autoleucel) were driven by the ongoing launch, share gains and capacity improvement. Additionally, sales from the launch of TECVAYLI (teclistamab-cqyv), included in Other Oncology, contributed to the growth. Growth was partially offset by ZYTIGA (abiraterone acetate) due to loss of exclusivity and IMBRUVICA (ibrutinib) due to global competitive pressures.", "text": "Additionally, sales from the launch of TECVAYLI (teclistamab-cqyv), included in Other Oncology, contributed to the growth.", "length": 122, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1232, "tag": "div", "text_raw": "Oncology products achieved operational sales growth of 10.4% as compared to the same period a year ago. Strong sales of DARZALEX (daratumumab) were driven by continued share gains in all regions and market growth. Growth of ERLEADA (apalutamide) was due to continued share gains and market growth in Metastatic Castrate Resistant Prostate Cancer. Sales of CARVYKTI (ciltacabtagene autoleucel) were driven by the ongoing launch, share gains and capacity improvement. Additionally, sales from the launch of TECVAYLI (teclistamab-cqyv), included in Other Oncology, contributed to the growth. Growth was partially offset by ZYTIGA (abiraterone acetate) due to loss of exclusivity and IMBRUVICA (ibrutinib) due to global competitive pressures.", "text": "Growth was partially offset by ZYTIGA (abiraterone acetate) due to loss of exclusivity and IMBRUVICA (ibrutinib) due to global competitive pressures.", "length": 149, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1234, "tag": "div", "text_raw": "Pulmonary Hypertension achieved operational sales growth of 12.4% as compared to the same period a year ago. Sales growth was due to favorable patient mix, share gains and market growth from UPTRAVI (selexipag) and OPSUMIT (macitentan) partially offset by declines in Other Pulmonary Hypertension.", "text": "Pulmonary Hypertension achieved operational sales growth of 12.4% as compared to the same period a year ago.", "length": 108, "numbers_raw": ["12.4"], "numbers": [12.4], "percents_raw": ["12.4%"], "percents": [0.124], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1234, "tag": "div", "text_raw": "Pulmonary Hypertension achieved operational sales growth of 12.4% as compared to the same period a year ago. Sales growth was due to favorable patient mix, share gains and market growth from UPTRAVI (selexipag) and OPSUMIT (macitentan) partially offset by declines in Other Pulmonary Hypertension.", "text": "Sales growth was due to favorable patient mix, share gains and market growth from UPTRAVI (selexipag) and OPSUMIT (macitentan) partially offset by declines in Other Pulmonary Hypertension.", "length": 188, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1236, "tag": "div", "text_raw": "Cardiovascular / Metabolism / Other products experienced an operational decline of 8.0% as compared to the same period a year ago. The decline of XARELTO (rivaroxaban) sales was primarily driven by unfavorable patient mix and access changes.", "text": "Cardiovascular / Metabolism / Other products experienced an operational decline of 8.0% as compared to the same period a year ago.", "length": 130, "numbers_raw": ["8.0"], "numbers": [8.0], "percents_raw": ["8.0%"], "percents": [0.08], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1236, "tag": "div", "text_raw": "Cardiovascular / Metabolism / Other products experienced an operational decline of 8.0% as compared to the same period a year ago. The decline of XARELTO (rivaroxaban) sales was primarily driven by unfavorable patient mix and access changes.", "text": "The decline of XARELTO (rivaroxaban) sales was primarily driven by unfavorable patient mix and access changes.", "length": 110, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1238, "tag": "div", "text_raw": "The Company maintains a policy that no end customer will be permitted direct delivery of product to a location other than the billing location. This policy impacts contract pharmacy transactions involving non-grantee 340B covered entities for most of the Companys drugs, subject to multiple exceptions. Both grantee and non-grantee covered entities can maintain certain contract pharmacy arrangements under policy exceptions. The Company has been and will continue to offer 340B discounts to covered entities on all of its covered outpatient drugs, and it believes its policy will improve its ability to identify inappropriate duplicate discounts and diversion prohibited by the 340B statute. The 340B Drug Pricing Program is a U.S. federal government program requiring drug manufacturers to provide significant discounts on covered outpatient drugs to covered entities. This policy had discount implications which positively impacted sales to customers in the fiscal nine months of 2023.", "text": "The Company maintains a policy that no end customer will be permitted direct delivery of product to a location other than the billing location.", "length": 143, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1238, "tag": "div", "text_raw": "The Company maintains a policy that no end customer will be permitted direct delivery of product to a location other than the billing location. This policy impacts contract pharmacy transactions involving non-grantee 340B covered entities for most of the Companys drugs, subject to multiple exceptions. Both grantee and non-grantee covered entities can maintain certain contract pharmacy arrangements under policy exceptions. The Company has been and will continue to offer 340B discounts to covered entities on all of its covered outpatient drugs, and it believes its policy will improve its ability to identify inappropriate duplicate discounts and diversion prohibited by the 340B statute. The 340B Drug Pricing Program is a U.S. federal government program requiring drug manufacturers to provide significant discounts on covered outpatient drugs to covered entities. This policy had discount implications which positively impacted sales to customers in the fiscal nine months of 2023.", "text": "This policy impacts contract pharmacy transactions involving non-grantee 340B covered entities for most of the Companys drugs, subject to multiple exceptions.", "length": 159, "numbers_raw": ["340"], "numbers": [340.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1238, "tag": "div", "text_raw": "The Company maintains a policy that no end customer will be permitted direct delivery of product to a location other than the billing location. This policy impacts contract pharmacy transactions involving non-grantee 340B covered entities for most of the Companys drugs, subject to multiple exceptions. Both grantee and non-grantee covered entities can maintain certain contract pharmacy arrangements under policy exceptions. The Company has been and will continue to offer 340B discounts to covered entities on all of its covered outpatient drugs, and it believes its policy will improve its ability to identify inappropriate duplicate discounts and diversion prohibited by the 340B statute. The 340B Drug Pricing Program is a U.S. federal government program requiring drug manufacturers to provide significant discounts on covered outpatient drugs to covered entities. This policy had discount implications which positively impacted sales to customers in the fiscal nine months of 2023.", "text": "Both grantee and non-grantee covered entities can maintain certain contract pharmacy arrangements under policy exceptions.", "length": 122, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1238, "tag": "div", "text_raw": "The Company maintains a policy that no end customer will be permitted direct delivery of product to a location other than the billing location. This policy impacts contract pharmacy transactions involving non-grantee 340B covered entities for most of the Companys drugs, subject to multiple exceptions. Both grantee and non-grantee covered entities can maintain certain contract pharmacy arrangements under policy exceptions. The Company has been and will continue to offer 340B discounts to covered entities on all of its covered outpatient drugs, and it believes its policy will improve its ability to identify inappropriate duplicate discounts and diversion prohibited by the 340B statute. The 340B Drug Pricing Program is a U.S. federal government program requiring drug manufacturers to provide significant discounts on covered outpatient drugs to covered entities. This policy had discount implications which positively impacted sales to customers in the fiscal nine months of 2023.", "text": "The Company has been and will continue to offer 340B discounts to covered entities on all of its covered outpatient drugs, and it believes its policy will improve its ability to identify inappropriate duplicate discounts and diversion prohibited by the 340B statute.", "length": 266, "numbers_raw": ["340", "340"], "numbers": [340.0, 340.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1238, "tag": "div", "text_raw": "The Company maintains a policy that no end customer will be permitted direct delivery of product to a location other than the billing location. This policy impacts contract pharmacy transactions involving non-grantee 340B covered entities for most of the Companys drugs, subject to multiple exceptions. Both grantee and non-grantee covered entities can maintain certain contract pharmacy arrangements under policy exceptions. The Company has been and will continue to offer 340B discounts to covered entities on all of its covered outpatient drugs, and it believes its policy will improve its ability to identify inappropriate duplicate discounts and diversion prohibited by the 340B statute. The 340B Drug Pricing Program is a U.S. federal government program requiring drug manufacturers to provide significant discounts on covered outpatient drugs to covered entities. This policy had discount implications which positively impacted sales to customers in the fiscal nine months of 2023.", "text": "The 340B Drug Pricing Program is a U.S.", "length": 39, "numbers_raw": ["340"], "numbers": [340.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1238, "tag": "div", "text_raw": "The Company maintains a policy that no end customer will be permitted direct delivery of product to a location other than the billing location. This policy impacts contract pharmacy transactions involving non-grantee 340B covered entities for most of the Companys drugs, subject to multiple exceptions. Both grantee and non-grantee covered entities can maintain certain contract pharmacy arrangements under policy exceptions. The Company has been and will continue to offer 340B discounts to covered entities on all of its covered outpatient drugs, and it believes its policy will improve its ability to identify inappropriate duplicate discounts and diversion prohibited by the 340B statute. The 340B Drug Pricing Program is a U.S. federal government program requiring drug manufacturers to provide significant discounts on covered outpatient drugs to covered entities. This policy had discount implications which positively impacted sales to customers in the fiscal nine months of 2023.", "text": "federal government program requiring drug manufacturers to provide significant discounts on covered outpatient drugs to covered entities.", "length": 137, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1238, "tag": "div", "text_raw": "The Company maintains a policy that no end customer will be permitted direct delivery of product to a location other than the billing location. This policy impacts contract pharmacy transactions involving non-grantee 340B covered entities for most of the Companys drugs, subject to multiple exceptions. Both grantee and non-grantee covered entities can maintain certain contract pharmacy arrangements under policy exceptions. The Company has been and will continue to offer 340B discounts to covered entities on all of its covered outpatient drugs, and it believes its policy will improve its ability to identify inappropriate duplicate discounts and diversion prohibited by the 340B statute. The 340B Drug Pricing Program is a U.S. federal government program requiring drug manufacturers to provide significant discounts on covered outpatient drugs to covered entities. This policy had discount implications which positively impacted sales to customers in the fiscal nine months of 2023.", "text": "This policy had discount implications which positively impacted sales to customers in the fiscal nine months of 2023.", "length": 117, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1239, "tag": "div", "text_raw": "47", "text": "47", "length": 2, "numbers_raw": ["47"], "numbers": [47.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1240, "tag": "div", "text_raw": "47", "text": "47", "length": 2, "numbers_raw": ["47"], "numbers": [47.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1241, "tag": "div", "text_raw": "47", "text": "47", "length": 2, "numbers_raw": ["47"], "numbers": [47.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1247, "tag": "div", "text_raw": "The MedTech segment sales in the fiscal nine months of 2023 were $22.7 billion, an increase of 10.0% as compared to the same period a year ago, with an operational increase of 12.0% and a negative currency impact of 2.0%. U.S. MedTech sales increased 14.2%. International MedTech sales increased by 6.2%, including an operational increase of 10.0% and a negative currency impact of 3.8%. In the fiscal nine months of 2023, the net impact of acquisitions and divestitures on the MedTech segment operational sales growth was a positive 4.6% primarily related to the Abiomed acquisition on December 22, 2022.", "text": "The MedTech segment sales in the fiscal nine months of 2023 were $22.7 billion, an increase of 10.0% as compared to the same period a year ago, with an operational increase of 12.0% and a negative currency impact of 2.0%.", "length": 221, "numbers_raw": ["202", "3", "$22.7 billion", "10.0", "12.0", "2.0"], "numbers": [202.0, 3.0, 22700000000.0, 10.0, 12.0, 2.0], "percents_raw": ["10.0%", "12.0%", "2.0%"], "percents": [0.1, 0.12, 0.02], "currencies": ["USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 1247, "tag": "div", "text_raw": "The MedTech segment sales in the fiscal nine months of 2023 were $22.7 billion, an increase of 10.0% as compared to the same period a year ago, with an operational increase of 12.0% and a negative currency impact of 2.0%. U.S. MedTech sales increased 14.2%. International MedTech sales increased by 6.2%, including an operational increase of 10.0% and a negative currency impact of 3.8%. In the fiscal nine months of 2023, the net impact of acquisitions and divestitures on the MedTech segment operational sales growth was a positive 4.6% primarily related to the Abiomed acquisition on December 22, 2022.", "text": "MedTech sales increased 14.2%.", "length": 30, "numbers_raw": ["14.2"], "numbers": [14.2], "percents_raw": ["14.2%"], "percents": [0.142], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1247, "tag": "div", "text_raw": "The MedTech segment sales in the fiscal nine months of 2023 were $22.7 billion, an increase of 10.0% as compared to the same period a year ago, with an operational increase of 12.0% and a negative currency impact of 2.0%. U.S. MedTech sales increased 14.2%. International MedTech sales increased by 6.2%, including an operational increase of 10.0% and a negative currency impact of 3.8%. In the fiscal nine months of 2023, the net impact of acquisitions and divestitures on the MedTech segment operational sales growth was a positive 4.6% primarily related to the Abiomed acquisition on December 22, 2022.", "text": "International MedTech sales increased by 6.2%, including an operational increase of 10.0% and a negative currency impact of 3.8%.", "length": 129, "numbers_raw": ["6.2", "10.0", "3.8"], "numbers": [6.2, 10.0, 3.8], "percents_raw": ["6.2%", "10.0%", "3.8%"], "percents": [0.062, 0.1, 0.038], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1247, "tag": "div", "text_raw": "The MedTech segment sales in the fiscal nine months of 2023 were $22.7 billion, an increase of 10.0% as compared to the same period a year ago, with an operational increase of 12.0% and a negative currency impact of 2.0%. U.S. MedTech sales increased 14.2%. International MedTech sales increased by 6.2%, including an operational increase of 10.0% and a negative currency impact of 3.8%. In the fiscal nine months of 2023, the net impact of acquisitions and divestitures on the MedTech segment operational sales growth was a positive 4.6% primarily related to the Abiomed acquisition on December 22, 2022.", "text": "In the fiscal nine months of 2023, the net impact of acquisitions and divestitures on the MedTech segment operational sales growth was a positive 4.6% primarily related to the Abiomed acquisition on December 22, 2022.", "length": 217, "numbers_raw": ["202", "3", "4.6", "22", "202", "2"], "numbers": [202.0, 3.0, 4.6, 22.0, 202.0, 2.0], "percents_raw": ["4.6%"], "percents": [0.046], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1249, "tag": "div", "text_raw": "Major MedTech Franchise Sales**  Fiscal Nine Months Ended", "text": "Major MedTech Franchise Sales**  Fiscal Nine Months Ended", "length": 58, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1250, "tag": "div", "text_raw": "(Dollars in Millions) October 1, 2023 October 2, 2022 Total Change Operations Change Currency Change Surgery $ 7,507 $ 7,306 2.7 % 5.3 % (2.6) % Advanced 3,504 3,460 1.3 3.8 (2.5) General 4,002 3,846 4.1 6.5 (2.4) Orthopaedics 6,674 6,440 3.6 4.5 (0.9) Hips 1,162 1,129 2.9 3.8 (0.9) Knees 1,069 1,005 6.4 7.2 (0.8) Trauma 2,238 2,161 3.5 4.0 (0.5) Spine, Sports & Other 2,205 2,144 2.8 4.0 (1.2) Interventional Solutions 4,681 3,202 46.2 48.9 (2.7) Electrophysiology 3,449 2,943 17.2 19.8 (2.6) Abiomed 966  * *  Other Interventional Solutions 267 258 3.3 6.8 (3.5) Vision 3,864 3,704 4.3 6.6 (2.3) Contact Lenses/Other 2,820 2,712 4.0 6.6 (2.6) Surgical 1,044 992 5.3 6.6 (1.3) Total MedTech Sales $ 22,727 $ 20,651 10.0 % 12.0 % (2.0) %", "text": "(Dollars in Millions) October 1, 2023 October 2, 2022 Total Change Operations Change Currency Change Surgery $ 7,507 $ 7,306 2.7 % 5.3 % (2.6) % Advanced 3,504 3,460 1.3 3.8 (2.5) General 4,002 3,846 4.1 6.5 (2.4) Orthopaedics 6,674 6,440 3.6 4.5 (0.9) Hips 1,162 1,129 2.9 3.8 (0.9) Knees 1,069 1,005 6.4 7.2 (0.8) Trauma 2,238 2,161 3.5 4.0 (0.5) Spine, Sports & Other 2,205 2,144 2.8 4.0 (1.2) Interventional Solutions 4,681 3,202 46.2 48.9 (2.7) Electrophysiology 3,449 2,943 17.2 19.8 (2.6) Abiomed 966  * *  Other Interventional Solutions 267 258 3.3 6.8 (3.5) Vision 3,864 3,704 4.3 6.6 (2.3) Contact Lenses/Other 2,820 2,712 4.0 6.6 (2.6) Surgical 1,044 992 5.3 6.6 (1.3) Total MedTech Sales $ 22,727 $ 20,651 10.0 % 12.0 % (2.0) %", "length": 741, "numbers_raw": ["1", "202", "3", "2", "202", "2", "7,507", "7,306", "2.7", "5.3", "2.6", "3,504", "3,460", "1.3", "3.8", "2.5", "4,002", "3,846", "4.1", "6.5", "2.4", "6,674", "6,440", "3.6", "4.5", "0.9", "1,162", "1,129", "2.9", "3.8", "0.9", "1,069", "1,005", "6.4", "7.2", "0.8", "2,238", "2,161", "3.5", "4.0", "0.5", "2,205", "2,144", "2.8", "4.0", "1.2", "4,681", "3,202", "46.2", "48.9", "2.7", "3,449", "2,943", "17.2", "19.8", "2.6", "966", "267", "258", "3.3", "6.8", "3.5", "3,864", "3,704", "4.3", "6.6", "2.3", "2,820", "2,712", "4.0", "6.6", "2.6", "1,044", "992", "5.3", "6.6", "1.3", "22,727", "20,651", "10.0", "12.0", "2.0"], "numbers": [1.0, 202.0, 3.0, 2.0, 202.0, 2.0, 7507.0, 7306.0, 2.7, 5.3, 2.6, 3504.0, 3460.0, 1.3, 3.8, 2.5, 4002.0, 3846.0, 4.1, 6.5, 2.4, 6674.0, 6440.0, 3.6, 4.5, 0.9, 1162.0, 1129.0, 2.9, 3.8, 0.9, 1069.0, 1005.0, 6.4, 7.2, 0.8, 2238.0, 2161.0, 3.5, 4.0, 0.5, 2205.0, 2144.0, 2.8, 4.0, 1.2, 4681.0, 3202.0, 46.2, 48.9, 2.7, 3449.0, 2943.0, 17.2, 19.8, 2.6, 966.0, 267.0, 258.0, 3.3, 6.8, 3.5, 3864.0, 3704.0, 4.3, 6.6, 2.3, 2820.0, 2712.0, 4.0, 6.6, 2.6, 1044.0, 992.0, 5.3, 6.6, 1.3, 22727.0, 20651.0, 10.0, 12.0, 2.0], "percents_raw": ["2.7 %", "5.3 %", "10.0 %", "12.0 %"], "percents": [0.027000000000000003, 0.053, 0.1, 0.12], "currencies": ["USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 1252, "tag": "div", "text_raw": "Other Interventional Solutions", "text": "Other Interventional Solutions", "length": 30, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1253, "tag": "div", "text_raw": "* Percentage greater than 100% or not meaningful", "text": "* Percentage greater than 100% or not meaningful", "length": 48, "numbers_raw": ["100"], "numbers": [100.0], "percents_raw": ["100%"], "percents": [1.0], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1254, "tag": "div", "text_raw": "**Certain prior year amounts have been reclassified to conform to current year presentation", "text": "**Certain prior year amounts have been reclassified to conform to current year presentation", "length": 91, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1256, "tag": "div", "text_raw": "The MedTech segment sales in the fiscal third quarter of 2023 were $7.5 billion, an increase of 10.0% as compared to the same period a year ago, which included operational growth of 10.4% and a negative currency impact of 0.4%. U.S. MedTech sales increased 11.6%. International MedTech sales increased by 8.3%, including operational growth of 9.2% and a negative currency impact of 0.9%. In the fiscal third quarter of 2023, the net impact of acquisitions and divestitures on the MedTech segment operational sales growth was a positive 4.4%, primarily related to the Abiomed acquisition.", "text": "The MedTech segment sales in the fiscal third quarter of 2023 were $7.5 billion, an increase of 10.0% as compared to the same period a year ago, which included operational growth of 10.4% and a negative currency impact of 0.4%.", "length": 227, "numbers_raw": ["202", "3", "$7.5 billion", "10.0", "10.4", "0.4"], "numbers": [202.0, 3.0, 7500000000.0, 10.0, 10.4, 0.4], "percents_raw": ["10.0%", "10.4%", "0.4%"], "percents": [0.1, 0.10400000000000001, 0.004], "currencies": ["USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 1256, "tag": "div", "text_raw": "The MedTech segment sales in the fiscal third quarter of 2023 were $7.5 billion, an increase of 10.0% as compared to the same period a year ago, which included operational growth of 10.4% and a negative currency impact of 0.4%. U.S. MedTech sales increased 11.6%. International MedTech sales increased by 8.3%, including operational growth of 9.2% and a negative currency impact of 0.9%. In the fiscal third quarter of 2023, the net impact of acquisitions and divestitures on the MedTech segment operational sales growth was a positive 4.4%, primarily related to the Abiomed acquisition.", "text": "MedTech sales increased 11.6%.", "length": 30, "numbers_raw": ["11.6"], "numbers": [11.6], "percents_raw": ["11.6%"], "percents": [0.11599999999999999], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1256, "tag": "div", "text_raw": "The MedTech segment sales in the fiscal third quarter of 2023 were $7.5 billion, an increase of 10.0% as compared to the same period a year ago, which included operational growth of 10.4% and a negative currency impact of 0.4%. U.S. MedTech sales increased 11.6%. International MedTech sales increased by 8.3%, including operational growth of 9.2% and a negative currency impact of 0.9%. In the fiscal third quarter of 2023, the net impact of acquisitions and divestitures on the MedTech segment operational sales growth was a positive 4.4%, primarily related to the Abiomed acquisition.", "text": "International MedTech sales increased by 8.3%, including operational growth of 9.2% and a negative currency impact of 0.9%.", "length": 123, "numbers_raw": ["8.3", "9.2", "0.9"], "numbers": [8.3, 9.2, 0.9], "percents_raw": ["8.3%", "9.2%", "0.9%"], "percents": [0.083, 0.092, 0.009000000000000001], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1256, "tag": "div", "text_raw": "The MedTech segment sales in the fiscal third quarter of 2023 were $7.5 billion, an increase of 10.0% as compared to the same period a year ago, which included operational growth of 10.4% and a negative currency impact of 0.4%. U.S. MedTech sales increased 11.6%. International MedTech sales increased by 8.3%, including operational growth of 9.2% and a negative currency impact of 0.9%. In the fiscal third quarter of 2023, the net impact of acquisitions and divestitures on the MedTech segment operational sales growth was a positive 4.4%, primarily related to the Abiomed acquisition.", "text": "In the fiscal third quarter of 2023, the net impact of acquisitions and divestitures on the MedTech segment operational sales growth was a positive 4.4%, primarily related to the Abiomed acquisition.", "length": 199, "numbers_raw": ["202", "3", "4.4"], "numbers": [202.0, 3.0, 4.4], "percents_raw": ["4.4%"], "percents": [0.044000000000000004], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1274, "tag": "div", "text_raw": "48", "text": "48", "length": 2, "numbers_raw": ["48"], "numbers": [48.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1275, "tag": "div", "text_raw": "48", "text": "48", "length": 2, "numbers_raw": ["48"], "numbers": [48.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1276, "tag": "div", "text_raw": "48", "text": "48", "length": 2, "numbers_raw": ["48"], "numbers": [48.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1281, "tag": "div", "text_raw": "Major MedTech Franchise Sales**  Fiscal Third Quarter Ended", "text": "Major MedTech Franchise Sales**  Fiscal Third Quarter Ended", "length": 60, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1282, "tag": "div", "text_raw": "(Dollars in Millions) October 1, 2023 October 2, 2022 Total Change Operations Change Currency Change Surgery $ 2,479 $ 2,422 2.3 % 3.2 % (0.9) % Advanced 1,164 1,158 0.5 1.5 (1.0) General 1,314 1,264 4.0 4.8 (0.8) Orthopaedics 2,164 2,095 3.4 2.6 0.8 Hips 375 352 6.5 5.8 0.7 Knees 338 317 6.7 5.7 1.0 Trauma 742 717 3.5 2.4 1.1 Spine, Sports & Other 710 708 0.2 (0.2) 0.4 Interventional Solutions 1,558 1,060 47.0 48.1 (1.1) Electrophysiology 1,161 973 19.3 20.3 (1.0) Abiomed 311  * *  Other Interventional Solutions 87 87 (0.3) 1.6 (1.9) Vision 1,256 1,206 4.2 5.4 (1.2) Contact Lenses/Other 928 908 2.2 4.0 (1.8) Surgical 328 298 10.3 9.5 0.8 Total MedTech Sales $ 7,458 $ 6,782 10.0 % 10.4 % (0.4) %", "text": "(Dollars in Millions) October 1, 2023 October 2, 2022 Total Change Operations Change Currency Change Surgery $ 2,479 $ 2,422 2.3 % 3.2 % (0.9) % Advanced 1,164 1,158 0.5 1.5 (1.0) General 1,314 1,264 4.0 4.8 (0.8) Orthopaedics 2,164 2,095 3.4 2.6 0.8 Hips 375 352 6.5 5.8 0.7 Knees 338 317 6.7 5.7 1.0 Trauma 742 717 3.5 2.4 1.1 Spine, Sports & Other 710 708 0.2 (0.2) 0.4 Interventional Solutions 1,558 1,060 47.0 48.1 (1.1) Electrophysiology 1,161 973 19.3 20.3 (1.0) Abiomed 311  * *  Other Interventional Solutions 87 87 (0.3) 1.6 (1.9) Vision 1,256 1,206 4.2 5.4 (1.2) Contact Lenses/Other 928 908 2.2 4.0 (1.8) Surgical 328 298 10.3 9.5 0.8 Total MedTech Sales $ 7,458 $ 6,782 10.0 % 10.4 % (0.4) %", "length": 706, "numbers_raw": ["1", "202", "3", "2", "202", "2", "2,479", "2,422", "2.3", "3.2", "0.9", "1,164", "1,158", "0.5", "1.5", "1.0", "1,314", "1,264", "4.0", "4.8", "0.8", "2,164", "2,095", "3.4", "2.6", "0.8", "375", "352", "6.5", "5.8", "0.7 K", "338", "317", "6.7", "5.7", "1.0", "742", "717", "3.5", "2.4", "1.1", "710", "708", "0.2", "0.2", "0.4", "1,558", "1,060", "47.0", "48.1", "1.1", "1,161", "973", "19.3", "20.3", "1.0", "311", "87", "87", "0.3", "1.6", "1.9", "1,256", "1,206", "4.2", "5.4", "1.2", "928", "908", "2.2", "4.0", "1.8", "328", "298", "10.3", "9.5", "0.8", "7,458", "6,782", "10.0", "10.4", "0.4"], "numbers": [1.0, 202.0, 3.0, 2.0, 202.0, 2.0, 2479.0, 2422.0, 2.3, 3.2, 0.9, 1164.0, 1158.0, 0.5, 1.5, 1.0, 1314.0, 1264.0, 4.0, 4.8, 0.8, 2164.0, 2095.0, 3.4, 2.6, 0.8, 375.0, 352.0, 6.5, 5.8, 700.0, 338.0, 317.0, 6.7, 5.7, 1.0, 742.0, 717.0, 3.5, 2.4, 1.1, 710.0, 708.0, 0.2, 0.2, 0.4, 1558.0, 1060.0, 47.0, 48.1, 1.1, 1161.0, 973.0, 19.3, 20.3, 1.0, 311.0, 87.0, 87.0, 0.3, 1.6, 1.9, 1256.0, 1206.0, 4.2, 5.4, 1.2, 928.0, 908.0, 2.2, 4.0, 1.8, 328.0, 298.0, 10.3, 9.5, 0.8, 7458.0, 6782.0, 10.0, 10.4, 0.4], "percents_raw": ["2.3 %", "3.2 %", "10.0 %", "10.4 %"], "percents": [0.023, 0.032, 0.1, 0.10400000000000001], "currencies": ["USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 1284, "tag": "div", "text_raw": "Other Interventional Solutions", "text": "Other Interventional Solutions", "length": 30, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1285, "tag": "div", "text_raw": "* Percentage greater than 100% or not meaningful", "text": "* Percentage greater than 100% or not meaningful", "length": 48, "numbers_raw": ["100"], "numbers": [100.0], "percents_raw": ["100%"], "percents": [1.0], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1286, "tag": "div", "text_raw": "**Certain prior year amounts have been reclassified to conform to current year presentation", "text": "**Certain prior year amounts have been reclassified to conform to current year presentation", "length": 91, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1288, "tag": "div", "text_raw": "The Surgery franchise achieved operational sales growth of 3.2% as compared to the prior year fiscal third quarter. The operational growth in Advanced Surgery was primarily driven by Biosurgery global procedure growth and strength of the portfolio as well as uptake of new products in Endocutters and Energy. The growth was partially offset by competitive pressures in Endocutters predominantly in the U.S., volume-based procurement impacts in Endocutters and Energy, Russia sanctions, modest Bariatric softness, supply challenges in Endocutters, and Energy product sales declines compared to elevated results in the prior year due to competitive supply challenges. The operational growth in General Surgery was primarily driven by increased procedures coupled with technology penetration and benefits from the differentiated Wound Closure portfolio. The growth was partially offset by Russia sanctions.", "text": "The Surgery franchise achieved operational sales growth of 3.2% as compared to the prior year fiscal third quarter.", "length": 115, "numbers_raw": ["3.2"], "numbers": [3.2], "percents_raw": ["3.2%"], "percents": [0.032], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1288, "tag": "div", "text_raw": "The Surgery franchise achieved operational sales growth of 3.2% as compared to the prior year fiscal third quarter. The operational growth in Advanced Surgery was primarily driven by Biosurgery global procedure growth and strength of the portfolio as well as uptake of new products in Endocutters and Energy. The growth was partially offset by competitive pressures in Endocutters predominantly in the U.S., volume-based procurement impacts in Endocutters and Energy, Russia sanctions, modest Bariatric softness, supply challenges in Endocutters, and Energy product sales declines compared to elevated results in the prior year due to competitive supply challenges. The operational growth in General Surgery was primarily driven by increased procedures coupled with technology penetration and benefits from the differentiated Wound Closure portfolio. The growth was partially offset by Russia sanctions.", "text": "The operational growth in Advanced Surgery was primarily driven by Biosurgery global procedure growth and strength of the portfolio as well as uptake of new products in Endocutters and Energy.", "length": 192, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1288, "tag": "div", "text_raw": "The Surgery franchise achieved operational sales growth of 3.2% as compared to the prior year fiscal third quarter. The operational growth in Advanced Surgery was primarily driven by Biosurgery global procedure growth and strength of the portfolio as well as uptake of new products in Endocutters and Energy. The growth was partially offset by competitive pressures in Endocutters predominantly in the U.S., volume-based procurement impacts in Endocutters and Energy, Russia sanctions, modest Bariatric softness, supply challenges in Endocutters, and Energy product sales declines compared to elevated results in the prior year due to competitive supply challenges. The operational growth in General Surgery was primarily driven by increased procedures coupled with technology penetration and benefits from the differentiated Wound Closure portfolio. The growth was partially offset by Russia sanctions.", "text": "The growth was partially offset by competitive pressures in Endocutters predominantly in the U.S., volume-based procurement impacts in Endocutters and Energy, Russia sanctions, modest Bariatric softness, supply challenges in Endocutters, and Energy product sales declines compared to elevated results in the prior year due to competitive supply challenges.", "length": 356, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1288, "tag": "div", "text_raw": "The Surgery franchise achieved operational sales growth of 3.2% as compared to the prior year fiscal third quarter. The operational growth in Advanced Surgery was primarily driven by Biosurgery global procedure growth and strength of the portfolio as well as uptake of new products in Endocutters and Energy. The growth was partially offset by competitive pressures in Endocutters predominantly in the U.S., volume-based procurement impacts in Endocutters and Energy, Russia sanctions, modest Bariatric softness, supply challenges in Endocutters, and Energy product sales declines compared to elevated results in the prior year due to competitive supply challenges. The operational growth in General Surgery was primarily driven by increased procedures coupled with technology penetration and benefits from the differentiated Wound Closure portfolio. The growth was partially offset by Russia sanctions.", "text": "The operational growth in General Surgery was primarily driven by increased procedures coupled with technology penetration and benefits from the differentiated Wound Closure portfolio.", "length": 184, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1288, "tag": "div", "text_raw": "The Surgery franchise achieved operational sales growth of 3.2% as compared to the prior year fiscal third quarter. The operational growth in Advanced Surgery was primarily driven by Biosurgery global procedure growth and strength of the portfolio as well as uptake of new products in Endocutters and Energy. The growth was partially offset by competitive pressures in Endocutters predominantly in the U.S., volume-based procurement impacts in Endocutters and Energy, Russia sanctions, modest Bariatric softness, supply challenges in Endocutters, and Energy product sales declines compared to elevated results in the prior year due to competitive supply challenges. The operational growth in General Surgery was primarily driven by increased procedures coupled with technology penetration and benefits from the differentiated Wound Closure portfolio. The growth was partially offset by Russia sanctions.", "text": "The growth was partially offset by Russia sanctions.", "length": 52, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1290, "tag": "div", "text_raw": "The Orthopaedics franchise achieved operational sales growth of 2.6% as compared to the prior year fiscal third quarter. The operational growth in hips reflects global procedure growth and continued strength of the portfolio partially offset by Russia Sanctions. The operational growth in knees was primarily driven by procedures, benefits from launches in the ATTUNE portfolio and pull through related to the VELYS Robotic assisted solution. This was partially offset by Russia sanctions and supply constraints, primarily outside the U.S. The operational growth in Trauma was driven by global procedures and the adoption of recently launched products. This was partially offset by the timing of international tenders and volume-based procurement impacts. The operational decline in Spine, Sports & Other was primarily driven by volume-based procurement impacts and Russia sanctions in Spine partially offset by growth in Digital Solutions, Shoulders, Sports and Craniomaxillofacial products.", "text": "The Orthopaedics franchise achieved operational sales growth of 2.6% as compared to the prior year fiscal third quarter.", "length": 120, "numbers_raw": ["2.6"], "numbers": [2.6], "percents_raw": ["2.6%"], "percents": [0.026000000000000002], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1290, "tag": "div", "text_raw": "The Orthopaedics franchise achieved operational sales growth of 2.6% as compared to the prior year fiscal third quarter. The operational growth in hips reflects global procedure growth and continued strength of the portfolio partially offset by Russia Sanctions. The operational growth in knees was primarily driven by procedures, benefits from launches in the ATTUNE portfolio and pull through related to the VELYS Robotic assisted solution. This was partially offset by Russia sanctions and supply constraints, primarily outside the U.S. The operational growth in Trauma was driven by global procedures and the adoption of recently launched products. This was partially offset by the timing of international tenders and volume-based procurement impacts. The operational decline in Spine, Sports & Other was primarily driven by volume-based procurement impacts and Russia sanctions in Spine partially offset by growth in Digital Solutions, Shoulders, Sports and Craniomaxillofacial products.", "text": "The operational growth in hips reflects global procedure growth and continued strength of the portfolio partially offset by Russia Sanctions.", "length": 141, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1290, "tag": "div", "text_raw": "The Orthopaedics franchise achieved operational sales growth of 2.6% as compared to the prior year fiscal third quarter. The operational growth in hips reflects global procedure growth and continued strength of the portfolio partially offset by Russia Sanctions. The operational growth in knees was primarily driven by procedures, benefits from launches in the ATTUNE portfolio and pull through related to the VELYS Robotic assisted solution. This was partially offset by Russia sanctions and supply constraints, primarily outside the U.S. The operational growth in Trauma was driven by global procedures and the adoption of recently launched products. This was partially offset by the timing of international tenders and volume-based procurement impacts. The operational decline in Spine, Sports & Other was primarily driven by volume-based procurement impacts and Russia sanctions in Spine partially offset by growth in Digital Solutions, Shoulders, Sports and Craniomaxillofacial products.", "text": "The operational growth in knees was primarily driven by procedures, benefits from launches in the ATTUNE portfolio and pull through related to the VELYS Robotic assisted solution.", "length": 179, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1290, "tag": "div", "text_raw": "The Orthopaedics franchise achieved operational sales growth of 2.6% as compared to the prior year fiscal third quarter. The operational growth in hips reflects global procedure growth and continued strength of the portfolio partially offset by Russia Sanctions. The operational growth in knees was primarily driven by procedures, benefits from launches in the ATTUNE portfolio and pull through related to the VELYS Robotic assisted solution. This was partially offset by Russia sanctions and supply constraints, primarily outside the U.S. The operational growth in Trauma was driven by global procedures and the adoption of recently launched products. This was partially offset by the timing of international tenders and volume-based procurement impacts. The operational decline in Spine, Sports & Other was primarily driven by volume-based procurement impacts and Russia sanctions in Spine partially offset by growth in Digital Solutions, Shoulders, Sports and Craniomaxillofacial products.", "text": "This was partially offset by Russia sanctions and supply constraints, primarily outside the U.S.", "length": 96, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1290, "tag": "div", "text_raw": "The Orthopaedics franchise achieved operational sales growth of 2.6% as compared to the prior year fiscal third quarter. The operational growth in hips reflects global procedure growth and continued strength of the portfolio partially offset by Russia Sanctions. The operational growth in knees was primarily driven by procedures, benefits from launches in the ATTUNE portfolio and pull through related to the VELYS Robotic assisted solution. This was partially offset by Russia sanctions and supply constraints, primarily outside the U.S. The operational growth in Trauma was driven by global procedures and the adoption of recently launched products. This was partially offset by the timing of international tenders and volume-based procurement impacts. The operational decline in Spine, Sports & Other was primarily driven by volume-based procurement impacts and Russia sanctions in Spine partially offset by growth in Digital Solutions, Shoulders, Sports and Craniomaxillofacial products.", "text": "The operational growth in Trauma was driven by global procedures and the adoption of recently launched products.", "length": 112, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1290, "tag": "div", "text_raw": "The Orthopaedics franchise achieved operational sales growth of 2.6% as compared to the prior year fiscal third quarter. The operational growth in hips reflects global procedure growth and continued strength of the portfolio partially offset by Russia Sanctions. The operational growth in knees was primarily driven by procedures, benefits from launches in the ATTUNE portfolio and pull through related to the VELYS Robotic assisted solution. This was partially offset by Russia sanctions and supply constraints, primarily outside the U.S. The operational growth in Trauma was driven by global procedures and the adoption of recently launched products. This was partially offset by the timing of international tenders and volume-based procurement impacts. The operational decline in Spine, Sports & Other was primarily driven by volume-based procurement impacts and Russia sanctions in Spine partially offset by growth in Digital Solutions, Shoulders, Sports and Craniomaxillofacial products.", "text": "This was partially offset by the timing of international tenders and volume-based procurement impacts.", "length": 102, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1290, "tag": "div", "text_raw": "The Orthopaedics franchise achieved operational sales growth of 2.6% as compared to the prior year fiscal third quarter. The operational growth in hips reflects global procedure growth and continued strength of the portfolio partially offset by Russia Sanctions. The operational growth in knees was primarily driven by procedures, benefits from launches in the ATTUNE portfolio and pull through related to the VELYS Robotic assisted solution. This was partially offset by Russia sanctions and supply constraints, primarily outside the U.S. The operational growth in Trauma was driven by global procedures and the adoption of recently launched products. This was partially offset by the timing of international tenders and volume-based procurement impacts. The operational decline in Spine, Sports & Other was primarily driven by volume-based procurement impacts and Russia sanctions in Spine partially offset by growth in Digital Solutions, Shoulders, Sports and Craniomaxillofacial products.", "text": "The operational decline in Spine, Sports & Other was primarily driven by volume-based procurement impacts and Russia sanctions in Spine partially offset by growth in Digital Solutions, Shoulders, Sports and Craniomaxillofacial products.", "length": 236, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1292, "tag": "div", "text_raw": "The Interventional Solutions franchise achieved operational sales growth of 48.1% as compared to the prior year fiscal third quarter which includes sales from Abiomed acquired on December 22, 2022. Electrophysiology grew by double digits due to global procedure growth, new product performance and commercial execution. This was partially offset by the impacts of volume-based procurement in China and Russia sanctions. Abiomed sales reflect the strength of all commercialized regions and continued adoption of Impella 5.5 and Impella RP.", "text": "The Interventional Solutions franchise achieved operational sales growth of 48.1% as compared to the prior year fiscal third quarter which includes sales from Abiomed acquired on December 22, 2022.", "length": 197, "numbers_raw": ["48.1", "22", "202", "2"], "numbers": [48.1, 22.0, 202.0, 2.0], "percents_raw": ["48.1%"], "percents": [0.48100000000000004], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1292, "tag": "div", "text_raw": "The Interventional Solutions franchise achieved operational sales growth of 48.1% as compared to the prior year fiscal third quarter which includes sales from Abiomed acquired on December 22, 2022. Electrophysiology grew by double digits due to global procedure growth, new product performance and commercial execution. This was partially offset by the impacts of volume-based procurement in China and Russia sanctions. Abiomed sales reflect the strength of all commercialized regions and continued adoption of Impella 5.5 and Impella RP.", "text": "Electrophysiology grew by double digits due to global procedure growth, new product performance and commercial execution.", "length": 121, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1292, "tag": "div", "text_raw": "The Interventional Solutions franchise achieved operational sales growth of 48.1% as compared to the prior year fiscal third quarter which includes sales from Abiomed acquired on December 22, 2022. Electrophysiology grew by double digits due to global procedure growth, new product performance and commercial execution. This was partially offset by the impacts of volume-based procurement in China and Russia sanctions. Abiomed sales reflect the strength of all commercialized regions and continued adoption of Impella 5.5 and Impella RP.", "text": "This was partially offset by the impacts of volume-based procurement in China and Russia sanctions.", "length": 99, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1292, "tag": "div", "text_raw": "The Interventional Solutions franchise achieved operational sales growth of 48.1% as compared to the prior year fiscal third quarter which includes sales from Abiomed acquired on December 22, 2022. Electrophysiology grew by double digits due to global procedure growth, new product performance and commercial execution. This was partially offset by the impacts of volume-based procurement in China and Russia sanctions. Abiomed sales reflect the strength of all commercialized regions and continued adoption of Impella 5.5 and Impella RP.", "text": "Abiomed sales reflect the strength of all commercialized regions and continued adoption of Impella 5.5 and Impella RP.", "length": 118, "numbers_raw": ["5.5"], "numbers": [5.5], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1294, "tag": "div", "text_raw": "The Vision franchise achieved operational sales growth of 5.4% as compared to the prior year fiscal third quarter. The Contact Lenses/Other operational growth was primarily driven by the continued strong performance in the ACUVUE OASYS 1-Day family (including recent launches) and commercial execution. This was partially offset by impacts of U.S. stocking dynamics, Russia sanctions, impacts from strategic portfolio decisions and continued but improving supply challenges. The Surgical operational growth was primarily driven by cataract procedure growth, continued strength of recent innovations and reduction", "text": "The Vision franchise achieved operational sales growth of 5.4% as compared to the prior year fiscal third quarter.", "length": 114, "numbers_raw": ["5.4"], "numbers": [5.4], "percents_raw": ["5.4%"], "percents": [0.054000000000000006], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1294, "tag": "div", "text_raw": "The Vision franchise achieved operational sales growth of 5.4% as compared to the prior year fiscal third quarter. The Contact Lenses/Other operational growth was primarily driven by the continued strong performance in the ACUVUE OASYS 1-Day family (including recent launches) and commercial execution. This was partially offset by impacts of U.S. stocking dynamics, Russia sanctions, impacts from strategic portfolio decisions and continued but improving supply challenges. The Surgical operational growth was primarily driven by cataract procedure growth, continued strength of recent innovations and reduction", "text": "The Contact Lenses/Other operational growth was primarily driven by the continued strong performance in the ACUVUE OASYS 1-Day family (including recent launches) and commercial execution.", "length": 187, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1294, "tag": "div", "text_raw": "The Vision franchise achieved operational sales growth of 5.4% as compared to the prior year fiscal third quarter. The Contact Lenses/Other operational growth was primarily driven by the continued strong performance in the ACUVUE OASYS 1-Day family (including recent launches) and commercial execution. This was partially offset by impacts of U.S. stocking dynamics, Russia sanctions, impacts from strategic portfolio decisions and continued but improving supply challenges. The Surgical operational growth was primarily driven by cataract procedure growth, continued strength of recent innovations and reduction", "text": "This was partially offset by impacts of U.S.", "length": 44, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1294, "tag": "div", "text_raw": "The Vision franchise achieved operational sales growth of 5.4% as compared to the prior year fiscal third quarter. The Contact Lenses/Other operational growth was primarily driven by the continued strong performance in the ACUVUE OASYS 1-Day family (including recent launches) and commercial execution. This was partially offset by impacts of U.S. stocking dynamics, Russia sanctions, impacts from strategic portfolio decisions and continued but improving supply challenges. The Surgical operational growth was primarily driven by cataract procedure growth, continued strength of recent innovations and reduction", "text": "stocking dynamics, Russia sanctions, impacts from strategic portfolio decisions and continued but improving supply challenges.", "length": 126, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1294, "tag": "div", "text_raw": "The Vision franchise achieved operational sales growth of 5.4% as compared to the prior year fiscal third quarter. The Contact Lenses/Other operational growth was primarily driven by the continued strong performance in the ACUVUE OASYS 1-Day family (including recent launches) and commercial execution. This was partially offset by impacts of U.S. stocking dynamics, Russia sanctions, impacts from strategic portfolio decisions and continued but improving supply challenges. The Surgical operational growth was primarily driven by cataract procedure growth, continued strength of recent innovations and reduction", "text": "The Surgical operational growth was primarily driven by cataract procedure growth, continued strength of recent innovations and reduction", "length": 137, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1295, "tag": "div", "text_raw": "49", "text": "49", "length": 2, "numbers_raw": ["49"], "numbers": [49.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1296, "tag": "div", "text_raw": "49", "text": "49", "length": 2, "numbers_raw": ["49"], "numbers": [49.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1297, "tag": "div", "text_raw": "49", "text": "49", "length": 2, "numbers_raw": ["49"], "numbers": [49.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1300, "tag": "div", "text_raw": "of prior year stocking outside the U.S. This was partially offset by softer Refractive and premium IOL markets and Russia sanctions.", "text": "of prior year stocking outside the U.S.", "length": 39, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1300, "tag": "div", "text_raw": "of prior year stocking outside the U.S. This was partially offset by softer Refractive and premium IOL markets and Russia sanctions.", "text": "This was partially offset by softer Refractive and premium IOL markets and Russia sanctions.", "length": 92, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1302, "tag": "div", "text_raw": "ANALYSIS OF CONSOLIDATED EARNINGS BEFORE PROVISION FOR TAXES ON INCOME", "text": "ANALYSIS OF CONSOLIDATED EARNINGS BEFORE PROVISION FOR TAXES ON INCOME", "length": 70, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1304, "tag": "div", "text_raw": "Consolidated earnings before provision for taxes on income for the fiscal nine months of 2023 was $10.2 billion representing 16.1% of sales as compared to $15.5 billion in the fiscal nine months of 2022, representing 25.8% of sales. The decline was primarily related to the talc settlement proposal in the fiscal first quarter.", "text": "Consolidated earnings before provision for taxes on income for the fiscal nine months of 2023 was $10.2 billion representing 16.1% of sales as compared to $15.5 billion in the fiscal nine months of 2022, representing 25.8% of sales.", "length": 232, "numbers_raw": ["202", "3", "$10.2 billion", "16.1", "$15.5 billion", "202", "2", "25.8"], "numbers": [202.0, 3.0, 10200000000.0, 16.1, 15500000000.0, 202.0, 2.0, 25.8], "percents_raw": ["16.1%", "25.8%"], "percents": [0.161, 0.258], "currencies": ["USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 1304, "tag": "div", "text_raw": "Consolidated earnings before provision for taxes on income for the fiscal nine months of 2023 was $10.2 billion representing 16.1% of sales as compared to $15.5 billion in the fiscal nine months of 2022, representing 25.8% of sales. The decline was primarily related to the talc settlement proposal in the fiscal first quarter.", "text": "The decline was primarily related to the talc settlement proposal in the fiscal first quarter.", "length": 94, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1306, "tag": "div", "text_raw": "Consolidated earnings before provision for taxes on income for the fiscal third quarter of 2023 was $5.2 billion representing 24.4% of sales as compared to $5.2 billion in the fiscal third quarter of 2022, representing 25.9% of sales.", "text": "Consolidated earnings before provision for taxes on income for the fiscal third quarter of 2023 was $5.2 billion representing 24.4% of sales as compared to $5.2 billion in the fiscal third quarter of 2022, representing 25.9% of sales.", "length": 234, "numbers_raw": ["202", "3", "$5.2 billion", "24.4", "$5.2 billion", "202", "2", "25.9"], "numbers": [202.0, 3.0, 5200000000.0, 24.4, 5200000000.0, 202.0, 2.0, 25.9], "percents_raw": ["24.4%", "25.9%"], "percents": [0.244, 0.259], "currencies": ["USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 1310, "tag": "div", "text_raw": "(Dollars in billions. Percentages in chart are as a percent to total sales)", "text": "Percentages in chart are as a percent to total sales)", "length": 53, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1312, "tag": "div", "text_raw": "Fiscal nine months Q3 2023 versus Fiscal nine months Q3 2022", "text": "Fiscal nine months Q3 2023 versus Fiscal nine months Q3 2022", "length": 60, "numbers_raw": ["3", "202", "3", "3", "202", "2"], "numbers": [3.0, 202.0, 3.0, 3.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1313, "tag": "div", "text_raw": "Cost of products sold increased as a percent to sales driven by:", "text": "Cost of products sold increased as a percent to sales driven by:", "length": 64, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1314, "tag": "div", "text_raw": " Favorable patient mix and lower one-time COVID-19 vaccine manufacturing related exit costs in 2023 in the Innovative Medicine business", "text": " Favorable patient mix and lower one-time COVID-19 vaccine manufacturing related exit costs in 2023 in the Innovative Medicine business", "length": 136, "numbers_raw": ["19", "202", "3"], "numbers": [19.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1315, "tag": "div", "text_raw": " Commodity inflation, restructuring related excess inventory costs and Abiomed amortization in the MedTech business", "text": " Commodity inflation, restructuring related excess inventory costs and Abiomed amortization in the MedTech business", "length": 116, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1317, "tag": "div", "text_raw": "The intangible asset amortization expense included in cost of products sold for the fiscal nine months of 2023 and 2022 was $3.4 billion and $3.0 billion, respectively.", "text": "The intangible asset amortization expense included in cost of products sold for the fiscal nine months of 2023 and 2022 was $3.4 billion and $3.0 billion, respectively.", "length": 168, "numbers_raw": ["202", "3", "202", "2", "$3.4 billion", "$3.0 billion"], "numbers": [202.0, 3.0, 202.0, 2.0, 3400000000.0, 3000000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1319, "tag": "div", "text_raw": "Q3 2023 versus Q3 2022", "text": "Q3 2023 versus Q3 2022", "length": 22, "numbers_raw": ["3", "202", "3", "3", "202", "2"], "numbers": [3.0, 202.0, 3.0, 3.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1320, "tag": "div", "text_raw": "Cost of products sold was flat as a percent to sales primarily driven by:", "text": "Cost of products sold was flat as a percent to sales primarily driven by:", "length": 73, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1321, "tag": "div", "text_raw": " Favorable patient mix and lower one-time COVID-19 vaccine manufacturing related exit costs in 2023 in the Innovative Medicine business", "text": " Favorable patient mix and lower one-time COVID-19 vaccine manufacturing related exit costs in 2023 in the Innovative Medicine business", "length": 136, "numbers_raw": ["19", "202", "3"], "numbers": [19.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1323, "tag": "div", "text_raw": " Commodity inflation, unfavorable product mix, restructuring related excess inventory costs and Abiomed amortization in the MedTech business", "text": " Commodity inflation, unfavorable product mix, restructuring related excess inventory costs and Abiomed amortization in the MedTech business", "length": 141, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1325, "tag": "div", "text_raw": "The intangible asset amortization expense included in cost of products sold for the fiscal third quarters of 2023 and 2022 was $1.1 billion and $1.0 billion, respectively.", "text": "The intangible asset amortization expense included in cost of products sold for the fiscal third quarters of 2023 and 2022 was $1.1 billion and $1.0 billion, respectively.", "length": 171, "numbers_raw": ["202", "3", "202", "2", "$1.1 billion", "$1.0 billion"], "numbers": [202.0, 3.0, 202.0, 2.0, 1100000000.0, 1000000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1327, "tag": "div", "text_raw": "50", "text": "50", "length": 2, "numbers_raw": ["50"], "numbers": [50.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1328, "tag": "div", "text_raw": "50", "text": "50", "length": 2, "numbers_raw": ["50"], "numbers": [50.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1329, "tag": "div", "text_raw": "50", "text": "50", "length": 2, "numbers_raw": ["50"], "numbers": [50.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1333, "tag": "div", "text_raw": "Selling, Marketing and Administrative Expenses", "text": "Selling, Marketing and Administrative Expenses", "length": 46, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1335, "tag": "div", "text_raw": "(Dollars in billions. Percentages in chart are as a percent to total sales)", "text": "Percentages in chart are as a percent to total sales)", "length": 53, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1337, "tag": "div", "text_raw": "Fiscal nine months Q3 2023 versus Fiscal nine months Q3 2022", "text": "Fiscal nine months Q3 2023 versus Fiscal nine months Q3 2022", "length": 60, "numbers_raw": ["3", "202", "3", "3", "202", "2"], "numbers": [3.0, 202.0, 3.0, 3.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1338, "tag": "div", "text_raw": "Selling, Marketing and Administrative Expenses decreased slightly as a percent to sales driven by:", "text": "Selling, Marketing and Administrative Expenses decreased slightly as a percent to sales driven by:", "length": 98, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1339, "tag": "div", "text_raw": " Leveraging in both the Innovative Medicine and MedTech businesses", "text": " Leveraging in both the Innovative Medicine and MedTech businesses", "length": 67, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1341, "tag": "div", "text_raw": "Q3 2023 versus Q3 2022", "text": "Q3 2023 versus Q3 2022", "length": 22, "numbers_raw": ["3", "202", "3", "3", "202", "2"], "numbers": [3.0, 202.0, 3.0, 3.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1342, "tag": "div", "text_raw": "Selling, Marketing and Administrative Expenses increased as a percent to sales primarily driven by:", "text": "Selling, Marketing and Administrative Expenses increased as a percent to sales primarily driven by:", "length": 99, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1343, "tag": "div", "text_raw": " Increased enterprise wide expenses", "text": " Increased enterprise wide expenses", "length": 36, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1345, "tag": "div", "text_raw": " Leveraging in the Innovative Medicine business", "text": " Leveraging in the Innovative Medicine business", "length": 48, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1348, "tag": "div", "text_raw": "Research and Development Expense", "text": "Research and Development Expense", "length": 32, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1350, "tag": "div", "text_raw": "(Dollars in billions. Percentages in chart are as a percent to total sales)", "text": "Percentages in chart are as a percent to total sales)", "length": 53, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1352, "tag": "div", "text_raw": "Fiscal nine months Q3 2023 versus Fiscal nine months Q3 2022", "text": "Fiscal nine months Q3 2023 versus Fiscal nine months Q3 2022", "length": 60, "numbers_raw": ["3", "202", "3", "3", "202", "2"], "numbers": [3.0, 202.0, 3.0, 3.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1353, "tag": "div", "text_raw": "Research and Development decreased as a percent to sales driven by:", "text": "Research and Development decreased as a percent to sales driven by:", "length": 67, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1354, "tag": "div", "text_raw": " Cost management initiatives in the MedTech business", "text": " Cost management initiatives in the MedTech business", "length": 53, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1355, "tag": "div", "text_raw": " Portfolio prioritization in the Innovative Medicine business", "text": " Portfolio prioritization in the Innovative Medicine business", "length": 62, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1357, "tag": "div", "text_raw": " acquired in-process research & development costs in the Innovative Medicine business", "text": " acquired in-process research & development costs in the Innovative Medicine business", "length": 86, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1359, "tag": "div", "text_raw": "Q3 2023 versus Q3 2022", "text": "Q3 2023 versus Q3 2022", "length": 22, "numbers_raw": ["3", "202", "3", "3", "202", "2"], "numbers": [3.0, 202.0, 3.0, 3.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1360, "tag": "div", "text_raw": "Research and Development decreased as a percent to sales driven by:", "text": "Research and Development decreased as a percent to sales driven by:", "length": 67, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1361, "tag": "div", "text_raw": " Portfolio prioritization in the Innovative Medicine business", "text": " Portfolio prioritization in the Innovative Medicine business", "length": 62, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1363, "tag": "div", "text_raw": " higher milestone payments in the Innovative Medicine business", "text": " higher milestone payments in the Innovative Medicine business", "length": 63, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1365, "tag": "div", "text_raw": "In-Process Research and Development (IPR&D) Impairments", "text": "In-Process Research and Development (IPR&D) Impairments", "length": 55, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1367, "tag": "div", "text_raw": "In the fiscal third quarter of 2023, the Company recorded a charge of approximately $0.2 billion related to market dynamics associated with a non-strategic asset (M710) acquired as part of the acquisition of Momenta Pharmaceuticals in 2020. In the fiscal first quarter of 2023, the Company recorded a charge of approximately $0.1 billion associated with the IPR&D acquired with Pulsar Vascular in 2016. In the first fiscal nine months of 2022, the Company recorded an intangible asset impairment", "text": "In the fiscal third quarter of 2023, the Company recorded a charge of approximately $0.2 billion related to market dynamics associated with a non-strategic asset (M710) acquired as part of the acquisition of Momenta Pharmaceuticals in 2020.", "length": 240, "numbers_raw": ["202", "3", "$0.2 billion", "710", "202", "0"], "numbers": [202.0, 3.0, 200000000.0, 710.0, 202.0, 0.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1367, "tag": "div", "text_raw": "In the fiscal third quarter of 2023, the Company recorded a charge of approximately $0.2 billion related to market dynamics associated with a non-strategic asset (M710) acquired as part of the acquisition of Momenta Pharmaceuticals in 2020. In the fiscal first quarter of 2023, the Company recorded a charge of approximately $0.1 billion associated with the IPR&D acquired with Pulsar Vascular in 2016. In the first fiscal nine months of 2022, the Company recorded an intangible asset impairment", "text": "In the fiscal first quarter of 2023, the Company recorded a charge of approximately $0.1 billion associated with the IPR&D acquired with Pulsar Vascular in 2016.", "length": 161, "numbers_raw": ["202", "3", "$0.1 billion", "201", "6"], "numbers": [202.0, 3.0, 100000000.0, 201.0, 6.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1367, "tag": "div", "text_raw": "In the fiscal third quarter of 2023, the Company recorded a charge of approximately $0.2 billion related to market dynamics associated with a non-strategic asset (M710) acquired as part of the acquisition of Momenta Pharmaceuticals in 2020. In the fiscal first quarter of 2023, the Company recorded a charge of approximately $0.1 billion associated with the IPR&D acquired with Pulsar Vascular in 2016. In the first fiscal nine months of 2022, the Company recorded an intangible asset impairment", "text": "In the first fiscal nine months of 2022, the Company recorded an intangible asset impairment", "length": 92, "numbers_raw": ["202", "2"], "numbers": [202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1368, "tag": "div", "text_raw": "51", "text": "51", "length": 2, "numbers_raw": ["51"], "numbers": [51.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1369, "tag": "div", "text_raw": "51", "text": "51", "length": 2, "numbers_raw": ["51"], "numbers": [51.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1370, "tag": "div", "text_raw": "51", "text": "51", "length": 2, "numbers_raw": ["51"], "numbers": [51.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1373, "tag": "div", "text_raw": "charge of approximately $0.6 billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). The Company acquired all rights to bermekimab from XBiotech, Inc. in the fiscal year 2020.", "text": "charge of approximately $0.6 billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS).", "length": 223, "numbers_raw": ["$0.6 billion", "774", "744", "62"], "numbers": [600000000.0, 774.0, 744.0, 62.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1373, "tag": "div", "text_raw": "charge of approximately $0.6 billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). The Company acquired all rights to bermekimab from XBiotech, Inc. in the fiscal year 2020.", "text": "The Company acquired all rights to bermekimab from XBiotech, Inc.", "length": 65, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1373, "tag": "div", "text_raw": "charge of approximately $0.6 billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). The Company acquired all rights to bermekimab from XBiotech, Inc. in the fiscal year 2020.", "text": "in the fiscal year 2020.", "length": 24, "numbers_raw": ["202", "0"], "numbers": [202.0, 0.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1377, "tag": "div", "text_raw": "Interest income in the first fiscal nine months of 2023 was $898 million as compared to $236 million in the same period a year ago primarily due to higher rates of interest earned on cash balances. Interest income in the fiscal third quarter of 2023 was $374 million as compared to $150 million in the fiscal third quarter of 2022 primarily due to higher rates of interest earned on cash balances. Interest expense in the first fiscal nine months of 2023 was $621 million as compared to $99 million in the same period a year ago primarily due to higher interest rates on the debt balance. Interest expense in the fiscal third quarter of 2023 was $192 million as compared to $51 million in the same period a year ago primarily due to higher interest rates on the debt balance. The balance of cash, cash equivalents and current marketable securities was $23.5 billion at the end of the fiscal third quarter of 2023 as compared to $33.1 billion at the end of the fiscal third quarter of 2022. The Companys debt position was $29.9 billion as of October 1, 2023, as compared to $32.0 billion the same period a year ago.", "text": "Interest income in the first fiscal nine months of 2023 was $898 million as compared to $236 million in the same period a year ago primarily due to higher rates of interest earned on cash balances.", "length": 197, "numbers_raw": ["202", "3", "$898 million", "$236 million"], "numbers": [202.0, 3.0, 898000000.0, 236000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1377, "tag": "div", "text_raw": "Interest income in the first fiscal nine months of 2023 was $898 million as compared to $236 million in the same period a year ago primarily due to higher rates of interest earned on cash balances. Interest income in the fiscal third quarter of 2023 was $374 million as compared to $150 million in the fiscal third quarter of 2022 primarily due to higher rates of interest earned on cash balances. Interest expense in the first fiscal nine months of 2023 was $621 million as compared to $99 million in the same period a year ago primarily due to higher interest rates on the debt balance. Interest expense in the fiscal third quarter of 2023 was $192 million as compared to $51 million in the same period a year ago primarily due to higher interest rates on the debt balance. The balance of cash, cash equivalents and current marketable securities was $23.5 billion at the end of the fiscal third quarter of 2023 as compared to $33.1 billion at the end of the fiscal third quarter of 2022. The Companys debt position was $29.9 billion as of October 1, 2023, as compared to $32.0 billion the same period a year ago.", "text": "Interest income in the fiscal third quarter of 2023 was $374 million as compared to $150 million in the fiscal third quarter of 2022 primarily due to higher rates of interest earned on cash balances.", "length": 199, "numbers_raw": ["202", "3", "$374 million", "$150 million", "202", "2"], "numbers": [202.0, 3.0, 374000000.0, 150000000.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1377, "tag": "div", "text_raw": "Interest income in the first fiscal nine months of 2023 was $898 million as compared to $236 million in the same period a year ago primarily due to higher rates of interest earned on cash balances. Interest income in the fiscal third quarter of 2023 was $374 million as compared to $150 million in the fiscal third quarter of 2022 primarily due to higher rates of interest earned on cash balances. Interest expense in the first fiscal nine months of 2023 was $621 million as compared to $99 million in the same period a year ago primarily due to higher interest rates on the debt balance. Interest expense in the fiscal third quarter of 2023 was $192 million as compared to $51 million in the same period a year ago primarily due to higher interest rates on the debt balance. The balance of cash, cash equivalents and current marketable securities was $23.5 billion at the end of the fiscal third quarter of 2023 as compared to $33.1 billion at the end of the fiscal third quarter of 2022. The Companys debt position was $29.9 billion as of October 1, 2023, as compared to $32.0 billion the same period a year ago.", "text": "Interest expense in the first fiscal nine months of 2023 was $621 million as compared to $99 million in the same period a year ago primarily due to higher interest rates on the debt balance.", "length": 190, "numbers_raw": ["202", "3", "$621 million", "$99 million"], "numbers": [202.0, 3.0, 621000000.0, 99000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1377, "tag": "div", "text_raw": "Interest income in the first fiscal nine months of 2023 was $898 million as compared to $236 million in the same period a year ago primarily due to higher rates of interest earned on cash balances. Interest income in the fiscal third quarter of 2023 was $374 million as compared to $150 million in the fiscal third quarter of 2022 primarily due to higher rates of interest earned on cash balances. Interest expense in the first fiscal nine months of 2023 was $621 million as compared to $99 million in the same period a year ago primarily due to higher interest rates on the debt balance. Interest expense in the fiscal third quarter of 2023 was $192 million as compared to $51 million in the same period a year ago primarily due to higher interest rates on the debt balance. The balance of cash, cash equivalents and current marketable securities was $23.5 billion at the end of the fiscal third quarter of 2023 as compared to $33.1 billion at the end of the fiscal third quarter of 2022. The Companys debt position was $29.9 billion as of October 1, 2023, as compared to $32.0 billion the same period a year ago.", "text": "Interest expense in the fiscal third quarter of 2023 was $192 million as compared to $51 million in the same period a year ago primarily due to higher interest rates on the debt balance.", "length": 186, "numbers_raw": ["202", "3", "$192 million", "$51 million"], "numbers": [202.0, 3.0, 192000000.0, 51000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1377, "tag": "div", "text_raw": "Interest income in the first fiscal nine months of 2023 was $898 million as compared to $236 million in the same period a year ago primarily due to higher rates of interest earned on cash balances. Interest income in the fiscal third quarter of 2023 was $374 million as compared to $150 million in the fiscal third quarter of 2022 primarily due to higher rates of interest earned on cash balances. Interest expense in the first fiscal nine months of 2023 was $621 million as compared to $99 million in the same period a year ago primarily due to higher interest rates on the debt balance. Interest expense in the fiscal third quarter of 2023 was $192 million as compared to $51 million in the same period a year ago primarily due to higher interest rates on the debt balance. The balance of cash, cash equivalents and current marketable securities was $23.5 billion at the end of the fiscal third quarter of 2023 as compared to $33.1 billion at the end of the fiscal third quarter of 2022. The Companys debt position was $29.9 billion as of October 1, 2023, as compared to $32.0 billion the same period a year ago.", "text": "The balance of cash, cash equivalents and current marketable securities was $23.5 billion at the end of the fiscal third quarter of 2023 as compared to $33.1 billion at the end of the fiscal third quarter of 2022.", "length": 213, "numbers_raw": ["$23.5 billion", "202", "3", "$33.1 billion", "202", "2"], "numbers": [23500000000.0, 202.0, 3.0, 33100000000.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1377, "tag": "div", "text_raw": "Interest income in the first fiscal nine months of 2023 was $898 million as compared to $236 million in the same period a year ago primarily due to higher rates of interest earned on cash balances. Interest income in the fiscal third quarter of 2023 was $374 million as compared to $150 million in the fiscal third quarter of 2022 primarily due to higher rates of interest earned on cash balances. Interest expense in the first fiscal nine months of 2023 was $621 million as compared to $99 million in the same period a year ago primarily due to higher interest rates on the debt balance. Interest expense in the fiscal third quarter of 2023 was $192 million as compared to $51 million in the same period a year ago primarily due to higher interest rates on the debt balance. The balance of cash, cash equivalents and current marketable securities was $23.5 billion at the end of the fiscal third quarter of 2023 as compared to $33.1 billion at the end of the fiscal third quarter of 2022. The Companys debt position was $29.9 billion as of October 1, 2023, as compared to $32.0 billion the same period a year ago.", "text": "The Companys debt position was $29.9 billion as of October 1, 2023, as compared to $32.0 billion the same period a year ago.", "length": 125, "numbers_raw": ["$29.9 billion", "1", "202", "3", "$32.0 billion"], "numbers": [29900000000.0, 1.0, 202.0, 3.0, 32000000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1381, "tag": "div", "text_raw": "Fiscal nine months Q3 2023 versus Fiscal nine months Q3 2022", "text": "Fiscal nine months Q3 2023 versus Fiscal nine months Q3 2022", "length": 60, "numbers_raw": ["3", "202", "3", "3", "202", "2"], "numbers": [3.0, 202.0, 3.0, 3.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1382, "tag": "div", "text_raw": "Other (income) expense, net for the fiscal nine months of 2023 was unfavorable by $7.0 billion as compared to the prior year primarily due to the following:", "text": "Other (income) expense, net for the fiscal nine months of 2023 was unfavorable by $7.0 billion as compared to the prior year primarily due to the following:", "length": 156, "numbers_raw": ["202", "3", "$7.0 billion"], "numbers": [202.0, 3.0, 7000000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1384, "tag": "div", "text_raw": "Fiscal Nine Months (Dollars in Billions)(Income)/Expense 2023 2022 Change Litigation related (1) $ 6.7 0.6 6.1 Changes in the fair value of securities (2) 1.1 0.7 0.4 COVID-19 Vaccine related exit costs 0.4 0.2 0.2 Employee benefit plan related (1.1) (0.9) (0.2) Other (0.1) (0.6) 0.5 Total Other (Income) Expense, Net $ 7.0 0.0 7.0", "text": "Fiscal Nine Months (Dollars in Billions)(Income)/Expense 2023 2022 Change Litigation related (1) $ 6.7 0.6 6.1 Changes in the fair value of securities (2) 1.1 0.7 0.4 COVID-19 Vaccine related exit costs 0.4 0.2 0.2 Employee benefit plan related (1.1) (0.9) (0.2) Other (0.1) (0.6) 0.5 Total Other (Income) Expense, Net $ 7.0 0.0 7.0", "length": 332, "numbers_raw": ["202", "3", "202", "2", "1", "6.7", "0.6", "6.1", "2", "1.1", "0.7", "0.4", "19", "0.4", "0.2", "0.2", "1.1", "0.9", "0.2", "0.1", "0.6", "0.5", "7.0", "0.0", "7.0"], "numbers": [202.0, 3.0, 202.0, 2.0, 1.0, 6.7, 0.6, 6.1, 2.0, 1.1, 0.7, 0.4, 19.0, 0.4, 0.2, 0.2, 1.1, 0.9, 0.2, 0.1, 0.6, 0.5, 7.0, 0.0, 7.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1385, "tag": "div", "text_raw": "Litigation related (1)", "text": "Litigation related (1)", "length": 22, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1386, "tag": "div", "text_raw": "Changes in the fair value of securities (2)", "text": "Changes in the fair value of securities (2)", "length": 43, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1387, "tag": "div", "text_raw": "(1) Primarily related to the talc settlement proposal. The fiscal nine months of 2023 includes favorable intellectual property related litigation settlements of approximately $0.3 billion. Primarily related to pelvic mesh in the fiscal nine months of 2022.", "text": "(1) Primarily related to the talc settlement proposal.", "length": 54, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1387, "tag": "div", "text_raw": "(1) Primarily related to the talc settlement proposal. The fiscal nine months of 2023 includes favorable intellectual property related litigation settlements of approximately $0.3 billion. Primarily related to pelvic mesh in the fiscal nine months of 2022.", "text": "The fiscal nine months of 2023 includes favorable intellectual property related litigation settlements of approximately $0.3 billion.", "length": 133, "numbers_raw": ["202", "3", "$0.3 billion"], "numbers": [202.0, 3.0, 300000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1387, "tag": "div", "text_raw": "(1) Primarily related to the talc settlement proposal. The fiscal nine months of 2023 includes favorable intellectual property related litigation settlements of approximately $0.3 billion. Primarily related to pelvic mesh in the fiscal nine months of 2022.", "text": "Primarily related to pelvic mesh in the fiscal nine months of 2022.", "length": 67, "numbers_raw": ["202", "2"], "numbers": [202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1388, "tag": "div", "text_raw": "(2) The fiscal nine months of 2023 includes $0.6 billion related to the unfavorable change in the fair value of the Kenvue securities and $0.4 billion related to the partial impairment of Idorsia convertible debt and the change in the fair value of the Idorsia equity securities held.", "text": "(2) The fiscal nine months of 2023 includes $0.6 billion related to the unfavorable change in the fair value of the Kenvue securities and $0.4 billion related to the partial impairment of Idorsia convertible debt and the change in the fair value of the Idorsia equity securities held.", "length": 284, "numbers_raw": ["2", "202", "3", "$0.6 billion", "$0.4 billion"], "numbers": [2.0, 202.0, 3.0, 600000000.0, 400000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1390, "tag": "div", "text_raw": "Q3 2023 versus Q3 2022", "text": "Q3 2023 versus Q3 2022", "length": 22, "numbers_raw": ["3", "202", "3", "3", "202", "2"], "numbers": [3.0, 202.0, 3.0, 3.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1391, "tag": "div", "text_raw": "Other (income) expense, net for the fiscal third quarter of 2023 was unfavorable by $0.3 billion as compared to the prior year primarily due to the following:", "text": "Other (income) expense, net for the fiscal third quarter of 2023 was unfavorable by $0.3 billion as compared to the prior year primarily due to the following:", "length": 158, "numbers_raw": ["202", "3", "$0.3 billion"], "numbers": [202.0, 3.0, 300000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1392, "tag": "div", "text_raw": "Fiscal Third Quarter (Dollars in Billions)(Income)/Expense 2023 2022 Change Changes in the fair value of securities (1) $ 1.0 0.2 0.8 Employee benefit plan related (0.3) (0.3)  Litigation related (0.1) 0.2 (0.3) COVID-19 Vaccine related exit costs 0.0 0.2 (0.2) Other (0.1) (0.1)  Total Other (Income) Expense, Net $ 0.5 0.2 0.3", "text": "Fiscal Third Quarter (Dollars in Billions)(Income)/Expense 2023 2022 Change Changes in the fair value of securities (1) $ 1.0 0.2 0.8 Employee benefit plan related (0.3) (0.3)  Litigation related (0.1) 0.2 (0.3) COVID-19 Vaccine related exit costs 0.0 0.2 (0.2) Other (0.1) (0.1)  Total Other (Income) Expense, Net $ 0.5 0.2 0.3", "length": 330, "numbers_raw": ["202", "3", "202", "2", "1", "1.0", "0.2", "0.8", "0.3", "0.3", "0.1", "0.2", "0.3", "19", "0.0", "0.2", "0.2", "0.1", "0.1", "0.5", "0.2", "0.3"], "numbers": [202.0, 3.0, 202.0, 2.0, 1.0, 1.0, 0.2, 0.8, 0.3, 0.3, 0.1, 0.2, 0.3, 19.0, 0.0, 0.2, 0.2, 0.1, 0.1, 0.5, 0.2, 0.3], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1393, "tag": "div", "text_raw": "Changes in the fair value of securities (1)", "text": "Changes in the fair value of securities (1)", "length": 43, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1394, "tag": "div", "text_raw": "(1) The fiscal third quarter of 2023 includes $0.6 billion related to the unfavorable change in the fair value of the Kenvue securities and $0.4 billion related to the partial impairment of Idorsia convertible debt and the change in the fair value of the Idorsia equity securities held.", "text": "(1) The fiscal third quarter of 2023 includes $0.6 billion related to the unfavorable change in the fair value of the Kenvue securities and $0.4 billion related to the partial impairment of Idorsia convertible debt and the change in the fair value of the Idorsia equity securities held.", "length": 286, "numbers_raw": ["1", "202", "3", "$0.6 billion", "$0.4 billion"], "numbers": [1.0, 202.0, 3.0, 600000000.0, 400000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1396, "tag": "div", "text_raw": "*Other (income) expense, net is the account where the Company records gains and losses related to the sale and write-down of certain investments in equity securities held by Johnson & Johnson Innovation - JJDC, Inc. (JJDC), changes in the fair value of securities, gains and losses on divestitures, gains and losses on sale of assets, certain transactional currency gains and losses, acquisition-related costs, litigation accruals and settlements, investment (income)/loss related to employee benefit plans, as well as royalty income.", "text": "*Other (income) expense, net is the account where the Company records gains and losses related to the sale and write-down of certain investments in equity securities held by Johnson & Johnson Innovation - JJDC, Inc.", "length": 215, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1396, "tag": "div", "text_raw": "*Other (income) expense, net is the account where the Company records gains and losses related to the sale and write-down of certain investments in equity securities held by Johnson & Johnson Innovation - JJDC, Inc. (JJDC), changes in the fair value of securities, gains and losses on divestitures, gains and losses on sale of assets, certain transactional currency gains and losses, acquisition-related costs, litigation accruals and settlements, investment (income)/loss related to employee benefit plans, as well as royalty income.", "text": "(JJDC), changes in the fair value of securities, gains and losses on divestitures, gains and losses on sale of assets, certain transactional currency gains and losses, acquisition-related costs, litigation accruals and settlements, investment (income)/loss related to employee benefit plans, as well as royalty income.", "length": 318, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1399, "tag": "div", "text_raw": "52", "text": "52", "length": 2, "numbers_raw": ["52"], "numbers": [52.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1400, "tag": "div", "text_raw": "52", "text": "52", "length": 2, "numbers_raw": ["52"], "numbers": [52.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1401, "tag": "div", "text_raw": "52", "text": "52", "length": 2, "numbers_raw": ["52"], "numbers": [52.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1405, "tag": "div", "text_raw": "EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT", "text": "EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT", "length": 46, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1407, "tag": "div", "text_raw": "Income before tax by segment of business for the fiscal nine months were as follows:", "text": "Income before tax by segment of business for the fiscal nine months were as follows:", "length": 84, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1408, "tag": "div", "text_raw": "Income Before Tax Segment Sales Percent of Segment Sales (Dollars in Millions) October 1, 2023 October 2, 2022 October 1, 2023 October 2, 2022 October 1, 2023 October 2, 2022 Innovative Medicine $ 14,008 $ 12,424 $ 41,037 $ 39,400 34.1 % 31.5 % MedTech 4,265 3,641 22,727 20,651 18.8 17.6 Segment earnings before tax 18,273 16,065 63,764 60,051 28.7 26.8 Less: Expenses not allocated to segments (1) 8,037 546 Worldwide income before tax $ 10,236 $ 15,519 $ 63,764 $ 60,051 16.1 % 25.8 %", "text": "Income Before Tax Segment Sales Percent of Segment Sales (Dollars in Millions) October 1, 2023 October 2, 2022 October 1, 2023 October 2, 2022 October 1, 2023 October 2, 2022 Innovative Medicine $ 14,008 $ 12,424 $ 41,037 $ 39,400 34.1 % 31.5 % MedTech 4,265 3,641 22,727 20,651 18.8 17.6 Segment earnings before tax 18,273 16,065 63,764 60,051 28.7 26.8 Less:", "length": 360, "numbers_raw": ["1", "202", "3", "2", "202", "2", "1", "202", "3", "2", "202", "2", "1", "202", "3", "2", "202", "2", "14,008", "12,424", "41,037", "39,400", "34.1", "31.5", "4,265", "3,641", "22,727", "20,651", "18.8", "17.6", "18,273", "16,065", "63,764", "60,051", "28.7", "26.8"], "numbers": [1.0, 202.0, 3.0, 2.0, 202.0, 2.0, 1.0, 202.0, 3.0, 2.0, 202.0, 2.0, 1.0, 202.0, 3.0, 2.0, 202.0, 2.0, 14008.0, 12424.0, 41037.0, 39400.0, 34.1, 31.5, 4265.0, 3641.0, 22727.0, 20651.0, 18.8, 17.6, 18273.0, 16065.0, 63764.0, 60051.0, 28.7, 26.8], "percents_raw": ["34.1 %", "31.5 %"], "percents": [0.341, 0.315], "currencies": ["USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 1408, "tag": "div", "text_raw": "Income Before Tax Segment Sales Percent of Segment Sales (Dollars in Millions) October 1, 2023 October 2, 2022 October 1, 2023 October 2, 2022 October 1, 2023 October 2, 2022 Innovative Medicine $ 14,008 $ 12,424 $ 41,037 $ 39,400 34.1 % 31.5 % MedTech 4,265 3,641 22,727 20,651 18.8 17.6 Segment earnings before tax 18,273 16,065 63,764 60,051 28.7 26.8 Less: Expenses not allocated to segments (1) 8,037 546 Worldwide income before tax $ 10,236 $ 15,519 $ 63,764 $ 60,051 16.1 % 25.8 %", "text": "Expenses not allocated to segments (1) 8,037 546 Worldwide income before tax $ 10,236 $ 15,519 $ 63,764 $ 60,051 16.1 % 25.8 %", "length": 126, "numbers_raw": ["1", "8,037", "546", "10,236", "15,519", "63,764", "60,051", "16.1", "25.8"], "numbers": [1.0, 8037.0, 546.0, 10236.0, 15519.0, 63764.0, 60051.0, 16.1, 25.8], "percents_raw": ["16.1 %", "25.8 %"], "percents": [0.161, 0.258], "currencies": ["USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 1409, "tag": "div", "text_raw": "Less: Expenses not allocated to segments (1)", "text": "Expenses not allocated to segments (1)", "length": 38, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1411, "tag": "div", "text_raw": "(1) Amounts not allocated to segments include interest (income) expense and general corporate (income) expense. The fiscal nine months of 2023 includes an approximately $7 billion charge related to the talc settlement proposal and the approximately $0.6 billion unfavorable change in the fair value of the retained stake in Kenvue.", "text": "(1) Amounts not allocated to segments include interest (income) expense and general corporate (income) expense.", "length": 111, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1411, "tag": "div", "text_raw": "(1) Amounts not allocated to segments include interest (income) expense and general corporate (income) expense. The fiscal nine months of 2023 includes an approximately $7 billion charge related to the talc settlement proposal and the approximately $0.6 billion unfavorable change in the fair value of the retained stake in Kenvue.", "text": "The fiscal nine months of 2023 includes an approximately $7 billion charge related to the talc settlement proposal and the approximately $0.6 billion unfavorable change in the fair value of the retained stake in Kenvue.", "length": 219, "numbers_raw": ["202", "3", "$7 billion", "$0.6 billion"], "numbers": [202.0, 3.0, 7000000000.0, 600000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1414, "tag": "div", "text_raw": "The Innovative Medicine segment income before tax as a percent of sales in the fiscal nine months of 2023 was 34.1% versus 31.5% for the same period a year ago. The increase in the income before tax as a percent of sales for the fiscal nine months of 2023 as compared to the prior year was primarily driven by the following:", "text": "The Innovative Medicine segment income before tax as a percent of sales in the fiscal nine months of 2023 was 34.1% versus 31.5% for the same period a year ago.", "length": 160, "numbers_raw": ["202", "3", "34.1", "31.5"], "numbers": [202.0, 3.0, 34.1, 31.5], "percents_raw": ["34.1%", "31.5%"], "percents": [0.341, 0.315], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1414, "tag": "div", "text_raw": "The Innovative Medicine segment income before tax as a percent of sales in the fiscal nine months of 2023 was 34.1% versus 31.5% for the same period a year ago. The increase in the income before tax as a percent of sales for the fiscal nine months of 2023 as compared to the prior year was primarily driven by the following:", "text": "The increase in the income before tax as a percent of sales for the fiscal nine months of 2023 as compared to the prior year was primarily driven by the following:", "length": 163, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1416, "tag": "div", "text_raw": " A lower IPR&D impairment charge of $0.2 billion in 2023 versus $0.6 billion in 2022", "text": " A lower IPR&D impairment charge of $0.2 billion in 2023 versus $0.6 billion in 2022", "length": 85, "numbers_raw": ["$0.2 billion", "202", "3", "$0.6 billion", "202", "2"], "numbers": [200000000.0, 202.0, 3.0, 600000000.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1417, "tag": "div", "text_raw": " Favorable changes in the fair value of securities in 2023 of $0.2 billion as compared to 2022", "text": " Favorable changes in the fair value of securities in 2023 of $0.2 billion as compared to 2022", "length": 95, "numbers_raw": ["202", "3", "$0.2 billion", "202", "2"], "numbers": [202.0, 3.0, 200000000.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1418, "tag": "div", "text_raw": " Leveraging in selling, marketing and administrative expenses", "text": " Leveraging in selling, marketing and administrative expenses", "length": 62, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1421, "tag": "div", "text_raw": " Restructuring charges of $0.4 billion in 2023", "text": " Restructuring charges of $0.4 billion in 2023", "length": 47, "numbers_raw": ["$0.4 billion", "202", "3"], "numbers": [400000000.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1422, "tag": "div", "text_raw": " Acquired in-process research & development costs of $0.2 billion", "text": " Acquired in-process research & development costs of $0.2 billion", "length": 66, "numbers_raw": ["$0.2 billion"], "numbers": [200000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1425, "tag": "div", "text_raw": "The MedTech segment income before tax as a percent of sales in the fiscal nine months of 2023 was 18.8% versus 17.6% for the same period a year ago. The increase in the income before tax as a percent of sales for the fiscal nine months of 2023 was primarily driven by the following:", "text": "The MedTech segment income before tax as a percent of sales in the fiscal nine months of 2023 was 18.8% versus 17.6% for the same period a year ago.", "length": 148, "numbers_raw": ["202", "3", "18.8", "17.6"], "numbers": [202.0, 3.0, 18.8, 17.6], "percents_raw": ["18.8%", "17.6%"], "percents": [0.188, 0.17600000000000002], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1425, "tag": "div", "text_raw": "The MedTech segment income before tax as a percent of sales in the fiscal nine months of 2023 was 18.8% versus 17.6% for the same period a year ago. The increase in the income before tax as a percent of sales for the fiscal nine months of 2023 was primarily driven by the following:", "text": "The increase in the income before tax as a percent of sales for the fiscal nine months of 2023 was primarily driven by the following:", "length": 133, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1426, "tag": "div", "text_raw": " Litigation expense of $0.5 billion in 2022", "text": " Litigation expense of $0.5 billion in 2022", "length": 44, "numbers_raw": ["$0.5 billion", "202", "2"], "numbers": [500000000.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1427, "tag": "div", "text_raw": " Leveraging in selling and marketing expenses", "text": " Leveraging in selling and marketing expenses", "length": 46, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1429, "tag": "div", "text_raw": " Higher amortization expense of $0.4 billion in 2023 related to Abiomed", "text": " Higher amortization expense of $0.4 billion in 2023 related to Abiomed", "length": 72, "numbers_raw": ["$0.4 billion", "202", "3"], "numbers": [400000000.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1430, "tag": "div", "text_raw": " An IPR&D charge in 2023 of approximately $0.1 billion related to the Pulsar Vascular acquisition", "text": " An IPR&D charge in 2023 of approximately $0.1 billion related to the Pulsar Vascular acquisition", "length": 98, "numbers_raw": ["202", "3", "$0.1 billion"], "numbers": [202.0, 3.0, 100000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1431, "tag": "div", "text_raw": " Acquisition costs related to Abiomed of $0.1 billion in 2023", "text": " Acquisition costs related to Abiomed of $0.1 billion in 2023", "length": 62, "numbers_raw": ["$0.1 billion", "202", "3"], "numbers": [100000000.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1432, "tag": "div", "text_raw": " Commodity inflation in 2023", "text": " Commodity inflation in 2023", "length": 29, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1434, "tag": "div", "text_raw": "Income before tax by segment of business for the fiscal third quarters were as follows:", "text": "Income before tax by segment of business for the fiscal third quarters were as follows:", "length": 87, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1435, "tag": "div", "text_raw": "Income Before Tax Segment Sales Percent of Segment Sales (Dollars in Millions) October 1, 2023 October 2, 2022 October 1, 2023 October 2, 2022 October 1, 2023 October 2, 2022 Innovative Medicine $ 4,794 $ 4,186 $ 13,893 $ 13,214 34.5 % 31.7 % MedTech 1,185 1,090 7,458 6,782 15.9 16.1 Segment earnings before tax 5,979 5,276 21,351 19,996 28.0 26.4 Less: Expenses not allocated to segments (1) 762 104 Worldwide income before tax $ 5,217 $ 5,172 $ 21,351 $ 19,996 24.4 % 25.9 %", "text": "Income Before Tax Segment Sales Percent of Segment Sales (Dollars in Millions) October 1, 2023 October 2, 2022 October 1, 2023 October 2, 2022 October 1, 2023 October 2, 2022 Innovative Medicine $ 4,794 $ 4,186 $ 13,893 $ 13,214 34.5 % 31.7 % MedTech 1,185 1,090 7,458 6,782 15.9 16.1 Segment earnings before tax 5,979 5,276 21,351 19,996 28.0 26.4 Less:", "length": 354, "numbers_raw": ["1", "202", "3", "2", "202", "2", "1", "202", "3", "2", "202", "2", "1", "202", "3", "2", "202", "2", "4,794", "4,186", "13,893", "13,214", "34.5", "31.7", "1,185", "1,090", "7,458", "6,782", "15.9", "16.1", "5,979", "5,276", "21,351", "19,996", "28.0", "26.4"], "numbers": [1.0, 202.0, 3.0, 2.0, 202.0, 2.0, 1.0, 202.0, 3.0, 2.0, 202.0, 2.0, 1.0, 202.0, 3.0, 2.0, 202.0, 2.0, 4794.0, 4186.0, 13893.0, 13214.0, 34.5, 31.7, 1185.0, 1090.0, 7458.0, 6782.0, 15.9, 16.1, 5979.0, 5276.0, 21351.0, 19996.0, 28.0, 26.4], "percents_raw": ["34.5 %", "31.7 %"], "percents": [0.345, 0.317], "currencies": ["USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 1435, "tag": "div", "text_raw": "Income Before Tax Segment Sales Percent of Segment Sales (Dollars in Millions) October 1, 2023 October 2, 2022 October 1, 2023 October 2, 2022 October 1, 2023 October 2, 2022 Innovative Medicine $ 4,794 $ 4,186 $ 13,893 $ 13,214 34.5 % 31.7 % MedTech 1,185 1,090 7,458 6,782 15.9 16.1 Segment earnings before tax 5,979 5,276 21,351 19,996 28.0 26.4 Less: Expenses not allocated to segments (1) 762 104 Worldwide income before tax $ 5,217 $ 5,172 $ 21,351 $ 19,996 24.4 % 25.9 %", "text": "Expenses not allocated to segments (1) 762 104 Worldwide income before tax $ 5,217 $ 5,172 $ 21,351 $ 19,996 24.4 % 25.9 %", "length": 122, "numbers_raw": ["1", "762", "104", "5,217", "5,172", "21,351", "19,996", "24.4", "25.9"], "numbers": [1.0, 762.0, 104.0, 5217.0, 5172.0, 21351.0, 19996.0, 24.4, 25.9], "percents_raw": ["24.4 %", "25.9 %"], "percents": [0.244, 0.259], "currencies": ["USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 1436, "tag": "div", "text_raw": "Less: Expenses not allocated to segments (1)", "text": "Expenses not allocated to segments (1)", "length": 38, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1437, "tag": "div", "text_raw": "53", "text": "53", "length": 2, "numbers_raw": ["53"], "numbers": [53.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1438, "tag": "div", "text_raw": "53", "text": "53", "length": 2, "numbers_raw": ["53"], "numbers": [53.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1439, "tag": "div", "text_raw": "53", "text": "53", "length": 2, "numbers_raw": ["53"], "numbers": [53.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1442, "tag": "div", "text_raw": "(1) Amounts not allocated to segments include interest (income) expense, certain litigation expenses and general corporate (income) expense. The fiscal third quarter of 2023 includes the unfavorable change in the fair value in the retained stake in Kenvue of approximately $0.6 billion.", "text": "(1) Amounts not allocated to segments include interest (income) expense, certain litigation expenses and general corporate (income) expense.", "length": 140, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1442, "tag": "div", "text_raw": "(1) Amounts not allocated to segments include interest (income) expense, certain litigation expenses and general corporate (income) expense. The fiscal third quarter of 2023 includes the unfavorable change in the fair value in the retained stake in Kenvue of approximately $0.6 billion.", "text": "The fiscal third quarter of 2023 includes the unfavorable change in the fair value in the retained stake in Kenvue of approximately $0.6 billion.", "length": 145, "numbers_raw": ["202", "3", "$0.6 billion"], "numbers": [202.0, 3.0, 600000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1445, "tag": "div", "text_raw": "The Innovative Medicine segment income before tax as a percent of sales in the fiscal third quarter of 2023 was 34.5% versus 31.7% for the same period a year ago. The increase in the income before tax as a percent of sales for the fiscal third quarter as compared to the prior year was primarily driven by the following:", "text": "The Innovative Medicine segment income before tax as a percent of sales in the fiscal third quarter of 2023 was 34.5% versus 31.7% for the same period a year ago.", "length": 162, "numbers_raw": ["202", "3", "34.5", "31.7"], "numbers": [202.0, 3.0, 34.5, 31.7], "percents_raw": ["34.5%", "31.7%"], "percents": [0.345, 0.317], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1445, "tag": "div", "text_raw": "The Innovative Medicine segment income before tax as a percent of sales in the fiscal third quarter of 2023 was 34.5% versus 31.7% for the same period a year ago. The increase in the income before tax as a percent of sales for the fiscal third quarter as compared to the prior year was primarily driven by the following:", "text": "The increase in the income before tax as a percent of sales for the fiscal third quarter as compared to the prior year was primarily driven by the following:", "length": 157, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1446, "tag": "div", "text_raw": " One-time COVID-19 Vaccine related exit costs of $0.4 billion in 2022", "text": " One-time COVID-19 Vaccine related exit costs of $0.4 billion in 2022", "length": 70, "numbers_raw": ["19", "$0.4 billion", "202", "2"], "numbers": [19.0, 400000000.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1448, "tag": "div", "text_raw": " Leveraging in selling, marketing and administrative expenses", "text": " Leveraging in selling, marketing and administrative expenses", "length": 62, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1451, "tag": "div", "text_raw": " An IPR&D charge of $0.2 billion in 2023", "text": " An IPR&D charge of $0.2 billion in 2023", "length": 41, "numbers_raw": ["$0.2 billion", "202", "3"], "numbers": [200000000.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1452, "tag": "div", "text_raw": " Restructuring charges of $0.1 billion in 2023", "text": " Restructuring charges of $0.1 billion in 2023", "length": 47, "numbers_raw": ["$0.1 billion", "202", "3"], "numbers": [100000000.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1453, "tag": "div", "text_raw": " Unfavorable changes in the fair value of securities in 2023 of $0.4 billion as compared to $0.2 billion in 2022", "text": " Unfavorable changes in the fair value of securities in 2023 of $0.4 billion as compared to $0.2 billion in 2022", "length": 113, "numbers_raw": ["202", "3", "$0.4 billion", "$0.2 billion", "202", "2"], "numbers": [202.0, 3.0, 400000000.0, 200000000.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1456, "tag": "div", "text_raw": "The MedTech segment income before tax as a percent of sales in the fiscal third quarter of 2023 was 15.9% versus 16.1% for the same period a year ago. The decline in the income before tax as a percent of sales for the fiscal third quarter was primarily driven by the following:", "text": "The MedTech segment income before tax as a percent of sales in the fiscal third quarter of 2023 was 15.9% versus 16.1% for the same period a year ago.", "length": 150, "numbers_raw": ["202", "3", "15.9", "16.1"], "numbers": [202.0, 3.0, 15.9, 16.1], "percents_raw": ["15.9%", "16.1%"], "percents": [0.159, 0.161], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1456, "tag": "div", "text_raw": "The MedTech segment income before tax as a percent of sales in the fiscal third quarter of 2023 was 15.9% versus 16.1% for the same period a year ago. The decline in the income before tax as a percent of sales for the fiscal third quarter was primarily driven by the following:", "text": "The decline in the income before tax as a percent of sales for the fiscal third quarter was primarily driven by the following:", "length": 126, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1457, "tag": "div", "text_raw": " Higher amortization expense of $0.4 billion in 2023 primarily related to Abiomed as compared to $0.3 billion in 2022.", "text": " Higher amortization expense of $0.4 billion in 2023 primarily related to Abiomed as compared to $0.3 billion in 2022.", "length": 119, "numbers_raw": ["$0.4 billion", "202", "3", "$0.3 billion", "202", "2"], "numbers": [400000000.0, 202.0, 3.0, 300000000.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1458, "tag": "div", "text_raw": " Higher restructuring charges of $0.2 billion in 2023 as compared to $0.1 billion in 2022", "text": " Higher restructuring charges of $0.2 billion in 2023 as compared to $0.1 billion in 2022", "length": 90, "numbers_raw": ["$0.2 billion", "202", "3", "$0.1 billion", "202", "2"], "numbers": [200000000.0, 202.0, 3.0, 100000000.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1459, "tag": "div", "text_raw": " Commodity inflation in 2023", "text": " Commodity inflation in 2023", "length": 29, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1462, "tag": "div", "text_raw": " Litigation expense of $0.2 billion in 2022", "text": " Litigation expense of $0.2 billion in 2022", "length": 44, "numbers_raw": ["$0.2 billion", "202", "2"], "numbers": [200000000.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1463, "tag": "div", "text_raw": " Leveraging in selling, marketing and administrative expenses", "text": " Leveraging in selling, marketing and administrative expenses", "length": 62, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1467, "tag": "div", "text_raw": "In the fiscal nine months of 2023, the Company completed a prioritization of its research and development (R&D) investment within the Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within therapeutic areas. The R&D program exits are primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, hepatitis and HIV development. The pre-tax restructuring charge of approximately $0.1 billion and $0.4 billion in the fiscal third quarter and fiscal nine months of 2023, respectively, included the termination of partnered and non-partnered program costs and asset impairments.", "text": "In the fiscal nine months of 2023, the Company completed a prioritization of its research and development (R&D) investment within the Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients.", "length": 241, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1467, "tag": "div", "text_raw": "In the fiscal nine months of 2023, the Company completed a prioritization of its research and development (R&D) investment within the Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within therapeutic areas. The R&D program exits are primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, hepatitis and HIV development. The pre-tax restructuring charge of approximately $0.1 billion and $0.4 billion in the fiscal third quarter and fiscal nine months of 2023, respectively, included the termination of partnered and non-partnered program costs and asset impairments.", "text": "This resulted in the exit of certain programs within therapeutic areas.", "length": 71, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1467, "tag": "div", "text_raw": "In the fiscal nine months of 2023, the Company completed a prioritization of its research and development (R&D) investment within the Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within therapeutic areas. The R&D program exits are primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, hepatitis and HIV development. The pre-tax restructuring charge of approximately $0.1 billion and $0.4 billion in the fiscal third quarter and fiscal nine months of 2023, respectively, included the termination of partnered and non-partnered program costs and asset impairments.", "text": "The R&D program exits are primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, hepatitis and HIV development.", "length": 196, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1467, "tag": "div", "text_raw": "In the fiscal nine months of 2023, the Company completed a prioritization of its research and development (R&D) investment within the Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within therapeutic areas. The R&D program exits are primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, hepatitis and HIV development. The pre-tax restructuring charge of approximately $0.1 billion and $0.4 billion in the fiscal third quarter and fiscal nine months of 2023, respectively, included the termination of partnered and non-partnered program costs and asset impairments.", "text": "The pre-tax restructuring charge of approximately $0.1 billion and $0.4 billion in the fiscal third quarter and fiscal nine months of 2023, respectively, included the termination of partnered and non-partnered program costs and asset impairments.", "length": 246, "numbers_raw": ["$0.1 billion", "$0.4 billion", "202", "3"], "numbers": [100000000.0, 400000000.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1469, "tag": "div", "text_raw": "In the third quarter of 2023, the Company initiated a restructuring program of its Orthopaedics franchise within its MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The pre-tax restructuring expense of $0.2 billion in the fiscal third quarter and fiscal nine months of 2023, of which $9 million was recorded in Restructuring and $226 million was recorded in Cost of products sold on the Consolidated Statement of Earnings, primarily included inventory and instrument charges related to market and product exits.", "text": "In the third quarter of 2023, the Company initiated a restructuring program of its Orthopaedics franchise within its MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements.", "length": 238, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1469, "tag": "div", "text_raw": "In the third quarter of 2023, the Company initiated a restructuring program of its Orthopaedics franchise within its MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The pre-tax restructuring expense of $0.2 billion in the fiscal third quarter and fiscal nine months of 2023, of which $9 million was recorded in Restructuring and $226 million was recorded in Cost of products sold on the Consolidated Statement of Earnings, primarily included inventory and instrument charges related to market and product exits.", "text": "The pre-tax restructuring expense of $0.2 billion in the fiscal third quarter and fiscal nine months of 2023, of which $9 million was recorded in Restructuring and $226 million was recorded in Cost of products sold on the Consolidated Statement of Earnings, primarily included inventory and instrument charges related to market and product exits.", "length": 346, "numbers_raw": ["$0.2 billion", "202", "3", "$9 million", "$226 million"], "numbers": [200000000.0, 202.0, 3.0, 9000000.0, 226000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1471, "tag": "div", "text_raw": "The Company recorded a pre-tax charge of $0.1 billion in the fiscal third quarter and $0.3 billion in the fiscal nine months of 2022, related to a restructuring program of its Global Supply Chain. The Global Supply Chain program was announced in the second quarter of 2018 and was completed in the fiscal fourth quarter of 2022.", "text": "The Company recorded a pre-tax charge of $0.1 billion in the fiscal third quarter and $0.3 billion in the fiscal nine months of 2022, related to a restructuring program of its Global Supply Chain.", "length": 196, "numbers_raw": ["$0.1 billion", "$0.3 billion", "202", "2"], "numbers": [100000000.0, 300000000.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1471, "tag": "div", "text_raw": "The Company recorded a pre-tax charge of $0.1 billion in the fiscal third quarter and $0.3 billion in the fiscal nine months of 2022, related to a restructuring program of its Global Supply Chain. The Global Supply Chain program was announced in the second quarter of 2018 and was completed in the fiscal fourth quarter of 2022.", "text": "The Global Supply Chain program was announced in the second quarter of 2018 and was completed in the fiscal fourth quarter of 2022.", "length": 131, "numbers_raw": ["201", "8", "202", "2"], "numbers": [201.0, 8.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1473, "tag": "div", "text_raw": "54", "text": "54", "length": 2, "numbers_raw": ["54"], "numbers": [54.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1474, "tag": "div", "text_raw": "54", "text": "54", "length": 2, "numbers_raw": ["54"], "numbers": [54.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1475, "tag": "div", "text_raw": "54", "text": "54", "length": 2, "numbers_raw": ["54"], "numbers": [54.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1481, "tag": "div", "text_raw": "The worldwide effective income tax rate for the fiscal nine months of 2023 was 10.2% and 15.3% in 2022.", "text": "The worldwide effective income tax rate for the fiscal nine months of 2023 was 10.2% and 15.3% in 2022.", "length": 103, "numbers_raw": ["202", "3", "10.2", "15.3", "202", "2"], "numbers": [202.0, 3.0, 10.2, 15.3, 202.0, 2.0], "percents_raw": ["10.2%", "15.3%"], "percents": [0.102, 0.153], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1482, "tag": "div", "text_raw": "On December 15, 2022, the European Union (EU) Member States formally adopted the EUs Pillar Two Directive, which generally provides for a minimum effective tax rate of 15%, as established by the Organization for Economic Co-operation and Development (OECD) Pillar Two Framework that was supported by over 130 countries worldwide. The EU effective dates are January 1, 2024, and January 1, 2025, for different aspects of the directive. On July 17, 2023, the OECD published Administrative Guidance proposing certain safe harbor rules that effectively extend certain effective dates to January 1, 2027. EU Member States will still need to adopt the OECD Administrative Guidance in their local Pillar Two legislation for such safe harbor rules to apply. A significant number of other countries are also considering implementing similar legislation. The Company is continuing to evaluate the potential impact on future periods of the Pillar Two Framework, pending legislative adoption by additional individual countries, including those within the European Union.", "text": "On December 15, 2022, the European Union (EU) Member States formally adopted the EUs Pillar Two Directive, which generally provides for a minimum effective tax rate of 15%, as established by the Organization for Economic Co-operation and Development (OECD) Pillar Two Framework that was supported by over 130 countries worldwide.", "length": 330, "numbers_raw": ["15", "202", "2", "15", "130"], "numbers": [15.0, 202.0, 2.0, 15.0, 130.0], "percents_raw": ["15%"], "percents": [0.15], "currencies": ["EUR"], "has_numbers": true, "has_percents": true}
{"idx_source": 1482, "tag": "div", "text_raw": "On December 15, 2022, the European Union (EU) Member States formally adopted the EUs Pillar Two Directive, which generally provides for a minimum effective tax rate of 15%, as established by the Organization for Economic Co-operation and Development (OECD) Pillar Two Framework that was supported by over 130 countries worldwide. The EU effective dates are January 1, 2024, and January 1, 2025, for different aspects of the directive. On July 17, 2023, the OECD published Administrative Guidance proposing certain safe harbor rules that effectively extend certain effective dates to January 1, 2027. EU Member States will still need to adopt the OECD Administrative Guidance in their local Pillar Two legislation for such safe harbor rules to apply. A significant number of other countries are also considering implementing similar legislation. The Company is continuing to evaluate the potential impact on future periods of the Pillar Two Framework, pending legislative adoption by additional individual countries, including those within the European Union.", "text": "The EU effective dates are January 1, 2024, and January 1, 2025, for different aspects of the directive.", "length": 104, "numbers_raw": ["1", "202", "4", "1", "202", "5"], "numbers": [1.0, 202.0, 4.0, 1.0, 202.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1482, "tag": "div", "text_raw": "On December 15, 2022, the European Union (EU) Member States formally adopted the EUs Pillar Two Directive, which generally provides for a minimum effective tax rate of 15%, as established by the Organization for Economic Co-operation and Development (OECD) Pillar Two Framework that was supported by over 130 countries worldwide. The EU effective dates are January 1, 2024, and January 1, 2025, for different aspects of the directive. On July 17, 2023, the OECD published Administrative Guidance proposing certain safe harbor rules that effectively extend certain effective dates to January 1, 2027. EU Member States will still need to adopt the OECD Administrative Guidance in their local Pillar Two legislation for such safe harbor rules to apply. A significant number of other countries are also considering implementing similar legislation. The Company is continuing to evaluate the potential impact on future periods of the Pillar Two Framework, pending legislative adoption by additional individual countries, including those within the European Union.", "text": "On July 17, 2023, the OECD published Administrative Guidance proposing certain safe harbor rules that effectively extend certain effective dates to January 1, 2027.", "length": 164, "numbers_raw": ["17", "202", "3", "1", "202", "7"], "numbers": [17.0, 202.0, 3.0, 1.0, 202.0, 7.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1482, "tag": "div", "text_raw": "On December 15, 2022, the European Union (EU) Member States formally adopted the EUs Pillar Two Directive, which generally provides for a minimum effective tax rate of 15%, as established by the Organization for Economic Co-operation and Development (OECD) Pillar Two Framework that was supported by over 130 countries worldwide. The EU effective dates are January 1, 2024, and January 1, 2025, for different aspects of the directive. On July 17, 2023, the OECD published Administrative Guidance proposing certain safe harbor rules that effectively extend certain effective dates to January 1, 2027. EU Member States will still need to adopt the OECD Administrative Guidance in their local Pillar Two legislation for such safe harbor rules to apply. A significant number of other countries are also considering implementing similar legislation. The Company is continuing to evaluate the potential impact on future periods of the Pillar Two Framework, pending legislative adoption by additional individual countries, including those within the European Union.", "text": "EU Member States will still need to adopt the OECD Administrative Guidance in their local Pillar Two legislation for such safe harbor rules to apply.", "length": 149, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1482, "tag": "div", "text_raw": "On December 15, 2022, the European Union (EU) Member States formally adopted the EUs Pillar Two Directive, which generally provides for a minimum effective tax rate of 15%, as established by the Organization for Economic Co-operation and Development (OECD) Pillar Two Framework that was supported by over 130 countries worldwide. The EU effective dates are January 1, 2024, and January 1, 2025, for different aspects of the directive. On July 17, 2023, the OECD published Administrative Guidance proposing certain safe harbor rules that effectively extend certain effective dates to January 1, 2027. EU Member States will still need to adopt the OECD Administrative Guidance in their local Pillar Two legislation for such safe harbor rules to apply. A significant number of other countries are also considering implementing similar legislation. The Company is continuing to evaluate the potential impact on future periods of the Pillar Two Framework, pending legislative adoption by additional individual countries, including those within the European Union.", "text": "A significant number of other countries are also considering implementing similar legislation.", "length": 94, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1482, "tag": "div", "text_raw": "On December 15, 2022, the European Union (EU) Member States formally adopted the EUs Pillar Two Directive, which generally provides for a minimum effective tax rate of 15%, as established by the Organization for Economic Co-operation and Development (OECD) Pillar Two Framework that was supported by over 130 countries worldwide. The EU effective dates are January 1, 2024, and January 1, 2025, for different aspects of the directive. On July 17, 2023, the OECD published Administrative Guidance proposing certain safe harbor rules that effectively extend certain effective dates to January 1, 2027. EU Member States will still need to adopt the OECD Administrative Guidance in their local Pillar Two legislation for such safe harbor rules to apply. A significant number of other countries are also considering implementing similar legislation. The Company is continuing to evaluate the potential impact on future periods of the Pillar Two Framework, pending legislative adoption by additional individual countries, including those within the European Union.", "text": "The Company is continuing to evaluate the potential impact on future periods of the Pillar Two Framework, pending legislative adoption by additional individual countries, including those within the European Union.", "length": 213, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": ["EUR"], "has_numbers": false, "has_percents": false}
{"idx_source": 1484, "tag": "div", "text_raw": "For further details related to the 2023 provision for taxes refer to Note 5 to the Consolidated Financial Statements.", "text": "For further details related to the 2023 provision for taxes refer to Note 5 to the Consolidated Financial Statements.", "length": 117, "numbers_raw": ["202", "3", "5"], "numbers": [202.0, 3.0, 5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1486, "tag": "div", "text_raw": "LIQUIDITY AND CAPITAL RESOURCES", "text": "LIQUIDITY AND CAPITAL RESOURCES", "length": 31, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1492, "tag": "div", "text_raw": "Cash and cash equivalents were $19.7 billion at the end of the fiscal third quarter of 2023 as compared with $14.1 billion at the end of fiscal year 2022. The primary sources and uses of cash that contributed to the $5.6 billion increase were:", "text": "Cash and cash equivalents were $19.7 billion at the end of the fiscal third quarter of 2023 as compared with $14.1 billion at the end of fiscal year 2022.", "length": 154, "numbers_raw": ["$19.7 billion", "202", "3", "$14.1 billion", "202", "2"], "numbers": [19700000000.0, 202.0, 3.0, 14100000000.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1492, "tag": "div", "text_raw": "Cash and cash equivalents were $19.7 billion at the end of the fiscal third quarter of 2023 as compared with $14.1 billion at the end of fiscal year 2022. The primary sources and uses of cash that contributed to the $5.6 billion increase were:", "text": "The primary sources and uses of cash that contributed to the $5.6 billion increase were:", "length": 88, "numbers_raw": ["$5.6 billion"], "numbers": [5600000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1493, "tag": "div", "text_raw": "(Dollars In Billions) 14.1 Q4 2022 Cash and cash equivalents balance 14.9 net cash generated from operating activities 2.1 net cash generated from investing activities (11.2) net cash used by financing activities (0.2) effect of exchange rate changes on cash and cash equivalents $ 19.7 Q3 2023 Cash and cash equivalents", "text": "(Dollars In Billions) 14.1 Q4 2022 Cash and cash equivalents balance 14.9 net cash generated from operating activities 2.1 net cash generated from investing activities (11.2) net cash used by financing activities (0.2) effect of exchange rate changes on cash and cash equivalents $ 19.7 Q3 2023 Cash and cash equivalents", "length": 320, "numbers_raw": ["14.1", "4", "202", "2", "14.9", "2.1", "11.2", "0.2", "19.7", "3", "202", "3"], "numbers": [14.1, 4.0, 202.0, 2.0, 14.9, 2.1, 11.2, 0.2, 19.7, 3.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1495, "tag": "div", "text_raw": "In addition, the Company had $3.8 billion in marketable securities at the end of the fiscal third quarter of 2023 and $9.4 billion at the end of fiscal year 2022.", "text": "In addition, the Company had $3.8 billion in marketable securities at the end of the fiscal third quarter of 2023 and $9.4 billion at the end of fiscal year 2022.", "length": 162, "numbers_raw": ["$3.8 billion", "202", "3", "$9.4 billion", "202", "2"], "numbers": [3800000000.0, 202.0, 3.0, 9400000000.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1497, "tag": "div", "text_raw": "Cash flow from operations of $14.9 billion was the result of:", "text": "Cash flow from operations of $14.9 billion was the result of:", "length": 61, "numbers_raw": ["$14.9 billion"], "numbers": [14900000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1498, "tag": "div", "text_raw": "55", "text": "55", "length": 2, "numbers_raw": ["55"], "numbers": [55.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1499, "tag": "div", "text_raw": "55", "text": "55", "length": 2, "numbers_raw": ["55"], "numbers": [55.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1500, "tag": "div", "text_raw": "55", "text": "55", "length": 2, "numbers_raw": ["55"], "numbers": [55.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1503, "tag": "div", "text_raw": "(Dollars In Billions) $ 31.1 Net earnings (21.0) gain on Kenvue separation 5.5 non-cash expenses and other adjustments primarily for depreciation and amortization, stock-based compensation and asset write-downs partially offset by the deferred tax provision and net gain on sale of assets/businesses (2.3) an increase in accounts receivable and inventories 2.9 an increase in accounts payable and accrued liabilities and other current and non-current liabilities (1.4) an increase in other current and non-current assets 0.1 Rounding $ 14.9 Cash Flow from operations", "text": "(Dollars In Billions) $ 31.1 Net earnings (21.0) gain on Kenvue separation 5.5 non-cash expenses and other adjustments primarily for depreciation and amortization, stock-based compensation and asset write-downs partially offset by the deferred tax provision and net gain on sale of assets/businesses (2.3) an increase in accounts receivable and inventories 2.9 an increase in accounts payable and accrued liabilities and other current and non-current liabilities (1.4) an increase in other current and non-current assets 0.1 Rounding $ 14.9 Cash Flow from operations", "length": 566, "numbers_raw": ["31.1", "21.0", "5.5", "2.3", "2.9", "1.4", "0.1", "14.9"], "numbers": [31.1, 21.0, 5.5, 2.3, 2.9, 1.4, 0.1, 14.9], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1505, "tag": "div", "text_raw": "Cash flow from investing activities of $2.1 billion was primarily from:", "text": "Cash flow from investing activities of $2.1 billion was primarily from:", "length": 71, "numbers_raw": ["$2.1 billion"], "numbers": [2100000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1506, "tag": "div", "text_raw": "(Dollars In Billions) (3.0) additions to property, plant and equipment 0.2 proceeds from the disposal of assets/businesses, net 5.8 net sales of investments (0.9) credit support agreements activity, net other and rounding $ 2.1 Net cash used by investing activities", "text": "(Dollars In Billions) (3.0) additions to property, plant and equipment 0.2 proceeds from the disposal of assets/businesses, net 5.8 net sales of investments (0.9) credit support agreements activity, net other and rounding $ 2.1 Net cash used by investing activities", "length": 265, "numbers_raw": ["3.0", "0.2", "5.8", "0.9", "2.1"], "numbers": [3.0, 0.2, 5.8, 0.9, 2.1], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1508, "tag": "div", "text_raw": "Cash flow used by financing activities of $11.2 billion was primarily from:", "text": "Cash flow used by financing activities of $11.2 billion was primarily from:", "length": 75, "numbers_raw": ["$11.2 billion"], "numbers": [11200000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1509, "tag": "div", "text_raw": "(Dollars In Billions) $ (8.9) dividends to shareholders (4.8) repurchase of common stock (9.7) net repayment of short and long term debt 8.0 Proceeds of short and long-term debt, net of issuance cost, related to the debt that transferred to Kenvue at separation 4.2 proceeds from Kenvue initial public offering (1.1) Cash transferred to Kenvue at separation 0.9 proceeds from stock options exercised/employee withholding tax on stock awards, net 0.1 credit support agreements activity, net 0.1 other and rounding $ (11.2) Net cash from financing activities", "text": "(Dollars In Billions) $ (8.9) dividends to shareholders (4.8) repurchase of common stock (9.7) net repayment of short and long term debt 8.0 Proceeds of short and long-term debt, net of issuance cost, related to the debt that transferred to Kenvue at separation 4.2 proceeds from Kenvue initial public offering (1.1) Cash transferred to Kenvue at separation 0.9 proceeds from stock options exercised/employee withholding tax on stock awards, net 0.1 credit support agreements activity, net 0.1 other and rounding $ (11.2) Net cash from financing activities", "length": 556, "numbers_raw": ["8.9", "4.8", "9.7", "8.0", "4.2", "1.1", "0.9", "0.1", "0.1", "11.2"], "numbers": [8.9, 4.8, 9.7, 8.0, 4.2, 1.1, 0.9, 0.1, 0.1, 11.2], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1511, "tag": "div", "text_raw": "The Company has access to substantial sources of funds at numerous banks worldwide. In September 2023, the Company secured a new 364-day Credit Facility of $10 billion, which expires on September 5, 2024. The Company early terminated the additional 364-day revolving Credit Facility of $10 billion, which had an expiration of November 21, 2023 . Interest charged on borrowings under the credit line agreement is based on either Secured Overnight Financing Rate (SOFR) Reference Rate or other applicable market rate as allowed plus applicable margins. Commitment fees under the agreement are not material.", "text": "The Company has access to substantial sources of funds at numerous banks worldwide.", "length": 83, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1511, "tag": "div", "text_raw": "The Company has access to substantial sources of funds at numerous banks worldwide. In September 2023, the Company secured a new 364-day Credit Facility of $10 billion, which expires on September 5, 2024. The Company early terminated the additional 364-day revolving Credit Facility of $10 billion, which had an expiration of November 21, 2023 . Interest charged on borrowings under the credit line agreement is based on either Secured Overnight Financing Rate (SOFR) Reference Rate or other applicable market rate as allowed plus applicable margins. Commitment fees under the agreement are not material.", "text": "In September 2023, the Company secured a new 364-day Credit Facility of $10 billion, which expires on September 5, 2024.", "length": 120, "numbers_raw": ["202", "3", "364", "$10 billion", "5", "202", "4"], "numbers": [202.0, 3.0, 364.0, 10000000000.0, 5.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1511, "tag": "div", "text_raw": "The Company has access to substantial sources of funds at numerous banks worldwide. In September 2023, the Company secured a new 364-day Credit Facility of $10 billion, which expires on September 5, 2024. The Company early terminated the additional 364-day revolving Credit Facility of $10 billion, which had an expiration of November 21, 2023 . Interest charged on borrowings under the credit line agreement is based on either Secured Overnight Financing Rate (SOFR) Reference Rate or other applicable market rate as allowed plus applicable margins. Commitment fees under the agreement are not material.", "text": "The Company early terminated the additional 364-day revolving Credit Facility of $10 billion, which had an expiration of November 21, 2023 .", "length": 140, "numbers_raw": ["364", "$10 billion", "21", "202", "3"], "numbers": [364.0, 10000000000.0, 21.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1511, "tag": "div", "text_raw": "The Company has access to substantial sources of funds at numerous banks worldwide. In September 2023, the Company secured a new 364-day Credit Facility of $10 billion, which expires on September 5, 2024. The Company early terminated the additional 364-day revolving Credit Facility of $10 billion, which had an expiration of November 21, 2023 . Interest charged on borrowings under the credit line agreement is based on either Secured Overnight Financing Rate (SOFR) Reference Rate or other applicable market rate as allowed plus applicable margins. Commitment fees under the agreement are not material.", "text": "Interest charged on borrowings under the credit line agreement is based on either Secured Overnight Financing Rate (SOFR) Reference Rate or other applicable market rate as allowed plus applicable margins.", "length": 204, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1511, "tag": "div", "text_raw": "The Company has access to substantial sources of funds at numerous banks worldwide. In September 2023, the Company secured a new 364-day Credit Facility of $10 billion, which expires on September 5, 2024. The Company early terminated the additional 364-day revolving Credit Facility of $10 billion, which had an expiration of November 21, 2023 . Interest charged on borrowings under the credit line agreement is based on either Secured Overnight Financing Rate (SOFR) Reference Rate or other applicable market rate as allowed plus applicable margins. Commitment fees under the agreement are not material.", "text": "Commitment fees under the agreement are not material.", "length": 53, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1513, "tag": "div", "text_raw": "On May 8, 2023, Kenvue, completed an initial public offering (the IPO) resulting in the issuance of 198,734,444 shares of its common stock, par value $0.01 per share (the Kenvue Common Stock), at an initial public offering of $22.00 per share for net proceeds of $4.2 billion. The excess of the net proceeds from the IPO over the net book value of the Johnson & Johnson divested interest was $2.5 billion and was recorded to additional paid-in capital. As of the closing of the IPO, Johnson & Johnson owned approximately 89.6% of the total outstanding shares of Kenvue Common Stock and at July 2, 2023, the non-controlling interest of $1.3 billion associated with Kenvue was reflected in equity attributable to non-controlling interests in the consolidated balance sheet.", "text": "On May 8, 2023, Kenvue, completed an initial public offering (the IPO) resulting in the issuance of 198,734,444 shares of its common stock, par value $0.01 per share (the Kenvue Common Stock), at an initial public offering of $22.00 per share for net proceeds of $4.2 billion.", "length": 278, "numbers_raw": ["8", "202", "3", "198,734,444", "$0.01", "$22.00", "$4.2 billion"], "numbers": [8.0, 202.0, 3.0, 198734444.0, 0.01, 22.0, 4200000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1513, "tag": "div", "text_raw": "On May 8, 2023, Kenvue, completed an initial public offering (the IPO) resulting in the issuance of 198,734,444 shares of its common stock, par value $0.01 per share (the Kenvue Common Stock), at an initial public offering of $22.00 per share for net proceeds of $4.2 billion. The excess of the net proceeds from the IPO over the net book value of the Johnson & Johnson divested interest was $2.5 billion and was recorded to additional paid-in capital. As of the closing of the IPO, Johnson & Johnson owned approximately 89.6% of the total outstanding shares of Kenvue Common Stock and at July 2, 2023, the non-controlling interest of $1.3 billion associated with Kenvue was reflected in equity attributable to non-controlling interests in the consolidated balance sheet.", "text": "The excess of the net proceeds from the IPO over the net book value of the Johnson & Johnson divested interest was $2.5 billion and was recorded to additional paid-in capital.", "length": 175, "numbers_raw": ["$2.5 billion"], "numbers": [2500000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1513, "tag": "div", "text_raw": "On May 8, 2023, Kenvue, completed an initial public offering (the IPO) resulting in the issuance of 198,734,444 shares of its common stock, par value $0.01 per share (the Kenvue Common Stock), at an initial public offering of $22.00 per share for net proceeds of $4.2 billion. The excess of the net proceeds from the IPO over the net book value of the Johnson & Johnson divested interest was $2.5 billion and was recorded to additional paid-in capital. As of the closing of the IPO, Johnson & Johnson owned approximately 89.6% of the total outstanding shares of Kenvue Common Stock and at July 2, 2023, the non-controlling interest of $1.3 billion associated with Kenvue was reflected in equity attributable to non-controlling interests in the consolidated balance sheet.", "text": "As of the closing of the IPO, Johnson & Johnson owned approximately 89.6% of the total outstanding shares of Kenvue Common Stock and at July 2, 2023, the non-controlling interest of $1.3 billion associated with Kenvue was reflected in equity attributable to non-controlling interests in the consolidated balance sheet.", "length": 318, "numbers_raw": ["89.6", "2", "202", "3", "$1.3 billion"], "numbers": [89.6, 2.0, 202.0, 3.0, 1300000000.0], "percents_raw": ["89.6%"], "percents": [0.8959999999999999], "currencies": ["USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 1514, "tag": "div", "text_raw": "56", "text": "56", "length": 2, "numbers_raw": ["56"], "numbers": [56.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1515, "tag": "div", "text_raw": "56", "text": "56", "length": 2, "numbers_raw": ["56"], "numbers": [56.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1516, "tag": "div", "text_raw": "56", "text": "56", "length": 2, "numbers_raw": ["56"], "numbers": [56.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1520, "tag": "div", "text_raw": "On August 23, 2023, Johnson & Johnson completed the disposition of an additional 80.1% ownership of Kenvue Common Stock through an exchange offer, which resulted in Johnson & Johnson acquiring 190,955,436 shares of the Companys common stock in exchange for 1,533,830,450 shares of Kenvue Common Stock. The $31.4 billion of Johnson & Johnson common stock received in the exchange offer is recorded in Treasury stock. Following the exchange offer, the Company owns 9.5% of the total outstanding shares of Kenvue Common Stock that was recorded in other assets within continuing operations at the fair market value of $4.3 billion as of August 23, 2023.", "text": "On August 23, 2023, Johnson & Johnson completed the disposition of an additional 80.1% ownership of Kenvue Common Stock through an exchange offer, which resulted in Johnson & Johnson acquiring 190,955,436 shares of the Companys common stock in exchange for 1,533,830,450 shares of Kenvue Common Stock.", "length": 302, "numbers_raw": ["23", "202", "3", "80.1", "190,955,436", "1,533,830,450"], "numbers": [23.0, 202.0, 3.0, 80.1, 190955436.0, 1533830450.0], "percents_raw": ["80.1%"], "percents": [0.8009999999999999], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1520, "tag": "div", "text_raw": "On August 23, 2023, Johnson & Johnson completed the disposition of an additional 80.1% ownership of Kenvue Common Stock through an exchange offer, which resulted in Johnson & Johnson acquiring 190,955,436 shares of the Companys common stock in exchange for 1,533,830,450 shares of Kenvue Common Stock. The $31.4 billion of Johnson & Johnson common stock received in the exchange offer is recorded in Treasury stock. Following the exchange offer, the Company owns 9.5% of the total outstanding shares of Kenvue Common Stock that was recorded in other assets within continuing operations at the fair market value of $4.3 billion as of August 23, 2023.", "text": "The $31.4 billion of Johnson & Johnson common stock received in the exchange offer is recorded in Treasury stock.", "length": 113, "numbers_raw": ["$31.4 billion"], "numbers": [31400000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1520, "tag": "div", "text_raw": "On August 23, 2023, Johnson & Johnson completed the disposition of an additional 80.1% ownership of Kenvue Common Stock through an exchange offer, which resulted in Johnson & Johnson acquiring 190,955,436 shares of the Companys common stock in exchange for 1,533,830,450 shares of Kenvue Common Stock. The $31.4 billion of Johnson & Johnson common stock received in the exchange offer is recorded in Treasury stock. Following the exchange offer, the Company owns 9.5% of the total outstanding shares of Kenvue Common Stock that was recorded in other assets within continuing operations at the fair market value of $4.3 billion as of August 23, 2023.", "text": "Following the exchange offer, the Company owns 9.5% of the total outstanding shares of Kenvue Common Stock that was recorded in other assets within continuing operations at the fair market value of $4.3 billion as of August 23, 2023.", "length": 233, "numbers_raw": ["9.5", "$4.3 billion", "23", "202", "3"], "numbers": [9.5, 4300000000.0, 23.0, 202.0, 3.0], "percents_raw": ["9.5%"], "percents": [0.095], "currencies": ["USD"], "has_numbers": true, "has_percents": true}
{"idx_source": 1522, "tag": "div", "text_raw": "Johnson & Johnson divested net assets of $11.6 billion as of August 23, 2023, and the accumulated other comprehensive loss attributable to the Consumer Health business at that date was $4.3 billion. Additionally, at the date of the exchange offer, Johnson & Johnson decreased the non-controlling interest by $1.2 billion to record the deconsolidation of Kenvue. This resulted in a gain on the exchange offer of $21.0 billion that was recorded in Net earnings from discontinued operations, net of taxes in the consolidated statements of earnings for the fiscal third quarter of 2023. This one-time gain includes a gain of $2.8 billion on the Kenvue Common Stock retained by Johnson & Johnson. The gain on the exchange offer qualifies as a tax-free transaction for U.S. federal income tax purposes.", "text": "Johnson & Johnson divested net assets of $11.6 billion as of August 23, 2023, and the accumulated other comprehensive loss attributable to the Consumer Health business at that date was $4.3 billion.", "length": 198, "numbers_raw": ["$11.6 billion", "23", "202", "3", "$4.3 billion"], "numbers": [11600000000.0, 23.0, 202.0, 3.0, 4300000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1522, "tag": "div", "text_raw": "Johnson & Johnson divested net assets of $11.6 billion as of August 23, 2023, and the accumulated other comprehensive loss attributable to the Consumer Health business at that date was $4.3 billion. Additionally, at the date of the exchange offer, Johnson & Johnson decreased the non-controlling interest by $1.2 billion to record the deconsolidation of Kenvue. This resulted in a gain on the exchange offer of $21.0 billion that was recorded in Net earnings from discontinued operations, net of taxes in the consolidated statements of earnings for the fiscal third quarter of 2023. This one-time gain includes a gain of $2.8 billion on the Kenvue Common Stock retained by Johnson & Johnson. The gain on the exchange offer qualifies as a tax-free transaction for U.S. federal income tax purposes.", "text": "Additionally, at the date of the exchange offer, Johnson & Johnson decreased the non-controlling interest by $1.2 billion to record the deconsolidation of Kenvue.", "length": 162, "numbers_raw": ["$1.2 billion"], "numbers": [1200000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1522, "tag": "div", "text_raw": "Johnson & Johnson divested net assets of $11.6 billion as of August 23, 2023, and the accumulated other comprehensive loss attributable to the Consumer Health business at that date was $4.3 billion. Additionally, at the date of the exchange offer, Johnson & Johnson decreased the non-controlling interest by $1.2 billion to record the deconsolidation of Kenvue. This resulted in a gain on the exchange offer of $21.0 billion that was recorded in Net earnings from discontinued operations, net of taxes in the consolidated statements of earnings for the fiscal third quarter of 2023. This one-time gain includes a gain of $2.8 billion on the Kenvue Common Stock retained by Johnson & Johnson. The gain on the exchange offer qualifies as a tax-free transaction for U.S. federal income tax purposes.", "text": "This resulted in a gain on the exchange offer of $21.0 billion that was recorded in Net earnings from discontinued operations, net of taxes in the consolidated statements of earnings for the fiscal third quarter of 2023.", "length": 220, "numbers_raw": ["$21.0 billion", "202", "3"], "numbers": [21000000000.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1522, "tag": "div", "text_raw": "Johnson & Johnson divested net assets of $11.6 billion as of August 23, 2023, and the accumulated other comprehensive loss attributable to the Consumer Health business at that date was $4.3 billion. Additionally, at the date of the exchange offer, Johnson & Johnson decreased the non-controlling interest by $1.2 billion to record the deconsolidation of Kenvue. This resulted in a gain on the exchange offer of $21.0 billion that was recorded in Net earnings from discontinued operations, net of taxes in the consolidated statements of earnings for the fiscal third quarter of 2023. This one-time gain includes a gain of $2.8 billion on the Kenvue Common Stock retained by Johnson & Johnson. The gain on the exchange offer qualifies as a tax-free transaction for U.S. federal income tax purposes.", "text": "This one-time gain includes a gain of $2.8 billion on the Kenvue Common Stock retained by Johnson & Johnson.", "length": 108, "numbers_raw": ["$2.8 billion"], "numbers": [2800000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1522, "tag": "div", "text_raw": "Johnson & Johnson divested net assets of $11.6 billion as of August 23, 2023, and the accumulated other comprehensive loss attributable to the Consumer Health business at that date was $4.3 billion. Additionally, at the date of the exchange offer, Johnson & Johnson decreased the non-controlling interest by $1.2 billion to record the deconsolidation of Kenvue. This resulted in a gain on the exchange offer of $21.0 billion that was recorded in Net earnings from discontinued operations, net of taxes in the consolidated statements of earnings for the fiscal third quarter of 2023. This one-time gain includes a gain of $2.8 billion on the Kenvue Common Stock retained by Johnson & Johnson. The gain on the exchange offer qualifies as a tax-free transaction for U.S. federal income tax purposes.", "text": "The gain on the exchange offer qualifies as a tax-free transaction for U.S.", "length": 75, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1524, "tag": "div", "text_raw": "As of October 1, 2023, the Company's cash, cash equivalents and marketable securities was approximately $23.5 billion and had approximately $29.9 billion of notes payable and long-term debt for a net debt position of $6.4 billion as compared to the prior year net cash position of $1.1 billion. The Company anticipates that operating cash flows, the ability to raise funds from external sources, borrowing capacity from existing committed credit facilities and access to the commercial paper markets will continue to provide sufficient resources to fund operating needs, including the Companys remaining balance to be paid on the agreement to settle opioid litigation for approximately $2.1 billion and the establishment of the approximately $9 billion reserve for the talc settlement proposal (See Note 11 to the Consolidated Financial Statements for additional details). In addition, the Company monitors the global capital markets on an ongoing basis and from time to time may raise capital when market conditions are favorable.", "text": "As of October 1, 2023, the Company's cash, cash equivalents and marketable securities was approximately $23.5 billion and had approximately $29.9 billion of notes payable and long-term debt for a net debt position of $6.4 billion as compared to the prior year net cash position of $1.1 billion.", "length": 294, "numbers_raw": ["1", "202", "3", "$23.5 billion", "$29.9 billion", "$6.4 billion", "$1.1 billion"], "numbers": [1.0, 202.0, 3.0, 23500000000.0, 29900000000.0, 6400000000.0, 1100000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1524, "tag": "div", "text_raw": "As of October 1, 2023, the Company's cash, cash equivalents and marketable securities was approximately $23.5 billion and had approximately $29.9 billion of notes payable and long-term debt for a net debt position of $6.4 billion as compared to the prior year net cash position of $1.1 billion. The Company anticipates that operating cash flows, the ability to raise funds from external sources, borrowing capacity from existing committed credit facilities and access to the commercial paper markets will continue to provide sufficient resources to fund operating needs, including the Companys remaining balance to be paid on the agreement to settle opioid litigation for approximately $2.1 billion and the establishment of the approximately $9 billion reserve for the talc settlement proposal (See Note 11 to the Consolidated Financial Statements for additional details). In addition, the Company monitors the global capital markets on an ongoing basis and from time to time may raise capital when market conditions are favorable.", "text": "The Company anticipates that operating cash flows, the ability to raise funds from external sources, borrowing capacity from existing committed credit facilities and access to the commercial paper markets will continue to provide sufficient resources to fund operating needs, including the Companys remaining balance to be paid on the agreement to settle opioid litigation for approximately $2.1 billion and the establishment of the approximately $9 billion reserve for the talc settlement proposal (See Note 11 to the Consolidated Financial Statements for additional details).", "length": 578, "numbers_raw": ["$2.1 billion", "$9 billion", "11"], "numbers": [2100000000.0, 9000000000.0, 11.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1524, "tag": "div", "text_raw": "As of October 1, 2023, the Company's cash, cash equivalents and marketable securities was approximately $23.5 billion and had approximately $29.9 billion of notes payable and long-term debt for a net debt position of $6.4 billion as compared to the prior year net cash position of $1.1 billion. The Company anticipates that operating cash flows, the ability to raise funds from external sources, borrowing capacity from existing committed credit facilities and access to the commercial paper markets will continue to provide sufficient resources to fund operating needs, including the Companys remaining balance to be paid on the agreement to settle opioid litigation for approximately $2.1 billion and the establishment of the approximately $9 billion reserve for the talc settlement proposal (See Note 11 to the Consolidated Financial Statements for additional details). In addition, the Company monitors the global capital markets on an ongoing basis and from time to time may raise capital when market conditions are favorable.", "text": "In addition, the Company monitors the global capital markets on an ongoing basis and from time to time may raise capital when market conditions are favorable.", "length": 158, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1526, "tag": "div", "text_raw": "In the fiscal nine months of 2023, the Company paid approximately $4.9 billion to the U.S. Treasury including $1.5 billion related to the current installment due on foreign undistributed earnings as part of the TCJA charge (see Note 1 to the Consolidated Financial Statements in the Companys Annual Report on Form 10-K for the fiscal year ended January 1, 2023), $1.4 billion in pre-payments to resolve certain items under examination in its 2013 through 2016 U.S. IRS audit, and $2.0 billion primarily related to the normal estimated payments for the first nine months of fiscal 2023.", "text": "In the fiscal nine months of 2023, the Company paid approximately $4.9 billion to the U.S.", "length": 90, "numbers_raw": ["202", "3", "$4.9 billion"], "numbers": [202.0, 3.0, 4900000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1526, "tag": "div", "text_raw": "In the fiscal nine months of 2023, the Company paid approximately $4.9 billion to the U.S. Treasury including $1.5 billion related to the current installment due on foreign undistributed earnings as part of the TCJA charge (see Note 1 to the Consolidated Financial Statements in the Companys Annual Report on Form 10-K for the fiscal year ended January 1, 2023), $1.4 billion in pre-payments to resolve certain items under examination in its 2013 through 2016 U.S. IRS audit, and $2.0 billion primarily related to the normal estimated payments for the first nine months of fiscal 2023.", "text": "Treasury including $1.5 billion related to the current installment due on foreign undistributed earnings as part of the TCJA charge (see Note 1 to the Consolidated Financial Statements in the Companys Annual Report on Form 10-K for the fiscal year ended January 1, 2023), $1.4 billion in pre-payments to resolve certain items under examination in its 2013 through 2016 U.S.", "length": 374, "numbers_raw": ["$1.5 billion", "1", "10", "1", "202", "3", "$1.4 billion", "201", "3", "201", "6"], "numbers": [1500000000.0, 1.0, 10.0, 1.0, 202.0, 3.0, 1400000000.0, 201.0, 3.0, 201.0, 6.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1526, "tag": "div", "text_raw": "In the fiscal nine months of 2023, the Company paid approximately $4.9 billion to the U.S. Treasury including $1.5 billion related to the current installment due on foreign undistributed earnings as part of the TCJA charge (see Note 1 to the Consolidated Financial Statements in the Companys Annual Report on Form 10-K for the fiscal year ended January 1, 2023), $1.4 billion in pre-payments to resolve certain items under examination in its 2013 through 2016 U.S. IRS audit, and $2.0 billion primarily related to the normal estimated payments for the first nine months of fiscal 2023.", "text": "IRS audit, and $2.0 billion primarily related to the normal estimated payments for the first nine months of fiscal 2023.", "length": 120, "numbers_raw": ["$2.0 billion", "202", "3"], "numbers": [2000000000.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1527, "tag": "div", "text_raw": "On September 14, 2022, the Company announced that its Board of Directors approved a share repurchase program, authorizing the Company to purchase up to $5.0 billion of the Companys Common Stock. As of April 2, 2023, $5.0 billion has been repurchased and the repurchase program was completed.", "text": "On September 14, 2022, the Company announced that its Board of Directors approved a share repurchase program, authorizing the Company to purchase up to $5.0 billion of the Companys Common Stock.", "length": 195, "numbers_raw": ["14", "202", "2", "$5.0 billion"], "numbers": [14.0, 202.0, 2.0, 5000000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1527, "tag": "div", "text_raw": "On September 14, 2022, the Company announced that its Board of Directors approved a share repurchase program, authorizing the Company to purchase up to $5.0 billion of the Companys Common Stock. As of April 2, 2023, $5.0 billion has been repurchased and the repurchase program was completed.", "text": "As of April 2, 2023, $5.0 billion has been repurchased and the repurchase program was completed.", "length": 96, "numbers_raw": ["2", "202", "3", "$5.0 billion"], "numbers": [2.0, 202.0, 3.0, 5000000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1531, "tag": "div", "text_raw": "On July 20, 2023, the Board of Directors declared a regular cash dividend of $1.19 per share, payable on September 7, 2023, to shareholders of record as of August 28, 2023.", "text": "On July 20, 2023, the Board of Directors declared a regular cash dividend of $1.19 per share, payable on September 7, 2023, to shareholders of record as of August 28, 2023.", "length": 172, "numbers_raw": ["20", "202", "3", "$1.19", "7", "202", "3", "28", "202", "3"], "numbers": [20.0, 202.0, 3.0, 1.19, 7.0, 202.0, 3.0, 28.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1533, "tag": "div", "text_raw": "On October 19, 2023, the Board of Directors declared a regular cash dividend of $1.19 per share, payable on December 5, 2023, to shareholders of record as of November 21, 2023. The Company expects to continue the practice of paying regular quarterly cash dividends.", "text": "On October 19, 2023, the Board of Directors declared a regular cash dividend of $1.19 per share, payable on December 5, 2023, to shareholders of record as of November 21, 2023.", "length": 176, "numbers_raw": ["19", "202", "3", "$1.19", "5", "202", "3", "21", "202", "3"], "numbers": [19.0, 202.0, 3.0, 1.19, 5.0, 202.0, 3.0, 21.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1533, "tag": "div", "text_raw": "On October 19, 2023, the Board of Directors declared a regular cash dividend of $1.19 per share, payable on December 5, 2023, to shareholders of record as of November 21, 2023. The Company expects to continue the practice of paying regular quarterly cash dividends.", "text": "The Company expects to continue the practice of paying regular quarterly cash dividends.", "length": 88, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1539, "tag": "div", "text_raw": "Refer to Note 1 to the Consolidated Financial Statements for new accounting pronouncements.", "text": "Refer to Note 1 to the Consolidated Financial Statements for new accounting pronouncements.", "length": 91, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1542, "tag": "div", "text_raw": "In July 2023, Janssen Pharmaceuticals, Inc. (Janssen) filed litigation against the U.S. Department of Health and Human Services as well as the Centers for Medicare and Medicaid Services challenging the constitutionality of the Inflation Reduction Acts (IRA) Medicare Drug Price Negotiation Program. The litigation requests a declaration that the IRA violates Janssens rights under the First Amendment and the Fifth Amendment to the Constitution and therefore that Janssen is not subject to the IRAs mandatory pricing scheme.", "text": "In July 2023, Janssen Pharmaceuticals, Inc.", "length": 43, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1542, "tag": "div", "text_raw": "In July 2023, Janssen Pharmaceuticals, Inc. (Janssen) filed litigation against the U.S. Department of Health and Human Services as well as the Centers for Medicare and Medicaid Services challenging the constitutionality of the Inflation Reduction Acts (IRA) Medicare Drug Price Negotiation Program. The litigation requests a declaration that the IRA violates Janssens rights under the First Amendment and the Fifth Amendment to the Constitution and therefore that Janssen is not subject to the IRAs mandatory pricing scheme.", "text": "(Janssen) filed litigation against the U.S.", "length": 43, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1542, "tag": "div", "text_raw": "In July 2023, Janssen Pharmaceuticals, Inc. (Janssen) filed litigation against the U.S. Department of Health and Human Services as well as the Centers for Medicare and Medicaid Services challenging the constitutionality of the Inflation Reduction Acts (IRA) Medicare Drug Price Negotiation Program. The litigation requests a declaration that the IRA violates Janssens rights under the First Amendment and the Fifth Amendment to the Constitution and therefore that Janssen is not subject to the IRAs mandatory pricing scheme.", "text": "Department of Health and Human Services as well as the Centers for Medicare and Medicaid Services challenging the constitutionality of the Inflation Reduction Acts (IRA) Medicare Drug Price Negotiation Program.", "length": 211, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1542, "tag": "div", "text_raw": "In July 2023, Janssen Pharmaceuticals, Inc. (Janssen) filed litigation against the U.S. Department of Health and Human Services as well as the Centers for Medicare and Medicaid Services challenging the constitutionality of the Inflation Reduction Acts (IRA) Medicare Drug Price Negotiation Program. The litigation requests a declaration that the IRA violates Janssens rights under the First Amendment and the Fifth Amendment to the Constitution and therefore that Janssen is not subject to the IRAs mandatory pricing scheme.", "text": "The litigation requests a declaration that the IRA violates Janssens rights under the First Amendment and the Fifth Amendment to the Constitution and therefore that Janssen is not subject to the IRAs mandatory pricing scheme.", "length": 227, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1545, "tag": "div", "text_raw": "Although the long-term implications of Russias invasion of Ukraine are difficult to predict at this time, the financial impact of the conflict in the fiscal third quarter and fiscal nine months of 2023, including accounts receivable or inventory reserves, was not material. As of the fiscal nine months ending October 1, 2023, the business of the Companys Russian subsidiaries", "text": "Although the long-term implications of Russias invasion of Ukraine are difficult to predict at this time, the financial impact of the conflict in the fiscal third quarter and fiscal nine months of 2023, including accounts receivable or inventory reserves, was not material.", "length": 274, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1545, "tag": "div", "text_raw": "Although the long-term implications of Russias invasion of Ukraine are difficult to predict at this time, the financial impact of the conflict in the fiscal third quarter and fiscal nine months of 2023, including accounts receivable or inventory reserves, was not material. As of the fiscal nine months ending October 1, 2023, the business of the Companys Russian subsidiaries", "text": "As of the fiscal nine months ending October 1, 2023, the business of the Companys Russian subsidiaries", "length": 103, "numbers_raw": ["1", "202", "3"], "numbers": [1.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1546, "tag": "div", "text_raw": "57", "text": "57", "length": 2, "numbers_raw": ["57"], "numbers": [57.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1547, "tag": "div", "text_raw": "57", "text": "57", "length": 2, "numbers_raw": ["57"], "numbers": [57.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1548, "tag": "div", "text_raw": "57", "text": "57", "length": 2, "numbers_raw": ["57"], "numbers": [57.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1551, "tag": "div", "text_raw": "represented less than 1% of both Companys consolidated assets and revenues. The Company does not maintain Ukraine subsidiaries within continuing operations post the Kenvue separation.", "text": "represented less than 1% of both Companys consolidated assets and revenues.", "length": 76, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": ["1%"], "percents": [0.01], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1551, "tag": "div", "text_raw": "represented less than 1% of both Companys consolidated assets and revenues. The Company does not maintain Ukraine subsidiaries within continuing operations post the Kenvue separation.", "text": "The Company does not maintain Ukraine subsidiaries within continuing operations post the Kenvue separation.", "length": 107, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1553, "tag": "div", "text_raw": "In early March of 2022, the Company took steps to suspend all advertising, enrollment in clinical trials, and any additional investment in Russia. The Company continues to supply products relied upon by patients for healthcare purposes.", "text": "In early March of 2022, the Company took steps to suspend all advertising, enrollment in clinical trials, and any additional investment in Russia.", "length": 146, "numbers_raw": ["202", "2"], "numbers": [202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1553, "tag": "div", "text_raw": "In early March of 2022, the Company took steps to suspend all advertising, enrollment in clinical trials, and any additional investment in Russia. The Company continues to supply products relied upon by patients for healthcare purposes.", "text": "The Company continues to supply products relied upon by patients for healthcare purposes.", "length": 89, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1556, "tag": "div", "text_raw": "Although the long-term implications of Israel's conflict are difficult to predict at this time, the financial impact of the conflict in the fiscal third quarter and fiscal nine months of 2023, including accounts receivable or inventory reserves, was not material. As of the fiscal nine months ending October 1, 2023, the business of the Companys Israel subsidiaries represented 1% of the Companys consolidated assets and represented less than 1% of revenues.", "text": "Although the long-term implications of Israel's conflict are difficult to predict at this time, the financial impact of the conflict in the fiscal third quarter and fiscal nine months of 2023, including accounts receivable or inventory reserves, was not material.", "length": 263, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1556, "tag": "div", "text_raw": "Although the long-term implications of Israel's conflict are difficult to predict at this time, the financial impact of the conflict in the fiscal third quarter and fiscal nine months of 2023, including accounts receivable or inventory reserves, was not material. As of the fiscal nine months ending October 1, 2023, the business of the Companys Israel subsidiaries represented 1% of the Companys consolidated assets and represented less than 1% of revenues.", "text": "As of the fiscal nine months ending October 1, 2023, the business of the Companys Israel subsidiaries represented 1% of the Companys consolidated assets and represented less than 1% of revenues.", "length": 196, "numbers_raw": ["1", "202", "3", "1", "1"], "numbers": [1.0, 202.0, 3.0, 1.0, 1.0], "percents_raw": ["1%", "1%"], "percents": [0.01, 0.01], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1558, "tag": "div", "text_raw": "The Company operates in certain countries where the economic conditions continue to present significant challenges. The Company continues to monitor these situations and take appropriate actions. Inflation rates and currency exchange rates continue to have an effect on worldwide economies and, consequently, on the way the Company operates. The Company has accounted for operations in Venezuela, Argentina and Turkey (beginning in the fiscal second quarter of 2022) as highly inflationary, as the prior three-year cumulative inflation rate surpassed 100%. In the face of increasing costs, the Company strives to maintain its profit margins through cost reduction programs, productivity improvements and periodic price increases.", "text": "The Company operates in certain countries where the economic conditions continue to present significant challenges.", "length": 115, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1558, "tag": "div", "text_raw": "The Company operates in certain countries where the economic conditions continue to present significant challenges. The Company continues to monitor these situations and take appropriate actions. Inflation rates and currency exchange rates continue to have an effect on worldwide economies and, consequently, on the way the Company operates. The Company has accounted for operations in Venezuela, Argentina and Turkey (beginning in the fiscal second quarter of 2022) as highly inflationary, as the prior three-year cumulative inflation rate surpassed 100%. In the face of increasing costs, the Company strives to maintain its profit margins through cost reduction programs, productivity improvements and periodic price increases.", "text": "The Company continues to monitor these situations and take appropriate actions.", "length": 79, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1558, "tag": "div", "text_raw": "The Company operates in certain countries where the economic conditions continue to present significant challenges. The Company continues to monitor these situations and take appropriate actions. Inflation rates and currency exchange rates continue to have an effect on worldwide economies and, consequently, on the way the Company operates. The Company has accounted for operations in Venezuela, Argentina and Turkey (beginning in the fiscal second quarter of 2022) as highly inflationary, as the prior three-year cumulative inflation rate surpassed 100%. In the face of increasing costs, the Company strives to maintain its profit margins through cost reduction programs, productivity improvements and periodic price increases.", "text": "Inflation rates and currency exchange rates continue to have an effect on worldwide economies and, consequently, on the way the Company operates.", "length": 145, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1558, "tag": "div", "text_raw": "The Company operates in certain countries where the economic conditions continue to present significant challenges. The Company continues to monitor these situations and take appropriate actions. Inflation rates and currency exchange rates continue to have an effect on worldwide economies and, consequently, on the way the Company operates. The Company has accounted for operations in Venezuela, Argentina and Turkey (beginning in the fiscal second quarter of 2022) as highly inflationary, as the prior three-year cumulative inflation rate surpassed 100%. In the face of increasing costs, the Company strives to maintain its profit margins through cost reduction programs, productivity improvements and periodic price increases.", "text": "The Company has accounted for operations in Venezuela, Argentina and Turkey (beginning in the fiscal second quarter of 2022) as highly inflationary, as the prior three-year cumulative inflation rate surpassed 100%.", "length": 214, "numbers_raw": ["202", "2", "100"], "numbers": [202.0, 2.0, 100.0], "percents_raw": ["100%"], "percents": [1.0], "currencies": [], "has_numbers": true, "has_percents": true}
{"idx_source": 1558, "tag": "div", "text_raw": "The Company operates in certain countries where the economic conditions continue to present significant challenges. The Company continues to monitor these situations and take appropriate actions. Inflation rates and currency exchange rates continue to have an effect on worldwide economies and, consequently, on the way the Company operates. The Company has accounted for operations in Venezuela, Argentina and Turkey (beginning in the fiscal second quarter of 2022) as highly inflationary, as the prior three-year cumulative inflation rate surpassed 100%. In the face of increasing costs, the Company strives to maintain its profit margins through cost reduction programs, productivity improvements and periodic price increases.", "text": "In the face of increasing costs, the Company strives to maintain its profit margins through cost reduction programs, productivity improvements and periodic price increases.", "length": 172, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1560, "tag": "div", "text_raw": "Governments around the world consider various proposals to make changes to tax laws, which may include increasing or decreasing existing statutory tax rates. In connection with various government initiatives, companies are required to disclose more information to tax authorities on operations around the world, which may lead to greater audit scrutiny of profits earned in other countries. A change in statutory tax rate in any country would result in the revaluation of the Companys deferred tax assets and liabilities related to that particular jurisdiction in the period in which the new tax law is enacted. This change would result in an expense or benefit recorded to the Companys Consolidated Statement of Earnings. The Company closely monitors these proposals as they arise in the countries where it operates. Changes to the statutory tax rate may occur at any time, and any related expense or benefit recorded may be material to the fiscal quarter and year in which the law change is enacted.", "text": "Governments around the world consider various proposals to make changes to tax laws, which may include increasing or decreasing existing statutory tax rates.", "length": 157, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1560, "tag": "div", "text_raw": "Governments around the world consider various proposals to make changes to tax laws, which may include increasing or decreasing existing statutory tax rates. In connection with various government initiatives, companies are required to disclose more information to tax authorities on operations around the world, which may lead to greater audit scrutiny of profits earned in other countries. A change in statutory tax rate in any country would result in the revaluation of the Companys deferred tax assets and liabilities related to that particular jurisdiction in the period in which the new tax law is enacted. This change would result in an expense or benefit recorded to the Companys Consolidated Statement of Earnings. The Company closely monitors these proposals as they arise in the countries where it operates. Changes to the statutory tax rate may occur at any time, and any related expense or benefit recorded may be material to the fiscal quarter and year in which the law change is enacted.", "text": "In connection with various government initiatives, companies are required to disclose more information to tax authorities on operations around the world, which may lead to greater audit scrutiny of profits earned in other countries.", "length": 232, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1560, "tag": "div", "text_raw": "Governments around the world consider various proposals to make changes to tax laws, which may include increasing or decreasing existing statutory tax rates. In connection with various government initiatives, companies are required to disclose more information to tax authorities on operations around the world, which may lead to greater audit scrutiny of profits earned in other countries. A change in statutory tax rate in any country would result in the revaluation of the Companys deferred tax assets and liabilities related to that particular jurisdiction in the period in which the new tax law is enacted. This change would result in an expense or benefit recorded to the Companys Consolidated Statement of Earnings. The Company closely monitors these proposals as they arise in the countries where it operates. Changes to the statutory tax rate may occur at any time, and any related expense or benefit recorded may be material to the fiscal quarter and year in which the law change is enacted.", "text": "A change in statutory tax rate in any country would result in the revaluation of the Companys deferred tax assets and liabilities related to that particular jurisdiction in the period in which the new tax law is enacted.", "length": 221, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1560, "tag": "div", "text_raw": "Governments around the world consider various proposals to make changes to tax laws, which may include increasing or decreasing existing statutory tax rates. In connection with various government initiatives, companies are required to disclose more information to tax authorities on operations around the world, which may lead to greater audit scrutiny of profits earned in other countries. A change in statutory tax rate in any country would result in the revaluation of the Companys deferred tax assets and liabilities related to that particular jurisdiction in the period in which the new tax law is enacted. This change would result in an expense or benefit recorded to the Companys Consolidated Statement of Earnings. The Company closely monitors these proposals as they arise in the countries where it operates. Changes to the statutory tax rate may occur at any time, and any related expense or benefit recorded may be material to the fiscal quarter and year in which the law change is enacted.", "text": "This change would result in an expense or benefit recorded to the Companys Consolidated Statement of Earnings.", "length": 111, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1560, "tag": "div", "text_raw": "Governments around the world consider various proposals to make changes to tax laws, which may include increasing or decreasing existing statutory tax rates. In connection with various government initiatives, companies are required to disclose more information to tax authorities on operations around the world, which may lead to greater audit scrutiny of profits earned in other countries. A change in statutory tax rate in any country would result in the revaluation of the Companys deferred tax assets and liabilities related to that particular jurisdiction in the period in which the new tax law is enacted. This change would result in an expense or benefit recorded to the Companys Consolidated Statement of Earnings. The Company closely monitors these proposals as they arise in the countries where it operates. Changes to the statutory tax rate may occur at any time, and any related expense or benefit recorded may be material to the fiscal quarter and year in which the law change is enacted.", "text": "The Company closely monitors these proposals as they arise in the countries where it operates.", "length": 94, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1560, "tag": "div", "text_raw": "Governments around the world consider various proposals to make changes to tax laws, which may include increasing or decreasing existing statutory tax rates. In connection with various government initiatives, companies are required to disclose more information to tax authorities on operations around the world, which may lead to greater audit scrutiny of profits earned in other countries. A change in statutory tax rate in any country would result in the revaluation of the Companys deferred tax assets and liabilities related to that particular jurisdiction in the period in which the new tax law is enacted. This change would result in an expense or benefit recorded to the Companys Consolidated Statement of Earnings. The Company closely monitors these proposals as they arise in the countries where it operates. Changes to the statutory tax rate may occur at any time, and any related expense or benefit recorded may be material to the fiscal quarter and year in which the law change is enacted.", "text": "Changes to the statutory tax rate may occur at any time, and any related expense or benefit recorded may be material to the fiscal quarter and year in which the law change is enacted.", "length": 183, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1562, "tag": "div", "text_raw": "The Company faces various worldwide health care changes that may continue to result in pricing pressures that include health care cost containment and government legislation relating to sales, promotions and reimbursement of health care products.", "text": "The Company faces various worldwide health care changes that may continue to result in pricing pressures that include health care cost containment and government legislation relating to sales, promotions and reimbursement of health care products.", "length": 246, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1564, "tag": "div", "text_raw": "Changes in the behavior and spending patterns of purchasers of healthcare products and services, including delaying medical procedures, rationing prescription medications, reducing the frequency of physician visits and foregoing healthcare insurance coverage, as a result of the current global economic downturn, may continue to impact the Companys businesses.", "text": "Changes in the behavior and spending patterns of purchasers of healthcare products and services, including delaying medical procedures, rationing prescription medications, reducing the frequency of physician visits and foregoing healthcare insurance coverage, as a result of the current global economic downturn, may continue to impact the Companys businesses.", "length": 361, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1566, "tag": "div", "text_raw": "The Company faces regular intellectual property challenges from third parties, including generic and biosimilar manufacturers, seeking to manufacture and market generic and biosimilar versions of key pharmaceutical products prior to the expiration of the applicable patents. These challengers file Abbreviated New Drug Applications or abbreviated Biologics License Applications with the FDA or otherwise challenged the coverage and/or validity of the Companys patents. In the event the Company is not successful in defending the patent claims challenged in the resulting lawsuits, generic or biosimilar versions of the products at issue may be introduced to the market, resulting in the potential for substantial market share and revenue losses for those products, and which may result in a non-cash impairment charge in any associated intangible asset. There is also risk that one or more competitors could launch a generic or biosimilar version of the product at issue following regulatory approval even though one or more valid patents are in place.", "text": "The Company faces regular intellectual property challenges from third parties, including generic and biosimilar manufacturers, seeking to manufacture and market generic and biosimilar versions of key pharmaceutical products prior to the expiration of the applicable patents.", "length": 274, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1566, "tag": "div", "text_raw": "The Company faces regular intellectual property challenges from third parties, including generic and biosimilar manufacturers, seeking to manufacture and market generic and biosimilar versions of key pharmaceutical products prior to the expiration of the applicable patents. These challengers file Abbreviated New Drug Applications or abbreviated Biologics License Applications with the FDA or otherwise challenged the coverage and/or validity of the Companys patents. In the event the Company is not successful in defending the patent claims challenged in the resulting lawsuits, generic or biosimilar versions of the products at issue may be introduced to the market, resulting in the potential for substantial market share and revenue losses for those products, and which may result in a non-cash impairment charge in any associated intangible asset. There is also risk that one or more competitors could launch a generic or biosimilar version of the product at issue following regulatory approval even though one or more valid patents are in place.", "text": "These challengers file Abbreviated New Drug Applications or abbreviated Biologics License Applications with the FDA or otherwise challenged the coverage and/or validity of the Companys patents.", "length": 194, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1566, "tag": "div", "text_raw": "The Company faces regular intellectual property challenges from third parties, including generic and biosimilar manufacturers, seeking to manufacture and market generic and biosimilar versions of key pharmaceutical products prior to the expiration of the applicable patents. These challengers file Abbreviated New Drug Applications or abbreviated Biologics License Applications with the FDA or otherwise challenged the coverage and/or validity of the Companys patents. In the event the Company is not successful in defending the patent claims challenged in the resulting lawsuits, generic or biosimilar versions of the products at issue may be introduced to the market, resulting in the potential for substantial market share and revenue losses for those products, and which may result in a non-cash impairment charge in any associated intangible asset. There is also risk that one or more competitors could launch a generic or biosimilar version of the product at issue following regulatory approval even though one or more valid patents are in place.", "text": "In the event the Company is not successful in defending the patent claims challenged in the resulting lawsuits, generic or biosimilar versions of the products at issue may be introduced to the market, resulting in the potential for substantial market share and revenue losses for those products, and which may result in a non-cash impairment charge in any associated intangible asset.", "length": 384, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1566, "tag": "div", "text_raw": "The Company faces regular intellectual property challenges from third parties, including generic and biosimilar manufacturers, seeking to manufacture and market generic and biosimilar versions of key pharmaceutical products prior to the expiration of the applicable patents. These challengers file Abbreviated New Drug Applications or abbreviated Biologics License Applications with the FDA or otherwise challenged the coverage and/or validity of the Companys patents. In the event the Company is not successful in defending the patent claims challenged in the resulting lawsuits, generic or biosimilar versions of the products at issue may be introduced to the market, resulting in the potential for substantial market share and revenue losses for those products, and which may result in a non-cash impairment charge in any associated intangible asset. There is also risk that one or more competitors could launch a generic or biosimilar version of the product at issue following regulatory approval even though one or more valid patents are in place.", "text": "There is also risk that one or more competitors could launch a generic or biosimilar version of the product at issue following regulatory approval even though one or more valid patents are in place.", "length": 198, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1570, "tag": "div", "text_raw": "Item 3  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK", "text": "Item 3  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK", "length": 67, "numbers_raw": ["3"], "numbers": [3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1572, "tag": "div", "text_raw": "There has been no material change in the Companys assessment of its sensitivity to market risk since its presentation set forth in Item 7A, Quantitative and Qualitative Disclosures About Market Risk, in its Annual Report on Form 10-K for the fiscal year ended January 1, 2023.", "text": "There has been no material change in the Companys assessment of its sensitivity to market risk since its presentation set forth in Item 7A, Quantitative and Qualitative Disclosures About Market Risk, in its Annual Report on Form 10-K for the fiscal year ended January 1, 2023.", "length": 279, "numbers_raw": ["7", "10", "1", "202", "3"], "numbers": [7.0, 10.0, 1.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1576, "tag": "div", "text_raw": "Item 4  CONTROLS AND PROCEDURES", "text": "Item 4  CONTROLS AND PROCEDURES", "length": 32, "numbers_raw": ["4"], "numbers": [4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1578, "tag": "div", "text_raw": "Disclosure controls and procedures. At the end of the period covered by this report, the Company evaluated the effectiveness of the design and operation of its disclosure controls and procedures. The Companys disclosure controls and procedures are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SECs rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that", "text": "Disclosure controls and procedures.", "length": 35, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1578, "tag": "div", "text_raw": "Disclosure controls and procedures. At the end of the period covered by this report, the Company evaluated the effectiveness of the design and operation of its disclosure controls and procedures. The Companys disclosure controls and procedures are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SECs rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that", "text": "At the end of the period covered by this report, the Company evaluated the effectiveness of the design and operation of its disclosure controls and procedures.", "length": 159, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1578, "tag": "div", "text_raw": "Disclosure controls and procedures. At the end of the period covered by this report, the Company evaluated the effectiveness of the design and operation of its disclosure controls and procedures. The Companys disclosure controls and procedures are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SECs rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that", "text": "The Companys disclosure controls and procedures are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SECs rules and forms.", "length": 315, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1578, "tag": "div", "text_raw": "Disclosure controls and procedures. At the end of the period covered by this report, the Company evaluated the effectiveness of the design and operation of its disclosure controls and procedures. The Companys disclosure controls and procedures are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SECs rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that", "text": "Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that", "length": 111, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1579, "tag": "div", "text_raw": "58", "text": "58", "length": 2, "numbers_raw": ["58"], "numbers": [58.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1580, "tag": "div", "text_raw": "58", "text": "58", "length": 2, "numbers_raw": ["58"], "numbers": [58.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1581, "tag": "div", "text_raw": "58", "text": "58", "length": 2, "numbers_raw": ["58"], "numbers": [58.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1584, "tag": "div", "text_raw": "information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act is accumulated and communicated to the Companys management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Joaquin Duato, Chief Executive Officer; Chairman, Executive Committee and Joseph J. Wolk, Executive Vice President, Chief Financial Officer, reviewed and participated in this evaluation. Based on this evaluation, Messrs. Duato and Wolk concluded that, as of the end of the period covered by this report, the Companys disclosure controls and procedures were effective.", "text": "information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act is accumulated and communicated to the Companys management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.", "length": 368, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1584, "tag": "div", "text_raw": "information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act is accumulated and communicated to the Companys management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Joaquin Duato, Chief Executive Officer; Chairman, Executive Committee and Joseph J. Wolk, Executive Vice President, Chief Financial Officer, reviewed and participated in this evaluation. Based on this evaluation, Messrs. Duato and Wolk concluded that, as of the end of the period covered by this report, the Companys disclosure controls and procedures were effective.", "text": "Joaquin Duato, Chief Executive Officer;", "length": 39, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1584, "tag": "div", "text_raw": "information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act is accumulated and communicated to the Companys management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Joaquin Duato, Chief Executive Officer; Chairman, Executive Committee and Joseph J. Wolk, Executive Vice President, Chief Financial Officer, reviewed and participated in this evaluation. Based on this evaluation, Messrs. Duato and Wolk concluded that, as of the end of the period covered by this report, the Companys disclosure controls and procedures were effective.", "text": "Chairman, Executive Committee and Joseph J.", "length": 43, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1584, "tag": "div", "text_raw": "information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act is accumulated and communicated to the Companys management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Joaquin Duato, Chief Executive Officer; Chairman, Executive Committee and Joseph J. Wolk, Executive Vice President, Chief Financial Officer, reviewed and participated in this evaluation. Based on this evaluation, Messrs. Duato and Wolk concluded that, as of the end of the period covered by this report, the Companys disclosure controls and procedures were effective.", "text": "Wolk, Executive Vice President, Chief Financial Officer, reviewed and participated in this evaluation.", "length": 102, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1584, "tag": "div", "text_raw": "information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act is accumulated and communicated to the Companys management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Joaquin Duato, Chief Executive Officer; Chairman, Executive Committee and Joseph J. Wolk, Executive Vice President, Chief Financial Officer, reviewed and participated in this evaluation. Based on this evaluation, Messrs. Duato and Wolk concluded that, as of the end of the period covered by this report, the Companys disclosure controls and procedures were effective.", "text": "Based on this evaluation, Messrs.", "length": 33, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1584, "tag": "div", "text_raw": "information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act is accumulated and communicated to the Companys management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Joaquin Duato, Chief Executive Officer; Chairman, Executive Committee and Joseph J. Wolk, Executive Vice President, Chief Financial Officer, reviewed and participated in this evaluation. Based on this evaluation, Messrs. Duato and Wolk concluded that, as of the end of the period covered by this report, the Companys disclosure controls and procedures were effective.", "text": "Duato and Wolk concluded that, as of the end of the period covered by this report, the Companys disclosure controls and procedures were effective.", "length": 147, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1586, "tag": "div", "text_raw": "Internal control. During the period covered by this report, there were no changes in the Companys internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, the Companys internal control over financial reporting. The Company continues to monitor and assess the effectiveness of the design and operation of its disclosure controls and procedures.", "text": "During the period covered by this report, there were no changes in the Companys internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, the Companys internal control over financial reporting.", "length": 257, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1586, "tag": "div", "text_raw": "Internal control. During the period covered by this report, there were no changes in the Companys internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, the Companys internal control over financial reporting. The Company continues to monitor and assess the effectiveness of the design and operation of its disclosure controls and procedures.", "text": "The Company continues to monitor and assess the effectiveness of the design and operation of its disclosure controls and procedures.", "length": 132, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1592, "tag": "div", "text_raw": "Item 1  LEGAL PROCEEDINGS", "text": "Item 1  LEGAL PROCEEDINGS", "length": 26, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1594, "tag": "div", "text_raw": "The information called for by this item is incorporated herein by reference to Note 11 included in Part I, Item 1, Financial Statements (unaudited)  Notes to Consolidated Financial Statements.", "text": "The information called for by this item is incorporated herein by reference to Note 11 included in Part I, Item 1, Financial Statements (unaudited)  Notes to Consolidated Financial Statements.", "length": 193, "numbers_raw": ["11", "1"], "numbers": [11.0, 1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1598, "tag": "div", "text_raw": "Item 2  UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS", "text": "Item 2  UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS", "length": 68, "numbers_raw": ["2"], "numbers": [2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1600, "tag": "div", "text_raw": "(c) Purchases of Equity Securities by the Issuer and Affiliated Purchasers.", "text": "(c) Purchases of Equity Securities by the Issuer and Affiliated Purchasers.", "length": 75, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1602, "tag": "div", "text_raw": "On September 14, 2022, the Company announced that its Board of Directors approved a share repurchase program, authorizing the Company to purchase up to $5.0 billion of the Company's Common Stock. The repurchase program was completed during the fiscal first quarter of 2023.", "text": "On September 14, 2022, the Company announced that its Board of Directors approved a share repurchase program, authorizing the Company to purchase up to $5.0 billion of the Company's Common Stock.", "length": 195, "numbers_raw": ["14", "202", "2", "$5.0 billion"], "numbers": [14.0, 202.0, 2.0, 5000000000.0], "percents_raw": [], "percents": [], "currencies": ["USD"], "has_numbers": true, "has_percents": false}
{"idx_source": 1602, "tag": "div", "text_raw": "On September 14, 2022, the Company announced that its Board of Directors approved a share repurchase program, authorizing the Company to purchase up to $5.0 billion of the Company's Common Stock. The repurchase program was completed during the fiscal first quarter of 2023.", "text": "The repurchase program was completed during the fiscal first quarter of 2023.", "length": 77, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1604, "tag": "div", "text_raw": "The following table provides information with respect to Common Stock purchases by the Company during the fiscal third quarter of 2023. Common stock purchases on the open market are made as part of a systematic plan to meet the needs of the Company's compensation programs. The repurchases below also include the stock-for-stock option exercises that settled in the fiscal third quarter.", "text": "The following table provides information with respect to Common Stock purchases by the Company during the fiscal third quarter of 2023.", "length": 135, "numbers_raw": ["202", "3"], "numbers": [202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1604, "tag": "div", "text_raw": "The following table provides information with respect to Common Stock purchases by the Company during the fiscal third quarter of 2023. Common stock purchases on the open market are made as part of a systematic plan to meet the needs of the Company's compensation programs. The repurchases below also include the stock-for-stock option exercises that settled in the fiscal third quarter.", "text": "Common stock purchases on the open market are made as part of a systematic plan to meet the needs of the Company's compensation programs.", "length": 137, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1604, "tag": "div", "text_raw": "The following table provides information with respect to Common Stock purchases by the Company during the fiscal third quarter of 2023. Common stock purchases on the open market are made as part of a systematic plan to meet the needs of the Company's compensation programs. The repurchases below also include the stock-for-stock option exercises that settled in the fiscal third quarter.", "text": "The repurchases below also include the stock-for-stock option exercises that settled in the fiscal third quarter.", "length": 113, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1605, "tag": "div", "text_raw": "Fiscal Month Period Total Number of Shares Purchased (1) Avg. Price Per Share Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs July 3, 2023 through July 30, 2023     July 31, 2023 through August 27, 2023     August 28, 2023 through October 1, 2023 5,690,272 161.68   Total 5,690,272 161.68  ", "text": "Fiscal Month Period Total Number of Shares Purchased (1) Avg.", "length": 61, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1605, "tag": "div", "text_raw": "Fiscal Month Period Total Number of Shares Purchased (1) Avg. Price Per Share Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs July 3, 2023 through July 30, 2023     July 31, 2023 through August 27, 2023     August 28, 2023 through October 1, 2023 5,690,272 161.68   Total 5,690,272 161.68  ", "text": "Price Per Share Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs July 3, 2023 through July 30, 2023     July 31, 2023 through August 27, 2023     August 28, 2023 through October 1, 2023 5,690,272 161.68   Total 5,690,272 161.68  ", "length": 352, "numbers_raw": ["3", "202", "3", "30", "202", "3", "31", "202", "3", "27", "202", "3", "28", "202", "3", "1", "202", "3", "5,690,272", "161.68", "5,690,272", "161.68"], "numbers": [3.0, 202.0, 3.0, 30.0, 202.0, 3.0, 31.0, 202.0, 3.0, 27.0, 202.0, 3.0, 28.0, 202.0, 3.0, 1.0, 202.0, 3.0, 5690272.0, 161.68, 5690272.0, 161.68], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1607, "tag": "div", "text_raw": "of Shares Purchased (1)", "text": "of Shares Purchased (1)", "length": 23, "numbers_raw": ["1"], "numbers": [1.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1609, "tag": "div", "text_raw": "(1) During the fiscal third quarter of 2023, the Company repurchased an aggregate of 5,690,272 shares of Johnson & Johnson Common Stock in open-market transactions, all of which were purchased pursuant as part of a systematic plan to meet the needs of the Companys compensation programs.", "text": "(1) During the fiscal third quarter of 2023, the Company repurchased an aggregate of 5,690,272 shares of Johnson & Johnson Common Stock in open-market transactions, all of which were purchased pursuant as part of a systematic plan to meet the needs of the Companys compensation programs.", "length": 288, "numbers_raw": ["1", "202", "3", "5,690,272"], "numbers": [1.0, 202.0, 3.0, 5690272.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1613, "tag": "div", "text_raw": "Item 5  OTHER INFORMATION", "text": "Item 5  OTHER INFORMATION", "length": 26, "numbers_raw": ["5"], "numbers": [5.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1615, "tag": "div", "text_raw": "Securities Trading Plans of Directors and Executive Officers", "text": "Securities Trading Plans of Directors and Executive Officers", "length": 60, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1616, "tag": "div", "text_raw": "On August 31, 2023 , Peter Fasolo , Executive Vice President, Chief Human Resources Officer , adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) for the sale of up to 25,000 shares of the Companys Common Stock, subject to certain conditions. The arrangement's expiration date is November 29, 2024.", "text": "On August 31, 2023 , Peter Fasolo , Executive Vice President, Chief Human Resources Officer , adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) for the sale of up to 25,000 shares of the Companys Common Stock, subject to certain conditions.", "length": 314, "numbers_raw": ["31", "202", "3", "10", "5", "1", "10", "5", "1", "25,000"], "numbers": [31.0, 202.0, 3.0, 10.0, 5.0, 1.0, 10.0, 5.0, 1.0, 25000.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1616, "tag": "div", "text_raw": "On August 31, 2023 , Peter Fasolo , Executive Vice President, Chief Human Resources Officer , adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) for the sale of up to 25,000 shares of the Companys Common Stock, subject to certain conditions. The arrangement's expiration date is November 29, 2024.", "text": "The arrangement's expiration date is November 29, 2024.", "length": 55, "numbers_raw": ["29", "202", "4"], "numbers": [29.0, 202.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1620, "tag": "div", "text_raw": "59", "text": "59", "length": 2, "numbers_raw": ["59"], "numbers": [59.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1621, "tag": "div", "text_raw": "59", "text": "59", "length": 2, "numbers_raw": ["59"], "numbers": [59.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1622, "tag": "div", "text_raw": "59", "text": "59", "length": 2, "numbers_raw": ["59"], "numbers": [59.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1626, "tag": "div", "text_raw": "Item 6  EXHIBITS", "text": "Item 6  EXHIBITS", "length": 17, "numbers_raw": ["6"], "numbers": [6.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1628, "tag": "div", "text_raw": "Exhibit 10.1 Amendment One to the Johnson & Johnson Excess Savings Plan (amended and restated effective as of January 1, 2022)  Filed with this document.*", "text": "Exhibit 10.1 Amendment One to the Johnson & Johnson Excess Savings Plan (amended and restated effective as of January 1, 2022)  Filed with this document.*", "length": 155, "numbers_raw": ["10.1", "1", "202", "2"], "numbers": [10.1, 1.0, 202.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1630, "tag": "div", "text_raw": "Exhibit 10.2 Johnson & Johnson Executive Incentive Plan (Amended as of September 7, 2023)  Filed with this document.*", "text": "Exhibit 10.2 Johnson & Johnson Executive Incentive Plan (Amended as of September 7, 2023)  Filed with this document.*", "length": 118, "numbers_raw": ["10.2", "7", "202", "3"], "numbers": [10.2, 7.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1632, "tag": "div", "text_raw": "Exhibit 31.1 Certification of Chief Executive Officer under Rule 13a-14(a) of the Securities Exchange Act pursuant to Section 302 of the Sarbanes-Oxley Act of 2002  Filed with this document.", "text": "Exhibit 31.1 Certification of Chief Executive Officer under Rule 13a-14(a) of the Securities Exchange Act pursuant to Section 302 of the Sarbanes-Oxley Act of 2002  Filed with this document.", "length": 191, "numbers_raw": ["31.1", "13", "14", "302", "200", "2"], "numbers": [31.1, 13.0, 14.0, 302.0, 200.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1634, "tag": "div", "text_raw": "Exhibit 31.2 Certification of Chief Financial Officer under Rule 13a-14(a) of the Securities Exchange Act pursuant to Section 302 of the Sarbanes-Oxley Act of 2002  Filed with this document.", "text": "Exhibit 31.2 Certification of Chief Financial Officer under Rule 13a-14(a) of the Securities Exchange Act pursuant to Section 302 of the Sarbanes-Oxley Act of 2002  Filed with this document.", "length": 191, "numbers_raw": ["31.2", "13", "14", "302", "200", "2"], "numbers": [31.2, 13.0, 14.0, 302.0, 200.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1636, "tag": "div", "text_raw": "Exhibit 32.1 Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002  Furnished with this document.", "text": "Exhibit 32.1 Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002  Furnished with this document.", "length": 143, "numbers_raw": ["32.1", "906", "200", "2"], "numbers": [32.1, 906.0, 200.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1638, "tag": "div", "text_raw": "Exhibit 32.2 Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002  Furnished with this document.", "text": "Exhibit 32.2 Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002  Furnished with this document.", "length": 143, "numbers_raw": ["32.2", "906", "200", "2"], "numbers": [32.2, 906.0, 200.0, 2.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1640, "tag": "div", "text_raw": "Exhibit 101:", "text": "Exhibit 101:", "length": 12, "numbers_raw": ["101"], "numbers": [101.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1641, "tag": "div", "text_raw": "EX-101.INS Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document EX-101.SCH Inline XBRL Taxonomy Extension Schema EX-101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase EX-101.LAB Inline XBRL Taxonomy Extension Label Linkbase EX-101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase EX-101.DEF Inline XBRL Taxonomy Extension Definition Document Exhibit 104: Cover Page Interactive Data Filethe cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.", "text": "EX-101.INS Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document EX-101.SCH Inline XBRL Taxonomy Extension Schema EX-101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase EX-101.LAB Inline XBRL Taxonomy Extension Label Linkbase EX-101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase EX-101.DEF Inline XBRL Taxonomy Extension Definition Document Exhibit 104:", "length": 472, "numbers_raw": ["101", "101", "101", "101", "101", "101", "104"], "numbers": [101.0, 101.0, 101.0, 101.0, 101.0, 101.0, 104.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1641, "tag": "div", "text_raw": "EX-101.INS Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document EX-101.SCH Inline XBRL Taxonomy Extension Schema EX-101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase EX-101.LAB Inline XBRL Taxonomy Extension Label Linkbase EX-101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase EX-101.DEF Inline XBRL Taxonomy Extension Definition Document Exhibit 104: Cover Page Interactive Data Filethe cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.", "text": "Cover Page Interactive Data Filethe cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.", "length": 183, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1642, "tag": "div", "text_raw": "* Management contract or compensatory plan.", "text": "* Management contract or compensatory plan.", "length": 43, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1643, "tag": "div", "text_raw": "60", "text": "60", "length": 2, "numbers_raw": ["60"], "numbers": [60.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1644, "tag": "div", "text_raw": "60", "text": "60", "length": 2, "numbers_raw": ["60"], "numbers": [60.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1645, "tag": "div", "text_raw": "60", "text": "60", "length": 2, "numbers_raw": ["60"], "numbers": [60.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1653, "tag": "div", "text_raw": "Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.", "text": "Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.", "length": 184, "numbers_raw": ["193", "4"], "numbers": [193.0, 4.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1654, "tag": "div", "text_raw": "JOHNSON & JOHNSON (Registrant) Date: October 27, 2023 By /s/ J. J. WOLK J. J. WOLK Executive Vice President, Chief Financial Officer (Principal Financial Officer) Date: October 27, 2023 By /s/ R. J. DECKER Jr. R. J. DECKER Jr. Controller (Principal Accounting Officer)", "text": "JOHNSON & JOHNSON (Registrant) Date:", "length": 36, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1654, "tag": "div", "text_raw": "JOHNSON & JOHNSON (Registrant) Date: October 27, 2023 By /s/ J. J. WOLK J. J. WOLK Executive Vice President, Chief Financial Officer (Principal Financial Officer) Date: October 27, 2023 By /s/ R. J. DECKER Jr. R. J. DECKER Jr. Controller (Principal Accounting Officer)", "text": "October 27, 2023 By /s/ J.", "length": 26, "numbers_raw": ["27", "202", "3"], "numbers": [27.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1654, "tag": "div", "text_raw": "JOHNSON & JOHNSON (Registrant) Date: October 27, 2023 By /s/ J. J. WOLK J. J. WOLK Executive Vice President, Chief Financial Officer (Principal Financial Officer) Date: October 27, 2023 By /s/ R. J. DECKER Jr. R. J. DECKER Jr. Controller (Principal Accounting Officer)", "text": "WOLK Executive Vice President, Chief Financial Officer (Principal Financial Officer) Date:", "length": 90, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1654, "tag": "div", "text_raw": "JOHNSON & JOHNSON (Registrant) Date: October 27, 2023 By /s/ J. J. WOLK J. J. WOLK Executive Vice President, Chief Financial Officer (Principal Financial Officer) Date: October 27, 2023 By /s/ R. J. DECKER Jr. R. J. DECKER Jr. Controller (Principal Accounting Officer)", "text": "October 27, 2023 By /s/ R.", "length": 26, "numbers_raw": ["27", "202", "3"], "numbers": [27.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1654, "tag": "div", "text_raw": "JOHNSON & JOHNSON (Registrant) Date: October 27, 2023 By /s/ J. J. WOLK J. J. WOLK Executive Vice President, Chief Financial Officer (Principal Financial Officer) Date: October 27, 2023 By /s/ R. J. DECKER Jr. R. J. DECKER Jr. Controller (Principal Accounting Officer)", "text": "Controller (Principal Accounting Officer)", "length": 41, "numbers_raw": [], "numbers": [], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": false, "has_percents": false}
{"idx_source": 1655, "tag": "div", "text_raw": "Date: October 27, 2023", "text": "October 27, 2023", "length": 16, "numbers_raw": ["27", "202", "3"], "numbers": [27.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1656, "tag": "div", "text_raw": "Date: October 27, 2023", "text": "October 27, 2023", "length": 16, "numbers_raw": ["27", "202", "3"], "numbers": [27.0, 202.0, 3.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1658, "tag": "div", "text_raw": "61", "text": "61", "length": 2, "numbers_raw": ["61"], "numbers": [61.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1659, "tag": "div", "text_raw": "61", "text": "61", "length": 2, "numbers_raw": ["61"], "numbers": [61.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
{"idx_source": 1660, "tag": "div", "text_raw": "61", "text": "61", "length": 2, "numbers_raw": ["61"], "numbers": [61.0], "percents_raw": [], "percents": [], "currencies": [], "has_numbers": true, "has_percents": false}
